european journal of pharmacology

an international journal

ELSEVIER

Master Author and Keyword Indexes, Volumes 271–293, 1995
(EJP Molecular Pharmacology Section, Volumes 288–291, and EJP Environmental Toxicology and Pharmacology Section, Volumes 292–293, incorporated)

EUROPEAN JOURNAL OF PHARMACOLOGY

INDEXES 1995

european journal of pharmacology

Author and Keyword Indexes, 1995
Volumes 271–293
(EJP Molecular Pharmacology Section, Volumes 288–291, and EJP Environmental Toxicology and Pharmacology Section, Volumes 292–293, incorporated)

ELSEVIER

AMSTERDAM — LAUSANNE — NEW YORK — OXFORD – SHANNON – TOKYO

© 1996 Elsevier Science B.V. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Science B.V., Copyright and Permissions Department, P.O. Box 521, 1000 AM Amsterdam, The Netherlands.

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, U.S.A., Tel.: (508) 750-8400; FAX: (508) 750-4744. If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. The fee indicated on the first page of an article in this issue will apply retroactively to all articles published in the journal, regardless of the year of publication. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

This journal is in the ADONIS Service, whereby copies of individual articles can be printed out from CD-ROM on request. An explanatory leaflet can be obtained by writing to ADONIS B.V., P.O. Box 839, 1000 AV Amsterdam, The Netherlands.

Publication information

European Journal of Pharmacology (ISSN 0014-2999). As of 1996 the journal is no longer divided into sections. For 1996, volumes 294–316 are scheduled for publication. Vol. 294 appeared in 1995 but remains the first volume of the 1996 subscription year.

Subscription prices are available upon request from the publisher. Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by surface mail except to the following countries where air delivery via SAL mail is ensured: Argentina, Australia, Brazil, Canada, Hong Kong, India, Israel, Japan, Malaysia, Mexico, New Zealand, Pakistan, PR China, Singapore, South Africa, South Korea, Taiwan, Thailand, USA. For all other countries airmail rates are available upon request.

Claims for missing issues must be made within six months of our publication (mailing) date.

Please address all your requests regarding orders and subscription queries to: Elsevier Science B.V., Journal Department, P.O. Box 211, 1000 AE Amsterdam, The Netherlands. Tel.: 31-20-485.3642, Fax: 31-20-485.3598.

All questions arising after acceptance of a manuscript by the editor, especially those relating to proofs, publication and reprints, should be directed to the publisher, Elsevier Science B.V., P.O. Box 1527, 1000 BM Amsterdam, The Netherlands (Fax: 31-20-485.3271). Address for courier service: Molenwerf 1, 1014 AG Amsterdam, The Netherlands.

In the U.S.A. and Canada: for further information and personal subscriptions, contact Elsevier Science Inc., Journal Information Center, 655 Avenue of the Americas, New York, NY 10010, U.S.A. (Tel.: 212-633.3750; Fax: 212-633.3990; Telex: 420.643 AEP UI).

Advertising information: Advertising orders and enquiries may be sent to:

International: Elsevier Science, Advertising Department, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK; Tel. (+44) (0) 1865 843565; Fax (+44) (0) 1865 843952.

USA & Canada: Weston Media Associates, Dan Lipner, P.O. Box 1110, Greens Farms, CT 06436-1110, USA; Tel. (203) 261 2500; Fax: (203) 261 0101.

Japan: Elsevier Science Japan, Ms Noriko Kodama, 20-12 Yushima, 3 chome, Bunkyo-Ku, Tokyo 113, Japan; Tel. (+81) 3 3836 0810; Fax (+81) 3 3839 4344.

♾ The paper used in this publication meets the requirements of ANSI/NISO 239.48-1992 (Permanence of Paper).

US mailing notice - European Journal of Pharmacology (ISSN 0014-2999) is published weekly by Elsevier Science B.V. (Molenwerf 1, Postbus 211, 1000 AE Amsterdam, The Netherlands). Annual subscription price in the USA is US$ 5680.00 (valid in North, Central and South America only) including air speed delivery. Second class postage rate is paid at Jamaica, NY 11431.

USA POSTMASTERS: Send address changes to *European Journal of Pharmacology*, Publications Expediting, Inc., 200 Meacham Avenue, Elmont, NY 11003.

Airfreight and mailing in the USA by Publications Expediting.

Printed in The Netherlands

ELSEVIER

European Journal of Pharmacology

ejp

Master author index to volumes 271–293 (1995)

Aarts, J.M.M.J.G., Denison, M.S., Cox, M.A., Schalk, M.A.C., Garrison, P.M., Tullis, K., De Haan, L.H.J. and Brouwer, A.
Species-specific antagonism of Ah receptor action by 2,2′,5,5′-tetrachloro- and 2,2′,3,3′,4,4′-hexachlorobiphenyl (293) 463

Abad, F., Maroto, R., López, M.G., Sánchez-García, P. and García, A.G.
Pharmacological protection against the cytotoxicity induced by 6-hydroxydopamine and H_2O_2 in chromaffin cells (293) 55

Abadji, V., see Pertwee, R.G. (272) 73

Abbott, F.V., see Hong, Y. (277) 21

Abdel Ghani, E.M., see Storch, A. (290) 207

Abdi, S., Traber, L.D., Herndon, D.N., Rogers, C.S. and Traber, D.L.
Effects of ibuprofen on airway vascular response to cotton smoke injury (293) 475

Abdul-Ghaffar, T., see Canfield, P. (273) 1

Abe, Y., see He, H. (273) 209

Abiko, Y., see Hashizume, H. (271) 1

Abiko, Y., see Kamigaki, M. (287) 121

Abiru, T., Endo, K. and Machida, H.
Differential vasodilatory action of 2-octynyladenosine (YT-146), an adenosine A_2 receptor agonist, in the isolated rat femoral artery and vein (281) 9

Ableitner, A.
Brain sites involved in δ-opioid receptor-mediated actions (271) 213

Abram, T., see Gorenne, I. (275) 207

Abram, T.S., see Norman, P. (271) 73

Aburto, T., Jinsi, A., Zhu, QB. and Deth, R.C.
Involvement of protein kinase C activation in α_2-adrenoceptor-mediated contractions of rabbit saphenous vein (277) 35

Aceto, M.D., Scates, S.M., Lowe, J.A. and Martin, B.R.
Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A (282) R1

Acri, J.B., Carter, S.R., Alling, K., Geter-Douglass, B., Dijkstra, D., Wikström, H., Katz, J.L. and Witkin, J.M.
Assessment of cocaine-like discriminative stimulus effects of dopamine D_3 receptor ligands (281) R7

Acri, J.B., Wong, G. and Witkin, J.M.
Stereospecific transduction of behavioral effects via diazepam-insensitive $GABA_A$ receptors (278) 213

Adachi, T., Hori, S., Miyazaki, K., Takahashi, E., Nakagawa, M., Udagawa, A., Hayashi, N., Aikawa, N. and Ogawa, S.
Rapid increase in plasma nitrite concentration following intravenous administration of nipradilol (286) 201

Adams, J.U., see Chen, X.-H. (275) 105

Adcock, I.M., see Peters, M.J. (289) 275

Adeli, R., see Zarrindast, M.-R. (276) 3

Adelman, J.P., see Lee, K. (285) 309

Ädelroth, E., see Stevens, W.H.M. (293) 251

Adler, M.W., see Chen, X.-H. (275) 105

Adomeit, A., see Liebmann, C. (289) 403

Advenier, C., see Bétoin, F. (279) 241

Advenier, C., see Félétou, M. (274) 57

Advenier, C., see Molimard, M. (278) 49

Advenier, Ch., see Molimard, M. (278) 253

Ærø, C.E., see Røshol, H. (286) 9

Agabio, R., see Colombo, G. (273) 235

Agabio, R., see Colombo, G. (285) 103

Agapito-Serrano, M.T., see López-Burillo, S. (289) 259

Agnati, L.F., see Yang, S.-N. (271) 201

Agrawal, K.C., see Kaye, A.D. (276) 21

Aguirre, N., Galbete, J.L., Lasheras, B. and Del Río, J.
Methylenedioxymethamphetamine induces opposite changes in central pre- and postsynaptic 5-HT_{1A} receptors in rats (281) 101

Ahier, R.G., see Hume, S.P. (271) 515

Ahlborg, U.G., see Brouwer, A. (293) 1

Ahlborg, U.G., see Hemming, H. (292) 241

Ahluwalia, A., Newbold, P., Brain, S.D. and Flower, R.J.
Topical glucocorticoids inhibit neurogenic inflammation: involvement of lipocortin 1 (283) 193

Ahmed, G., see Parmar, D.V. (293) 225

Ahn, H.-S., Foster, M., Arik, L., Boykow, G. and Foster, C.
Cyclic nucleotide phosphodiesterase isozymes in rat mesangial cells (289) 49

Ahrén, B., Karlsson, S., Scheurink, A.J.W. and Steffens, A.B.
Involvement of nitric oxide in neuroglycopenia-induced insulin and glucagon secretion in the mouse (280) 27

Aikawa, N., see Adachi, T. (286) 201

Aiyar, N., Baker, E., Vickery-Clark, L., Ohlstein, E.H., Gellai, M., Fredrickson, T.A., Brooks, D.P., Weinstock, J., Weidley, E.F. and Edwards, R.M.
Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT_1 receptor antagonist (283) 63

Akahane, A., see Terai, T. (279) 217

Akaike, N., see Uneyama, C. (291) 381

Akarasereenont, P., Mitchell, J.A., Bakhle, Y.S., Thiemermann, C. and Vane, J.R.
Comparison of the induction of cyclooxygenase and nitric oxide synthase by endotoxin in endothelial cells and macrophages (273) 121

Akehira, K., Nakane, Y., Hioki, K. and Taniyama, K.
Site of action of galanin in the cholinergic transmission of guinea pig small intestine (284) 149

Åkerman, K.E.O., see Jansson, C.C. (290) 75

Åkerman, K.E.O., see Järv, J. (291) 43

Aki, Y., see He, H. (273) 209

Akiba, S., Nagatomo, R., Ishimoto, T. and Sato, T.
Effect of berbamine on cytosolic phospholipase A_2 activation in rabbit platelets (291) 343

Akiyama, K., see Hashizume, H. (271) 1

Akiyama, K., see Sutoo, D. (278) 33

Akkermans, L.M.A., see Briejer, M.R. (279) 123

Akuzawa, S., Miyata, K. and Fukutomi, H.
Characterization of [^{3}H]YM060, a potent and selective 5-HT_3 receptor radioligand, in the cerebral cortex of rats (281) 37

Alaoui, F., Pratt, J., Trocherie, S., Court, L. and Stutzmann, J.-M.
Acute effects of irradiation on the rat brain: protection by glutamate blockade (276) 55

Albin, R.L., see Feeley Kearney, J.A. (287) 115

Albuquerque, E.X., see Storch, A. (290) 207

Alcaraz, M.J., see Gil, B. (285) 281

Alemany, R., Olmos, G., Escribá, P.V., Menargues, A., Obach, R. and García-Sevilla, J.A.
LSL 60101, a selective ligand for imidazoline I_2 receptors, on glial fibrillary acidic protein concentration (280) 205
Alexander, P.B. and Cheung, D.W.
Ca^{2+} mobilization by caffeine in single smooth muscle cells of the rat tail artery (288) 79
Allard, M., see Garay, R.P. (274) 175
Allard, M.F., see Schönekess, B.O. (286) 155
Allen, G.T., see Tesfamariam, B. (281) 17
Allen, J., see Le Rouzic, M. (278) 261
Allen, M.J. and Coleman, R.A.
β_2-Adrenoceptors mediate a reduction in endothelial permeability in vitro (274) 7
Allescher, H.-D., see Franck, H. (271) 379
Allescher, H.-D., see Kurjak, M. (281) 295
Allgeier, H., see Knöpfel, T. (288) 389
Alling, K., see Acri, J.B. (281) R7
Allison, K., Ivanová, S. and Greenshaw, A.J.
Behavioural response to SKF 38393 and quinpirole following chronic antidepressant treatment (277) 139
Aloyo, V.J. and Pazdalski, P.S.
Evidence that β-endorphin is an agonist at bovine pineal δ-opioid receptors (288) 295
Alsasua, A., see Parra, L. (277) 99
Altavilla, D., Squadrito, F., Canale, P., Ioculano, M., Campo, G.M., Squadrito, G., Ammendolia, L. and Caputi, A.P.
E-selectin involvement in the pathogenesis of splanchnic artery occlusion shock (272) 223
Altavilla, D., Squadrito, F., Canale, P., Ioculano, M., Squadrito, G., Campo, G.M., Serranò, M., Sardella, A., Urna, G., Spignoli, G. and Caputi, A.P.
G 619, a dual thromboxane synthase inhibitor and thromboxane A_2 receptor antagonist, inhibits tumor necrosis factor-α biosynthesis (286) 31
Altier, H., see Ponzoni, A. (278) 111
Amakata, Y., see Sai, Y. (282) 235
Amann, R., Schuligoi, R., Lanz, I. and Donnerer, J.
Histamine-induced edema in the rat paw – effect of capsaicin denervation and a CGRP receptor antagonist (279) 227
Ammendolia, L., see Altavilla, D. (272) 223
Amobi, N. and Smith, I.C.H.
The human vas deferens: correlation of response pattern to noradrenaline and histological structure (273) 25
Andersen, J.V., see Videbæk, C. (281) 117
Andersen, L.F., see Atke, A. (281) 63
Anderson, D.J., see Decker, M.W. (280) 79
Andersson, I., see Westlind-Danielsson, A. (288) 89
Ando, H., see Hotta, Y. (282) 121
Ando, T., see Terai, T. (279) 217
Andrews, P.L.R., see Woods, A.J. (278) 275
Andrzejewski, W., see Tuomisto, J. (292) 277
Angel, I., see Le Rouzic, M. (278) 261
Ansay, M., see Delaunois, A. (277) 243
Anticevich, S.Z., Hughes, J.M., Black, J.L. and Armour, C.L.
Induction of human airway hyperresponsiveness by tumour necrosis factor-α (284) 221
Antunes, E., see Grassi-Kassisse, D.M. (282) 57
Antunes, E., see Medeiros, M.V. (285) 109
Antunes, E., see Moreno, Jr., H. (287) 93
Anwyl, R., see Wu, J. (284) R1
Anzai, M., Suzuki, Y., Takayasu, M., Kajita, Y., Mori, Y., Seki, Y., Saito, K. and Shibuya, M.
Vasorelaxant effect of PACAP-27 on canine cerebral arteries and rat intracerebral arterioles (285) 173
Aono, T., see Hamada, Y. (288) 45
Aoto, N., see Sakitama, K. (273) 47
Aoyagi, T., see Majima, M. (284) 1
Aoyagi, T., see Sata, M. (290) 55
Apaydin, S., see Van der Graaf, P.H. (287) 309
Aragonés, M.D., see Catalán, R.E. (290) 183
Arai, T., see Hagihara, K. (271) 159
Arakawa, H., see Kawikova, I. (280) 293
Araki, H., see Uchiyama-Tsuyuki, Y. (293) 245
Araki, T., Kato, H., Fujiwara, T., Kogure, K. and Itoyama, Y.
Post-ischemic changes of [^{3}H]glycine binding in the gerbil brain after cerebral ischemia (278) 91
Araki, T., see Kato, H. (272) 107
Arbaoui, J., see Protais, P. (271) 167
Arbilla, S., see Le Rouzic, M. (278) 261
Arce, A., see Esquifino, A.I. (285) 143
Arik, L., see Ahn, H.-S. (289) 49
Arilla, E., see Puebla, L. (289) 361
Arima, T., see Kitamura, Y. (289) 299
Arishima, K., see Naito, H. (272) 261
Arletti, R., see Poggioli, R. (271) 253
Arletti, R., see Poggioli, R. (287) 207
Armour, C.L., see Anticevich, S.Z. (284) 221
Arner, A., see Sjuve, R. (276) 137
Arneric, S.P., see Gopalakrishnan, M. (290) 237
Arnt, J., Sánchez, C., Lenz, S.M., Madsen, U. and Krogsgaard-Larsen, P.
Differentiation of in vivo effects of AMPA and NMDA receptor ligands using drug discrimination methods and convulsant/anticonvulsant activity (285) 289
Arnt, J.
Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine (283) 55
Arreola, J., Dirksen, R.T., Perez-Cornejo, P., Piech, K.M. and Sheu, S.-S.
Autonomic modulation of action potential and tension in guinea pig papillary muscles (271) 309
Arrigoni-Martelli, E., see Maresca, P. (287) 303
Asagoe, K., Murakami, M. and Kita, T.
Histamine chloramines have a persistent stimulating effect on histamine H_2 receptors and gastric acid secretion (275) 179
Asano, S., see Matsuda, T. (280) 235
Ashford, M.L.J., see Lee, K. (280) 215
Ashkenazi, R., see Fonia, O. (293) 335
Ashworth-Preece, M.A., see Routledge, C. (276) 281
Ashworth, S., see Hume, S.P. (271) 515
Asker, D.S., see Waterfield, C.J. (293) 141
Astier, H., see Roussel, J.-P. (289) 205
Atke, A., Vilhardt, H., Hauzerova, L., Barth, T. and Andersen, L.F.
Effects of the non-peptide inhibitor OPC-21268 on oxytocin and vasopressin stimulation of rat and human myometrium (281) 63
Atkinson, A.M., see Teale, D.M. (271) 87
Audet, R., Petitclerc, E., Drapeau, G., Rioux, F. and Marceau, F.
Further analysis of the upregulation of bradykinin B_1 receptors in isolated rabbit aorta by using metabolic inhibitors (271) 551
Audinot, V., see Millan, M.J. (280) 225
Auguet, M., Delaflotte, S. and Chabrier, P.-E.
Different α_1-adrenoceptor subtypes mediate contraction in rabbit aorta and urethra (287) 153
Aulakh, C.S., Mazzola-Pomietto, P. and Murphy, D.L.
Long-term antidepressant treatments alter 5-HT_{2A} and 5-HT_{2C} receptor-mediated hyperthermia in Fawn-Hooded rats (282) 65
Aydin, S., see Buyukuysal, R.L. (281) 179
Az-ma, T., Fujii, K. and Yuge, O.
Inhibitory effect of sevoflurane on nitric oxide release from cultured endothelial cells (289) 33

Baba, A., see Matsuda, T. (280) 235
Badesha, J.S., Maliji, G. and Flaks, B.
Immunotoxic effects of prolonged dietary exposure of male rats to 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (293) 429

Bagdy, G. and Makara, G.B.
Paraventricular nucleus controls 5-HT_{2C} receptor-mediated corticosterone and prolactin but not oxytocin and penile erection responses (275) 301
Bager, Y., see Hemming, H. (292) 241
Bagrov, A.Y., Roukoyatkina, N.I., Pinaev, A.G., Dmitrieva, R.I. and Fedorova, O.V.
Effects of two endogenous Na^+,K^+-ATPase inhibitors, marinobufagenin and ouabain, on isolated rat aorta (274) 151
Bai, X., see Weiser, S.D. (275) 1
Baird, A.J., see Grover, G.J. (277) 271
Baird, A.W., see Keely, S.J. (279) 203
Baird, A.W., see O'Malley, K.E. (275) 83
Bajaj, B.P.S., see Balmforth, A.J. (291) 135
Baker, E., see Aiyar, N. (283) 63
Bakhle, Y.S., see Akarasereenont, P. (273) 121
Balaklievskaia, N., see Colombo, G. (285) 103
Balasubramaniam, E., see Paul, V. (293) 355
Balasubramaniam, G., Lee, H.S. and Mah, S.C.
5-Carboxamidotryptamine attenuates the development of deoxycorticosterone acetate-salt hypertension in rats (276) 183
Balboni, G., see Damgé, C. (274) 133
Balestra, B., see Messori, E. (286) 205
Ball, D.I., see Beresford, I.J.M. (272) 241
Ball, S.G., see Balmforth, A.J. (291) 135
Ball, S.G., see Wintersgill, H.P. (288) 365
Ballati, L., see Perretti, F. (273) 129
Ballejo, G., see Martins, S.L.R. (284) 265
Balmforth, A.J., Lee, A.J., Bajaj, B.P.S., Dickinson, C.J., Warburton, P. and Ball, S.G.
Functional domains of the C-terminus of the rat angiotensin AT_{1A} receptor (291) 135
Balmforth, A.J., see Wintersgill, H.P. (288) 365
Balster, R., see Wiley, J. (276) 49
Balster, R.L., see Mansbach, R.S. (274) 167
Balster, R.L., see Woodward, J.J. (277) 7
Baltatu, O., see Brailoiu, E. (281) 209
Baltatu, O., see Costuleanu, M. (281) 89
Baltatu, O., see Filipeanu, C.M. (281) 29
Bandopadhyay, R. and De Belleroche, J.
Depletion of cortical cholecystokinin levels after excitotoxin injection into the nucleus basalis: sensitivity to MK-801 (275) 53
Banks, K.E. and Gratton, A.
Possible involvement of medial prefrontal cortex in amphetamine-induced sensitization of mesolimbic dopamine function (282) 157
Bansinath, M., see Shukla, V.K. (292) 293
Baran, H., Gramer, M. and Löscher, W.
Alterations in plasma and brain amino acids after administration of the glycine/NMDA receptor partial agonist, D-cycloserine, to mice and rats (273) 197
Baran, H., Gramer, M., Hönack, D. and Löscher, W.
Systemic administration of kainate induces marked increases of endogenous kynurenic acid in various brain regions and plasma of rats (286) 167
Barbeito, L., see Estevez, A.G. (280) 47
Barbier, A.J. and Lefebvre, R.A.
Relaxant influence of phosphodiesterase inhibitors in the cat gastric fundus (276) 41
Barbier, P., Renzetti, A.R., Turbanti, L., Di Bugno, C., Fornai, F., Vaglini, F., Maggio, R. and Corsini, G.U.
Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine (290) 125
Barg, J., Fride, E., Hanus, L., Levy, R., Matus-Leibovitch, N., Heldman, E., Bayewitch, M., Mechoulam, R. and Vogel, Z.
Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides (287) 145
Barg, J., see Novakova, M. (286) 19
Bargas, J., see Pineda, J.C. (281) 271
Barnard, E.A., see Simon, J. (291) 281
Barnes, P.J., see Belvisi, M. (283) 255
Barnes, P.J., see Haddad, E.-B. (290) 201
Barnes, P.J., see Haddad, E.-B. (293) 287
Barnes, P.J., see Hayes, J.P. (292) 127
Barnes, P.J., see Peters, M.J. (289) 275
Barnett, C.R., see Irizar, A. (293) 385
Baron, B.M., see Chapman, A.G. (274) 83
Baron, B.M., see Kehne, J.H. (284) 109
Barr, G., see Franco-Cereceda, A. (279) 105
Barrachina, M.D., Calatayud, S., Canet, A., Bello, R., Díaz de Rojas, F., Guth, P.H. and Esplugues, J.V.
Transdermal nitroglycerin prevents nonsteroidal anti-inflammatory drug gastropathy (281) R3
Barrachina, M.D., Calatayud, S., Moreno, L., Martínez-Cuesta, M.A., Whittle, B.J.R. and Esplugues, J.V.
Nitric oxide and sensory afferent neurones modulate the protective effects of low-dose endotoxin on rat gastric mucosal damage (280) 339
Barrenscheen, M., see Schmalix, W.A. (293) 123
Barrett, T.D., Hayes, E.S. and Walker, M.J.A.
Lack of selectivity for ventricular and ischaemic tissue limits the antiarrhythmic actions of lidocaine, quinidine and flecainide against ischaemia-induced arrhythmias (285) 229
Barrigón, S., see Salinas, P. (293) 65
Barrios, V.E., see Krause, D.N. (276) 207
Barth, T., see Atke, A. (281) 63
Barthò, L., see Patacchini, R. (278) 17
Bartolome, J.V., Chang, K.-J. and Bartolome, M.B.
The inhibition of ornithine decarboxylase activity in developing rat tissues by central nervous system β-endorphin is mediated by μ-opioid receptors, but not by δ- or ϵ-opioid receptors (284) 43
Bartolome, M.B., see Bartolome, J.V. (284) 43
Basak, A.K., see Koley, J. (293) 483
Bascands, J.-L., see Bompart, G. (278) 225
Baskaya, M.K., see Seki, Y. (275) 259
Bäsler, I., Kuhn, M., Müller, W. and Forssmann, W.-G.
Pituitary adenylate cyclase-activating polypeptide stimulates cardiodilatin/atrial natriuretic peptide (CDD/ANP-(99–126) secretion from cultured neonatal rat myocardiocytes (291) 335
Bassi, L., see Fornai, F. (283) 99
Bast, A., see Smit, M.J. (288) 17
Bast, A., see Westerveld, G.-J. (291) 27
Bataille, D., see Gros, L. (288) 319
Baubichon, D., see Bodjarian, N. (289) 291
Bauer, C., see Hocher, B. (293) 361
Baulieu, E.E., see Hauser, C.A.E. (289) 249
Baumann, M.H., Becketts, K.M. and Rothman, R.B.
Evidence for alterations in presynaptic serotonergic function during withdrawal from chronic cocaine in rats (282) 87
Baumann, P., see Knöpfel, T. (288) 389
Bäumner, D. and Nawrath, H.
Effects of inhibitors of cGMP-dependent protein kinase in atrial heart and aortic smooth muscle from rats (273) 295
Bax, W.A., Van der Graaf, P.H., Stam, W.B., Bos, E., Nisato, D. and Saxena, P.R.
[Arg^8]Vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists (285) 199
Bayewitch, M., see Barg, J. (287) 145
Bazan, E., Campbell, A.K. and Rapoport, R.M.
Time course of phorbol ester-induced contraction and protein kinase C activation in rat aorta (290) 253
Beani, L., see Tanganelli, S. (273) 63
Beattie, D.T. and Connor, H.E.
The pre- and postjunctional activity of CP-122,288, a conformationally restricted analogue of sumatriptan (276) 271

Beattie, D.T., see Escott, K.J. (284) 69
Beattie, D.T., see Walsh, D.M. (287) 79
Beauchemin, V., see Dennis, T. (272) 279
Becherucci, C., see Palmi, M. (281) 97
Beck-Sickinger, A.G., see Rudolf, K. (271) R11
Becketts, K.M., see Baumann, M.H. (282) 87
Bédard, P.J., see St-Pierre, J.-A. (272) 123
Beenhakker, M., see Von Lubitz, D.K.J.E. (283) 185
Behr, J.-P., see Foucaud, B. (289) 471
Belai, A., see Ralevic, V. (286) 193
Beleslin, D.B., see Jovanović-Mićić, D. (272) 21
Belfast, M., see Glaser, K. (281) 107
Bello, R., see Barrachina, M.D. (281) R3
Belloni, P., see Viganò, T. (291) 201
Beloshapko, G., see Lee, J.H. (285) 25
Belvisi, M., Barnes, P.J., Larkin, S., Yacoub, M., Tadjkarimi, S., Williams, T.J. and Mitchell, J.A.
Nitric oxide synthase activity is elevated in inflammatory lung disease in humans (283) 255
Benazzouz, A., Boraud, T., Dubédat, P., Boireau, A., Stutzmann, J.-M. and Gross, C.
Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study (284) 299
Bench, C.J., see Pike, V.W. (283) R1
Benediktsdóttir, V.E., Skúladóttir, G.V. and Gudbjarnason, S.
Effects of ageing and adrenergic stimulation on α_1- and β-adrenoceptors and phospholipid fatty acids in rat heart (289) 419
Benelli, A., see Poggioli, R. (271) 253
Benelli, A., see Poggioli, R. (287) 207
Bengen, J., see Galle, J. (273) 311
Bengtsson, A., see Jackson, D.M. (282) 137
Benishin, C.G., see Sun, Y.-D. (271) 453
Benrath, J., Eschenfelder, C., Zimmermann, M. and Gillardon, F.
Calcitonin gene-related peptide, substance P and nitric oxide are involved in cutaneous inflammation following ultraviolet irradiation (293) 87
Benrath, J., see Gillardon, F. (293) 395
Benthem, L., see Coppes, R.P. (274) 33
Berdeu, D., Gross, R., Puech, R., Loubatières-Mariani, M.-M. and Bertrand, G.
Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat (275) 91
Beresford, I.J.M., Sheldrick, R.L.G., Ball, D.I., Turpin, M.P., Walsh, D.M., Hawcock, A.B., Coleman, R.A., Hagan, R.M. and Tyers, M.B.
GR159897, a potent non-peptide antagonist at tachykinin NK_2 receptors (272) 241
Berger, I., Gillis, R.A., Vitagliano, S., Panico, W.H., Magee, S., Kelly, M., Norman, W.P., McManigle, J.E. and DaSilva, A.M.T.
NMDA receptors are involved at the ventrolateral nucleus tractus solitarii for termination of inspiration (277) 195
Bergstrom, D.A., see Kreiss, D.S. (277) 209
Berkowitz, D.E., Nardone, N.A., Smiley, R.M., Price, D.T., Kreutter, D.K., Fremeau, R.T. and Schwinn, D.A.
Distribution of β_3-adrenoceptor mRNA in human tissues (289) 223
Berlan, M., see Bousquet-Mélou, A. (289) 235
Bernabeu, R., see Fin, C. (271) 227
Bernauer, W.
Effect of antiarrhythmics on the release of adenosine in rat hearts with coronary occlusion and reperfusion (283) 91
Bernier, S.G., Fournier, A. and Guillemette, G.
A specific binding site recognizing a fragment of angiotensin II in bovine adrenal cortex membranes (271) 55
Bernier, S.G., Servant, G., Boudreau, M., Fournier, A. and Guillemette, G.
Characterization of a binding site for angiotensin IV on bovine aortic endothelial cells (291) 191
Berrang, B., see Popik, P. (291) 221
Berrino, L., see Leyva, J. (285) 123
Bertha, C.M., see Bowen, W.D. (278) 257
Bertha, C.M., see Bowen, W.D. (279) R1
Bertolini, A., see Poggioli, R. (271) 253
Bertolini, A., see Poggioli, R. (287) 207
Bertrand, D., see Gopalakrishnan, M. (290) 237
Bertrand, G., see Berdeu, D. (275) 91
Bervoets, K., see Maurel-Remy, S. (280) R9
Berzetei-Gurske, I.P., White, A., Polgar, W., DeCosta, B.R., Pasternak, G.W. and Toll, L.
The in vitro pharmacological characterization of naloxone benzoylhydrazone (277) 257
Bessho, H., see He, H. (273) 209
Besson, J.-M., see Honoré, P. (272) 249
Bétoin, F., Advenier, C., Fardin, V., Wilcox, G., Lavarenne, J. and Eschalier, A.
In vitro and in vivo evidence for a tachykinin NK_1 receptor antagonist effect of vapreotide, an analgesic cyclic analog of somatostatin (279) 241
Betto, P., see Popoli, P. (287) 215
Beyermann, M., see Cross, L.J.M. (291) 291
Bianchi, G., see Micheletti, R. (286) 147
Bianchi, N., see Feriotto, G. (290) 85
Bickerdike, M.J., Marsden, C.A., Dourish, C.T. and Fletcher, A.
The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze (271) 403
Biegon, A., see Eshhar, N. (283) 19
Bielanski, W., see Konturek, S.J. (278) 203
Bienert, M., see Cross, L.J.M. (291) 291
Bill, D.J., see Forster, E.A. (281) 81
Billard, J.-M., see Jouvenceau, A. (281) 131
Binhara, I.M., see Medeiros, M.V. (285) 109
Binnekade, R., see Schmidt, E.D. (285) 317
Birch, P., see Smith, G. (271) 481
Birnbaum, L.S., see Brouwer, A. (293) 1
Björklund, M., see Jäkälä, P. (282) 39
Björn, M., see Idänpään-Heikkilä, J.J. (292) 191
Black, J.L., see Anticevich, S.Z. (284) 221
Black, J.L., see Yang, K.X.F. (275) 283
Black, P.N., see Young, P.G. (273) 137
Blair, T.A., see Lee, K. (285) 309
Blanchard, J.-C., see Petitet, F. (291) 143
Blanchet, G., see Bodjarian, N. (289) 291
Bland-Ward, P.A., see Gaffen, Z. (271) 445
Blandizzi, C., Natale, G., Colucci, R., Carignani, D., Lazzeri, G. and Del Tacca, M.
Characterization of α_2-adrenoceptor subtypes involved in the modulation of gastric acid secretion (278) 179
Blengio, M., see Ferretti, C. (280) 19
Blier, P., see Mongeau, R. (271) 121
Block, F., see Schwarz, M. (276) 247
Blommaert, A., see Noble, F. (273) 145
Blommaert, A.G.S., see Valverde, O. (286) 79
Blumberg, P.M., see Szallasi, A. (289) 181
Blundell, J.E., see Garosi, V.L. (276) 285
Bobirnac, I., see Schoeffter, P. (289) 163
Bockaert, J., see Zumbihl, R. (288) 9
Böckmann, S. and Paegelow, I.
Bradykinin receptors and signal transduction pathways in peritoneal guinea pig macrophages (291) 159
Bodelsson, G. and Stjernquist, M.
Characterization of contractile adrenoceptors in the human umbilical artery (282) 95
Bodjarian, N., Carpentier, P., Baubichon, D., Blanchet, G. and Lallement, G.
Involvement of non-muscarinic receptors in phosphoinositide signalling during soman-induced seizures (289) 291

Boeckxstaens, G.E., see De Man, J.G. (285) 269
Boeckxstaens, G.E., see Michielsen, P.P. (273) 167
Boer, R., see Malkhandi, J. (288) 105
Boersma, E.R., see Brouwer, A. (293) 1
Bohmann, C., Schaible, U., Schollmeyer, P. and Rump, L.C.
α_{2D}-Adrenoceptors modulate renal noradrenaline release in normotensive and spontaneously hypertensive rats (271) 283
Bohus, B., see Korte, S.M. (272) 45
Boichot, E., see Hichami, A. (291) 91
Boireau, A., see Benazzouz, A. (284) 299
Boje, K.M.K.
Inhibition of nitric oxide synthase partially attenuates alterations in the blood-cerebrospinal fluid barrier during experimental meningitis in the rat (272) 297
Bolanos, C.A., see Pruitt, D.L. (283) 125
Bolego, C., see Pinna, C. (271) 151
Bolego, C., see Pinna, C. (276) 61
Bollen, A., see Ciccarelli, E. (288) 259
Bolser, D.C., DeGennaro, F.C., O'Reilly, S., Hey, J.A. and Chapman, R.W.
Pharmacological studies of allergic cough in the guinea pig (277) 159
Bolser, D.C., Del Prado, M., O'Reilly, S., Mingo, G. and Hey, J.A.
Evan's blue dye blocks capsaicin-induced cough and bronchospasm in the guinea pig (276) R1
Bompart, G., Tack, I., Bascands, J.-L. and Girolami, J.-P.
Intracellular Ca^{2+} depletion and Ca^{2+} channel blockers increase renal kallikrein secretion (278) 225
Bönisch, H., see Malinowska, B. (293) 71
Boomsma, F., see Verhage, M. (291) 387
Boraud, T., see Benazzouz, A. (284) 299
Bordi, F. and Ugolini, A.
Antagonists of the metabotropic glutamate receptor do not prevent induction of long-term potentiation in the dentate gyrus of rats (273) 291
Borella, A., see Whitaker-Azmitia, P.M. (275) 139
Borg, J., see Damgé, C. (274) 133
Bormann, J., see Feigenspan, A. (288) 97
Borowicz, K.K., Gasior, M., Kleinrok, Z. and Czuczwar, S.J.
The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics (281) 319
Borowicz, K.K., see Czuczwar, S.J. (281) 327
Borsini, F., see Ceci, A. (271) 231
Bos, E., see Bax, W.A. (285) 199
Bos, E., see Du, X.Y. (284) 119
Bosveld, B., see Brouwer, A. (293) 1
Boudreau, M., see Bernier, S.G. (291) 191
Bougria, M., Vitorica, J., Cano, J. and Machado, A.
Implication of dopamine transporter system on 1-methyl-4-phenylpyridinium and rotenone effect in striatal synaptosomes (291) 407
Bourdeaux, M.J., see Orsière, T.G. (291) 237
Bousquet-Mélou, A., Galitzky, J., Muñoz Moreno, C., Berlan, M. and Lafontan, M.
Desensitization of β-adrenergic responses in adipocytes involves receptor subtypes and cAMP phosphodiesterase (289) 235
Bousquet, P., see Greney, H. (271) 533
Bouvier, C., Bunzow, J.R., Guan, H.-C., Unteutsch, A., Civelli, O., Grandy, D.K. and Van Tol, H.H.M.
Functional characterization of the human dopamine $D_{4.2}$ receptor using vaccinia virus as an expression system (290) 11
Bouysset, F., see Vayssettes-Courchay, C. (285) 299
Bova, S., see Cargnelli, G. (292) 103
Bowe, M.A. and Nadler, J.V.
Polyamines antagonize *N*-methyl-D-aspartate-evoked depolarizations, but reduce Mg^{2+} block (278) 55
Bowen, W.D., Bertha, C.M., Vilner, B.J. and Rice, K.C.
CB-64D and CB-184: ligands with high σ_2 receptor affinity and subtype selectivity (278) 257
Bowen, W.D., Vilner, B.J., Williams, W., Bertha, C.M., Kuehne, M.E. and Jacobson, A.E.
Ibogaine and its congeners are σ_2 receptor-selective ligands with moderate affinity (279) R1
Bowen, W.D., see Matsumoto, R.R. (280) 301
Bowers, J., see Smith, G. (271) 481
Bowery, B.J., see Seabrook, G.R. (273) 113
Boykow, G., see Ahn, H.-S. (289) 49
Bradford, H.F., see Croucher, M.J. (286) 265
Brady, G., see Docherty, J.R. (287) 287
Braida, D., Gori, E. and Sala, M.
Relationship between morphine and etonitazene-induced working memory impairment and analgesia (271) 497
Braida, D., see Sala, M. (273) 35
Brailoiu, E., Baltatu, O., Costuleanu, M., Slatineanu, S., Filipeanu, C.M. and Branisteanu, D.D.
Effects of α-trinositol administered extra- and intracellularly (using liposomes) on rat aorta rings (281) 209
Brailoiu, E., see Costuleanu, M. (281) 89
Brailoiu, E., see Filipeanu, C.M. (281) 29
Brain, S.D., see Ahluwalia, A. (283) 193
Brain, S.D., see Escott, K.J. (284) 69
Branchek, T.A., see Zgombick, J.M. (291) 9
Branisteanu, D.D., see Brailoiu, E. (281) 209
Branisteanu, D.D., see Costuleanu, M. (281) 89
Branisteanu, D.D., see Filipeanu, C.M. (281) 29
Brasseur, R., see Van Bambeke, F. (289) 321
Braun, M., Grosser, T. and Schrör, K.
Bioactivation of nitroglycerin in vascular smooth muscle cells is different from that in non-vascular tissue (276) 239
Braunger, H., see Entzeroth, M. (278) 239
Brent, P.J. and Pang, G.T.
σ Binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture (278) 151
Breuiller-Fouché, M., see Héluy, V. (285) 89
Breuiller-Fouché, M., see Zumbihl, R. (288) 9
Briejer, M.R., Akkermans, L.M.A., Lefebvre, R.A. and Schuurkes, J.A.J.
Novel 5-HT_2-like receptor mediates neurogenic relaxation of the guinea-pig proximal colon (279) 123
Brink, C., see Gorenne, I. (275) 207
Brinkmann, S., see Dimmeler, S. (287) 257
Brioni, J.D., see Decker, M.W. (280) 79
Brixius, K., see Kojda, G. (284) 315
Broad, L.M., see Murphy, T.V. (290) 145
Brocco, M., see Schreiber, R. (271) 537
Brochez, V., see Van de Voorde, J. (271) 17
Brochu, M., see Roy, B. (280) 1
Brodde, O.-E., see Van Waarde, A. (272) 159
Brodsky, M., see Chan, K. (287) 135
Bronner, C., see Emadi-Khiav, B. (272) 97
Brooks, D.P., see Aiyar, N. (283) 63
Brooks, N., see Khan, S. (282) 229
Brotchie, J.M., see East, S.J. (277) 117
Brotchie, J.M., see Hill, M.P. (281) R1
Brough, P.A., see Molloy, L. (289) 447
Brouillet, E., Roeda, D., Valette, H., Fuseau, C., Guyot, M.-C. and Crouzel, C.
In vivo metabolites of N^{ω}-nitro-L-arginine methyl ester: methanol and N^{ω}-nitro-L-arginine (293) 487
Broutman, G., see Homaidan, F.R. (271) 561
Brouwer, A., Ahlborg, U.G., Van den Berg, M., Birnbaum, L.S., Boersma, E.R., Bosveld, B., Denison, M.S., Gray, L.E., Hagmar, L., Holene, E., Huisman, M., Jacobson, S.W., Jacobson, J.L., Koopman-Esseboom, C., Koppe, J.G., Kulig, B.M., Morse, D.C., Muckle, G.,

Peterson, R.E. and Sauer, P.J.J.
Functional aspects of developmental toxicity of polyhalogenated aromatic hydrocarbons in experimental animals and human infants (293) 1
Brouwer, A., see Aarts, J.M.M.J.G. (293) 463
Brouwer, A., see Van Birgelen, A.P.J.M. (293) 77
Brown, C.R., see Peters, M.J. (289) 275
Brown, J.F., Tepperman, B.L., Hanson, P.J. and Whittle, B.J.R.
Lipopolysaccharide induces Ca^{2+}-independent nitric oxide synthase activity in rat gastric mucosal cells (292) 111
Bruggeman, C.A., see Garssen, J. (292) 223
Bruhwyler, J., see Liégeois, J.-F. (273) R1
Brune, K., see Pallapies, D. (271) 335
Bruning, H.W., see Van Ree, J.M. (279) 187
Bruns, C., see Hoyer, D. (289) 151
Bruns, C., see Schoeffter, P. (289) 163
Bruns, R.F., see Gitter, B.D. (289) 439
Brusa, R., Gamalero, S.R., Genazzani, E. and Eva, C.
In primary neuronal cultures muscarinic m1 and m3 receptor mRNA levels are regulated by agonists, partial agonists and antagonists (289) 9
Bryson, S.E., see Wintersgill, H.P. (288) 365
Brzozowski, T., see Konturek, S.J. (273) 57
Brzozowski, T., see Konturek, S.J. (278) 203
Bubser, M., see Kretschmer, B.D. (280) 37
Bucharles, C., Vaudry, H. and Leroux, P.
Pharmacological characterization of somatostatin receptors in rat cerebellar nuclei (271) 79
Bucher, B., see Hecker, M. (275) R1
Buchheit, K.-H., Hofmann, A. and Fozard, J.R.
Salbutamol-induced airway hyperreactivity in guinea pigs is not due to a loss of its bronchodilator effect (287) 85
Buciński, A., see Nasal, A. (274) 125
Buckett, W.R., see Heal, D.J. (277) 215
Buckley, T.L., Garssen, J., Kerkhoff, B., Nijkamp, F.P. and Van Loveren, H.
LCB 2183 inhibits tracheal hyperreactivity and pulmonary inflammation in mouse airways (282) 103
Buczko, W., see Malinowska, B. (293) 71
Budai, D., Wilcox, G.L. and Larson, A.A.
Effects of nitric oxide availability on responses of spinal wide dynamic range neurons to excitatory amino acids (278) 39
Buhot, M.-C., Patra, S.K. and Naïli, S.
Spatial memory deficits following stimulation of hippocampal 5-HT_{1B} receptors in the rat (285) 221
Buijs, J., Egbers, M.W.E.C. and Nijkamp, F.P.
Toxocara canis-induced airway eosinophilia and tracheal hyporeactivity in guinea pigs and mice (293) 207
Buisson, B., see Gopalakrishnan, M. (290) 237
Bulbena, O., see Vega, T. (276) 231
Bunn, S.J. and Saunders, H.I.
Staurosporine inhibits inositol phosphate formation in bovine adrenal medullary cells (290) 227
Bunzow, J.R., see Bouvier, C. (290) 11
Burford, N.T., Tobin, A.B. and Nahorski, S.R.
Coupling of muscarinic m1, m2 and m3 acetylcholine receptors, expressed in Chinese hamster ovary cells, to pertussis toxin-sensitive/insensitive guanine nucleotide-binding proteins (289) 343
Burgoyne, R.D., see Graham, M.E. (288) 115
Buritova, J., see Honoré, P. (272) 249
Burnette, E., see Xiong, Z. (290) 117
Burnstock, G., see Ralevic, V. (286) 193
Burnstock, G., see Simon, J. (291) 281
Busch, A.E., see Herzer, T. (291) 205
Bush, L.G., see Hanson, G.R. (278) 167
Busse, R., see Hecker, M. (275) R1
Butelman, E.R., Negus, S.S., Gatch, M.B., Chang, K.-J. and Woods, J.H.
BW373U86, a δ-opioid receptor agonist, reverses bradykinin-induced thermal allodynia in rhesus monkeys (277) 285
Butler, S.A., see Heal, D.J. (277) 215
Buwalda, B., see Korte, S.M. (272) 45
Buxton, S.T., see Dwoskin, L.P. (276) 195
Buyukuysal, R.L., Ulus, I.H., Aydin, S. and Kiran, B.K.
3,4-Diaminopyridine and choline increase in vivo acetylcholine release in rat striatum (281) 179
Byam-Smith, M., see Izumi, H. (278) 187

Caddick, S.J., Stanford, I.M. and Chad, J.E.
2-Hydroxy-saclofen causes a phaclofen-reversible reduction in population spike amplitude in the rat hippocampal slice (274) 41
Cadet, J.L., see Elmer, G.I. (283) 227
Cadieux, A., see Jacques, D. (278) R3
Cahill, P.A., Redmond, E.M., Foster, C. and Sitzmann, J.V.
Nitric oxide regulates angiotensin II receptors in vascular smooth muscle cells (288) 219
Cai, G., see Gurdal, H. (274) 117
Cai, H., Ibayashi, S., Yao, H., Sugimori, H., Sadoshima, S. and Fujishima, M.
The α_1-adrenoceptor antagonist, doxazosin, modulates the lower limit of autoregulation of cerebral blood flow during hemorrhagic hypotension in anesthetized hypertensive rats (286) 249
Cai, S.X., see Lutfy, K. (273) 187
Caine, S.B., see De Fonseca, F.R. (274) 47
Calatayud, S., see Barrachina, M.D. (280) 339
Calatayud, S., see Barrachina, M.D. (281) R3
Calcutt, N.A., Li, L., Yaksh, T.L. and Malmberg, A.B.
Different effects of two aldose reductase inhibitors on nociception and prostaglandin E (285) 189
Caldwell, M., O'Neill, M., Earley, B., Kelly, J.P. and Leonard, B.E.
N^G-Nitro-L-arginine methyl ester protects against lipid peroxidation in the gerbil following cerebral ischaemia (285) 203
Caldwell, M., see Maginn, M. (282) 259
Caldwell, M., see O'Neill, M. (283) 217
Caldwell, R.W., see Chiao, H. (283) 103
Calignano, A., see Mancuso, F. (271) 329
Calixto, J.B.
Multiple mechanisms of bradykinin-induced contraction in rat and guinea pig smooth muscles in vitro (281) 279
Calixto, J.B., see Schlemper, V. (282) 177
Callaghan, R. and Riordan, J.R.
Opiates inhibit ion conductances elicited by cell swelling and cAMP in cultured cells (291) 183
Callahan, R.J., see Kurata, C. (293) 109
Camarasa, J., see Camins, A. (272) 289
Cameron, N.E., see Dines, K.C. (281) 303
Camins, A., Diez-Fernandez, C., Pujadas, E., Camarasa, J. and Escubedo, E.
A new aspect of the antiproliferative action of peripheral-type benzodiazepine receptor ligands (272) 289
Camm, A.J., see Gill, J.S. (292) 337
Campbell, A.D., Womer, D.E. and Simon, J.R.
The 5-HT_3 receptor agonist 1-(*m*-chlorophenyl)-biguanide interacts with the dopamine transporter in rat brain synaptosomes (290) 157
Campbell, A.K., see Bazan, E. (290) 253
Campbell, I.C., see Tsvetnitsky, V. (282) 255
Campbell, J.E., see Gopalakrishnan, M. (290) 237
Campo, G.M., see Altavilla, D. (272) 223
Campo, G.M., see Altavilla, D. (286) 31
Camps, M., see Dickenson, J.M. (288) 393
Canale, P., see Altavilla, D. (272) 223
Canale, P., see Altavilla, D. (286) 31
Cancedda, E., see Giorgi, O. (290) 37

Cándido, A., see Torres, C. (280) 277
Candura, S.M., see Messori, E. (286) 205
Canet, A., see Barrachina, M.D. (281) R3
Canet, E., see Félétou, M. (274) 57
Canfield, P., Abdul-Ghaffar, T. and English, S.
Stimulation of bicarbonate secretion by α- and β-adrenoceptor agonists in rat caecum in vitro (273) 1
Cannas, S., see Cargnelli, G. (292) 103
Canney, M., see O'Neill, M. (283) 217
Cannizzaro, C., Cannizzaro, E., Gagliano, M., Mineo, A., Sabatino, M. and Cannizzaro, G.
Effects of desipramine and alprazolam on forced swimming behaviour of adult rats exposed to prenatal diazepam (273) 239
Cannizzaro, E., see Cannizzaro, C. (273) 239
Cannizzaro, G., see Cannizzaro, C. (273) 239
Cano, J., see Bougria, M. (291) 407
Cano, J., see Santiago, M. (280) 251
Cantoni, L., Carelli, M., Ghezzi, P., Delgado, R., Faggioni, R. and Rizzardini, M.
Mechanisms of interleukin-2-induced depression of hepatic cytochrome P-450 in mice (292) 257
Cantoni, O., see Palomba, L. (291) 167
Capasso, F., see Izzo, A.A. (271) 31
Caporali, M.G., see Popoli, P. (272) 119
Caputi, A.P., see Altavilla, D. (272) 223
Caputi, A.P., see Altavilla, D. (286) 31
Carboni, S., see Rossetti, Z.L. (283) 177
Cardinali, D.P., see Esquifino, A.I. (285) 143
Carelli, M., see Cantoni, L. (292) 257
Cargnelli, G., Bova, S., Cannas, S., Debetto, P. and Luciani, S.
Effect of amiloride on inotropic and toxic actions of ouabain in guinea-pig left atria (292) 103
Carignani, D., see Blandizzi, C. (278) 179
Carilla, E., see Kleven, M. (281) 219
Carli, M., Luschi, R. and Samanin, R.
(*S*)-WAY 100135, a 5-HT_{1A} receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine (283) 133
Carlson, R., see Glaser, K. (281) 107
Carlsson, A., see Kujacic, M. (273) 247
Carlsson, A., see Kujacic, M. (278) 9
Carpenter, D.O., see Oyama, Y. (293) 101
Carpentier, P., see Bodjarian, N. (289) 291
Carrasco, M.P., see Sanchez-Amate, M.C. (292) 215
Carrette, J., see Zumbihl, R. (288) 9
Carroll, F.I., see Weiser, S.D. (275) 1
Carruba, M.O., see Garosi, V.L. (276) 285
Carter, C., see Nankai, M. (286) 61
Carter, D., Champney, M., Hwang, B. and Eglen, R.M.
Characterization of a postjunctional 5-HT receptor mediating relaxation of guinea-pig isolated ileum (280) 243
Carter, L., see Wallace, J.L. (271) 525
Carter, M.F., see Von Lubitz, D.K.J.E. (275) 23
Carter, M.F., see Von Lubitz, D.K.J.E. (283) 185
Carter, S.R., see Acri, J.B. (281) R7
Casini, G., see Tricarico, D. (287) 17
Castañeda-Hernández, G., see Granados-Soto, V. (277) 281
Catalán, R.E., Martínez, A.M., Aragonés, M.D., Lombardía, M. and Garde, E.
PCA-4248, a PAF receptor antagonist, inhibits PAF-induced phosphoinositide turnover (290) 183
Catalioto, R.-M., Porchia, R., Renzetti, A.R., Criscuoli, M., Subissi, A. and Giachetti, A.
Angiotensin II-induced responses in vascular smooth muscle cells: inhibition by non-peptide receptor antagonists (280) 285
Cattabeni, F., see Palomba, L. (291) 167
Cattaneo, M.G., Fesce, R. and Vicentini, L.M.
Mitogenic effect of serotonin in human small cell lung carcinoma cells via both 5-HT_{1A} and 5-HT_{1D} receptors (291) 209
Cavazzuti, E., see Poggioli, R. (287) 207
Cazaubon, C., see Christophe, B. (281) 161
Cazes, M., Provost, D., Versigny, A. and Cloarec, A.
In vivo pharmacological characterization of UP 269-6, a novel non-peptide angiotensin II receptor antagonist (284) 157
Cebers, G. and Liljequist, S.
Modulation of AMPA/kainate receptors by cyclothiazide increases cytoplasmic free Ca^{2+} and $^{45}Ca^{2+}$ uptake in brain neurons (290) 105
Ceci, A., Fodritto, F. and Borsini, F.
Repeated treatment with fluoxetine decreases the number of spontaneously active cells per track in frontal cortex (271) 231
Celuch, S.M.
Possible participation of histamine H_3 receptors in the modulation of noradrenaline release from rat spinal cord slices (287) 127
Cervo, L. and Samanin, R.
Presynaptic 5-HT_{1A} receptors mediate the effect of ipsapirone on punished responding in rats (284) 249
Chabrier, P.-E., see Auguet, M. (287) 153
Chad, J.E., see Caddick, S.J. (274) 41
Chad, J.E., see Stanford, I.M. (277) 229
Chagraoui, A., see Protais, P. (271) 167
Chakir, M., D'Orléans-Juste, P. and Plante, G.E.
Neutral endopeptidase inhibition, a new approach in the exploration of diabetic vasculopathy in rats (285) 11
Champion, H.C., see Santiago, J.A. (272) 115
Champney, M., see Carter, D. (280) 243
Chan, B., see Yoshihara, S. (280) 113
Chan, K., Brodsky, M., Davis, T., Franklin, S., Inturrisi, C.E. and Yoburn, B.C.
The effect of the irreversible μ-opioid receptor antagonist clocinnamox on morphine potency, receptor binding and receptor mRNA (287) 135
Chan, S.L.F., see Tsoli, E. (284) 199
Chan, T.-Y., see Hui, S.-C.G. (283) 141
Chandrakasan, G., see Venkatesan, N. (292) 75
Chang, C.C., see Chiou, L.C. (292) 151
Chang, K.-J., see Bartolome, J.V. (284) 43
Chang, K.-J., see Butelman, E.R. (277) 285
Chang, K.-J., see Lee, P.H.K. (280) 211
Chang, K.C. and Hahn, K.H.
Is α-adrenoceptor blockade responsible for atropine flush? (284) 331
Chang, L.-C., see Wang, J.-P. (272) 87
Chang, L.-C., see Wang, J.-P. (273) 73
Chao, C.C.-K., see Song, E.-J. (292) 119
Chapal, J., see Damgé, C. (274) 133
Chapman, A.G., Dürmüller, N., Harrison, B.L., Baron, B.M., Parvez, N. and Meldrum, B.S.
Anticonvulsant activity of a novel NMDA/glycine site antagonist, MDL 104,653, against kindled and sound-induced seizures (274) 83
Chapman, A.G., see Millan, M.H. (279) 75
Chapman, A.G., see Smith, S.E. (273) 259
Chapman, R.W., see Bolser, D.C. (277) 159
Charles, I.G., see Moss, D.W. (289) 41
Chatelain, P., see Christophe, B. (281) 161
Chatelain, P., see Dol, F. (280) 135
Chatelain, P., see Hodeige, D. (279) 25
Chauvelot-Moachon, L., see Chen, Y.-L. (271) 319
Chauvet, M.M., see Orsière, T.G. (291) 237
Che, S., Johnson, M., Hanson, G.R. and Gibb, J.W.
Body temperature effect on methylenedioxymethamphetamine-induced acute decrease in tryptophan hydroxylase activity (293) 447
Cheetham, S.C., see Heal, D.J. (277) 215
Chen, C. and Lokhandwala, M.F.

Identification of α_1-adrenoceptor subtypes involved in the antinatriuretic response to intrarenal infusion of phenylephrine (287) 1
Chen, C., see Gopalakrishnan, S.M. (288) 139
Chen, C., see Kansra, V. (289) 391
Chen, I.-J., see Lo, Y.-C. (292) 321
Chen, K. and Zimmerman, B.G.
Angiotensin II-mediated renal vasoconstriction amenable to α_1-adrenoceptor blockade (284) 281
Chen, M.-J., see Chiu, T.-H. (285) 261
Chen, R., see Gatley, S.J. (281) 141
Chen, X.-H., Adams, J.U., Geller, E.B., DeRiel, J.K., Adler, M.W. and Liu-Chen, L.-Y.
An antisense oligodeoxynucleotide to μ-opioid receptors inhibits μ-opioid receptor agonist-induced analgesia in rats (275) 105
Chen, Y.-L., Le Vraux, V., Giroud, J.-P. and Chauvelot-Moachon, L.
Anti-tumor necrosis factor properties of non-peptide drugs in acute-phase responses (271) 319
Cheng, Z.-J., see Yu, S.-M. (280) 69
Chesnoy-Marchais, D., see Hauser, C.A.E. (289) 249
Cheung, D.W., see Alexander, P.B. (288) 79
Cheung, D.W., see Xiong, Z. (290) 117
Chhajlani, V., see Schiöth, H.B. (288) 311
Chhajlani, V., see Xia, Y. (288) 277
Chiang, C.D., see Song, E.-J. (292) 119
Chiao, H., Pelletier, S.W., Desai, H.K., Rebagay, W.R. and Caldwell, R.W.
Effect of diterpenoid alkaloids on cardiac sympathetic efferent and vagal afferent nerve activity (283) 103
Chiba, K., Kobayashi, K., Itoh, K., Itoh, S., Chiba, T., Ishizaki, T. and Kamataki, T.
N-oxygenation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by the rat liver flavin-containing monooxygenase expressed in yeast cells (293) 97
Chiba, T., see Chiba, K. (293) 97
Chiba, Y. and Misawa, M.
Alteration in Ca^{2+} availability involved in antigen-induced airway hyperresponsiveness in rats (278) 79
Chio, C.L., see Mierau, J. (290) 29
Chiou, L.C., Ling, J.Y. and Chang, C.C.
β-Eudesmol as an antidote for intoxication from organophosphorus anticholinesterase agents (292) 151
Chipperfield, A.R., see Harper, A.A. (286) 299
Chiu, T.-H., Chen, M.-J., Yang, Y.-R., Yang, J.-J. and Tang, F.-I.
Action of dexmedetomidine on rat locus coeruleus neurones: intracellular recording in vitro (285) 261
Chiu, T.H., see Wu, Y. (278) 125
Cho, C.H., see Woo, P.C.Y. (293) 217
Chow, L., De Gasparo, M. and Levens, N.
Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT_1 receptors (282) 77
Chowdhury, S.A., Kawashima, T., Konishi, T., Niwa, M. and Matsunami, K.
$GABA_B$ receptor antagonist CGP 35348 shortens transcallosal response latency of pyramidal tract neurons (285) 99
Christophe, B., Libon, R., Cazaubon, C., Nisato, D., Manning, A. and Chatelain, P.
Effects of irbesartan (SR 47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action (281) 161
Christopoulos, A. and Mitchelson, F.
[^{3}H]*N*-Methylscopolamine dissociation from muscarine receptors affected by low concentrations of allosteric modulators (290) 259
Chulia, T., Gonzalez, P., Del Rio, M. and Tejerina, T.
Comparative study of elgodipine and nisoldipine on the contractile responses of various isolated blood vessels (285) 115
Chung, K.F., see Haddad, E.-B. (293) 287
Chung, K.F., see Hayes, J.P. (292) 127
Chung, N.N., see Lee, P.H.K. (280) 211
Church, J., see Sawyer, D.C. (284) 309
Ciccarelli, E., Svoboda, M., De Neef, P., Di Paolo, E., Bollen, A., Dubeaux, C., Vilardaga, J.-P., Waelbroeck, M. and Robberecht, P.
Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells (288) 259
Ciccocioppo, R., see Polidori, C. (277) 223
Cirillo, R., see Polidori, C. (277) 223
Cirino, G., see Wallace, J.L. (280) 63
Civelli, O., see Bouvier, C. (290) 11
Clark, D., Exner, M., Furmidge, L.J., Svensson, K. and Sonesson, C.
Effects of the dopamine autoreceptor antagonist (−)-DS121 on the discriminative stimulus properties of *d*-amphetamine and cocaine (275) 67
Clark, K.L., Robertson, M.J. and Drew, G.M.
Renal pharmacology of GR138950, a novel non-peptide angiotensin AT_1 receptor antagonist (280) 195
Clementi, E., Martini, A., Stefani, G., Meldolesi, J. and Volpe, P.
LU52396, an inhibitor of the store-dependent (capacitative) Ca^{2+} influx (289) 23
Clementi, E., Vecchio, I., Corasaniti, M.T. and Nisticò, G.
Nitric oxide modulates agonist-evoked Ca^{2+} release and influx responses in PC12-64 cells (289) 113
Cliffe, I.A., see Forster, E.A. (281) 81
Cliffe, I.A., see Hume, S.P. (271) 515
Cliffe, I.A., see Pike, V.W. (283) R1
Cloarec, A., see Cazes, M. (284) 157
Coccini, T., see Messori, E. (286) 205
Coderre, T.J., see Fundytus, M.E. (286) 105
Cohen, M.L., see Killam, A.L. (273) 7
Colado, M.I. and Green, A.R.
The spin trap reagent α-phenyl-*N*-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones (280) 343
Coleman, R.A., see Allen, M.J. (274) 7
Coleman, R.A., see Beresford, I.J.M. (272) 241
Collado, M.C., see Martinez, E. (282) 169
Collins, K.A., see Tseng, L.F. (277) 251
Collins, K.A., see Tseng, L.F. (277) 71
Colombo, G., Agabio, R., Balaklievskaia, N., Diaz, G., Lobina, C., Reali, R. and Gessa, G.L.
Oral self-administration of γ-hydroxybutyric acid in the rat (285) 103
Colombo, G., Agabio, R., Lobina, C., Reali, R., Fadda, F. and Gessa, G.L.
Cross-tolerance to ethanol and γ-hydroxybutyric acid (273) 235
Colpaert, F., see Tellez, S. (277) 113
Colucci, R., see Blandizzi, C. (278) 179
Combadière, C., see Djerdjouri, B. (288) 193
Commandeur, J.N.M., see Remirez, D. (293) 301
Compton, D.M., see Woodward, J.J. (277) 7
Concha, G., see Vahter, M. (293) 455
Conlon, D., Johnston, A., O'Malley, K., Turner, P. and Kilfeather, S.
Effect of ageing and propranolol administration on myocardial β-adrenoceptor receptor function in mature rats (289) 283
Connelly, S.T., see Shepard, P.D. (285) 79
Connor, H.E., see Beattie, D.T. (276) 271
Connor, H.E., see Escott, K.J. (284) 69
Connor, H.E., see Walsh, D.M. (287) 79
Connor, J.R., Manning, P.T., Settle, S.L., Moore, W.M., Jerome, G.M., Webber, R.K., Tjoeng, F.S. and Currie, M.G.
Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase (273) 15
Consolandi, O., see Pizzi, M. (275) 311
Conte, B., see Parlani, M. (278) 117
Conte Camerino, D., see Tricarico, D. (287) 17
Contreras, E., see Norris, B. (280) 221

Contreras, G., see Norris, B. (280) 221
Cools, A.R., Miwa, Y. and Koshikawa, N.
Role of dopamine D_1 and D_2 receptors in the nucleus accumbens in jaw movements of rats: a critical role of the shell (286) 41
Cools, A.R., see Miwa, Y. (277) 63
Cools, A.R., see Saigusa, T. (274) 213
Cooper, J.C., see Storch, A. (290) 207
Cooper, M.E., see Haynes, J.M. (280) 91
Coppes, R.P., Smit, J., Benthem, L., Van der Leest, J. and Zaagsma, J.
Co-released adrenaline markedly facilitates noradrenaline overflow through prejunctional β_2-adrenoceptors during swimming exercise (274) 33
Corasaniti, M.T., see Clementi, E. (289) 113
Corbett, R., see Roehr, J. (278) 75
Corda, M.G., see Giorgi, O. (290) 37
Correia-de-Sá, P. and Ribeiro, J.A.
Tonic adenosine A_{2A} receptor activation modulates nicotinic autoreceptor function at the rat neuromuscular junction (271) 349
Corsico, N., see Maresca, P. (287) 303
Corsini, A., see Viganò, T. (291) 201
Corsini, G.U., see Barbier, P. (290) 125
Corsini, G.U., see Fornai, F. (283) 99
Costuleanu, M., Brailoiu, E., Filipeanu, C.M., Baltatu, O., Slatineanu, S., Saila, L., Nechifor, M. and Branisteanu, D.D.
Effects of liposome-entrapped platelet-activating factor in the isolated rat trachea (281) 89
Costuleanu, M., see Brailoiu, E. (281) 209
Cotman, C.W., see Korotzer, A.R. (288) 125
Cotter, M.A., see Dines, K.C. (281) 303
Cotterell, K.L., see Croucher, M.J. (286) 265
Court, L., see Alaoui, F. (276) 55
Cox, M.A., see Aarts, J.M.M.J.G. (293) 463
Coy, D.H., see Lach, E. (273) 313
Coy, D.H., see Ladenheim, E.E. (271) R7
Coy, D.H., see Santiago, J.A. (272) 115
Coy, D.H., see Varga, G. (286) 109
Crankshaw, D.
Effects of the isoprostane, 8-epi-prostaglandin $F_{2\alpha}$, on the contractility of the human myometrium in vitro (285) 151
Crankshaw, D., see Fernandes, B. (283) 73
Craven, R., Grahame-Smith, D. and Newberry, N.
WAY-100635 and GR127935: effects on 5-hydroxytryptamine-containing neurones (271) R1
Cremades, A., see Martinez-Garcia, F. (293) 271
Cressier, F., Criscione, L. and Hofbauer, K.G.
Mechanism of interaction between neuropeptide Y and angiotensin II in the rabbit femoral artery (272) 57
Criddle, D.N. and Soares de Moura, R.
Inhibitory effects of Rb^+ on the responses to levcromakalim and P1060 in the isolated human myometrium (272) 293
Criddle, D.N., Jazbik, W. and Soares de Moura, R.
Differential vasorelaxant effects of levcromakalim and P1060 in the isolated KCl- and RbCl-precontracted human saphenous vein: possible involvement of intracellular Ca^{2+} stores (286) 123
Criscione, L., see Cressier, F. (272) 57
Criscuoli, M., see Catalioto, R.-M. (280) 285
Criscuoli, M., see Renzetti, A.R. (290) 151
Crooks, P.A., see Dwoskin, L.P. (276) 195
Cross, L.J.M., Ennis, M., Krause, E., Dathe, M., Lorenz, D., Krause, G., Beyermann, M. and Bienert, M.
Influence of α-helicity, amphipathicity and D-amino acid incorporation on the peptide-induced mast cell activation (291) 291
Croucher, M.J., Cotterell, K.L. and Bradford, H.F.
Amygdaloid kindling by repeated focal *N*-methyl-D-aspartate administration: comparison with electrical kindling (286) 265
Crouzel, C., see Brouillet, E. (293) 487
Crucianelli, M., see Giardinà, D. (287) 13
Culman, J., see Höhle, S. (275) 277
Currie, M.G., see Connor, J.R. (273) 15
Curtis, C.A.M., see Jones, P.G. (288) 251
Curtis, C.A.M., see Page, K.M. (289) 429
Cuthbert, N., see Gorenne, I. (275) 207
Cuthbert, N.J., see Norman, P. (271) 73
Cutler, D.J., see Piggins, H.D. (271) 413
Czich, A., see Glatt, H. (293) 173
Czuczwar, S.J., Borowicz, K.K., Kleinrok, Z., Tutka, P., Żarnowski, T. and Turski, W.A.
Influence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice (281) 327
Czuczwar, S.J., see Borowicz, K.K. (281) 319

Dahlbäck, M., see Stevens, W.H.M. (293) 251
Dahlén, S.-E., see Raud, J. (282) 207
Dalgaard, L., see Videbæk, C. (281) 117
D'Alonzo, A.J., Grover, G.J., Darbenzio, R.B., Hess, T.A., Sleph, P.G., Dzwonczyk, S., Zhu, J.L. and Sewter, J.C.
In vitro effects of capsaicin: antiarrhythmic and antiischemic activity (272) 269
Daly, J.W., see Von Lubitz, D.K.J.E. (283) 185
Damas, J., see Liégeois, J.-F. (273) R1
Damas, J., see Souza Pinto, J.C. (274) 101
Damgé, C., Hillaire-Buys, D., Koenig, M., Gross, R., Hoeltzel, A., Chapal, J., Balboni, G., Borg, J. and Ribes, G.
Effect of *n*-hexacosanol on insulin secretion in the rat (274) 133
Danhof, M., see Van der Wenden, E.M. (290) 189
Danilov, A.F., Grigoriev, V.M., Prokhorenko, N.K. and Sherstobitov, O.E.
Alkylating derivative of hexadecamethonium protects muscle synaptic acetylcholinesterase against inhibition (277) 15
Danysz, W., see Wenk, G.L. (293) 267
Da Prada, M., see Napolitano, A. (273) 215
Darbenzio, R.B., see D'Alonzo, A.J. (272) 269
Darius, H., see Fisch, A. (289) 455
Darlington, C.L., see Jerram, A.H. (275) 291
Das, M., see Koley, J. (293) 483
Das, S., see Luo, D. (290) 247
Dasgupta, S., see Koley, J. (293) 483
Dasgupta, S., see Odagaki, Y. (291) 245
DaSilva, A.M.T., see Berger, I. (277) 195
DaSilva, A.M.T., see McManigle, J.E. (280) 257
Da Silva, R.C., see Fin, C. (271) 227
Dathe, M., see Cross, L.J.M. (291) 291
David-Dufilho, M., see Iouzalen, L. (289) 189
Davies, D.J., see Sugden, D. (287) 239
Davies, J.A., see Hu, R.Q. (287) 251
Davies, M.F., see Maguire, P.A. (280) 167
Davis, T., see Chan, K. (287) 135
Deacon, R.M.J. and Rawlins, J.N.P.
Effects of the competitive NMDA receptor antagonist CGP 37849 on performance of reference and working memory tasks by rats (280) 239
De Belleroche, J., see Bandopadhyay, R. (275) 53
Debetto, P., see Cargnelli, G. (292) 103
De Bie, J.J., see Hessel, E.M. (293) 401
De Bigontina, P., see Giamberardino, M.A. (278) 97
De Castiglione, R., see Miasiro, N. (278) 103
Decker, M.W., Anderson, D.J., Brioni, J.D., Donnelly-Roberts, D.L., Kang, C.H., O'Neill, A.B., Piattoni-Kaplan, M., Swanson, S. and Sullivan, J.P.
Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors (280) 79
De Costa, B.R., see Matsumoto, R.R. (280) 301
DeCosta, B.R., see Berzetei-Gurske, I.P. (277) 257
Decrinis, M., see Stark, G. (286) 71

De Fonseca, F.R., Rubio, P., Martín-Calderón, J.L., Caine, S.B., Koob, G.F. and Navarro, M.
The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference (274) 47
De Gasparo, M., see Chow, L. (282) 77
DeGennaro, F.C., see Bolser, D.C. (277) 159
De Giorgio, R., see Patacchini, R. (271) 111
De Giulio, A., see Gil, B. (285) 281
De Graaf-in 't Veld, T., see Garrelds, I.M. (275) 295
De Graan, P.N.E., see Verhage, M. (291) 387
De Groat, W.C., see Yoshiyama, M. (287) 73
De Groene, E.M., Seinen, W. and Horbach, G.J.M.J.
A NIH/3T3 cell line stably expressing human cytochrome P450-3A4 used in combination with a lacZ' shuttle vector to study mutagenicity (293) 47
De Haan, L.H.J., see Aarts, J.M.M.J.G. (293) 463
DeHaven-Hudkins, D.L., see Hudkins, R.L. (271) 235
Dei, S., see Voigt, W. (291) 255
De Juan, E., see Miquel, J. (292) 333
Dekker, I., see Westerveld, G.-J. (291) 27
De Klerk, A., see Garssen, J. (292) 223
De Klippel, N., see Smolders, I. (284) 83
De Kloet, E.R., see Korte, S.M. (272) 45
De Koster, B.M., see Elferink, J.G.R. (288) 335
Delaey, C. and Van de Voorde, J.
Prostanoid-induced contractions are blocked by sulfonylureas (280) 179
Delaflotte, S., see Auguet, M. (287) 153
DeLander, G.E., see Keil, II, G.J. (271) 37
Delarge, J., see Liégeois, J.-F. (273) R1
Delaunois, A., Gustin, P., Garbarg, M. and Ansay, M.
Modulation of acetylcholine, capsaicin and substance P effects by histamine H_3 receptors in isolated perfused rabbit lungs (277) 243
Delgado, R., see Cantoni, L. (292) 257
Dell'Amico, M.H., see Orsière, T.G. (291) 237
Delpech, N., Soustre, H. and Potreau, D.
Antagonism of β-adrenergic stimulation of L-type Ca^{2+} current by endothelin in guinea-pig atrial cells (285) 217
Del Prado, M., see Bolser, D.C. (276) R1
Del Río, J., see Aguirre, N. (281) 101
Del Rio, M., see Chulia, T. (285) 115
Del Tacca, M., see Blandizzi, C. (278) 179
De Man, J.G., Boeckxstaens, G.E., De Winter, B.Y., Moreels, T.G., Herman, A.G. and Pelckmans, P.A.
Inhibition of non-adrenergic non-cholinergic relaxations by nitric oxide donors (285) 269
De Meyer, E., Van Hove, C.E., Feng, X.J., Rampart, M. and Herman, A.G.
Thrombin triggers the de novo expression of an inducible NO synthase in porcine aortic valve endothelial cells (291) 67
De Montigny, C., see Mongeau, R. (271) 121
Den Besten, C., see Rietjens, I.M.C.M. (293) 293
De Neef, P., see Ciccarelli, E. (288) 259
De Neef, P., see Gourlet, P. (287) 7
Den Hertog, A., see Van der Zee, L. (289) 463
Denison, M.S., see Aarts, J.M.M.J.G. (293) 463
Denison, M.S., see Brouwer, A. (293) 1
Dennis, T., Beauchemin, V. and Lavoie, N.
Antidepressants reverse the olfactory bulbectomy-induced decreases in splenic peripheral-type benzodiazepine receptors in rats (272) 279
De Nucci, G., see Grassi-Kassisse, D.M. (282) 57
De Nucci, G., see Medeiros, M.V. (285) 109
De Nucci, G., see Moreno, Jr., H. (287) 93
Deo, N., see Dwoskin, L.P. (276) 195
De Oliveira, R.B., see Martins, S.L.R. (284) 265
De Pascual, R., see Vega, T. (276) 231
Depoortere, I., Macielag, M.J., Galdes, A. and Peeters, T.L.
Antagonistic properties of [Phe^3,Leu^{13}]porcine motilin (286) 241
De Potter, W., see Velez Pardo, C. (288) 209
De Reuck, J., see Sprumont, P. (274) 95
DeRiel, J.K., see Chen, X.-H. (275) 105
De Rosa, S., see Gil, B. (285) 281
Desai, H.K., see Chiao, H. (283) 103
Deschepper, C.F., Houweling, A.D. and Picard, S.
The membranes of cultured rat brain astrocytes contain endothelin-converting enzyme activity (275) 61
Deshpande, S.B. and Warnick, J.E.
Analogs of thyrotropin-releasing hormone in potentiating the spinal monosynaptic reflex in vitro (271) 439
De Souza, E.B., see Levant, B. (278) 243
Deth, R.C., see Aburto, T. (277) 35
Deth, R.C., see Jinsi, A. (277) 29
Deutsch, S.I., see Von Lubitz, D.K.J.E. (275) 23
Devillers, J.-P. and Simonnet, G.
Modulation of neuropeptide FF release from rat spinal cord slices by glutamate. Involvement of NMDA receptors (271) 185
De Vries, R., see Van Leeuwen, R. (287) 211
De Vries, T.J., see Schmidt, E.D. (285) 317
De Vries, T.J., see Schoffelmeer, A.N.M. (286) 311
De Vries, T.J., see Tjon, G.H.K. (283) 169
Devynck, M.-A., see Iouzalen, L. (289) 189
De Winter, B.Y., see De Man, J.G. (285) 269
De Witt, B.J., see Kaye, A.D. (287) 163
Dhawan, B.N., see Kumar, A. (279) 1
Dhouib, M., Gendrault, J.-L. and Lugnier, A.-A.
Kinetics of nitric oxide synthase induction by *Propionibacterium avidum* and lipopolysaccharide (293) 439
Diaz, G., see Colombo, G. (285) 103
Díaz de Rojas, F., see Barrachina, M.D. (281) R3
Di Bugno, C., see Barbier, P. (290) 125
Di Carlo, G., see Izzo, A.A. (271) 31
Dickenson, J.M., Camps, M., Gierschik, P. and Hill, S.J.
Activation of phospholipase C by G-protein $\beta\gamma$ subunits in DDT_1MF-2 cells (288) 393
Dickinson, C.J., see Balmforth, A.J. (291) 135
Didriksen, M.
Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match to position paradigm (281) 241
Diekmann, F., see Hocher, B. (293) 361
Diener, M., see Strabel, D. (274) 181
Diez-Fernandez, C., see Camins, A. (272) 289
Dijkstra, D., see Acri, J.B. (281) R7
Dimmeler, S., Brinkmann, S. and Neugebauer, E.
Endotoxin-induced changes of endothelial cell viability and permeability: protective effect of a 21-aminosteroid (287) 257
Dines, K.C., Cotter, M.A. and Cameron, N.E.
Nerve function in galactosaemic rats: effects of evening primrose oil and doxazosin (281) 303
Ding, Y.-S., see Gatley, S.J. (281) 141
Diop, L., Rivière, P.J.M., Pascaud, X. and Junien, J.-L.
Peripheral κ-opioid receptors mediate the antinociceptive effect of fetodozine on the duodenal pain reflex in rat (271) 65
Diop, L., see Langlois, A. (271) 245
Di Paolo, E., see Ciccarelli, E. (288) 259
Dirksen, R.T., see Arreola, J. (271) 309
Di Rosa, M., see Sautebin, L. (286) 219
DiSanto, M.E. and Heaslip, R.J.
Rolipram inhibition of phosphodiesterase-4 activation (290) 169
Djerdjouri, B., Combadière, C., Pedruzzi, E., Hakim, J. and Périanin, A.
Contrasting effects of calyculin A and okadaic acid on the respiratory burst of human neutrophils (288) 193
Dmitrieva, R.I., see Bagrov, A.Y. (274) 151

Doak, G.J. and Sawynok, J.
Complex role of peripheral adenosine in the genesis of the response to subcutaneous formalin in the rat (281) 311
Doble, A., see Petitet, F. (291) 143
Docherty, J.R. and Brady, G.
Prejunctional actions of K^+ channel blockers in rat vas deferens (287) 287
Dodd, R.H., see Zezula, J. (281) 93
Doehmer, J., see Schmalix, W.A. (293) 123
Dol, F., Schaeffer, P., Lamarche, I., Mares, A.-M., Chatelain, P. and Herbert, J.-M.
Effect of SR 33805 on arterial smooth muscle cell proliferation and neointima formation following vascular injury (280) 135
Domenici, M.R., Sagratella, S., Ongini, E., Longo, R. and Scotti de Carolis, A.
Felbamate displays in vitro antiepileptic effects as a broad spectrum excitatory amino acid receptor antagonist (271) 259
Donato di Paola, E., see Micheletti, R. (286) 147
Donigi-Gale, D., see Seeds, E.A.-M. (293) 369
Donnelly-Roberts, D., see Gopalakrishnan, M. (290) 237
Donnelly-Roberts, D.L., see Decker, M.W. (280) 79
Donnerer, J., see Amann, R. (279) 227
Dontenwill, M., see Greney, H. (271) 533
Doods, H.N., see Entzeroth, M. (278) 239
Doods, H.N., see Rudolf, K. (271) R11
Doolette, D.J., see Kerr, D.I.B. (287) 185
Dooley, D.J., see Wessler, I. (278) 83
D'Orléans-Juste, P., see Chakir, M. (285) 11
D'Orléans-Juste, P., see Maas, J. (276) 113
Dormans, J.A.M.A., see Garssen, J. (292) 223
Dourish, C.T., see Bickerdike, M.J. (271) 403
Dourish, C.T., see Routledge, C. (276) 281
Dover, G.M., see Forster, E.A. (281) 81
Downie, J.W., see Espey, M.J. (287) 173
Downing-Park, J., see Weiser, S.D. (275) 1
Drapeau, G., see Audet, R. (271) 551
Drew, G.M., see Clark, K.L. (280) 195
Drewe, J.A., see Yang, W. (291) 319
Drozdowicz, D., see Konturek, S.J. (273) 57
Du, X.Y., Schoemaker, R.G., Bos, E. and Saxena, P.R.
Characterization of the positive and negative inotropic effects of acetylcholine in the human myocardium (284) 119
Du, X.Y., see Van Gelderen, E.M. (284) 51
Duan, N., see Mosaddeghi, M. (289) 411
Duarte, J., Pérez-Vizcaíno, F., Torres, A.I., Zarzuelo, A., Jiménez, J. and Tamargo, J.
Vasodilator effects of visnagin in isolated rat vascular smooth muscle (286) 115
Dube, S.N., see Koley, J. (293) 483
Dubeaux, C., see Ciccarelli, E. (288) 259
Dubédat, P., see Benazzouz, A. (284) 299
Duckles, S.P., see Glenn, T.C. (276) 191
Duckles, S.P., see Krause, D.N. (276) 207
Dufour, M.-N., see Zumbihl, R. (288) 9
Duittoz, A.H., see Martin, R.J. (276) 9
Dulout, F., see Vahter, M. (293) 455
Dumont, M. and Lemaire, S.
Dynorphin potentiation of [^{3}H]CGP-39653 binding to rat brain membranes (271) 241
Dumont, P., see Lach, E. (273) 313
Dumont, Y., see Jacques, D. (278) R3
Dürmüller, N., see Chapman, A.G. (274) 83
Düsing, R., see Flesch, M. (289) 399
Dusting, G.J., see Ralevic, V. (284) 231
Dutar, P., see Jouvenceau, A. (281) 131
Dvorkin, B., see Makman, M.H. (273) R5
Dwoskin, L.P., Teng, L.H., Buxton, S.T., Ravard, A., Deo, N. and Crooks, P.A.
Minor alkaloids of tobacco release [^{3}H]dopamine from superfused rat striatal slices (276) 195
Dybvik, T., Osnes, J.-B. and Skomedal, T.
Location of α_1-adrenoceptors relative to β-adrenoceptors in rat myocardium (281) 21
Dyer, D.C., see Zhang, L. (280) 335
Dzoljic, M.R., see Van Leeuwen, R. (287) 211
Dzwonczyk, S., see D'Alonzo, A.J. (272) 269
Dzwonczyk, S., see Grover, G.J. (277) 271

Earley, B., see Caldwell, M. (285) 203
Earley, B., see O'Neill, M. (283) 217
East, S.J., Hill, M.P. and Brotchie, J.M.
Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes (277) 117
Ebenezer, I.S.
Intraperitoneal administration of baclofen increases consumption of both solid and liquid diets in rats (273) 183
Eberlein, W., see Entzeroth, M. (278) 239
Eberlein, W., see Rudolf, K. (271) R11
Ebert, B., see Nielsen, M. (289) 109
Ebinger, G., see Smolders, I. (284) 83
Ebinger, G., see Velez Pardo, C. (288) 209
Eblen, F., see Löschmann, P.-A. (284) 129
Eckly, A.E., Stoclet, J.-C. and Lugnier, C.
Isoprenaline induces endothelium-independent relaxation and accumulation of cyclic nucleotides in the rat aorta (271) 237
Edvinsson, L., see Erlinge, D. (289) 135
Edwards, R.M., see Aiyar, N. (283) 63
Egbers, M.W.E.C., see Buijs, J. (293) 207
Eglen, R.M., see Carter, D. (280) 243
Eglen, R.M., see Watson, N. (278) 195
Eglen, R.M., see Watson, N. (285) 135
Eguchi, H., see Hagihara, K. (271) 159
Eilam, Y., see Novakova, M. (286) 19
Eisenbrand, G., see Schmalix, W.A. (293) 123
El-Fakahany, E.E., see Hejnová, L. (291) 427
El-Fakahany, E.E., see Wang, S.Z. (291) R1
Ela, C., see Novakova, M. (286) 19
Elferink, J.G.R. and De Koster, B.M.
Atrial natriuretic factor stimulates migration by human neutrophils (288) 335
Elhawary, A.M., Poon, J.S. and Pang, C.C.Y.
Receptor subtypes mediating renal actions of calcitonin gene-related peptide (286) 255
Elías, M.M., see Monasterolo, L.A. (276) 201
Eliasson, E., see Schmalix, W.A. (293) 123
Elliott, S.N., see Wallace, J.L. (280) 63
Elmer, G.I., Evans, J.L., Ladenheim, B., Epstein, C.J. and Cadet, J.L.
Transgenic superoxide dismutase mice differ in opioid-induced analgesia (283) 227
Elsinga, P.H., see Van Waarde, A. (272) 159
Elzinga, C.R.S., see Hoiting, B.H. (290) R5
Emadi-Khiav, B., Mousli, M., Bronner, C. and Landry, Y.
Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli (272) 97
Emaduddin, M., Liu, G.J. and Takeuchi, H.
Effects of dopamine on snail neurones (283) 113
Emoto, M., see Inoue, Y. (284) 77
Endo, K., see Abiru, T. (281) 9
Endoh, M., see Okuyama, N. (285) 61
Enero, M.A., see Taira, C.A. (271) 9
Engel, J.A., see Johnson, D.H. (276) 155
Engel, W., see Entzeroth, M. (278) 239

Engel, W., see Rudolf, K. (271) R11
Engels, F., see Folkerts, G. (285) R1
England, S. and McFadzean, I.
Inhibition of voltage-dependent Ca^{2+}-current by α-adrenoceptor agonists in smooth muscle cells (288) 355
English, S., see Canfield, P. (273) 1
Ennis, M., see Cross, L.J.M. (291) 291
Ensinger, H.A., see Mierau, J. (290) 29
Entzeroth, M., Braunger, H., Eberlein, W., Engel, W., Rudolf, K., Wienen, W., Wieland, H.A., Willim, K.-D. and Doods, H.N.
Labeling of neuropeptide Y receptors in SK-N-MC cells using the novel, nonpeptide Y_1 receptor-selective antagonist [^{3}H]BIBP3226 (278) 239
Entzeroth, M., see Rudolf, K. (271) R11
Epstein, C.J., see Elmer, G.I. (283) 227
Erdő, S.L., see Molnár, P. (273) 303
Eriksson, P., see Johansson, U. (293) 159
Erlinge, D., You, J., Wahlestedt, C. and Edvinsson, L.
Characterisation of an ATP receptor mediating mitogenesis in vascular smooth muscle cells (289) 135
Esbenshade, T.A., Wang, X., Williams, N.G. and Minneman, K.P.
Inducible expression of α_{1B}-adrenoceptors in DDT_1 MF-2 cells: comparison of receptor density and response (289) 305
Eschalier, A., see Bétoin, F. (279) 241
Eschenfelder, C., see Benrath, J. (293) 87
Escott, K.J., Beattie, D.T., Connor, H.E. and Brain, S.D.
The modulation of the increase in rat facial skin blood flow observed after trigeminal ganglion stimulation (284) 69
Escribá, P.V., see Alemany, R. (280) 205
Escubedo, E., see Camins, A. (272) 289
Eshhar, N., Striem, S., Kohen, R., Tirosh, O. and Biegon, A.
Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist (283) 19
Espey, M.J. and Downie, J.W.
Serotonergic modulation of cat bladder function before and after spinal transection (287) 173
Esplugues, J.V., see Barrachina, M.D. (280) 339
Esplugues, J.V., see Barrachina, M.D. (281) R3
Esquifino, A.I., Arce, A., Stern, J.E. and Cardinali, D.P.
Effect of stress and cyclosporine on ornithine decarboxylase activity in rat submaxillary lymph nodes (285) 143
Esser, C., see Kremer, J. (293) 413
Estevez, A.G., Stutzmann, J.-M. and Barbeito, L.
Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures (280) 47
Eto, T., see Kato, J. (289) 383
Eto, T., see Niina, H. (286) 95
Eva, C., see Brusa, R. (289) 9
Evangelista, S., see Perretti, F. (273) 129
Evans, A.M., see Robertson, S.J. (271) 273
Evans, D.Y., see Heaslip, R.J. (286) 281
Evans, J.L., see Elmer, G.I. (283) 227
Evans, S.M., see László, F. (283) 47
Evans, S.M., see Laszlo, F. (272) 169
Exner, M., see Clark, D. (275) 67

Fabel, H., see Flüge, T. (271) 395
Fadayel, G.M., see Schmidt, C.J. (273) 273
Fadda, F., see Colombo, G. (273) 235
Fage, D., see Nankai, M. (286) 61
Faggioni, R., see Cantoni, L. (292) 257
Falany, C.N., see Glatt, H. (293) 173
Falany, J.L., see Glatt, H. (293) 173
Falcone, J., see Grider, J. (287) 101
Fanous, K., see Garay, R.P. (274) 175
Fardin, V., see Bétoin, F. (279) 241
Faro, R., see Grassi-Kassisse, D.M. (282) 57
Farrell, C.B., see O'Malley, K.E. (275) 83
Fase, K.M., see Van Birgelen, A.P.J.M. (293) 77
Fauchère, J.-L., see Félétou, M. (274) 57
Fedan, J.S. and Grant, L.J.R.
Potentiating and inhibitory effects of periodate-oxidized ATP analogs on contractions of vas deferens to ATP (281) 213
Fedorova, O.V., see Bagrov, A.Y. (274) 151
Feeley Kearney, J.A. and Albin, R.L.
Adenosine A_2 receptor-mediated modulation of contralateral rotation induced by metabotropic glutamate receptor activation (287) 115
Feigenspan, A. and Bormann, J.
Differential pharmacology of $GABA_A$ and $GABA_C$ receptors on rat retinal bipolar cells (288) 97
Fekete, M.I.K., see Kiem, D.T. (272) 145
Feldmann, K.F., see Wamil, A.W. (271) 301
Félétou, M., Martin, C.A.E., Molimard, M., Naline, E., Germain, M., Thurieau, C., Fauchère, J.-L., Canet, E. and Advenier, C.
In vitro effects of HOE 140 in human bronchial and vascular tissue (274) 57
Feltkamp, H., see Flesch, M. (289) 399
Feng, C.J., see Kaye, A.D. (276) 21
Feng, X.J., see De Meyer, E. (291) 67
Feng, Y., see Narita, M. (271) 543
Feng, Y., see Narita, M. (271) 547
Feng, Y., see Tokuyama, S. (279) 93
Feng, Y., see Tokuyama, S. (284) 101
Férézou, J., see Hajri, T. (286) 131
Feriotto, G., Mischiati, C., Bianchi, N., Passadore, M. and Gambari, R.
Binding of distamycin and chromomycin to human immunodeficiency type 1 virus DNA: a non-radioactive automated footprinting study (290) 85
Fernandes, B. and Crankshaw, D.
Functional characterization of the prostanoid DP receptor in human myometrium (283) 73
Fernandez-Gallardo, S., see Salinas, P. (293) 65
Fernández-Guasti, A. and Picazo, O.
Flumazenil blocks the anxiolytic action of allopregnanolone (281) 113
Fernandez-Sanpablo, R., see Salinas, P. (293) 65
Fernando, S.R., see Pertwee, R.G. (272) 73
Feron, V.J., see Gangolli, S.D. (292) 1
Ferrándiz, M.L., see Miquel, J. (292) 333
Ferraro, L., see Tanganelli, S. (273) 63
Ferré, F., see Héluy, V. (285) 89
Ferré, F., see Zumbihl, R. (288) 9
Ferré, S., see Giménez-Llort, L. (275) 171
Ferretti, C., Blengio, M., Gamalero, S.R. and Ghi, P.
Biochemical and behaviour changes induced by acute stress in a chronic variate stress model of depression: the effect of amitriptyline (280) 19
Ferry, D.R., see Malkhandi, J. (288) 105
Fesce, R., see Cattaneo, M.G. (291) 209
Fickel, J., see Winkler, A. (291) 51
Field, M.J., see Singh, L. (286) 185
Filipeanu, C.M., Brailoiu, E., Huhurez, G., Slatineanu, S., Baltatu, O. and Branisteanu, D.D.
Multiple effects of tyrosine kinase inhibitors on vascular smooth muscle contraction (281) 29
Filipeanu, C.M., see Brailoiu, E. (281) 209
Filipeanu, C.M., see Costuleanu, M. (281) 89
Fin, C., Schmitz, P.K., Da Silva, R.C., Bernabeu, R., Medina, J.H. and Izquierdo, I.
Intrahippocampal, but not intra-amygdala, infusion of an inhibitor of heme oxygenase causes retrograde amnesia in the rat (271) 227
Fior, D.R., see Yang, S.-N. (271) 201
Fisch, A., Michael-Hepp, J., Meyer, J. and Darius, H.
Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP (289) 455

Fischer, H., Prast, H. and Philippu, A.
Adenosine release in the ventral striatum of the rat is modulated by endogenous nitric oxide (275) R5
Fischman, A.J., see Kurata, C. (293) 109
Fiscus, R.R., see Zhang, L. (280) 335
Fisher, S.K.
Homologous and heterologous regulation of receptor-stimulated phosphoinositide hydrolysis (288) 231
Flaks, B., see Badesha, J.S. (293) 429
Flatt, P.R., see Irizar, A. (293) 385
Flesch, M., Ko, Y., Seul, C., Düsing, R., Feltkamp, H., Vetter, H. and Sachinidis, A.
Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells (289) 399
Fletcher, A., see Bickerdike, M.J. (271) 403
Fletcher, A., see Forster, E.A. (281) 81
Fletcher, A., see Hume, S.P. (271) 515
Fletcher, A., see Pike, V.W. (283) R1
Flodström, S., see Hemming, H. (292) 241
Flood, J.F., Scherrer, J.F. and Morley, J.E.
Localized injections of various compounds effecting neurotransmitter activity in the mammillary complex enhance (T-maze) avoidance retention (275) 223
Flor, P.J., see Knöpfel, T. (288) 389
Flores-Hernández, J., see Pineda, J.C. (281) 271
Flores-Murrieta, F.J., see Granados-Soto, V. (277) 281
Flower, R.J., see Ahluwalia, A. (283) 193
Flower, R.J., see Harris, J.G. (279) 149
Flower, R.J., see Harris, J.G. (283) 9
Flüge, T., Hoymann, H.-G., Hohlfeld, J., Heinrich, U., Fabel, H., Wagner, T.O.F. and Forssmann, W.-G.
Type A natriuretic peptides exhibit different bronchoprotective effects in rats (271) 395
Fodritto, F., see Ceci, A. (271) 231
Foged, C., see Videbæk, C. (281) 117
Foglar, R., Shibata, K., Horie, K., Hirasawa, A. and Tsujimoto, G.
Use of recombinant α_1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy (288) 201
Foglar, R., see Obika, K. (291) 327
Folco, G., see Viganò, T. (291) 201
Foley, T.D. and Linnoila, M.
Nanomolar concentrations of ouabain block ethanol-inducible Na^+,K^+-ATPase activity in brain (292) 287
Folkerts, G., Van der Linde, H., Van de Loo, P.G.F., Engels, F. and Nijkamp, F.P.
Leukotrienes mediate tracheal hyperresponsiveness after nitric oxide synthesis inhibition (285) R1
Fonia, O., Weizman, R., Zisman, E., Ashkenazi, R. and Gavish, M.
Down-regulation of hepatic peripheral-type benzodiazepine receptors caused by acute lead intoxication (293) 335
Fornai, F., Bassi, L., Torracca, M.T., Scalori, V. and Corsini, G.U.
Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice (283) 99
Fornai, F., see Barbier, P. (290) 125
Forssmann, W.-G., see Bäsler, I. (291) 335
Forssmann, W.-G., see Flüge, T. (271) 395
Forster, C.
Inhibition of vascular contractions to α-adrenoceptor agonists by polymyxin B: impact of heart failure state (283) 241
Forster, E.A., Cliffe, I.A., Bill, D.J., Dover, G.M., Jones, D., Reilly, Y. and Fletcher, A.
A pharmacological profile of the selective silent 5-HT_{1A} receptor antagonist, WAY-100635 (281) 81
Foss, J.F., see Yuan, C.-S. (276) 107
Foster, A.C., see Grimwood, S. (290) 221
Foster, C., see Ahn, H.-S. (289) 49
Foster, C., see Cahill, P.A. (288) 219
Foster, M., see Ahn, H.-S. (289) 49
Foucaud, B., Gambs, S., Schmid, N., Behr, J.-P. and Goeldner, M.
A photoaffinity probe for the polyamine site regulating the NMDA receptor (289) 471
Fournié-Zaluski, M.-C., see Noble, F. (273) 145
Fournié-Zaluski, M.-C., see Valverde, O. (286) 79
Fournier, A., see Bernier, S.G. (271) 55
Fournier, A., see Bernier, S.G. (291) 191
Fournier, T., see Héluy, V. (285) 89
Fowler, J.S., see Gatley, S.J. (281) 141
Fozard, J.R., see Buchheit, K.-H. (287) 85
Frąckowiak, T., see Nasal, A. (274) 125
Franchini, A., see Ottaviani, E. (276) 35
Franck, H., Puschmann, A., Schusdziarra, V. and Allescher, H.-D.
Functional evidence for a glibenclamide-sensitive K^+ channel in rat ileal smooth muscle (271) 379
Franco-Cereceda, A., Barr, G., Öwall, A., Liska, J. and Lundberg, J.M.
Is endothelin-1 release at reperfusion of the ischaemic human heart due to cold-induced displacement of endothelin from binding sites? (279) 105
Franklin, S., see Chan, K. (287) 135
Franková, D., see Zídek, Z. (286) 307
Fredrickson, T.A., see Aiyar, N. (283) 63
Fredriksson, A., see Johansson, U. (293) 159
Fremeau, R.T., see Berkowitz, D.E. (289) 223
Frey, K., see Kilbourn, M. (278) 249
Fride, E., see Barg, J. (287) 145
Friedman, E., see Tilakaratne, N. (290) 263
Frielingsdorf, J., see Sommermeyer, H. (276) 267
Frosini, M., see Palmi, M. (281) 97
Fu, L., see Kaneko, T. (292) 251
Fuchs, K., Zezula, J., Slany, A. and Sieghart, W.
Endogenous [^{3}H]flunitrazepam binding in human embryonic kidney cell line 293 (289) 87
Fuchs, K., see Slany, A. (291) 99
Fujii, E., Irie, K., Uchida, Y., Ohba, K. and Muraki, T.
Role of eicosanoids but not nitric oxide in the platelet-activating factor-induced increase in vascular permeability in mouse skin (273) 267
Fujii, E., see Irie, K. (275) 45
Fujii, E., see Uchida, Y. (291) 33
Fujii, K., see Az-ma, T. (289) 33
Fujimoto, M., see Hara, M. (289) 267
Fujimoto, M., see Itazaki, K. (291) 417
Fujimoto, S. and Itoh, T.
Denopamine as an α_{1H}-adrenoceptor antagonist in isolated blood vessels (280) 143
Fujisawa, Y., see He, H. (273) 209
Fujishima, K., see Nagura, J. (274) 201
Fujishima, M., see Cai, H. (286) 249
Fujishita, T., see Hara, M. (289) 267
Fujita, K., Matsumura, Y., Miyazaki, Y., Takaoka, M. and Morimoto, S.
Role of endothelin-1 in hypertension induced by long-term inhibition of nitric oxide synthase (280) 311
Fujita, M., see Hotta, Y. (282) 121
Fujitsuka, T., see Kinoshita, K. (274) 65
Fujiwara, M., see Shinozuka, K. (292) 115
Fujiwara, T., see Araki, T. (278) 91
Fukami, T., see Ihara, M. (274) 1
Fukao, M., see Hattori, Y. (279) 51
Fukuda, N., see Mizuno, M. (285) 181
Fukuda, T., see Irifune, M. (272) 79
Fukui, S., see Sasaki, H. (282) 71

Fukumura, K., see Mineo, H. (280) 149
Fukushima, T., Okinaga, S., Sekizawa, K., Ohrui, T., Yamaya, M. and Sasaki, H.
The role of carbon monoxide in lucigenin-dependent chemiluminescence of rat alveolar macrophages (289) 103
Fukutomi, H., see Akuzawa, S. (281) 37
Fulcrand, P., see Lallement, J.-C. (290) 61
Fumagalli, P., see Galvani, P. (293) 377
Fumagalli, R., see Viganò, T. (291) 201
Fumero, B., see Mas, M. (280) 331
Funada, M., see Suzuki, T. (280) 327
Fundytus, M.E., Schiller, P.W., Shapiro, M., Weltrowska, G. and Coderre, T.J.
Attenuation of morphine tolerance and dependence with the highly selective δ-opioid receptor antagonist TIPP[ψ] (286) 105
Furmidge, L.J., see Clark, D. (275) 67
Furuhama, K., see Tabuchi, Y. (272) 195
Furuhama, K., see Tabuchi, Y. (273) 281
Furuhashi, K., see Ikeda, U. (288) 379
Furukawa, H., see Noda, Y. (286) 291
Furukawa, K.-I., see Takahashi, Y. (288) 285
Furukawa, T., see Habuchi, Y. (292) 143
Furukawa, T., see Katsuragi, T. (282) 213
Furusawa, M., see Tabuchi, Y. (272) 195
Furuse, M., see Mabayo, R.T. (273) 161
Fuseau, C., see Brouillet, E. (293) 487
Fuxe, K., see Odagaki, Y. (288) 385
Fuxe, K., see Odagaki, Y. (291) 245
Fuxe, K., see Tanganelli, S. (273) 63
Fuxe, K., see Yang, S.-N. (271) 201

Gaffen, Z., Bland-Ward, P.A., Pitcher, A., Wallace, P. and Moore, P.K.
Augmented antinociception following 7-nitro indazole and flurbiprofen in the conscious mouse (271) 445
Gagliano, M., see Cannizzaro, C. (273) 239
Gailis, L.
Cleland's reagents block lethal and hypnotic effects of pentobarbital (292) 39
Galarraga, E., see Pineda, J.C. (281) 271
Galas, M.-C. and Harden, T.K.
Receptor-induced heterologous desensitization of receptor-regulated phospholipase C (291) 175
Galbete, J.L., see Aguirre, N. (281) 101
Galdes, A., see Depoortere, I. (286) 241
Galitzky, J., see Bousquet-Mélou, A. (289) 235
Gallagher, T., see Molloy, L. (289) 447
Galle, J., Bengen, J., Schollmeyer, P. and Wanner, C.
Erratum to 'Oxidized lipoprotein(a) inhibits endothelium-dependent dilation: prevention by high density lipoprotein' [Eur. J. Pharmacol. 265 (1994) 111–115] (273) 311
Galleyrand, J.-C., see Lallement, J.-C. (290) 61
Galligan, J.J., see Pan, H. (278) 67
Galvani, P., Fumagalli, P. and Santagostino, A.
Vulnerability of mitochondrial complex I in PC12 cells exposed to manganese (293) 377
Gamalero, S.R., see Brusa, R. (289) 9
Gamalero, S.R., see Ferretti, C. (280) 19
Gambari, R., see Feriotto, G. (290) 85
Gambs, S., see Foucaud, B. (289) 471
Gando, S., Nishihira, J., Hattori, Y. and Kanno, M.
Endothelin-1 does not phosphorylate phospholamban and troponin I in intact beating rat hearts (289) 175
Gangolli, S.D., Van den Brandt, P.A., Feron, V.J., Janzowsky, C., Koeman, J.H., Speijers, G.J.A., Spiegelhalder, B., Walker, R. and Wishnok, J.S.
Nitrate, nitrite and *N*-nitroso compounds (292) 1
Gao, Z.-g. and Liu, C.-g.
Competitive and allosteric binding of 2α-DHET and its optical isomers to rat cardiac muscarinic receptors (289) 369
Garay, R.P., Rosati, C., Fanous, K., Allard, M., Morin, E., Lamiable, D. and Vistelle, R.
Evidence for (+)-cicletanine sulfate as an active natriuretic metabolite of cicletanine in the rat (274) 175
Garay, R.P., see López-Burillo, S. (289) 259
Garbarg, M., see Delaunois, A. (277) 243
García, A.G., see Abad, F. (293) 55
García, A.G., see Uceda, G. (289) 73
García, A.G., see Vega, T. (276) 231
García-Sáinz, J.A., Romero-Avila, Ma.T. and González-Espinosa, C.
Characterization of the α_1-adrenoceptors of dog liver: predominance of the α_{1A}-subtype (272) 139
García-Sáinz, J.A., Romero-Avila, Ma.T. and Tórres-Márquez, M.E.
Characterization of the human liver α_1-adrenoceptors: predominance of the α_{1A} subtype (289) 81
García-Sáinz, J.A., Romero-Avila, Ma.T., Villalobos-Molina, R. and Minneman, K.P.
α_1-Adrenoceptor subtype selectivity of tamsulosin: studies using livers from different species (289) 1
García-Sevilla, J.A., see Alemany, R. (280) 205
Garde, E., see Catalán, R.E. (290) 183
Gardier, A.M., see Malagié, I. (286) 213
Gardiner, P., see Gorenne, I. (275) 207
Gardiner, P.J., see Norman, P. (271) 73
Garfield, R.E., see Izumi, H. (278) 187
Garland, C.J., see Murphy, T.V. (290) 141
Garland, C.J., see Murphy, T.V. (290) 145
Garosi, V.L., Nisoli, E., Blundell, J.E. and Carruba, M.O.
Pharmacological antagonism of lipoprivic feeding induced by sodium mercaptoacetate (276) 285
Garratt, P.J., see Sugden, D. (287) 239
Garrelds, I.M., De Graaf-in 't Veld, T., Nahori, M.-A., Vargaftig, B.B., Gerth van Wijk, R. and Zijlstra, F.J.
Interleukin-5 and eosinophil cationic protein in nasal lavages of rhinitis patients (275) 295
Garrison, E., see Santiago, J.A. (272) 115
Garrison, P.M., see Aarts, J.M.M.J.G. (293) 463
Garssen, J., Van der Vliet, H., De Klerk, A., Goettsch, W., Dormans, J.A.M.A., Bruggeman, C.A., Osterhaus, A.D.M.E. and Van Loveren, H.
A rat cytomegalovirus infection model as a tool for immunotoxicity testing (292) 223
Garssen, J., see Buckley, T.L. (282) 103
Garssen, J., see Hessel, E.M. (293) 401
Gasior, M., see Borowicz, K.K. (281) 319
Gatch, M.B., see Butelman, E.R. (277) 285
Gatley, S.J., Ding, Y.-S., Volkow, N.D., Chen, R., Sugano, Y. and Fowler, J.S.
Binding of *d-threo*-[^{11}C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine (281) 141
Gavish, M., see Fonia, O. (293) 335
Geczy, J., see Liégeois, J.-F. (273) R1
Gee, K.W., see McCauley, L.D. (276) 145
Gekeler, V., see Malkhandi, J. (288) 105
Gellai, M., see Aiyar, N. (283) 63
Geller, E.B., see Chen, X.-H. (275) 105
Genazzani, E., see Brusa, R. (289) 9
Gendrault, J.-L., see Dhouib, M. (293) 439
Geppetti, P., see Yoshihara, S. (280) 113
Gerecke, U., see Rundfeldt, C. (274) 73
Germain, G., see Héluy, V. (285) 89
Germain, M., see Félétou, M. (274) 57
Germain, N., see Hichami, A. (291) 91
Gerth van Wijk, R., see Garrelds, I.M. (275) 295
Gessa, G.L., see Colombo, G. (273) 235

Gessa, G.L., see Colombo, G. (285) 103
Geter-Douglass, B., see Acri, J.B. (281) R7
Ghazi-Khansari, M., see Zarrindast, M.-R. (273) 203
Ghezzi, P., see Cantoni, L. (292) 257
Ghezzi, P., see Villa, P. (292) 341
Ghi, P., see Ferretti, C. (280) 19
Ghijsen, W.E.J.M., see Verhage, M. (291) 387
Giachetti, A., see Catalioto, R.-M. (280) 285
Giachetti, A., see Patacchini, R. (271) 111
Giacobini, E., see Zhu, X.-d. (276) 93
Giamberardino, M.A., Valente, R., De Bigontina, P., Iezzi, S. and Vecchiet, L.
Effects of spasmolytic and/or non-steroidal antiinflammatory drugs on muscle hyperalgesia of ureteral origin in rats (278) 97
Giardinà, D., Crucianelli, M., Melchiorre, C., Taddei, C. and Testa, R.
Receptor binding profile of cyclazosin, a new α_{1B}-adrenoceptor antagonist (287) 13
Gibb, J.W., see Che, S. (293) 447
Gibb, J.W., see Hanson, G.R. (278) 167
Gibbons, W.A., see Tsvetnitsky, V. (282) 255
Gidener, S., LePard, K.J. and Stephens, Jr., R.L.
8-OH-DPAT stimulates gastric acid secretion through a vagal-independent, adrenal-mediated mechanism (284) 19
Gierschik, P., see Dickenson, J.M. (288) 393
Gies, J.-P., see Lach, E. (273) 313
Gies, J.-P., see Mousli, M. (289) 125
Gieschen, H., see Rauschenbach, R. (293) 183
Gil, B., Sanz, M.J., Terencio, M.C., De Giulio, A., De Rosa, S., Alcaraz, M.J. and Payá, M.
Effects of marine 2-polyprenyl-1,4-hydroquinones on phospholipase A_2 activity and some inflammatory responses (285) 281
Giles, H., see Matsugi, T. (275) 245
Gill, J.S., McKenna, W.J. and Camm, A.J.
Free radicals irreversibly decrease Ca^{2+} currents in isolated guinea-pig ventricular myocytes (292) 337
Gillard, M., see Noyer, M. (286) 137
Gillardon, F., Moll, I., Michel, S., Benrath, J., Weihe, E. and Zimmermann, M.
Calcitonin gene-related peptide and nitric oxide are involved in ultraviolet radiation-induced immunosuppression (293) 395
Gillardon, F., see Benrath, J. (293) 87
Gillis, R.A., see Berger, I. (277) 195
Gillis, R.A., see McManigle, J.E. (280) 257
Giménez-Llort, L., Martínez, E. and Ferré, S.
Dopamine-independent and adenosine-dependent mechanisms involved in the effects of *N*-methyl-D-aspartate on motor activity in mice (275) 171
Giordano, T., see Gopalakrishnan, M. (290) 237
Giorgi, O., Lecca, D., Cancedda, E., Serra, G.P. and Corda, M.G.
Modulation of [^{35}S]TBPS binding by ligands with preferential affinity for benzodiazepine BZ_1 sites in the cerebral cortex of newborn and adult rats (290) 37
Girolami, J.-P., see Bompart, G. (278) 225
Giroud, J.-P., see Chen, Y.-L. (271) 319
Gispen, W.H., see Verhage, M. (291) 387
Gitter, B.D., Waters, D.C., Threlkeld, P.G., Lovelace, A.M., Matsumoto, K. and Bruns, R.F.
Cyclosporin A is a substance P (tachykinin NK_1) receptor antagonist (289) 439
Glaser, K., Sung, M.-L., O'Neill, K., Belfast, M., Hartman, D., Carlson, R., Kreft, A., Kubrak, D., Hsiao, C.-L. and Weichman, B.
Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1 (281) 107
Glatt, H., Pauly, K., Czich, A., Falany, J.L. and Falany, C.N.
Activation of benzylic alcohols to mutagens by rat and human sulfotransferases expressed in *Escherichia coli* (293) 173
Glenn, T.C., Huang, S.-L. and Duckles, S.P.
Cocaine promotes an apparent direct vasoconstrictor effect of neuropeptide Y in the rat tail artery (276) 191
Glinka, Y.Y. and Youdim, M.B.H.
Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine (292) 329
Glover, V., see Pattichis, K. (292) 173
Glowinski, J., see Pirot, S. (285) 45
Gnanalingham, K.K., Milkowski, N.A., Smith, L.A., Hunter, A.J., Jenner, P. and Marsden, C.D.
Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset (277) 235
Gobert, A., see Schreiber, R. (271) 537
Godlewski, G., see Malinowska, B. (293) 71
Goeldner, M., see Foucaud, B. (289) 471
Goettsch, W., see Garssen, J. (292) 223
Goldberg, D.M., see Sannerud, C.A. (271) 461
Goldberg, S.R., see Sannerud, C.A. (271) 461
Goldstein, D.S., see Yadid, G. (288) 399
Golomb, E., see Yadid, G. (288) 399
Gommans, J., Hijzen, T.H., Maes, R.A., Mos, J. and Olivier, B.
Discriminative stimulus properties of flesinoxan: effects of enantiomers, (*S*)-UH301 and WAY-100635 (284) 135
Gomoll, A.W. and Ogletree, M.L.
Failure of aspirin to interfere with the cardioprotective effects of ifetroban (271) 471
Gonzalez, A.M. and Sibley, D.R.
[^{3}H]7-OH-DPAT is capable of labeling dopamine D_2 as well as D_3 receptors (272) R1
Gonzalez, A.M., see Kreiss, D.S. (277) 209
González-Espinosa, C., see García-Sáinz, J.A. (272) 139
Gonzalez, F., see Schmalix, W.A. (293) 123
Gonzalez, P., see Chulia, T. (285) 115
Goodnough, D.B. and Hawkinson, J.E.
Neuroactive steroid modulation of [^{3}H]muscimol binding to the $GABA_A$ receptor complex in rat cortex (288) 157
Gopalakrishnan, M., Buisson, B., Touma, E., Giordano, T., Campbell, J.E., Hu, I.C., Donnelly-Roberts, D., Arneric, S.P., Bertrand, D. and Sullivan, J.P.
Stable expression and pharmacological properties of the human α_7 nicotinic acetylcholine receptor (290) 237
Gopalakrishnan, S.M., Chen, C. and Lokhandwala, M.F.
α_1-Adrenoceptor subtypes mediating stimulation of Na^+,K^+-ATPase activity in rat renal proximal tubules (288) 139
Gorenne, I., Ortiz, J.L., Labat, C., Abram, T., Tudhop, S., Cuthbert, N., Norman, P., Gardiner, P., Morcillo, E. and Brink, C.
Antagonism of leukotriene responses in human airways by BAY x7195 (275) 207
Gori, E., see Braida, D. (271) 497
Gori, E., see Sala, M. (273) 35
Gosden, J., see Heal, D.J. (277) 215
Gosteli, P., see Schiffer, E.R. (286) 49
Göthert, M., see Malinowska, B. (293) 71
Goto, K., see Gyoda, Y. (279) 83
Goto, Y., see Takakura, K. (271) 367
Gourlet, P., Vandermeers, A., Vandermeers-Piret, M.-C., Rathé, J., De Neef, P. and Robberecht, P.
Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors (287) 7
Gozlan, H., Thibault, S., Laporte, A.-M., Lima, L. and Hamon, M.
The selective 5-HT_{1A} antagonist radioligand [^{3}H]WAY 100635 labels both G-protein-coupled and free 5-HT_{1A} receptors in rat brain membranes (288) 173
Gozlan, H., see Laporte, A.-M. (271) 505
Gozzard, N., see Herd, C.M. (282) 111
Grabner Weiss, C., see Luger, T.J. (275) 153
Graff, C.B., see Jackson, D.L. (284) 321
Graham, D., see Pimoule, C. (290) 49

Graham, M.E. and Burgoyne, R.D.
Activation of metabotropic glutamate receptors by L-AP4 stimulates survival of rat cerebellar granule cells in culture (288) 115
Grahame-Smith, D., see Craven, R. (271) R1
Gramer, M., see Baran, H. (273) 197
Gramer, M., see Baran, H. (286) 167
Granados-Soto, V., Flores-Murrieta, F.J., Castañeda-Hernández, G. and López-Muñoz, F.J.
Evidence for the involvement of nitric oxide in the antinociceptive effect of ketorolac (277) 281
Granata, A., see Viganò, T. (291) 201
Grandy, D.K., see Bouvier, C. (290) 11
Granero, L., see Santiago, M. (280) 251
Graneß, A., see Liebmann, C. (288) 35
Graneß, A., see Liebmann, C. (289) 403
Grant, L.J.R., see Fedan, J.S. (281) 213
Grasby, P.M., see Pike, V.W. (283) R1
Grassi-Kassisse, D.M., Faro, R., Withrington, P.G., Zatz, R., Opgenorth, T.J., Antunes, E. and De Nucci, G.
Characterisation of functional endothelin receptors in the canine isolated perfused spleen (282) 57
Gratton, A., see Banks, K.E. (282) 157
Gray, A.M., see Rafieian-Kopaei, M. (275) 185
Gray, L.E., see Brouwer, A. (293) 1
Grazzini, E., see Roussel, J.-P. (289) 205
Grbović, L., see Jovanović, A. (280) 101
Grbović, L., see Jovanović, A. (280) 95
Green, A.R., see Colado, M.I. (280) 343
Greenshaw, A.J., see Allison, K. (277) 139
Greim, H., see Schmalix, W.A. (293) 123
Greney, H., Molines, A., Bousquet, P. and Dontenwill, M.
Heterogeneity of imidazoline binding sites revealed by a cirazoline derivative (271) 533
Grider, J., Falcone, J., Kilpatrick, E., Ott, C. and Jackson, B.
Effect of bradykinin on NaCl transport in the medullary thick ascending limb of the rat (287) 101
Griffin, A.
The effect of K^+ channel openers on submucosal gland function and epithelial transport of the ferret trachea, in vitro (280) 317
Griffin, G., see Pertwee, R.G. (272) 67
Griffin, G., see Pertwee, R.G. (272) 73
Griffin, G., see Pertwee, R.G. (284) 241
Griffioen, D.H., see Westerveld, G.-J. (291) 27
Griffiths, H.R., see Willets, J.M. (293) 319
Griffon, N., Pilon, C., Schwartz, J.-C. and Sokoloff, P.
The preferential dopamine D_3 receptor ligand, (+)-UH 232, is a partial agonist (282) R3
Grignaschi, G., Sironi, F. and Samanin, R.
The 5-HT_{1B} receptor mediates the effect of *d*-fenfluramine on eating caused by intra-hypothalamic injection of neuropeptide Y (274) 221
Grigoriadis, D.E., see Levant, B. (278) 243
Grigoriev, V.M., see Danilov, A.F. (277) 15
Grimwood, S., Kulagowski, J.J., Mawer, I.M., Rowley, M., Leeson, P.D. and Foster, A.C.
Allosteric modulation of the glutamate site on the NMDA receptor by four novel glycine site antagonists (290) 221
Grobaski, K.C., see Shepard, P.D. (285) 79
Groeneveld, C.N., see Van Birgelen, A.P.J.M. (293) 77
Groenink, L., Van der Gugten, J., Mos, J., Maes, R.A.A. and Olivier, B.
The corticosterone-enhancing effects of the 5-HT_{1A} receptor antagonist, (S)-UH301, are not mediated by the 5-HT_{1A} receptor (272) 177
Groenink, L., Van der Gugten, J., Verdouw, P.M., Maes, R.A.A. and Olivier, B.
The anxiolytic effects of flesinoxan, a 5-HT_{1A} receptor agonist, are not related to its neuroendocrine effects (280) 185
Groh, W.J., see Lee, K. (285) 309
Groot, E., see Remirez, D. (293) 301
Gros, L., Hollande, F., Thorens, B., Kervran, A. and Bataille, D.
Comparative effects of GLP-1-(7–36) amide, oxyntomodulin and glucagon on rabbit gastric parietal cell function (288) 319
Gross, C., see Benazzouz, A. (284) 299
Gross, R., see Berdeu, D. (275) 91
Gross, R., see Damgé, C. (274) 133
Gross, S.S., see Hattori, Y. (291) 83
Grosser, T., see Braun, M. (276) 239
Grover, G.J., Murray, H.N., Baird, A.J. and Dzwonczyk, S.
The K_{ATP} blocker sodium 5-hydroxydecanoate does not abolish preconditioning in isolated rat hearts (277) 271
Grover, G.J., see D'Alonzo, A.J. (272) 269
Gruber, L., see Maksay, G. (288) 61
Grujic, Z., see Zhang, L. (280) 335
Grünberg, B., Negrescu, E. and Siess, W.
Synergistic phosphorylation of platelet rap1B by SIN-1 and iloprost (288) 329
Gualtieri, F., see Voigt, W. (291) 255
Guan, H.-C., see Bouvier, C. (290) 11
Guan, H.-C., see Schoots, O. (289) 67
Guan, H.-C., see Seeman, P. (286) R3
Guan, Z., see Maurer, J.A. (288) 163
Guantes, J.M., see Uceda, G. (289) 73
Guaza, C., see Sandi, C. (274) 17
Guaza, C., see Sandi, C. (277) 89
Gudbjarnason, S., see Benediktsdóttir, V.E. (289) 419
Gudelsky, G.A.
Effects of σ receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat (286) 223
Guéritte Voegelein, F., see Rasolonjanahary, R. (285) 19
Guh, J.-H., Ko, F.-N., Yu, S.-M., Wu, Y.-C. and Teng, C.-M.
Pharmacological evaluation of *N*-methyl-actinodaphnine, a new vascular α-adrenoceptor antagonist, isolated from *Illigera luzonensis* (279) 33
Guidarelli, A., see Palomba, L. (291) 167
Guilbaud, G., see Keïta, H. (277) 275
Guillaume, J.-L., see Méjean, A. (291) 359
Guillemette, G., see Bernier, S.G. (271) 55
Guillemette, G., see Bernier, S.G. (291) 191
Gundlach, A.L., see King, P.R. (281) 341
Guo, J.-Z., Yoshioka, K., Zhao, F.-Y., Hosoki, R., Maehara, T., Yanagisawa, M., Hagan, R.M. and Otsuka, M.
Pharmacological characterization of GR82334, a tachykinin NK_1 receptor antagonist, in the isolated spinal cord of the neonatal rat (281) 49
Gupta, A.K., see Koley, J. (293) 483
Gurdal, H., Cai, G. and Johnson, M.D.
α_1-Adrenoceptor responsiveness in the aging aorta (274) 117
Gurling, J., see Routledge, C. (276) 281
Gustafson, M., see Levy, A.D. (274) 141
Gustafsson, K., see Westlind-Danielsson, A. (288) 89
Gustin, P., see Delaunois, A. (277) 243
Gutbrod, O., see Storch, A. (290) 207
Guth, P.H., see Barrachina, M.D. (281) R3
Guyot, M.-C., see Brouillet, E. (293) 487
Gyoda, Y., Tsukada, Y., Saito, A. and Goto, K.
Role of nitric oxide and neuropeptides in neurogenic vasodilatation of the guinea pig mesenteric artery (279) 83

Haapalinna, A., see Valtonen, P. (285) 239
Haas, J., see Rietjens, I.M.C.M. (293) 293
Habuchi, Y., Furukawa, T., Tanaka, H., Lu, L.-L., Morikawa, J. and Yoshimura, M.
Ethanol inhibition of Ca^{2+} and Na^+ currents in the guinea-pig heart (292) 143

Hachisu, M., see Nagura, J. (274) 201
Haddad, E.-B., Liu, S.F., Salmon, M., Robichaud, A., Barnes, P.J. and Chung, K.F.
Expression of inducible nitric oxide synthase mRNA in Brown Norway rats exposed to ozone: effect of dexamethasone (293) 287
Haddad, E.-B., Rousell, J. and Barnes, P.J.
Muscarinic M_2 receptor synthesis: study of receptor turnover with propylbenzilylcholine mustard (290) 201
Hadingham, K.L., Wafford, K.A., Thompson, S.A., Palmer, K.J. and Whiting, P.J.
Expression and pharmacology of human $GABA_A$ receptors containing $\gamma 3$ subunits (291) 301
Hadjiconstantinou, M., Rossetti, Z.L., Wemlinger, T.A. and Neff, N.H.
Dizocilpine enhances striatal tyrosine hydroxylase and aromatic L-amino acid decarboxylase activity (289) 97
Hagan, J.J., see Rompré, P.-P. (287) 263
Hagan, R.M., see Beresford, I.J.M. (272) 241
Hagan, R.M., see Guo, J.-Z. (281) 49
Hagihara, K., Hayakawa, T., Arai, T., Eguchi, H., Mino, S. and Kawase, S.
Antagonistic activities of N-3389, a newly synthesized diazabicyclo derivative, at 5-HT_3 and 5-HT_4 receptors (271) 159
Hagiwara, T., see Yamashita, H. (289) 387
Hagmar, L., see Brouwer, A. (293) 1
Hahn, K.H., see Chang, K.C. (284) 331
Hajri, T., Férézou, J., Laruelle, C. and Lutton, C.
Crilvastatin, a new 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, inhibits cholesterol absorption in genetically hypercholesterolemic rats (286) 131
Hakim, J., see Djerdjouri, B. (288) 193
Halaka, N.N., see Lodge, N.J. (287) 279
Halonen, T., see Valtonen, P. (285) 239
Hamada, A., see Matsushita, M. (276) 177
Hamada, N., see Nishiguchi, E. (286) 1
Hamada, S.-i., see Hamada, Y. (288) 45
Hamada, Y., Nakaya, Y., Hamada, S.-i., Kamada, M. and Aono, T.
Activation of K^+ channels by ritodrine hydrochloride in uterine smooth muscle cells from pregnant women (288) 45
Hamelin, S.M. and Lehmann, J.C.
Effects of putative cognition enhancers on the NMDA receptor by [^{3}H]MK801 binding (281) R11
Hammer, Jr., R.P., see Zhou, L. (278) 271
Hamon, M., see Gozlan, H. (288) 173
Hamon, M., see Kleven, M. (281) 219
Hamon, M., see Laporte, A.-M. (271) 505
Hamon, M., see Nevo, I. (281) 229
Hampson, D.R., see Yue, K.-T. (291) 229
Handa, H., see Tanaka, H. (291) 121
Hansen, H.C., see Wong, G. (289) 335
Hanson, G.R., Midgley, L.P., Bush, L.G. and Gibb, J.W.
Response of extrapyramidal and limbic neurotensin systems to phencyclidine treatment (278) 167
Hanson, G.R., see Che, S. (293) 447
Hanson, P.J., see Brown, J.F. (292) 111
Hansson, L.O., see Kujacic, M. (273) 247
Hanus, L., see Barg, J. (287) 145
Haq, W., see Knapp, R.J. (291) 129
Hara, C., see Yamamoto, Y. (281) 335
Hara, M., Kai, Y. and Ikemoto, Y.
Local anesthetics reduce the inhibitory neurotransmitter-induced current in dissociated hippocampal neurons of the rat (283) 83
Hara, M., Kiyama, R., Nakajima, S., Kawabata, T., Kawakami, M., Ohtani, K., Itazaki, K., Fujishita, T. and Fujimoto, M.
Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor (289) 267
Hara, M., see Itazaki, K. (291) 417
Hara, M., see Yoshihara, S. (280) 113
Harada, H., see Kamiyama, T. (272) 151
Harden, T.K., see Galas, M.-C. (291) 175
Hargreaves, K.M., see Jackson, D.L. (284) 321
Harper, A.A. and Chipperfield, A.R.
Chronotropic actions of Na^+,K^+,Cl^- cotransport inhibition in the isolated rat heart (286) 299
Harris, H.J., see Klemm, P. (281) 69
Harris, J.G., Flower, R.J. and Perretti, M.
Alteration of neutrophil trafficking by a lipocortin 1 N-terminus peptide (279) 149
Harris, J.G., Flower, R.J. and Perretti, M.
Endogenous corticosteroids mediate the neutrophilia caused by platelet-activating factor in the mouse (283) 9
Harrison, B.L., see Chapman, A.G. (274) 83
Harrison, B.L., see Kehne, J.H. (284) 109
Harrison, S., see Smith, G. (271) 481
Hartikainen, T., see Ylinen, A. (274) 159
Hartman, D., see Glaser, K. (281) 107
Hartmann, M., Stumpe, T. and Schrader, J.
α_1-Adrenoceptor stimulation inhibits the isoproterenol-induced effects on myocardial contractility and protein phosphorylation (287) 57
Hartog-Witte, H.R., see Van der Wenden, E.M. (290) 189
Hasegawa, T., see Maeda, Y. (275) 163
Hashimoto, K. and London, E.D.
Interactions of *erythro*-ifenprodil, *threo*-ifenprodil, *erythro*-iodo-ifenprodil, and eliprodil with subtypes of σ receptors (273) 307
Hashimoto, K., see Narita, N. (293) 277
Hashimoto, K., see Sasaki, H. (282) 71
Hashimoto, K., see Tomitaka, S.-i. (285) 207
Hashitani, H. and Suzuki, H.
Electrical and mechanical responses produced by nerve stimulation in detrusor smooth muscle of the guinea-pig (284) 177
Hashizume, H., Akiyama, K. and Abiko, Y.
Effects of antiischemic drugs on veratridine-induced hypercontracture in rat cardiac myocytes (271) 1
Hasin, Y., see Novakova, M. (286) 19
Hatake, K., Wakabayashi, I. and Hishida, S.
Endothelium-dependent relaxation resistant to N^G-nitro-L-arginine in rat aorta (274) 25
Hatake, K., see Wakabayashi, I. (293) 133
Hatta, K., Wolterink, G. and Van Ree, J.M.
Prolyl-leucyl-glycinamide, thyrotropin-releasing hormone and β-endorphin-(10–16), like antidepressants, antagonize melatonin-induced behavioural changes in rats (284) 327
Hatta, S., Watanabe, M., Ikeda, H., Kamada, H., Saito, T. and Ohshika, H.
Impairment of adenylyl cyclase signal transduction in mecobalamin-deficient rats (291) 351
Hattori, K., see Shinozuka, K. (292) 115
Hattori, Y., Kawasaki, H., Fukao, M. and Kanno, M.
Phorbol esters elicit Ca^{2+}-dependent delayed contractions in diabetic rat aorta (279) 51
Hattori, Y., Szabó, C., Gross, S.S., Thiemermann, C. and Vane, J.R.
Lipid A and the lipid A analogue anti-tumour compound ONO-4007 induce nitric oxide synthase in vitro and in vivo (291) 83
Hattori, Y., see Gando, S. (289) 175
Hauser, C.A.E., Chesnoy-Marchais, D., Robel, P. and Baulieu, E.E.
Modulation of recombinant $\alpha_6\beta_2\gamma_2$ $GABA_A$ receptors by neuroactive steroids (289) 249
Hautala, R., see Järv, J. (291) 43
Hauzerova, L., see Atke, A. (281) 63
Hawcock, A.B., see Beresford, I.J.M. (272) 241
Hawkinson, J.E., see Goodnough, D.B. (288) 157
Hayakawa, H., see Koumi, S.-i. (277) 165
Hayakawa, T., see Hagihara, K. (271) 159
Hayashi, H., see Oyama, Y. (293) 101
Hayashi, K., see Kuraishi, Y. (275) 229

Hayashi, N., see Adachi, T. (286) 201
Hayashi, T., see Luger, T.J. (271) 421
Hayashi, T., see Luger, T.J. (275) 153
Hayes, E.S., see Barrett, T.D. (285) 229
Hayes, J.P., Kuo, H.-P., Rohde, J.A.L., Newman Taylor, A.J., Barnes, P.J., Chung, K.F. and Rogers, D.F.
Neurogenic goblet cell secretion and bronchoconstriction in guinea pigs sensitised to trimellitic anhydride (292) 127
Haynes, J.M. and Cooper, M.E.
Adrenomedullin and calcitonin gene-related peptide in the rat isolated kidney and in the anaesthetised rat: in vitro and in vivo effects (280) 91
He, H., Bessho, H., Fujisawa, Y., Horiuchi, K., Tomohiro, A., Kita, T., Aki, Y., Kimura, S., Tamaki, T. and Abe, Y.
Effects of a synthetic rat adrenomedullin on regional hemodynamics in rats (273) 209
Heal, D.J., Cheetham, S.C., Butler, S.A., Gosden, J., Prow, M.R. and Buckett, W.R.
Receptor binding and functional evidence suggest that postsynaptic α_2-adrenoceptors in rat brain are of the α_{2D} subtype (277) 215
Heaslip, R.J. and Evans, D.Y.
Emetic, central nervous system and pulmonary activities of rolipram in the dog (286) 281
Heaslip, R.J., see DiSanto, M.E. (290) 169
Hecker, M., Schott, C., Bucher, B., Busse, R. and Stoclet, J.-C.
Increase in serum N^G-hydroxy-L-arginine in rats treated with bacterial lipopolysaccharide (275) R1
Hedlund, P.B., see Yang, S.-N. (271) 201
Hehl, S., see Moser, C. (284) 35
Heidbreder, C., see Shippenberg, T.S. (280) 55
Heinemann, A. and Stauber, R.E.
The role of inducible nitric oxide synthase in vascular hyporeactivity of endotoxin-treated and portal hypertensive rats (278) 87
Heinrich, U., see Flüge, T. (271) 395
Heinz-Erian, P., see Schremmer-Danninger, E. (283) 207
Hejnová, L., Tuček, S. and El-Fakahany, E.E.
Positive and negative allosteric interactions on muscarinic receptors (291) 427
Heldman, E., see Barg, J. (287) 145
Hellewell, P.G., see Teixeira, M.M. (272) 185
Helme, R.D., see Ralevic, V. (284) 231
Helmeste, D.M. and Tang, S.W.
Erratum to 'Tyrosine kinase inhibitors regulate serotonin uptake in platelets' [Eur. J. Pharmacol. 280 (1995) R5–R7] (286) 113
Helmeste, D.M. and Tang, S.W.
Tyrosine kinase inhibitors regulate serotonin uptake in platelets (280) R5
Helmeste, D.M., Tang, S.W., Reist, C. and Vu, R.
Erratum to: 'Serotonin uptake inhibitors modulate intracellular Ca^{2+} mobilization in platelets'. Eur. J. Pharmacol. — Mol. Pharmacol. Sect. 288 (1995) 373—477 (290) 173
Helmeste, D.M., Tang, S.W., Reist, C. and Vu, R.
Serotonin uptake inhibitors modulate intracellular Ca^{2+} mobilization in platelets (288) 373
Héluy, V., Germain, G., Fournier, T., Ferré, F. and Breuiller-Fouché, M.
Endothelin ET_A receptors mediate human uterine smooth muscle contraction (285) 89
Hemming, H., Bager, Y., Flodström, S., Nordgren, I., Kronevi, T., Ahlborg, U.G. and Wärngård, L.
Liver tumour promoting activity of 3,4,5,3',4'-pentachlorobiphenyl and its interaction with 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (292) 241
Hempelmann, R.G., Papadopoulos, I. and Herzig, S.
Non-synergistic relaxant effects of vasoactive intestinal polypeptide and SIN-1 in human isolated cavernous artery and corpus cavernosum (276) 277
Hénichart, J.-P., see Noyer, M. (286) 137
Henmi, S., Imaizumi, Y., Muraki, K. and Watanabe, M.
Characteristics of caffeine-induced and spontaneous inward currents and related intracellular Ca^{2+} storage sites in guinea-pig tracheal smooth muscle cells (282) 219
Hens, J.J.H., see Verhage, M. (291) 387
Herbert, J.-M., see Dol, F. (280) 135
Herbert, M.K. and Hering, S.
Tumor necrosis factor-α prevents interleukin-1β from augmenting capsaicin-induced vasodilatation in the rat skin (286) 273
Herbst, C., see Tippler, B. (271) 131
Herd, C.M., Gozzard, N. and Page, C.P.
Capsaicin pre-treatment prevents the development of antigen-induced airway hyperresponsiveness in neonatally immunised rabbits (282) 111
Hering, S., see Herbert, M.K. (286) 273
Herman, A.G., see De Man, J.G. (285) 269
Herman, A.G., see De Meyer, E. (291) 67
Herman, A.G., see Michielsen, P.P. (273) 167
Hermsen, B., see Storch, A. (290) 207
Hernandez, A., see Viganò, T. (291) 201
Hernández, J., see Martinez, E. (282) 169
Herndon, D.N., see Abdi, S. (293) 475
Herzer, T., Wagner, C.A., Waldegger, S., Lang, F. and Busch, A.E.
Effects of channel modulation and pH on I_{sK} inhibition by the novel class III antiarrhythmic azimilide (NE-10064) (291) 205
Herzig, S., see Hempelmann, R.G. (276) 277
Hess, T.A., see D'Alonzo, A.J. (272) 269
Hessel, E.M., Van Oosterhout, A.J.M., Hofstra, C.L., De Bie, J.J., Garssen, J., Van Loveren, H., Verheyen, A.K.C.P., Savelkoul, H.F.J. and Nijkamp, F.P.
Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice (293) 401
Hey, J.A., see Bolser, D.C. (276) R1
Hey, J.A., see Bolser, D.C. (277) 159
Heya, T., see Miyamoto, M. (271) 357
Heyndrickx, J.-P., see Hodeige, D. (279) 25
Hichami, A., Boichot, E., Germain, N., Legrand, A., Moodley, I. and Lagente, V.
Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells (291) 91
Higgins, G.A., see Varty, G.B. (287) 201
Higuchi, S., see Ito, C. (285) 37
Hijzen, T.H., see Gommans, J. (284) 135
Hilakivi, I.
Early postnatal antidepressant treatment and juvenile stereotyped behaviour in rats (271) 223
Hildebrand, M., see Rauschenbach, R. (293) 183
Hildebrandt, C., see Pfaff, O. (286) 229
Hill, D.R., see Singh, L. (286) 185
Hill, H.F., see Luger, T.J. (271) 421
Hill, H.F., see Luger, T.J. (275) 153
Hill, M.P. and Brotchie, J.M.
Modulation of glutamate release by a κ-opioid receptor agonist in rodent and primate striatum (281) R1
Hill, M.P., see East, S.J. (277) 117
Hill, R.G., see Razzaque, Z. (283) 199
Hill, R.G., see Seabrook, G.R. (273) 113
Hill, S.J., see Dickenson, J.M. (288) 393
Hillaire-Buys, D., see Damgé, C. (274) 133
Himes, C.S., see Tang, A.H. (284) 13
Hioki, K., see Akehira, K. (284) 149
Hirahashi, J., see Hishikawa, K. (291) 435
Hirai, K., see Miyamoto, M. (271) 357
Hiramatsu, M., Sasaki, M. and Kameyama, T.
Effects of dynorphin A-(1–13) on carbon monoxide-induced delayed amnesia in mice studied in a step-down type passive avoidance task (282) 185
Hiramoto, M., see Tanaka, H. (291) 121

Hiraoka, M., see Tsuchida, S. (281) 251
Hirasawa, A., see Foglar, R. (288) 201
Hirasawa, Y., Nishio, M., Maeda, K., Yoshida, K. and Kita, Y.
Comparison of antiplatelet effects of FK409, a spontaneous nitric oxide releaser, with those of TRK-100, a prostacyclin analogue (272) 39
Hirasawa, Y., see Kita, Y. (275) 125
Hirose, H., Ide, K., Sasaki, T., Takahashi, R., Kobayashi, M., Ikemoto, F., Yano, M. and Nishikibe, M.
Corrigendum to 'The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog' [Eur. J. Pharmacol. 277 (1995) 77–87] (284) 335
Hirose, H., Ide, K., Sasaki, T., Takahashi, R., Kobayashi, M., Ikemoto, F., Yano, M. and Nishikibe, M.
The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog (277) 77
Hirsch, A., see Molimard, M. (278) 253
Hirsch, A., see Molimard, M. (278) 49
Hisatome, I., see Saito, M. (291) 217
Hishida, S., see Hatake, K. (274) 25
Hishikawa, K., Nakaki, T., Hirahashi, J., Marumo, T. and Saruta, T.
Tranilast inhibits the effects of platelet-derived growth factor on cell proliferation and induction of nitric oxide (291) 435
Ho, I.K., see Narita, M. (271) 543
Ho, I.K., see Narita, M. (271) 547
Ho, I.K., see Tokuyama, S. (279) 93
Ho, I.K., see Tokuyama, S. (284) 101
Hobara, T., see Ishiyama, H. (292) 135
Hocher, B., Zart, R., Diekmann, F., Slowinski, T., Thöne-Reineke, C., Lutz, J. and Bauer, C.
Role of the paracrine liver endothelin system in the pathogenesis of CCl_4-induced liver injury (293) 361
Hodeige, D., Heyndrickx, J.-P., Chatelain, P. and Manning, A.
SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs (279) 25
Hoeltzel, A., see Damgé, C. (274) 133
Hofbauer, K.G., see Cressier, F. (272) 57
Hoffman, P.L., see Szabó, G. (287) 35
Hofmann, A., see Buchheit, K.-H. (287) 85
Hofstra, C.L., see Hessel, E.M. (293) 401
Höhle, S., Spitznagel, H., Rascher, W., Culman, J. and Unger, T.
Angiotensin AT_1 receptor-mediated vasopressin release and drinking are potentiated by an AT_2 receptor antagonist (275) 277
Hohlfeld, J., see Flüge, T. (271) 395
Hoiting, B.H., Kuipers, R., Elzinga, C.R.S., Zaagsma, J. and Meurs, H.
Feedforward control of agonist-induced Ca^{2+} signalling by protein kinase C in airway smooth muscle cells (290) R5
Holene, E., see Brouwer, A. (293) 1
Hollande, F., see Gros, L. (288) 319
Hollingsworth, M., see Piper, A.S. (280) 125
Hollingsworth, M., see Piper, I.T. (283) 1
Holtzman, S.G., see Schad, C.A. (275) 9
Holý, A., see Zídek, Z. (286) 307
Holzer, P., see Patacchini, R. (278) 17
Homaidan, F.R. and Broutman, G.
Regulation of ileal electrolyte transport by K^+ channel activators (271) 561
Hönack, D., see Baran, H. (286) 167
Hondo, H., see Yonezawa, Y. (285) 305
Hong, E., see Villalobos-Molina, R. (277) 181
Hong, Y. and Abbott, F.V.
Peripheral opioid modulation of pain and inflammation in the formalin test (277) 21
Honoré, P., Buritova, J. and Besson, J.-M.
Carrageenin-evoked c-Fos expression in rat lumbar spinal cord: the effects of indomethacin (272) 249
Hope, W., see White, P.J. (286) 315
Horbach, G.J.M.J., see De Groene, E.M. (293) 47
Hori, M., see Sudjarwo, S.A. (289) 197
Hori, S., see Adachi, T. (286) 201
Horiai, H., see Terai, T. (279) 217
Horie, K. and Tsujimoto, G.
Effect of receptor density on the receptor-effector coupling: Use of cloned and stably expressed α_{1B}-adrenoceptors in CHO cells (288) 303
Horie, K., see Foglar, R. (288) 201
Horie, K., see Obika, K. (291) 327
Horinouchi, T., see Koike, K. (279) 159
Horiuchi, H., Uejima, Y., Sakuma, Y., Kadota, T., Okada, N., Taniguchi, K., Takenouchi, K., Yamanaka, Y., Uno, H. and Komoriya, K.
Beneficial effects of a novel anti-hypoxemic agent, TEI-7322, on bleomycin-induced experimental hypoxemia in rats (287) 27
Horiuchi, K., see He, H. (273) 209
Horiuchi, T., see Tabuchi, Y. (272) 195
Hornsperger, J.-M., see Zhu, X.-d. (276) 93
Horwell, D.C., see Singh, L. (286) 185
Hoskins, B., see Narita, M. (271) 543
Hoskins, B., see Narita, M. (271) 547
Hosoki, E. and Iijima, T.
Modulation of cytosolic Ca^{2+} concentration by thapsigargin and cyclopiazonic acid in human aortic endothelial cells (288) 131
Hosoki, R., see Guo, J.-Z. (281) 49
Hosseini-semnani, S., see Zarrindast, M.-R. (276) 3
Hotta, Y., Ando, H., Fujita, M., Nakagawa, J., Takeya, K. and Sakakibara, J.
Different effects of isoproterenol and dihydroouabain on cardiac Ca^{2+} transients (282) 121
Hou, X., see Pfaff, O. (286) 229
Houweling, A.D., see Deschepper, C.F. (275) 61
Hoyer, D., Pérez, J., Schoeffter, P., Langenegger, D., Schüpbach, E., Kaupmann, K., Lübbert, H., Bruns, C. and Reubi, J.C.
Pharmacological identity between somatostatin SS-2 binding sites and SSTR-1 receptors (289) 151
Hoyer, D., see Schoeffter, P. (289) 163
Hoymann, H.-G., see Flüge, T. (271) 395
Hruby, V.J., see Knapp, R.J. (291) 129
Hsiao, C.-L., see Glaser, K. (281) 107
Hsu, K.-S. and Lin-Shiau, S.-Y.
Antagonism by paraquat of the relaxing effects of acetylcholine and A23187 in rat thoracic aorta (292) 315
Hsu, K.-S. and Lin-Shiau, S.-Y.
Relaxation of rat thoracic aorta induced by pyridine (292) 265
Hsu, M.-F., see Wang, J.-P. (273) 73
Hu, I.C., see Gopalakrishnan, M. (290) 237
Hu, R.Q. and Davies, J.A.
The effect of the desglycinyl metabolite of remacemide on cortical wedges prepared from DBA/2 mice (287) 251
Huang, C. and Johns, E.J.
Effect of nitrendipine on renal cortical and papillary autoregulation in hypertensive rats (282) 1
Huang, K.-X., see Kreiss, D.S. (277) 209
Huang, N.-Y. and Kostrzewa, R.M.
Persistent oral dyskinesias in haloperidol-withdrawn neonatal 6-hydroxydopamine-lesioned rats (271) 433
Huang, Q., Tezuka, Y., Kikuchi, T. and Momose, Y.
Trichokonin VI, a new Ca^{2+} channel agonist in bullfrog cardiac myocytes (271) R5
Huang, S.-L., see Glenn, T.C. (276) 191
Huang, Y.
4-Aminopyridine-induced phasic contractions in rat caudal epididymis are mediated through release of noradrenaline (280) 231
Huchet, C. and Léoty, C.
Sarcoplasmic reticulum function in newborn ferret cremaster skeletal muscles (271) 141

Hudkins, R.L., Mailman, R.B. and DeHaven-Hudkins, D.L.
RLH-033, a novel, potent and selective ligand for the σ_1 recognition site (271) 235
Huff, R.M., see Mierau, J. (290) 29
Huffman, J.W., see Pertwee, R.G. (284) 241
Hughes, J.M., see Anticevich, S.Z. (284) 221
Huhurez, G., see Filipeanu, C.M. (281) 29
Hui, C., see Nagura, J. (274) 201
Hui, S.-C.G. and Chan, T.-Y.
Mechanisms mediating N^G-nitro-L-arginine methyl ester-induced hypophagia in mice (283) 141
Huisman, M., see Brouwer, A. (293) 1
Hulme, E.C., see Jones, P.G. (288) 251
Hulme, E.C., see Page, K.M. (289) 429
Hume, S.P., Ashworth, S., Opacka-Juffry, J., Ahier, R.G., Lammertsma, A.A., Pike, V.W., Cliffe, I.A., Fletcher, A. and White, A.C.
Evaluation of [*O-methyl*-^{3}H]WAY-100635 as an in vivo radioligand for 5-HT_{1A} receptors in rat brain (271) 515
Hume, S.P., see Pike, V.W. (283) R1
Hunter, A.J., see Gnanalingham, K.K. (277) 235
Husemann, M., see Rauschenbach, R. (293) 183
Hüsken, B.C.P., Vroom, M.B., Timmenga, E.-J.F., Pfaffendorf, M. and Van Zwieten, P.A.
Relaxant effect of levcromakalim in isolated human small subcutaneous arteries (287) 313
Hussain, S.N.A., see Kosmas, E.N. (274) 193
Huupponen, R., see Rouru, J. (273) 99
Hwang, B., see Carter, D. (280) 243
Hyytiä, P. and Koob, G.F.
$GABA_A$ receptor antagonism in the extended amygdala decreases ethanol self-administration in rats (283) 151

Ialenti, A., see Sautebin, L. (286) 219
Ianaro, A., see Sautebin, L. (286) 219
Ibarra, M., see Villalobos-Molina, R. (277) 181
Ibayashi, S., see Cai, H. (286) 249
Ibrahim, I.N., see Kaye, A.D. (276) 21
Ibrahim, I.N., see Kaye, A.D. (287) 163
Ichihara, K., see Kamigaki, M. (287) 121
Ichihara, K., see Satoh, K. (292) 271
Ichihara, M., see Shibasaki, M. (271) 341
Ichikawa, J. and Meltzer, H.Y.
Effect of antidepressants on striatal and accumbens extracellular dopamine levels (281) 255
Ichikawa, J., Kuroki, T., Kitchen, M.T. and Meltzer, H.Y.
R(+)-8-OH-DPAT, a 5-HT_{1A} receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens (287) 179
Ida, K., see Nakayama, K. (276) 77
Idänpään-Heikkilä, J.J., Björn, M. and Seppälä, T.
The effects of ethanol in combination with the α_2-adrenoceptor agonist dexmedetomidine and the α_2-adrenoceptor antagonist atipamezole on brain monoamine metabolites and motor performance of mice (292) 191
Idänpään-Heikkilä, J.J., Rauhala, P. and Männistö, P.T.
μ- and δ-opioid receptor antisense oligodeoxynucleotides antagonize morphine-induced growth hormone secretion in rats (284) 227
Idänpään-Heikkilä, J.J., see Rauhala, P. (285) 69
Ide, K., see Hirose, H. (277) 77
Ide, K., see Hirose, H. (284) 335
Iezzi, S., see Giamberardino, M.A. (278) 97
Igarashi, Y., see Van Ree, J.M. (279) 187
Ihara, M., Yamanaka, R., Ohwaki, K., Ozaki, S., Fukami, T., Ishikawa, K., Towers, P. and Yano, M.
[^{3}H]BQ-123, a highly specific and reversible radioligand for the endothelin ET_A receptor subtype (274) 1
Iijima, T., see Hosoki, E. (288) 131
Iino, T., Katsura, M. and Kuriyama, K.
Effect of vinconate on the extracellular levels of dopamine and its metabolites in the rat striatum: microdialysis studies (286) 99
IJzerman, A.P., see Van der Wenden, E.M. (290) 189
Ikeda, H., see Hatta, S. (291) 351
Ikeda, H., see Kaneko, T. (292) 251
Ikeda, M., see Mizuno, M. (285) 181
Ikeda, U., Furuhashi, K., Kanbe, T. and Shimada, K.
Ouabain enhances nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β (288) 379
Ikeda, U., Kanbe, T., Nakayama, I., Kawahara, Y., Yokoyama, M. and Shimada, K.
Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β (290) 69
Ikeda, Y., see Majima, M. (284) 1
Ikeda, Y., see Takiguchi, Y. (281) 205
Ikemoto, F., see Hirose, H. (277) 77
Ikemoto, F., see Hirose, H. (284) 335
Ikemoto, Y., see Hara, M. (283) 83
Imai, Y., see Schäfer, M. (279) 165
Imaizumi, M., see Miyazaki, S. (271) 179
Imaizumi, R., see Kitamura, Y. (289) 299
Imaizumi, Y., see Henmi, S. (282) 219
Imanaga, I., see Inoue, M. (276) 123
Inada, T., see Sasaki, H. (282) 71
Inagaki, M., see Nakachi, N. (281) 195
Inagaki, O., see Shibasaki, M. (271) 341
Inazu, M., see Nakachi, N. (281) 195
Ingelman-Sundberg, M., see Schmalix, W.A. (293) 123
Inglis, A., see Tseng, A. (271) 265
Ingvarson, T., see Sjuve, R. (276) 137
Injoyan, R., see Rompré, P.-P. (287) 263
Inoue, H., see Inoue, Y. (284) 77
Inoue, M., Sakamoto, Y. and Imanaga, I.
Phosphatidylinositol hydrolysis is involved in production of Ca^{2+}-dependent currents, but not non-selective cation currents, by muscarine in chromaffin cells (276) 123
Inoue, M., see Ohkubo, T. (273) 83
Inoue, Y., Emoto, M., Inoue, H., Kaku, K. and Kaneko, T.
Characterization of the binding sites for [^{3}H]glibenclamide in rat liver membranes (284) 77
Inturrisi, C.E., see Chan, K. (287) 135
Ioannides, C., see Irizar, A. (293) 385
Ioculano, M., see Altavilla, D. (272) 223
Ioculano, M., see Altavilla, D. (286) 31
Iouzalen, L., Devynck, M.-A. and David-Dufilho, M.
Isradipine affects histamine-induced cytosolic Ca^{2+} movements in human endothelial cells (289) 189
Irie, K., Uchida, Y., Fujii, E. and Muraki, T.
Developmental changes in response to endothelins and receptor subtypes of isolated rat duodenum (275) 45
Irie, K., see Fujii, E. (273) 267
Irie, K., see Uchida, Y. (291) 33
Irifune, M., Nomoto, M. and Fukuda, T.
Effects of GBR 12909 on locomotor activity and dopamine turnover in mice: comparison with apomorphine (272) 79
Irizar, A., Barnett, C.R., Flatt, P.R. and Ioannides, C.
Defective expression of cytochrome P450 proteins in the liver of the genetically obese Zucker rat (293) 385
Isaka, N., see Miyahara, M. (284) 25
Ise, W., see Malkhandi, J. (288) 105
Ishibashi, M., see Takahashi, Y. (288) 285
Ishihara, K., see Momiyama, T. (280) 119
Ishii, K., see Nakahara, T. (287) 49
Ishii, K., see Tanaka, Y. (289) 59
Ishii, K., see Yamagishi, T. (281) 151
Ishikawa, K., see Ihara, M. (274) 1

Ishikawa, M., see Sakitama, K. (273) 47
Ishimoto, T., see Akiba, S. (291) 343
Ishiro, H., see Tanaka, Y. (289) 59
Ishiyama, H., Ogino, K. and Hobara, T.
Role of Kupffer cells in rat liver injury induced by diethyldithiocarbamate (292) 135
Ishiyama, H., see Takahashi, Y. (288) 285
Ishiye, M., Umemura, K., Uematsu, T. and Nakashima, M.
Angiotensin AT_1 receptor-mediated attenuation of cardiac hypertrophy due to volume overload: involvement of endothelin (280) 11
Ishiye, M., see Umemura, K. (275) 17
Ishizaki, T., see Chiba, K. (293) 97
Iskric, S., see Perovic, S. (288) 27
Isobe, Y., see Ito, C. (285) 37
Itagaki, M., see Komori, S. (277) 173
Itazaki, K., Hara, M., Itoh, N. and Fujimoto, M.
A long-term receptor stimulation is requisite for angiotensin II-dependent DNA synthesis in vascular smooth muscle cells from spontaneously hypertensive rats (291) 417
Itazaki, K., see Hara, M. (289) 267
Ito, C., Isobe, Y., Kijima, H., Kiuchi, Y., Ohtsuki, H., Kawamura, R., Tsuchida, K. and Higuchi, S.
The anti-emetic activity of GK-128 in *Suncus murinus* (285) 37
Ito, H. and Tamura, K.
Inhibitory effect of YM060 on 5-HT_3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig (283) 107
Ito, K., see Seto, M. (276) 27
Ito, M., see Miyahara, M. (284) 25
Itoh, H., see Miyahara, M. (284) 25
Itoh, K., see Chiba, K. (293) 97
Itoh, N., see Itazaki, K. (291) 417
Itoh, S., see Chiba, K. (293) 97
Itoh, T., see Fujimoto, S. (280) 143
Itoyama, Y., see Araki, T. (278) 91
Itoyama, Y., see Kato, H. (272) 107
Itsuno, M., see Sawa, T. (276) 223
Ivanová, S., see Allison, K. (277) 139
Iwamura, T., see Katsumata, S. (291) 367
Iwata, K., see Matsushita, M. (276) 177
Iwata, S., see Tanaka, Y. (289) 59
Iyo, M., see Narita, N. (293) 277
Iyo, M., see Sasaki, H. (282) 71
Izquierdo, I., see Fin, C. (271) 227
Izumi, F., see Mizuki, T. (277) 133
Izumi, H., Byam-Smith, M. and Garfield, R.E.
Gestational changes in oxytocin- and endothelin-1-induced contractility of pregnant rat myometrium (278) 187
Izumi, H., Takahashi, H. and Karita, K.
Pentylenetetrazole-induced parasympathetic blood flow increase in the lower lip of the cat (273) 299
Izzo, A.A., Mascolo, N., Di Carlo, G. and Capasso, F.
N^G-Nitro-L-arginine methyl ester modulates intestinal secretion and motility produced by carbachol (271) 31

Jackson, B., see Grider, J. (287) 101
Jackson, D.L., Graff, C.B., Richardson, J.D. and Hargreaves, K.M.
Glutamate participates in the peripheral modulation of thermal hyperalgesia in rats (284) 321
Jackson, D.M., Mohell, N., Bengtsson, A. and Malmberg, Å.
Why does clozapine stimulate the motor activity of reserpine-pretreated rats when combined with a dopamine D_1 receptor agonist? (282) 137
Jacobson, A.E., see Bowen, W.D. (279) R1
Jacobson, J.L., see Brouwer, A. (293) 1
Jacobson, K.A., see Von Lubitz, D.K.J.E. (275) 23
Jacobson, K.A., see Von Lubitz, D.K.J.E. (283) 185
Jacobson, K.A., see Von Lubitz, D.K.J.E. (287) 295
Jacobson, S.W., see Brouwer, A. (293) 1
Jacques, D., Cadieux, A., Dumont, Y. and Quirion, R.
Apparent affinity and potency of BIBP3226, a non-peptide neuropeptide Y receptor antagonist, on purported neuropeptide Y Y_1, Y_2 and Y_3 receptors (278) R3
Jacquot, C., see Malagié, I. (286) 213
Jairath, M., see Waterfield, C.J. (293) 141
Jäkälä, P., Sirviö, J., Koivisto, E., Björklund, M., Kaukua, J. and Riekkinen, Jr., P.
Modulation of rat neocortical high-voltage spindle activity by 5-HT_1/5-HT_2 receptor subtype specific drugs (282) 39
Jakubík, J. and Tuček, S.
Positive allosteric interactions on cardiac muscarinic receptors: effects of chemical modifications of disulphide and carboxyl groups (289) 311
Jansson, C.C., Karp, M., Oker-Blom, C., Näsman, J., Savola, J.-M. and Åkerman, K.E.O.
Two human α_2-adrenoceptor subtypes α_2A-C10 and α_2B-C2 expressed in *Sf9* cells couple to transduction pathway resulting in opposite effects on cAMP production (290) 75
Jansson, L., see Svensson, A.M. (275) 99
Janszen, A.W.J.W., see Schmidt, E.D. (285) 317
Jantos, H., see Ponzoni, A. (278) 111
Janzowski, C., see Schmalix, W.A. (293) 123
Janzowsky, C., see Gangolli, S.D. (292) 1
Jarman, J., see Pattichis, K. (292) 173
Järv, J., Hautala, R. and Åkerman, K.E.O.
Dual effect of muscarinic receptor agonists on Ca^{2+} mobilization in SH-SY5Y neuroblastoma cells (291) 43
Jayakumar, A.R., see Paul, V. (293) 355
Jazbik, W., see Criddle, D.N. (286) 123
Jenkinson, K.M., Reid, J.J. and Rand, M.J.
Hydroxocobalamin and haemoglobin differentiate between exogenous and neuronal nitric oxide in the rat gastric fundus (275) 145
Jenner, P., see Gnanalingham, K.K. (277) 235
Jerome, G.M., see Connor, J.R. (273) 15
Jerram, A.H., Darlington, C.L. and Smith, P.F.
Methylprednisolone reduces spontaneous nystagmus following unilateral labyrinthectomy in guinea pig (275) 291
Jewett, D., see Kilbourn, M. (278) 249
Jeziorski, M. and White, F.J.
Dopamine receptor antagonists prevent expression, but not development, of morphine sensitization (275) 235
Jhanwar-Uniyal, M., see Rouru, J. (273) 99
Jiang, Q., see Lau, W.A.K. (272) 31
Jiménez, J., see Duarte, J. (286) 115
Jimenez del Rio, M., see Velez Pardo, C. (288) 209
Jinsi, A. and Deth, R.C.
α_2-Adrenoceptor-mediated vasoconstriction requires a tyrosine kinase (277) 29
Jinsi, A., see Aburto, T. (277) 35
Johansen, P.A. and Robinson, M.B.
Identification of 2-amino-2-methyl-4-phosphonobutanoic acid as an antagonist at the $mGlu_{4a}$ receptor (290) R1
Johansson, U., Fredriksson, A. and Eriksson, P.
Bioallethrin causes permanent changes in behavioural and muscarinic acetylcholine receptor variables in adult mice exposed neonatally to DDT (293) 159
Johns, E.J., see Huang, C. (282) 1
Johnson, D.H., Svensson, A.I., Engel, J.A. and Söderpalm, B.
Induction but not expression of behavioural sensitization to nicotine in the rat is dependent on glucocorticoids (276) 155
Johnson, M., see Che, S. (293) 447
Johnson, M.D., see Gurdal, H. (274) 117
Johnston, A., see Conlon, D. (289) 283
Jolles, J., see Terwel, D. (287) 65
Jones, D., see Forster, E.A. (281) 81

Jones, P.G., Curtis, C.A.M. and Hulme, E.C.
The function of a highly-conserved arginine residue in activation of the muscarinic M_1 receptor (288) 251
Jones, P.G., see Page, K.M. (289) 429
Jones, R., see Sugden, D. (287) 239
Jones, R.L., see Wise, H. (278) 265
Joos, G.F., Lefebvre, R.A., Kips, J.C. and Pauwels, R.A.
Tachykinins contract trachea from Fischer 344 rats by interaction with a tachykinin NK_1 receptor (271) 47
Jortani, S.A., see Mansbach, R.S. (274) 167
Jouvenceau, A., Dutar, P. and Billard, J.-M.
Presynaptic depression of inhibitory postsynaptic potentials by metabotropic glutamate receptors in rat hippocampal CA1 pyramidal cells (281) 131
Jovanović, A. and Terzic, A.
Diadenosine-hexaphosphate is an inhibitory ligand of myocardial ATP-sensitive K^+ channels (286) R1
Jovanović, A., Grbović, L. and Jovanović, S.
K^+ channel blockers do not modify relaxation of guinea-pig uterine artery evoked by acetylcholine (280) 95
Jovanović, A., Grbović, L., Jovanović, S. and Žikić, I.
Effect of pregnancy on vasopressin-mediated responses in guinea-pig uterine arteries with intact and denuded endothelium (280) 101
Jovanović-Mićić, D., Samardžić, R. and Beleslin, D.B.
The role of α-adrenergic mechanisms within the area postrema in dopamine-induced emesis (272) 21
Jovanović, S., see Jovanović, A. (280) 101
Jovanović, S., see Jovanović, A. (280) 95
Junien, J.-L., see Diop, L. (271) 65
Junien, J.-L., see Langlois, A. (271) 245
Junien, J.-L., see O'Neill, M. (283) 217
Justice, Jr., J.B., see Schad, C.A. (275) 9
Juvonen, R.O., see Pelkonen, P. (292) 67

Kaan, S.K., see Woo, P.C.Y. (293) 217
Kadota, T., see Horiuchi, H. (287) 27
Kadowitz, P.J., see Kaye, A.D. (276) 21
Kadowitz, P.J., see Kaye, A.D. (287) 163
Kadowitz, P.J., see Santiago, J.A. (272) 115
Kaelin-Lang, A., see Sprumont, P. (274) 95
Kageyama, M., see Matsugi, T. (275) 245
Kai, Y., see Hara, M. (283) 83
Kajita, Y., see Anzai, M. (285) 173
Kakinoki, B., see Sakai, H. (291) 153
Kaku, K., see Inoue, Y. (284) 77
Kaku, S., Kawasaki, T., Sakai, Y., Taniuchi, Y., Yano, S., Suzuki, K.-i., Terazaki, C., Kawamura, K., Masuho, Y., Satoh, N., Takenaka, T., Yanagi, K. and Ohshima, N.
Antithrombotic effect of a humanized anti-GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys (279) 115
Kalant, H., see Wu, P.H. (281) 263
Kaliszan, R., see Nasal, A. (274) 125
Kalkman, H.O. and Neumann, V.
Evidence for a 5-HT_{1D} receptor-mediated hypothermic effect of the α_1-adrenoceptor agonist, SDZ NVI-085, in guinea-pigs (285) 313
Kamada, H., see Hatta, S. (291) 351
Kamada, M., see Hamada, Y. (288) 45
Kamataki, T., see Chiba, K. (293) 97
Kamato, T., see Miyata, K. (276) 165
Kamei, H., Kameyama, T. and Nabeshima, T.
Activation of both dopamine D_1 and D_2 receptors necessary for amelioration of conditioned fear stress (273) 229
Kamei, J., Saitoh, A., Ohsawa, M., Suzuki, T., Misawa, M., Nagase, H. and Kasuya, Y.
Antinociceptive effects of the selective non-peptidic δ-opioid receptor agonist TAN-67 in diabetic mice (276) 131
Kamei, J., Saitoh, A., Ohsawa, M., Suzuki, T., Misawa, M., Nagase, H. and Kasuya, Y.
Corrigendum to 'Antinociceptive effects of the selective non-peptide δ-opioid receptor agonist TAN-67 in diabetic mice' [Eur. J. Pharmacol. 276 (1995) 131–135] (280) 347
Kamei, J., Suzuki, T., Misawa, M., Nagase, H. and Kasuya, Y.
Antinociceptive effect of dihydroetorphine in diabetic mice (275) 109
Kameyama, T., see Hiramatsu, M. (282) 185
Kameyama, T., see Kamei, H. (273) 229
Kameyama, T., see Ukai, M. (274) 89
Kameyama, T., see Ukai, M. (281) 173
Kameyama, T., see Ukai, M. (287) 245
Kamigaki, M., Ichihara, K., Kohgo, Y. and Abiko, Y.
Effect of glibenclamide on ischemic canine myocardium with glucose infusion (287) 121
Kamiyama, T., Tanonaka, K., Harada, H., Nakai, K. and Takeo, S.
Mexiletine and lidocaine reduce post-ischemic functional and biochemical dysfunction of perfused hearts (272) 151
Kampen, I.M., see Van Birgelen, A.P.J.M. (293) 77
Kampine, J.P., see Tseng, L.F. (287) 169
Kanaide, H., see Kodama, M. (288) 69
Kanbe, T., see Ikeda, U. (288) 379
Kanbe, T., see Ikeda, U. (290) 69
Kaneko, T., Ikeda, H., Fu, L., Nishiyama, H. and Okubo, T.
Platelet-activating factor mediates the ozone-induced increase in airway microvascular leakage in guinea pigs (292) 251
Kaneko, T., see Inoue, Y. (284) 77
Kang, C.H., see Decker, M.W. (280) 79
Kangawa, K., see Kato, J. (289) 383
Kankaanranta, H., Wuorela, H., Siltaloppi, E., Vuorinen, P., Vapaatalo, H. and Moilanen, E.
Inhibition of human neutrophil function by tolfenamic acid involves inhibition of Ca^{2+} influx (291) 17
Kanno, M., see Gando, S. (289) 175
Kanno, M., see Hattori, Y. (279) 51
Kano, T., see Seki, Y. (275) 259
Kansra, V., Chen, C. and Lokhandwala, M.F.
Dopamine causes stimulation of protein kinase C in rat renal proximal tubules by activating dopamine D_1 receptors (289) 391
Kao, L.-S., see Liu, P.-S. (291) 265
Kapusta, D.R., see Mosaddeghi, M. (289) 411
Karaki, H., see Miasiro, N. (285) 247
Karaki, H., see Sudjarwo, S.A. (289) 197
Karall, S., see Zezula, J. (281) 93
Karcz-Kubicha, M. and Liljequist, S.
Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test (279) 171
Karhu, S., Perttula, S., Weckström, M., Kivistõ, T. and Sellin, L.C.
Salicylaldoxime blocks K^+ and Ca^{2+} currents in rat cardiac myocytes (279) 7
Karita, K., see Izumi, H. (273) 299
Karle, J. and Nielsen, M.
Modest reduction of benzodiazepine binding in rat brain in vivo induced by antisense oligonucleotide to $GABA_A$ receptor γ_2 subunit subtype (291) 439
Karliner, J.S., see Rocha-Singh, K.J. (288) 349
Karlsson, S., see Ahrén, B. (280) 27
Karp, M., see Jansson, C.C. (290) 75
Kashima, K., see Kato, M. (292) 47
Kashiwai, K.T., see Tseng, Y.T. (289) 353
Kasper, K., see Stark, G. (286) 71
Kasuya, Y., see Kamei, J. (275) 109
Kasuya, Y., see Kamei, J. (276) 131

Kasuya, Y., see Kamei, J. (280) 347
Katano, K., see Nagura, J. (274) 201
Kataoka, K., see Kato, M. (292) 47
Kataoka, Y., Koizumi, S., Kohzuma, M., Shibaguchi, H., Shigematsu, K., Niwa, M. and Taniyama, K.
NMDA receptor involvement in endothelin neurotoxicity in rat striatal slices (273) 285
Katayama, T., see Mineo, H. (280) 149
Katayama, Y., see Kita, Y. (275) 125
Kato, H., Araki, T., Itoyama, Y. and Kogure, K.
Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil (272) 107
Kato, H., see Araki, T. (278) 91
Kato, J., Kitamura, K., Kangawa, K. and Eto, T.
Receptors for adrenomedullin in human vascular endothelial cells (289) 383
Kato, K., see Nakayama, K. (276) 77
Kato, K., see Nakayama, K. (276) 85
Kato, M., Ohkuma, S., Kataoka, K., Kashima, K., Mukainaka, T. and Kuriyama, K.
Mechanisms for pancreatic hypertrophy induced by long-term administration of bethanechol (292) 47
Kato, M., see Kita, Y. (275) 125
Kato, S., see Mineo, H. (280) 149
Katoh, F., see Niina, H. (286) 95
Katori, M., see Majima, M. (284) 1
Katsumata, S., Minami, M., Nakagawa, T. and Satoh, M.
Intracisternal administration of interleukin-1β attenuates naloxone-precipitated withdrawal in morphine-dependent mice (278) 143
Katsumata, S., Minami, M., Nakagawa, T., Iwamura, T. and Satoh, M.
Pharmacological study of dihydroetorphine in cloned μ-, δ- and κ-opioid receptors (291) 367
Katsura, M., see Iino, T. (286) 99
Katsuragi, T., Tokunaga, T., Sato, C. and Furukawa, T.
Possible neuronal origin of ATP release evoked by forskolin and ouabain from guinea-pig atrial segments (282) 213
Katyare, S.S., see Parmar, D.V. (293) 225
Katz, J.L., see Acri, J.B. (281) R7
Kaukua, J., see Jäkälä, P. (282) 39
Kaupmann, K., see Hoyer, D. (289) 151
Kaur, S. and Starr, M.S.
Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse (280) 159
Kawabata, T., see Hara, M. (289) 267
Kawahara, Y., see Ikeda, U. (290) 69
Kawakami, H., see Yamashita, H. (289) 387
Kawakami, M., see Hara, M. (289) 267
Kawamura, K., see Kaku, S. (279) 115
Kawamura, R., see Ito, C. (285) 37
Kawano, K.-i., see Nagura, J. (274) 201
Kawasaki, H., see Hattori, Y. (279) 51
Kawasaki, T., see Kaku, S. (279) 115
Kawase, S., see Hagihara, K. (271) 159
Kawashima, A., see Nitta, K. (293) 491
Kawashima, T., see Chowdhury, S.A. (285) 99
Kawikova, I., Arakawa, H., Petersson, M., Löfdahl, C.-G., Skoogh, B.-E. and Lötvall, J.
Bradykinin-induced release of thromboxane B_2 into bronchoalveolar lavage fluid of guinea pigs: relationship to airflow obstruction (280) 293
Kaya, H., see Ohkubo, T. (273) 83
Kaye, A.D., Nossaman, B.D., Ibrahim, I.N., Feng, C.J., McNamara, D.B., Agrawal, K.C. and Kadowitz, P.J.
Analysis of responses of allicin, a compound from garlic, in the pulmonary vascular bed of the cat and in the rat (276) 21
Kaye, A.D., Nossaman, B.D., Kivlighn, S., Ibrahim, I.N., De Witt, B.J. and Kadowitz, P.J.
Responses to L-163,491, a nonpeptide angiotensin II mimic, in the pulmonary vascular bed of the cat (287) 163
Kayser, V., see Keïta, H. (277) 275
Kazi, M., see Paul, V. (293) 355
Keana, J.F.W., see Lutfy, K. (273) 187
Keely, S.J., Stack, W.A., O'Donoghue, D.P. and Baird, A.W.
Regulation of ion transport by histamine in human colon (279) 203
Kehne, J.H., Baron, B.M., Harrison, B.L., McCloskey, T.C., Palfreyman, M.G., Poirot, M., Salituro, F.G., Siegel, B.W., Slone, A.L., Van Giersbergen, P.L.M. and White, H.S.
MDL 100,458 and MDL 102,288: two potent and selective glycine receptor antagonists with different functional profiles (284) 109
Keil, II, G.J. and DeLander, G.E.
Adenosine kinase and adenosine deaminase inhibition modulate spinal adenosine- and opioid agonist-induced antinociception in mice (271) 37
Keïta, H., Kayser, V. and Guilbaud, G.
Antinociceptive effect of a κ-opioid receptor agonist that minimally crosses the blood-brain barrier (ICI 204448) in a rat model of mononeuropathy (277) 275
Kellar, K.J., see London, E.D. (278) R1
Kelly, J., see O'Neill, M. (283) 217
Kelly, J.P., see Caldwell, M. (285) 203
Kelly, J.P., see Maginn, M. (282) 259
Kelly, M., see Berger, I. (277) 195
Kennedy, C., see McLaren, G.J. (277) 57
Keränen, A., see Komulainen, H. (293) 167
Kerezoudis, N.P., Nomikos, G.G., Olgart, L.M. and Svensson, T.H.
Serotonin in rat oral tissues: role of 5-HT_1 receptors in sympathetic vascular control (275) 191
Kerkhoff, B., see Buckley, T.L. (282) 103
Kerr, D.I.B., Ong, J., Doolette, D.J., Schafer, K. and Prager, R.H.
The (*S*)-enantiomer of 2-hydroxysaclofen is the active $GABA_B$ receptor antagonist in central and peripheral preparations (287) 185
Kerr, D.I.B., see Ong, J. (287) 197
Kerr, D.J., see Malkhandi, J. (288) 105
Kervran, A., see Gros, L. (288) 319
Kessler, T. and Lugnier, C.
Rolipram increases cyclic GMP content in L-arginine-treated cultured bovine aortic endothelial cells (290) 163
Keuskamp, Z.J., see Van Dijk, J.P.M. (278) R11
Khalil, Z., see Ralevic, V. (284) 231
Khan, R., see Lindberg, S. (285) 275
Khan, S., Brooks, N., Whelpton, R. and Michael-Titus, A.T.
Substance P-(1–7) and substance P-(5–11) locally modulate dopamine release in rat striatum (282) 229
Khandkar, M.A., see Parmar, D.V. (293) 225
Kiang, J.G.
Mystixin-7 and mystixin-11 increase cytosolic free Ca^{2+} and inositol trisphosphates in human A-431 cells (291) 107
Kiem, D.T., Fekete, M.I.K. and Makara, G.B.
Diurnal alteration in opiate effects on the hypothalamo-pituitary-adrenal axis: changes in the mechanism of action (272) 145
Kiem, D.T., see Makara, G.B. (287) 43
Kigoshi, S., see Takakura, K. (271) 367
Kijima, H., see Ito, C. (285) 37
Kikuchi, T., see Huang, Q. (271) R5
Kikusui, M., see Ohno, M. (271) 557
Kilbourn, M., Lee, L., Vander Borght, T., Jewett, D. and Frey, K.
Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific (278) 249
Kilfeather, S., see Conlon, D. (289) 283
Kilfeather, S., see Seeds, E.A.-M. (293) 369
Killam, A.L., Watts, S.W. and Cohen, M.L.

Role of α_1-adrenoceptors and 5-HT_2 receptors in serotonin-induced contraction of rat prostate: autoradiographical and functional studies (273) 7
Kilpatrick, E., see Grider, J. (287) 101
Kilpatrick, I.C., see Main, D.C.J. (287) 221
Kim, J., see Von Lubitz, D.K.J.E. (283) 185
Kimata, N., see Nitta, K. (293) 491
Kimes, A.S., see London, E.D. (278) R1
Kimura, K., see Obika, K. (291) 327
Kimura, R., see Nozawa, Y. (287) 191
Kimura, S., see He, H. (273) 209
Kimura, S., see Nishiyama, M. (286) 209
King, B.F., see Simon, J. (291) 281
King, K.A., Lim, S.L. and Pang, C.C.Y.
Regional haemodynamic effects of platelet activating factor in the rat (281) 187
King, P.R., Suzuki, S., Louis, W.J. and Gundlach, A.L.
Differential characteristics and localisation of [^{3}H]oxazoline and [^{3}H]imidazoline binding sites in rat kidney (281) 341
Kinoshita, K., Fujitsuka, T., Yamamura, M. and Matsuoka, Y.
Effects of TA-0910, a novel orally active thyrotropin-releasing hormone analog, on the gait of ataxic animals (274) 65
Kips, J.C., see Joos, G.F. (271) 47
Kiran, B.K., see Buyukuysal, R.L. (281) 179
Kita, T., see Asagoe, K. (275) 179
Kita, T., see He, H. (273) 209
Kita, Y., Ohkubo, K., Hirasawa, Y., Katayama, Y., Ohno, M., Nishino, S., Kato, M. and Yoshida, K.
FR144420, a novel, slow, nitric oxide-releasing agent (275) 125
Kita, Y., see Hirasawa, Y. (272) 39
Kita, Y., see Terai, T. (279) 217
Kitagawa, S., see Shinozuka, K. (292) 115
Kitamura, K., see Kato, J. (289) 383
Kitamura, K., see Niina, H. (286) 95
Kitamura, M., see Saigusa, T. (274) 213
Kitamura, Y., Arima, T., Imaizumi, R., Sato, T. and Nomura, Y.
Inhibition of constitutive nitric oxide synthase in the brain by pentamidine, a calmodulin antagonist (289) 299
Kitchen, M.T., see Ichikawa, J. (287) 179
Kiuchi, Y., see Ito, C. (285) 37
Kiuchi, Y., see Nakachi, N. (281) 195
Kivistö, T., see Karhu, S. (279) 7
Kivlighn, S., see Kaye, A.D. (287) 163
Kiyama, R., see Hara, M. (289) 267
Kizawa, Y., see Kusama, T. (291) 431
Kleinrok, Z., see Borowicz, K.K. (281) 319
Kleinrok, Z., see Czuczwar, S.J. (281) 327
Klemm, P., Harris, H.J. and Perretti, M.
Effect of rolipram in a murine model of acute inflammation: comparison with the corticoid dexamethasone (281) 69
Kleven, M., Ybema, C., Carilla, E., Hamon, M. and Koek, W.
Modification of behavioral effects of 8-hydroxy-2-(di-*n*-propylamino)tetralin following chronic ethanol consumption in the rat: evidence for the involvement of 5-HT_{1A} receptors in ethanol dependence (281) 219
Kleven, M., see Nevo, I. (281) 229
Klockgether, T., see Löschmann, P.-A. (284) 129
Knapp, R.J., Landsman, R., Waite, S., Malatynska, E., Varga, E., Haq, W., Hruby, V.J., Roeske, W.R., Nagase, H. and Yamamura, H.I.
Properties of TAN-67, a nonpeptidic δ-opioid receptor agonist, at cloned human δ- and μ-opioid receptors (291) 129
Knight, D.A., Stewart, G.A. and Thompson, P.J.
Prostaglandin E_2, but not prostacyclin inhibits histamine-induced contraction of human bronchial smooth muscle (272) 13
Knight, D.A., Stewart, G.A., Lai, M.L. and Thompson, P.J.
Epithelium-derived inhibitory prostaglandins modulate human bronchial smooth muscle responses to histamine (272) 1
Knöpfel, T., Sakaki, J., Flor, P.J., Baumann, P., Sacaan, A.I., Veliçelebi, G., Kuhn, R. and Allgeier, H.
Profiling of trans-azetidine-2,4-dicarboxylic acid at the human metabotropic glutamate receptors $mGlu_{1b}$, $_{2}$, $_{4a}$ and $_{5a}$ (288) 389
Knorr, A., see Sommermeyer, H. (276) 267
Ko, F.-N., see Guh, J.-H. (279) 33
Ko, Y., see Flesch, M. (289) 399
Kobayashi, H., see Mizuki, T. (277) 133
Kobayashi, H., see Niina, H. (286) 95
Kobayashi, J., see Takahashi, Y. (288) 285
Kobayashi, K., see Chiba, K. (293) 97
Kobayashi, M., see Hirose, H. (277) 77
Kobayashi, M., see Hirose, H. (284) 335
Kobayashi, M., see Miwa, Y. (277) 63
Kobayashi, M., see Saigusa, T. (274) 213
Kobayashi, T., see Ukai, M. (274) 89
Kobayashi, T., see Ukai, M. (287) 245
Koch, R., see Rundfeldt, C. (274) 73
Koch, T., see Sebens, J.B. (273) 175
Kodama, M., Yamamoto, H. and Kanaide, H.
Myosin phosphorylation and Ca^{2+} sensitization in porcine coronary arterial smooth muscle stimulated with endothelin-1 (288) 69
Koek, W., see Kleven, M. (281) 219
Koek, W., see Nevo, I. (281) 229
Koeman, J.H., see Gangolli, S.D. (292) 1
Koeman, J.H., see Van Birgelen, A.P.J.M. (293) 77
Koenig, M., see Damgé, C. (274) 133
Kogure, K., see Araki, T. (278) 91
Kogure, K., see Kato, H. (272) 107
Kohen, R., see Eshhar, N. (283) 19
Kohgo, Y., see Kamigaki, M. (287) 121
Kohno, S., see Yamamura, H. (288) 269
Kohzuma, M., see Kataoka, Y. (273) 285
Koike, H., see Mizuno, M. (285) 181
Koike, K., Horinouchi, T. and Takayanagi, I.
Possible mechanisms of β-adrenoceptor-mediated relaxation induced by noradrenaline in guinea pig taenia caecum (279) 159
Koivisto, E., see Jäkälä, P. (282) 39
Koivisto, E., see Ylinen, A. (274) 159
Koizumi, S., see Kataoka, Y. (273) 285
Kojda, G., Brixius, K., Kottenberg, K., Nix, P., Schlüter, K.-D., Piper, H.M. and Noack, E.
The new NO donor SPM3672 increases cGMP and improves contraction in rat cardiomyocytes and isolated heart (284) 315
Kokubu, N., Satoh, M. and Takayanagi, I.
Involvement of botulinum C_3-sensitive GTP-binding proteins in α_1-adrenoceptor subtypes mediating Ca^{2+}-sensitization (290) 19
Koley, B., see Koley, J. (293) 483
Koley, J., Sinha, S., Basak, A.K., Das, M., Dube, S.N., Majumder, P.K., Gupta, A.K., Dasgupta, S. and Koley, B.
Cardiovascular and respiratory changes following exposure to a synthetic toxin of *Ptychodiscus brevis* (293) 483
Komori, S., Itagaki, M., Unno, T. and Ohashi, H.
Caffeine and carbachol act on common Ca^{2+} stores to release Ca^{2+} in guinea-pig ileal smooth muscle (277) 173
Komoriya, K., see Horiuchi, H. (287) 27
Komulainen, H., Keränen, A. and Saano, V.
Triethyllead decreases central benzodiazepine receptor binding in rat cerebellum ex vivo (293) 167
Kondo, M., see Sakai, A. (291) 375
Kongsamut, S., see Roehr, J. (278) 75
Konishi, T., see Chowdhury, S.A. (285) 99
Konishi, T., see Miyahara, M. (284) 25
Konno, F., see Nagura, J. (274) 201
Konno, K., see Sakai, A. (291) 375
Konno, K., see Tamaoki, J. (278) 161
Konno, K., see Tamaoki, J. (287) 233

Konrad, D., see Raud, J. (282) 207
Konturek, S.J., Brzozowski, T., Bielanski, W. and Schally, A.V.
Role of endogenous gastrin in gastroprotection (278) 203
Konturek, S.J., Brzozowski, T., Pytko-Polonczyk, J. and Drozdowicz, D.
Exogenous and endogenous cholecystokinin protects gastric mucosa against the damage caused by ethanol in rats (273) 57
Koob, G.F., see De Fonseca, F.R. (274) 47
Koob, G.F., see Hyytiä, P. (283) 151
Koopman-Esseboom, C., see Brouwer, A. (293) 1
Kopin, I.J., see Yadid, G. (288) 399
Koppe, J.G., see Brouwer, A. (293) 1
Kordon, C., see Rasolonjanahary, R. (285) 19
Korf, J., see Sebens, J.B. (273) 175
Környei, J.L., see Vértes, Z. (291) 115
Korotzer, A.R., Whittemore, E.R. and Cotman, C.W.
Differential regulation by β-amyloid peptides of intracellular free Ca^{2+} concentration in cultured rat microglia (288) 125
Korpi, E.R., see Wong, G. (289) 335
Korte, S.M., Buwalda, B., Meijer, O., De Kloet, E.R. and Bohus, B.
Socially defeated male rats display a blunted adrenocortical response to a low dose of 8-OH-DPAT (272) 45
Koshida, Y., see Miwa, Y. (277) 63
Koshikawa, N., see Cools, A.R. (286) 41
Koshikawa, N., see Miwa, Y. (277) 63
Koshikawa, N., see Saigusa, T. (274) 213
Kosmas, E.N., Levy, R.D. and Hussain, S.N.A.
Acute effects of glyburide on the regulation of peripheral blood flow in normal humans (274) 193
Kostenis, E., see Maaß, A. (272) 103
Kostrzewa, R.M., see Huang, N.-Y. (271) 433
Kosuge, K., see Umemura, K. (275) 17
Kottenberg, K., see Kojda, G. (284) 315
Koulu, M., see Rouru, J. (273) 99
Koumi, S.-i., Sato, R. and Hayakawa, H.
The activation gate of cardiac Na^+ channel modulates voltage- and pH-dependent unbinding of disopyramide (277) 165
Kovács, K.J. and Larson, A.A.
Discrepancies in characterization of σ sites in the mouse central nervous system (285) 127
Kovács, S., see Vértes, Z. (291) 115
Kow, L.-M. and Pfaff, D.W.
Functional analyses of α_1-adrenoceptor subtypes in rat hypothalamic ventromedial nucleus neurons (282) 199
Kozutsumi, D., see Takahashi, Y. (288) 285
Kradel, B.K., see Monroe, P.J. (272) 51
Krause, D.N., Barrios, V.E. and Duckles, S.P.
Melatonin receptors mediate potentiation of contractile responses to adrenergic nerve stimulation in rat caudal artery (276) 207
Krause, E., see Cross, L.J.M. (291) 291
Krause, G., see Cross, L.J.M. (291) 291
Kreft, A., see Glaser, K. (281) 107
Kreiss, D.S., Bergstrom, D.A., Gonzalez, A.M., Huang, K.-X., Sibley, D.R. and Walters, J.R.
Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D_3 receptor binding affinities (277) 209
Kremer, J., Lai, Z.-W. and Esser, C.
Evidence for the promotion of positive selection of thymocytes by Ah receptor agonist 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (293) 413
Krenning, E.P., see Reubi, J.C. (271) 371
Kretschmer, B.D., Bubser, M. and Schmidt, W.J.
Behavioral and neurochemical actions of the strychnine-insensitive glycine receptor antagonist, 7-chlorokynurenate, in rats (280) 37
Kreutter, D.K., see Berkowitz, D.E. (289) 223
Krieglstein, J., see Prehn, J.H.M. (292) 179
Krogsgaard-Larsen, P., see Arnt, J. (285) 289
Krogsgaard-Larsen, P., see Nielsen, M. (289) 109
Kronevi, T., see Hemming, H. (292) 241
Kubrak, D., see Glaser, K. (281) 107
Kucharewicz, S.A., see Zgombick, J.M. (291) 9
Kuehne, M.E., see Bowen, W.D. (279) R1
Kuhn, M., see Bäsler, I. (291) 335
Kuhn, R., see Knöpfel, T. (288) 389
Kuipers, R., see Hoiting, B.H. (290) R5
Kujacic, M. and Carlsson, A.
In vivo activity of tyrosine hydroxylase in rat adrenal glands following administration of quinpirole and dopamine (278) 9
Kujacic, M., Hansson, L.O. and Carlsson, A.
Acute dopaminergic influence on plasma adrenaline levels in the rat (273) 247
Kulagowski, J.J., see Grimwood, S. (290) 221
Kulig, B.M., see Brouwer, A. (293) 1
Kumagai, S., see Sakai, H. (291) 153
Kumar, A., Raghubir, R. and Dhawan, B.N.
Possible involvement of nitric oxide in red nucleus stimulation-induced analgesia in the rat (279) 1
Kunitomo, M., see Shinozuka, K. (292) 115
Kunos, G., see Varga, K. (278) 279
Kuo, H.-P., see Hayes, J.P. (292) 127
Kuo, J.-S., see Wang, J.-P. (273) 73
Kuo, S.-C., see Wang, J.-P. (272) 87
Kuo, S.-C., see Wang, J.-P. (273) 73
Kuo, S.-C., see Yu, S.-M. (280) 69
Kuo, Y.-H., see Wang, J.-P. (288) 341
Kurahashi, K., see Nishimura, Y. (275) 217
Kuraishi, Y., Nagasawa, T., Hayashi, K. and Satoh, M.
Scratching behavior induced by pruritogenic but not algesiogenic agents in mice (275) 229
Kurata, C., Callahan, R.J., Molea, N., Wilkinson, R., Fischman, A.J. and Strauss, H.W.
Localization of [^{125}I]endothelin-1 in injured aorta of rabbits (293) 109
Kuribara, H.
Modification of morphine sensitization by opioid and dopamine receptor antagonists: evaluation by studying ambulation in mice (275) 251
Kuribayashi, Y., see Majima, M. (284) 1
Kuriyama, K., see Iino, T. (286) 99
Kuriyama, K., see Kato, M. (292) 47
Kurjak, M., Schusdziarra, V. and Allescher, H.-D.
Release of somatostatin-like immunoreactivity from enriched enteric nerve varicosities of rat ileum (281) 295
Kuroiwa, A., see Mizuki, T. (277) 133
Kuroki, T., see Ichikawa, J. (287) 179
Kuroki, T., see Yonezawa, Y. (285) 305
Kusaka, M. and Sperelakis, N.
Veratridine actions on two types of fast Na^+ channels in human uterine leiomyosarcoma cells (271) 387
Kusama, T., Sakurai, M., Kizawa, Y., Uhl, G.R. and Murakami, H.
GABA ρ_1 receptor: inhibition by protein kinase C activators (291) 431
Kusunoki, T., see Terai, T. (279) 217
Kvist, S., see Videbæk, L.M. (274) 109
Kwon, I.-S., see Lutfy, K. (273) 187

Labat, C., see Gorenne, I. (275) 207
LaBella, F.S. and Queen, G.
Subanesthetic concentrations of drugs inhibit cytochrome P450-mediated metabolism of aniline (293) 231
Lach, E., Coy, D.H., Dumont, P., Landry, Y. and Gies, J.-P.
Erratum to 'Gastrin releasing peptide-preferring bombesin binding sites in human lung' [Eur. J. Pharmacol. 265 (1994) 117–120] (273) 313
Lad, N., see Laight, D.W. (292) 81
Ladenheim, B., see Elmer, G.I. (283) 227
Ladenheim, E.E., Taylor, J.E., Coy, D.H. and Moran, T.H.

Blockade of feeding inhibition by neuromedin B using a selective receptor antagonist (271) R7
Lafontan, M., see Bousquet-Mélou, A. (289) 235
Lagente, V., see Hichami, A. (291) 91
Lai, M.L., see Knight, D.A. (272) 1
Lai, Z.-W., see Kremer, J. (293) 413
Laight, D.W., Lad, N., Woodward, B. and Waterfall, J.F.
Assessment of myeloperoxidase activity in renal tissue after ischaemia/reperfusion (292) 81
Lainton, J.A.H., see Pertwee, R.G. (284) 241
Laissue, J.A., see Reubi, J.C. (271) 371
Laitinen, J.T., see Laitinen, K.S.M. (285) 159
Laitinen, K.S.M., Tuomisto, L. and Laitinen, J.T.
Endogenous serotonin modulates histamine release in the rat hypothalamus as measured by in vivo microdialysis (285) 159
Laitinen, K.S.M., Tuomisto, L. and MacDonald, E.
Effects of a selective α_2-adrenoceptor antagonist, atipamezole, on hypothalamic histamine and noradrenaline release in vivo (285) 255
Lajiness, M.E., see Mierau, J. (290) 29
Lake, K., see Varga, K. (278) 279
Lallement, G., see Bodjarian, N. (289) 291
Lallement, J.-C., Oiry, C., Lima-Leite, A.-C., Lignon, M.-F., Fulcrand, P., Galleyrand, J.-C. and Martinez, J.
Cholecystokinin and gastrin are not equally sensitive to GTPγS at CCK_B receptors: importance of the sulphated tyrosine (290) 61
Lamarche, I., see Dol, F. (280) 135
Lamarque, D. and Whittle, B.J.R.
Role of oxygen-derived metabolites in the rat gastric mucosal injury induced by nitric oxide donors (277) 187
Lambert, D.G., see Willets, J.M. (293) 319
Lambert, K.A., see Woodcock, E.A. (291) 213
Lambrecht, G., see Pfaff, O. (286) 229
Lamiable, D., see Garay, R.P. (274) 175
Lammerstma, A.A., see Pike, V.W. (283) R1
Lammertsma, A.A., see Hume, S.P. (271) 515
Lampugnani, P., see Sala, M. (273) 35
Lan, N.C., see McCauley, L.D. (276) 145
Lan, N.C., see Yang, W. (291) 319
Lança, A.J., see Wu, P.H. (281) 263
Landry, Y., see Emadi-Khiav, B. (272) 97
Landry, Y., see Lach, E. (273) 313
Landry, Y., see Mousli, M. (289) 125
Landsiedel, R., see Schmalix, W.A. (293) 123
Landsman, R., see Knapp, R.J. (291) 129
Lang, A., see Männistö, P.T. (274) 229
Lang, F., see Herzer, T. (291) 205
Lang, M.A., see Pelkonen, P. (292) 67
Langenegger, D., see Hoyer, D. (289) 151
Langenegger, D., see Schoeffter, P. (289) 163
Langer, S.Z., see Le Rouzic, M. (278) 261
Langer, S.Z., see Pimoule, C. (290) 49
Langlois, A., Diop, L., Rivière, P.J.M., Pascaud, X. and Junien, J.-L.
Effect of fedotozine on the cardiovascular pain reflex induced by distension of the irritated colon in the anesthetized rat (271) 245
Langlois, X., see Nevo, I. (281) 229
Lanz, I., see Amann, R. (279) 227
Laporte, A.-M., Lima, L., Gozlan, H. and Hamon, M.
Selective in vivo labelling of brain 5-HT_{1A} receptors by [^{3}H]WAY 100635 in the mouse (271) 505
Laporte, A.-M., see Gozlan, H. (288) 173
Laporte, A.-M., see Nevo, I. (281) 229
La Riccia, M., see Pontieri, F.E. (284) 205
Larkin, S., see Belvisi, M. (283) 255
Larson, A.A., see Budai, D. (278) 39
Larson, A.A., see Kovács, K.J. (285) 127
Laruelle, C., see Hajri, T. (286) 131
Lasheras, B., see Aguirre, N. (281) 101
Lassen, A.N., see Videbæk, C. (281) 117
László, F. and Whittle, B.J.R.
Colonic microvascular integrity in acute endotoxaemia: interactions between constitutive nitric oxide and 5-lipoxygenase products (277) R1
László, F., Whittle, B.J.R., Evans, S.M. and Moncada, S.
Association of microvascular leakage with induction of nitric oxide synthase: effects of nitric oxide synthase inhibitors in various organs (283) 47
Laszlo, F., Evans, S.M. and Whittle, B.J.R.
Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo (272) 169
Lau, W.A.K., Ventura, S., Jiang, Q. and Pennefather, J.N.
Endothelin-induced facilitation of sympathetic neurotransmission to the rat vas deferens: effects of suramin (272) 31
Laubie, M., see Vayssettes-Courchay, C. (285) 299
Laufer, S., see Wallace, J.L. (271) 525
Lavarenne, J., see Bétoin, F. (279) 241
Lavidis, N.A.
The effect of opiates on the secretion of transmitter from amphibian motor nerve terminals (276) 71
Lavie, P., see Nave, R. (275) 213
Lavoie, N., see Dennis, T. (272) 279
Laycock, J.F.
Desamino-8D-arginine vasopressin treatment of Brattleboro rats: effect on sensitivity to pressor hormones (271) 193
Layer, R., see Popik, P. (291) 221
Lazzeri, G., see Blandizzi, C. (278) 179
Lecca, D., see Giorgi, O. (290) 37
Leclerc, L., see Zaidi, A. (290) 133
Lee, A.J., see Balmforth, A.J. (291) 135
Lee, H.S., see Balasubramaniam, G. (276) 183
Lee, J.H., Rosenshtraukh, L., Beloshapko, G. and Rosen, M.R.
The electrophysiologic effects of ersentilide on canine hearts (285) 25
Lee, K., Groh, W.J., Blair, T.A., Maylie, J.G. and Adelman, J.P.
Imidazoline compounds inhibit K_{ATP} channels in guinea pig ventricular myocytes (285) 309
Lee, K., Rowe, I.C.M. and Ashford, M.L.J.
NS 1619 activates BK_{Ca} channel activity in rat cortical neurones (280) 215
Lee, L., see Kilbourn, M. (278) 249
Lee, P.H.K., Nguyen, T.M.-D., Chung, N.N., Schiller, P.W. and Chang, K.-J.
Tyrosine-iodination converts the δ-opioid peptide antagonist TIPP to an agonist (280) 211
Lee, Y.-M., Sheu, J.-R. and Yen, M.-H.
BN-063, a newly synthesized adenosine A_1 receptor agonist, attenuates myocardial reperfusion injury in rats (279) 251
Leeson, P.D., see Grimwood, S. (290) 221
Lefebvre, R.A., see Barbier, A.J. (276) 41
Lefebvre, R.A., see Briejer, M.R. (279) 123
Lefebvre, R.A., see Joos, G.F. (271) 47
Leffler, C.W., see Parfenova, H. (278) 133
Legrand, A., see Hichami, A. (291) 91
Lehmann, H., see Shepard, P.D. (285) 79
Lehmann, J.C., see Hamelin, S.M. (281) R11
Leist, M. and Wendel, A.
Tunicamycin potently inhibits tumor necrosis factor-induced hepatocyte apoptosis (292) 201
Lejeune, F. and Millan, M.J.
Activation of dopamine D_3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo (275) R7
Lemaire, S., see Dumont, M. (271) 241
Lemaire, S., see Maurice, T. (283) 251
Lemaire, S., see Maurice, T. (287) 219
Lemmer, B., see Witte, K. (290) 1
Lemoine, H., see Voigt, W. (291) 255

Lenz, S.M., see Arnt, J. (285) 289
Leonard, B.E., see Caldwell, M. (285) 203
Leonard, B.E., see Maginn, M. (282) 259
Leonard, B.E., see O'Neill, M. (283) 217
Leone, M.P., see Sala, M. (273) 35
Léoty, C., see Huchet, C. (271) 141
LePard, K.J., see Gidener, S. (284) 19
Leroux, P., see Bucharles, C. (271) 79
Le Rouzic, M., Angel, I., Schoemaker, H., Allen, J., Arbilla, S. and Langer, S.Z.
Binding of [^{3}H]cirazoline to an imidazoline site in rat brain and kidney membranes (278) 261
Leurs, R., see Smit, M.J. (288) 17
Levant, B., Grigoriadis, D.E. and De Souza, E.B.
Relative affinities of dopaminergic drugs at dopamine D_2 and D_3 receptors (278) 243
Levens, N., see Chow, L. (282) 77
Levine, J.D., see Ouseph, A.K. (273) 107
Le Vraux, V., see Chen, Y.-L. (271) 319
Levy, A.D., Li, Q., Gustafson, M. and Van de Kar, L.D.
Neuroendocrine profile of the potential anxiolytic drug S-20499 (274) 141
Levy, R., see Barg, J. (287) 145
Levy, R.D., see Kosmas, E.N. (274) 193
Lewin, A., see Popik, P. (291) 221
Lewinski, A., see Sewerynek, E. (293) 327
Leyva, J., Maione, S., Pallotta, M., Berrino, L. and Rossi, F.
Metabotropic and ionotropic glutamate receptors mediate opposite effects on periaqueductal gray matter (285) 123
Leza, J.-C., Lizasoain, I., San-Martín-Clark, O. and Lorenzo, P.
Morphine-induced changes in cerebral and cerebellar nitric oxide synthase activity (285) 95
Li, L., see Calcutt, N.A. (285) 189
Li, Q., see Levy, A.D. (274) 141
Li, X.-S., Wang, Q.-D. and Pernow, J.
Beneficial effects of the endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischaemia/reperfusion in the rat (283) 161
Li, X.-S., see Wang, Q.-D. (271) 25
Libon, R., see Christophe, B. (281) 161
Lidaks, M.J., see Van der Wenden, E.M. (290) 189
Liebmann, C., Graneß, A., Adomeit, A. and Nawrath, S.
The adenylate cyclase-inhibiting bradykinin receptor in guinea pig ileum membranes exhibits an unique antagonist profile (289) 403
Liebmann, C., Mammery, K. and Graneß, A.
Bradykinin inhibits adenylate cyclase activity in guinea pig ileum membranes via a separate high-affinity bradykinin B_2 receptor (288) 35
Liégeois, J.-F., Bruhwyler, J., Damas, J., Rogister, F., Masereel, B., Geczy, J. and Delarge, J.
Modulation of the clozapine structure increases its selectivity for the dopamine D_4 receptor (273) R1
Liehr, R.-M., see Varga, G. (286) 109
Liew, F.Y., see Moss, D.W. (289) 41
Lignon, M.-F., see Lallement, J.-C. (290) 61
Liliom, K., see Molnár, A. (291) 73
Liljequist, S., see Cebers, G. (290) 105
Liljequist, S., see Karcz-Kubicha, M. (279) 171
Lim, S.L., see King, K.A. (281) 187
Lima, L., see Gozlan, H. (288) 173
Lima, L., see Laporte, A.-M. (271) 505
Lima, L., see Nevo, I. (281) 229
Lima-Leite, A.-C., see Lallement, J.-C. (290) 61
Lin, R.C.-S., see Von Lubitz, D.K.J.E. (275) 23
Lin, R.C.-S., see Von Lubitz, D.K.J.E. (283) 185
Lin, R.C.S., see Von Lubitz, D.K.J.E. (287) 295
Lin-Shiau, S.-Y., see Hsu, K.-S. (292) 265
Lin-Shiau, S.-Y., see Hsu, K.-S. (292) 315
Lin-Shiau, S.-Y., see Liu, S.-H. (292) 95
Lin, W.-C.
Stimulatory effect of muscimol on gastric acid secretion stimulated by secretagogues in vagotomized rats under anesthesia (279) 43
Lin, W.W.
Effects of protein kinase A activation on endothelin- and ATP-induced signal transduction (291) 1
Lin, Y.-J., see Liu, P.-S. (291) 265
Lindberg, S., Khan, R. and Runer, T.
The effects of formoterol, a long-acting β_2-adrenoceptor agonist, on mucociliary activity (285) 275
Lindén, A., see Yoshihara, S. (280) 113
Lindén, J., see Pohjanvirta, R. (293) 341
Linden, J., see Tuomisto, J. (292) 277
Ling, J.Y., see Chiou, L.C. (292) 151
Linnoila, M., see Foley, T.D. (292) 287
Lippert, K., see Prehn, J.H.M. (292) 179
Liska, J., see Franco-Cereceda, A. (279) 105
Liu, C.-F., see Tao, P.-L. (278) 233
Liu, C.-g., see Gao, Z.-g. (289) 369
Liu-Chen, L.-Y., see Chen, X.-H. (275) 105
Liu, G.J., see Emaduddin, M. (283) 113
Liu, G.J., see Santos, D.E. (272) 231
Liu, J.-F., see Wu, P.H. (281) 263
Liu, P.-S., Lin, Y.-J. and Kao, L.-S.
Effects of caffeine on Ca^{2+} fluxes and secretion in bovine chromaffin cells (291) 265
Liu, S.-H. and Lin-Shiau, S.-Y.
Studies on the contracture inducing action of triphenyltin in the mouse diaphragm (292) 95
Liu, S.F., see Haddad, E.-B. (293) 287
Livett, B.G., see Molloy, L. (289) 447
Lizasoain, I., see Leza, J.-C. (285) 95
Lo, Y.-C., Wu, S.-N., Wu, J.-R. and Chen, I.-J.
Effect of capsaicin on membrane currents in cultured vascular smooth muscle cells of rat aorta (292) 321
Lobina, C., see Colombo, G. (273) 235
Lobina, C., see Colombo, G. (285) 103
Lobron, C., see Storch, A. (290) 207
Lodge, N.J., Zhang, R., Halaka, N.N. and Moreland, S.
Functional role of endothelin ET_A and ET_B receptors in venous and arterial smooth muscle (287) 279
Loew, G.H., see Maguire, P.A. (280) 167
Löfdahl, C.-G., see Kawikova, I. (280) 293
Lohr, B., see Wessler, I. (278) 83
Lokhandwala, M.F., see Chen, C. (287) 1
Lokhandwala, M.F., see Gopalakrishnan, S.M. (288) 139
Lokhandwala, M.F., see Kansra, V. (289) 391
Lombardi, G., Moroni, F. and Moroni, F.
Glutamate receptor antagonists protect against ischemia-induced retinal damage (271) 489
Lombardía, M., see Catalán, R.E. (290) 183
London, E.D., Scheffel, U., Kimes, A.S. and Kellar, K.J.
In vivo labeling of nicotinic acetylcholine receptors in brain with [^{3}H]epibatidine (278) R1
London, E.D., see Hashimoto, K. (273) 307
Longmore, J., see Razzaque, Z. (283) 199
Longo, L.D., see Zhang, L. (289) 375
Longo, R., see Domenici, M.R. (271) 259
Lopaschuk, G.D., see Schönekess, B.O. (286) 155
Lopes da Silva, F.H., see Verhage, M. (291) 387
Lopez-Belmonte, J. and Whittle, B.J.R.
Calcitonin-gene related peptide can augment or prevent endothelin-1 induced gastric microvascular leakage (271) R15

Lopez-Belmonte, J. and Whittle, B.J.R.
Endothelin-1 induces neutrophil-independent vascular injury in the rat gastric microcirculation (278) R7
López-Burillo, S., Agapito-Serrano, M.T., Garay, R.P. and Macías, J.F.
Inhibition by nitrendipine of $^{86}Rb^{+}$ fluxes in subconfluent MDCK cells (289) 259
López, M.G., see Abad, F. (293) 55
López-Muñoz, F.J., see Granados-Soto, V. (277) 281
Lorenz, D., see Cross, L.J.M. (291) 291
Lorenz, I.H., see Luger, T.J. (271) 421
Lorenzo, P., see Leza, J.-C. (285) 95
Löscher, W., see Baran, H. (273) 197
Löscher, W., see Baran, H. (286) 167
Löscher, W., see Rundfeldt, C. (274) 73
Löschmann, P.-A., Eblen, F., Wüllner, U., Wachtel, H. and Klockgether, T.
Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease (284) 129
Lötvall, J., see Kawikova, I. (280) 293
Loubatières-Mariani, M.-M., see Berdeu, D. (275) 91
Louca, L.L., see Pattichis, K. (292) 173
Louis, W.J., see King, P.R. (281) 341
Lovelace, A.M., see Gitter, B.D. (289) 439
Lowe, J.A., see Aceto, M.D. (282) R1
Lu, L.-L., see Habuchi, Y. (292) 143
Lübbert, H., see Hoyer, D. (289) 151
Lübbert, H., see Schoeffter, P. (289) 163
Luciani, S., see Cargnelli, G. (292) 103
Lucion, A.B., see Padoin, M.J. (277) 1
Ludbrook, J. and Ventura, S.
ACTH-(1–24) blocks the decompensatory phase of the haemodynamic response to acute hypovolaemia in conscious rabbits (275) 267
Ludbrook, J., see Ventura, S. (277) 265
Luger, T.J., Hayashi, T., Grabner Weiss, C. and Hill, H.F.
The spinal potentiating effect and the supraspinal inhibitory effect of midazolam on opioid-induced analgesia in rats (275) 153
Luger, T.J., Hayashi, T., Lorenz, I.H. and Hill, H.F.
Mechanisms of the influence of midazolam on morphine antinociception at spinal and supraspinal levels in rats (271) 421
Lugnier, A.-A., see Dhouib, M. (293) 439
Lugnier, C., see Eckly, A.E. (271) 237
Lugnier, C., see Kessler, T. (290) 163
Lundberg, J.M., see Franco-Cereceda, A. (279) 105
Lundberg, J.M., see Szallasi, A. (289) 181
Lundy, D.F. and McBean, G.J.
Pre-incubation of synaptosomes with arachidonic acid potentiates inhibition of [^{3}H]D-aspartate transport (291) 273
Lunec, J., see Willets, J.M. (293) 319
Luo, D., Das, S. and Vincent, S.R.
Effects of methylene blue and LY83583 on neuronal nitric oxide synthase and NADPH-diaphorase (290) 247
Luschi, R., see Carli, M. (283) 133
Lutfy, K., Shen, K.-Z., Kwon, I.-S., Cai, S.X., Woodward, R.M., Keana, J.F.W. and Weber, E.
Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor/glycine site antagonist (273) 187
Lutton, C., see Hajri, T. (286) 131
Lutz, J., see Hocher, B. (293) 361

Ma, Z.-Q., Violani, E., Villa, F., Picotti, G.B. and Maggi, A.
Estrogenic control of monoamine oxidase A activity in human neuroblastoma cells expressing physiological concentrations of estrogen receptor (284) 171
Maaß, A., Kostenis, E. and Mohr, K.
Potentiation by alcuronium of the antimuscarinic effect of *N*-methylscopolamine in guinea pig left atria (272) 103
Maas, J., D'Orléans-Juste, P., Yano, M. and Rae, G.A.
Evidence for atypical endothelin receptors and for presence of endothelin-converting enzyme activity in the mouse isolated vas deferens (276) 113
Mabayo, R.T., Furuse, M. and Okumura, J.-i.
Inhibition of food passage by omeprazole in the chicken (273) 161
MacDonald, E., see Laitinen, K.S.M. (285) 255
MacDonald, J.F., see Yue, K.-T. (291) 229
Machado, A., see Bougria, M. (291) 407
Machado, A., see Santiago, M. (280) 251
Machida, H., see Abiru, T. (281) 9
Machida, H., see Miyazaki, S. (271) 179
Macías, J.F., see López-Burillo, S. (289) 259
Macielag, M.J., see Depoortere, I. (286) 241
Madretsma, G.S., see Van Dijk, J.P.M. (278) R11
Madsen, U., see Arnt, J. (285) 289
Maeda, K., see Hirasawa, Y. (272) 39
Maeda, Y., Yamada, K., Hasegawa, T. and Nabeshima, T.
Neuronal mechanism of the inhibitory effect of calcitonin on *N*-methyl-D-aspartate-induced aversive behavior (275) 163
Maehara, T., see Guo, J.-Z. (281) 49
Maelicke, A., see Storch, A. (290) 207
Maenhaut, W., see Sprumont, P. (274) 95
Maes, R.A., see Gommans, J. (284) 135
Maes, R.A.A., see Groenink, L. (272) 177
Maes, R.A.A., see Groenink, L. (280) 185
Magee, S., see Berger, I. (277) 195
Maggi, A., see Ma, Z.-Q. (284) 171
Maggi, C.A., see Patacchini, R. (271) 111
Maggi, C.A., see Patacchini, R. (278) 17
Maggi, C.A., see Patacchini, R. (283) 233
Maggi, C.A., see Perretti, F. (273) 129
Maggi, C.A., see Santicioli, P. (289) 17
Maggio, R., see Barbier, P. (290) 125
Maginn, M., Caldwell, M., Kelly, J.P. and Leonard, B.E.
The effect of 2-amino-3-phosphonopropionic acid (AP-3) in the gerbil model of cerebral ischaemia (282) 259
Magnussen, H., see Watson, N. (275) 307
Maguire, P.A., Davies, M.F. and Loew, G.H.
Binding of 1,4-benzodiazepines to a novel [^{3}H]Ro15-4513 binding site in the rat spinal cord (280) 167
Mah, S.C., see Balasubramaniam, G. (276) 183
Maier, P., see Ohno, K. (292) 205
Mailman, R.B., see Hudkins, R.L. (271) 235
Main, D.C.J., Waterman, A.E. and Kilpatrick, I.C.
Behavioural analysis of changes in nociceptive thresholds produced by remoxipride in sheep and rats (287) 221
Mainero, C., see Pontieri, F.E. (284) 205
Maione, S., see Leyva, J. (285) 123
Majima, M., Ikeda, Y., Kuribayashi, Y., Mizogami, S., Katori, M. and Aoyagi, T.
Ebelactone B, an inhibitor of urinary carboxypeptidase Y-like kininase, prevents the development of deoxycorticosterone acetate-salt hypertension in rats (284) 1
Majumder, P.K., see Koley, J. (293) 483
Makara, G.B., Kiem, D.T. and Vizi, E.S.
Hypothalamic α_{2A}-adrenoceptors stimulate growth hormone release in the rat (287) 43
Makara, G.B., see Bagdy, G. (275) 301
Makara, G.B., see Kiem, D.T. (272) 145
Makimura, M., see Narita, M. (271) 543
Makimura, M., see Narita, M. (271) 547
Makino, I., see Tanaka, H. (291) 121
Makino, Y., see Tanaka, H. (291) 121
Makiyama, K., see Sawa, T. (276) 223
Makman, M.H., Dvorkin, B. and Stefano, G.B.
Murine macrophage cell lines contain μ_3-opiate receptors (273) R5
Makriyannis, A., see Pertwee, R.G. (272) 73

Maksay, G., Molnár, P. and Gruber, L.
Common modes of action of γ-butyrolactones and pentylenetetrazol on the $GABA_A$ receptor-ionophore complex (288) 61
Malagié, I., Trillat, A.-C., Jacquot, C. and Gardier, A.M.
Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study (286) 213
Malatynska, E., see Knapp, R.J. (291) 129
Maldonado, A., see Torres, C. (280) 277
Maldonado, R., see Valverde, O. (286) 79
Maliji, G., see Badesha, J.S. (293) 429
Malinowska, B., Göthert, M., Godlewski, G., Wróbel, B., Bönisch, H. and Buczko, W.
Inhibitory effect of ethanol on the 5-hydroxytryptamine-induced Bezold-Jarisch reflex – involvement of peripheral $5\text{-}HT_3$ receptors (293) 71
Malizia, A., see Pike, V.W. (283) R1
Malkhandi, J., Ferry, D.R., Boer, R., Gekeler, V., Ise, W. and Kerr, D.J.
Dexniguldipine-HCl is a potent allosteric inhibitor of [^{3}H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells (288) 105
Malmberg, Å., see Jackson, D.M. (282) 137
Malmberg, A.B. and Yaksh, T.L.
Capsaicin-evoked prostaglandin E_2 release in spinal cord slices: relative effect of cyclooxygenase inhibitors (271) 293
Malmberg, A.B., see Calcutt, N.A. (285) 189
Mamatha, R.K. and Nagendra, S.N.
Effect of disulfiram administration on glutamate uptake by synaptosomes in the rat brain (292) 89
Mameya, S., see Sawa, T. (276) 223
Mammery, K., see Liebmann, C. (288) 35
Man, C.-F., see Wu, P.H. (281) 263
Mancinelli, R., see Maresca, P. (287) 303
Mancuso, F., Calignano, A. and Sorrentino, L.
Endogenous nitric oxide modulates behavioural effects elicited by substance P in rat (271) 329
Mannhold, R., see Voigt, W. (291) 255
Manni, E., see Maresca, P. (287) 303
Manning, A., see Christophe, B. (281) 161
Manning, A., see Hodeige, D. (279) 25
Manning, P.T., see Connor, J.R. (273) 15
Männistö, P.T., Lang, A., Rauhala, P. and Vasar, E.
Beneficial effects of co-administration of catechol-*O*-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression (274) 229
Männistö, P.T., see Ilänpään-Heikkilä, J.J. (284) 227
Männistö, P.T., see Rauhala, P. (285) 69
Mansbach, R.S., Jortani, S.A. and Balster, R.L.
Discriminative stimulus effects of esteratic local anesthetics in squirrel monkeys (274) 167
Mansikka, H. and Pertovaara, A.
Influence of selective α_2-adrenergic agents on mustard oil-induced central hyperalgesia in rats (281) 43
Manzini, S., see Parlani, M. (278) 117
Manzini, S., see Perretti, F. (273) 129
Marceau, F., see Audet, R. (271) 551
Marco, C., see Sanchez-Amate, M.C. (292) 215
Marden, M.C., see Zaidi, A. (290) 133
Mares, A.-M., see Dol, F. (280) 135
Maresca, P., Mancinelli, R., Corsico, N., Arrigoni-Martelli, E. and Manni, E.
Positive action of propionyl-L-carnitine on mechanical performance of papillary muscle from Syrian hamsters with hereditary dilated cardiomyopathy (287) 303
Margineanu, D.G. and Wülfert, E.
ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo (286) 321
Marien, M., see Tellez, S. (277) 113
Markusse, H.M., see Reubi, J.C. (271) 371
Marona-Lewicka, D., Rhee, G.-S., Sprague, J.E. and Nichols, D.E.
Psychostimulant-like effects of *p*-fluoroamphetamine in the rat (287) 105
Maroto, R., see Abad, F. (293) 55
Marsden, C.A., see Bickerdike, M.J. (271) 403
Marsden, C.A., see Wongwitdecha, N. (279) 99
Marsden, C.D., see Gnanalingham, K.K. (277) 235
Martin, B., see Wiley, J. (276) 49
Martin, B.R., see Aceto, M.D. (282) R1
Martin, B.R., see Varga, K. (278) 279
Martin, B.R., see Woodward, J.J. (277) 7
Martin, C.A.E., see Félétou, M. (274) 57
Martin, C.A.E., see Molimard, M. (278) 49
Martín-Calderón, J.L., see De Fonseca, F.R. (274) 47
Martin, G.R., see Mills, A. (280) 175
Martín, M.I., see Milanés, M.V. (271) 103
Martín, M.I., see Parra, L. (277) 99
Martin, R.J., Sitamze, J.-M., Duittoz, A.H. and Wermuth, C.G.
Novel arylaminopyridazine-GABA receptor antagonists examined electrophysiologically in *Ascaris suum* (276) 9
Martin, R.J., see Robertson, S.J. (271) 273
Martínez, A.M., see Catalán, R.E. (290) 183
Martínez-Cuesta, M.A., see Barrachina, M.D. (280) 339
Martinez, E., Peñafiel, R., Collado, M.C. and Hernández, J.
Diazepam potentiates the positive inotropic effect of isoprenaline in rat ventricle strips: role of cyclic AMP (282) 169
Martínez, E., see Giménez-Llort, L. (275) 171
Martinez-Garcia, F., Martínez-Ruiz, F., Vicente, I., Peñafiel, R. and Cremades, A.
Effect of environmental temperature on tissue lead accumulation in mice repeatedly treated with lead acetate (293) 271
Martinez, J., see Lallement, J.-C. (290) 61
Martínez, M., see Miquel, J. (292) 333
Martínez-Ruiz, F., see Martinez-Garcia, F. (293) 271
Martini, A., see Clementi, E. (289) 23
Martins, S.L.R., De Oliveira, R.B. and Ballejo, G.
Rat duodenum nitrergic-induced relaxations are cGMP-independent and apamin-sensitive (284) 265
Martres, M.-P., see Nevo, I. (281) 229
Marumo, T., see Hishikawa, K. (291) 435
Mas, M., Fumero, B. and Perez-Rodriguez, I.
Induction of mating behavior by apomorphine in sexually sated rats (280) 331
Masaki, T., see Nishiyama, M. (286) 209
Mascarella, S.W., see Weiser, S.D. (275) 1
Mascolo, N., see Izzo, A.A. (271) 31
Masereel, B., see Liégeois, J.-F. (273) R1
Mason, S.L., see Reynolds, G.P. (281) R5
Massi, M., see Polidori, C. (277) 223
Mastropaolo, J., see Von Lubitz, D.K.J.E. (275) 23
Masuho, Y., see Kaku, S. (279) 115
Matagne, A., see Noyer, M. (286) 137
Mathôt, R.A.A., see Van der Wenden, E.M. (290) 189
Matsuda, T., Somboonthum, P., Suzuki, M., Asano, S. and Baba, A.
Antidepressant-like effect by postsynaptic $5\text{-}HT_{1A}$ receptor activation in mice (280) 235
Matsuda, Y., see Sudjarwo, S.A. (289) 197
Matsugi, T., Kageyama, M., Nishimura, K., Giles, H. and Shirasawa, E.
Selective prostaglandin D_2 receptor stimulation elicits ocular hypotensive effects in rabbits and cats (275) 245
Matsumoto, C., see Sakai, H. (291) 153
Matsumoto, K., see Gitter, B.D. (289) 439
Matsumoto, K., see Tanaka, K. (279) 143
Matsumoto, R.R., Bowen, W.D., Tom, M.A., Vo, V.N., Truong, D.D. and De Costa, B.R.
Characterization of two novel σ receptor ligands: antidystonic effects in rats suggest σ receptor antagonism (280) 301

Matsumoto, R.R., Nguyen, D. and Truong, D.D.
Strychnine-insensitive glycine site antagonists attenuate a cardiac arrest-induced movement disorder (275) 117
Matsumura, K.
A monoclonal antibody against tetrodotoxin that reacts to the active group for the toxicity (293) 41
Matsumura, Y., see Fujita, K. (280) 311
Matsunami, K., see Chowdhury, S.A. (285) 99
Matsuo, R., see Rocha-Singh, K.J. (288) 349
Matsuoka, Y., see Kinoshita, K. (274) 65
Matsushita, M., Yonemori, F., Hamada, A., Toide, K. and Iwata, K.
Effect of JTP-2942, a novel thyrotropin-releasing hormone analogue, on pentobarbital-induced anesthesia in rats (276) 177
Matsutani, S., see Tanaka, K. (279) 143
Matus-Leibovitch, N., see Barg, J. (287) 145
Maudhuit, C., see Nevo, I. (281) 229
Maurel-Remy, S., Bervoets, K. and Millan, M.J.
Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT_{2A} receptors (280) R9
Maurer, J.A., Wenger, B.W., Guan, Z., Stokes, B.T. and McKay, D.B.
Staurosporine affects calcium homeostasis in cultured bovine adrenal chromaffin cells (288) 163
Maurice, T., Privat, A. and Lemaire, S.
Corrigendum to 'The pentadecapeptide [Ser^1]histogranin impairs passive avoidance learning in mice' [Eur. J. Pharmacol. 283 (1995) 251–254] (287) 219
Maurice, T., Privat, A. and Lemaire, S.
The pentadecapeptide [Ser^1]histogranin impairs passive avoidance learning in mice (283) 251
Mawer, I.M., see Grimwood, S. (290) 221
Maylie, J.G., see Lee, K. (285) 309
Mazzola-Pomietto, P., see Aulakh, C.S. (282) 65
McBean, G.J., see Lundy, D.F. (291) 273
McCall, R., see Nally, J.E. (288) 53
McCann, U.D., Yuan, J. and Ricaurte, G.A.
Fenfluramine's appetite suppression and serotonin neurotoxicity are separable (283) R5
McCarron, J.A., see Pike, V.W. (283) R1
McCarron, R.M., see Stanimirovic, D.B. (288) 1
McCarron, R.M., see Stanimirovic, D.B. (289) 409
McCauley, L.D., Park, C.H., Lan, N.C., Tomich, J.M., Shively, J.E. and Gee, K.W.
Benzodiazepines and peptides stimulate pregnenolone synthesis in brain mitochondria (276) 145
McCloskey, T.C., see Kehne, J.H. (284) 109
McCullough, L.A. and Westfall, T.C.
Neuropeptide Y inhibits depolarization-stimulated catecholamine synthesis in rat pheochromocytoma cells (287) 271
McDougall, S.A., see Pruitt, D.L. (283) 125
McFadzean, I., see England, S. (288) 355
McGrath, J.C., see Nally, J.E. (288) 53
McKay, D.B., see Maurer, J.A. (288) 163
McKenna, W.J., see Gill, J.S. (292) 337
McKernan, R.M., see Quirk, K. (290) 175
McKnight, A.T., see Singh, L. (286) 185
McKnight, G.W., see Wallace, J.L. (280) 63
McKnight, W., see Wallace, J.L. (271) 525
McLaren, G.J., Kennedy, C. and Sneddon, P.
The effects of suramin on purinergic and noradrenergic neurotransmission in the rat isolated tail artery (277) 57
McLarnon, J.G., see Sawyer, D.C. (284) 309
McLean, M.J., see Wamil, A.W. (271) 301
McManigle, J.E., Panico, W.H., DaSilva, A.M.T. and Gillis, R.A.
Respiratory effects produced by microinjection of L-glutamate and an uptake inhibitor of L-glutamate into the caudal subretrofacial area of the medulla (280) 257
McManigle, J.E., see Berger, I. (277) 195
McNamara, D.B., see Kaye, A.D. (276) 21
McQuade, RD., see Taylor, L.A. (289) 229
Mechoulam, R., see Barg, J. (287) 145
Medeiros, M.V., Binhara, I.M., Moreno Jr., H., Zatz, R., De Nucci, G. and Antunes, E.
Effect of chronic nitric oxide synthesis inhibition on the inflammatory responses induced by carrageenin in rats (285) 109
Medford, R.M., see Sahin-Erdemli, I. (292) 163
Medina, J.H., see Fin, C. (271) 227
Meehan, S.M., see Schechter, M.D. (279) 59
Meijer, F., Ruijter, J.M., Van Delft, J.L. and Van Haeringen, N.J.
Nitric oxide induces vascular permeability changes in the guinea pig conjunctiva (284) 61
Meijer, O., see Korte, S.M. (272) 45
Méjean, A., Guillaume, J.-L. and Strosberg, A.D.
Carazolol: a potent, selective β_3-adrenoceptor agonist (291) 359
Melchiorre, C., see Giardinà, D. (287) 13
Melchiorri, D., see Sewerynek, E. (293) 327
Meldolesi, J., see Clementi, E. (289) 23
Meldrum, B.S., see Chapman, A.G. (274) 83
Meldrum, B.S., see Millan, M.H. (279) 75
Meldrum, B.S., see Smith, S.E. (273) 259
Mellemkjær, S. and Nielsen-Kudsk, J.E.
Effects of levcromakalim and glibenclamide on paced guinea-pig atrial strips exposed to hypoxia (277) 51
Melon, C., see Millan, M.J. (280) 225
Meltzer, H.Y., see Ichikawa, J. (281) 255
Meltzer, H.Y., see Ichikawa, J. (287) 179
Melzig, M.F., see Winkler, A. (291) 51
Memo, M., see Pizzi, M. (275) 311
Menargues, A., see Alemany, R. (280) 205
Méndez-Franco, J., see Tanganelli, S. (273) 63
Meng, F., see Terwel, D. (287) 65
Mennini, T., Miari, A., Presti, M.L., Rizzi, M., Samanin, R. and Vezzani, A.
Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551 (271) 93
Menozzi, B., see Poggioli, R. (271) 253
Mentha, G., see Schiffer, E.R. (286) 49
Merriam, L.A., see Mulvaney, J.M. (287) 97
Meshulam, Y., see Von Lubitz, D.K.J.E. (275) 23
Meshulam, Y., see Von Lubitz, D.K.J.E. (283) 185
Messori, E., Candura, S.M., Coccini, T., Balestra, B. and Tonini, M.
5-HT_3 receptor involvement in descending reflex relaxation in the rabbit isolated distal colon (286) 205
Methfessel, C., see Storch, A. (290) 207
Metze, K., see Moreno, Jr., H. (287) 93
Meurs, H., see Hoiting, B.H. (290) R5
Meurs, H., see Santing, R.E. (275) 75
Mevissen, M., see Rundfeldt, C. (274) 73
Meyer, J., see Fisch, A. (289) 455
Miari, A., see Mennini, T. (271) 93
Miasiro, N., De Castiglione, R. and Paiva, A.C.M.
Role of positions 9 and 10 in the endothelin molecule for biological activity and discrimination of receptor subtypes (278) 103
Miasiro, N., Karaki, H. and Paiva, A.C.M.
Heterogenous endothelin receptors mediate relaxation and contraction in the guinea-pig ileum (285) 247
Michael-Hepp, J., see Fisch, A. (289) 455
Michael-Titus, A.T., see Khan, S. (282) 229
Michel, S., see Gillardon, F. (293) 395
Michelena, P., see Uceda, G. (289) 73
Micheletti, R., Donato di Paola, E., Schiavone, A., Rossi, R. and Bianchi, G.
Effect of propionyl-l-carnitine and enalapril on cardiac function of pressure-overloaded rats during increase in load (286) 147

Michielsen, P.P., Boeckxstaens, G.E., Sys, S.U., Herman, A.G. and Pelckmans, P.A.
Role of nitric oxide in hyporeactivity to noradrenaline of isolated aortic rings in portal hypertensive rats (273) 167
Michotte, Y., see Smolders, I. (284) 83
Middlefell, V.C., see Spokes, R.A. (281) 75
Midgley, L.P., see Hanson, G.R. (278) 167
Mierau, J., Schneider, F.J., Ensinger, H.A., Chio, C.L., Lajiness, M.E. and Huff, R.M.
Pramipexole binding and activation of cloned and expressed dopamine D_2, D_3 and D_4 receptors (290) 29
Milanés, M.V., Vargas, M.L. and Martín, M.I.
Involvement of κ-opioid receptor mechanisms in the calcitonin-induced potentiation of opioid effects at the hypothalamus-pituitary-adrenocortical axis (271) 103
Milikan, J.M., see Zwart, R. (291) 399
Milkowski, N.A., see Gnanalingham, K.K. (277) 235
Millan, M.H., Chapman, A.G. and Meldrum, B.S.
Dual inhibitory action of enadoline (CI977) on release of amino acids in the rat hippocampus (279) 75
Millan, M.J., Audinot, V., Melon, C. and Newman-Tancredi, A.
Evidence that dopamine D_3 receptors participate in clozapine-induced hypothermia (280) 225
Millan, M.J., see Lejeune, F. (275) R7
Millan, M.J., see Maurel-Remy, S. (280) R9
Millan, M.J., see Schreiber, R. (271) 537
Miller, A.S. and Walker, J.M.
Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata (279) 179
Mills, A. and Martin, G.R.
Autoradiographic mapping of [^{3}H]sumatriptan binding in cat brain stem and spinal cord (280) 175
Milne, A.A.Y. and Piper, P.J.
Role of the VLA-4 integrin in leucocyte recruitment and bronchial hyperresponsiveness in the guinea-pig (282) 243
Minabe, Y., see Narita, N. (293) 277
Minabe, Y., see Tomitaka, S.-i. (285) 207
Minami, M., see Katsumata, S. (278) 143
Minami, M., see Katsumata, S. (291) 367
Mineo, A., see Cannizzaro, C. (273) 239
Mineo, H., Ohdate, T., Fukumura, K., Katayama, T., Onaga, T., Kato, S. and Yanaihara, N.
Effects of benzoic acid and its analogues on insulin and glucagon secretion in sheep (280) 149
Mingeot-Leclercq, M.-P., see Van Bambeke, F. (289) 321
Mingo, G., see Bolser, D.C. (276) R1
Minneman, K.P., see Esbenshade, T.A. (289) 305
Minneman, K.P., see García-Sáinz, J.A. (289) 1
Mino, S., see Hagihara, K. (271) 159
Minor, L.D., see Mosaddeghi, M. (289) 411
Miquel, J., Ferrándiz, M.L., De Juan, E., Sevila, I. and Martínez, M.
N-Acetylcysteine protects against age-related decline of oxidative phosphorylation in liver mitochondria (292) 333
Mironneau, C., see Pelet, C. (279) 15
Mirtella, A., see Montuschi, P. (275) 31
Mirtella, A., see Montuschi, P. (282) 263
Misawa, M., see Chiba, Y. (278) 79
Misawa, M., see Kamei, J. (275) 109
Misawa, M., see Kamei, J. (276) 131
Misawa, M., see Kamei, J. (280) 347
Misawa, M., see Suzuki, T. (280) 327
Misawa, M., see Suzuki, T. (284) 195
Mischiati, C., see Feriotto, G. (290) 85
Mitchell, J.A., see Akarasereenont, P. (273) 121
Mitchell, J.A., see Belvisi, M. (283) 255
Mitchelson, F., see Christopoulos, A. (290) 259
Miura, T., see Yui, K. (279) 135
Miwa, I., see Nakayama, K. (276) 77
Miwa, I., see Nakayama, K. (276) 85
Miwa, Y., Koshikawa, N., Miyata, N., Koshida, Y., Kobayashi, M. and Cools, A.R.
YM-14673, a thyrotropin-releasing hormone analogue, injected into the nucleus accumbens and the striatum produces repetitive jaw movements in rats (277) 63
Miwa, Y., see Cools, A.R. (286) 41
Miyahara, M., Ito, M., Itoh, H., Shiraishi, T., Isaka, N., Konishi, T. and Nakano, T.
Isoenzymes of cyclic nucleotide phosphodiesterase in the human aorta: characterization and the effects of E4021 (284) 25
Miyake, H., see Nozawa, Y. (287) 191
Miyamoto, M., Hirai, K., Heya, T. and Nagaoka, A.
Effects of a sustained release formulation of thyrotropin-releasing hormone on behavioral abnormalities in senescence-accelerated mice (271) 357
Miyamoto, M., see Mizuno, M. (285) 181
Miyata, K., Kamato, T., Nishida, A., Takizawa, K. and Takeda, M.
Gastric mucosal protection by YM638, a novel leukotriene D_4 receptor antagonist, in rats (276) 165
Miyata, K., see Akuzawa, S. (281) 37
Miyata, N., see Miwa, Y. (277) 63
Miyawaki, N., see Stark, G. (286) 71
Miyazaki, K., see Adachi, T. (286) 201
Miyazaki, S., Imaizumi, M. and Machida, H.
Effects of 1-amino-5-bromouracil on the benzodiazepine-GABA$_A$ receptor complex (271) 179
Miyazaki, Y., see Fujita, K. (280) 311
Mizogami, S., see Majima, M. (284) 1
Mizoguchi, H., see Narita, M. (280) R1
Mizota, M., see Nakayama, K. (276) 77
Mizota, M., see Nakayama, K. (276) 85
Mizuki, T., Kobayashi, H., Nakashima, Y., Kuroiwa, A. and Izumi, F.
Effect of lidocaine on α_1-adrenoceptors in cultured neonatal rat cardiocytes (277) 133
Mizuki, Y., see Ushijima, I. (285) 55
Mizuno, M., Sada, T., Ikeda, M., Fukuda, N., Miyamoto, M., Yanagisawa, H. and Koike, H.
Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist (285) 181
Mizutani, K., see Saigusa, T. (274) 213
Mobley, S.L., see Wenk, G.L. (293) 267
Mocaër, E., see Protais, P. (271) 167
Mohell, N., see Jackson, D.M. (282) 137
Mohr, K., see Maaß, A. (272) 103
Moilanen, E., see Kankaanranta, H. (291) 17
Molea, N., see Kurata, C. (293) 109
Molimard, M., Martin, C.A.E., Naline, E., Hirsch, A. and Advenier, C.
Role of thromboxane A_2 in bradykinin-induced human isolated small bronchi contraction (278) 49
Molimard, M., Naline, E., Hirsch, A. and Advenier, Ch.
Furosemide inhibits bradykinin-induced contraction of human bronchi: role of thromboxane A_2 receptor antagonism (278) 253
Molimard, M., see Félétou, M. (274) 57
Molines, A., see Greney, H. (271) 533
Moll, I., see Gillardon, F. (293) 395
Molloy, L., Wonnacott, S., Gallagher, T., Brough, P.A. and Livett, B.G.
Anatoxin-a is a potent agonist of the nicotinic acetylcholine receptor of bovine adrenal chromaffin cells (289) 447
Molnár, A., Liliom, K., Orosz, F., Vértessy, B.G. and Ovádi, J.
Anti-calmodulin potency of indol alkaloids in in vitro systems (291) 73
Molnár, P. and Erdő, S.L.
Vinpocetine is as potent as phenytoin to block voltage-gated Na^+ channels in rat cortical neurons (273) 303
Molnár, P., see Maksay, G. (288) 61

Momiyama, T., Ishihara, K., Serikawa, T., Moritake, K. and Sasa, M.
Effect of nicardipine on abnormal excitability of CA3 pyramidal cells in hippocampal slices of spontaneously epileptic rats (280) 119
Momomura, S.-i., see Sata, M. (290) 55
Momose, Y., see Huang, Q. (271) R5
Monasterolo, L.A., Ochoa, J.E., Trumper, L. and Elías, M.M.
Vascular and tubular actions of diazepam in isolated and perfused rat kidney (276) 201
Moncada, S., see László, F. (283) 47
Moncada, S., see Moss, D.W. (289) 41
Mongeau, R., De Montigny, C. and Blier, P.
Effect of long-term administration of antidepressant drugs on the 5-HT_3 receptors that enhance the electrically evoked release of [^{3}H]noradrenaline in the rat hippocampus (271) 121
Monroe, P.J., Kradel, B.K., Smith, D.L. and Smith, D.J.
Opioid effects on spinal [^{3}H]5-hydroxytryptamine release are not related to their antinociceptive action (272) 51
Monti, D., see Ponzoni, A. (278) 111
Monti, J.M., see Ponzoni, A. (278) 111
Montiel, C., see Uceda, G. (289) 73
Montuschi, P., Tringali, G., Mirtella, A., Parente, L., Preziosi, P. and Navarra, P.
Corrigendum to 'Interleukin-1 receptor antagonist displays intrinsic agonist activity on rat gastric fundus motility in vitro' [Eur. J. Pharmacol. 275 (1995) 31–37] (282) 263
Montuschi, P., Tringali, G., Mirtella, A., Parente, L., Preziosi, P. and Navarra, P.
Interleukin-1 receptor antagonist displays intrinsic agonist activity on rat gastric fundus motility in vitro (275) 31
Moodley, I., see Hichami, A. (291) 91
Moore, P.K., see Gaffen, Z. (271) 445
Moore, W.M., see Connor, J.R. (273) 15
Morales, A., see Torres, C. (280) 277
Moran, T.H., see Ladenheim, E.E. (271) R7
Morbidelli, L., see Santicioli, P. (289) 17
Morcillo, E., see Gorenne, I. (275) 207
Moreels, T.G., see De Man, J.G. (285) 269
Morel, D.R., see Schiffer, E.R. (286) 49
Moreland, S., see Lodge, N.J. (287) 279
Moreno, Jr., H., Piovesan Nathan, L., Pereira Costa, S.K., Metze, K., Antunes, E., Zatz, R. and De Nucci, G.
Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis (287) 93
Moreno, L., see Barrachina, M.D. (280) 339
Moreno Jr., H., see Medeiros, M.V. (285) 109
Morgan, N.G., see Tsoli, E. (284) 199
Mori, K., see Ukai, M. (287) 245
Mori, T., see Suzuki, T. (284) 195
Mori, Y., see Anzai, M. (285) 173
Moriarty, M., see Tseng, A. (271) 265
Morikawa, J., see Habuchi, Y. (292) 143
Morimoto, S., see Fujita, K. (280) 311
Morin, E., see Garay, R.P. (274) 175
Morinobu, S., see Okuyama, N. (285) 61
Morishita, W., see Shew, T.R. (284) 93
Moritake, K., see Momiyama, T. (280) 119
Morley, J.E., see Flood, J.F. (275) 223
Moroi, K., see Nishiyama, M. (286) 209
Moroni, F., see Lombardi, G. (271) 489
Moroni, F., see Lombardi, G. (271) 489
Morse, D.C., see Brouwer, A. (293) 1
Mos, J., see Gommans, J. (284) 135
Mos, J., see Groenink, L. (272) 177
Mosaddeghi, M., Kapusta, D.R., Minor, L.D., Duan, N. and Paul, D.
Effects of κ-opioid receptor agonists on stimulated phosphoinositide hydrolysis in rat kidney (289) 411
Moser, C., Hehl, S. and Neumcke, B.
Inhibition of ATP-sensitive K^+ channels of mouse skeletal muscle by disopyramide (284) 35
Moser, U., see Pfaff, O. (286) 229
Moskowitz, M.A., see Waeber, C. (283) 31
Moss, D.W., Wei, X., Liew, F.Y., Moncada, S. and Charles, I.G.
Enzymatic characterisation of recombinant murine inducible nitric oxide synthase (289) 41
Moss, J., see Yuan, C.-S. (276) 107
Mousli, M., Trifilieff, A., Pelton, J.T., Gies, J.-P. and Landry, Y.
Structural requirements for neuropeptide Y in mast cell and G protein activation (289) 125
Mousli, M., see Emadi-Khiav, B. (272) 97
Muceniece, R., see Schiöth, H.B. (288) 311
Muceniece, R., see Xia, Y. (288) 277
Muckle, G., see Brouwer, A. (293) 1
Mue, S., see Tanabe, J.-i. (284) 257
Mukainaka, T., see Kato, M. (292) 47
Mulder, A.H., see Schoffelmeer, A.N.M. (286) 311
Mulder, A.H., see Tjon, G.H.K. (283) 169
Mulè, F., Serio, R. and Postorino, A.
Motility pattern of isolated rat proximal colon and excitatory action of neurotensin (275) 131
Müller, W., see Bäsler, I. (291) 335
Müller, W.E.G., see Perovic, S. (288) 27
Mulvaney, J.M., Merriam, L.A. and Parsons, R.L.
Galantide distinguishes putative subtypes of galanin receptors in mudpuppy parasympathetic neurons (287) 97
Mulvany, M.J., see Videbæk, L.M. (274) 109
Muneoka, K., see Nankai, M. (281) 123
Muñoz Moreno, C., see Bousquet-Mélou, A. (289) 235
Murakami, H., see Kusama, T. (291) 431
Murakami, K., see Shibasaki, M. (271) 341
Murakami, M., see Asagoe, K. (275) 179
Murakami, N., see Nakayama, K. (276) 77
Murakami, N., see Nakayama, K. (276) 85
Muraki, K., see Henmi, S. (282) 219
Muraki, T., see Fujii, E. (273) 267
Muraki, T., see Irie, K. (275) 45
Muraki, T., see Uchida, Y. (291) 33
Muramatsu, I., see Takakura, K. (271) 367
Muramatsu, I., see Tsuchida, S. (281) 251
Murphy, D.L., see Aulakh, C.S. (282) 65
Murphy, T.V. and Garland, C.J.
Specific accumulation of inositol 1,4,5-trisphosphate in rabbit basilar artery in response to noradrenaline but not 5-hydroxytryptamine (290) 141
Murphy, T.V., Broad, L.M. and Garland, C.J.
Characterisation of inositol 1,4,5-trisphosphate binding sites in rabbit aortic smooth muscle (290) 145
Murphy, W.A., see Santiago, J.A. (272) 115
Murray, H.N., see Grover, G.J. (277) 271
Mutafova-Yambolieva, V.N. and Westfall, D.P.
Endothelin-3 can both facilitate and inhibit transmitter release in the guinea-pig vas deferens (285) 213
Mutschler, E., see Pfaff, O. (286) 229

Nabe, T., see Yamamura, H. (288) 269
Nabeshima, T., see Kamei, H. (273) 229
Nabeshima, T., see Maeda, Y. (275) 163
Nabeshima, T., see Noda, Y. (286) 291
Nadel, J.A., see Yoshihara, S. (280) 113
Nadler, J.V., see Bowe, M.A. (278) 55
Nagano, M., see Takiguchi, Y. (281) 205
Nagao, T., see Ohashi, K. (285) 165
Nagaoka, A., see Miyamoto, M. (271) 357
Nagasawa, T., see Kuraishi, Y. (275) 229
Nagase, H., see Kamei, J. (275) 109

Nagase, H., see Kamei, J. (276) 131
Nagase, H., see Kamei, J. (280) 347
Nagase, H., see Knapp, R.J. (291) 129
Nagase, H., see Suzuki, T. (284) 195
Nagase, M., see Yui, K. (279) 135
Nagatomo, R., see Akiba, S. (291) 343
Nagendra, S.N., see Mamatha, R.K. (292) 89
Nagura, J., Yasuda, S., Fujishima, K., Yamamoto, M., Hui, C., Kawano, K.-i., Katano, K., Ogino, H., Hachisu, M. and Konno, F.
Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist (274) 201
Nahori, M.-A., see Garrelds, I.M. (275) 295
Nahorski, S.R., see Burford, N.T. (289) 343
Naïli, S., see Buhot, M.-C. (285) 221
Naito, H., Arishima, K. and Tonoue, T.
Neonatal damage to neocortex abolishes the anxiolytic action of diazepam in adult rats (272) 261
Nakachi, N., Kiuchi, Y., Inagaki, M., Inazu, M., Yamazaki, Y. and Oguchi, K.
Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats (281) 195
Nakagawa, J., see Hotta, Y. (282) 121
Nakagawa, M., see Adachi, T. (286) 201
Nakagawa, T., see Katsumata, S. (278) 143
Nakagawa, T., see Katsumata, S. (291) 367
Nakahara, T., Ishii, K., Tanaka, Y. and Nakayama, K.
Involvement of neurohumoral factors in the pressor mechanism of N^G-nitro-L-arginine (287) 49
Nakai, K., see Kamiyama, T. (272) 151
Nakajima, S., see Hara, M. (289) 267
Nakajima, S., see Saito, M. (291) 217
Nakaki, T., see Hishikawa, K. (291) 435
Nakamura, K., see Sakitama, K. (273) 47
Nakamura, S., see Yamashita, H. (289) 387
Nakane, Y., see Akehira, K. (284) 149
Nakano, T., see Miyahara, M. (284) 25
Nakao, K., see Yano, S. (289) 217
Nakashima, M., see Ishiye, M. (280) 11
Nakashima, M., see Takiguchi, Y. (281) 205
Nakashima, M., see Umemura, K. (275) 17
Nakashima, Y., see Mizuki, T. (277) 133
Nakata, Y., see Nishio, H. (288) 149
Nakaya, Y., see Hamada, Y. (288) 45
Nakayama, I., see Ikeda, U. (290) 69
Nakayama, K., Murakami, N., Ohta, M., Kato, K., Ida, K., Mizota, M., Miwa, I. and Okuda, J.
Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats (276) 77
Nakayama, K., Murakami, N., Ohta, M., Kato, K., Notsu, T., Mizota, M., Miwa, I. and Okuda, J.
Effects of M16209 on insulin secretion in isolated, perfused pancreases of normal and diabetic rats (276) 85
Nakayama, K., see Nakahara, T. (287) 49
Nakayama, K., see Tanaka, Y. (289) 59
Nakazawa, T., see Tanaka, Y. (289) 59
Naline, E., see Félétou, M. (274) 57
Naline, E., see Molimard, M. (278) 253
Naline, E., see Molimard, M. (278) 49
Nally, J.E., McCall, R., Young, L.C., Wakelam, M.J.O., Thomson, N.C. and McGrath, J.C.
Mechanical and biochemical responses to endothelin-1 and endothelin-3 in human bronchi (288) 53
Nankai, M., Fage, D. and Carter, C.
Striatal NMDA receptor subtypes: the pharmacology of *N*-methyl-D-aspartate-evoked dopamine, γ-aminobutyric acid, acetylcholine and spermidine release (286) 61
Nankai, M., Yamada, S., Muneoka, K. and Toru, M.
Increased 5-HT_2 receptor-mediated behavior 11 days after shock in learned helplessness rats (281) 123
Napolitano, A., Zürcher, G. and Da Prada, M.
Effects of tolcapone, a novel catechol-*O*-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats (273) 215
Naraba, H., see Ueno, A. (284) 211
Nardone, N.A., see Berkowitz, D.E. (289) 223
Narita, M. and Tseng, L.F.
Stimulation of spinal δ-opioid receptors in mice selectively enhances the attenuation of δ-opioid receptor-mediated antinociception by antisense oligodeoxynucleotide (284) 185
Narita, M., Feng, Y., Makimura, M., Hoskins, B. and Ho, I.K.
A protein kinase inhibitor, H-7, inhibits the development of tolerance to opioid antinociception (271) 543
Narita, M., Feng, Y., Makimura, M., Hoskins, B. and Ho, I.K.
Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain (271) 547
Narita, M., Narita, M., Mizoguchi, H. and Tseng, L.F.
Inhibition of protein kinase C, but not of protein kinase A, blocks the development of acute antinociceptive tolerance to an intrathecally administered μ-opioid receptor agonist in the mouse (280) R1
Narita, M., see Narita, M. (280) R1
Narita, M., see Tseng, L.F. (287) 169
Narita, N., Hashimoto, K., Iyo, M., Minabe, Y. and Yamazaki, K.
Lack of neuroprotective effect of σ receptor ligands in the neurotoxicity of *p*-chloroamphetamine in rat brain (293) 277
Narita, N., see Tomitaka, S.-i. (285) 207
Nasal, A., Frąckowiak, T., Petrusewicz, J., Buciński, A. and Kaliszan, R.
Mydriasis elicited by imidazol(in)e α_2-adrenomimetics in comparison with other adrenoceptor-mediated effects and hydrophobicity (274) 125
Näsman, J., see Jansson, C.C. (290) 75
Natale, G., see Blandizzi, C. (278) 179
Natarajan, A.T., see Vahter, M. (293) 455
Navarra, P., see Montuschi, P. (275) 31
Navarra, P., see Montuschi, P. (282) 263
Navarro, M., see De Fonseca, F.R. (274) 47
Nave, R., Peled, R. and Lavie, P.
Melatonin improves evening napping (275) 213
Nawrath, H., see Bäumner, D. (273) 295
Nawrath, H., see Wegener, J.W. (287) 89
Nawrath, S., see Liebmann, C. (289) 403
Nechifor, M., see Costuleanu, M. (281) 89
Neff, N.H., see Hadjiconstantinou, M. (289) 97
Negishi, M., see Pelkonen, P. (292) 67
Negrescu, E., see Grünberg, B. (288) 329
Negrev, N., Nyagolov, Y. and Stanchewa, E.
Somatotropin and somatostatin effects on vitamin K-dependent plasma coagulation factors (277) 145
Negus, S.S., see Butelman, E.R. (277) 285
Nelemans, A., see Van der Zee, L. (289) 463
Nermell, B., see Vahter, M. (293) 455
Nestby, P., see Schoffelmeer, A.N.M. (286) 311
Nestby, P., see Tjon, G.H.K. (283) 169
Neugebauer, E., see Dimmeler, S. (287) 257
Neuilly, G., see Pelet, C. (279) 15
Neumann, V., see Kalkman, H.O. (285) 313
Neumcke, B., see Moser, C. (284) 35
Nevo, I., Langlois, X., Laporte, A.-M., Kleven, M., Koek, W., Lima, L., Maudhuit, C., Martres, M.-P. and Hamon, M.
Chronic alcoholization alters the expression of 5-HT_{1A} and 5-HT_{1B} receptor subtypes in rat brain (281) 229
Newberry, N., see Craven, R. (271) R1
Newbold, P., see Ahluwalia, A. (283) 193
Newman-Tancredi, A., see Millan, M.J. (280) 225
Newman Taylor, A.J., see Hayes, J.P. (292) 127
Nezasa, K., see Nishio, H. (288) 149

Nguyen, D., see Matsumoto, R.R. (275) 117
Nguyen, T.M.-D., see Lee, P.H.K. (280) 211
Nichols, D.E., see Marona-Lewicka, D. (287) 105
Nielsen-Kudsk, J.E., see Mellemkjær, S. (277) 51
Nielsen, M., Witt, M.-R., Ebert, B. and Krogsgaard-Larsen, P.
Thiomuscimol, a new photoaffinity label for the $GABA_A$ receptor (289) 109
Nielsen, M., see Karle, J. (291) 439
Niesink, R.J.M., see Vanderschuren, L.J.M.J. (276) 257
Nihei, H., see Nitta, K. (293) 491
Nihonyanagi, K., see Oba, T. (292) 301
Niina, H., Kobayashi, H., Kitamura, K., Katoh, F., Eto, T. and Wada, A.
Inhibition of catecholamine synthesis by proadrenomedullin N-terminal 20 peptide in cultured bovine adrenal medullary cells (286) 95
Nijkamp, F.P., see Buckley, T.L. (282) 103
Nijkamp, F.P., see Buijs, J. (293) 207
Nijkamp, F.P., see Folkerts, G. (285) R1
Nijkamp, F.P., see Hessel, E.M. (293) 401
Nikodijevic, B., see Stanimirovic, D.B. (288) 1
Nikodijevic, B., see Stanimirovic, D.B. (289) 409
Nikodijevic-Kedeva, D., see Stanimirovic, D.B. (288) 1
Nikodijevic-Kedeva, D., see Stanimirovic, D.B. (289) 409
Nilsson, R., see Vahter, M. (293) 455
Nisato, D., see Bax, W.A. (285) 199
Nisato, D., see Christophe, B. (281) 161
Nishida, A., see Miyata, K. (276) 165
Nishiguchi, E., Hamada, N. and Shindo, J.
Lidocaine action and conformational changes in cytoskeletal protein network in human red blood cells (286) 1
Nishihira, J., see Gando, S. (289) 175
Nishikibe, M., see Hirose, H. (277) 77
Nishikibe, M., see Hirose, H. (284) 335
Nishimura, K., see Matsugi, T. (275) 245
Nishimura, M., see Satoh, N. (272) 233
Nishimura, Y., Usui, H., Kurahashi, K. and Suzuki, A.
Endothelium-dependent contraction induced by acetylcholine in isolated rat renal arteries (275) 217
Nishino, S., see Kita, Y. (275) 125
Nishio, H., Nezasa, K. and Nakata, Y.
Role of calcium ion in platelet serotonin uptake regulation (288) 149
Nishio, M., see Hirasawa, Y. (272) 39
Nishiyama, H., see Kaneko, T. (292) 251
Nishiyama, M., Shan, L.-h., Moroi, K., Masaki, T. and Kimura, S.
Heterogeneity of endothelin ET_A receptor-mediated contractions in the rabbit saphenous vein (286) 209
Nisoli, E., see Garosi, V.L. (276) 285
Nisticò, G., see Clementi, E. (289) 113
Nitta, K., Uchida, K., Kimata, N., Kawashima, A., Yumura, W. and Nihei, H.
Endothelin-1 mediates erythropoietin-stimulated glomerular endothelial cell-dependent proliferation of mesangial cells (293) 491
Niwa, M., see Chowdhury, S.A. (285) 99
Niwa, M., see Kataoka, Y. (273) 285
Niwa, M., see Sawa, T. (276) 223
Nix, P., see Kojda, G. (284) 315
Noack, E., see Kojda, G. (284) 315
Noble, F., Blommaert, A., Fournié-Zaluski, M.-C. and Roques, B.P.
A selective CCK_B receptor antagonist potentiates μ-, but not δ-opioid receptor-mediated antinociception in the formalin test (273) 145
Noda, Y., Yamada, K., Furukawa, H. and Nabeshima, T.
Involvement of nitric oxide in phencyclidine-induced hyperlocomotion in mice (286) 291
Nomikos, G.G., see Kerezoudis, N.P. (275) 191
Nomoto, M., see Irifune, M. (272) 79
Nomura, Y., see Kitamura, Y. (289) 299
Nordgren, I., see Hemming, H. (292) 241
Norman, P., Abram, T.S., Cuthbert, N.J., Tudhope, S.R. and Gardiner, P.J.
Characterisation of leukotriene receptors on rat lung strip (271) 73
Norman, P., see Gorenne, I. (275) 207
Norman, W.P., see Berger, I. (277) 195
Norris, B., Contreras, E., Nunez, G. and Contreras, G.
Diazepam induces tolerance in the isolated skin of *Pleurodema thaul* (280) 221
Nossaman, B.D., see Kaye, A.D. (276) 21
Nossaman, B.D., see Kaye, A.D. (287) 163
Notsu, T., see Nakayama, K. (276) 85
Novakova, M., Ela, C., Barg, J., Vogel, Z., Hasin, Y. and Eilam, Y.
Inotropic action of σ receptor ligands in isolated cardiac myocytes from adult rats (286) 19
Nowak, G., see Popik, P. (291) 221
Noyer, M., Gillard, M., Matagne, A., Hénichart, J.-P. and Wülfert, E.
The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes (286) 137
Nozawa, Y., Miyake, H., Yamada, S., Uchida, S., Ohkura, T. and Kimura, R.
Receptor occupation and pharmacokinetics of MPC-1304, a new Ca^{2+} channel antagonist, in spontaneously hypertensive rats (287) 191
Nunes, J.P.
Central α_2-adrenoceptors and blood pressure regulation in the rat (278) 183
Nunez, G., see Norris, B. (280) 221
Nyagolov, Y., see Negrev, N. (277) 145

Oba, T., Nihonyanagi, K. and Yamaguchi, M.
Possible involvement of Ca^{2+}-induced Ca^{2+} release mechanism in Ag^+-induced contracture in frog skeletal muscle (292) 301
Obach, R., see Alemany, R. (280) 205
Obika, K., Shibata, K., Horie, K., Foglar, R., Kimura, K. and Tsujimoto, G.
NS-49, a novel α_{1a}-adrenoceptor-selective agonist characterization using recombinant human α_1-adrenoceptors (291) 327
O'Boyle, K.M., see O'Malley, K.E. (275) 83
O'Byrne, P.M., see Stevens, W.H.M. (293) 251
Ochoa, J.E., see Monasterolo, L.A. (276) 201
O'Connor, M.P., see Southan, G.J. (291) 311
O'Connor, W.T., see Stengård, K. (292) 43
Odagaki, Y. and Fuxe, K.
5-HT_{1A} receptor-mediated activation of high-affinity GTPase in rat hippocampal membranes (288) 385
Odagaki, Y., Dasgupta, S. and Fuxe, K.
Additivity and non-additivity between dopamine-, norepinephrine-, carbachol- and GABA-stimulated GTPase activity (291) 245
Odarjuk, J., see Winkler, A. (291) 51
O'Donoghue, D.P., see Keely, S.J. (279) 203
Ogawa, A., see Uchida, Y. (291) 33
Ogawa, N., see Ohdo, S. (293) 151
Ogawa, N., see Ohdo, S. (293) 281
Ogawa, S., see Adachi, T. (286) 201
Ogino, H., see Nagura, J. (274) 201
Ogino, K., see Ishiyama, H. (292) 135
Ogle, C.W., see Wong, D. (292) 157
Ogletree, M.L., see Gomoll, A.W. (271) 471
Oguchi, K., see Nakachi, N. (281) 195
Oh-ishi, S., see Tokumasu, T. (274) 225
Oh-ishi, S., see Ueno, A. (284) 211
O'Halloran, A., see O'Neill, M. (283) 217
Ohashi, H., see Komori, S. (277) 173
Ohashi, K., Yamazaki, J. and Nagao, T.
Contractions and relaxations accompanied by endothelial nitric oxide

production induced in the porcine coronary artery by Ca^{2+}, Ba^{2+} and Sr^{2+} (285) 165
Ohata, K., see Yamamura, H. (288) 269
Ohba, K., see Fujii, E. (273) 267
Ohba, K.-i., see Uchida, Y. (291) 33
Ohdate, T., see Mineo, H. (280) 149
Ohdo, S., Ogawa, N. and Song, J.G.
Chronopharmacological study of acetylsalicylic acid in mice (293) 151
Ohdo, S., Watanabe, H., Ogawa, N., Yoshiyama, Y. and Sugiyama, T.
Circadian rhythm of embryotoxicity induced by sodium valproate in mice (293) 281
Ohizumi, Y., see Takahashi, Y. (288) 285
Ohkubo, K., see Kita, Y. (275) 125
Ohkubo, T. and Shibata, M.
ATP-sensitive K^+ channels mediate regulation of substance P release via the prejunctional histamine H_3 receptor (277) 45
Ohkubo, T., Shibata, M., Inoue, M., Kaya, H. and Takahashi, H.
Regulation of substance P release mediated via prejunctional histamine H_3 receptors (273) 83
Ohkuma, S., see Kato, M. (292) 47
Ohkura, T., see Nozawa, Y. (287) 191
Ohlstein, E.H., see Aiyar, N. (283) 63
Ohno, K. and Maier, P.
Tumor necrosis factor α differentially modulates the cellular response of rat hepatocytes in periportal- and pericentral-equivalent cultures (292) 205
Ohno, M. and Watanabe, S.
Nitric oxide synthase inhibitors block behavioral sensitization to methamphetamine in mice (275) 39
Ohno, M., Kikusui, M., Yoshimatsu, A., Yamamoto, T. and Watanabe, S.
Somatostatin alleviates impairment of working memory induced by hippocampal muscarinic M_1 receptor blockade in rats (271) 557
Ohno, M., see Kita, Y. (275) 125
Ohrui, T., see Fukushima, T. (289) 103
Ohsawa, M., see Kamei, J. (276) 131
Ohsawa, M., see Kamei, J. (280) 347
Ohshika, H., see Hatta, S. (291) 351
Ohshima, N., see Kaku, S. (279) 115
Ohta, M., see Nakayama, K. (276) 77
Ohta, M., see Nakayama, K. (276) 85
Ohtani, K., see Hara, M. (289) 267
Ohtsuki, H., see Ito, C. (285) 37
Ohuchi, K., see Tanabe, J.-i. (284) 257
Ohwaki, K., see Ihara, M. (274) 1
Oiry, C., see Lallement, J.-C. (290) 61
Okada, N., see Horiuchi, H. (287) 27
Okamura, T., see Sai, Y. (282) 235
Oker-Blom, C., see Jansson, C.C. (290) 75
Okiji, S., see Seeds, E.A.-M. (293) 369
Okinaga, S., see Fukushima, T. (289) 103
Okubo, T., see Kaneko, T. (292) 251
Okuda, J., see Nakayama, K. (276) 77
Okuda, J., see Nakayama, K. (276) 85
Okuma, Y., see Yokotani, K. (279) 233
Okumura, J.-i., see Mabayo, R.T. (273) 161
Okuyama, N., Morinobu, S., Totsuka, S. and Endoh, M.
Enhancement of 5-hydroxytryptamine-stimulated phosphoinositide hydrolysis in the rat cerebral cortex by repeated immobilization stress (285) 61
Olbrich, H.-G., see Witte, K. (290) 1
Olgart, L.M., see Kerezoudis, N.P. (275) 191
Olivier, B., see Gommans, J. (284) 135
Olivier, B., see Groenink, L. (272) 177
Olivier, B., see Groenink, L. (280) 185
Olmos, G., see Alemany, R. (280) 205
Olymulder, C.G., see Santing, R.E. (275) 75
O'Malley, K., see Conlon, D. (289) 283
O'Malley, K.E., Farrell, C.B., O'Boyle, K.M. and Baird, A.W.
Cholinergic activation of Cl^- secretion in rat colonic epithelia (275) 83
Onaga, T., see Mineo, H. (280) 149
O'Neill, A.B., see Decker, M.W. (280) 79
O'Neill, K., see Glaser, K. (281) 107
O'Neill, M., Caldwell, M., Earley, B., Canney, M., O'Halloran, A., Kelly, J., Leonard, B.E. and Junien, J.-L.
The σ receptor ligand JO 1784 (igmesine hydrochloride) is neuroprotective in the gerbil model of global cerebral ischaemia (283) 217
O'Neill, M., see Caldwell, M. (285) 203
Ong, J. and Kerr, D.I.B.
Interactions of *N*-ethylmaleimide and aluminium fluoride with $GABA_B$ receptor function in rat neocortical slices (287) 197
Ong, J., see Kerr, D.I.B. (287) 185
Ongini, E., see Domenici, M.R. (271) 259
Ono, M., see Yui, K. (279) 135
Oortgiesen, M., see Zwart, R. (291) 399
Opacka-Juffry, J., see Hume, S.P. (271) 515
Opgenorth, T.J., see Grassi-Kassisse, D.M. (282) 57
O'Reilly, S., see Bolser, D.C. (276) R1
O'Reilly, S., see Bolser, D.C. (277) 159
Orosz, F., see Molnár, A. (291) 73
Orsière, T.G., Chauvet, M.M., Dell'Amico, M.H. and Bourdeaux, M.J.
Effects of benfluorex metabolites on membrane fluidity and insulin-related processes (291) 237
Ortiz, G.G., see Sewerynek, E. (293) 327
Ortiz, J.L., see Gorenne, I. (275) 207
Orzi, F., see Pontieri, F.E. (284) 205
Osnes, J.-B., see Dybvik, T. (281) 21
Ossowska, K. and Wolfarth, S.
Stimulation of glutamate receptors in the intermediate/caudal striatum induces contralateral turning (273) 89
Osterhaus, A.D.M.E., see Garssen, J. (292) 223
Osumi, Y., see Yokotani, K. (279) 233
Otomo, S., see Uchiyama-Tsuyuki, Y. (293) 245
Otová, B., see Zídek, Z. (286) 307
Otsuka, M., see Guo, J.-Z. (281) 49
Ott, C., see Grider, J. (287) 101
Ottaviani, E., Franchini, A., Sonetti, D. and Stefano, G.B.
Antagonizing effect of morphine on the mobility and phagocytic activity of invertebrate immunocytes (276) 35
Ouseph, A.K. and Levine, J.D.
α_1-Adrenoceptor-mediated sympathetically dependent mechanical hyperalgesia in the rat (273) 107
Ovádi, J., see Molnár, A. (291) 73
Öwall, A., see Franco-Cereceda, A. (279) 105
Oyama, Y., Carpenter, D.O., Ueno, S., Hayashi, H. and Tomiyoshi, F.
Methylmercury induces Ca^{2+}-dependent hyperpolarization of mouse thymocytes: a flow cytometric study using fluorescent dyes (293) 101
Oyekan, A.O.
Cryptolepine-induced vasodilation in the isolated perfused kidney of the rat: role of G-proteins, K^+ and Ca^{2+} channels (285) 1
Oyekan, A.O.
The suppression by lipopolysaccharide of cytochrome P450-dependent renal vasodilation in the rat is mediated by nitric oxide (277) 123
Ozaki, S., see Ihara, M. (274) 1
Ozawa, Y., see Sakitama, K. (273) 47

Pacak, K., see Yadid, G. (288) 399
Padbury, J.F., see Tseng, Y.T. (289) 353
Padoin, M.J. and Lucion, A.B.
The effect of testosterone and DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) on male sexual behavior of rats (277) 1
Paegelow, I., Werner, H. and Reißmann, S.

Effects of bradykinin and bradykinin analogues on spleen cells of mice (279) 211
Paegelow, I., see Böckmann, S. (291) 159
Page, C.P., see Herd, C.M. (282) 111
Page, C.P., see Seeds, E.A.-M. (293) 369
Page, K.M., Curtis, C.A.M., Jones, P.G. and Hulme, E.C.
The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesis (289) 429
Paiva, A.C.M., see Miasiro, N. (278) 103
Paiva, A.C.M., see Miasiro, N. (285) 247
Palfreyman, M.G., see Kehne, J.H. (284) 109
Pallapies, D., Peskar, B.A. and Peskar, B.M.
Interaction of 5-aminosalicylic acid with nitric oxide on rat aortic strips and human platelets (282) 145
Pallapies, D., Peskar, B.A., Brune, K. and Zeilhofer, H.U.
Modulation of nitric oxide effects by flurbiprofen enantiomers and nefopam and its relation to antinociception (271) 335
Pallotta, M., see Leyva, J. (285) 123
Palmer, K.J., see Hadingham, K.L. (291) 301
Palmi, M., Frosini, M., Sgaragli, G.P., Becherucci, C., Perretti, M. and Parente, L.
Inhibition of interleukin-1β-induced pyresis in the rabbit by peptide 204–212 of lipocortin 5 (281) 97
Palmier, C., see Pauwels, P.J. (290) 95
Palomba, L., Guidarelli, A., Cattabeni, F. and Cantoni, O.
The effect of hydrogen peroxide/L-histidine-induced DNA single- vs. double-strand breaks on poly(ADP-ribose)polymerase (291) 167
Pan, H. and Galligan, J.J.
Effects of 5-HT_{1A} and 5-HT_4 receptor agonists on slow synaptic potentials in enteric neurons (278) 67
Pang, C.C.Y., see Elhawary, A.M. (286) 255
Pang, C.C.Y., see King, K.A. (281) 187
Pang, G.T., see Brent, P.J. (278) 151
Panico, W.H., see Berger, I. (277) 195
Panico, W.H., see McManigle, J.E. (280) 257
Paoletti, R., see Viganò, T. (291) 201
Papadopoulos, I., see Hempelmann, R.G. (276) 277
Papsdorf, G., see Winkler, A. (291) 51
Parente, L., see Montuschi, P. (275) 31
Parente, L., see Montuschi, P. (282) 263
Parente, L., see Palmi, M. (281) 97
Parenti, A., see Santicioli, P. (289) 17
Parfenova, H. and Leffler, C.W.
Functional study on vasodilator effects of prostaglandin E_2 in the newborn pig cerebral circulation (278) 133
Park, C.H., see McCauley, L.D. (276) 145
Parlani, M., Conte, B. and Manzini, S.
Opposite modulation by tachykinin (NK_1) and CGRP receptors of sympathetic control of mouse vas deferens motility (278) 117
Parmar, D.V., Ahmed, G., Khandkar, M.A. and Katyare, S.S.
Mitochondrial ATPase: a target for paracetamol-induced hepatotoxicity (293) 225
Parra, L., Pérez-Vizcaíno, F., Alsasua, A., Martín, M.I. and Tamargo, J.
μ- and δ-opioid receptor-mediated contractile effects on rat aortic vascular smooth muscle (277) 99
Parsons, R.L., see Mulvaney, J.M. (287) 97
Parvez, N., see Chapman, A.G. (274) 83
Parvez, N.S., see Smith, S.E. (273) 259
Pasanen, M., see Pellinen, P. (292) 57
Pascaud, X., see Diop, L. (271) 65
Pascaud, X., see Langlois, A. (271) 245
Passadore, M., see Feriotto, G. (290) 85
Passarelli, F., see Pontieri, F.E. (284) 205
Pasternak, G.W., see Berzetei-Gurske, I.P. (277) 257
Patacchini, R. and Maggi, C.A.
Tachykinin NK_1 receptors mediate both vasoconstrictor and vasodilator responses in the rabbit isolated jugular vein (283) 233
Patacchini, R., Barthò, L., Holzer, P. and Maggi, C.A.
Activity of SR 142801 at peripheral tachykinin receptors (278) 17
Patacchini, R., De Giorgio, R., Giachetti, A. and Maggi, C.A.
Different mechanism of tachykinin NK_2 receptor blockade by SR 48968 and MEN 10,627 in the guinea-pig isolated gallbladder and colon (271) 111
Paterson, A.D., see Schoots, O. (289) 67
Patra, S.K., see Buhot, M.-C. (285) 221
Patrick, R.L., see Weiser, S.D. (275) 1
Patrick, S.L., see Tsou, K. (280) R13
Patrick, S.L., see Weiser, S.D. (275) 1
Pattarini, R., see Pittaluga, A. (272) 203
Pattichis, K., Louca, L.L., Jarman, J., Sandler, M. and Glover, V.
5-Hydroxytryptamine release from platelets by different red wines: implications for migraine (292) 173
Paul, D. and Tran, J.G.
Differential cross-tolerance between analgesia produced by α_2-adrenoceptor agonists and receptor subtype selective opioid treatments (272) 111
Paul, D., see Mosaddeghi, M. (289) 411
Paul, V., Balasubramaniam, E., Jayakumar, A.R. and Kazi, M.
A sex-related difference in the neurobehavioral and hepatic effects following chronic endosulfan treatment in rats (293) 355
Paulson, O.B., see Videbæk, C. (281) 117
Pauly, K., see Glatt, H. (293) 173
Pauwels, P.J. and Palmier, C.
Functional effects of the 5-HT_{1D} receptor antagonist GR 127,935 at human 5-$HT_{1D\alpha}$, 5-$HT_{1D\beta}$, 5-HT_{1A} and opossum 5-HT_{1B} receptors (290) 95
Pauwels, R.A., see Joos, G.F. (271) 47
Payá, M., see Gil, B. (285) 281
Pazdalski, P.S., see Aloyo, V.J. (288) 295
Pearce, W.J., see Zhang, L. (289) 375
Pedruzzi, E., see Djerdjouri, B. (288) 193
Peeters, B.W.M.M., see Reijmers, L.G.J.E. (272) 131
Peeters, T.L., see Depoortere, I. (286) 241
Pekhletski, R., see Yue, K.-T. (291) 229
Pelckmans, P.A., see De Man, J.G. (285) 269
Pelckmans, P.A., see Michielsen, P.P. (273) 167
Peled, R., see Nave, R. (275) 213
Pelet, C., Mironneau, C., Rakotoarisoa, L. and Neuilly, G.
Angiotensin II receptor subtypes and contractile responses in portal vein smooth muscle (279) 15
Pelkonen, O., see Pellinen, P. (292) 57
Pelkonen, P., Lang, M.A., Wild, C.P., Negishi, M. and Juvonen, R.O.
Activation of aflatoxin B_1 by mouse CYP2A enzymes and cytotoxicity in recombinant yeast cells (292) 67
Pelletier, S.W., see Chiao, H. (283) 103
Pellinen, P., Stenbäck, F., Raunio, H., Pelkonen, O. and Pasanen, M.
Modification of hepatic cytochrome P450 profile by cocaine-induced hepatotoxicity in DBA/2 mouse (292) 57
Pelton, J.T., see Mousli, M. (289) 125
Peñafiel, R., see Martinez, E. (282) 169
Peñafiel, R., see Martinez-Garcia, F. (293) 271
Penn, N.W.
Potentiation of morphine analgesic action in mice by β-carotene (284) 191
Pennefather, J.N., see Lau, W.A.K. (272) 31
Pennington, A.J., see Robertson, S.J. (271) 273
Perchermeier, M., see Schmalix, W.A. (293) 123
Perdew, G.H., see Wang, X. (293) 191
Pereira, E.F.R., see Storch, A. (290) 207
Pereira Costa, S.K., see Moreno, Jr., H. (287) 93
Perez-Cornejo, P., see Arreola, J. (271) 309
Pérez, J., see Hoyer, D. (289) 151
Pérez, J., see Schoeffter, P. (289) 163
Perez, M.D., see Salinas, P. (293) 65

Perez-Rodriguez, I., see Mas, M. (280) 331
Pérez-Vizcaíno, F., see Duarte, J. (286) 115
Pérez-Vizcaíno, F., see Parra, L. (277) 99
Pérez de la Mora, M., see Tanganelli, S. (273) 63
Pergande, G., see Perovic, S. (288) 27
Pergande, G., see Schwarz, M. (276) 247
Périanin, A., see Djerdjouri, B. (288) 193
Pernow, J., see Li, X.-S. (283) 161
Pernow, J., see Wang, Q.-D. (271) 25
Perovic, S., Schleger, C., Pergande, G., Iskric, S., Ushijima, H., Rytik, P. and Müller, W.E.G.
The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-Methyl-D-aspartate and gp120 of HIV-1 (288) 27
Perretti, F., Ballati, L., Manzini, S., Maggi, C.A. and Evangelista, S.
Antibronchospastic activity of MEN10,627, a novel tachykinin NK_2 receptor antagonist, in guinea-pig airways (273) 129
Perretti, M., see Harris, J.G. (279) 149
Perretti, M., see Harris, J.G. (283) 9
Perretti, M., see Klemm, P. (281) 69
Perretti, M., see Palmi, M. (281) 97
Pertovaara, A., see Mansikka, H. (281) 43
Perttula, S., see Karhu, S. (279) 7
Pertwee, R.G. and Griffin, G.
A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferens (272) 67
Pertwee, R.G., Fernando, S.R., Griffin, G., Abadji, V. and Makriyannis, A.
Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations (272) 73
Pertwee, R.G., Griffin, G., Lainton, J.A.H. and Huffman, J.W.
Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens (284) 241
Pertwee, R.G., see Wickens, A.P. (282) 251
Peskar, B.A., see Pallapies, D. (271) 335
Peskar, B.A., see Pallapies, D. (282) 145
Peskar, B.M., see Pallapies, D. (282) 145
Pesonen, U., see Rouru, J. (273) 99
Peters, M.J., Adcock, I.M., Brown, C.R. and Barnes, P.J.
β-Adrenoceptor agonists interfere with glucocorticoid receptor DNA binding in rat lung (289) 275
Peterson, R.E., see Brouwer, A. (293) 1
Petersson, M., see Kawikova, I. (280) 293
Petitclerc, E., see Audet, R. (271) 551
Petitet, F., Blanchard, J.-C. and Doble, A.
Effects of AMPA receptor modulators on the production of arachidonic acid from striatal neurons (291) 143
Petrusewicz, J., see Nasal, A. (274) 125
Pettersson, E.
Studies of four novel diphenylbutylpiperazinepyridyl derivatives on release and inhibition of reuptake of dopamine, serotonin and noradrenaline by rat brain in vitro (282) 131
Pfaff, D.W., see Kow, L.-M. (282) 199
Pfaff, O., Hildebrandt, C., Waelbroeck, M., Hou, X., Moser, U., Mutschler, E. and Lambrecht, G.
The (*S*)-(+)-enantiomer of dimethindene: a novel M_2-selective muscarinic receptor antagonist (286) 229
Pfaffendorf, M., see Hüsken, B.C.P. (287) 313
Philippu, A., see Fischer, H. (275) R5
Phung-Ba, V., Warnery, A., Scherman, D. and Wils, P.
Erratum to 'Interaction of pristinamycin I_A with P-glycoprotein in human intestinal epithelial cells'. [Eur. J. Pharmacol. – Mol. Pharmacol. Sect. 288 (1995) 187–192] (289) 479
Phung-Ba, V., Warnery, A., Scherman, D. and Wils, P.
Interaction of pristinamycin I_A with P-glycoprotein in human intestinal epithelial cells (288) 187
Piattoni-Kaplan, M., see Decker, M.W. (280) 79
Picard, S., see Deschepper, C.F. (275) 61
Picazo, O., see Fernández-Guasti, A. (281) 113
Picotti, G.B., see Ma, Z.-Q. (284) 171
Pidoplichko, V.I., see Wilsch, V.W. (284) 141
Piech, K.M., see Arreola, J. (271) 309
Piggins, H.D., Cutler, D.J. and Rusak, B.
Effects of ionophoretically applied bombesin-like peptides on hamster suprachiasmatic nucleus neurons in vitro (271) 413
Pike, V.W., McCarron, J.A., Lammerstma, A.A., Hume, S.P., Poole, K., Grasby, P.M., Malizia, A., Cliffe, I.A., Fletcher, A. and Bench, C.J.
First delineation of 5-HT_{1A} receptors in human brain with PET and [^{11}C]WAY-100635 (283) R1
Pike, V.W., see Hume, S.P. (271) 515
Pilon, C., see Griffon, N. (282) R3
Pimoule, C., Langer, S.Z. and Graham, D.
Further evidence that the classical α_{1A}- and cloned α_{1c}-adrenoceptors are the same subtype (290) 49
Pinaev, A.G., see Bagrov, A.Y. (274) 151
Pineda, J.C., Bargas, J., Flores-Hernández, J. and Galarraga, E.
Muscarinic receptors modulate the afterhyperpolarizing potential in neostriatal neurons (281) 271
Pinna, C., Bolego, C. and Puglisi, L.
Effect of substance P and capsaicin on stomach fundus and ileum of streptozotocin-diabetic rats (276) 61
Pinna, C., Bolego, C. and Puglisi, L.
Effect of substance P and capsaicin on urinary bladder of diabetic rats and the role of the epithelium (271) 151
Pinxteren, J., see Velez Pardo, C. (288) 209
Piovesan Nathan, L., see Moreno, Jr., H. (287) 93
Piper, A.S. and Hollingsworth, M.
The purinoceptors of the guinea-pig isolated taenia caeci (280) 125
Piper, H.M., see Kojda, G. (284) 315
Piper, I.T. and Hollingsworth, M.
Cromakalim- and RP 49356-induced $^{42}K^+$ and $^{86}Rb^+$ efflux in rat myometrium (283) 1
Piper, P.J., see Milne, A.A.Y. (282) 243
Pirot, S., Glowinski, J. and Thierry, A.-M.
Excitatory responses evoked in prefrontal cortex by mediodorsal thalamic nucleus stimulation: influence of anaesthesia (285) 45
Pirovano, I.M., see Van der Wenden, E.M. (290) 189
Pitcher, A., see Gaffen, Z. (271) 445
Pitkänen, M., see Ylinen, A. (274) 159
Pittaluga, A., Pattarini, R. and Raiteri, M.
Putative cognition enhancers reverse kynurenic acid antagonism at hippocampal NMDA receptors (272) 203
Pizzi, M., Consolandi, O., Memo, M. and Spano, P.F.
N-Methyl-D-aspartate neurotoxicity in hippocampal slices: protection by aniracetam (275) 311
Plante, G.E., see Chakir, M. (285) 11
Poggioli, R., Benelli, A., Arletti, R., Cavazzuti, E. and Bertolini, A.
K^+ channel openers delay intestinal transit and have antidiarrheal activity (287) 207
Poggioli, R., Benelli, A., Arletti, R., Vergoni, A.V., Menozzi, B. and Bertolini, A.
Old rats are unresponsive to the behavioral effects of adrenocorticotropin (271) 253
Pohjanvirta, R., Unkila, M., Lindén, J., Tuomisto, J.T. and Tuomisto, J.
Toxic equivalency factors do not predict the acute toxicities of dioxins in rats (293) 341
Pohjanvirta, R., see Tuomisto, J. (292) 277
Pohjanvirta, R., see Tuomisto, J.T. (293) 309
Pohjanvirta, R., see Unkila, M. (293) 115
Poiger, H., see Van Birgelen, A.P.J.M. (293) 77
Poinsot, O., see Schiffer, E.R. (286) 49
Poirot, M., see Kehne, J.H. (284) 109
Polgar, W., see Berzetei-Gurske, I.P. (277) 257
Polidori, C., Ciccocioppo, R., Pompei, P., Cirillo, R. and Massi, M.

The selective angiotensin AT_1 receptor antagonist LR-B/081 potently inhibits drinking induced by central injection of angiotensin II in rats (277) 223
Pompei, P., see Polidori, C. (277) 223
Pontieri, F.E., Mainero, C., La Riccia, M., Passarelli, F. and Orzi, F.
Functional correlates of repeated administration of cocaine and apomorphine in the rat (284) 205
Ponzoni, A., Monti, J.M., Jantos, H., Altier, H. and Monti, D.
Increased waking after intra-accumbens injection of *m*-chlorophenylbiguanide: prevention with serotonin or dopamine receptor antagonists (278) 111
Poole, K., see Pike, V.W. (283) R1
Poon, A. and Sawynok, J.
Antinociception by adenosine analogs and an adenosine kinase inhibitor: dependence on formalin concentration (286) 177
Poon, J.S., see Elhawary, A.M. (286) 255
Popik, P., Lewin, A., Berrang, B., Nowak, G., Layer, R. and Skolnick, P.
[^{3}H]1-Aminocyclopropanecarboxylic acid, a novel probe for strychnine-insensitive glycine receptors (291) 221
Popoli, P., Betto, P., Reggio, R. and Ricciarello, G.
Adenosine A_{2A} receptor stimulation enhances striatal extracellular glutamate levels in rats (287) 215
Popoli, P., Caporali, M.G. and Scotti de Carolis, A.
Influence of NMDA receptor ligands on thyrotropin-releasing hormone-induced scratching in rabbits (272) 119
Porchia, R., see Catalioto, R.-M. (280) 285
Portet, C., see Wamil, A.W. (271) 301
Portoghese, P.S., see Tseng, L.F. (277) 251
Postorino, A., see Mulè, F. (275) 131
Potreau, D., see Delpech, N. (285) 217
Potter, E.K., see Tseng, A. (271) 265
Powell, J.R., see Tesfamariam, B. (281) 17
Poyart, C., see Zaidi, A. (290) 133
Prada, J., see Sannerud, C.A. (271) 461
Prager, R.H., see Kerr, D.I.B. (287) 185
Prast, H., see Fischer, H. (275) R5
Pratt, J., see Alaoui, F. (276) 55
Prehn, J.H.M., Lippert, K. and Krieglstein, J.
Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury? (292) 179
Presti, M.L., see Mennini, T. (271) 93
Preziosi, P., see Montuschi, P. (275) 31
Preziosi, P., see Montuschi, P. (282) 263
Price, D.T., see Berkowitz, D.E. (289) 223
Prickaerts, J., see Terwel, D. (287) 65
Privat, A., see Maurice, T. (283) 251
Privat, A., see Maurice, T. (287) 219
Prokhorenko, N.K., see Danilov, A.F. (277) 15
Protais, P., Chagraoui, A., Arbaoui, J. and Mocaër, E.
Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents (271) 167
Provost, D., see Cazes, M. (284) 157
Prow, M.R., see Heal, D.J. (277) 215
Pruitt, D.L., Bolanos, C.A. and McDougall, S.A.
Effects of dopamine D_1 and D_2 receptor antagonists on cocaine-induced place preference conditioning in preweanling rats (283) 125
Puebla, L. and Arilla, E.
Exogenous histamine increases the somatostatin receptor/effector system in the rat frontoparietal cortex (289) 361
Puech, R., see Berdeu, D. (275) 91
Puglisi, L., see Pinna, C. (271) 151
Puglisi, L., see Pinna, C. (276) 61
Pujadas, E., see Camins, A. (272) 289
Purnell, W.L., see Santiago, J.A. (272) 115
Puschmann, A., see Franck, H. (271) 379
Pytko-Polonczyk, J., see Konturek, S.J. (273) 57
Qian, Y.-m., see Wise, H. (278) 265
Queen, G., see LaBella, F.S. (293) 231
Quirion, R., see Jacques, D. (278) R3
Quirk, K., Whiting, P.J., Ragan, C.I. and McKernan, R.M.
Characterisation of δ-subunit containing $GABA_A$ receptors from rat brain (290) 175
Rabe, K.F., see Watson, N. (275) 307
Rae, G.A., see Maas, J. (276) 113
Rafieian-Kopaei, M., Gray, A.M., Spencer, P.S.J. and Sewell, R.D.E.
Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioning (275) 185
Ragan, C.I., see Quirk, K. (290) 175
Raghubir, R., see Kumar, A. (279) 1
Raio, D., see Whitaker-Azmitia, P.M. (275) 139
Raio, M., see Whitaker-Azmitia, P.M. (275) 139
Raiteri, M., see Pittaluga, A. (272) 203
Rakotoarisoa, L., see Pelet, C. (279) 15
Ralevic, V., Belai, A. and Burnstock, G.
Effects of streptozotocin-diabetes on sympathetic nerve, endothelial and smooth muscle function in the rat mesenteric arterial bed (286) 193
Ralevic, V., Khalil, Z., Helme, R.D. and Dusting, G.J.
Role of nitric oxide in the actions of substance P and other mediators of inflammation in rat skin microvasculature (284) 231
Rambert, F.A., see Tanganelli, S. (273) 63
Rampart, M., see De Meyer, E. (291) 67
Rand, M.J., see Jenkinson, K.M. (275) 145
Rao, M.-R., see Xu, Y. (278) 1
Rapoport, R.M., see Bazan, E. (290) 253
Rascher, W., see Höhle, S. (275) 277
Rashed, S.M.K. and Songu-Mize, E.
Regulation of Na^+-pump activity by dopamine in rat tail arteries (284) 289
Rasolonjanahary, R., Sévenet, T., Guéritte Voegelein, F. and Kordon, C.
Psycholeine, a natural alkaloid extracted from *Psychotria oleoides*, acts as a weak antagonist of somatostatin (285) 19
Rathé, J., see Gourlet, P. (287) 7
Raud, J., Konrad, D. and Dahlén, S.-E.
Delayed anti-inflammatory action of nedocromil sodium in the rat paw is dependent on de novo protein synthesis (282) 207
Rauhala, P., Idänpään-Heikkilä, J.J., Tuominen, R.K. and Männistö, P.T.
Differential disappearance of tolerance to thermal, hormonal and locomotor effects of morphine in the male rat (285) 69
Rauhala, P., see Idänpään-Heikkilä, J.J. (284) 227
Rauhala, P., see Männistö, P.T. (274) 229
Raung, S.-L., see Wang, J.-P. (272) 87
Raung, S.-L., see Wang, J.-P. (288) 341
Raunio, H., see Pellinen, P. (292) 57
Rauschenbach, R., Gieschen, H., Husemann, M., Salomon, B. and Hildebrand, M.
Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives (293) 183
Ravard, A., see Dwoskin, L.P. (276) 195
Rawlins, J.N.P., see Deacon, R.M.J. (280) 239
Razzaque, Z., Longmore, J. and Hill, R.G.
Differences in the effects of ketanserin and GR127935 on 5-HT-receptor mediated responses in rabbit saphenous vein and guinea-pig jugular vein (283) 199
Reali, R., see Colombo, G. (273) 235
Reali, R., see Colombo, G. (285) 103
Rebagay, W.R., see Chiao, H. (283) 103
Reddy, H., see Watson, N. (278) 195
Reddy, H., see Watson, N. (285) 135
Redmond, E.M., see Cahill, P.A. (288) 219
Reggio, R., see Popoli, P. (287) 215

Reid, J.J., see Jenkinson, K.M. (275) 145
Reijmers, L.G.J.E., Vanderheyden, P.M.L. and Peeters, B.W.M.M.
Changes in prepulse inhibition after local administration of NMDA receptor ligands in the core region of the rat nucleus accumbens (272) 131
Reilly, Y., see Forster, E.A. (281) 81
Reinhardt, S., see Storch, A. (290) 207
Reis, D.J., see Sun, M.-K. (276) 291
Reis, D.J., see Sun, M.-K. (293) 237
Reißmann, S., see Paegelow, I. (279) 211
Reist, C., see Helmeste, D.M. (288) 373
Reist, C., see Helmeste, D.M. (290) 173
Reiter, R.J., see Sewerynek, E. (293) 327
Remacle-Volon, G., see Souza Pinto, J.C. (274) 101
Remirez, D., Commandeur, J.N.M., Groot, E. and Vermeulen, N.P.E.
Mechanism of protection of lobenzarit against paracetamol-induced toxicity in rat hepatocytes (293) 301
Renzetti, A.R., Criscuoli, M., Salimbeni, A. and Subissi, A.
Molecular pharmacology of LR-B/081, a new non-peptide angiotensin AT_1 receptor antagonist (290) 151
Renzetti, A.R., see Barbier, P. (290) 125
Renzetti, A.R., see Catalioto, R.-M. (280) 285
Reubi, J.C., Waser, B., Markusse, H.M., Krenning, E.P., VanHagen, M. and Laissue, J.A.
Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis (271) 371
Reubi, J.C., see Hoyer, D. (289) 151
Reymann, K.G., see Wilsch, V.W. (284) 141
Reynolds, G.P. and Mason, S.L.
Absence of detectable striatal dopamine D_4 receptors in drug-treated schizophrenia (281) R5
Rezayat, M., see Zarrindast, M.-R. (273) 203
Rhee, G.-S., see Marona-Lewicka, D. (287) 105
Ribeiro, J.A., see Correia-de-Sá, P. (271) 349
Ribes, G., see Damgé, C. (274) 133
Ricaurte, G.A., see McCann, U.D. (283) R5
Ricciardolo, F.L.M., see Yoshihara, S. (280) 113
Ricciarello, G., see Popoli, P. (287) 215
Rice, K.C., see Bowen, W.D. (278) 257
Richardson, J.D., see Jackson, D.L. (284) 321
Richter, A., see Rundfeldt, C. (274) 73
Riekkinen, Jr., P., see Jäkälä, P. (282) 39
Riekkinen, M., see Riekkinen Jr., P. (279) 65
Riekkinen, Sr., P., see Valtonen, P. (285) 239
Riekkinen, Sr., P.J., see Ylinen, A. (274) 159
Riekkinen Jr., P. and Riekkinen, M.
Effects of tetrahydroaminoacridine and nicotine in nucleus basalis and serotonin-lesioned rats (279) 65
Rietjens, I.M.C.M., Steensma, A., Den Besten, C., Van Tintelen, G., Haas, J., Van Ommen, B. and Van Bladeren, P.J.
Comparative biotransformation of hexachlorobenzene and hexafluorobenzene in relation to the induction of porphyria (293) 293
Riordan, J.R., see Callaghan, R. (291) 183
Rioux, F., see Audet, R. (271) 551
Rivière, P.J.M., see Diop, L. (271) 65
Rivière, P.J.M., see Langlois, A. (271) 245
Rizzardini, M., see Cantoni, L. (292) 257
Rizzi, M., see Mennini, T. (271) 93
Robberecht, P., see Ciccarelli, E. (288) 259
Robberecht, P., see Gourlet, P. (287) 7
Robel, P., see Hauser, C.A.E. (289) 249
Roberts, E., see Singh, L. (286) 185
Robertson, M.J., see Clark, K.L. (280) 195
Robertson, S.J., Pennington, A.J., Evans, A.M. and Martin, R.J.
The action of pyrantel as an agonist and an open channel blocker at acetylcholine receptors in isolated *Ascaris suum* muscle vesicles (271) 273
Robichaud, A., see Haddad, E.-B. (293) 287
Robinson, M.B., see Johansen, P.A. (290) R1
Rocha-Singh, K.J., Matsuo, R. and Karliner, J.S.
Prolonged incubation with neuropeptide Y upregulates β-adrenoceptors yet does not cause supersensitivity of β-adrenoceptor signaling (288) 349
Rodriguez, E., see Roussel, J.-P. (289) 205
Roeda, D., see Brouillet, E. (293) 487
Roehr, J., Woods, A., Corbett, R. and Kongsamut, S.
Changes in paroxetine binding in the cerebral cortex of polydipsic rats (278) 75
Roelen, H.C.P.F., see Van der Wenden, E.M. (290) 189
Roeske, W.R., see Knapp, R.J. (291) 129
Roffel, A.F., see Ten Berge, R.E.J. (275) 199
Rogers, C.S., see Abdi, S. (293) 475
Rogers, D.F., see Hayes, J.P. (292) 127
Rogister, F., see Liégeois, J.-F. (273) R1
Rohde, J.A.L., see Hayes, J.P. (292) 127
Romanelli, M.N., see Voigt, W. (291) 255
Romero-Avila, Ma.T., see García-Sáinz, J.A. (272) 139
Romero-Avila, Ma.T., see García-Sáinz, J.A. (289) 1
Romero-Avila, Ma.T., see García-Sáinz, J.A. (289) 81
Rompré, P.-P., Injoyan, R. and Hagan, J.J.
Effects of granisetron, a 5-HT_3 receptor antagonist, on morphine-induced potentiation of brain stimulation reward (287) 263
Roppolo, J.R., see Yoshiyama, M. (287) 73
Roques, B.P., see Noble, F. (273) 145
Roques, B.P., see Valverde, O. (286) 79
Rosati, C., see Garay, R.P. (274) 175
Roscher, A.A., see Schremmer-Danninger, E. (283) 207
Rose'Meyer, R.B., see White, P.J. (286) 315
Rosen, M.R., see Lee, J.H. (285) 25
Rosenberg, H.C., see Wu, Y. (278) 125
Rosengren, R., see Wang, X. (293) 191
Rosenshtraukh, L., see Lee, J.H. (285) 25
Røshol, H., Skrede, K.K., Ærø, C.E. and Wiik, P.
Dexamethasone and methylprednisolone affect rat peritoneal phagocyte chemiluminescence after administration in vivo (286) 9
Rossetti, Z.L. and Carboni, S.
Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum (283) 177
Rossetti, Z.L., see Hadjiconstantinou, M. (289) 97
Rossi, F., see Leyva, J. (285) 123
Rossi, R., see Micheletti, R. (286) 147
Rothman, R.B., see Baumann, M.H. (282) 87
Roukoyatkina, N.I., see Bagrov, A.Y. (274) 151
Rouot, B., see Zumbihl, R. (288) 9
Rouru, J., Pesonen, U., Koulu, M., Huupponen, R., Santti, E., Virtanen, K., Rouvari, T. and Jhanwar-Uniyal, M.
Anorectic effect of metformin in obese Zucker rats: lack of evidence for the involvement of neuropeptide Y (273) 99
Rousell, J., see Haddad, E.-B. (290) 201
Roussel, J.-P., Grazzini, E., Zumbihl, R., Rodriguez, E. and Astier, H.
Triiodo-L-thyronine enhances TRH-induced TSH release from perifused rat pituitaries and intracellular Ca^{2+} levels from dispersed pituitary cells (289) 205
Routledge, C., Gurling, J., Ashworth-Preece, M.A. and Dourish, C.T.
Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190 (276) 281
Rouvari, T., see Rouru, J. (273) 99
Rowan, M.J., see Wu, J. (284) R1
Rowe, I.C.M., see Lee, K. (280) 215
Rowley, M., see Grimwood, S. (290) 221
Roy, B., Sicotte, B., Brochu, M. and St-Louis, J.
Effects of nifedipine and Bay K 8644 on myotropic responses in aortic rings of pregnant rats (280) 1
Rubio, P., see De Fonseca, F.R. (274) 47

Rudolf, K., Eberlein, W., Engel, W., Wieland, H.A., Willim, K.D., Entzeroth, M., Wienen, W., Beck-Sickinger, A.G. and Doods, H.N.
The first highly potent and selective non-peptide neuropeptide Y Y_1 receptor antagonist: BIBP3226 (271) R11
Rudolf, K., see Entzeroth, M. (278) 239
Ruijter, J.M., see Meijer, F. (284) 61
Rump, L.C., see Bohmann, C. (271) 283
Rundfeldt, C., Koch, R., Richter, A., Mevissen, M., Gerecke, U. and Löscher, W.
Dose-dependent anticonvulsant and proconvulsant effects of nitric oxide synthase inhibitors on seizure threshold in a cortical stimulation model in rats (274) 73
Runer, T., see Lindberg, S. (285) 275
Rusak, B., see Piggins, H.D. (271) 413
Rust, C.J.J., see Van Ree, J.M. (279) 187
Rutledge, A. and Triggle, D.J.
The binding interactions of Ro 40-5967 at the L-type Ca^{2+} channel in cardiac tissue (280) 155
Rytik, P., see Perovic, S. (288) 27

Saano, V., see Komulainen, H. (293) 167
Saba, P.L., see Vaccari, A. (292) 309
Sabatino, M., see Cannizzaro, C. (273) 239
Sacaan, A.I., see Knöpfel, T. (288) 389
Sachinidis, A., see Flesch, M. (289) 399
Sada, T., see Mizuno, M. (285) 181
Sadoshima, S., see Cai, H. (286) 249
Safe, S., see Wang, X. (293) 191
Sagratella, S., see Domenici, M.R. (271) 259
Sahin-Erdemli, I., Medford, R.M. and Songu-Mize, E.
Regulation of Na^+,K^+-ATPase α-subunit isoforms in rat tissues during hypertension (292) 163
Sai, Y., Okamura, T., Amakata, Y. and Toda, N.
Comparison of responses of canine pulmonary artery and vein to angiotensin II, bradykinin and vasopressin (282) 235
Saigusa, T., Koshikawa, N., Kitamura, M., Mizutani, K., Kobayashi, M. and Cools, A.R.
Dissimilarities between cholinergic and dopaminergic turning elicited by nucleus accumbens stimulation in freely moving rats (274) 213
Saila, L., see Costuleanu, M. (281) 89
Saito, A., see Gyoda, Y. (279) 83
Saito, K., see Anzai, M. (285) 173
Saito, K., see Seki, Y. (275) 259
Saito, M., Hisatome, I., Nakajima, S. and Sato, R.
Possible mechanism of oxygen radical production by human eosinophils mediated by K^+ channel activation (291) 217
Saito, M., see Tanaka, Y. (289) 59
Saito, T., see Hatta, S. (291) 351
Saitoh, A., see Kamei, J. (276) 131
Saitoh, A., see Kamei, J. (280) 347
Sajedian, M., see Zarrindast, M.-R. (273) 203
Sakai, A., Kondo, M., Tamaoki, J. and Konno, K.
Nitric oxide modulation of Ca^{2+} responses in cow tracheal epithelium (291) 375
Sakai, A., see Tamaoki, J. (278) 161
Sakai, H., Tabuchi, Y., Kakinoki, B., Seike, H., Kumagai, S., Matsumoto, C. and Takeguchi, N.
Ca^{2+}-activated outward-rectifier K^+ channels and histamine release by rat gastric enterochromaffin-like cells (291) 153
Sakai, Y., see Kaku, S. (279) 115
Sakaki, J., see Knöpfel, T. (288) 389
Sakakibara, J., see Hotta, Y. (282) 121
Sakamoto, K., see Wakabayashi, I. (293) 133
Sakamoto, Y., see Inoue, M. (276) 123
Sakitama, K., Ozawa, Y., Aoto, N., Nakamura, K. and Ishikawa, M.
Pharmacological properties of NK433, a new centrally acting muscle relaxant (273) 47
Sakuma, Y., see Horiuchi, H. (287) 27
Sakurai, M., see Kusama, T. (291) 431
Sala, M., Leone, M.P., Lampugnani, P., Braida, D. and Gori, E.
Different kinetics of tolerance to behavioral and electroencephalographic effects of chlordiazepoxide in the rat (273) 35
Sala, M., see Braida, D. (271) 497
Salimbeni, A., see Renzetti, A.R. (290) 151
Salinas, P., Perez, M.D., Fernandez-Sanpablo, R., Fernandez-Gallardo, S., Sanchez-Crespo, M. and Barrigón, S.
Lack of platelet-activating factor release on acute myocardial ischemia in the isolated interventricular septum of rabbit heart (293) 65
Salituro, F.G., see Kehne, J.H. (284) 109
Salmon, M., see Haddad, E.-B. (293) 287
Salomon, B., see Rauschenbach, R. (293) 183
Salzman, A.L., see Southan, G.J. (291) 311
Samanin, R., see Carli, M. (283) 133
Samanin, R., see Cervo, L. (284) 249
Samanin, R., see Grignaschi, G. (274) 221
Samanin, R., see Mennini, T. (271) 93
Samardžić, R., see Jovanović-Mićić, D. (272) 21
Sampaio, C.A.M., see Souza Pinto, J.C. (274) 101
San-Martín-Clark, O., see Leza, J.-C. (285) 95
Sanchez-Amate, M.C., Carrasco, M.P., Zurera, J.M., Segovia, J.L. and Marco, C.
Persistence of the effects of ethanol in vitro on the lipid order and enzyme activities of chick-liver membranes (292) 215
Sánchez, C., see Arnt, J. (285) 289
Sanchez-Crespo, M., see Salinas, P. (293) 65
Sánchez-García, P., see Abad, F. (293) 55
Sandi, C. and Guaza, C.
Evidence for a role of nitric oxide in the corticotropin-releasing factor release induced by interleukin-1β (274) 17
Sandi, C., Venero, C. and Guaza, C.
Decreased spontaneous motor activity and startle response in nitric oxide synthase inhibitor-treated rats (277) 89
Sandler, M., see Pattichis, K. (292) 173
Sandler, S., see Svensson, A.M. (275) 99
Sannerud, C.A., Prada, J., Goldberg, D.M. and Goldberg, S.R.
The effects of sertraline on nicotine self-administration and food-maintained responding in squirrel monkeys (271) 461
Santagostino, A., see Galvani, P. (293) 377
Santiago, J.A., Garrison, E., Purnell, W.L., Smith, R.E., Champion, H.C., Coy, D.H., Murphy, W.A. and Kadowitz, P.J.
Comparison of responses to adrenomedullin and adrenomedullin analogs in the mesenteric vascular bed of the cat (272) 115
Santiago, M., Granero, L., Machado, A. and Cano, J.
Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine (280) 251
Santicioli, P., Morbidelli, L., Parenti, A., Ziche, M. and Maggi, C.A.
Calcitonin gene-related peptide selectively increases cAMP levels in the guinea-pig ureter (289) 17
Santing, R.E., Olymulder, C.G., Van der Molen, K., Meurs, H. and Zaagsma, J.
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs (275) 75
Santos, D.E., Liu, G.J. and Takeuchi, H.
Blockers for excitatory effects of achatin-I, a tetrapeptide having a D-phenylalanine residue, on a snail neurone (272) 231
Santostefano, M., see Wang, X. (293) 191
Santti, E., see Rouru, J. (273) 99
Sanz, M.J., see Gil, B. (285) 281
Sardella, A., see Altavilla, D. (286) 31
Sarre, S., see Smolders, I. (284) 83
Saruta, T., see Hishikawa, K. (291) 435
Sasa, M., see Momiyama, T. (280) 119

Sasaki, H., Hashimoto, K., Inada, T., Fukui, S. and Iyo, M.
Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol (282) 71
Sasaki, H., see Fukushima, T. (289) 103
Sasaki, M., see Hiramatsu, M. (282) 185
Sasaki, T., see Hirose, H. (277) 77
Sasaki, T., see Hirose, H. (284) 335
Sasaki, Y., see Seto, M. (276) 27
Sasaki, Y., see Ukai, M. (287) 245
Sastry, B.R., see Shew, T.R. (284) 93
Sata, M., Sugiura, S., Yamashita, H., Aoyagi, T., Momomura, S.-i. and Serizawa, T.
Pimobendan directly sensitizes reconstituted thin filament to slide on cardiac myosin (290) 55
Satake, N., see Zhou, Q. (273) 153
Sato, C., see Katsuragi, T. (282) 213
Sato, R., see Koumi, S.-i. (277) 165
Sato, R., see Saito, M. (291) 217
Sato, T., see Akiba, S. (291) 343
Sato, T., see Kitamura, Y. (289) 299
Satoh, K. and Ichihara, K.
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts (292) 271
Satoh, M., see Katsumata, S. (278) 143
Satoh, M., see Katsumata, S. (291) 367
Satoh, M., see Kokubu, N. (290) 19
Satoh, M., see Kuraishi, Y. (275) 229
Satoh, N., Nishimura, M. and Watanabe, Y.
Electrophysiologic alterations in the rabbit nodal cells induced by membrane lipid peroxidation (272) 233
Satoh, N., see Kaku, S. (279) 115
Sauer, P.J.J., see Brouwer, A. (293) 1
Saugstad, J.A., Segerson, T.P. and Westbrook, G.L.
L-2-amino-3-phosphonopropionic acid competitively antagonizes metabotropic glutamate receptors 1α and 5 in *Xenopus* oocytes (289) 395
Saunders, H.I., see Bunn, S.J. (290) 227
Sautebin, L., Ialenti, A., Ianaro, A. and Di Rosa, M.
Endogenous nitric oxide increases prostaglandin biosynthesis in carrageenin rat paw oedema (286) 219
Savelkoul, H.F.J., see Hessel, E.M. (293) 401
Savola, J.-M., see Jansson, C.C. (290) 75
Sawa, T., Mameya, S., Yoshimura, M., Itsuno, M., Makiyama, K., Niwa, M. and Taniyama, K.
Differential mechanism of peptide YY and neuropeptide Y in inhibiting motility of guinea-pig colon (276) 223
Sawyer, D.C., McLarnon, J.G. and Church, J.
(−)-β-Cyclazocine is an antagonist of NMDA receptor-mediated responses and a potent neuroprotectant in rat cortical neurons (284) 309
Sawynok, J., see Doak, G.J. (281) 311
Sawynok, J., see Poon, A. (286) 177
Saxena, P.R., see Bax, W.A. (285) 199
Saxena, P.R., see Du, X.Y. (284) 119
Saxena, P.R., see Van Gelderen, E.M. (284) 51
Saxena, P.R., see Van der Graaf, P.H. (287) 309
Scalori, V., see Fornai, F. (283) 99
Scarpignato, C., see Varga, G. (286) 109
Scates, S.M., see Aceto, M.D. (282) R1
Schad, C.A., Justice, Jr., J.B. and Holtzman, S.G.
Naloxone reduces the neurochemical and behavioral effects of amphetamine but not those of cocaine (275) 9
Schaeffer, P., see Dol, F. (280) 135
Schafer, K., see Kerr, D.I.B. (287) 185
Schäfer, M., Imai, Y., Uhl, G.R. and Stein, C.
Inflammation enhances peripheral μ-opioid receptor-mediated analgesia, but not μ-opioid receptor transcription in dorsal root ganglia (279) 165
Schaible, U., see Bohmann, C. (271) 283
Schalk, M.A.C., see Aarts, J.M.M.J.G. (293) 463
Schally, A.V., see Konturek, S.J. (278) 203
Schechter, J.B., see Schechter, M.D. (279) 59
Schechter, L.E., see Zgombick, J.M. (291) 9
Schechter, M.D., Meehan, S.M. and Schechter, J.B.
Genetic selection for nicotine activity in mice correlates with conditioned place preference (279) 59
Scheeren, R.A., see Westerveld, G.-J. (291) 27
Scheffel, U., see London, E.D. (278) R1
Scherman, D., see Phung-Ba, V. (288) 187
Scherman, D., see Phung-Ba, V. (289) 479
Scherrer, J.F., see Flood, J.F. (275) 223
Scheurink, A.J.W., see Ahrén, B. (280) 27
Schiavone, A., see Micheletti, R. (286) 147
Schiffer, E.R., Schwieger, I.M., Gosteli, P., Poinsot, O., Mentha, G. and Morel, D.R.
Systemic and splanchnic oxygen supply-demand relationship with fenoldopam, dopamine and noradrenaline in sheep (286) 49
Schiller, P.W., see Fundytus, M.E. (286) 105
Schiller, P.W., see Lee, P.H.K. (280) 211
Schiöth, H.B., Muceniece, R., Wikberg, J.E.S. and Chhajlani, V.
Characterisation of melanocortin receptor subtypes by radioligand binding analysis (288) 311
Schleger, C., see Perovic, S. (288) 27
Schlemper, V. and Calixto, J.B.
Mechanisms involved in the relaxant response of bradykinin in epithelium intact strips of the guinea-pig trachea (282) 177
Schlüter, K.-D., see Kojda, G. (284) 315
Schmalix, W.A., Barrenscheen, M., Landsiedel, R., Janzowski, C., Eisenbrand, G., Gonzalez, F., Eliasson, E., Ingelman-Sundberg, M., Perchermeier, M., Greim, H. and Doehmer, J.
Stable expression of human cytochrome P450 2E1 in V79 Chinese hamster cells (293) 123
Schmid, N., see Foucaud, B. (289) 471
Schmidt, C.J. and Fadayel, G.M.
The selective 5-HT_{2A} receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat (273) 273
Schmidt, E.D., Tilders, F.J.H., Janszen, A.W.J.W., Binnekade, R., De Vries, T.J. and Schoffelmeer, A.N.M.
Intermittent cocaine exposure causes delayed and long-lasting sensitization of cocaine-induced ACTH secretion in rats (285) 317
Schmidt, W.J., see Kretschmer, B.D. (280) 37
Schmitt, T., see Schwarz, M. (276) 247
Schmitz, P.K., see Fin, C. (271) 227
Schmutz, M., see Wamil, A.W. (271) 301
Schnecko, A., see Witte, K. (290) 1
Schneider, F.J., see Mierau, J. (290) 29
Schoeffter, P., Pérez, J., Langenegger, D., Schüpbach, E., Bobirnac, I., Lübbert, H., Bruns, C. and Hoyer, D.
Characterization and distribution of somatostatin SS-1 and SRIF-1 binding sites in rat brain: identitity with SSTR-2 receptors (289) 163
Schoeffter, P., see Hoyer, D. (289) 151
Schoemaker, H., see Le Rouzic, M. (278) 261
Schoemaker, R.G., see Du, X.Y. (284) 119
Schoemaker, R.G., see Van Gelderen, E.M. (284) 51
Schoffelmeer, A.N.M., Nestby, P., Tjon, G.H.K., Wardeh, G., De Vries, T.J., Vanderschuren, L.J.M.J. and Mulder, A.H.
Intermittent morphine treatment causes a protracted increase in cholinergic striatal neurotransmission measured ex vivo (286) 311
Schoffelmeer, A.N.M., see Schmidt, E.D. (285) 317
Schoffelmeer, A.N.M., see Tjon, G.H.K. (283) 169
Schölkens, B.A., see Wirth, K.J. (288) R1
Schollmeyer, P., see Bohmann, C. (271) 283
Schollmeyer, P., see Galle, J. (273) 311

Schönekess, B.O., Allard, M.F. and Lopaschuk, G.D.
Propionyl L-carnitine improvement of hypertrophied rat heart function is associated with an increase in cardiac efficiency (286) 155
Schoots, O., Seeman, P., Guan, H.-C., Paterson, A.D. and Van Tol, H.H.M.
Long-term haloperidol elevates dopamine D_4 receptors by 2-fold in rats (289) 67
Schott, C., see Hecker, M. (275) R1
Schoupe, T.S., see Seeds, E.A.-M. (293) 369
Schrader, J., see Hartmann, M. (287) 57
Schrattenholz, A., see Storch, A. (290) 207
Schreiber, R., Brocco, M., Gobert, A., Veiga, S. and Millan, M.J.
The potent activity of the 5-HT_{1A} receptor agonists, S 14506 and S 14671, in the rat forced swim test is blocked by novel 5-HT_{1A} receptor antagonists (271) 537
Schremmer-Danninger, E., Heinz-Erian, P., Töpfer-Petersen, E. and Roscher, A.A.
Autoradiographic localization and characterization of bradykinin receptors in human skin (283) 207
Schrör, K., see Braun, M. (276) 239
Schuligoi, R., see Amann, R. (279) 227
Schüpbach, E., see Hoyer, D. (289) 151
Schüpbach, E., see Schoeffter, P. (289) 163
Schusdziarra, V., see Franck, H. (271) 379
Schusdziarra, V., see Kurjak, M. (281) 295
Schuurkes, J.A.J., see Briejer, M.R. (279) 123
Schwarcz, R., see Wu, H.-Q. (281) 55
Schwartz, J.-C., see Griffon, N. (282) R3
Schwarz, M., Schmitt, T., Pergande, G. and Block, F.
N-Methyl-D-aspartate and α_2-adrenergic mechanisms are involved in the depressent action of flupirtine on spinal reflexes in rats (276) 247
Schwieger, I.M., see Schiffer, E.R. (286) 49
Schwinn, D.A., see Berkowitz, D.E. (289) 223
Scotti de Carolis, A., see Domenici, M.R. (271) 259
Scotti de Carolis, A., see Popoli, P. (272) 119
Seabrook, G.R., Bowery, B.J. and Hill, R.G.
Pharmacology of tachykinin receptors on neurones in the ventral tegmental area of rat brain slices (273) 113
Sebens, J.B., Koch, T., Ter Horst, G.J. and Korf, J.
Differential Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment (273) 175
Seeds, E.A.-M., Kilfeather, S., Okiji, S., Schoupe, T.S., Donigi-Gale, D. and Page, C.P.
Role of lipoxygenase metabolites in platelet-activating factor- and antigen-induced bronchial hyperresponsiveness and eosinophil infiltration (293) 369
Seegal, R.F., Smits-Van Prooije, A.E., Touwen, B.C.L., Weisglas-Kuperus, N. and Winneke, G.
(293) 1
Seeman, P. and Van Tol, H.H.M.
Deriving the therapeutic concentrations for clozapine and haloperidol: The apparent dissociation constant of a neuroleptic at the dopamine D_2 or D_4 receptor varies with the affinity of the competing radioligand (291) 59
Seeman, P., Guan, H.-C. and Van Tol, H.H.M.
Schizophrenia: elevation of dopamine D_4-like sites, using [^{3}H]-nemonapride and [^{125}I]epidepride (286) R3
Seeman, P., see Schoots, O. (289) 67
Segerson, T.P., see Saugstad, J.A. (289) 395
Segovia, J.L., see Sanchez-Amate, M.C. (292) 215
Seike, H., see Sakai, H. (291) 153
Seinen, W., see De Groene, E.M. (293) 47
Seki, Y., Suzuki, Y., Baskaya, M.K., Kano, T., Saito, K., Takayasu, M., Shibuya, M. and Sugita, K.
The effects of pituitary adenylate cyclase-activating polypeptide on cerebral arteries and vertebral artery blood flow in anesthetized dogs (275) 259
Seki, Y., see Anzai, M. (285) 173
Sekizawa, K., see Fukushima, T. (289) 103
Selbie, L.A., see Tseng, A. (271) 265
Sellin, L.C., see Karhu, S. (279) 7
Seppälä, T., see Idänpään-Heikkilä, J.J. (292) 191
Serikawa, T., see Momiyama, T. (280) 119
Serio, R., see Mulè, F. (275) 131
Serizawa, T., see Sata, M. (290) 55
Serra, G.P., see Giorgi, O. (290) 37
Serranò, M., see Altavilla, D. (286) 31
Servant, G., see Bernier, S.G. (291) 191
Seto, M., Shindo, K., Ito, K. and Sasaki, Y.
Selective inhibition of myosin phosphorylation and tension of hyperplastic arteries by the kinase inhibitor HA1077 (276) 27
Settle, S.L., see Connor, J.R. (273) 15
Seul, C., see Flesch, M. (289) 399
Sévenet, T., see Rasolonjanahary, R. (285) 19
Sevila, I., see Miquel, J. (292) 333
Sewell, R.D.E., see Rafieian-Kopaei, M. (275) 185
Sewerynek, E., Melchiorri, D., Reiter, R.J., Ortiz, G.G. and Lewinski, A.
Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin (293) 327
Sewter, J.C., see D'Alonzo, A.J. (272) 269
Sgaragli, G.P., see Palmi, M. (281) 97
Shan, L.-h., see Nishiyama, M. (286) 209
Shan-Wu, X., see Ukai, M. (274) 89
Shapiro, M., see Fundytus, M.E. (286) 105
Sharifzadeh, M., see Zarrindast, M.-R. (276) 3
Sheldrick, R.L.G., see Beresford, I.J.M. (272) 241
Shen, K.-Z., see Lutfy, K. (273) 187
Shepard, P.D., Connelly, S.T., Lehmann, H. and Grobaski, K.C.
Effects of the enantiomers of (±)-HA-966 on dopamine neurons: an electrophysiological study of a chiral molecule (285) 79
Sherstobitov, O.E., see Danilov, A.F. (277) 15
Sheu, J.-R., see Lee, Y.-M. (279) 251
Sheu, S.-S., see Arreola, J. (271) 309
Shew, T.R., Morishita, W. and Sastry, B.R.
Presynaptic actions of glutamate receptor agonists in the CA1 region of rat hippocampus in vitro (284) 93
Shi, D., see Von Lubitz, D.K.J.E. (283) 185
Shibaguchi, H., see Kataoka, Y. (273) 285
Shibasaki, K., see Shibasaki, M. (271) 341
Shibasaki, M., Shibasaki, K., Ichihara, M., Inagaki, O., Yanagisawa, I., Takenaka, T. and Murakami, K.
Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitor (271) 341
Shibata, K., see Foglar, R. (288) 201
Shibata, K., see Obika, K. (291) 327
Shibata, M., see Ohkubo, T. (273) 83
Shibata, M., see Ohkubo, T. (277) 45
Shibata, S., Tominaga, K. and Watanabe, S.
κ-Opioid receptor agonist protects against ischemic reduction of 2-deoxyglucose uptake in morphine-tolerant rats (279) 197
Shibata, S., Tominaga, K. and Watanabe, S.
Glutathione protects against hypoxic/hypoglycemic decreases in 2-deoxyglucose uptake and presynaptic spikes in hippocampal slices (273) 191
Shibata, S., Yamamoto, Y., Tanaka, T. and Watanabe, S.
N^G-Nitro-L-arginine protects against hypoxia/hypoglycemia-induced decrease in CA1 presynaptic spikes in rat hippocampal slices (273) 223
Shibata, S., see Yamamoto, Y. (281) 335
Shibata, S., see Zhou, Q. (273) 153

Shibuya, M., see Anzai, M. (285) 173
Shibuya, M., see Seki, Y. (275) 259
Shiga, T. and Yoshikawa, D.
Platelet-activating factor-induced loss of vascular responsiveness to noradrenaline in pithed rats: involvement of nitric oxide (282) 151
Shigematsu, K., see Kataoka, Y. (273) 285
Shikada, K.-i. and Tanaka, S.
K^+ channel openers produce epithelium-dependent relaxation of the guinea-pig trachea (282) 193
Shimada, K., see Ikeda, U. (288) 379
Shimada, K., see Ikeda, U. (290) 69
Shimazaki, T., see Terai, T. (279) 217
Shindo, J., see Nishiguchi, E. (286) 1
Shindo, K., see Seto, M. (276) 27
Shinkai, N., see Ukai, M. (274) 89
Shinkai, N., see Ukai, M. (281) 173
Shinkai, N., see Ukai, M. (287) 245
Shinozuka, K., Kitagawa, S., Kunitomo, M., Yamaguchi, Y., Tanabe, Y., Fujiwara, M. and Hattori, K.
Release of endogenous ATP from the caudal artery in rats with arteriosclerosis (292) 115
Shiokawa, Y., see Terai, T. (279) 217
Shippenberg, T.S. and Heidbreder, C.
The δ-opioid receptor antagonist naltrindole prevents sensitization to the conditioned rewarding effects of cocaine (280) 55
Shiraishi, T., see Miyahara, M. (284) 25
Shirasaka, Y. and Wasterlain, C.G.
The effect of urethane anesthesia on evoked potentials in dentate gyrus (282) 11
Shirasawa, E., see Matsugi, T. (275) 245
Shively, J.E., see McCauley, L.D. (276) 145
Shukla, V.K., Turndorf, H. and Bansinath, M.
Pertussis and cholera toxins modulate κ-opioid receptor agonists-induced hypothermia and gut inhibition (292) 293
Shukrula, S.R., see Smit, M.J. (288) 17
Sibley, D.R., see Gonzalez, A.M. (272) R1
Sibley, D.R., see Kreiss, D.S. (277) 209
Sicotte, B., see Roy, B. (280) 1
Siegel, B.W., see Kehne, J.H. (284) 109
Sieghart, W., see Fuchs, K. (289) 87
Sieghart, W., see Slany, A. (291) 99
Sieghart, W., see Zezula, J. (281) 93
Siems, W.-E., see Winkler, A. (291) 51
Siess, W., see Grünberg, B. (288) 329
Siltaloppi, E., see Kankaanranta, H. (291) 17
Sim, M.K. and Soh, K.S.
Effects of des-Asp-angiotensin I on the electrically stimulated contraction of the rabbit pulmonary artery (284) 215
Sim, M.K. and Yuan, H.T.
Effects of des-Asp-angiotensin I on the contractile action of angiotensin II and angiotensin III (278) 175
Simmet, T., see Tippler, B. (271) 131
Simon, J., Webb, T.E., King, B.F., Burnstock, G. and Barnard, E.A.
Characterisation of a recombinant P_{2Y} purinoceptor (291) 281
Simon, J.R., see Campbell, A.D. (290) 157
Simonnet, G., see Devillers, J.-P. (271) 185
Singh, L., Field, M.J., Hill, D.R., Horwell, D.C., McKnight, A.T., Roberts, E., Tang, K.W. and Woodruff, G.N.
Peptoid CCK receptor antagonists: pharmacological evaluation of CCK_A, CCK_B and mixed $CCK_{A/B}$ receptor antagonists (286) 185
Sinha, S., see Koley, J. (293) 483
Sipma, H., see Van der Zee, L. (289) 463
Sironi, F., see Grignaschi, G. (274) 221
Sirviö, J., see Jäkälä, P. (282) 39
Sirviö, J., see Ylinen, A. (274) 159
Sitamze, J.-M., see Martin, R.J. (276) 9
Sitzmann, J.V., see Cahill, P.A. (288) 219
Sivenius, J., see Ylinen, A. (274) 159
Sjögren, C., see Tobin, G. (281) 1
Sjuve, R., Ingvarson, T., Arner, A. and Uvelius, B.
Effects of purinoceptor agonists on smooth muscle from hypertrophied rat urinary bladder (276) 137
Skarsfeldt, T.
Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat (281) 289
Skinner, S.J.M., see Young, P.G. (273) 137
Skolnick, P., see Popik, P. (291) 221
Skomedal, T., see Dybvik, T. (281) 21
Skoog, V., see Xia, Y. (288) 277
Skoogh, B.-E., see Kawikova, I. (280) 293
Skrede, K.K., see Røshol, H. (286) 9
Skúladóttir, G.V., see Benediktsdóttir, V.E. (289) 419
Slany, A., Zezula, J., Fuchs, K. and Sieghart, W.
Allosteric modulation of [^{3}H]flunitrazepam binding to recombinant $GABA_A$ receptors (291) 99
Slany, A., see Fuchs, K. (289) 87
Slatineanu, S., see Brailoiu, E. (281) 209
Slatineanu, S., see Costuleanu, M. (281) 89
Slatineanu, S., see Filipeanu, C.M. (281) 29
Sleph, P.G., see D'Alonzo, A.J. (272) 269
Slone, A.L., see Kehne, J.H. (284) 109
Slowinski, T., see Hocher, B. (293) 361
Smiley, R.M., see Berkowitz, D.E. (289) 223
Smit, E.A., see Van Birgelen, A.P.J.M. (293) 77
Smit, J., see Coppes, R.P. (274) 33
Smit, M.J., Leurs, R., Shukrula, S.R., Bast, A. and Timmerman, H.
Rapid desensitization of the histamine H_2 receptor on the human monocytic cell line U937 (288) 17
Smith, D.J., see Monroe, P.J. (272) 51
Smith, D.L., see Monroe, P.J. (272) 51
Smith, G., Harrison, S., Bowers, J., Wiseman, J. and Birch, P.
Non-specific effects of the tachykinin NK_1 receptor antagonist, CP-99,994, in antinociceptive tests in rat, mouse and gerbil (271) 481
Smith, I.C.H., see Amobi, N. (273) 25
Smith, L.A., see Gnanalingham, K.K. (277) 235
Smith, P.F., see Jerram, A.H. (275) 291
Smith, R.E., see Santiago, J.A. (272) 115
Smith, S.E., Parvez, N.S., Chapman, A.G. and Meldrum, B.S.
The γ-aminobutyric acid uptake inhibitor, tiagabine, is anticonvulsant in two animal models of reflex epilepsy (273) 259
Smits-Van Prooije, A.E., see Seegal, R.F. (293) 1
Smolders, I., De Klippel, N., Sarre, S., Ebinger, G. and Michotte, Y.
Tonic GABA-ergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat (284) 83
Sneddon, P., see McLaren, G.J. (277) 57
Soares de Moura, R., see Criddle, D.N. (272) 293
Soares de Moura, R., see Criddle, D.N. (286) 123
Söderpalm, B., see Johnson, D.H. (276) 155
Soh, K.S., see Sim, M.K. (284) 215
Sokoloff, P., see Griffon, N. (282) R3
Somboonthum, P., see Matsuda, T. (280) 235
Sommermeyer, H., Frielingsdorf, J. and Knorr, A.
Effects of prazosin on the dopaminergic neurotransmission in rat brain (276) 267
Sonesson, C., see Clark, D. (275) 67
Sonetti, D., see Ottaviani, E. (276) 35
Song, E.-J., Yang, V.C., Chiang, C.D. and Chao, C.C.-K.
Potentiation of growth inhibition due to vincristine by ascorbic acid in a resistant human non-small cell lung cancer cell line (292) 119
Song, J.G., see Ohdo, S. (293) 151
Songu-Mize, E., see Rashed, S.M.K. (284) 289
Songu-Mize, E., see Sahin-Erdemli, I. (292) 163
Soper, B.D., see Tepperman, B.L. (293) 259

Sorrentino, L., see Mancuso, F. (271) 329
Šoškiç, V., see Storch, A. (290) 207
Soudijn, W., see Van der Wenden, E.M. (290) 189
Soustre, H., see Delpech, N. (285) 217
Southan, G.J., Szabó, C., O'Connor, M.P., Salzman, A.L. and Thiemermann, C.
Amidines are potent inhibitors of nitric oxide synthases: preferential inhibition of the inducible isoform (291) 311
Souza Pinto, J.C., Remacle-Volon, G., Sampaio, C.A.M. and Damas, J.
Collagenase-induced oedema in the rat paw and the kinin system (274) 101
Spano, P.F., see Pizzi, M. (275) 311
Spatz, M., see Stanimirovic, D.B. (288) 1
Spatz, M., see Stanimirovic, D.B. (289) 409
Speijers, G.J.A., see Gangolli, S.D. (292) 1
Spencer, P.S.J., see Rafieian-Kopaei, M. (275) 185
Sperelakis, N., see Kusaka, M. (271) 387
Spiegelhalder, B., see Gangolli, S.D. (292) 1
Spignoli, G., see Altavilla, D. (286) 31
Spitznagel, H., see Höhle, S. (275) 277
Spokes, R.A. and Middlefell, V.C.
Simultaneous measurement of plasma protein extravasation and carotid vascular resistance in the rat (281) 75
Sprague, J.E., see Marona-Lewicka, D. (287) 105
Spruijt, B.M., see Vanderschuren, L.J.M.J. (276) 257
Sprumont, P., Kaelin-Lang, A., Van Lierde, S., Maenhaut, W. and De Reuck, J.
Effect of neurotropin on cerebral edema, calcium and other elements in mice subarachnoidally injected with carrageenan (274) 95
Squadrito, F., see Altavilla, D. (272) 223
Squadrito, F., see Altavilla, D. (286) 31
Squadrito, G., see Altavilla, D. (272) 223
Squadrito, G., see Altavilla, D. (286) 31
St-Louis, J., see Roy, B. (280) 1
St-Pierre, J.-A. and Bédard, P.J.
Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine (272) 123
Stack, W.A., see Keely, S.J. (279) 203
Stam, W.B., see Bax, W.A. (285) 199
Stanchewa, E., see Negrev, N. (277) 145
Stanford, I.M., Wheal, H.V. and Chad, J.E.
Bicuculline enhances the late $GABA_B$ receptor-mediated paired-pulse inhibition observed in rat hippocampal slices (277) 229
Stanford, I.M., see Caddick, S.J. (274) 41
Stanimirovic, D.B., Nikodijevic, B., Nikodijevic-Kedeva, D., McCarron, R.M. and Spatz, M.
Signal transduction and Ca^{2+} uptake activated by endothelins in rat brain endothelial cells (288) 1
Stanimirovic, D.B., Nikodijevic, B., Nikodijevic-Kedeva, D., McCarron, R.M. and Spatz, M.
Signal transduction and Ca^{2+} uptake activated by endothelins in rat brain endothelial cells. European Journal of Pharmacology - Molecular Pharmacology Section 288 (1994) 1–8 (289) 409
Stankovičová, T., Zemková, H., Ziegelhöffer, A. and Vyskočil, F.
7-Oxo-prostacyclin affects the electrogenic Na^+/K^+ pump in mouse diaphragm fibers (276) 101
Stanton, P.K.
Phospholipase A_2 activation is not required for long-term synaptic depression (273) R7
Stark, G., Kasper, K., Stark, U., Miyawaki, N., Decrinis, M. and Tritthart, H.A.
Effects of semotiadil, a novel Ca^{2+} channel antagonist, on the electrical activity of Langendorff-perfused guinea pig hearts in comparison with diltiazem, amlodipine and nifedipine (286) 71
Stark, U., see Stark, G. (286) 71
Starke, K., see Urban, R. (282) 19
Starke, K., see Urban, R. (282) 29
Starr, B.S., see Starr, M.S. (272) 211
Starr, B.S., see Starr, M.S. (277) 151
Starr, M.S. and Starr, B.S.
Do NMDA receptor-mediated changes in motor behaviour involve nitric oxide? (272) 211
Starr, M.S. and Starr, B.S.
Motor actions of 7-OH-DPAT in normal and reserpine-treated mice suggest involvement of both dopamine D_2 and D_3 receptors (277) 151
Starr, M.S., see Kaur, S. (280) 159
Stauber, R.E., see Heinemann, A. (278) 87
Steensma, A., see Rietjens, I.M.C.M. (293) 293
Stefani, G., see Clementi, E. (289) 23
Stefanich, E., see Watson, N. (285) 135
Stefano, G.B., see Makman, M.H. (273) R5
Stefano, G.B., see Ottaviani, E. (276) 35
Steffens, A.B., see Ahrén, B. (280) 27
Stein, C., see Schäfer, M. (279) 165
Stenbäck, F., see Pellinen, P. (292) 57
Stengård, K. and O'Connor, W.T.
Acute toluene exposure decreases extracellular γ-aminobutyric acid in the globus pallidus but not in striatum: a microdialysis study in awake, freely moving rats (292) 43
Stephens, Jr., R.L., see Gidener, S. (284) 19
Stern, J.E., see Esquifino, A.I. (285) 143
Stevens, W.H.M., Ädelroth, E., Woolley, M.J., Wattie, J., Dahlbäck, M. and O'Byrne, P.M.
The effects of an inhaled corticosteroid on oxygen radical production by bronchoalveolar cells after allergen or ozone in dogs (293) 251
Stewart, G.A., see Knight, D.A. (272) 1
Stewart, G.A., see Knight, D.A. (272) 13
Stjernquist, M., see Bodelsson, G. (282) 95
Stoclet, J.-C., see Eckly, A.E. (271) 237
Stoclet, J.-C., see Hecker, M. (275) R1
Stokes, B.T., see Maurer, J.A. (288) 163
Storch, A., Schrattenholz, A., Cooper, J.C., Abdel Ghani, E.M., Gutbrod, O., Weber, K.-H., Reinhardt, S., Lobron, C., Hermsen, B., Šoškiç, V., Pereira, E.F.R., Albuquerque, E.X., Methfessel, C. and Maelicke, A.
Physostigmine, galanthamine and codeine act as 'noncompetitive nicotinic receptor agonists' on clonal rat pheochromocytoma cells (290) 207
Strabel, D. and Diener, M.
Evidence against direct activation of chloride secretion by carbachol in the rat distal colon (274) 181
Strauss, H.W., see Kurata, C. (293) 109
Striem, S., see Eshhar, N. (283) 19
Strosberg, A.D., see Méjean, A. (291) 359
Stumpe, T., see Hartmann, M. (287) 57
Stutzmann, J.-M., see Alaoui, F. (276) 55
Stutzmann, J.-M., see Benazzouz, A. (284) 299
Stutzmann, J.-M., see Estevez, A.G. (280) 47
Subissi, A., see Catalioto, R.-M. (280) 285
Subissi, A., see Renzetti, A.R. (290) 151
Sudjarwo, S.A., Hori, M., Tanaka, T., Matsuda, Y. and Karaki, H.
Coupling of the endothelin ET_A and ET_B receptors to Ca^{2+} mobilization and Ca^{2+} sensitization in vascular smooth muscle (289) 197
Sudo, M., see Tsuchida, S. (281) 251
Sugano, Y., see Gatley, S.J. (281) 141
Sugden, D., Davies, D.J., Garratt, P.J., Jones, R. and Vonhoff, S.
Radioligand binding affinity and biological activity of the enantiomers of a chiral melatonin analogue (287) 239
Sugimori, H., see Cai, H. (286) 249
Sugita, K., see Seki, Y. (275) 259
Sugiura, S., see Sata, M. (290) 55
Sugiyama, K., see Yui, K. (279) 135
Sugiyama, N., see Tabuchi, Y. (272) 195

Sugiyama, T., see Ohdo, S. (293) 281
Sullivan, J.P., see Decker, M.W. (280) 79
Sullivan, J.P., see Gopalakrishnan, M. (290) 237
Sun, M.-K. and Reis, D.J.
GABA-mediated inhibition of pacemaker neurons of rostral ventrolateral medulla by clonidine in vitro (276) 291
Sun, M.-K. and Reis, D.J.
Urethane directly inhibits chemoreflex excitation of medullary vasomotor neurons in rats (293) 237
Sun, Y.-D. and Benishin, C.G.
K^+ channel openers relax longitudinal muscle of guinea pig ileum (271) 453
Sung, M.-L., see Glaser, K. (281) 107
Sutoo, D., Akiyama, K. and Takita, H.
Hypertension in epileptic mice: a phenomenon related to reduction of Ca^{2+}-dependent catecholamine synthesis in the brain (278) 33
Suzdak, P.D., see Wong, G. (289) 335
Suzuki, A., see Nishimura, Y. (275) 217
Suzuki, H., see Hashitani, H. (284) 177
Suzuki, K.-i., see Kaku, S. (279) 115
Suzuki, M., see Matsuda, T. (280) 235
Suzuki, S., see King, P.R. (281) 341
Suzuki, T., Mori, T., Tsuji, M., Misawa, M. and Nagase, H.
Discriminative stimulus properties of morphine mediated by μ_1-opioid receptors (284) 195
Suzuki, T., Tsuda, M., Funada, M. and Misawa, M.
Blockade of morphine-induced place preference by diazepam in mice (280) 327
Suzuki, T., see Kamei, J. (275) 109
Suzuki, T., see Kamei, J. (276) 131
Suzuki, T., see Kamei, J. (280) 347
Suzuki, Y., see Anzai, M. (285) 173
Suzuki, Y., see Seki, Y. (275) 259
Svensson, A.I., see Johnson, D.H. (276) 155
Svensson, A.M., Sandler, S. and Jansson, L.
The blood flow in pancreatico-duodenal grafts in rats: inhibition of nitric oxide synthase preferentially decreases islet blood flow (275) 99
Svensson, K., see Clark, D. (275) 67
Svensson, T.H., see Kerezoudis, N.P. (275) 191
Svoboda, M., see Ciccarelli, E. (288) 259
Swanson, S., see Decker, M.W. (280) 79
Sys, S.U., see Michielsen, P.P. (273) 167
Szabo, B., see Urban, R. (282) 19
Szabo, B., see Urban, R. (282) 29
Szabó, C., see Hattori, Y. (291) 83
Szabó, C., see Southan, G.J. (291) 311
Szabó, G. and Hoffman, P.L.
Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 maintain functional tolerance to ethanol (287) 35
Szallasi, A., Blumberg, P.M. and Lundberg, J.M.
Proton inhibition of [^{3}H]resiniferatoxin binding to vanilloid (capsaicin) receptors in rat spinal cord (289) 181

Tabuchi, Y. and Furuhama, K.
Protective effect of DS-4574, a peptidoleukotriene receptor antagonist, against endotoxin-induced intestinal injury in rats (273) 281
Tabuchi, Y., Sugiyama, N., Horiuchi, T., Furusawa, M. and Furuhama, K.
Ebselen, a seleno-organic compound, protects against ethanol-induced murine gastric mucosal injury in both in vivo and in vitro systems (272) 195
Tabuchi, Y., see Sakai, H. (291) 153
Tack, I., see Bompart, G. (278) 225
Taddei, C., see Giardinà, D. (287) 13
Tadjkarimi, S., see Belvisi, M. (283) 255
Tagaya, E., see Tamaoki, J. (278) 161
Tagaya, E., see Tamaoki, J. (287) 233
Taira, C.A. and Enero, M.A.
Central α_1- and α_2-adrenoceptors and brain cholinergic stimulation in sinoaortic denervated rats (271) 9
Taira, N., see Yamagishi, T. (281) 151
Takahashi, E., see Adachi, T. (286) 201
Takahashi, H., see Izumi, H. (273) 299
Takahashi, H., see Ohkubo, T. (273) 83
Takahashi, M., see Uneyama, C. (291) 381
Takahashi, R., see Hirose, H. (277) 77
Takahashi, R., see Hirose, H. (284) 335
Takahashi, Y., Furukawa, K.-I., Ishibashi, M., Kozutsumi, D., Ishiyama, H., Kobayashi, J. and Ohizumi, Y.
Structure-activity relationship of bromoeudistomin D, a powerful Ca^{2+} releaser in skeletal muscle sarcoplasmic reticulum (288) 285
Takakura, K., Goto, Y., Kigoshi, S. and Muramatsu, I.
Selective inhibition of sympathetic nerve-mediated contraction by L-arginine in lipopolysaccharide-treated tail artery of rats (271) 367
Takaoka, M., see Fujita, K. (280) 311
Takayanagi, I., see Koike, K. (279) 159
Takayanagi, I., see Kokubu, N. (290) 19
Takayasu, M., see Anzai, M. (285) 173
Takayasu, M., see Seki, Y. (275) 259
Takeda, M., see Miyata, K. (276) 165
Takeguchi, N., see Sakai, H. (291) 153
Takemura, H., see Tamaoki, J. (278) 161
Takenaka, T., see Kaku, S. (279) 115
Takenaka, T., see Shibasaki, M. (271) 341
Takenouchi, K., see Horiuchi, H. (287) 27
Takeo, S., see Kamiyama, T. (272) 151
Takeuchi, H., see Emaduddin, M. (283) 113
Takeuchi, H., see Santos, D.E. (272) 231
Takeya, K., see Hotta, Y. (282) 121
Takiguchi, Y., Nagano, M., Ikeda, Y. and Nakashima, M.
Early administration of YT-146, an adenosine A_2 receptor agonist, inhibits neointimal thickening after rat femoral artery endothelium injury (281) 205
Takita, H., see Sutoo, D. (278) 33
Takizawa, K., see Miyata, K. (276) 165
Tamaki, T., see He, H. (273) 209
Tamaoki, J., Tagaya, E., Yamawaki, I. and Konno, K.
Lipoxin A_4 inhibits cholinergic neurotransmission through nitric oxide generation in the rabbit trachea (287) 233
Tamaoki, J., Takemura, H., Tagaya, E., Sakai, A., Yamawaki, I. and Konno, K.
Effect of azelastine on airway hyperresponsiveness mediated by stimulated macrophages (278) 161
Tamaoki, J., see Sakai, A. (291) 375
Tamargo, J., see Duarte, J. (286) 115
Tamargo, J., see Parra, L. (277) 99
Tamura, A., see Tomitaka, S.-i. (285) 207
Tamura, K., see Ito, H. (283) 107
Tanabe, J.-i., Watanabe, M., Mue, S. and Ohuchi, K.
Dexamethasone inhibits the production of macrophage inflammatory protein 2 in the leukocytes in rat allergic inflammation (284) 257
Tanabe, Y., see Shinozuka, K. (292) 115
Tanaka, H., Makino, Y., Hiramoto, M., Handa, H. and Makino, I.
Potentiation of glucocorticoid-mediated gene expression by the novel benzoquinone derivative (2E)-3-[5-(2,3-dimethoxy-*o*-methyl-1,4-benzoquinoyl)]-2-nonyl-2-propenoic acid (E3330) (291) 121
Tanaka, H., see Habuchi, Y. (292) 143
Tanaka, K., Matsutani, S., Matsumoto, K. and Yoshida, T.
Effect of thielocin A1β on bee venom phospholipase A_2-induced edema in mouse paw (279) 143
Tanaka, K., see Yamashita, H. (289) 387
Tanaka, M., see Yano, S. (289) 217
Tanaka, S., see Shikada, K.-i. (282) 193
Tanaka, T., see Shibata, S. (273) 223

Tanaka, T., see Sudjarwo, S.A. (289) 197
Tanaka, Y., Nakazawa, T., Ishiro, H., Saito, M., Uneyama, H., Iwata, S., Ishii, K. and Nakayama, K.
Ca^{2+} handling mechanisms underlying neuropeptide Y-induced contraction in canine basilar artery (289) 59
Tanaka, Y., see Nakahara, T. (287) 49
Tang, A.H. and Himes, C.S.
Apomorphine produced more yawning in Sprague-Dawley rats than in F344 rats: a pharmacological study (284) 13
Tang, F.-I., see Chiu, T.-H. (285) 261
Tang, K.W., see Singh, L. (286) 185
Tang, S.W., see Helmeste, D.M. (280) R5
Tang, S.W., see Helmeste, D.M. (286) 113
Tang, S.W., see Helmeste, D.M. (288) 373
Tang, S.W., see Helmeste, D.M. (290) 173
Tanganelli, S., Pérez de la Mora, M., Ferraro, L., Méndez-Franco, J., Beani, L., Rambert, F.A. and Fuxe, K.
Modafinil and cortical γ-aminobutyric acid outflow. Modulation by 5-hydroxytryptamine neurotoxins (273) 63
Taniguchi, K., see Horiuchi, H. (287) 27
Taniuchi, Y., see Kaku, S. (279) 115
Taniyama, K., see Akehira, K. (284) 149
Taniyama, K., see Kataoka, Y. (273) 285
Taniyama, K., see Sawa, T. (276) 223
Tanonaka, K., see Kamiyama, T. (272) 151
Tao, P.-L., Liu, C.-F. and Tsai, H.-C.
Chronic intracerebroventricular administration of morphine down-regulates spinal adenosine A_1 receptors in rats (278) 233
Tashiro, N., see Yonezawa, Y. (285) 305
Taylor, J.E., see Ladenheim, E.E. (271) R7
Taylor, L.A., McQuade, RD. and Tice, M.A.B.
Felbamate, a novel antiepileptic drug, reverses *N*-methyl-D-aspartate /glycine-stimulated increases in intracellular Ca^{2+} concentration (289) 229
Teale, D.M. and Atkinson, A.M.
L-Canavanine restores blood pressure in a rat model of endotoxic shock (271) 87
Teixeira, M.M., Williams, T.J. and Hellewell, P.G.
Anti-inflammatory effects of a short-acting and a long-acting β_2-adrenoceptor agonist in guinea pig skin (272) 185
Tejerina, T., see Chulia, T. (285) 115
Tellez, S., Colpaert, F. and Marien, M.
The α_2-adrenoceptor antagonist, (+)-efaroxan, enhances acetylcholine release in the rat cortex in vivo (277) 113
Ten Berge, R.E.J., Weening, E.C., Roffel, A.F. and Zaagsma, J.
β_2- but not β_3-adrenoceptors mediate prejunctional inhibition of non-adrenergic non-cholinergic contraction of guinea pig main bronchi (275) 199
Teng, C.-M., see Guh, J.-H. (279) 33
Teng, C.-M., see Wang, J.-P. (288) 341
Teng, L.H., see Dwoskin, L.P. (276) 195
Teodori, E., see Voigt, W. (291) 255
Tepperman, B.L. and Soper, B.D.
Ca^{2+}-mediated damage to rabbit gastric mucosal cells: modulation by nitric oxide (293) 259
Tepperman, B.L., see Brown, J.F. (292) 111
Terai, T., Kita, Y., Kusunoki, T., Shimazaki, T., Ando, T., Horiai, H., Akahane, A., Shiokawa, Y. and Yoshida, K.
A novel non-xanthine adenosine A_1 receptor antagonist (279) 217
Terazaki, C., see Kaku, S. (279) 115
Terencio, M.C., see Gil, B. (285) 281
Ter Horst, G.J., see Sebens, J.B. (273) 175
Terwel, D., Prickaerts, J., Meng, F. and Jolles, J.
Brain enzyme activities after intracerebroventricular injection of streptozotocin in rats receiving acetyl-L-carnitine (287) 65
Terzic, A., see Jovanović, A. (286) R1
Tesfamariam, B., Allen, G.T. and Powell, J.R.
Bradykinin B_2 receptor-mediated chronotropic effect of bradykinin in isolated guinea pig atria (281) 17
Testa, R., see Giardinà, D. (287) 13
Tezuka, Y., see Huang, Q. (271) R5
Thibault, S., see Gozlan, H. (288) 173
Thiemermann, C., see Akarasereenont, P. (273) 121
Thiemermann, C., see Hattori, Y. (291) 83
Thiemermann, C., see Southan, G.J. (291) 311
Thierry, A.-M., see Pirot, S. (285) 45
Thomas, G.P.
Studies on the protective effect of azepexole on ouabain-induced cardiac arrhythmias and lethality in guinea-pig (276) 215
Thompson, P.J., see Knight, D.A. (272) 1
Thompson, P.J., see Knight, D.A. (272) 13
Thompson, S.A., see Hadingham, K.L. (291) 301
Thomsen, J.S., see Wang, X. (293) 191
Thomson, N.C., see Nally, J.E. (288) 53
Thöne-Reineke, C., see Hocher, B. (293) 361
Thorens, B., see Gros, L. (288) 319
Threlkeld, P.G., see Gitter, B.D. (289) 439
Thurieau, C., see Félétou, M. (274) 57
Tice, M.A.B., see Taylor, L.A. (289) 229
Tilakaratne, N., Yang, Z. and Friedman, E.
Chronic fluoxetine or desmethylimipramine treatment alters 5-HT_2 receptor mediated c-*fos* gene expression (290) 263
Tilders, F.J.H., see Schmidt, E.D. (285) 317
Timbrell, J.A., see Waterfield, C.J. (293) 141
Timmenga, E.-J.F., see Hüsken, B.C.P. (287) 313
Timmerman, H., see Smit, M.J. (288) 17
Tippler, B., Herbst, C. and Simmet, T.
Evidence for the formation of endothelin by lysed red blood cells from endogenous precursor (271) 131
Tirosh, O., see Eshhar, N. (283) 19
Tjoeng, F.S., see Connor, J.R. (273) 15
Tjon, G.H.K., De Vries, T.J., Nestby, P., Wardeh, G., Mulder, A.H. and Schoffelmeer, A.N.M.
Intermittent and chronic morphine treatment induces long-lasting changes in δ-opioid receptor-regulated acetylcholine release in rat striatum and nucleus accumbens (283) 169
Tjon, G.H.K., see Schoffelmeer, A.N.M. (286) 311
Tobin, A.B., see Burford, N.T. (289) 343
Tobin, G. and Sjögren, C.
In vivo and in vitro effects of muscarinic receptor antagonists on contractions and release of [^{3}H]acetylcholine in the rabbit urinary bladder (281) 1
Toda, N., see Sai, Y. (282) 235
Toide, K., see Matsushita, M. (276) 177
Tokumasu, T., Ueno, A. and Oh-ishi, S.
A hypotensive response induced by des-Arg^9-bradykinin in young Brown/Norway rats pretreated with endotoxin (274) 225
Tokumasu, T., see Ueno, A. (284) 211
Tokunaga, T., see Katsuragi, T. (282) 213
Tokuyama, S., Feng, Y., Wakabayashi, H. and Ho, I.K.
Ca^{2+} channel blocker, diltiazem, prevents physical dependence and the enhancement of protein kinase C activity by opioid infusion in rats (279) 93
Tokuyama, S., Feng, Y., Wakabayashi, H. and Ho, I.K.
Possible involvement of protein kinases in physical dependence on opioids: studies using protein kinase inhibitors, H-7 and H-8 (284) 101
Toll, L., see Berzetei-Gurske, I.P. (277) 257
Tom, M.A., see Matsumoto, R.R. (280) 301
Tomich, J.M., see McCauley, L.D. (276) 145
Tominaga, K., see Shibata, S. (273) 191
Tominaga, K., see Shibata, S. (279) 197

Tomitaka, S.-i., Hashimoto, K., Narita, N., Minabe, Y. and Tamura, A.
Amantadine induces c-*fos* in rat striatum: reversal with dopamine D_1 and NMDA receptor antagonists (285) 207
Tomiyoshi, F., see Oyama, Y. (293) 101
Tomohiro, A., see He, H. (273) 209
Tonini, M., see Messori, E. (286) 205
Tonoue, T., see Naito, H. (272) 261
Töpfer-Petersen, E., see Schremmer-Danninger, E. (283) 207
Torracca, M.T., see Fornai, F. (283) 99
Torres, A.I., see Duarte, J. (286) 115
Torres, C., Morales, A., Cándido, A. and Maldonado, A.
Differential effect of buspirone and diazepam on negative contrast in one-way avoidance learning (280) 277
Tórres-Márquez, M.E., see García-Sáinz, J.A. (289) 81
Toru, M., see Nankai, M. (281) 123
Totsuka, S., see Okuyama, N. (285) 61
Touma, E., see Gopalakrishnan, M. (290) 237
Touwen, B.C.L., see Seegal, R.F. (293) 1
Towers, P., see Ihara, M. (274) 1
Traber, D.L., see Abdi, S. (293) 475
Traber, L.D., see Abdi, S. (293) 475
Tran, J.G., see Paul, D. (272) 111
Tricarico, D., Casini, G. and Conte Camerino, D.
Effects of high energy phosphates and L-arginine on the electrical parameters of ischemic-reperfused rat skeletal muscle fibers (287) 17
Tries, S., see Wallace, J.L. (271) 525
Trifilieff, A., see Mousli, M. (289) 125
Triggle, D.J., see Rutledge, A. (280) 155
Trillat, A.-C., see Malagié, I. (286) 213
Tringali, G., see Montuschi, P. (275) 31
Tringali, G., see Montuschi, P. (282) 263
Tripathi, A. and Welch, S.P.
Blockade of the antinociceptive activity of centrally administered ketorolac by nor-binaltorphimine (278) 27
Tritthart, H.A., see Stark, G. (286) 71
Trocherie, S., see Alaoui, F. (276) 55
Trumper, L., see Monasterolo, L.A. (276) 201
Truong, D.D., see Matsumoto, R.R. (275) 117
Truong, D.D., see Matsumoto, R.R. (280) 301
Tsai, H.-C., see Tao, P.-L. (278) 233
Tsai, J.H.H., see Tseng, L.F. (277) 251
Tseng, A., Inglis, A., Selbie, L.A., Moriarty, M. and Potter, E.K.
Neuropeptide Y analog with selective antagonism of effects mediated by postjunctional Y_1 receptors (271) 265
Tseng, L.F., Collins, K.A. and Wang, Q.
Differential ontogenesis of thermal and mechanical antinociception induced by morphine and β-endorphin (277) 71
Tseng, L.F., Narita, M. and Kampine, J.P.
Pretreatment with β-endorphin facilitates the attenuation of δ-opioid receptor-mediated antinociception caused by δ-opioid receptor antisense oligodeoxynucleotide (287) 169
Tseng, L.F., Tsai, J.H.H., Collins, K.A. and Portoghese, P.S.
Spinal δ_2-, but not δ_1-, μ-, or κ-opioid receptors are involved in the tail-flick inhibition induced by β-endorphin from nucleus raphe obscurus in the pentobarbital-anesthetized rat (277) 251
Tseng, L.F., see Narita, M. (280) R1
Tseng, L.F., see Narita, M. (284) 185
Tseng, Y.T., Tucker, M.A., Kashiwai, K.T., Waschek, J.A. and Padbury, J.F.
Regulation of β_1-adrenoceptors by glucocorticoids and thyroid hormones in fetal sheep (289) 353
Tsoli, E., Chan, S.L.F. and Morgan, N.G.
The imidazoline I_1 receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of Langerhans (284) 199
Tsou, K., Patrick, S.L. and Walker, J.M.
Physical withdrawal in rats tolerant to Δ^9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist (280) R13
Tsuchida, K., see Ito, C. (285) 37
Tsuchida, S., Hiraoka, M., Sudo, M. and Muramatsu, I.
Hyporesponsiveness to nitrovasodilators in rat aorta incubated with endotoxin and L-arginine (281) 251
Tsuda, M., see Suzuki, T. (280) 327
Tsuji, M., see Suzuki, T. (284) 195
Tsujimoto, G., see Foglar, R. (288) 201
Tsujimoto, G., see Horie, K. (288) 303
Tsujimoto, G., see Obika, K. (291) 327
Tsukada, Y., see Gyoda, Y. (279) 83
Tsukahara, F., see Uchida, Y. (291) 33
Tsvetnitsky, V., Campbell, I.C. and Gibbons, W.A.
S-Adenosyl-L-homocysteine and 5'-methylthioadenosine inhibit binding of [^{3}H]flunitrazepam to rat brain membranes (282) 255
Tuček, S., see Hejnová, L. (291) 427
Tuček, S., see Jakubík, J. (289) 311
Tucker, M.A., see Tseng, Y.T. (289) 353
Tudhop, S., see Gorenne, I. (275) 207
Tudhope, S.R., see Norman, P. (271) 73
Tulkens, P.M., see Van Bambeke, F. (289) 321
Tullis, K., see Aarts, J.M.M.J.G. (293) 463
Tuominen, R.K., see Rauhala, P. (285) 69
Tuomisto, J., Andrzejewski, W., Unkila, M., Pohjanvirta, R., Linden, J., Vartiainen, T. and Tuomisto, L.
Modulation of TCDD-induced wasting syndrome by portocaval anastomosis and vagotomy in Long-Evans and Han/Wistar rats (292) 277
Tuomisto, J., see Pohjanvirta, R. (293) 341
Tuomisto, J., see Tuomisto, J.T. (293) 309
Tuomisto, J., see Unkila, M. (293) 115
Tuomisto, J.T., Pohjanvirta, R., Unkila, M. and Tuomisto, J.
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin-induced anorexia and wasting syndrome in rats: aggravation after ventromedial hypothalamic lesion (293) 309
Tuomisto, J.T., see Pohjanvirta, R. (293) 341
Tuomisto, J.T., see Unkila, M. (293) 115
Tuomisto, L., see Laitinen, K.S.M. (285) 159
Tuomisto, L., see Laitinen, K.S.M. (285) 255
Tuomisto, L., see Tuomisto, J. (292) 277
Turbanti, L., see Barbier, P. (290) 125
Turndorf, H., see Shukla, V.K. (292) 293
Turner, P., see Conlon, D. (289) 283
Turpin, M.P., see Beresford, I.J.M. (272) 241
Turski, W.A., see Czuczwar, S.J. (281) 327
Tutka, P., see Czuczwar, S.J. (281) 327
Tyers, M.B., see Beresford, I.J.M. (272) 241

Uceda, G., García, A.G., Guantes, J.M., Michelena, P. and Montiel, C.
Effects of Ca^{2+} channel antagonist subtypes on mitochondrial Ca^{2+} transport (289) 73
Uchida, K., see Nitta, K. (293) 491
Uchida, S., see Nozawa, Y. (287) 191
Uchida, Y., Irie, K., Tsukahara, F., Ohba, K.-i., Ogawa, A., Fujii, E. and Muraki, T.
Endothelin-1, but not endothelin-3, suppresses lipoprotein lipase gene expression in brown adipocytes differentiated in culture (291) 33
Uchida, Y., see Fujii, E. (273) 267
Uchida, Y., see Irie, K. (275) 45
Uchimura, H., see Yonezawa, Y. (285) 305
Uchiyama-Tsuyuki, Y., Araki, H. and Otomo, S.
Depolarization and hypoxia-induced cell damage in serum-free cultures of the rat cortex, and related extracellular glutamate changes (293) 245
Udagawa, A., see Adachi, T. (286) 201
Uejima, Y., see Horiuchi, H. (287) 27
Uematsu, T., see Ishiye, M. (280) 11
Ueno, A., Tokumasu, T., Naraba, H. and Oh-ishi, S.

Involvement of bradykinin in endotoxin-induced vascular permeability increase in the skin of rats (284) 211
Ueno, A., see Tokumasu, T. (274) 225
Ueno, S., see Oyama, Y. (293) 101
Ugolini, A., see Bordi, F. (273) 291
Uhl, G.R., see Kusama, T. (291) 431
Uhl, G.R., see Schäfer, M. (279) 165
Uhlén, S., see Wikberg-Matsson, A. (284) 271
Ukai, M., Kobayashi, T., Mori, K., Shinkai, N., Sasaki, Y. and Kameyama, T.
Attenuation of memory with Tyr-D-Arg-Phe-β-Ala-NH_2, a novel dermorphin analog with high affinity for μ-opioid receptors (287) 245
Ukai, M., Kobayashi, T., Shinkai, N., Shan-Wu, X. and Kameyama, T.
Dynorphin A-(1–13) potently improves scopolamine-induced impairment of passive avoidance response in mice (274) 89
Ukai, M., Shinkai, N. and Kameyama, T.
κ-Opioid receptor agonists improve pirenzepine-induced disturbance of spontaneous alternation performance in the mouse (281) 173
Ulus, I.H., see Buyukuysal, R.L. (281) 179
Umemura, K., Ishiye, M., Kosuge, K. and Nakashima, M.
Effect of combination of a tissue-type plasminogen activator and an endothelin receptor antagonist, FR139317, in the rat cerebral infarction model (275) 17
Umemura, K., see Ishiye, M. (280) 11
Uneyama, C., Uneyama, H., Takahashi, M. and Akaike, N.
Pharmacological studies on mechanisms involved in Ca^{2+} oscillations in rat megakaryocytes (291) 381
Uneyama, H., see Tanaka, Y. (289) 59
Uneyama, H., see Uneyama, C. (291) 381
Unger, T., see Höhle, S. (275) 277
Ungerstedt, U., see Wu, H.-Q. (281) 55
Unkila, M., Pohjanvirta, R., Tuomisto, J.T. and Tuomisto, J.
Alterations in plasma tryptophan binding to albumin in 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated Long-Evans rats (293) 115
Unkila, M., see Pohjanvirta, R. (293) 341
Unkila, M., see Tuomisto, J. (292) 277
Unkila, M., see Tuomisto, J.T. (293) 309
Unno, T., see Komori, S. (277) 173
Uno, H., see Horiuchi, H. (287) 27
Unteutsch, A., see Bouvier, C. (290) 11
Urban, R., Szabo, B. and Starke, K.
Involvement of α_2-adrenoceptors in the cardiovascular effects of moxonidine (282) 19
Urban, R., Szabo, B. and Starke, K.
Involvement of peripheral presynaptic inhibition in the reduction of sympathetic tone by moxonidine, rilmenidine and UK 14304 (282) 29
Urna, G., see Altavilla, D. (286) 31
Ushijima, H., see Perovic, S. (288) 27
Ushijima, I., Mizuki, Y. and Yamada, M.
Alteration of cataleptic responses induced by dopamine receptor antagonists after chronic cocaine administration in mice (285) 55
Usui, H., see Nishimura, Y. (275) 217
Uusi-Oukari, M., see Wong, G. (289) 335
Uvelius, B., see Sjuve, R. (276) 137

Vaalburg, W., see Van Waarde, A. (272) 159
Vaccari, A. and Saba, P.L.
The tyramine-labelled vesicular transporter for dopamine: a putative target of pesticides and neurotoxins (292) 309
Vaglini, F., see Barbier, P. (290) 125
Vahter, M., Concha, G., Nermell, B., Nilsson, R., Dulout, F. and Natarajan, A.T.
A unique metabolism of inorganic arsenic in native Andean women (293) 455
Valente, R., see Giamberardino, M.A. (278) 97
Valette, H., see Brouillet, E. (293) 487
Valtonen, P., Haapalinna, A., Riekkinen, Sr., P. and Halonen, T.
Effect of α_2-adrenergic drugs dexmedetomidine and atipamezole on extracellular amino acid levels in vivo (285) 239
Valverde, O., Blommaert, A.G.S., Fournié-Zaluski, M.-C., Roques, B.P. and Maldonado, R.
Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCK_B receptor antagonist (286) 79
Van Aerschot, A., see Van der Wenden, E.M. (290) 189
Van Bambeke, F., Tulkens, P.M., Brasseur, R. and Mingeot-Leclercq, M.-P.
Aminoglycoside antibiotics induce aggregation but not fusion of negatively-charged liposomes (289) 321
Van Birgelen, A.P.J.M., Smit, E.A., Kampen, I.M., Groeneveld, C.N., Fase, K.M., Van der Kolk, J., Poiger, H., Van den Berg, M., Koeman, J.H. and Brouwer, A.
Subchronic effects of 2,3,7,8-TCDD or PCBs on thyroid hormone metabolism: use in risk assessment (293) 77
Van Bladeren, P.J., see Rietjens, I.M.C.M. (293) 293
Van de Kar, L.D., see Levy, A.D. (274) 141
Van Delft, J.L., see Meijer, F. (284) 61
Van de Loo, P.G.F., see Folkerts, G. (285) R1
Van den Berg, M., see Brouwer, A. (293) 1
Van den Berg, M., see Van Birgelen, A.P.J.M. (293) 77
Van den Brandt, P.A., see Gangolli, S.D. (292) 1
Vander Borght, T., see Kilbourn, M. (278) 249
Van der Graaf, P.H., Apaydin, S. and Saxena, P.R.
The α_1-adrenoceptor agonist, SDZ NVI-085, behaves as a potent, competitive antagonist of 5-hydroxytryptamine-induced contraction of rat aorta (287) 309
Van der Graaf, P.H., see Bax, W.A. (285) 199
Van der Gugten, J., see Groenink, L. (272) 177
Van der Gugten, J., see Groenink, L. (280) 185
Vanderheyden, P.M.L., see Reijmers, L.G.J.E. (272) 131
Van der Kolk, J., see Van Birgelen, A.P.J.M. (293) 77
Van der Leest, J., see Coppes, R.P. (274) 33
Van der Linde, H., see Folkerts, G. (285) R1
Vandermeers, A., see Gourlet, P. (287) 7
Vandermeers-Piret, M.-C., see Gourlet, P. (287) 7
Van der Molen, K., see Santing, R.E. (275) 75
Vanderschuren, L., see Van Ree, J.M. (279) 187
Vanderschuren, L.J.M.J., Niesink, R.J.M., Spruijt, B.M. and Van Ree, J.M.
μ- and κ-opioid receptor-mediated opioid effects on social play in juvenile rats (276) 257
Vanderschuren, L.J.M.J., see Schoffelmeer, A.N.M. (286) 311
Van der Vliet, H., see Garssen, J. (292) 223
Van der Wenden, E.M., Hartog-Witte, H.R., Roelen, H.C.P.F., Von Frijtag Drabbe Künzel, J.K., Pirovano, I.M., Mathôt, R.A.A., Danhof, M., Van Aerschot, A., Lidaks, M.J., IJzerman, A.P. and Soudijn, W.
8-Substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine A_1 receptor (290) 189
Van der Zee, L., Sipma, H., Nelemans, A. and Den Hertog, A.
The role of inositol 1,3,4,5-tetrakisphosphate in internal Ca^{2+} mobilization following histamine H_1 receptor stimulation in DDT1 MF-2 cells (289) 463
Van de Voorde, J., Brochez, V. and Vanheel, B.
Heterogenous effects of histamine on isolated rat coronary arteries (271) 17
Van de Voorde, J., see Delaey, C. (280) 179
Van Dijk, J.P.M., Madretsma, G.S., Keuskamp, Z.J. and Zijlstra, F.J.
Nicotine inhibits cytokine synthesis by mouse colonic mucosa (278) R11
Vane, J.R., see Akarasereenont, P. (273) 121
Vane, J.R., see Hattori, Y. (291) 83
Van Gelderen, E.M., Du, X.Y., Schoemaker, R.G. and Saxena, P.R.
Carotid blood flow distribution, haemodynamics and inotropic responses following calcitonin gene-related peptide in the pig (284) 51
Van Giersbergen, P.L.M., see Kehne, J.H. (284) 109

Van Haeringen, N.J., see Meijer, F. (284) 61
VanHagen, M., see Reubi, J.C. (271) 371
Vanheel, B., see Van de Voorde, J. (271) 17
Van Hove, C.E., see De Meyer, E. (291) 67
Van Kleef, R.G.D.M., see Zwart, R. (291) 399
Van Leeuwen, R., De Vries, R. and Dzoljic, M.R.
7-Nitro indazole, an inhibitor of neuronal nitric oxide synthase, attenuates pilocarpine-induced seizures (287) 211
Van Lierde, S., see Sprumont, P. (274) 95
Van Loveren, H., see Buckley, T.L. (282) 103
Van Loveren, H., see Garssen, J. (292) 223
Van Loveren, H., see Hessel, E.M. (293) 401
Van Ommen, B., see Rietjens, I.M.C.M. (293) 293
Van Oosterhout, A.J.M., see Hessel, E.M. (293) 401
Van Ree, J.M., Wolterink, G., Igarashi, Y., Vanderschuren, L., Wiegant, V.M., Rust, C.J.J. and Bruning, H.W.
Behavioral studies on the putative γ-type endorphin receptor using different antibodies (279) 187
Van Ree, J.M., see Hatta, K. (284) 327
Van Ree, J.M., see Vanderschuren, L.J.M.J. (276) 257
Van Tintelen, G., see Rietjens, I.M.C.M. (293) 293
Van Tol, H.H.M., see Bouvier, C. (290) 11
Van Tol, H.H.M., see Schoots, O. (289) 67
Van Tol, H.H.M., see Seeman, P. (286) R3
Van Tol, H.H.M., see Seeman, P. (291) 59
Van Waarde, A., Elsinga, P.H., Brodde, O.-E., Visser, G.M. and Vaalburg, W.
Myocardial and pulmonary uptake of *S*-1'-[^{18}F]fluorocarazolol in intact rats reflects radioligand binding to β-adrenoceptors (272) 159
Van Zwieten, P.A., see Hüsken, B.C.P. (287) 313
Vapaatalo, H., see Kankaanranta, H. (291) 17
Varga, E., see Knapp, R.J. (291) 129
Varga, G., Liehr, R.-M., Scarpignato, C. and Coy, D.H.
Distinct receptors mediate gastrin-releasing peptide and neuromedin B-induced delay of gastric emptying of liquids in rats (286) 109
Varga, K., Lake, K., Martin, B.R. and Kunos, G.
Novel antagonist implicates the CB_1 cannabinoid receptor in the hypotensive action of anandamide (278) 279
Vargaftig, B.B., see Garrelds, I.M. (275) 295
Vargas, M.L., see Milanés, M.V. (271) 103
Vartiainen, T., see Tuomisto, J. (292) 277
Varty, G.B. and Higgins, G.A.
Reversal of a dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT_2 receptor antagonist ketanserin (287) 201
Vasar, E., see Männistö, P.T. (274) 229
Vaudry, H., see Bucharles, C. (271) 79
Vauquelin, G., see Velez Pardo, C. (288) 209
Vayssettes-Courchay, C., Bouysset, F., Verbeuren, T.J. and Laubie, M.
Evidence against the involvement of the nucleus tractus solitarii in the sympatholytic effect of 8-hydroxy-2-(di-*n*-propylamino)tetralin in the cat (285) 299
Vecchiet, L., see Giamberardino, M.A. (278) 97
Vecchio, I., see Clementi, E. (289) 113
Vega, T., De Pascual, R., Bulbena, O. and García, A.G.
Effects of ω-toxins on noradrenergic neurotransmission in beating guinea pig atria (276) 231
Veiga, S., see Schreiber, R. (271) 537
Velez Pardo, C., Jimenez del Rio, M., Pinxteren, J., De Potter, W., Ebinger, G. and Vauquelin, G.
Fe^{2+}-mediated binding of serotonin and dopamine to skeletal muscle actin: resemblance to serotonin binding proteins (288) 209
Veliçelebi, G., see Knöpfel, T. (288) 389
Venero, C., see Sandi, C. (277) 89
Venkatesan, N. and Chandrakasan, G.
In vivo administration of taurine and niacin modulate cyclophosphamide-induced lung injury (292) 75
Ventura, S. and Ludbrook, J.
N-Nitro-L-arginine methyl ester blocks the decompensatory phase of acute hypovolaemia in conscious rabbits by a brainstem mechanism (277) 265
Ventura, S., see Lau, W.A.K. (272) 31
Ventura, S., see Ludbrook, J. (275) 267
Verbeuren, T.J., see Vayssettes-Courchay, C. (285) 299
Verdouw, P.M., see Groenink, L. (280) 185
Vergoni, A.V., see Poggioli, R. (271) 253
Verhage, M., Hens, J.J.H., De Graan, P.N.E., Boomsma, F., Wiegant, V.M., Lopes da Silva, F.H., Gispen, W.H. and Ghijsen, W.E.J.M.
Ba^{2+} replaces Ca^{2+}/calmodulin in the activation of protein phosphatases and in exocytosis of all major transmitters (291) 387
Verheyen, A.K.C.P., see Hessel, E.M. (293) 401
Vermeulen, N.P.E., see Remirez, D. (293) 301
Versigny, A., see Cazes, M. (284) 157
Vértes, M., see Vértes, Z. (291) 115
Vértes, Z., Környei, J.L., Kovács, S. and Vértes, M.
Role of opioid peptides in the regulation of DNA synthesis in immature rat uterus (291) 115
Vértessy, B.G., see Molnár, A. (291) 73
Vetter, H., see Flesch, M. (289) 399
Vezzani, A., see Mennini, T. (271) 93
Vicente, I., see Martinez-Garcia, F. (293) 271
Vicentini, L.M., see Cattaneo, M.G. (291) 209
Vickery-Clark, L., see Aiyar, N. (283) 63
Videbæk, C., Andersen, J.V., Dalgaard, L., Foged, C., Paulson, O.B. and Lassen, A.N.
Neuroreceptor quantification in vivo by the steady state principle and [^{123}I]iomazenil in rats (281) 117
Videbæk, L.M., Kvist, S. and Mulvany, M.J.
Time course of action of amlodipine and felodipine in the rat is most rapid in small arteries (274) 109
Viganò, T., Hernandez, A., Corsini, A., Granata, A., Belloni, P., Fumagalli, R., Paoletti, R. and Folco, G.
Mevalonate pathway and isoprenoids regulate human bronchial myocyte proliferation (291) 201
Vijverberg, H.P.M., see Zwart, R. (291) 399
Vilardaga, J.-P., see Ciccarelli, E. (288) 259
Vilhardt, H., see Atke, A. (281) 63
Villa, F., see Ma, Z.-Q. (284) 171
Villa, P. and Ghezzi, P.
Effect of *N*-acetyl-L-cysteine on sepsis in mice (292) 341
Villalobos-Molina, R., Ibarra, M. and Hong, E.
The 5-HT_2 receptor antagonist, pelanserin, inhibits α_1-adrenoceptor-mediated vasoconstriction in vitro (277) 181
Villalobos-Molina, R., see García-Sáinz, J.A. (289) 1
Vilner, B.J., see Bowen, W.D. (278) 257
Vilner, B.J., see Bowen, W.D. (279) R1
Vincent, S.R., see Luo, D. (290) 247
Violani, E., see Ma, Z.-Q. (284) 171
Virtanen, K., see Rouru, J. (273) 99
Visser, G.M., see Van Waarde, A. (272) 159
Vistelle, R., see Garay, R.P. (274) 175
Vitagliano, S., see Berger, I. (277) 195
Vitorica, J., see Bougria, M. (291) 407
Vizi, E.S., see Makara, G.B. (287) 43
Vo, V.N., see Matsumoto, R.R. (280) 301
Vogel, Z., see Barg, J. (287) 145
Vogel, Z., see Novakova, M. (286) 19
Voigt, W., Romanelli, M.N., Lemoine, H., Mannhold, R., Dei, S., Teodori, E. and Gualtieri, F.
Structural dependence of the allosteric interaction of semi-rigid verapamil analogues with dihydropyridine-binding in kitten heart (291) 255
Volkow, N.D., see Gatley, S.J. (281) 141
Volpe, P., see Clementi, E. (289) 23

Von Frijtag Drabbe Künzel, J.K., see Van der Wenden, E.M. (290) 189
Vonhoff, S., see Sugden, D. (287) 239
Von Lubitz, D.K.J.E., Carter, M.F., Deutsch, S.I., Lin, R.C.-S., Mastropaolo, J., Meshulam, Y. and Jacobson, K.A.
The effects of adenosine A_3 receptor stimulation on seizures in mice (275) 23
Von Lubitz, D.K.J.E., Kim, J., Beenhakker, M., Carter, M.F., Lin, R.C.-S., Meshulam, Y., Daly, J.W., Shi, D., Zhou, L.-M. and Jacobson, K.A.
Chronic NMDA receptor stimulation: therapeutic implications of its effect on adenosine A_1 receptors (283) 185
Von Lubitz, D.K.J.E., Lin, R.C.S. and Jacobson, K.A.
Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A_{2A} receptor agonist and antagonist (287) 295
Voss, H.-P., see Westerveld, G.-J. (291) 27
Vroom, M.B., see Hüsken, B.C.P. (287) 313
Vu, R., see Helmeste, D.M. (288) 373
Vu, R., see Helmeste, D.M. (290) 173
Vuorinen, P., see Kankaanranta, H. (291) 17
Vyskočil, F., see Stankovičová, T. (276) 101

Wachtel, H., see Löschmann, P.-A. (284) 129
Wada, A., see Niina, H. (286) 95
Waeber, C. and Moskowitz, M.A.
Autoradiographic visualisation of [^{3}H]5-carboxamidotryptamine binding sites in the guinea pig and rat brain (283) 31
Waelbroeck, M., see Ciccarelli, E. (288) 259
Waelbroeck, M., see Pfaff, O. (286) 229
Wafford, K.A., see Hadingham, K.L. (291) 301
Wagner, C.A., see Herzer, T. (291) 205
Wagner, T.O.F., see Flüge, T. (271) 395
Wahlestedt, C., see Erlinge, D. (289) 135
Waite, S., see Knapp, R.J. (291) 129
Wakabayashi, H., see Tokuyama, S. (279) 93
Wakabayashi, H., see Tokuyama, S. (284) 101
Wakabayashi, I., Sakamoto, K. and Hatake, K.
Inhibitory effects of cadmium ion on extracellular Ca^{2+}-independent contraction of rat aorta (293) 133
Wakabayashi, I., see Hatake, K. (274) 25
Wakelam, M.J.O., see Nally, J.E. (288) 53
Waldegger, S., see Herzer, T. (291) 205
Walker, J.M., see Miller, A.S. (279) 179
Walker, J.M., see Tsou, K. (280) R13
Walker, J.M., see Weiser, S.D. (275) 1
Walker, M.J.A., see Barrett, T.D. (285) 229
Walker, R., see Gangolli, S.D. (292) 1
Wallace, J.L., Carter, L., McKnight, W., Tries, S. and Laufer, S.
ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury (271) 525
Wallace, J.L., Cirino, G., McKnight, G.W. and Elliott, S.N.
Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester (280) 63
Wallace, P., see Gaffen, Z. (271) 445
Walsh, D.M., Beattie, D.T. and Connor, H.E.
The activity of 5-HT_{1D} receptor ligands at cloned human 5-$HT_{1D\alpha}$ and 5-$HT_{1D\beta}$ receptors (287) 79
Walsh, D.M., see Beresford, I.J.M. (272) 241
Walters, J.R., see Kreiss, D.S. (277) 209
Wamil, A.W., Schmutz, M., Portet, C., Feldmann, K.F. and McLean, M.J.
Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures (271) 301
Wang, J.-P., Hsu, M.-F., Chang, L.-C., Kuo, J.-S. and Kuo, S.-C.
Inhibition of plasma extravasation by abruquinone A, a natural isoflavanquinone isolated from *Abrus precatorius* (273) 73
Wang, J.-P., Raung, S.-L., Chang, L.-C. and Kuo, S.-C.
Inhibition of hind-paw edema and cutaneous vascular plasma extravasation in mice by acetylshikonin (272) 87
Wang, J.-P., Raung, S.-L., Kuo, Y.-H. and Teng, C.-M.
Daphnoretin-induced respiratory burst in rat neutrophils is, probably, mainly through protein kinase C activation (288) 341
Wang, Q., see Tseng, L.F. (277) 71
Wang, Q.-D., Li, X.-S. and Pernow, J.
Characterization of endothelin-1-induced vascular effects in the rat heart by using endothelin receptor antagonists (271) 25
Wang, Q.-D., see Li, X.-S. (283) 161
Wang, S.Z., Zhu, S.Z. and El-Fakahany, E.E.
Expression of endogenous muscarinic acetylcholine receptors in Chinese hamster ovary cells (291) R1
Wang, X., Thomsen, J.S., Santostefano, M., Rosengren, R., Safe, S. and Perdew, G.H.
Comparative properties of the nuclear aryl hydrocarbon (Ah) receptor complex from several human cell lines (293) 191
Wang, X., see Esbenshade, T.A. (289) 305
Wang, X., see Zhang, L. (280) 335
Wanner, C., see Galle, J. (273) 311
Warburton, P., see Balmforth, A.J. (291) 135
Warburton, P., see Wintersgill, H.P. (288) 365
Wardeh, G., see Schoffelmeer, A.N.M. (286) 311
Wardeh, G., see Tjon, G.H.K. (283) 169
Warnery, A., see Phung-Ba, V. (288) 187
Warnery, A., see Phung-Ba, V. (289) 479
Wärngård, L., see Hemming, H. (292) 241
Warnick, J.E., see Deshpande, S.B. (271) 439
Waschek, J.A., see Tseng, Y.T. (289) 353
Waser, B., see Reubi, J.C. (271) 371
Wasterlain, C.G., see Shirasaka, Y. (282) 11
Watanabe, H., see Ohdo, S. (293) 281
Watanabe, M., see Hatta, S. (291) 351
Watanabe, M., see Henmi, S. (282) 219
Watanabe, M., see Tanabe, J.-i. (284) 257
Watanabe, S., see Ohno, M. (271) 557
Watanabe, S., see Ohno, M. (275) 39
Watanabe, S., see Shibata, S. (273) 191
Watanabe, S., see Shibata, S. (273) 223
Watanabe, S., see Shibata, S. (279) 197
Watanabe, S., see Yamamoto, Y. (281) 335
Watanabe, Y., see Satoh, N. (272) 233
Waterfall, J.F., see Laight, D.W. (292) 81
Waterfield, C.J., Jairath, M., Asker, D.S. and Timbrell, J.A.
The biochemical effects of clenbuterol: with particular reference to taurine and muscle damage (293) 141
Waterman, A.E., see Main, D.C.J. (287) 221
Waters, D.C., see Gitter, B.D. (289) 439
Watson, N., Magnussen, H. and Rabe, K.F.
Antagonism of β-adrenoceptor-mediated relaxations of human bronchial smooth muscle by carbachol (275) 307
Watson, N., Reddy, H. and Eglen, R.M.
Role of muscarinic M_2 and M_3 receptors in guinea-pig trachea: effects of receptor alkylation (278) 195
Watson, N., Reddy, H., Stefanich, E. and Eglen, R.M.
Characterization of the interaction of zamifenacin at muscarinic receptors in vitro (285) 135
Wattie, J., see Stevens, W.H.M. (293) 251
Watts, S.W., see Killam, A.L. (273) 7
Webb, T.E., see Simon, J. (291) 281
Webber, R.K., see Connor, J.R. (273) 15
Weber, E., see Lutfy, K. (273) 187
Weber, K.-H., see Storch, A. (290) 207
Weckström, M., see Karhu, S. (279) 7
Weening, E.C., see Ten Berge, R.E.J. (275) 199
Wegener, J.W. and Nawrath, H.
Alkalinisation does not modify the effect of verapamil on myocardial Ca^{2+} current (287) 89
Wei, X., see Moss, D.W. (289) 41

Weichman, B., see Glaser, K. (281) 107
Weidley, E.F., see Aiyar, N. (283) 63
Weihe, E., see Gillardon, F. (293) 395
Weinshank, R.L., see Zgombick, J.M. (291) 9
Weinstock, J., see Aiyar, N. (283) 63
Weiser, S.D., Patrick, S.L., Mascarella, S.W., Downing-Park, J., Bai, X., Carroll, F.I., Walker, J.M. and Patrick, R.L.
Stimulation of rat striatal tyrosine hydroxylase activity following intranigral administration of σ receptor ligands (275) 1
Weisglas-Kuperus, N., see Seegal, R.F. (293) 1
Weizman, R., see Fonia, O. (293) 335
Welch, S.P., see Tripathi, A. (278) 27
Weltrowska, G., see Fundytus, M.E. (286) 105
Wemlinger, T.A., see Hadjiconstantinou, M. (289) 97
Wendel, A., see Leist, M. (292) 201
Wenger, B.W., see Maurer, J.A. (288) 163
Wenk, G.L., Danysz, W. and Mobley, S.L.
MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis (293) 267
Wermuth, C.G., see Martin, R.J. (276) 9
Werner, H., see Paegelow, I. (279) 211
Wessinger, W.D.
Sexual dimorphic effects of chronic phencyclidine in rats (277) 107
Wessler, I., Dooley, D.J. and Lohr, B.
P-type Ca^{2+} channels trigger stimulus-evoked [^{3}H]acetylcholine release from mammalian motor endplates (278) 83
Westbrook, G.L., see Saugstad, J.A. (289) 395
Westerveld, G.-J., Scheeren, R.A., Dekker, I., Griffioen, D.H., Voss, H.-P. and Bast, A.
Anti-oxidant actions of oxymethazoline and xylomethazoline (291) 27
Westfall, D.P., see Mutafova-Yambolieva, V.N. (285) 213
Westfall, T.C., see McCullough, L.A. (287) 271
Westlind-Danielsson, A., Gustafsson, K. and Andersson, I.
Remoxipride shows low propensity to block functional striatal dopamine D_2 receptors in vitro (288) 89
Wheal, H.V., see Stanford, I.M. (277) 229
Whelpton, R., see Khan, S. (282) 229
Whitaker-Azmitia, P.M., Raio, M., Raio, D. and Borella, A.
A 5-HT_3 receptor antagonist fails to prevent cisplatin-induced toxicity in immature rat spinal cord (275) 139
White, A., see Berzetei-Gurske, I.P. (277) 257
White, A.C., see Hume, S.P. (271) 515
White, F.J., see Jeziorski, M. (275) 235
White, H.S., see Kehne, J.H. (284) 109
White, P.J., Hope, W. and Rose'Meyer, R.B.
The role of adenosine in the hypotensive actions of morphine (286) 315
Whiting, P.J., see Hadingham, K.L. (291) 301
Whiting, P.J., see Quirk, K. (290) 175
Whittemore, E.R., see Korotzer, A.R. (288) 125
Whittle, B.J.R., see Barrachina, M.D. (280) 339
Whittle, B.J.R., see Brown, J.F. (292) 111
Whittle, B.J.R., see László, F. (277) R1
Whittle, B.J.R., see László, F. (283) 47
Whittle, B.J.R., see Lamarque, D. (277) 187
Whittle, B.J.R., see Laszlo, F. (272) 169
Whittle, B.J.R., see Lopez-Belmonte, J. (271) R15
Whittle, B.J.R., see Lopez-Belmonte, J. (278) R7
Wickens, A.P. and Pertwee, R.G.
Effect of Δ^9-tetrahydrocannabinol on circling in rats induced by intranigral muscimol administration (282) 251
Wiegant, V.M., see Van Ree, J.M. (279) 187
Wiegant, V.M., see Verhage, M. (291) 387
Wieland, H.A., see Entzeroth, M. (278) 239
Wieland, H.A., see Rudolf, K. (271) R11
Wiemer, G., see Wirth, K.J. (288) R1
Wienen, W., see Entzeroth, M. (278) 239
Wienen, W., see Rudolf, K. (271) R11
Wiesenfeld-Hallin, Z., see Xu, X.-J. (272) 219
Wiik, P., see Røshol, H. (286) 9
Wikberg, J.E.S., see Schiöth, H.B. (288) 311
Wikberg, J.E.S., see Wikberg-Matsson, A. (284) 271
Wikberg, J.E.S., see Xia, Y. (288) 277
Wikberg-Matsson, A., Wikberg, J.E.S. and Uhlén, S.
Identification of drugs subtype-selective for α_{2A}-, α_{2B}-, and α_{2C}-adrenoceptors in the pig cerebellum and kidney cortex (284) 271
Wikström, H., see Acri, J.B. (281) R7
Wilcox, G., see Bétoin, F. (279) 241
Wilcox, G.L., see Budai, D. (278) 39
Wild, C.P., see Pelkonen, P. (292) 67
Wiley, J., Balster, R. and Martin, B.
Discriminative stimulus effects of anandamide in rats (276) 49
Wilkinson, R., see Kurata, C. (293) 109
Willets, J.M., Lambert, D.G., Lunec, J. and Griffiths, H.R.
Studies on the neurotoxicity of 6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (salsolinol) in SH-SY5Y cells (293) 319
Williams, N.G., see Esbenshade, T.A. (289) 305
Williams, T.J., see Belvisi, M. (283) 255
Williams, T.J., see Teixeira, M.M. (272) 185
Williams, W., see Bowen, W.D. (279) R1
Willim, K.-D., see Entzeroth, M. (278) 239
Willim, K.D., see Rudolf, K. (271) R11
Wils, P., see Phung-Ba, V. (288) 187
Wils, P., see Phung-Ba, V. (289) 479
Wilsch, V.W., Pidoplichko, V.I. and Reymann, K.G.
Preferential block of desensitizing AMPA receptor in hippocampal neurons by γ-D-glutamylaminomethylsulfonic acid (284) 141
Winkler, A., Papsdorf, G., Odarjuk, J., Siems, W.-E., Fickel, J. and Melzig, M.F.
Expression and characterization of the substance P (NK_1) receptor in the rat pituitary and AtT20 mouse pituitary tumor cells (291) 51
Winneke, G., see Seegal, R.F. (293) 1
Wintersgill, H.P., Warburton, P., Bryson, S.E., Ball, S.G. and Balmforth, A.J.
Glucocorticoids regulate the expression of angiotensin AT_1 receptors, in the human hepatoma cell line, PLC-PRF-5 (288) 365
Wirth, K.J., Schölkens, B.A. and Wiemer, G.
The bradykinin B_2 receptor antagonist WIN 64338 inhibits the effect of des-Arg^9-bradykinin in endothelial cells (288) R1
Wise, H., Qian, Y.-m. and Jones, R.L.
A study of prostacyclin mimetics distinguishes neuronal from neutrophil IP receptors (278) 265
Wiseman, J., see Smith, G. (271) 481
Wishnok, J.S., see Gangolli, S.D. (292) 1
Withrington, P.G., see Grassi-Kassisse, D.M. (282) 57
Witkin, J.M., see Acri, J.B. (278) 213
Witkin, J.M., see Acri, J.B. (281) R7
Witt, M.-R., see Nielsen, M. (289) 109
Witte, K., Schnecko, A., Olbrich, H.-G. and Lemmer, B.
Efficiency of β-adrenoceptor subtype coupling to cardiac adenylyl cyclase in cardiomyopathic and control hamsters (290) 1
Wolfarth, S., see Ossowska, K. (273) 89
Wolterink, G., see Hatta, K. (284) 327
Wolterink, G., see Van Ree, J.M. (279) 187
Womer, D.E., see Campbell, A.D. (290) 157
Wong, C.-L.
Effects of a histamine H_2 receptor agonist and antagonist on restraint-induced antinociception in female mice (279) 109
Wong, D. and Ogle, C.W.
Chronic parenterally administered nicotine and stress- or ethanol-induced gastric mucosal damage in rats (292) 157
Wong, G., Uusi-Oukari, M., Hansen, H.C., Suzdak, P.D. and Korpi, E.R.
Characterization of novel ligands for wild-type and natural mutant diazepam-insensitive benzodiazepine receptors (289) 335

Wong, G., see Acri, J.B. (278) 213
Wongwitdecha, N. and Marsden, C.A.
Isolation rearing prevents the reinforcing properties of amphetamine in a conditioned place preference paradigm (279) 99
Wonnacott, S., see Molloy, L. (289) 447
Woo, P.C.Y., Kaan, S.K. and Cho, C.H.
Evidence for potential application of zinc as an antidote to acetaminophen-induced hepatotoxicity (293) 217
Woodcock, E.A. and Lambert, K.A.
The inositol phosphate response to thrombin in rat right atria differs from the response to noradrenaline (291) 213
Woodruff, G.N., see Singh, L. (286) 185
Woods, A., see Roehr, J. (278) 75
Woods, A.J. and Andrews, P.L.R.
Cisplatin acutely reduces 5-hydroxytryptamine-induced vagal depolarization in the rat: protective action of dexamethasone (278) 275
Woods, J.H., see Butelman, E.R. (277) 285
Woodward, B., see Laight, D.W. (292) 81
Woodward, J.J., Compton, D.M., Balster, R.L. and Martin, B.R.
In vitro and in vivo effects of cocaine and selected local anesthetics on the dopamine transporter (277) 7
Woodward, R.M., see Lutfy, K. (273) 187
Woolley, M.J., see Stevens, W.H.M. (293) 251
Wróbel, B., see Malinowska, B. (293) 71
Wu, H.-Q., Ungerstedt, U. and Schwarcz, R.
L-α-Aminoadipic acid as a regulator of kynurenic acid production in the hippocampus: a microdialysis study in freely moving rats (281) 55
Wu, J., Anwyl, R. and Rowan, M.J.
β-amyloid-(1–40) increases long-term potentiation in rat hippocampus in vitro (284) R1
Wu, J.-R., see Lo, Y.-C. (292) 321
Wu, P.H., Lança, A.J., Liu, J.-F., Man, C.-F. and Kalant, H.
Peripheral injection of arginine^8-vasopressin increases Fos in specific brain areas (281) 263
Wu, S.-N., see Lo, Y.-C. (292) 321
Wu, Y., Rosenberg, H.C. and Chiu, T.H.
Rapid down-regulation of [^{3}H]zolpidem binding to rat brain benzodiazepine receptors during flurazepam treatment (278) 125
Wu, Y.-C., see Guh, J.-H. (279) 33
Wülfert, E., see Margineanu, D.G. (286) 321
Wülfert, E., see Noyer, M. (286) 137
Wüllner, U., see Löschmann, P.-A. (284) 129
Wuorela, H., see Kankaanranta, H. (291) 17

Xia, Y., Skoog, V., Muceniece, R., Chhajlani, V. and Wikberg, J.E.S.
Polyclonal antibodies against human melanocortin MC_1 receptor: preliminary immunohistochemical localisation of melanocortin MC_1 receptor to malignant melanoma cells (288) 277
Xiong, Z., Burnette, E. and Cheung, D.W.
Modulation of Ca^{2+}-activated K^+ channel activity by tyrosine kinase inhibitors in vascular smooth muscle cell (290) 117
Xu, X.-J. and Wiesenfeld-Hallin, Z.
Intrathecal α-trinositol facilitates the flexor reflex but does not block the depressive effect of neuropeptide Y (272) 219
Xu, Y. and Rao, M.-R.
Effects of tetrandrine on left ventricle hypertrophy in deoxycorticosterone acetate-salt hypertensive rats (278) 1

Yacoub, M., see Belvisi, M. (283) 255
Yadid, G., Goldstein, D.S., Pacak, K., Kopin, I.J. and Golomb, E.
Functional α_3-glycine receptors in rat adrenal (288) 399
Yaksh, T.L., see Calcutt, N.A. (285) 189
Yaksh, T.L., see Malmberg, A.B. (271) 293
Yamada, K., see Maeda, Y. (275) 163
Yamada, K., see Noda, Y. (286) 291
Yamada, M., see Ushijima, I. (285) 55
Yamada, S., see Nankai, M. (281) 123
Yamada, S., see Nozawa, Y. (287) 191
Yamagishi, T., Ishii, K. and Taira, N.
Antiarrhythmic and bradycardic drugs inhibit currents of cloned K^+ channels, $K_{V1.2}$ and $K_{V1.4}$ (281) 151
Yamaguchi, M., see Oba, T. (292) 301
Yamaguchi, Y., see Shinozuka, K. (292) 115
Yamamoto, H., see Kodama, M. (288) 69
Yamamoto, M., see Nagura, J. (274) 201
Yamamoto, T., see Ohno, M. (271) 557
Yamamoto, Y., Shibata, S., Hara, C. and Watanabe, S.
Methylcobalamin attenuates the hypoxia/hypoglycemia- or glutamate-induced reduction in hippocampal fiber spikes in vitro (281) 335
Yamamoto, Y., see Shibata, S. (273) 223
Yamamura, H., Nabe, T., Kohno, S. and Ohata, K.
Mechanism of histamine release by endothelin-1 distinct from that by antigen in mouse bone marrow-derived mast cells (288) 269
Yamamura, H.I., see Knapp, R.J. (291) 129
Yamamura, M., see Kinoshita, K. (274) 65
Yamanaka, R., see Ihara, M. (274) 1
Yamanaka, Y., see Horiuchi, H. (287) 27
Yamashita, H., Kawakami, H., Zhang, Y.-x., Hagiwara, T., Tanaka, K. and Nakamura, S.
Inhibition by folded isomers of L-2-(carboxycyclopropyl)glycine of glutamate uptake via the human glutamate transporter hGluT-1 (289) 387
Yamashita, H., see Sata, M. (290) 55
Yamawaki, I., see Tamaoki, J. (278) 161
Yamawaki, I., see Tamaoki, J. (287) 233
Yamaya, M., see Fukushima, T. (289) 103
Yamazaki, J., see Ohashi, K. (285) 165
Yamazaki, K., see Narita, N. (293) 277
Yamazaki, Y., see Nakachi, N. (281) 195
Yanagi, K., see Kaku, S. (279) 115
Yanagisawa, H., see Mizuno, M. (285) 181
Yanagisawa, I., see Shibasaki, M. (271) 341
Yanagisawa, M., see Guo, J.-Z. (281) 49
Yanaihara, N., see Mineo, H. (280) 149
Yang, J.-J., see Chiu, T.-H. (285) 261
Yang, K.X.F. and Black, J.L.
The involvement of protein kinase C in the contraction of human airway smooth muscle (275) 283
Yang, S.-N., Fior, D.R., Hedlund, P.B., Agnati, L.F. and Fuxe, K.
Antagonistic regulation of α_2-adrenoceptors by neuropeptide Y receptor subtypes in the nucleus tractus solitarii (271) 201
Yang, V.C., see Song, E.-J. (292) 119
Yang, W., Drewe, J.A. and Lan, N.C.
Cloning and characterization of the human $GABA_A$ receptor α4 subunit: identification of a unique diazepam-insensitive binding site (291) 319
Yang, Y.-R., see Chiu, T.-H. (285) 261
Yang, Z., see Tilakaratne, N. (290) 263
Yano, M., see Hirose, H. (277) 77
Yano, M., see Hirose, H. (284) 335
Yano, M., see Ihara, M. (274) 1
Yano, M., see Maas, J. (276) 113
Yano, S., Tanaka, M. and Nakao, K.
Anti-tumour effect of aromatase inhibitor, CGS16949A, on human breast cancer cells (289) 217
Yano, S., see Kaku, S. (279) 115
Yao, H., see Cai, H. (286) 249
Yasuda, S., see Nagura, J. (274) 201
Ybema, C., see Kleven, M. (281) 219
Yen, M.-H., see Lee, Y.-M. (279) 251
Ylinen, A., Pitkänen, M., Sirviö, J., Hartikainen, T., Sivenius, J., Koivisto, E. and Riekkinen, Sr., P.J.
The effects of NMDA receptor antagonists at anticonvulsive doses on the performance of rats in the water maze task (274) 159

Yoburn, B.C., see Chan, K. (287) 135
Yokotani, K., Okuma, Y. and Osumi, Y.
Recombinant interleukin-1β inhibits gastric acid secretion by activation of central sympatho-adrenomedullary outflow in rats (279) 233
Yokoyama, M., see Ikeda, U. (290) 69
Yonemori, F., see Matsushita, M. (276) 177
Yonezawa, Y., Kuroki, T., Tashiro, N., Hondo, H. and Uchimura, H.
Potentiation of phencyclidine-induced dopamine release in the rat striatum by the blockade of dopamine D_2 receptor (285) 305
Yoshida, K., see Hirasawa, Y. (272) 39
Yoshida, K., see Kita, Y. (275) 125
Yoshida, K., see Terai, T. (279) 217
Yoshida, T., see Tanaka, K. (279) 143
Yoshihara, S., Ricciardolo, F.L.M., Geppetti, P., Lindén, A., Hara, M., Chan, B. and Nadel, J.A.
Corticotropin-releasing factor inhibits antigen-induced plasma extravasation in airways (280) 113
Yoshikawa, D., see Shiga, T. (282) 151
Yoshimatsu, A., see Ohno, M. (271) 557
Yoshimura, M., see Habuchi, Y. (292) 143
Yoshimura, M., see Sawa, T. (276) 223
Yoshioka, K., see Guo, J.-Z. (281) 49
Yoshiyama, M., Roppolo, J.R. and De Groat, W.C.
Interactions between NMDA and AMPA/kainate receptors in the control of micturition in the rat (287) 73
Yoshiyama, Y., see Ohdo, S. (293) 281
You, J., see Erlinge, D. (289) 135
Youdim, M.B.H., see Glinka, Y.Y. (292) 329
Young, L.C., see Nally, J.E. (288) 53
Young, P.G., Skinner, S.J.M. and Black, P.N.
Effects of glucocorticoids and β-adrenoceptor agonists on the proliferation of airway smooth muscle (273) 137
Yu, S.-M., Cheng, Z.-J. and Kuo, S.-C.
Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor (280) 69
Yu, S.-M., see Guh, J.-H. (279) 33
Yuan, C.-S., Foss, J.F. and Moss, J.
Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine (276) 107
Yuan, H.T., see Sim, M.K. (278) 175
Yuan, J., see McCann, U.D. (283) R5
Yue, K.-T., MacDonald, J.F., Pekhletski, R. and Hampson, D.R.
Differential effects of lectins on recombinant glutamate receptors (291) 229
Yuge, O., see Az-ma, T. (289) 33
Yui, K., Miura, T., Sugiyama, K., Ono, M. and Nagase, M.
Methamphetamine plus scopolamine potentiates behavioral sensitization and conditioning (279) 135
Yumura, W., see Nitta, K. (293) 491

Zaagsma, J., see Coppes, R.P. (274) 33
Zaagsma, J., see Hoiting, B.H. (290) R5
Zaagsma, J., see Santing, R.E. (275) 75
Zaagsma, J., see Ten Berge, R.E.J. (275) 199
Zaidi, A., Marden, M.C., Poyart, C. and Leclerc, L.
Protection by lazaroids of the erythrocyte (Ca^{2+}, Mg^{2+})-ATPase against iron-induced inhibition (290) 133
Żarnowski, T., see Czuczwar, S.J. (281) 327
Zarrindast, M.-R., Adeli, R., Hosseini-semnani, S. and Sharifzadeh, M.
Effects of adenosine receptor agonists and antagonists on physostigmine-induced yawning (276) 3
Zarrindast, M.-R., Sajedian, M., Rezayat, M. and Ghazi-Khansari, M.
Effects of 5-HT receptor antagonists on morphine-induced tolerance in mice (273) 203
Zart, R., see Hocher, B. (293) 361
Zarzuelo, A., see Duarte, J. (286) 115
Zatz, R., see Grassi-Kassisse, D.M. (282) 57
Zatz, R., see Medeiros, M.V. (285) 109
Zatz, R., see Moreno, Jr., H. (287) 93
Zeilhofer, H.U., see Pallapies, D. (271) 335
Zemková, H., see Stankovičová, T. (276) 101
Zezula, J., Karall, S., Dodd, R.H. and Sieghart, W.
[^{3}H]Propyl-6-azido-β-carboline-3-carboxylate: a new photoaffinity label for the $GABA_A$-benzodiazepine receptor (281) 93
Zezula, J., see Fuchs, K. (289) 87
Zezula, J., see Slany, A. (291) 99
Zgombick, J.M., Schechter, L.E., Kucharewicz, S.A., Weinshank, R.L. and Branchek, T.A.
Ketanserin and ritanserin discriminate between recombinant human 5-$HT_{1D\alpha}$ and 5-$HT_{1D\beta}$ receptor subtypes (291) 9
Zhang, L., Dyer, D.C., Fiscus, R.R., Grujic, Z. and Wang, X.
5-Hydroxytryptamine induces endothelium-independent relaxations of sheep pulmonary vein: role of cyclic nucleotide (280) 335
Zhang, L., Pearce, W.J. and Longo, L.D.
Noradrenaline-mediated contractions of ovine uterine artery: role of inositol 1,4,5-trisphosphate (289) 375
Zhang, R., see Lodge, N.J. (287) 279
Zhang, Y.-x., see Yamashita, H. (289) 387
Zhao, F.-Y., see Guo, J.-Z. (281) 49
Zhou, L. and Hammer, Jr., R.P.
Gonadal steroid hormones upregulate medial preoptic μ-opioid receptors in the rat (278) 271
Zhou, L.-M., see Von Lubitz, D.K.J.E. (283) 185
Zhou, Q., Satake, N. and Shibata, S.
The inhibitory mechanisms of nicorandil in isolated rat urinary bladder and femoral artery (273) 153
Zhu, J.L., see D'Alonzo, A.J. (272) 269
Zhu, QB., see Aburto, T. (277) 35
Zhu, S.Z., see Wang, S.Z. (291) R1
Zhu, X.-d., Giacobini, E. and Hornsperger, J.-M.
Effect of MDL 73,745 on acetylcholine and biogenic amine levels in rat cortex (276) 93
Ziche, M., see Santicioli, P. (289) 17
Zídek, Z., Holý, A., Franková, D. and Otová, B.
Suppression of rat adjuvant arthritis by some acyclic nucleotide analogs (286) 307
Ziegelhöffer, A., see Stankovičová, T. (276) 101
Zijlstra, F.J., see Garrelds, I.M. (275) 295
Zijlstra, F.J., see Van Dijk, J.P.M. (278) R11
Žikić, I., see Jovanović, A. (280) 101
Zimmerman, B.G., see Chen, K. (284) 281
Zimmermann, M., see Benrath, J. (293) 87
Zimmermann, M., see Gillardon, F. (293) 395
Zisman, E., see Fonia, O. (293) 335
Zumbihl, R., Breuiller-Fouché, M., Carrette, J., Dufour, M.-N., Ferré, F., Bockaert, J. and Rouot, B.
Up-regulation in late pregnancy of both $G_{o1}\alpha$ and $G_{o2}\alpha$ isoforms in human myometrium (288) 9
Zumbihl, R., see Roussel, J.-P. (289) 205
Zürcher, G., see Napolitano, A. (273) 215
Zurera, J.M., see Sanchez-Amate, M.C. (292) 215
Zwart, R., Van Kleef, R.G.D.M., Milikan, J.M., Oortgiesen, M. and Vijverberg, H.P.M.
Potentiation and inhibition of subtypes of neuronal nicotinic acetylcholine receptors by Pb^{2+} (291) 399

ELSEVIER

European Journal of Pharmacology

ejp

Master keyword index to volumes 271–293 (1995)

A23187
Endothelial cell; Bradykinin; Fura-2; Nitric oxide (NO); Anesthetic, volatile; Sevoflurane; D-Arg-[Hyp^3, Thi^{5,8}, D-Phe^7] bradykinin; Des-Arg^9-[Leu^8] bradykinin; Ca^{2+} channel (Az-ma, T. (289) 33)

Paraquat; Superoxide anion; Nitric oxide (NO); Acetylcholine (Hsu, K.-S. (292) 315)

Abruquinone A
Paw edema; Neurogenic inflammation; Passive cutaneous anaphylaxis; Vascular permeability; Compound 48/80; Mast cell degranulation (Wang, J.-P. (273) 73)

Abstinence
Analgesia; Opiate; δ-Opioid receptor antagonist; Opioid withdrawal (Fundytus, M.E. (286) 105)

Accumbens
Dopamine; NMDA (*N*-methyl-D-aspartate); Prepulse inhibition; Schizophrenia; (Rat) (Reijmers, L.G.J.E. (272) 131)

ACEA-1011
Myoclonus; Hypoxia; NMDA (*N*-methyl-D-aspartate); Ischemia; HA-966; ACEA-1021; Glycine (Matsumoto, R.R. (275) 117)

ACEA-1021
Myoclonus; Hypoxia; NMDA (*N*-methyl-D-aspartate); Ischemia; HA-966; ACEA-1011; Glycine (Matsumoto, R.R. (275) 117)

Acetaminophen
Zinc sulfate; *N*-acetylcysteine; Hepatotoxicity; Glutathione; Alanine aminotransferase; Malondialdehyde (Woo, P.C.Y. (293) 217)

Acetyl-L-carnitine
Streptozotocin; Brain; Alzheimer's disease; Oxidative stress (Terwel, D. (287) 65)

Acetylcholine
Pyrantel; Ion channel; *Ascaris*, muscle; Anthelmintic; Parasitic nematode (Robertson, S.J. (271) 273)

Urodilatin; Natriuretic peptide, type A; Bronchoprotection; Lung function, rat (Flüge, T. (271) 395)

Atrium, rat; Contraction, force of; Aortic ring; Relaxation; cGMP-dependent protein kinase (Bäumner, D. (273) 295)

Endothelium; N^G-Nitro-L-arginine; EDHF (endothelium-derived hyperpolarizing factor); Aorta; (Rat) (Hatake, K. (274) 25)

Renal artery, rat; Endothelium-dependent contraction; Arachidonic acid metabolite (Nishimura, Y. (275) 217)

Mammillary complex; Memory; Retention; Dopamine; Norepinephrine; NMDA (*N*-methyl-D-asparate); Nicotine; Neuropeptide Y; GABA (γ-aminobutyric acid); (Mouse) (Flood, J.F. (275) 223)

MDL 73,745; Microdialysis; Cholinesterase; Norepinephrine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Zhu, X.-d. (276) 93)

Histamine H_3 receptor; Lung, rabbit; C-fiber; Neuropeptide; Edema (Delaunois, A. (277) 243)

Airway hyperresponsiveness; Bronchus; Ca^{2+} channel, voltage-dependent and receptor-operated; Inositol 1,4,5-trisphosphate; (Rat) (Chiba, Y. (278) 79)

Aminoguanidine; Lipopolysaccharide; Mesenteric arterial bed; N^G-Nitro-L-arginine methyl ester; Portal vein ligation; (Portal hypertensive rat) (Heinemann, A. (278) 87)

K^+ channel blocker; Uterine artery; Endothelium; Nitric oxide (NO) (Jovanović, A. (280) 95)

Choline; 3,4-Diaminopyridine; Microdialysis (Buyukuysal, R.L. (281) 179)

Somatostatin; Synaptosome; Ileum, rat; Presynaptic mechanism (Kurjak, M. (281) 295)

Spatial learning; Hippocampus; Scopolamine; 5-HT_{1A} receptor; (*S*)-WAY 100135; Alzheimer disease; (Rat) (Carli, M. (283) 133)

Atrium AF-DX 116, human; HHSiD (*p*-fluorohexahydro-siladifenidol hydrochloride); McN-A-343; Muscarinic receptor; Myocardial contractility; Pirenzepine; Ventricle (Du, X.Y. (284) 119)

Morphine; Muscarinic receptor; Striatum (Schoffelmeer, A.N.M. (286) 311)

Paraquat; Superoxide anion; Nitric oxide (NO); A23187 (Hsu, K.-S. (292) 315)

Nucleus basalis magnocellularis; Neuroprotection; Memantine; (+)-MK-801; Amantadine; Ataxia; Stereotypy; (Rat) (Wenk, G.L. (293) 267)

Acetylcholine receptor
Caffeine; Chromaffin cell (Liu, P.-S. (291) 265)

Neurotoxicity; DDT (1,1,1-trichloro-2,2-bis(*p*-chlorophenyl)-ethane); Pyrethroid; Interaction; Behavior (Johansson, U. (293) 159)

Acetylcholine release
Noradrenaline release; Neuropeptide Y Y_1 receptor; Neuropeptide Y Y_2 receptor (Sawa, T. (276) 223)

Efaroxan; α_2-Adrenoceptor antagonist; Microdialysis; Cortex, rat (Tellez, S. (277) 113)

Motor endplate; ω-Agatoxin-IVA; Ca^{2+} channel, P-type (Wessler, I. (278) 83)

Urinary bladder, rabbit; Muscarinic receptor subtype; Contractile response; Muscarinic receptor antagonist (Tobin, G. (281) 1)

Striatum; Nucleus accumbens; Morphine; Opioid receptor; Sensitization (Tjon, G.H.K. (283) 169)

Noradrenaline release; GABA release; Galantide (Akehira, K. (284) 149)

NMDA receptor subtype; Striatum; GABA (γ-aminobutyric acid) release; Spermidine release (Nankai, M. (286) 61)

[^{3}H]Acetylcholine release
Adenosine receptor, presynaptic; Adenosine, endogenous; Nicotinic autoreceptor; Nicotinic receptor desensitization; Phrenic motor nerve ending (Correia-de-Sá, P. (271) 349)

Acetylcholinesterase inhibitor
End-plate potential; Alkylating derivative of hexadecamethonium (Danilov, A.F. (277) 15)

Acetylcholine turnover
JTP-2942 (*Nα*-((1*S*,2*R*)-2-methyl-4-oxocyclopentylcarbonyl)-L-histidyl-L-prolinamide monohydrate); TRH (thyrotropin-releasing hormone) analog (Matsushita, M. (276) 177)

***N*-Acetylcysteine**
Aging; Mitochondria; Thiol (Miquel, J. (292) 333)

Zinc sulfate; Acetaminophen; Hepatotoxicity; Glutathione; Alanine aminotransferase; Malondialdehyde (Woo, P.C.Y. (293) 217)

***N*-Acetyl-L-cysteine**
Allopurinol; Xanthine oxidase; Sepsis; Free radicals; Cecal ligation and puncture (Villa, P. (292) 341)

Acetylsalicylic acid
Chronopharmacology; Chronotoxicity; Chronopharmacokinetics (Ohdo, S. (293) 151)

Acetylshikonin
Hind-paw edema; Cutaneous anaphylaxis, passive; Neurogenic inflammation; Vascular permeability; Compound 48/80; [Thi^{5,8},D-Phe^7]-Bradykinin; [D-Pro^2,D-Trp^{7,9}]Substance P (Wang, J.-P. (272) 87)

Achatin-I
Histamine H_1 receptor antagonist, blocking effect; Neuropeptide; (Snail) (Santos, D.E. (272) 231)

Acid
Omeprazole; Crop emptying; Medium chain triacylglycerol; Long chain triacylglycerol; (Chick) (Mabayo, R.T. (273) 161)

8-OH-DPAT ((±)-8-hydroxy-2-(*n*-dipropylamino)tetralin); Adrenal gland; Gastrointestinal system, rat; 5-HT_{1A} receptor (Gidener, S. (284) 19)

Acid secretion
Glucagon-related peptides; Histamine; [^{14}C]aminopyrine accumulation (Gros, L. (288) 319)

ACPC (1-aminocyclopropanecarboxylic acid)
Glycine receptor, strychnine-insensitive; NMDA receptor (Popik, P. (291) 221)

***trans*-ACPD ((±)-*trans*-1-aminocyclopentane-1,3-dicarboxylic acid)**
Metabotropic glutamate receptor; Inhibitory postsynaptic potential; Hippocampus; CA1 pyramidal cell (Jouvenceau, A. (281) 131)

NMDA receptor; mGlu receptor; NMDA (*N*-methyl-D-asparate); L-AP-3 (L-2-amino-3-phosphono-propionate); Periaqueductal gray matter (Leyva, J. (285) 123)

ACTH-(1–24)
Hypovolemia; Hemorrhagic shock; (Conscious rabbit) (Ludbrook, J. (275) 267)

ACTH (adrenocorticotrophin)
Aging; Melanocortin; Grooming; Stretching; Yawning; Penile erection (Poggioli, R. (271) 253)

Diurnal alteration; Opioid mechanism; Corticosterone; Prolactin (Kiem, D.T. (272) 145)

Cocaine; Corticosterone; Hypothalamus-pituitary-adrenal axis (Schmidt, E.D. (285) 317)

5-HT (5-hydroxytryptamine, serotonin); Corticosterone; Prolactin; Renin; Blood pressure; Heart rate (Levy, A.D. (274) 141)

Actinomycin-D
5-HT (5-hydroxytryptamine, serotonin); Dexamethasone; Mast cell; Nedocromil sodium; Paw edema, rat (Raud, J. (282) 207)

Action potential
K^+ channel blocker; Langendorff; Refractory period; (Rat); (Guinea-pig) (D'Alonzo, A.J. (272) 269)

Antiarrhythmic; Ca^{2+} current; K^+ current; Oxime; Cardiac myocyte (Karhu, S. (279) 7)

Activation
Benzylic alcohol; Mutagenicity; Sulfotransferase; (*Salmonella typhimurium*) (Glatt, H. (293) 173)

Activation, ex vivo
Glucocorticoid; Peritoneal leukocyte; Respiratory burst; (Rat) (Røshol, H. (286) 9)

Activation gate
Na^+ current; Disopyramide; Chloramine-T; Use-dependent block; (Fast inactivation gate) (Koumi, S.-i. (277) 165)

γ-Activity
Muscle relaxant, centrally acting; NK433; Decerebrate rigidity; Straub tail reaction (Sakitama, K. (273) 47)

Acute inflammation
Iloprost; Nitric oxide (NO); Captopril; Hypertension; (2K-1C rat) (Medeiros, M.V. (285) 109)

Acute liver dysfunction
Endothelin; Endothelin receptor antagonist; Bosentan; Carbon tetrachloride; Hepatotoxicity (Hocher, B. (293) 361)

Acute toxicity
Dioxin; Toxic equivalency; Risk evaluation; Strain difference (Pohjanvirta, R. (293) 341)

Acyclic nucleotide analog
PMEA (9-(2-phosphomethoxyethyl)adenine); HPMPC (1-(*S*)-(3-hydroxy-2-phosphonomethoxyethyl)cytosine); Antiarthritic effect; Adjuvant arthritis (Zídek, Z. (286) 307)

Adenosine
Formalin test; Antinociception; Methylxanthine; Pain mechanism (Doak, G.J. (281) 311)

Morphine; Hypotension; Adenosine receptor (White, P.J. (286) 315)

Ischemia; Adenosine receptor; Therapy; (Gerbil) (Von Lubitz, D.K.J.E. (287) 295)

Adenosine receptor; 8-Alkylaminoadenosine analogue; Theophylline-7-riboside and derivative; Affinity; Intrinsic activity (Van der Wenden, E.M. (290) 189)

Adenosine analgesia
Formalin test; Adenosine kinase; Stimulus intensity (Poon, A. (286) 177)

Adenosine, endogenous
Adenosine receptor, presynaptic; Nicotinic autoreceptor; Nicotinic receptor desensitization; [^{3}H]Acetylcholine release; Phrenic motor nerve ending (Correia-de-Sá, P. (271) 349)

Adenosine kinase
Formalin test; Adenosine analgesia; Stimulus intensity (Poon, A. (286) 177)

Adenosine, pharmacology
Opioid, pharmacology; Antinociception; Spinal cord; (Mouse) (Keil, II, G.J. (271) 37)

Adenosine receptor
Morphine; Antinociception; Tolerance; Cyclohexyladenosine; (Rat) (Tao, P.-L. (278) 233)

FK453; Atrium; Aorta; Binding assay (Terai, T. (279) 217)

Endothelium-dependent relaxation; Femoral artery; Femoral vein; 2-Octynyladenosine; YT-146 (Abiru, T. (281) 9)

Morphine; Adenosine; Hypotension (White, P.J. (286) 315)

Adenosine; Ischemia; Therapy; (Gerbil) (Von Lubitz, D.K.J.E. (287) 295)

Adenosine; 8-Alkylaminoadenosine analogue; Theophylline-7-riboside and derivative; Affinity; Intrinsic activity (Van der Wenden, E.M. (290) 189)

Adenosine A_1 receptor
NMDA receptor; Seizure; Alzheimer's disease; (Mouse) (Von Lubitz, D.K.J.E. (283) 185)

Adenosine A_2 receptor
Basal ganglia; Metabotropic glutamate receptor; Striatum; Subthalamic nucleus (Feeley Kearney, J.A. (287) 115)

Adenosine A_{2A} receptor
Glutamate release; Striatum; (Rat) (Popoli, P. (287) 215)

Adenosine A_3 receptor
Seizure; Protection; (Mouse) (Von Lubitz, D.K.J.E. (275) 23)

Adenosine receptor agonist
TNF (tumor necrosis factor); Interleukin-6; Dexamethasone; Pentoxifylline; Fusidic acid; Pentamidine isethionate (Chen, Y.-L. (271) 319)

Yawning; Physostigmine; Atropine; Adenosine receptor antagonist; (Rat) (Zarrindast, M.-R. (276) 3)

Adenosine A_1 receptor agonist
Myocardial ischemia; Reperfusion injury; Infarct (Lee, Y.-M. (279) 251)

Adenosine A_2 receptor agonist
YT-146; Neointimal thickening; (Rat) (Takiguchi, Y. (281) 205)

Adenosine receptor antagonist
Yawning; Physostigmine; Atropine; Adenosine receptor agonist; (Rat) (Zarrindast, M.-R. (276) 3)

Adenosine receptor, presynaptic
Adenosine, endogenous; Nicotinic autoreceptor; Nicotinic receptor desensitization; [^{3}H]Acetylcholine release; Phrenic motor nerve ending (Correia-de-Sá, P. (271) 349)

Adenosine release
Nitric oxide (NO); Ventral striatum, rat (Fischer, H. (275) R5)

Coronary occlusion; Reperfusion arrhythmia; Lidocaine; Quinidine; Gallopamil (Bernauer, W. (283) 91)

Adenosine 5′-triphosphate
P_1 purinoceptor; P_{2Y} purinoceptor; Taenia caeci, guinea-pig; Suramin; PPADS (pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid) (Piper, A.S. (280) 125)

***S*-Adenosylhomocysteine**
Methylation inhibitor; Benzodiazepine binding; 5′-Methylthioadenosine; (Rat) (Tsvetnitsky, V. (282) 255)

Adenylate cyclase
Psycholeine; Quadrigemine C; Somatostatin; Growth hormone (Rasolonjanahary, R. (285) 19)

Anandamide; Cannabinoid receptor; GTP-binding protein (Barg, J. (287) 145)

CGRP (Calcitonin gene-related peptide); Forskolin; Guinea-pig ureter; K^+ channel (Santicioli, P. (289) 17)

Somatostatin; SS-2 binding site; SRIF-2 binding site; Recombinant SSTR-1 receptor; Receptor autoradiography; In situ hybridization (Hoyer, D. (289) 151)

Somatostatin; SS-1 binding site; SRIF-1 binding site; Recombinant SSTR-2 receptor; Receptor autoradiography; In situ hybridization (Schoeffter, P. (289) 163)

Bradykinin receptor; Ileum, guinea pig; Inhibitory B_2 receptor; Antagonist profile (unique) (Liebmann, C. (289) 403)

Adenylate cyclase, inhibition
Bradykinin; Ileum; Guinea pig; G protein activation; Bradykinin receptor; (High-affinity binding site) (Liebmann, C. (288) 35)

Adenylylcyclase
Neuropeptide Y; β-Adrenoceptor (Rocha-Singh, K.J. (288) 349)

5-HT_{1A} receptor; GTP hydrolysis; G protein (GTP-binding protein); Hippocampus (Odagaki, Y. (288) 385)

Histamine; Somatostatin receptor; Frontoparietal cortex; (Rat) (Puebla, L. (289) 361)

Cardiomyopathy; β-adrenoceptor subtype; Coupling efficiency; Hamster; Age-dependent (Witte, K. (290) 1)

Dopamine $D_{4.2}$ receptor; Vaccinia virus; (Functional expression) (Bouvier, C. (290) 11)

Endorphin receptor; Recombinant cell; Radioligand binding; cAMP (Knapp, R.J. (291) 129)

Vitamin B_{12} deficiency; β-Adrenoceptor; G_s; Signal transduction (Hatta, S. (291) 351)

Carazolol; β-Adrenoceptor antagonist; β_3-Adrenoceptor agonist; Lipolyse (Méjean, A. (291) 359)

Adhesion molecule
Bronchial hyperresponsiveness; Eosinophilia; VLA-4 integrin (Milne, A.A.Y. (282) 243)

Myeloperoxidase; Tetramethylbenzidine; Polymorphonucleocyte; Renal ischemia/reperfusion (Laight, D.W. (292) 81)

Adipocyte
Desensitization; β-Adrenoceptor agonists; Phosphodiesterase; β-Adrenoceptor subtypes; Lipolysis (Bousquet-Mélou, A. (289) 235)

Adipose tissue
β_3-Adrenoceptor; Gallbladder; Obesity; RNase protection; (Human) (Berkowitz, D.E. (289) 223)

2α-(2′,2′-disubstituted-hydroxy-ethoxy)tropane
Muscarinic receptor; 2α-DHET; Allosteric interaction; Heart (Gao, Z.-g. (289) 369)

Adjuvant arthritis
Acyclic nucleotide analog; PMEA (9-(2-phosphomethoxyethyl)adenine); HPMPC (1-(*S*)-(3-hydroxy-2-phosphonomethoxyethyl)cytosine); Antiarthritic effect (Zídek, Z. (286) 307)

Adrenal
Benzodiazepine receptor, peripheral type; Olfactory bulbectomy; Thymus; Spleen; Antidepressant (Dennis, T. (272) 279)

Catecholamine; Glycine; Microdialysis; Polymerase chain reaction; Strychnine (Yadid, G. (288) 399)

Adrenal chromaffin cell
Staurosporine; Ca^{2+} homeostasis; Catecholamine release; Fura-2 (Maurer, J.A. (288) 163)

Histamine; Phospholipase C; Protein kinase C; Phorbol ester; Staurosporine; Ro 31-8220 (Bunn, S.J. (290) 227)

Adrenalectomy
Corticosteroid; Dopamine; Limbic forebrain; Locomotor activity; Nicotine; Sensitization; (Rat) (Johnson, D.H. (276) 155)

Lipocortin 1; RU486; Interleukin-8; PAF (platelet-activating factor) (Harris, J.G. (283) 9)

Adrenal gland
8-OH-DPAT ((±)-8-hydroxy-2-(*n*-dipropylamino)tetralin); Gastrointestinal system, rat; $5\text{-}HT_{1A}$ receptor; Acid (Gidener, S. (284) 19)

Adrenaline
Dopamine receptor; Heart; Plasma; Dopamine; Adrenal medulla; (Partial least squares regression) (Kujacic, M. (273) 247)

Noradrenaline; Catecholamine overflow; Exercise; β_2-Adrenoceptor, prejunctional; (Freely moving rat) (Coppes, R.P. (274) 33)

Adrenaline release
Anatoxin-a; Chromaffin cell; Nicotinic acetylcholine receptor, neuronal type; Nicotinic receptor agonist; Mecamylamine; Noradrenaline release (Molloy, L. (289) 447)

Adrenal medulla
Dopamine receptor; Adrenaline; Heart; Plasma; Dopamine; (Partial least squares regression) (Kujacic, M. (273) 247)

Dopamine; Dopamine receptor agonist; Catecholamine, synthesis; DOPA (3,4-dihydroxyphenylalanine), accumulation (Kujacic, M. (278) 9)

PAMP (proadrenomedullin N-terminal 20 peptide); Catecholamine synthesis; Tyrosine hydroxylase; Nicotinic receptor (Niina, H. (286) 95)

Mitochondrial Ca^{2+}; Ca^{2+} channel antagonist (Uceda, G. (289) 73)

Adrenergic nerve
Nitric oxide (NO); Lipopolysaccharide; Tail artery, rat; Sepsis (Takakura, K. (271) 367)

Melatonin receptor; Caudal artery, rat; Contraction (Krause, D.N. (276) 207)

Adrenoceptor
Noradrenaline; Umbilical artery, human; Smooth muscle, vascular (Bodelsson, G. (282) 95)

Norepinephrine; Inositol phosphate; Receptor reserve; Spare receptor (Esbenshade, T.A. (289) 305)

Ageing; Epinephrine; Fatty acid; Phospholipid; Heart muscle; (Rat) (Benediktsdóttir, V.E. (289) 419)

α-Adrenoceptor
$5\text{-}HT_2$ receptor; Prostate, rat; Smooth muscle; Autoradiography (Killam, A.L. (273) 7)

Blood pressure; Central nervous system; RG20 gene; (Rat) (Nunes, J.P. (278) 183)

Cirazoline; Imidazoline site (Le Rouzic, M. (278) 261)

Gastric acid secretion; Interleukin-1β; Indomethacin; Sympatho-adrenomedullary system (Yokotani, K. (279) 233)

4-Aminopyridine; Contraction, phasic; K^+ channel; Caudal epididymis, rat (Huang, Y. (280) 231)

Pacing-induced heart failure; Protein kinase C; Polymyxin B; Smooth muscle, vascular (Forster, C. (283) 241)

Renal blood flow; Catecholamine release; Angiotensin II; Renal nerve; Prazosin (Chen, K. (284) 281)

Atropine; Aorta; Cerebral cortex; (Rat) (Chang, K.C. (284) 331)

Cerebral blood flow autoregulation; Doxazosin; Hemorrhagic hypotension; Spontaneously hypertensive rat (SHR) (Cai, H. (286) 249)

α_1-Adrenoceptor
Muscarinic acetylcholine receptor; Cardiac action potential; Positive inotropic effect; Protein kinase C; Arachidonic acid metabolism (Arreola, J. (271) 309)

Blood pressure; Dopaminergic neurotransmission; Microdialysis; Prazosin (Sommermeyer, H. (276) 267)

Lidocaine; Up-regulation; Cardiocyte; Culture (Mizuki, T. (277) 133)

β-Adrenoceptor; Localisation; Myocardium, rat; Noradrenaline; Uptake blocker (Dybvik, T. (281) 21)

Dopamine receptor; 5-HT_2 receptor; Hyperactivity; Amphetamine; (Rat) (Arnt, J. (283) 55)

Renal function; Phenylephrine; Prazosin (Chen, C. (287) 1)

Heart, rat; β-Adrenoceptor; Myocardial contractility; Protein phosphorylation (Hartmann, M. (287) 57)

Aorta; Urethra (Auguet, M. (287) 153)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_2 receptor; Aorta, rat; SDZ NVI-085; SK&F 89748-A (Van der Graaf, P.H. (287) 309)

Inositol triphosphate; Protein kinase C; Na^+,K^+-ATPase; Second messenger; Renal proximal tubule (Gopalakrishnan, S.M. (288) 139)

Ca^{2+} current, L-type; Inactivation, Ca^{2+}-dependent; Ca^{2+} release, IP_3-mediated (England, S. (288) 355)

Liver; Hepatocyte; Tamsulosin (García-Sáinz, J.A. (289) 1)

Liver, human; α_{1A}-Adrenoceptor (García-Sáinz, J.A. (289) 81)

Inositol 1,4,5-trisphosphate; Uterine artery; Pregnancy (Zhang, L. (289) 375)

ATP release; Noradrenaline; Calcification; Arteriosclerosis; Caudal artery, rat (Shinozuka, K. (292) 115)

α_{1A}-Adrenoceptor
α_1-Adrenoceptor subtype; Liver; Hepatocyte membrane (García-Sáinz, J.A. (272) 139)

α_1-Adrenoceptor; Liver, human (García-Sáinz, J.A. (289) 81)

α_{1B}-Adrenoceptor
Chinese hamster ovary (CHO) cell; Radioligand binding studies; Concentration, cytosolic Ca^{2+}; Receptor occupancy-response relationship (Horie, K. (288) 303)

α_2-Adrenoceptor
Nucleus tractus solitarii; Neuropeptide Y receptor; Receptor autoradiography; Cardiovascular (Yang, S.-N. (271) 201)

Noradrenaline release; Kidney, SHR (spontaneously hypertensive rat) and WKY (Wistar-Kyoto rat) (Bohmann, C. (271) 283)

Emesis; Dopamine; Area postrema; (Cat); (Intracerebroventricular injection) (Jovanović-Mićić, D. (272) 21)

Bradycardic activity; Hypotensive activity; Imidazole derivative; Imidazoline derivative; Lipophilicity; Mydriatic activity (Nasal, A. (274) 125)

Tyrosine kinase inhibitor; Phospholipase D (Jinsi, A. (277) 29)

Protein kinase C; Smooth muscle, vascular; Phospholipase D (Aburto, T. (277) 35)

Imidazoline receptor; Sympathoinhibition; Presynaptic inhibition; Moxonidine; UK 14304 (Urban, R. (282) 19)

Imidazoline receptor; Presynaptic inhibition; Moxonidine; Rilmenidine; UK 14304 (Urban, R. (282) 29)

Hypothalamus; Pituitary; Growth hormone; Clonidine; Oxymetazoline; α_2-Adrenoceptor antagonist; α_{2A}-Adrenoceptor subtype; α_{2B}-Adrenoceptor subtype (Makara, G.B. (287) 43)

Vas deferens, rat; Xylazine; 4-Aminopyridine; Tetraethylammonium; Charybdotoxin; Phorbol dibutyrate; Bay K 8644 (Docherty, J.R. (287) 287)

Ethanol; Atipamezole; Dexmedetomidine; Monoamine; Motor performance; (Mouse) (Idänpään-Heikkilä, J.J. (292) 191)

α_{2A}-Adrenoceptor
Imidazoline receptor; α_{2B}-Adrenoceptor; Kidney, rat; [^{3}H]Rilmenidine; [^{3}H]Idazoxan; Autoradiography (King, P.R. (281) 341)

Dexmedetomidine; Locus ceruleus; Brain slice; Intracellular recording (Chiu, T.-H. (285) 261)

α_{2B}-Adrenoceptor
Imidazoline receptor; α_{2A}-Adrenoceptor; Kidney, rat; [^{3}H]Rilmenidine; [^{3}H]Idazoxan; Autoradiography (King, P.R. (281) 341)

α_{2D}-Adrenoceptor
DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); α_2-Adrenoceptor, postsynaptic; Brain, rat; [^{3}H]RX 821002 binding; Clonidine-induced mydriasis (Heal, D.J. (277) 215)

β-Adrenoceptor
PET (positron emission tomography); Receptor imaging; Radioligand (Van Waarde, A. (272) 159)

Endothelium; Vascular permeability; Protein extravasation; Salbutamol; Salmeterol (Allen, M.J. (274) 7)

Calcitonin; NMDA (*N*-methyl-D-aspartate); Aversive behavior; 5-HT receptor; GABA receptor (Maeda, Y. (275) 163)

Muscarinic receptor; Receptor alkylation, irreversible (Watson, N. (278) 195)

Chronic variate stress; Foot-shock stress, acute; 5-HT_{1A} receptor; 5-HT_2 receptor; Amitriptyline; Open-field; Brain cortex, rat (Ferretti, C. (280) 19)

α_1-Adrenoceptor; Localisation; Myocardium, rat; Noradrenaline; Uptake blocker (Dybvik, T. (281) 21)

Heart, rat; α_1-Adrenoceptor; Myocardial contractility; Protein phosphorylation (Hartmann, M. (287) 57)

Airway hyperreactivity; β-Adrenoceptor agonist; Salbutamol; Receptor desensitisation; (Guinea pig) (Buchheit, K.-H. (287) 85)

Neuropeptide Y; Adenylylcyclase (Rocha-Singh, K.J. (288) 349)

Ageing; β-Adrenoceptor blockade; Receptor upregulation; cAMP; (Rat) (Conlon, D. (289) 283)

Vitamin B_{12} deficiency; Adenylyl cyclase; G_s; Signal transduction (Hatta, S. (291) 351)

β_1-Adrenoceptor
Catecholamine; Transcriptional regulation; Corticosteroid; Thyroid hormone; (Sheep) (Tseng, Y.T. (289) 353)

β_2-Adrenoceptor
β_3-Adrenoceptor; Electrical field stimulation; Cholinergic contraction; NANC (non-adrenergic non-cholinergic) contraction; Bronchus, main, guinea pig (Ten Berge, R.E.J. (275) 199)

β_3-Adrenoceptor
β_2-Adrenoceptor; Electrical field stimulation; Cholinergic contraction; NANC (non-adrenergic non-cholinergic) contraction; Bronchus, main, guinea pig (Ten Berge, R.E.J. (275) 199)

Adipose tissue; Gallbladder; Obesity; RNase protection; (Human) (Berkowitz, D.E. (289) 223)

α-Adrenoceptor agonist
Bicarbonate secretion; α-Adrenoceptor antagonist; β-Adrenoceptor agonist; β-Adrenoceptor antagonist (Canfield, P. (273) 1)

Vas deferens, human; Noradrenaline; Phenoxybenzamine; α-Adrenoceptor antagonist (Amobi, N. (273) 25)

α_1-Adrenoceptor agonist
5-HT_{1D} receptor agonist; Hypothermia (Kalkman, H.O. (285) 313)

β-Adrenoceptor agonist
Eosinophil; Allergy; Inflammation; Passive cutaneous anaphylactic reaction (Teixeira, M.M. (272) 185)

Bicarbonate secretion; α-Adrenoceptor agonist; α-Adrenoceptor antagonist; β-Adrenoceptor antagonist (Canfield, P. (273) 1)

Endothelin-1; Cardiac myocyte; L-type Ca^{2+} current; (Guinea-pig) (Delpech, N. (285) 217)

Airway hyperreactivity; Salbutamol; β-Adrenoceptor; Receptor desensitisation; (Guinea pig) (Buchheit, K.-H. (287) 85)

Myometrium; Pregnancy; K^+ channel; Ritodrine hydrochloride (Hamada, Y. (288) 45)

Desensitization; Adipocyte; Phosphodiesterase; β-Adrenoceptor subtypes; Lipolysis (Bousquet-Mélou, A. (289) 235)

Dexamethasone; DNA binding; Lung; (Rat) (Peters, M.J. (289) 275)

Clenbuterol; Taurine; Urinary marker; Protein synthesis (Waterfield, C.J. (293) 141)

β_2-Adrenoceptor agonist
Phosphodiesterase inhibitor; Peripheral blood mononuclear cell; Arachidonate; cAMP; Forskolin (Hichami, A. (291) 91)

β_3-Adrenoceptor agonist
Carazolol; β-Adrenoceptor antagonist; Adenylyl cyclase; Lipolyse (Méjean, A. (291) 359)

β-Adrenoceptor agonist, cell culture
Smooth muscle, airway; Asthma; Glucocorticoid; Cell proliferation (Young, P.G. (273) 137)

α-Adrenoceptor antagonist
Bicarbonate secretion; α-Adrenoceptor agonist; β-Adrenoceptor agonist; β-Adrenoceptor antagonist (Canfield, P. (273) 1)

Vas deferens, human; Noradrenaline; Phenoxybenzamine; α-Adrenoceptor agonist (Amobi, N. (273) 25)

α_1-Adrenoceptor subtype; *N*-Methyl-actinodaphnine; (*Illigera luzonensis*) (Guh, J.-H. (279) 33)

α_1-Adrenoceptor antagonist
Cyclazosin; Prazosin-related antagonist; α_1-Adrenoceptor subtype (Giardinà, D. (287) 13)

α_2-Adrenoceptor antagonist
Efaroxan; Microdialysis; Acetylcholine release; Cortex, rat (Tellez, S. (277) 113)

Histamine; Noradrenaline; Atipamezole; Microdialysis, in vivo; Hypothalamus (Laitinen, K.S.M. (285) 255)

Hypothalamus; Pituitary; α_2-Adrenoceptor; Growth hormone; Clonidine; Oxymetazoline; α_{2A}-Adrenoceptor subtype; α_{2B}-Adrenoceptor subtype (Makara, G.B. (287) 43)

β-Adrenoceptor antagonist
Veratridine; Na^+ channel; Ca^{2+} channel blocker; Dilazep; Ca^{2+}, cytosolic (Hashizume, H. (271) 1)

Bicarbonate secretion; α-Adrenoceptor agonist; α-Adrenoceptor antagonist; β-Adrenoceptor agonist (Canfield, P. (273) 1)

Carazolol; β_3-Adrenoceptor agonist; Adenylyl cyclase; Lipolyse (Méjean, A. (291) 359)

β-Adrenoceptor, atypical
Taenia caecum, guinea-pig; Muscle relaxation; Noradrenaline (Koike, K. (279) 159)

β-Adrenoceptor blockade
β-Adrenoceptor; Ageing; Receptor upregulation; cAMP; (Rat) (Conlon, D. (289) 283)

β-Adrenoceptor-mediated relaxation
Muscarinic M_2 receptor; Smooth muscle, human, bronchial (Watson, N. (275) 307)

α_2-Adrenoceptor, postsynaptic
DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); Brain, rat; [^{3}H]RX 821002 binding; Clonidine-induced mydriasis; α_{2D}-Adrenoceptor (Heal, D.J. (277) 215)

β_2-Adrenoceptor, prejunctional
Noradrenaline; Adrenaline; Catecholamine overflow; Exercise; (Freely moving rat) (Coppes, R.P. (274) 33)

Adrenoceptor subtype
Blood vessel; Denopamine (Fujimoto, S. (280) 143)

α_1-Adrenoceptor subtype
Liver; Hepatocyte membrane; α_{1A}-Adrenoceptor (García-Sáinz, J.A. (272) 139)

Aging; Aorta, rat (Gurdal, H. (274) 117)

α-Adrenoceptor antagonist; *N*-Methyl-actinodaphnine; (*Illigera luzonensis*) (Guh, J.-H. (279) 33)

Cyclazosin; α_1-Adrenoceptor antagonist; Prazosin-related antagonist (Giardinà, D. (287) 13)

COS-7 cells; Radioligand binding study; Benign prostatic hypertrophy (Foglar, R. (288) 201)

Thoracic aorta; Ca^{2+}-sensitization; Myosin light chain phosphorylation; Botulinum C_3-sensitive GTP-binding protein (Kokubu, N. (290) 19)

Chlorethylclonidine; SZL-49; [^{3}H]prazosin binding (Pimoule, C. (290) 49)

NS-49; Oxymetazoline; Cloned receptor; Radioligand binding study; Cytosolic Ca^{2+} concentration (Obika, K. (291) 327)

α_2-Adrenoceptor subtype
Presynaptic α_2-adrenoceptor; Gastric acid secretion; Vagus nerve; (Rat) (Blandizzi, C. (278) 179)

[^{3}H]MK912; [^{3}H]RX821002; (Pig) (Wikberg-Matsson, A. (284) 271)

Ligand binding; cAMP level; (*Autographa californica* nuclear polyhedrosis virus); (*Spodoptera frugiperda*) (Jansson, C.C. (290) 75)

α_{2A}-Adrenoceptor subtype
Hypothalamus; Pituitary; α_2-Adrenoceptor; Growth hormone; Clonidine; Oxymetazoline; α_2-Adrenoceptor antagonist; α_{2B}-Adrenoceptor subtype (Makara, G.B. (287) 43)

α_{2B}-Adrenoceptor subtype
Hypothalamus; Pituitary; α_2-Adrenoceptor; Growth hormone; Clonidine; Oxymetazoline; α_2-Adrenoceptor antagonist; α_{2A}-Adrenoceptor subtype (Makara, G.B. (287) 43)

β-Adrenoceptor subtype
Cardiomyopathy; Coupling efficiency; Adenylyl cyclase; Hamster; Age-dependent (Witte, K. (290) 1)

Desensitization; β-Adrenoceptor agonists; Adipocyte; Phosphodiesterase; Lipolysis (Bousquet-Mélou, A. (289) 235)

Adrenomedullin
Vascular bed, intestinal; Vasoactive peptide; CGRP (calcitonin gene-related peptide); (Six-membered ring structure) (Santiago, J.A. (272) 115)

Hemodynamics, regional; Spontaneously hypertensive rat (SHR); Microsphere (He, H. (273) 209)

Kidney, rat; CGRP receptor; Anesthetized rat (Haynes, J.M. (280) 91)

cAMP; Endothelium; (Receptors) (Kato, J. (289) 383)

Afferent nerve
Blood flow; 5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindole acetic acid); Dopamine; Gingiva; Dental pulp; Sympathetic nerve; (Rat) (Kerezoudis, N.P. (275) 191)

Afferent nerve stimulation
TNF-α (tumor necrosis factor-α); Capsaicin; Cutaneous hyperemia; CGRP (calcitonin gene-related peptide); Bradykinin (Herbert, M.K. (286) 273)

Affinity
Adenosine receptor; Adenosine; 8-Alkylaminoadenosine analogue; Theophylline-7-riboside and derivative; Intrinsic activity (Van der Wenden, E.M. (290) 189)

Aflatoxin B_1
Saccharomyces cerevisiae; CYP2A; Metabolic activation (Pelkonen, P. (292) 67)

Afterhyperpolarization
Muscarinic receptor; Firing pattern, modulation; Neostriatum; Neuromodulation (Pineda, J.C. (281) 271)

ω-Agatoxin IVA
ω-Conotoxin GVIA; ω-Conotoxin MVIIC; ω-Conotoxin MVIIA; Sympathetic neurotransmission; Ca^{2+} channel; Heart (Vega, T. (276) 231)

Motor endplate; Ca^{2+} channel, P-type; Acetylcholine release (Wessler, I. (278) 83)

Age-dependent
Cardiomyopathy; β-adrenoceptor subtype; Coupling efficiency; Adenylyl cyclase; Hamster (Witte, K. (290) 1)

Ageing
ACTH (adrenocorticotropin); Melanocortin; Grooming; Stretching; Yawning; Penile erection (Poggioli, R. (271) 253)

α_1-Adrenoceptor subtype; Aorta, rat (Gurdal, H. (274) 117)

Noradrenaline release, spontaneous; Vasoconstrictor; Potentiation (Glenn, T.C. (276) 191)

Tardive dyskinesia, rat; cAMP; Phosphodiesterase; Rolipram (Sasaki, H. (282) 71)

β-Adrenoceptor; β-Adrenoceptor blockade; Receptor upregulation; cAMP; (Rat) (Conlon, D. (289) 283)

Adrenoceptor; Epinephrine; Fatty acid; Phospholipid; Heart muscle; (Rat) (Benediktsdóttir, V.E. (289) 419)

Mitochondria; *N*-Acetylcysteine; Thiol (Miquel, J. (292) 333)

Ag^+-induced contracture
Caffeine; Procaine; Dithiothreitol; Skeletal muscle; (Frog) (Oba, T. (292) 301)

Agonist, dual effect
Muscarinic receptor; Ca^{2+} mobilization; Receptor theory, modified (Järv, J. (291) 43)

Ah (aryl hydrocarbon) receptor
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Developmental toxicity; Neurobehavioral effect; Reproduction effect; Endocrine effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Experimental animal; Human infant; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

Ah receptor complex, human
Ah receptor responsiveness (Wang, X. (293) 191)

Ah receptor responsiveness
Ah receptor complex, human (Wang, X. (293) 191)

Airflow obstruction
Bradykinin; Thromboxane; WEB2086; ICI192,605; OKY-046 (Kawikova, I. (280) 293)

Airway
Histamine; Prostaglandin E_2; Prostacyclin; (Human) (Knight, D.A. (272) 1)

Histamine; Prostanoid; (Human) (Knight, D.A. (272) 13)

Bradykinin; Furosemide; Thromboxane A_2 receptor; Smooth muscle (Molimard, M. (278) 253)

Vapreotide; Somatostatin analog; Substance P; Tachykinin NK_1 receptor; Tachykinin NK_2 receptor; Binding (Bétoin, F. (279) 241)

Airway epithelium
Nitric oxide (NO); Ca^{2+}; Bradykinin; ATP (Sakai, A. (291) 375)

Airway, human
Leukotriene; Anti-immunoglobulin E; Contraction; Cysteinyl leukotriene receptor antagonist (Gorenne, I. (275) 207)

Asthma; TNF-α (tumor necrosis factor-α); Cytokine; Bronchial hyperresponsiveness; Electrical field stimulation (Anticevich, S.Z. (284) 221)

Airway hyperreactivity
β-Adrenoceptor agonist; Salbutamol; β-Adrenoceptor; Receptor desensitisation; (Guinea pig) (Buchheit, K.-H. (287) 85)

Airway hyperreactivity, mouse
Delayed-type hypersensitivity; Vascular permeability; Pulmonary inflammation; LCB 2183 (Buckley, T.L. (282) 103)

Airway hyperresponsiveness
Bronchus; Ca^{2+} channel, voltage-dependent and receptor-operated; Inositol 1,4,5-trisphosphate; Acetylcholine; (Rat) (Chiba, Y. (278) 79)

Macrophage; Thromboxane; Azelastine (Tamaoki, J. (278) 161)

Capsaicin; Sensory nerve; Inflammation; (Rabbit) (Herd, C.M. (282) 111)

Airway inflammation
Phosphodiesterase inhibitor; Bronchial hyperreactivity; Early and late asthmatic reaction; (Guinea pig, allergic) (Santing, R.E. (275) 75)

Airway microvascular leakage; PAF (platelet-activating factor); Ozone; E6123; (Guinea-pig) (Kaneko, T. (292) 251)

Toxocara canis; Eosinophil; Tracheal reactivity (Buijs, J. (293) 207)

Airway microvascular leakage
Airway inflammation; PAF (platelet-activating factor); Ozone; E6123; (Guinea-pig) (Kaneko, T. (292) 251)

Airway smooth muscle
Protein kinase C; Ca^{2+} (Hoiting, B.H. (290) R5)

Alanine
GABA (γ-aminobutyric acid); Glutamate; Epilepsy (Baran, H. (273) 197)

Alanine aminotransferase
Zinc sulfate; *N*-acetylcysteine; Acetaminophen; Hepatotoxicity; Glutathione; Malondialdehyde (Woo, P.C.Y. (293) 217)

Alanine analog
Endothelin; Receptor subtype; Ileum, guinea-pig; Sarafotoxin S6c; Tachyphylaxis (Miasiro, N. (278) 103)

Albumin
TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Tryptophan, free; Fatty acid, free (Unkila, M. (293) 115)

Alcoholism
GBH (γ-hydroxybutyric acid); Voluntary γ-hydroxybutyric acid intake; (Rat) (Colombo, G. (285) 103)

Alcoholization
5-HT (5-hydroxytryptamine, serotonin); Receptor; mRNA; Binding; Autoradiography; (Rat) (Nevo, I. (281) 229)

Alcohol sensitivity
Ro 15-4513; $GABA_A$ receptor; Diazepam-insensitive; Cerebellum; Benzodiazepine; Imidazoquinoxaline; Imidazoquinazoline; Cyclopyrrolone (Wong, G. (289) 335)

Alcuronium
Muscarinic receptor; Allosteric modulation; Heart (Maaß, A. (272) 103)

Muscarinic receptor; Methylscopolamine; Allosteric interaction; Chemical modification (Jakubík, J. (289) 311)

Muscarinic receptor, heart; Allosteric interaction; Positive allostericity (Hejnová, L. (291) 427)

Aldose reductase
Diabetes; Formalin test; Polyol pathway; Pain; Diabetic neuropathy (Calcutt, N.A. (285) 189)

Aldose reductase inhibitor
M16209; Antihyperglycemic effect; Streptozotocin-induced diabetes; Insulin secretion (Nakayama, K. (276) 77)

M16209; Insulin secretion; Pancreas, perfused; K^+ channel, ATP-sensitive (Nakayama, K. (276) 85)

8-Alkylaminoadenosine analogue
Adenosine receptor; Adenosine; Theophylline-7-riboside and derivative; Affinity; Intrinsic activity (Van der Wenden, E.M. (290) 189)

Alkylating derivative of hexadecamethonium
End-plate potential; Acetylcholinesterase inhibitor (Danilov, A.F. (277) 15)

Allergen
Oxygen radical; Chemiluminescence; Neutrophil; Corticosteroid; Ozone (Stevens, W.H.M. (293) 251)

Allergic asthma
Immunoglobulin E; Bronchoconstrictive response; Hyperresponsiveness; Ovalbumin; (Mouse) (Hessel, E.M. (293) 401)

Allergic conjunctivitis
Nitric oxide (NO); Vascular permeability; N^G-Nitro-L-arginine methyl ester; Aminoguanidine; Histamine; PAF (platelet-activating factor) (Meijer, F. (284) 61)

Allergic inflammation
Macrophage inflammatory protein 2; Dexamethasone; Chemotactic factor (Tanabe, J.-i. (284) 257)

Allergy
Eosinophil; β-Adrenoceptor agonist; Inflammation; Passive cutaneous anaphylactic reaction (Teixeira, M.M. (272) 185)

Allicin
Pulmonary vascular bed, rat; Pulmonary vascular bed, cat; Vasodilator response; N^{ω}-Nitro-L-arginine methyl ester; Methylene blue; Hypoxic pulmonary vasoconstriction; Guanylate cyclase (Kaye, A.D. (276) 21)

Allodynia
BW373U86; δ-Opioid receptor agonist; Hyperalgesia; Rhesus monkey (Butelman, E.R. (277) 285)

Allopregnanolone
Flumazenil; Anxiety; Burying behavior (Fernández-Guasti, A. (281) 113)

Allopurinol
Lipopolysaccharide; Antioxidant; Vitamin E; Vitamin C; Glucocorticoid (Dimmeler, S. (287) 257)

N-Acetyl-L-cysteine; Xanthine oxidase; Sepsis; Free radicals; Cecal ligation and puncture (Villa, P. (292) 341)

Allosteric interaction
Dexniguldipine-HCl; P-glycoprotein; Multidrug resistance (Malkhandi, J. (288) 105)

Muscarinic receptor; Alcuronium; Methylscopolamine; Chemical modification (Jakubík, J. (289) 311)

Muscarinic receptor; 2α-DHET; 2α-(2′,2′-disubstituted-hydroxy-ethoxy)tropane; Heart (Gao, Z.-g. (289) 369)

NMDA receptor; Glycine site antagonist; Glutamate; Glycine (Grimwood, S. (290) 221)

Dihydropyridine; Phenylalkylamine; Structural determinant; Molecular modeling (Voigt, W. (291) 255)

Muscarinic receptor, heart; Alcuronium; Positive allostericity (Hejnová, L. (291) 427)

Allosteric modulation
Muscarinic receptor; Alcuronium; Heart (Maaß, A. (272) 103)

Allosterism
Gallamine; [^{3}H]*N*-methylscopolamine; Dissociation kinetics (Christopoulos, A. (290) 259)

***N*-Allylnormetazocine**
(+)-Pentazocine; σ Receptor; Dopamine; Striatum; Microdialysis (Gudelsky, G.A. (286) 223)

Almitrine
Bleomycin; Experimental hypoxemia; Prednisolone; Doxapram; TEI-7322 (Horiuchi, H. (287) 27)

Alphaxalone
$GABA_A$ receptor; Flunitrazepam binding; Propofol; Chlormethiazole; (+)-Etomidate; Etazolate (Slany, A. (291) 99)

Alpidem-insensitive site
Benzodiazepine; Receptor binding; Spinal cord (Maguire, P.A. (280) 167)

Alprazolam
Prenatal diazepam; Forced swimming test; Desipramine (Cannizzaro, C. (273) 239)

Alternation performance, spontaneous
Dynorphin A-(1–13); U-50,488H; κ-Opioid receptor; Mouse (Ukai, M. (281) 173)

Alternative splicing
PACAP type I receptors; Recombinant receptors (Ciccarelli, E. (288) 259)

Aluminum fluoride
$GABA_B$ receptor; Baclofen; Neocortical slice, rat; *N*-Ethylmaleimide; G-protein (Ong, J. (287) 197)

Alveolar macrophage
Carbon monoxide (CO); Nitric oxide (NO); Heme oxygenase; Cyclic GMP; Superoxide anion (Fukushima, T. (289) 103)

Alzheimer's disease
Nicotinic acetylcholine receptor; Brain imaging (London, E.D. (278) R1)

Tetrahydroaminoacridine; Nicotine; Nucleus basalis lesion; *p*-Chlorophenylalanine treatment (Riekkinen Jr., P. (279) 65)

Spatial learning; Hippocampus; Acetylcholine; Scopolamine; 5-HT_{1A} receptor; (*S*)-WAY 100135; (Rat) (Carli, M. (283) 133)

Adenosine A_1 receptor; NMDA receptor; Seizure; (Mouse) (Von Lubitz, D.K.J.E. (283) 185)

Dimethindene, enantiomer; Muscarinic M_2 receptor antagonist; Histamine H_1 receptor; Muscarinic receptor subtype; Enantioselectivity; Stereoselectivity, inverse; PET (positron emission tomography) (Pfaff, O. (286) 229)

Streptozotocin; Acetyl-L-carnitine; Brain; Oxidative stress (Terwel, D. (287) 65)

Amantadine
c-*fos*; Dopamine; NMDA (*N*-methyl-D-aspartate); Striatum (Tomitaka, S.-i. (285) 207)

Nucleus basalis magnocellularis; Acetylcholine; Neuroprotection; Memantine; (+)-MK-801; Ataxia; Stereotypy; (Rat) (Wenk, G.L. (293) 267)

Ambulation, mouse
Morphine; Sensitization; μ-Opioid receptor; Dopamine receptor (Kuribara, H. (275) 251)

Amidine
Nitric oxide, NO; Butyramidine; Blood pressure; Shock; Inflammation; Endothelium; Endotoxin; Isothiourea (Southan, G.J. (291) 311)

Amiloride
EIPA (5-(*N*-ethyl-*N*-isopropyl)amiloride); Ouabain; Cardiac contractility; Na^+/Ca^{2+} exchange; Na^+/H^+ exchange (Cargnelli, G. (292) 103)

L-α-Aminoadipic acid
Excitotoxicity; Kynurenic acid; Kynurenine; Microdialysis; Neurodegeneration (Wu, H.-Q. (281) 55)

Aminoalkylindole
Basal ganglia; Cannabinoid; Substantia nigra; Cannabinoid receptor; Motor system; Marijuana; Tetrahydrocannabinol; WIN 55,212-2 (Miller, A.S. (279) 179)

1-Amino-5-bromouracil
Anesthetic activity; Anticonvulsive activity; Barbiturate; Benzodiazepine-$GABA_A$ receptor complex (Miyazaki, S. (271) 179)

Aminoglycoside
Spermine; Melittin; Phosphatidylinositol; Membrane aggregation; Membrane fusion (Van Bambeke, F. (289) 321)

Aminoguanidine
Nitric oxide (NO); Nitric oxide (NO) synthase; Microcirculation; Blood pressure; Endotoxin (Laszlo, F. (272) 169)

Nitric oxide (NO); Meningitis; Blood-cerebrospinal fluid barrier (Boje, K.M.K. (272) 297)

Inflammation; Nitric oxide (NO); (Rat) (Connor, J.R. (273) 15)

Acetylcholine; Lipopolysaccharide; Mesenteric arterial bed; N^G-Nitro-L-arginine methyl ester; Portal vein ligation; (Portal hypertensive rat) (Heinemann, A. (278) 87)

Nitric oxide (NO); Allergic conjunctivitis; Vascular permeability; N^G-Nitro-L-arginine methyl ester; Histamine; PAF (platelet-activating factor) (Meijer, F. (284) 61)

α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor
Arachidonic acid; Carbachol; Cyclothiazide; Kainate receptor; Striatal neuron (Petitet, F. (291) 143)

L-2-Amino-4-phosphonobutanoic acid
Metabotropic glutamate receptor; $MGlu_{4a}$ receptor antagonist (Johansen, P.A. (290) R1)

4-Aminopyridine
α-Adrenoceptor; Contraction, phasic; K^+ channel; Caudal epididymis, rat (Huang, Y. (280) 231)

Vas deferens, rat; α_2-Adrenoceptor; Xylazine; Tetraethylammonium; Charybdotoxin; Phorbol dibutyrate; Bay K 8644 (Docherty, J.R. (287) 287)

[^{14}C]Aminopyrine accumulation
Acid secretion; Glucagon-related peptides; Histamine (Gros, L. (288) 319)

5-Aminosalicylic acid
Nitric oxide (NO); Inflammatory bowel disease (Pallapies, D. (282) 145)

Amiodarone
SR 33589; Antiarrhythmic (class III); Anti-adrenoceptor activity (Hodeige, D. (279) 25)

Amitriptyline
Chronic variate stress; Foot-shock stress, acute; β-Adrenoceptor; 5-HT_{1A} receptor; 5-HT_2 receptor; Open-field; Brain cortex, rat (Ferretti, C. (280) 19)

Amlodipine
Felodipine; Smooth muscle, vascular; Drug effect; (Rat) (Videbæk, L.M. (274) 109)

Semotiadil; Diltiazem; Nifedipine; Conduction interval; Refractoriness (Stark, G. (286) 71)

Amnesia
Inhibitory avoidance; Heme oxygenase; Hippocampus; Zinc protoporphyrin-9 (Fin, C. (271) 227)

Dynorphin A-(1–13); Scopolamine; Passive avoidance response; Memory; (Mouse) (Ukai, M. (274) 89)

cAMP
Isoprenaline-induced relaxation; cGMP; Pre-contraction; Endothelium; Aorta, rat (Eckly, A.E. (271) 237)

Cerebral ischemia; Rolipram; Phosphodiesterase; Hippocampus; (Gerbil) (Kato, H. (272) 107)

Prostaglandin E_2; Iloprost; Desensitization; Indomethacin; Vasorelaxation (Parfenova, H. (278) 133)

Butein; EDRF (endothelium-derived relaxing factor); Phosphodiesterase; cGMP; Thoracic aorta, rat (Yu, S.-M. (280) 69)

Tardive dyskinesia, rat; Phosphodiesterase; Rolipram; Ageing (Sasaki, H. (282) 71)

Cardiac contractility; Isoprenaline; Diazepam; Forskolin (Martinez, E. (282) 169)

G 619; TNF-α (tumor necrosis factor-α); Endotoxin shock (Altavilla, D. (286) 31)

Histamine; Histamine H_2 receptor; U937 cell; Homologous desensitization (Smit, M.J. (288) 17)

Remoxipride; Striatum; Dopamine D_2 receptor; Metabolite, remoxipride (Westlind-Danielsson, A. (288) 89)

Platelet inhibition; cGMP; Prostacyclin; Nitric oxide (NO); Protein phosphorylation (Grünberg, B. (288) 329)

Phospholipase C; G-protein; mGluR (Knöpfel, T. (288) 389)

Mesangial cell, rat; Cyclic nucleotide phosphodiesterase; cyclic GMP; ANF-(1–28) (Atrial natriuretic factor-(1–28); E4021 (Ahn, H.-S. (289) 49)

β-Adrenoceptor; Ageing; β-Adrenoceptor blockade; Receptor upregulation; (Rat) (Conlon, D. (289) 283)

Adrenomedullin; Endothelium; (Receptors) (Kato, J. (289) 383)

Platelet; Iloprost; cGMP; Synergism (Fisch, A. (289) 455)

Endothelial cell; Phosphodiesterase inhibitor; Nitric oxide; cGMP (Kessler, T. (290) 163)

Phosphatidic acid; Phosphodiesterase; Phospholipid; Rolipram; U937 (DiSanto, M.E. (290) 169)

5-HT_{1D} receptor subtype, recombinant, human; Ketanserin; Ritanserin; 5-HT_{2A} receptor antagonist; Subtype selectivity; 5-$HT_{1D\alpha}$ receptor antagonist (Zgombick, J.M. (291) 9)

Neutrophil; Degranulation; Ca^{2+}; cGMP; Protein kinase C; Tolfenamic acid (Kankaanranta, H. (291) 17)

Phosphodiesterase inhibitor; Peripheral blood mononuclear cell; Arachidonate; Forskolin; β_2-adrenoceptor agonist (Hichami, A. (291) 91)

Endorphin receptor; Recombinant cell; Radioligand binding; Adenylyl cyclase (Knapp, R.J. (291) 129)

PACAP (pituitary adenylate cyclase-activating peptide); VIP (vasoactive intestinal polypeptide); Cardiac myocyte; CDD/ANP-(99–126) (Bäsler, I. (291) 335)

Dihydroetorphine; Morphine; Opioid receptor, cloned; Binding characteristic (Katsumata, S. (291) 367)

cAMP accumulation
Muscarinic receptor synthesis; Propylbenzilylcholine mustard; HEL 299 cell; Receptor inactivation; Radioligand binding (Haddad, E.-B. (290) 201)

cAMP formation
Mitogenesis; Intrinsic activity (Griffon, N. (282) R3)

GR 127,935; 5-HT_{1A}, 5-$HT_{1D\alpha}$ and 5-$HT_{1D\beta}$ receptors , cloned, human; 5-HT_{1B} receptor, opossum kidney; 5-HT_{1D} receptor antagonist (Pauwels, P.J. (290) 95)

cAMP level
α_2-Adrenoceptor subtype; Ligand binding; (*Autographa californica* nuclear polyhedrosis virus); (*Spodoptera frugiperda*) (Jansson, C.C. (290) 75)

AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)
Retina; Excitatory amino acid receptor antagonist; NMDA (*N*-methyl-D-aspartate); Thiokynurenic acid; Rose bengal (Lombardi, G. (271) 489)

NMDA (*N*-methyl-D-aspartate); ATPA ((*RS*)-2-amino-3-(3-hydroxy-5-*tert*-butylisoxazol-4-yl)propionic acid); Cue; Convulsion; Glutamate receptor; (Rat); (Mouse) (Arnt, J. (285) 289)

AMPA/kainate receptor
Desensitizing current, fast; GAMS (γ-D-glutamylaminomethylsulfonic acid); 6-Cyano-7-nitroquinoxaline-2,3-dione; Hippocampal neuron, rat (Wilsch, V.W. (284) 141)

Glutamate; Excitotoxicity; NMDA receptor; Ca^{2+} channel, L-type, voltage-sensitive; Neuroprotection (Prehn, J.H.M. (292) 179)

AMPA receptor
Cyclothiazide; Receptor desensitization; Ca^{2+} uptake; $[Ca^{2+}]_i$; Cerebellar granule neuron; Cortical neuron; Primary culture (Cebers, G. (290) 105)

AMPA receptor antagonist
LY326325; NBQX (6-nitro-7-sulfamoylbenzo(*f*)quinoxaline-2,3-(1*H*,4*H*dione); Anxiety; Plus maze; Locomotor activity; (Mouse) (Karcz-Kubicha, M. (279) 171)

NMDA receptor antagonist; Seizure (Czuczwar, S.J. (281) 327)

Amperozide
Risperidone; Olanzapine; Seroquel; Ziprasidone; Schizophrenia; Ventral tegmental area; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (281) 289)

Amphetamine
Cocaine; Locomotor activity; Microdialysis, in vivo; Opioid receptor antagonist; Dopamine; Striatum; Nucleus accumbens (Schad, C.A. (275) 9)

Dopamine receptor; 5-HT_2 receptor; α_1-Adrenoceptor; Hyperactivity; (Rat) (Arnt, J. (283) 55)

***d*-Amphetamine**
(−)-DS121; Dopamine autoreceptor antagonist; Dopamine D_3 receptor; Cocaine; Drug discrimination; Caffeine (Clark, D. (275) 67)

Isolation rearing; Place preference; (Rat) (Wongwitdecha, N. (279) 99)

R(+)-8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY 100,635 (*n*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*n*-(2-pyridinyl)-cyclohexanecarboxamide trihydrochloride); Dopamine; 5-HT_{1A} receptor; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (287) 179)

Amphipathic α-helix
Mast cell; Histamine liberation; Magainin; Neuropeptide Y; Substance P; Liposome (Cross, L.J.M. (291) 291)

Amygdala
Haloperidol; Clozapine; Fos protein; Tolerance; Nucleus accumbens; Striatum; (Long-term treatment) (Sebens, J.B. (273) 175)

Kindling; NMDA (*N*-methyl-D-aspartate); Seizure; Epilepsy; Excitatory amino acid (Croucher, M.J. (286) 265)

Amygdala, extended
Ethanol self-administration; $GABA_A$ receptor (Hyytiä, P. (283) 151)

Amygdala kindling
Strychnine-insensitive glycine site; NMDA receptor antagonist; Anticonvulsant; (DBA/2 mouse) (Chapman, A.G. (274) 83)

β-Amyloid-(1–40)
Long-term potentiation; Glutamatergic synaptic transmission (Wu, J. (284) R1)

β-Amyloid peptide
Fura-2; Cell culture (Korotzer, A.R. (288) 125)

Anabaseine
Nicotine; Nornicotine; Anabasine; *N*-Methylanabasine; Dopamine release; Striatum (Dwoskin, L.P. (276) 195)

Anabasine
Nicotine; Nornicotine; Anabaseine; *N*-Methylanabasine; Dopamine release; Striatum (Dwoskin, L.P. (276) 195)

Analgesia
Antisense oligodeoxynucleotide; μ-Opioid receptor; Cold water tail-flick test; (Rat) (Chen, X.-H. (275) 105)

Red nucleus; L-Arginine; Nitric oxide (NO); cGMP (Kumar, A. (279) 1)

β-Carotene; Morphine (Penn, N.W. (284) 191)

Glutamate; MK-801; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); Inflammation; Pain (Jackson, D.L. (284) 321)

Opiate; δ-Opioid receptor antagonist; Opioid withdrawal; Abstinence (Fundytus, M.E. (286) 105)

Clocinnamox; Morphine; Opioid receptor antagonist; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U69,593; Opioid receptor alkylation; Opioid receptor binding; mRNA; Solution hybridization; (Irreversible antagonist) (Chan, K. (287) 135)

Analgesic
Nociception; Neurokinin; Substance P; Spinal cord (Smith, G. (271) 481)

Anandamide
Cannabinoid; Phenylmethylsulphonyl fluoride; *R*-(+)-Arachidonyl-1′-hydroxy-2′-propylamide; Vas deferens, mouse; Myenteric plexus preparation, guinea-pig (Pertwee, R.G. (272) 73)

CP 55,940; Drug discrimination; Δ^9-Tetrahydrocannabinol (Wiley, J. (276) 49)

Cannabinoid; Blood pressure; CB_1 cannabinoid receptor antagonist (Varga, K. (278) 279)

Adenylate cyclase; Cannabinoid receptor; GTP-binding protein (Barg, J. (287) 145)

Anatoxin-a
Chromaffin cell; Nicotinic acetylcholine receptor, neuronal type; Nicotinic receptor agonist; Mecamylamine; Noradrenaline release; Adrenaline release (Molloy, L. (289) 447)

Anesthesia
Mediodorsal thalamic nucleus; Prefrontal cortex; Excitatory amino acid (Pirot, S. (285) 45)

Urethane; Chemoreflex; Reticulospinal vasomotor neuron; Rostral ventrolateral medulla; (Rats) (Sun, M.-K. (293) 237)

Anesthesia, general
Anesthetics, general; Cytochrome P450; Aniline hydroxylase (LaBella, F.S. (293) 231)

Anesthesia reversal
Dithiothreitol; Dithioerythritol; Pentobarbital; Toxicity; (Rodents) (Gailis, L. (292) 39)

Anesthetic activity
1-Amino-5-bromouracil; Anticonvulsive activity; Barbiturate; Benzodiazepine-$GABA_A$ receptor complex (Miyazaki, S. (271) 179)

Anesthetic, general
Anesthesia, general; Cytochrome P450; Aniline hydroxylase (LaBella, F.S. (293) 231)

Anesthetic, volatile
Endothelial cell; Bradykinin; Fura-2; Nitric oxide (NO); Sevoflurane; A23187; D-Arg-[Hyp^3, $Thi^{5,8}$, D-Phe^7] bradykinin; Des-Arg^9-[Leu^8] bradykinin; Ca^{2+} channel (Az-ma, T. (289) 33)

Anesthetized rat
Adrenomedullin; Kidney, rat; CGRP receptor (Haynes, J.M. (280) 91)

ANF (atrial natriuretic factor)
Neutrophil; Migration; cGMP (Elferink, J.G.R. (288) 335)

ANF-(1–28) (atrial natriuretic factor-(1–28))
Mesangial cell, rat; Cyclic nucleotide phosphodiesterase; cyclic GMP; cyclic AMP; E4021 (Ahn, H.-S. (289) 49)

Angiotensin
Desamino-8D-arginine vasopressin; Brattleboro rat; Vasopressin; Noradrenaline; Hemorrhage (Laycock, J.F. (271) 193)

Angiotensin AT_1 receptor
Angiotensin AT_2 receptor; Losartan; PD 123177; Vasopressin; Drinking response (Höhle, S. (275) 277)

SB 203220; Angiotensin II; SK&F 108566; (In vitro and in vivo pharmacology) (Aiyar, N. (283) 63)

PLC-PRF-5; Hepatoma cell; Dexamethasone; Steroid; Glucocorticoid effect (Wintersgill, H.P. (288) 365)

Angiotensin AT_{1A} receptor
Protein kinase C; Receptor internalization; G-protein coupling; Regulation (Balmforth, A.J. (291) 135)

Angiotensin AT_2 receptor
Angiotensin AT_1 receptor; Losartan; PD 123177; Vasopressin; Drinking response (Höhle, S. (275) 277)

Angiotensin AT_1 receptor antagonist
Angiotensin II-induced drinking; Losartan; EXP3174; LR-B/081 (Polidori, C. (277) 223)

Captopril; Angiotensin converting enzyme inhibitor; Renal function; (Anesthetized dog) (Clark, K.L. (280) 195)

Spontaneously hypertensive rat (SHR); Glucose tolerance; Blood pressure; Angiotensin converting enzyme inhibitor (Chow, L. (282) 77)

Angiotensin receptor; Kinetics; Association; Dissociation (Hara, M. (289) 267)

Angiotensin II; LR-B/081; Losartan; Receptor binding studies (Renzetti, A.R. (290) 151)

Angiotensin II; Platelet-derived growth factor; Basic fibroblast growth factor; DNA synthesis (Itazaki, K. (291) 417)

Angiotensin AT_1 receptor antagonist, surmountable
ME3221; Antihypertensive drug; Losartan; Telemetry (Nagura, J. (274) 201)

Angiotensin AT_1 receptor, selective
Angiotensin II; CS-866; Nonpeptide; Angiotensin receptor antagonist (Mizuno, M. (285) 181)

Angiotensin converting enzyme inhibitor
Angiotensin AT_1 receptor antagonist; Captopril; Renal function; (Anesthetized dog) (Clark, K.L. (280) 195)

Spontaneously hypertensive rat (SHR); Glucose tolerance; Blood pressure; Angiotensin AT_1 receptor antagonist (Chow, L. (282) 77)

des-Asp-Angiotensin I
Aortic ring; Captopril; Indomethacin (Sim, M.K. (278) 175)

Losartan; PD123319; Pulmonary artery, rabbit; Transmural stimulation; (Superfusion) (Sim, M.K. (284) 215)

Angiotensin II
Neuropeptide Y; Vasoconstriction; Second messenger; Femoral artery (Cressier, F. (272) 57)

Losartan; DuP 532; PD 123319; CGP 42112A; Smooth muscle, portal vein (Pelet, C. (279) 15)

Cardiac hypertrophy; Volume overload; Losartan; Endothelin-1; FR139317 (Ishiye, M. (280) 11)

LR-B/081; Smooth muscle cell; Inositol trisphosphate; Prostaglandin; Hypertrophy (Catalioto, R.-M. (280) 285)

Irbesartan (SR 47436/BMS-186295); SR 47155A; Losartan; EXP 3174; Pithed rat (Christophe, B. (281) 161)

Bradykinin; Vasopressin; Pulmonary artery; Pulmonary vein; Nitric oxide (NO); Prostaglandin I_2 (Sai, Y. (282) 235)

SB 203220; SK&F 108566; Angiotensin AT_1 receptor; (In vitro and in vivo pharmacology) (Aiyar, N. (283) 63)

UP 269-6; Losartan; Angiotensin II receptor antagonist; Blood pressure; Heart rate (Cazes, M. (284) 157)

Renal blood flow; Catecholamine release; Renal nerve; Prazosin; α-Adrenoceptor (Chen, K. (284) 281)

CS-866; Nonpeptide; Angiotensin receptor antagonist; Angiotensin AT_1 receptor, selective (Mizuno, M. (285) 181)

Nitric oxide (NO); Angiotensin receptor; Downregulation; Portal hypertension (Cahill, P.A. (288) 219)

Angiotensin AT_1 receptor antagonist; LR-B/081; Losartan; Receptor binding studies (Renzetti, A.R. (290) 151)

Angiotensin AT_1 receptor antagonist; Platelet-derived growth factor; Basic fibroblast growth factor; DNA synthesis (Itazaki, K. (291) 417)

Angiotensin II-induced drinking
Angiotensin AT_1 receptor antagonist; Losartan; EXP3174; LR-B/081 (Polidori, C. (277) 223)

Angiotensin II receptor antagonist
UP 269-6; Losartan; Angiotensin II; Blood pressure; Heart rate (Cazes, M. (284) 157)

Angiotensin IV
Renin-angiotensin system; (Receptor) (Bernier, S.G. (271) 55)

Angiotensin IV receptor; Endothelial cell (Bernier, S.G. (291) 191)

Angiotensin IV receptor
Angiotensin IV; Endothelial cell (Bernier, S.G. (291) 191)

Angiotensin receptor
Angiotensin II; Nitric oxide (NO); Downregulation; Portal hypertension (Cahill, P.A. (288) 219)

Angiotensin AT_1 receptor antagonist; Kinetics; Association; Dissociation (Hara, M. (289) 267)

Angiotensin receptor antagonist
Angiotensin II; CS-866; Nonpeptide; Angiotensin AT_1 receptor, selective (Mizuno, M. (285) 181)

Angiotensin receptor-mediated response
L-163,491; Pulmonary vascular bed, cat; Captopril; PD 123319; DuP 532 (Kaye, A.D. (287) 163)

Aniline hydroxylase
Anesthesia, general; Anesthetics, general; Cytochrome P450 (LaBella, F.S. (293) 231)

Animal model
Anxiety; Buspirone; Diazepam; One-way avoidance; Successive negative contrast (Torres, C. (280) 277)

Parkinson's disease; Lamotrigine (Löschmann, P.-A. (284) 129)

Animal toxicology
Nitrate; Nitrite; *N*-nitroso compound; Human diet; Dietary intake; Endogenous synthesis; Metabolism; Toxicokinetics; Human effects (Gangolli, S.D. (292) 1)

Aniracetam
D-Cycloserine; Oxiracetam; NMDA receptor; Noradrenaline release; Kynurenic acid (Pittaluga, A. (272) 203)

NMDA (*N*-methyl-D-aspartate); Hippocampus (Pizzi, M. (275) 311)

Anorectic drug
Hyperphagia, experimentally induced; 2-Deoxy-D-glucose; Insulin; Sodium mercaptoacetate; Neural circuit (Garosi, V.L. (276) 285)

Anorexia
Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; 5-HT (5-hydroxytryptamine, serotonin); Gastric emptying; Food intake (Hui, S.-C.G. (283) 141)

Dioxin; TCDD (2,3,7,8-Tetrachlorodibenzo-*p*-dioxin); Portocaval anastomosis; Food intake; Vagotomy (Tuomisto, J. (292) 277)

Antagonist profile, unique
Bradykinin receptor; Ileum, guinea pig; Adenylate cyclase; Inhibitory B_2 receptor (Liebmann, C. (289) 403)

Anthelmintic
Pyrantel; Acetylcholine; Ion channel; *Ascaris*, muscle; Parasitic nematode (Robertson, S.J. (271) 273)

Anti-adrenoceptor activity
Amiodarone; SR 33589; Antiarrhythmic (class III) (Hodeige, D. (279) 25)

Antiarrhythmic
Action potential; Ca^{2+} current; K^+ current; Oxime; Cardiac myocyte (Karhu, S. (279) 7)

K^+ channel, cloned; $K_{V1.2}$; $K_{V1.4}$; Bradycardic drug (Yamagishi, T. (281) 151)

Cardiac electropharmacology; Mechanism of arrhythmia (Lee, J.H. (285) 25)

Antiarrhythmic, class I
Ischemic arrhythmia; ECG (electrocardiogram); (Selectivity) (Barrett, T.D. (285) 229)

Antiarrhythmic, class Ia
Patch clamp; Disopyramide; Skeletal muscle; K_{ATP} channel; Channel inhibition, pH dependent (Moser, C. (284) 35)

Antiarrhythmic, class III
Amiodarone; SR 33589; Anti-adrenoceptor activity (Hodeige, D. (279) 25)

K^+ channel; pH (Herzer, T. (291) 205)

Antiarthritic effect
Acyclic nucleotide analog; PMEA (9-(2-phosphomethoxyethyl)adenine); HPMPC (1-(*S*)-(3-hydroxy-2-phosphonomethoxyethyl)cytosine); Adjuvant arthritis (Zídek, Z. (286) 307)

Antibody
Desenkephalin-γ-endorphin; Endorphin receptor, γ-type; Apomorphine; Nucleus accumbens; Neuroleptic-like action; Anti-idiotype antibody; Behavioral effect (Van Ree, J.M. (279) 187)

Melanocortin receptor; Malignant melanoma (Xia, Y. (288) 277)

Anti-cancer drug
Endotoxin; Nitric oxide (NO) synthase; Chemotherapy; Cytotoxicity; Cancer (Hattori, Y. (291) 83)

Anticholinesterase agent
β-Eudesmol; Organophosphate intoxication; Obidoxime; Diisopropylfluorophosphate; Neuromuscular transmission (Chiou, L.C. (292) 151)

Anticonvulsant
Felbamate; Epileptiform bursting (Domenici, M.R. (271) 259)

Vinpocetine; Phenytoin; Na^+ channel, voltage-gated; Neuroprotection; Cortical neuron; (Rat) (Molnár, P. (273) 303)

Amygdala kindling; Strychnine-insensitive glycine site; NMDA receptor antagonist; (DBA/2 mouse) (Chapman, A.G. (274) 83)

Anxiolytic; Separation-induced vocalization; Audiogenic seizure; Glycine receptor, strychnine-insensitive; NMDA receptor; (DBA/2J mouse); (Rat pup) (Kehne, J.H. (284) 109)

Levetiracetam; ucb L059; Epilepsy; Receptor binding (Noyer, M. (286) 137)

Anticonvulsant action
Epilepsy; Kynurenate; Kynurenine; Excitotoxicity; Dizocilpine; Piriform cortex (Baran, H. (286) 167)

Anticonvulsive activity
1-Amino-5-bromouracil; Anesthetic activity; Barbiturate; Benzodiazepine-GABA$_A$ receptor complex (Miyazaki, S. (271) 179)

Antidepressant
Desipramine; Fluoxetine; Maprotiline; Moclobemide; Trimipramine; 2-Methyl-5-hydroxytryptamine; 5-HT (5-hydroxytryptamine, serotonin); Reuptake inhibition; Hippocampus; Presynaptic modulation (Mongeau, R. (271) 121)

Benzodiazepine receptor, peripheral type; Olfactory bulbectomy; Thymus; Spleen; Adrenal (Dennis, T. (272) 279)

Dopamine receptor; Quinpirole; SKF 38393; Motor activity (Allison, K. (277) 139)

Learned helplessness; 5-HT$_2$ receptor; Corticosterone (Nankai, M. (281) 123)

Fluoxetine; Clomipramine; Imipramine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Extrapyramidal symptom; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (281) 255)

β-Endorphin-(10–16); Prolyl-leucyl-glycinamide; TRH (thyrotropin-releasing hormone); Melatonin; Nucleus accumbens (Hatta, K. (284) 327)

5-HT$_2$ receptor; 5-HT uptake inhibitor; c-*fos* (Tilakaratne, N. (290) 263)

Antidepressant activity
5-HT$_{1A}$ receptor; MKC-242 (5-[3-[((2*S*)-1,4-benzodioxan-2-ylmethyl)-amino]propoxy]-1,3-benzodioxole); Forced swimming test; (Mouse) (Matsuda, T. (280) 235)

Antidiarrheal agent
Opiate; Ion conductance; P-glycoprotein; CFTR (cystic fibrosis transmembrane conductance regulator) (Callaghan, R. (291) 183)

Anti-epileptic
GYKI 52466; Seizure (Borowicz, K.K. (281) 319)

Antigen challenge
CRF (corticotropin-releasing factor); CP 99,994; Plasma extravasation; Neurogenic inflammation, guinea pig; Substance P (Yoshihara, S. (280) 113)

Antihistamine
Cough; Antitussive; (Guinea pig) (Bolser, D.C. (277) 159)

Antihyperglycemic effect
M16209; Aldose reductase inhibitor; Streptozotocin-induced diabetes; Insulin secretion (Nakayama, K. (276) 77)

Antihypertensive drug
ME3221; Angiotensin AT$_1$ receptor antagonist, surmountable; Losartan; Telemetry (Nagura, J. (274) 201)

Anti-idiotype antibody
Desenkephalin-γ-endorphin; Endorphin receptor, γ-type; Apomorphine; Nucleus accumbens; Neuroleptic-like action; Antibody; Behavioral effect (Van Ree, J.M. (279) 187)

Anti-immunoglobulin E
Airway human; Leukotriene; Contraction; Cysteinyl leukotriene receptor antagonist (Gorenne, I. (275) 207)

Anti-inflammatory drug
Phospholipase A$_2$; Thielocin A1β; Paw edema (Tanaka, K. (279) 143)

2-Polyprenyl-1,4-hydroquinone; Marine product; Phospholipase A$_2$; Neutrophil, human (Gil, B. (285) 281)

Anti-inflammatory peptide
Lipocortin/annexin; Interleukin-1β; Fever; Prostaglandin E$_2$ (Palmi, M. (281) 97)

Anti-mitotic drug
Vinca alkaloid; Bis-indol; Navelbine; Vinblastine; Vincristine; Calmodulin antagonism; Tubulin (Molnár, A. (291) 73)

Antinociception
Adenosine, pharmacology; Opioid, pharmacology; Spinal cord; (Mouse) (Keil, II, G.J. (271) 37)

μ-Opioid receptor; κ-Opioid receptor; Visceral pain (Diop, L. (271) 65)

Flurbiprofen; Nefopam; Nitric oxide (NO); Arterial relaxation; Platelet aggregation (Pallapies, D. (271) 335)

7-Nitro indazole; Flurbiprofen; Nitric oxide (NO); Nitric oxide (NO) synthase; (Mouse) (Gaffen, Z. (271) 445)

Morphine tolerance; Methysergide; Metergoline; Ritanserin; Mianserin (Zarrindast, M.-R. (273) 203)

Benzodiazepine; Nociceptive test; Opioid; (Intracerebroventricular); (Intrathecal) (Luger, T.J. (275) 153)

TAN-67; δ-Opioid receptor; 7-Benzylidenenaltrexone; Naltriben diabetes (Kamei, J. (276) 131)

β-Endorphin; Morphine; Ontogenesis (Tseng, L.F. (277) 71)

β-Endorphin; δ_2-Opioid receptor; Naltriben; Tail-flick inhibition (Tseng, L.F. (277) 251)

Ketorolac tromethamine; κ-Opioid receptor; (Intracerebroventricular administration) (Tripathi, A. (278) 27)

Morphine; Tolerance; Adenosine receptor; Cyclohexyladenosine; (Rat) (Tao, P.-L. (278) 233)

Histamine H$_2$ receptor; Restraint; Hot plate test (Wong, C.-L. (279) 109)

μ-Opioid receptor; Dorsal root ganglion; Primary afferent neuron; Ribonuclease protection assay; β-Funaltrexamine (Schäfer, M. (279) 165)

TAN-67; δ-Opioid receptor; 7-Benzylidenenaltrexone; Naltriben diabetes (Kamei, J. (280) 347)

Formalin test; Adenosine; Methylxanthine; Pain mechanism (Doak, G.J. (281) 311)

Transgenic mouse; Superoxide dismutase; Opiate receptor; Genetics (Elmer, G.I. (283) 227)

Antisense oligodeoxynucleotide; δ-Opioid receptor; Desensitization (Narita, M. (284) 185)

Enkephalin catabolism inhibitor; Enkephalin, endogenous; CCK (cholecystokinin); RB 101; PD-134,308; Tail-flick; Hot-plate; CCK$_B$ receptor antagonist; Tolerance (Valverde, O. (286) 79)

Antisense oligodeoxynucleotide; β-Endorphin; δ-Opioid receptor (Tseng, L.F. (287) 169)

Remoxipride; Catalepsy; Rotarod; (Sheep) (Main, D.C.J. (287) 221)

Antinociception, i.c.v., i.t.
GABA receptor antagonist; Benzodiazepine; Nociceptive test; Opioid (Luger, T.J. (271) 421)

Antinociceptive effect
Dihydroetorphine; Diabetes; Opioid receptor; (Mouse) (Kamei, J. (275) 109)

Anti-opioid
Neuropeptide FF release; Spinal cord slice; NMDA (*N*-methyl-D-aspartate); Opioid tolerance (Devillers, J.-P. (271) 185)

Anti-oxidant
Toxicity; Free radical; NMDA receptor; Cortical culture (Eshhar, N. (283) 19)

Lipopolysaccharide; Vitamin E; Vitamin C; Allopurinol; Glucocorticoid (Dimmeler, S. (287) 257)

Lazaroid; (Ca^{2+}, Mg^{2+})-ATPase; Lipid peroxidation; Iron; Erythrocyte (Zaidi, A. (290) 133)

Decongestive nose drops; Hydroxyl radical scavenging; Lipid peroxidation; Nasal inflammation; Reactive oxygen species (Westerveld, G.-J. (291) 27)

Antiplatelet activity
FK409; TRK-100 (Hirasawa, Y. (272) 39)

Antipsychotic
Prefrontal cortex; 5-HT_2 receptor; Microdialysis; Clozapine (Schmidt, C.J. (273) 273)

Dopamine D_3 receptor; Core temperature; Thermoregulation; Clozapine (Millan, M.J. (280) 225)

Cognition; Delay non-match to position; (Rat) (Didriksen, M. (281) 241)

Dopamine D_4 receptor; Schizophrenia (Reynolds, G.P. (281) R5)

Prepulse inhibition, rat; 5-HT (5-hydroxytryptamine, serotonin); Glutamate; Schizophrenia (Varty, G.B. (287) 201)

Dopamine receptor; mRNA; Dopamine D_4 receptor; Neuroleptics; Haloperidol (Schoots, O. (289) 67)

Dopamine D_2 receptor; Dopamine D_4 receptor; Nemonapride; Raclopride (Seeman, P. (291) 59)

Antipsychotic, atypical
Dopamine receptor agonist; Clozapine; Dopamine D_1 receptor; Dopamine D_2 receptor; Quinpirole; Scopolamine; SKF38393; (Rat) (Jackson, D.M. (282) 137)

Antisense oligodeoxynucleotide
Analgesia; μ-Opioid receptor; Cold water tail-flick test; (Rat) (Chen, X.-H. (275) 105)

δ-Opioid receptor; Desensitization; Antinociception (Narita, M. (284) 185)

Morphine; μ-Opioid receptor; δ-Opioid receptor; Growth hormone; Prolactin (Idänpään-Heikkilä, J.J. (284) 227)

β-Endorphin; δ-Opioid receptor; Antinociception (Tseng, L.F. (287) 169)

Antisense oligonucleotide
$GABA_A$ receptor; Receptor subunit; Benzodiazepine receptor; Brain, rat (Karle, J. (291) 439)

Antitussive
Cough; Antihistamine; (Guinea pig) (Bolser, D.C. (277) 159)

Anxiety
TRH (thyrotropin-releasing hormone); Sustained release formulation; Senescence-accelerated mouse (SAM); Neophobia; Learning and memory (Miyamoto, M. (271) 357)

Cholecystokinin; CCK receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin); Zero-maze; (Rat) (Bickerdike, M.J. (271) 403)

LY326325; NBQX (6-nitro-7-sulfamoylbenzo(*f*)quinoxaline-2,3-(1*H*,4*H*dione); AMPA receptor antagonist; Plus maze; Locomotor activity; (Mouse) (Karcz-Kubicha, M. (279) 171)

5-HT_{1A} receptor; Corticosterone; Glucose; Prolactin; Flesinoxan; Defensive burying (Groenink, L. (280) 185)

Animal model; Buspirone; Diazepam; One-way avoidance; Successive negative contrast (Torres, C. (280) 277)

Flumazenil; Allopregnanolone; Burying behavior (Fernández-Guasti, A. (281) 113)

Anxiolytic
Anticonvulsant; Separation-induced vocalization; Audiogenic seizure; Glycine receptor, strychnine-insensitive; NMDA receptor; (DBA/2J mouse); (Rat pup) (Kehne, J.H. (284) 109)

CCK_A receptor; CCK_B receptor; $CCK_{A/B}$ receptor antagonist, mixed; Radioligand binding; Gall bladder, guinea pig (Singh, L. (286) 185)

Anxiolytic activity
5-HT_{1A} receptor; Ipsapirone; (*S*)-WAY 100135; Punishment; Conflict (Cervo, L. (284) 249)

Anxiolytic mechanism
Ultrasonic distress call; Cerebral cortex; Lesion; Diazepam; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide) (Naito, H. (272) 261)

Aorta
Endothelium; N^G-Nitro-L-arginine; EDHF (endothelium-derived hyperpolarizing factor); Acetylcholine; (Rat) (Hatake, K. (274) 25)

Adenosine receptor; FK453; Atrium; Binding assay (Terai, T. (279) 217)

Atropine; α-Adrenoceptor; Cerebral cortex; (Rat) (Chang, K.C. (284) 331)

α_1-Adrenoceptor; Urethra (Auguet, M. (287) 153)

Aorta, human
Phosphodiesterase; cGMP-specific phosphodiesterase (phosphodiesterase V); E4021; Vasorelaxant (Miyahara, M. (284) 25)

Aorta, isolated, rabbit
Bradykinin B_1 receptor; Cycloheximide; Brefeldin A; Tunicamycin; Receptor upregulation (Audet, R. (271) 551)

Aorta, rat
Isoprenaline-induced relaxation; cAMP; cGMP; Pre-contraction; Endothelium (Eckly, A.E. (271) 237)

α_1-Adrenoceptor subtype; Aging (Gurdal, H. (274) 117)

Morphine; Opioid receptor; Contractile force (Parra, L. (277) 99)

Diabetes mellitus; Phorbol ester; Protein kinase C; Ca^{2+}, extracellular; Ca^{2+} channel (Hattori, Y. (279) 51)

Sulfonylurea; Prostanoid; Prostaglandin $F_{2\alpha}$; Glibenclamide; Tolbutamide; Thromboxane A_2 (Delaey, C. (280) 179)

Tyrosine kinase inhibitor; Contraction; Ca^{2+} store refilling; Vanadate (Filipeanu, C.M. (281) 29)

Visnagin; Portal vein (Duarte, J. (286) 115)

α_1-Adrenoceptor; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_2 receptor; SDZ NVI-085; SK&F 89748-A (Van der Graaf, P.H. (287) 309)

Cadmium ion; Vasoconstriction; Ca^{2+} channel; Contractile protein (Wakabayashi, I. (293) 133)

Aortic endothelial cell
Ca^{2+} mobilization; Cl^-, extracellular; Fura-2; Thapsigargin; Cyclopiazonic acid (Hosoki, E. (288) 131)

Aortic ring
Atrium, rat; Contraction, force of; Relaxation; cGMP-dependent protein kinase; Acetylcholine (Bäumner, D. (273) 295)

des-Asp-angiotensin I; Captopril; Indomethacin (Sim, M.K. (278) 175)

Ca^{2+} channel; Pregnancy; Vasoconstriction; Nifedipine; Bay K 8644 (Roy, B. (280) 1)

Aortic valve cusp, porcine
Nitric oxide (NO); Cyclic GMP; Nitric oxide synthase, constitutive; Nitric oxide synthase, inducible; Thrombin (De Meyer, E. (291) 67)

Apamin
Lemakalim; Glibenclamide; ATP-sensitive Ca^{2+} channel; Charybdotoxin; Nitric oxide (NO) (Franck, H. (271) 379)

Bradykinin; Trachea, guinea-pig; Epithelium; Bradykinin B_2 receptor; Relaxation; Ca^{2+}; Ryanodine; HOE 140; NPC 17761 (Schlemper, V. (282) 177)

Proximal duodenum, rat; Nitric oxide (NO); NANC (non-adrenergic, non-cholinergic) nerve; Smooth muscle relaxation; K^+ channel; cGMP (Martins, S.L.R. (284) 265)

AP-3 (2-amino-3-phosphonopropionate)
Metabotropic glutamate receptor; Ischemia (Maginn, M. (282) 259)

L-AP-3 (L-2-amino-3-phosphono-propionate)
NMDA receptor; mGlu receptor; NMDA (*N*-methyl-D-asparate); *t*-ACPD (*trans*-(±)-1-amino-1,3-cyclopentanedicarboxylic acid); Periaqueductal gray matter (Leyva, J. (285) 123)

MCPG ((RS)-α-methyl-4-carboxyphenylglycine); Metabotropic glutamate receptor; Phosphatidyl inositide hydrolysis; *Xenopus* oocyte (Saugstad, J.A. (289) 395)

L-AP-4 (L(+)-2-amino-4-phosphonobutyric acid)
Metabotropic glutamate receptor; Cerebellar granule cell; Neurotrophic (Graham, M.E. (288) 115)

Apneusis
Excitatory amino acid; Respiratory activity; Ventrolateral nucleus of the tractus solitarius; NMDA receptor (Berger, I. (277) 195)

Apomorphine
Desipramine; Development; Nomifensine; Stereotypy; Zimelidine (Hilakivi, I. (271) 223)

5-HT (5-hydroxytryptamine, serotonin); Grooming, excessive; Penile erection; Oxytocin; Prolactin; Corticosterone; 5-HT_{2C} receptor; m-CPP (1-3-chlorophenylpiperazine); Hypothalamic paraventricular nucleus (Bagdy, G. (275) 301)

Desenkephalin-γ-endorphin; Endorphin receptor, γ-type; Nucleus accumbens; Neuroleptic-like action; Antibody; Anti-idiotype antibody; Behavioral effect (Van Ree, J.M. (279) 187)

Sexual satiety; Mating; Dopamine (Mas, M. (280) 331)

Cocaine; Deoxyglucose; Brain metabolism; Nucleus accumbens (Pontieri, F.E. (284) 205)

Apoptosis
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; Thymocyte selection; Arylhydrocarbon receptor; Bcl-2; Thymus organ culture, mouse fetal (Kremer, J. (293) 413)

Appetite
Fenfluramine; Neurotoxicity (McCann, U.D. (283) R5)

2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; Ventromedial hypothalamic nucleus; Body weight; Eating; (Rat) (Tuomisto, J.T. (293) 309)

Arachidonate
Phosphodiesterase inhibitor; Peripheral blood mononuclear cell; cAMP; Forskolin; β_2-adrenoceptor agonist (Hichami, A. (291) 91)

Arachidonic acid
Lipopolysaccharide; Cytochrome *P*-450; Nitric oxide (NO) (Oyekan, A.O. (277) 123)

α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor; Carbachol; Cyclothiazide; Kainate receptor; Striatal neuron (Petitet, F. (291) 143)

Glutamate; Transport; Synaptosome; Ca^{2+} (Lundy, D.F. (291) 273)

Biscoclaurine alkaloid; Phospholipase A_2; Platelet (Akiba, S. (291) 343)

Arachidonic acid metabolism
α_1-Adrenoceptor; Muscarinic acetylcholine receptor; Cardiac action potential; Positive inotropic effect; Protein kinase C (Arreola, J. (271) 309)

Arachidonic acid metabolite
Acetylcholine; Renal artery, rat; Endothelium-dependent contraction (Nishimura, Y. (275) 217)

***R*-(+)-Arachidonyl-1′-hydroxy-2′-propylamide**
Cannabinoid; Phenylmethylsulphonyl fluoride; Anandamide; Vas deferens, mouse; Myenteric plexus preparation, guinea-pig (Pertwee, R.G. (272) 73)

Area postrema
Emesis; Dopamine; α_2-Adrenoceptor; (Cat); (Intracerebroventricular injection) (Jovanović-Mićić, D. (272) 21)

Arginine
Muscarinic receptor; G-protein; Mutation (Jones, P.G. (288) 251)

L-Arginine
Carbachol; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; Diarrhea; Intestinal secretion; Small intestinal transit (Izzo, A.A. (271) 31)

Red nucleus; Analgesia; Nitric oxide (NO); cGMP (Kumar, A. (279) 1)

Nitric oxide (NO); Muscle-derived nitric oxide (NO); Endotoxin; Nitrovasodilator; Tolerance (Tsuchida, S. (281) 251)

Ischemia; Reperfusion; Skeletal muscle; Phosphocreatine disodium salt; Phosphocreatine di-L-arginine salt; Current clamp; Electrophysiology (Tricarico, D. (287) 17)

Arginine vasopressin
Uterine artery; Pregnancy; Vasopressin receptor; (Guinea-pig) (Jovanović, A. (280) 101)

Aromatase inhibitor
CGS16949A; Fadrozole hydrochloride; MCF-7; T47D (Yano, S. (289) 217)

Aromatic L-amino acid decarboxylase
Dizocilpine; Tyrosine hydroxylase; Dopamine; Parkinson's disease (Hadjiconstantinou, M. (289) 97)

Arrhenius kinetics
Paracetamol; Hepatotoxicity; Mitochondrial ATPase; Mitochondrial particle, sonic (Parmar, D.V. (293) 225)

Arrhythmia
Digitalis; Ouabain; Azepexole; B-HT 933 (Thomas, G.P. (276) 215)

Arterial relaxation
Flurbiprofen; Nefopam; Nitric oxide (NO); Platelet aggregation; Antinociception (Pallapies, D. (271) 335)

Arteriosclerosis
ATP release; Noradrenaline; α_1-Adrenoceptor; Calcification; Caudal artery, rat (Shinozuka, K. (292) 115)

Arteriovenous anastomose
α-CGRP (calcitonin gene-related peptide); Dihydroergotamine; Heart; Migraine, pig; Sumatriptan (Van Gelderen, E.M. (284) 51)

Artery, small
Coronary artery, rat; Histamine; Histamine receptor; Nitric oxide (NO) (Van de Voorde, J. (271) 17)

Artery, subcutaneous
Levcromakalim; Glibenclamide; (Human) (Hüsken, B.C.P. (287) 313)

Arylaminopyridazine
GABA (γ-aminobutyric acid) derivative; SR 95103; GABA receptor antagonist; (*Ascaris suum*) (Martin, R.J. (276) 9)

Arylhydrocarbon receptor
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; Thymocyte selection; Apoptosis; Bcl-2; Thymus organ culture, mouse fetal (Kremer, J. (293) 413)

PCB; 2,3,7,8-TCDD; Reporter gene; Biomarker; (Interaction) (Aarts, J.M.M.J.G. (293) 463)

***Ascaris*, muscle**
Pyrantel; Acetylcholine; Ion channel; Anthelmintic; Parasitic nematode (Robertson, S.J. (271) 273)

Ascorbic acid
Drug resistance; Vincristine; Lung cancer (Song, E.-J. (292) 119)

Aspartate
Atipamezole; Dexmedetomidine; Glutamate; GABA (γ-aminobutyric acid); Microdialysis; Hippocampus (Valtonen, P. (285) 239)

Muscarinic receptor; G-protein; Mutation (Page, K.M. (289) 429)

Aspirin
Thromboxane receptor antagonist; Myocardial ischemia; Reperfusion injury (Gomoll, A.W. (271) 471)

Association
Angiotensin receptor; Angiotensin AT_1 receptor antagonist; Kinetics; Dissociation (Hara, M. (289) 267)

Asthma
Smooth muscle, airway; Glucocorticoid; β-Adrenoceptor agonist, cell culture; Cell proliferation (Young, P.G. (273) 137)

Nitric oxide (NO); Cystic fibrosis; Inflammation; Cytokine (Belvisi, M. (283) 255)

TNF-α (tumor necrosis factor-α); Cytokine; Bronchial hyperresponsiveness; Electrical field stimulation; Airway, human (Anticevich, S.Z. (284) 221)

Bronchodilation; Cardiovascular; Central nervous system, dog; Emesis; Phosphodiesterase; Rolipram (Heaslip, R.J. (286) 281)

Trimellitic anhydride; Mucus secretion; Bronchoconstriction; Occupational asthma (Hayes, J.P. (292) 127)

Astrocyte
Endothelin; Big-endothelin; Endothelin-converting enzyme; Brain; Phospholipase A_2 (Deschepper, C.F. (275) 61)

Imidazoline; Imidazoline receptor; GFAP (glial fibrillary acidic protein); [^{3}H]Idazoxan (Alemany, R. (280) 205)

Ataxia
TRH (thyrotropin-releasing hormone); TA-0910 (TRH analog); Oral administration (Kinoshita, K. (274) 65)

Phencyclidine; Nitric oxide (NO) synthase inhibitor; Locomotion; (Mouse) (Noda, Y. (286) 291)

Nucleus basalis magnocellularis; Acetylcholine; Neuroprotection; Memantine; (+)-MK-801; Amantadine; Stereotypy; (Rat) (Wenk, G.L. (293) 267)

Atherogenic diet
Endothelin-1; Atherosclerosis; De-endothelialization; (Tissue distribution) (Kurata, C. (293) 109)

Atherosclerosis
Endothelin-1; De-endothelialization; Atherogenic diet; (Tissue distribution) (Kurata, C. (293) 109)

Atipamezole
Neuropathy; Hyperalgesia; Medetomidine; Mustard oil (Mansikka, H. (281) 43)

Aspartate; Dexmedetomidine; Glutamate; GABA (γ-aminobutyric acid); Microdialysis; Hippocampus (Valtonen, P. (285) 239)

Histamine; Noradrenaline; α_2-Adrenoceptor antagonist; Microdialysis, in vivo; Hypothalamus (Laitinen, K.S.M. (285) 255)

Ethanol; α_2-Adrenoceptor; Dexmedetomidine; Monoamine; Motor performance; (Mouse) (Idänpään-Heikkilä, J.J. (292) 191)

ATP
Smooth muscle; Hypertrophy; Urinary bladder; Caged-ATP (Sjuve, R. (276) 137)

P_2 purinoceptor; Vas deferens, guinea-pig; Periodate-oxidized nucleotide; 2',3'-Dialdehyde ATP analog (Fedan, J.S. (281) 213)

Nitric oxide (NO); Endothelium; Microvasculature; Neurogenic inflammation; Substance P; 5-HT (5-hydroxytryptamine, serotonin) (Ralevic, V. (284) 231)

Mitosis; ATP receptor; Smooth muscle cell (Erlinge, D. (289) 135)

Nitric oxide (NO); Ca^{2+}; Airway epithelium; Bradykinin (Sakai, A. (291) 375)

ATPA ((*RS*)-2-amino-3-(3-hydroxy-5-*tert*-butylisoxazol-4-yl)propionic acid)
AMPA ((*RS*)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid); NMDA (*N*-methyl-D-aspartate); Cue; Convulsion; Glutamate receptor; (Rat); (Mouse) (Arnt, J. (285) 289)

(Ca^{2+},Mg^{2+})-ATPase
Lazaroid; Lipid peroxidation; Iron; Antioxidant; Erythrocyte (Zaidi, A. (290) 133)

ATPase, vascular type
Lidocaine; Spectrin; Carbonic anhydrase; Erythrocyte membrane, human (Nishiguchi, E. (286) 1)

ATP receptor
ATP; Mitosis; Smooth muscle cell (Erlinge, D. (289) 135)

ATP release
Noradrenaline; α_1-Adrenoceptor; Calcification; Arteriosclerosis; Caudal artery, rat (Shinozuka, K. (292) 115)

ATP release, neuronal
Forskolin; Ouabain; Atrium, guinea-pig; W-7; Vinblastine; Okadaic acid (Katsuragi, T. (282) 213)

ATP-sensitive Ca^{2+} channel
Lemakalim; Glibenclamide; Apamin; Charybdotoxin; Nitric oxide (NO) (Franck, H. (271) 379)

ATP-sensitive K^+ channel
Diadenosine hexaphosphate; Heart (Jovanović, A. (286) R1)

Atrioventricular node
Free radical; *t*-Butyl hydroperoxide; Sinoatrial node; Reperfusion arrhythmia; Lipid peroxidation (Satoh, N. (272) 233)

Atrium
Adenosine receptor; FK453; Aorta; Binding assay (Terai, T. (279) 217)

Atrium AF-DX 116, human
Acetylcholine; HHSiD (*p*-fluorohexahydro-siladifenidol hydrochloride); McN-A-343; Muscarinic receptor; Myocardial contractility; Pirenzepine; Ventricle (Du, X.Y. (284) 119)

Atrium, guinea pig
Bradykinin; Bradykinin B_2 receptor; Sinus rate (Tesfamariam, B. (281) 17)

ATP release, neuronal; Forskolin; Ouabain; W-7; Vinblastine; Okadaic acid (Katsuragi, T. (282) 213)

Atrium, rat
Contraction, force of; Aortic ring; Relaxation; cGMP-dependent protein kinase; Acetylcholine (Bäumner, D. (273) 295)

Thrombin; Inositol phosphate; Phospholipase C inhibitor; Pertussis toxin; Noradrenaline (Woodcock, E.A. (291) 213)

Atropine
Yawning; Physostigmine; Adenosine receptor agonist; Adenosine receptor antagonist; (Rat) (Zarrindast, M.-R. (276) 3)

α-Adrenoceptor; Aorta; Cerebral cortex; (Rat) (Chang, K.C. (284) 331)

AtT20 cell
Substance P receptor; Tachykinin NK_1 receptor; Gene expression; Polymerase chain reaction; Pituitary (Winkler, A. (291) 51)

Audiogenic seizure
Anticonvulsant; Anxiolytic; Separation-induced vocalization; Glycine receptor, strychnine-insensitive; NMDA receptor; (DBA/2J mouse); (Rat pup) (Kehne, J.H. (284) 109)

Automation
DNA-binding drug; Human immunodeficiency virus type 1 (HIV-1); DNase I footprinting (Feriotto, G. (290) 85)

Autonomic nerve
Diterpenoid alkaloid; Blood pressure; Heart rate (Chiao, H. (283) 103)

Autoradiography
Somatostatin; Receptor; sstr1 receptor; Cerebellar nuclei (Bucharles, C. (271) 79)

Chronic CGP 39551; NMDA receptor; [^{3}H]Noradrenaline release; Quinolinic acid neurotoxicity; Hippocampus (Mennini, T. (271) 93)

5-HT_2 receptor; α-Adrenoceptor; Prostate, rat; Smooth muscle (Killam, A.L. (273) 7)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); [^{3}H]Mazindol binding; Basal ganglion; Motor recovery; (Marmoset) (Gnanalingham, K.K. (277) 235)

[^{3}H]Sumatriptan; Trigeminal nucleus caudalis; Nucleus tractus solitarius; (Cat) (Mills, A. (280) 175)

Alcoholization; 5-HT (5-hydroxytryptamine, serotonin); Receptor; mRNA; Binding; (Rat) (Nevo, I. (281) 229)

Imidazoline receptor; α_{2A}-Adrenoceptor; α_{2B}-Adrenoceptor; Kidney, rat; [^{3}H]Rilmenidine; [^{3}H]Idazoxan (King, P.R. (281) 341)

Skin, human; Bradykinin receptor (Schremmer-Danninger, E. (283) 207)

Autoradiography, quantitative
5-HT_{1A} receptor; G-protein; 5-HT_{1A} receptor antagonist; [^{3}H]8-OH-DPAT ([^{3}H]8-hydroxy-2-(di-*n*-propylamino)tetralin); [^{3}H]WAY 100635 (Gozlan, H. (288) 173)

Autoreceptor
Dopamine D_2 receptor; Dopamine D_3 receptor; Substantia nigra pars compacta; Single unit recording; 7-OH-DPAT ((±)-7-hydroxy-dipropylaminotetralin) (Kreiss, D.S. (277) 209)

Presynaptic action; Glutamate; Grease-gap; Hippocampus; (D.C. potential) (Shew, T.R. (284) 93)

Autoregulation
Kidney; Ca^{2+} channel antagonist (Huang, C. (282) 1)

Aversive behavior
Calcitonin; NMDA (*N*-methyl-D-aspartate); β-Adrenoceptor; 5-HT receptor; GABA receptor (Maeda, Y. (275) 163)

Azelastine
Macrophage; Thromboxane; Airway hyperresponsiveness (Tamaoki, J. (278) 161)

Azepexole
Arrhythmia; Digitalis; Ouabain; B-HT 933 (Thomas, G.P. (276) 215)

AZT (3'-azido-2',3'-dideoxythymidine)
Pentamidine; Nitric oxide (NO); Neuronal NO synthase; Calmodulin antagonist (Kitamura, Y. (289) 299)

Ba^{2+}
Ca^{2+}; Sr^{2+}; Nitric oxide (NO); Coronary artery, porcine; Diltiazem (Ohashi, K. (285) 165)

Exocytosis; Ca^{2+}-dependent release; Calmodulin; Okadaic acid; Phosphatase (Verhage, M. (291) 387)

Baclofen
$GABA_B$ receptor; Food intake; Water intake; Palatable liquid diet (Ebenezer, I.S. (273) 183)

$GABA_B$ receptor; Neocortical slice, rat; *N*-Ethylmaleimide; Aluminum fluoride; G-protein (Ong, J. (287) 197)

(*RS*)-(±)-Baclofen
$GABA_B$ receptor; (*S*)-2-Hydroxysaclofen; (*R*)-2-Hydroxysaclofen; Ileum, guinea pig; Hippocampus, rat; Neocortex, rat (Kerr, D.I.B. (287) 185)

Bacterial lipopolysaccharide
Nitric oxide synthase, inducible; N^G-Hydroxy-L-arginine (Hecker, M. (275) R1)

Baculovirus
Nitric oxide(NO); Nitric oxide synthase; Cloning; Expression; Endotoxic shock (Moss, D.W. (289) 41)

BAPTA-AM (acetoxymethyl bis(*O*-aminophenoxy)ethane-*N*,*N*,*N'*,*N'*-tetraacetate)
Blood platelet; 5-HT (Serotonin) uptake; Ca^{2+} chelation; EGTA (Ethyleneglycoltetraacetic acid); Ca^{2+} storage pool (Nishio, H. (288) 149)

Barbiturate
1-Amino-5-bromouracil; Anesthetic activity; Anticonvulsive activity; Benzodiazepine-$GABA_A$ receptor complex (Miyazaki, S. (271) 179)

Baroreflex sensitivity
5-Carboxamidotryptamine; DOCA-salt (deoxycorticosterone acetate-salt) hypertensive rat; Blood pressure; (Chronic i.v. infusion) (Balasubramaniam, G. (276) 183)

Basal ganglion
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); [^{3}H]Mazindol binding; Autoradiography; Motor recovery; (Marmoset) (Gnanalingham, K.K. (277) 235)

Cannabinoid; Substantia nigra; Cannabinoid receptor; Motor system; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole (Miller, A.S. (279) 179)

Adenosine A_2 receptor; Metabotropic glutamate receptor; Striatum; Subthalamic nucleus (Feeley Kearney, J.A. (287) 115)

Basic fibroblast growth factor
Angiotensin II; Angiotensin AT_1 receptor antagonist; Platelet-derived growth factor; DNA synthesis (Itazaki, K. (291) 417)

Basilar artery
Neuropeptide Y; U46619 (9,11-dideoxy-11α,9α-epoxymethano prostaglandin $F_{2\alpha}$); Ca^{2+} concentration; Cytosolic; Ca^{2+} influx; Ca^{2+} sensitivity (Tanaka, Y. (289) 59)

Bay K 8644
Ca^{2+} channel; Pregnancy; Vasoconstriction; Aortic ring; Nifedipine (Roy, B. (280) 1)

Vas deferens, rat; α_2-Adrenoceptor; Xylazine; 4-Aminopyridine; Tetraethylammonium; Charybdotoxin; Phorbol dibutyrate (Docherty, J.R. (287) 287)

Bcl-2
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; Thymocyte selection; Arylhydrocarbon receptor; Apoptosis; Thymus organ culture, mouse fetal (Kremer, J. (293) 413)

BDNF (brain-derived neurotrophic factor)
Ethanol tolerance; Neurotrophin-3; Neurotrophin-4/5 (Szabó, G. (287) 35)

Behavior
Chronic chlordiazepoxide; EEG (electroencephalographic); Tolerance; Dependence; (Rat) (Sala, M. (273) 35)

Neurotoxicity; DDT (1,1,1-trichloro-2,2-bis(*p*-chlorophenyl)-ethane); Pyrethroid; Interaction; Acetylcholine receptor (Johansson, U. (293) 159)

Behavioral effect
Desenkephalin-γ-endorphin; Endorphin receptor, γ-type; Apomorphine; Nucleus accumbens; Neuroleptic-like action; Antibody; Anti-idiotype antibody (Van Ree, J.M. (279) 187)

Behavioral pharmacology
Schedule-controlled behavior; Receptor binding; Phencyclidine; Drug dependence; Drug tolerance; Sex difference; (Rat) (Wessinger, W.D. (277) 107)

Behavioral sensitization
Dopamine D_1 receptor; Dopamine D_2 receptor; Nucleus accumbens; Ventral tegmental area; Drug addiction (Jeziorski, M. (275) 235)

Methamphetamine; Scopolamine; Cholinergic system; Drug conditioning; Low-frequency tone (Yui, K. (279) 135)

Behavioral syndrome
$5\text{-}HT_{1A}$ receptor; Corticosterone; Glucose; 5-HT (5-hydroxytryptamine, serotonin); (S)-UH301; Flesinoxan (Groenink, L. (272) 177)

Benfluorex metabolite
Diabetes mellitus; Non insulin-dependent; Membrane fluidity; Hepatocyte, isolated; (Rat) (Orsière, T.G. (291) 237)

Benign prostatic hypertrophy
α_1-Adrenoceptor subtype; COS-7 cells; Radioligand binding study (Foglar, R. (288) 201)

Benzalkonium chloride
Mast cell, cutaneous; Neuropeptide Y; Mastoparan; G-protein; Pertussis toxin; Neuraminidase (Emadi-Khiav, B. (272) 97)

Mast cell; Neuropeptide Y; Circular dichroism spectrum; Heterotrimeric G protein; Pertussis toxin; (Rat); (Human) (Mousli, M. (289) 125)

Benzodiazepine
GABA receptor antagonist; Antinociception, i.c.v., i.t.; Nociceptive test; Opioid (Luger, T.J. (271) 421)

Cell proliferation; Lung; (Chinese hamster) (Camins, A. (272) 289)

Antinociception; Nociceptive test; Opioid; (Intracerebroventricular); (Intrathecal) (Luger, T.J. (275) 153)

$GABA_A$ receptor, diazepam-insensitive; Drug discrimination; Bretazenil; Flumazenil; Ro 19-0528; GABA (γ-aminobutyric acid); (Receptor partial agonist); (Pigeon) (Acri, J.B. (278) 213)

Receptor binding; Spinal cord; Alpidem-insensitive site (Maguire, P.A. (280) 167)

Ro 15-4513; $GABA_A$ receptor; Diazepam-insensitive; Cerebellum; Alcohol sensitivity; Imidazoquinoxaline; Imidazoquinazoline; Cyclopyrrolone (Wong, G. (289) 335)

$GABA_A$ receptor, α4 subunit; Diazepam-insensitive (Yang, W. (291) 319)

Benzodiazepine binding
Methylation inhibitor; *S*-Adenosylhomocysteine; 5′-Methylthioadenosine; (Rat) (Tsvetnitsky, V. (282) 255)

Benzodiazepine-$GABA_A$ receptor complex
1-Amino-5-bromouracil; Anesthetic activity; Anticonvulsive activity; Barbiturate (Miyazaki, S. (271) 179)

Benzodiazepine receptor
Iomazenil; Flumazenil; Steady state; K_d; Partition coefficient (Videbæk, C. (281) 117)

$GABA_A$ receptor; Antisense oligonucleotide; Receptor subunit; Brain, rat (Karle, J. (291) 439)

Triethyllead; $GABA_A$ receptor; Flunitrazepam; Muscimol; (Rat); (Brain) (Komulainen, H. (293) 167)

Benzodiazepine receptor, central
Benzodiazepine receptor, peripheral; PK 11195; Ro 15-1788; Lead poisoning; Liver (Fonia, O. (293) 335)

Benzodiazepine receptor, peripheral
Olfactory bulbectomy; Thymus; Spleen; Adrenal; Antidepressant (Dennis, T. (272) 279)

Steroidogenesis; Brain, rat; Mitochondrion (McCauley, L.D. (276) 145)

Benzodiazepine receptor, central; PK 11195; Ro 15-1788; Lead poisoning; Liver (Fonia, O. (293) 335)

Benzodiazepine site
Pentylenetetrazol; γ-Butyrolactone bicyclic; $GABA_A$ receptor-ionophore complex; Convulsant (picrotoxin) site; [^{35}S]TBPS binding (Maksay, G. (288) 61)

$GABA_A$ receptor, γ3 subunit (Hadingham, K.L. (291) 301)

Benzodiazepine BZ_1 site
$GABA_A$ receptor; Benzodiazepine BZ_2 site; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate) binding; Ontogenesis; Flunitrazepam; CL 218,872; Zolpidem; Cerebral cortex, rat (Giorgi, O. (290) 37)

Benzodiazepine BZ_2 site
$GABA_A$ receptor; Benzodiazepine BZ_1 site; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate) binding; Ontogenesis; Flunitrazepam; CL 218,872; Zolpidem; Cerebral cortex, rat (Giorgi, O. (290) 37)

Benzodiazepine type I receptor
[^{3}H]Zolpidem; Tolerance; Receptor down-regulation; Midazolam; Flurazepam (Wu, Y. (278) 125)

Benzoic acid
Endocrine pancreas; Insulin; Glucagon; Ruminant; (Sheep) (Mineo, H. (280) 149)

Benzomorphan
NMDA receptor; NMDA (*N*-methyl-D-aspartate); Excitotoxicity (Sawyer, D.C. (284) 309)

Benzylic alcohol
Activation; Mutagenicity; Sulfotransferase; (*Salmonella typhimurium*) (Glatt, H. (293) 173)

7-Benzylidenenaltrexone
TAN-67; Antinociception; δ-Opioid receptor; Naltriben diabetes (Kamei, J. (276) 131)

TAN-67; Antinociception; δ-Opioid receptor; Naltriben diabetes (Kamei, J. (280) 347)

Bethanechol
Pancreatic hypertrophy; Pentagastrin; Muscarinic receptor; CCK receptor; CR1505 (Kato, M. (292) 47)

Bezold-Jarisch reflex
Ethanol; 5-HT_3 receptor; Capsaicin (Malinowska, B. (293) 71)

BIBP3226
Neuropeptide Y; Neuropeptide Y Y_1 receptor antagonist (Rudolf, K. (271) R11)

Neuropeptide Y; SK-N-MC cell; Radioligand binding (Entzeroth, M. (278) 239)

Bicarbonate secretion
α-Adrenoceptor agonist; α-Adrenoceptor antagonist; β-Adrenoceptor agonist; β-Adrenoceptor antagonist (Canfield, P. (273) 1)

Bicuculline
ucb L059; Hippocampal CA3, rat; Input-output curve; Paired-pulse inhibition (Margineanu, D.G. (286) 321)

Patch clamp; GABA receptor; Cl^- channel; Retina; Bipolar cell; Rod pathway (Feigenspan, A. (288) 97)

Big-endothelin
Endothelin; Endothelin-converting enzyme; Brain; Astrocyte; Phospholipase A_2 (Deschepper, C.F. (275) 61)

Binding
Vapreotide; Somatostatin analog; Substance P; Tachykinin NK_1 receptor; Tachykinin NK_2 receptor; Airway (Bétoin, F. (279) 241)

Alcoholization; 5-HT (5-hydroxytryptamine, serotonin); Receptor; mRNA; Autoradiography; (Rat) (Nevo, I. (281) 229)

Binding affinity
Muscarinic receptors; Stereoselectivity; CHO (Chinese hamster ovary) cells; Pirenzepine (Barbier, P. (290) 125)

Binding assay
Adenosine receptor; FK453; Atrium; Aorta (Terai, T. (279) 217)

Binding characteristic
Dihydroetorphine; Morphine; Opioid receptor, cloned; cAMP (Katsumata, S. (291) 367)

Binding site
Glibenclamide (Glyburide); Hypoglycemic agent; Liver; Sulfonylurea compound (Inoue, Y. (284) 77)

Ca^{2+} current, L-type; Verapamil; Ventricular myocyte, rat; Patch-clamp technique (Wegener, J.W. (287) 89)

Melatonin; Chiral analog; Melanophore, *Xenopus laevis* (Sugden, D. (287) 239)

σ Binding site, heterogeneity
Radioreceptor assay; DTG (1,3-di(2-tolyl)guanidine); (+)-Pentazocine; Brain; Spinal cord; (Mouse) (Kovács, K.J. (285) 127)

σ Binding site, subtype
[^{3}H]DTG ([^{3}H]1,3-di(2-tolyl)guanidine); [^{3}H](+)-Pentazocine (Hudkins, R.L. (271) 235)

Binding, specific
Imidazoline; Clonidine; Idazoxan; Brain, human (Greney, H. (271) 533)

Bioavailability
Renin inhibitor; Spontaneously hypertensive rat (SHR); Renin, recombinant human; Pressor response; Oral absorption (Shibasaki, M. (271) 341)

Biomarker
Aryl hydrocarbon receptor; PCB; 2,3,7,8-TCDD; Reporter gene; (Interaction) (Aarts, J.M.M.J.G. (293) 463)

Biotransformation
Cytochrome P450-3A4, human; NIH/3T3 cell; lacZ′ shuttle vector; Mutagenicity (De Groene, E.M. (293) 47)

Hexafluorobenzene; Hexachlorobenzene; Porphyria; Mercapturic acid; Phenolic metabolite (Rietjens, I.M.C.M. (293) 293)

Bipolar cell
Patch clamp; GABA receptor; Cl^- channel; Bicuculline; Retina; Rod pathway (Feigenspan, A. (288) 97)

Biscoclaurine alkaloid
Phospholipase A_2; Arachidonic acid; Platelet (Akiba, S. (291) 343)

Bis-indol
Vinca alkaloid; Navelbine; Vinblastine; Vincristine; Calmodulin antagonism; Tubulin; Anti-mitotic drug (Molnár, A. (291) 73)

Bis(tri-*n*-butyltin)oxide
Cytomegalovirus; Immunotoxicity testing; Ultraviolet light (Garssen, J. (292) 223)

BK_{Ca} channel
NS 1619; Niflumic acid; Motor cortex (Lee, K. (280) 215)

Bladder reflex
GYKI 52466; MK-801; Cystometrogram; Urethral sphincter, external (Yoshiyama, M. (287) 73)

Bleeding time
Humanized antibody; GPIIb/IIIa; Thrombosis, photochemically induced; Microcirculation; (Squirrel monkey) (Kaku, S. (279) 115)

Bleomycin
Experimental hypoxemia; Prednisolone; Doxapram; Almitrine; TEI-7322 (Horiuchi, H. (287) 27)

Blood
Metabolite; Methylation; Urine; Water; Food (Vahter, M. (293) 455)

Blood-cerebrospinal fluid barrier
Nitric oxide (NO); Meningitis; Aminoguanidine (Boje, K.M.K. (272) 297)

Blood flow
Afferent nerve; 5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindole acetic acid); Dopamine; Gingiva; Dental pulp; Sympathetic nerve; (Rat) (Kerezoudis, N.P. (275) 191)

Blood flow, regional
PAF (platelet activating factor); Hemodynamics; PAF receptor antagonist; Microsphere (King, K.A. (281) 187)

Blood flow regulation
Pancreatic islet; Pancreas transplantation; Nitric oxide (NO) synthase; Nitric oxide (NO) (Svensson, A.M. (275) 99)

Blood flow, vertebral artery
PACAP (pituitary adenylate cyclase-activating polypeptide); Cerebral artery, canine; VIP (vasoactive intestinal peptide); Vasodilation (Seki, Y. (275) 259)

Blood platelet
5-HT (Serotonin) uptake; Ca^{2+} chelation; EGTA (Ethyleneglycol-tetraacetic acid); BAPTA-AM (acetoxymethyl bis(*O*-aminophenoxy)ethane-*N*,*N*,*N*′,*N*′-tetraacetate); Ca^{2+} storage pool (Nishio, H. (288) 149)

Blood pressure
Neuropeptide Y; Neuropeptide Y Y_1 receptor antagonist; Ca^{2+}, intracellular; Spontaneously hypertensive rat (SHR) (Tseng, A. (271) 265)

Nitric oxide (NO); Aminoguanidine; Nitric oxide (NO) synthase; Microcirculation; Endotoxin (Laszlo, F. (272) 169)

5-HT (5-hydroxytryptamine, serotonin); ACTH (adrenocorticotropin); Corticosterone; Prolactin; Renin; Heart rate (Levy, A.D. (274) 141)

5-Carboxamidotryptamine; DOCA-salt (deoxycorticosterone acetate-salt) hypertensive rat; Baroreflex sensitivity; (Chronic i.v. infusion) (Balasubramaniam, G. (276) 183)

α_1-Adrenoceptor; Dopaminergic neurotransmission; Microdialysis; Prazosin (Sommermeyer, H. (276) 267)

Ca^{2+}-calmodulin; Dopamine; Epilepsy; (El mouse) (Sutoo, D. (278) 33)

α-Adrenoceptor; Central nervous system; RG20 gene; (Rat) (Nunes, J.P. (278) 183)

Cannabinoid; Anandamide; CB_1 cannabinoid receptor antagonist (Varga, K. (278) 279)

Ventrolateral medulla; Glutamate receptor; L-Glutamate uptake inhibitor; Respiratory function; Excitatory amino acid receptor antagonist; Heart rate (McManigle, J.E. (280) 257)

Sumatriptan; Plasma protein extravasation; Trigeminal ganglion stimulation; Dura mater; Carotid vascular resistance (Spokes, R.A. (281) 75)

Spontaneously hypertensive rat (SHR); Glucose tolerance; Angiotensin converting enzyme inhibitor; Angiotensin AT_1 receptor antagonist (Chow, L. (282) 77)

Diterpenoid alkaloid; Autonomic nerve; Heart rate (Chiao, H. (283) 103)

UP 269-6; Losartan; Angiotensin II; Angiotensin II receptor antagonist; Heart rate (Cazes, M. (284) 157)

Nitric oxide, NO; Amidine; Butyramidine; Shock; Inflammation; Endothelium; Endotoxin; Isothiourea (Southan, G.J. (291) 311)

Blood pressure control
Sinoaortic denervation; Neostigmine; 6-Hydroxydopamine; Prazosin; Yohimbine (Taira, C.A. (271) 9)

Blood vessel
Hyperemia; Vascular control; K^+ channel (Kosmas, E.N. (274) 193)

Adrenoceptor subtype; Denopamine (Fujimoto, S. (280) 143)

B lymphocyte
TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Dioxin; Concanavalin A; Immunotoxicity; Interleukin; Thymus; Spleen; T lymphocyte; Macrophage; (Rat) (Badesha, J.S. (293) 429)

Body weight
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; Ventromedial hypothalamic nucleus; Appetite; Eating; (Rat) (Tuomisto, J.T. (293) 309)

Endosulfan; Liver weight; Spontaneous motor activity; Rota-rod endurance time; Liver injury; Learning; Memory (Paul, V. (293) 355)

Bombesin
Suprachiasmatic nucleus; Entrainment; Gastrin-releasing peptide; Neuromedin B; Ionophoresis; Neurophysiology; (Hamster) (Piggins, H.D. (271) 413)

Neuromedin B; Gastrin-releasing peptide (Ladenheim, E.E. (271) R7)

GRP (gastrin-releasing peptide); Bombesin binding site; Lung, human; GRP-preferring bombesin receptor (Lach, E. (273) 313)

Bombesin receptor subtype; Bombesin receptor antagonist; Gastric emptying (Varga, G. (286) 109)

Bombesin binding site
Bombesin; GRP (gastrin-releasing peptide); Lung, human; GRP-preferring bombesin receptor (Lach, E. (273) 313)

Bombesin receptor antagonist
Bombesin; Bombesin receptor subtype; Gastric emptying (Varga, G. (286) 109)

Bombesin receptor subtype
Bombesin; Bombesin receptor antagonist; Gastric emptying (Varga, G. (286) 109)

Bosentan
Endothelin; Endothelin receptor antagonist; Carbon tetrachloride; Hepatotoxicity; Acute liver dysfunction (Hocher, B. (293) 361)

Botulinum C_3-sensitive GTP-binding protein
α_1-Adrenoceptor subtype; Thoracic aorta; Ca^{2+}-sensitization; Myosin light chain phosphorylation (Kokubu, N. (290) 19)

BQ-123
Endothelin; Sarafotoxin; Vas deferens; IRL 1620; BQ-788; Endothelin-converting enzyme; Phosphoramidon; Neurotransmission; (Mouse) (Maas, J. (276) 113)

Endothelin; Nitric oxide (NO); Cerebral vasospasm; Subarachnoid hemorrhage (Hirose, H. (277) 77)

Endothelin; Nitric oxide (NO); Cerebral vasospasm; Subarachnoid hemorrhage (Hirose, H. (284) 335)

Endothelin receptor; Cotransmission; Vas deferens; Endothelin-3; Sarafotoxin S6c; (Guinea-pig) (Mutafova-Yambolieva, V.N. (285) 213)

Endothelin; IRL1620; Endothelin receptor subtype; PD145065; Tachyphylaxis (Miasiro, N. (285) 247)

Endothelin; Sarafotoxin; Endothelin ET_A receptor; Saphenous vein, rabbit (Nishiyama, M. (286) 209)

[^{3}H]BQ-123
Endothelin; Endothelin ET_A receptor (Ihara, M. (274) 1)

BQ-788
Endothelin; Sarafotoxin; Vas deferens; BQ-123; IRL 1620; Endothelin-converting enzyme; Phosphoramidon; Neurotransmission; (Mouse) (Maas, J. (276) 113)

Bradycardic activity
α_2-Adrenoceptor; Hypotensive activity; Imidazole derivative; Imidazoline derivative; Lipophilicity; Mydriatic activity (Nasal, A. (274) 125)

Bradycardic drug
K^+ channel, cloned; $K_{V1.2}$; $K_{V1.4}$; Antiarrhythmic drug (Yamagishi, T. (281) 151)

Bradykinesia
Riluzole; Neuroprotection; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Rigidity; Dopamine release; Parkinson's disease; (Rhesus monkey) (Benazzouz, A. (284) 299)

Bradykinin
Hypotension; Bradykinin B_1 receptor antagonist; Des-Arg^9-bradykinin; Endotoxin (Tokumasu, T. (274) 225)

Capsaicin; Thromboxane A_2; Smooth muscle, airway (Molimard, M. (278) 49)

Furosemide; Thromboxane A_2 receptor; Smooth muscle; Airway (Molimard, M. (278) 253)

Bradykinin analog; Bradykinin receptor antagonist; HOE 140; Mononuclear cell; Cytokine; Interleukine (Paegelow, I. (279) 211)

Thromboxane; Airflow obstruction; WEB2086; ICI192,605; OKY-046 (Kawikova, I. (280) 293)

Bradykinin B_2 receptor; Sinus rate; Atrium, guinea pig (Tesfamariam, B. (281) 17)

Uterus, rat; Vas deferens, rat; Trachea, guinea pig; Ileum, guinea pig; Urinary bladder, guinea pig; Ca^{2+}; G protein; Protein kinase C (Calixto, J.B. (281) 279)

Trachea, guinea-pig; Epithelium; Bradykinin B_2 receptor; Relaxation; Ca^{2+}; Ryanodine; Apamin; HOE 140; NPC 17761 (Schlemper, V. (282) 177)

Angiotensin II; Vasopressin; Pulmonary artery; Pulmonary vein; Nitric oxide (NO); Prostaglandin I_2 (Sai, Y. (282) 235)

Endotoxin; Vascular permeability; Kininogen-deficient rat; PAF (platelet-activating factor); PAF receptor antagonist (Ueno, A. (284) 211)

TNF-α (tumor necrosis factor-α); Capsaicin; Cutaneous hyperemia; Afferent nerve stimulation; CGRP (calcitonin gene-related peptide) (Herbert, M.K. (286) 273)

Loop of Henle; Ion transport; Ca^{2+} (Grider, J. (287) 101)

Adenylate cyclase (inhibition); Ileum; Guinea pig; G protein activation; Bradykinin receptor; (High-affinity binding site) (Liebmann, C. (288) 35)

WIN 64338; HOE 140 (Wirth, K.J. (288) R1)

Endothelial cell; Fura-2; Nitric oxide (NO); Anesthetic, volatile; Sevoflurane; A23187; D-Arg-[Hyp^3, Thi^{5,8}, D-Phe^7] bradykinin; Des-Arg^9-[Leu^8] bradykinin; Ca^{2+} channel (Az-ma, T. (289) 33)

Nitric oxide (NO); Ca^{2+}; Airway epithelium; ATP (Sakai, A. (291) 375)

D-Arg-[Hyp^3,Thi^{5,8},D-Phe^7]Bradykinin
Endothelial cell; Bradykinin; Fura-2; Nitric oxide (NO); Anesthetic, volatile; Sevoflurane; A23187; Des-Arg^9-[Leu^8] bradykinin; Ca^{2+} channel (Az-ma, T. (289) 33)

des-Arg^9-Bradykinin
Hypotension; Bradykinin B_1 receptor antagonist; Bradykinin; Endotoxin (Tokumasu, T. (274) 225)

des-Arg^9-[Leu^8]Bradykinin
Endothelial cell; Bradykinin; Fura-2; Nitric oxide (NO); Anesthetic, volatile; Sevoflurane; A23187; D-Arg-[Hyp^3, Thi^{5,8}, D-Phe^7] bradykinin; Ca^{2+} channel (Az-ma, T. (289) 33)

[Thi^{5,8},D-Phe^7]Bradykinin
Acetylshikonin; Hind-paw edema; Cutaneous anaphylaxis, passive; Neurogenic inflammation; Vascular permeability; Compound 48/80; [D-Pro^2,D-Trp^{7,9}]Substance P (Wang, J.-P. (272) 87)

Bradykinin analog
Bradykinin; Bradykinin receptor antagonist; HOE 140; Mononuclear cell; Cytokine; Interleukine (Paegelow, I. (279) 211)

Bradykinin receptor
Autoradiography; Skin, human (Schremmer-Danninger, E. (283) 207)

Bradykinin; Adenylate cyclase (inhibition); Ileum; Guinea pig; G protein activation; (High-affinity binding site) (Liebmann, C. (288) 35)

Ileum, guinea pig; Adenylate cyclase; Inhibitory B_2 receptor; Antagonist profile (unique) (Liebmann, C. (289) 403)

Macrophage; Phospholipase C; Ca^{2+}, intracellular (Böckmann, S. (291) 159)

Bradykinin B_1 receptor
Cycloheximide; Brefeldin A; Tunicamycin; Receptor upregulation; Aorta, isolated, rabbit (Audet, R. (271) 551)

Bradykinin B_2 receptor
Bradykinin; Sinus rate; Atrium, guinea pig (Tesfamariam, B. (281) 17)

Bradykinin; Trachea, guinea-pig; Epithelium; Relaxation; Ca^{2+}; Ryanodine; Apamin; HOE 140; NPC 17761 (Schlemper, V. (282) 177)

Bradykinin receptor antagonist
Bradykinin; Bradykinin analog; HOE 140; Mononuclear cell; Cytokine; Interleukine (Paegelow, I. (279) 211)

Bradykinin B_1 receptor antagonist
Hypotension; Bradykinin; Des-Arg^9-bradykinin; Endotoxin (Tokumasu, T. (274) 225)

Brain
Endothelin; Big-endothelin; Endothelin-converting enzyme; Astrocyte; Phospholipase A_2 (Deschepper, C.F. (275) 61)

Opioid; Growth; Development; Liver; (Intracerebroventricular) (Bartolome, J.V. (284) 43)

Morphine; Nitric oxide (NO); Nitric oxide (NO) synthase (Leza, J.-C. (285) 95)

σ Binding site, heterogeneity; Radioreceptor assay; DTG (1,3-di(2-tolyl)guanidine); (+)-Pentazocine; Spinal cord; (Mouse) (Kovács, K.J. (285) 127)

Streptozotocin; Acetyl-L-carnitine; Alzheimer's disease; Oxidative stress (Terwel, D. (287) 65)

Na^+,K^+-ATPase; α Isoforms of Na^+,K^+-ATPase; DOCA-salt hypertension; Heart; Skeletal muscle (Sahin-Erdemli, I. (292) 163)

p-Chloroamphetamine; Dextromethorphan; Neurotoxicity; σ Receptor; 5-HT (5-hydroxytryptamine, serotonin) (Narita, N. (293) 277)

Nitric oxide (NO) synthase; N^{ω}-Nitro-L-arginine methyl ester metabolism; Methanol; Mitochondrial toxin (Brouillet, E. (293) 487)

Brain, chicken
G-protein-coupled receptor; Recombinant P_{2Y1} purinoceptor; *Xenopus* oocyte expression; COS-7 cell, transient expression; Inositol 1,4,5-trisphosphate, formation (Simon, J. (291) 281)

Brain cortex, rat
Chronic variate stress; Foot-shock stress, acute; β-Adrenoceptor; 5-HT_{1A} receptor; 5-HT_2 receptor; Amitriptyline; Open-field (Ferretti, C. (280) 19)

Brain edema
Carrageenan; Calcium; Kallikrein-kinin; Neurotropin; Particle-induced X-ray emission (Sprumont, P. (274) 95)

Brain, human
Imidazoline; Clonidine; Idazoxan; Binding, specific (Greney, H. (271) 533)

Brain imaging
Nicotinic acetylcholine receptor; Alzheimer's disease (London, E.D. (278) R1)

Brain metabolism
Cocaine; Apomorphine; Deoxyglucose; Nucleus accumbens (Pontieri, F.E. (284) 205)

Brain microdialysis
Dopamine uptake inhibitor; [^{3}H]GBR12935 binding; Dopamine; Stereotypy (Nakachi, N. (281) 195)

Brain, mouse
5-HT_{1A} receptor; In vivo labeling; [^{3}H]WAY 100635 (Laporte, A.-M. (271) 505)

Brain, rat
WAY-100635; 5-HT_{1A} receptor; Radioligand, in vivo; PET (positron emission tomography) (Hume, S.P. (271) 515)

σ Receptor; Ifenprodil; Eliprodil; Subtype; Receptor binding (Hashimoto, K. (273) 307)

Steroidogenesis; Benzodiazepine receptor, peripheral; Mitochondrion (McCauley, L.D. (276) 145)

DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); α_2-Adrenoceptor, postsynaptic; [^{3}H]RX 821002 binding; Clonidine-induced mydriasis; α_{2D}-Adrenoceptor (Heal, D.J. (277) 215)

δ-Opioid receptor; TIPP (H-Tyr-Tic-Phe-Phe-OH); [Tyr(3′-I)^1]TIPP; N4TG1 cell; Vas deferens, mouse (Lee, P.H.K. (280) 211)

Thiomuscimol; Photoaffinity labeling; $GABA_A$ receptor (Nielsen, M. (289) 109)

$GABA_A$ receptor; Antisense oligonucleotide; Receptor subunit; Benzodiazepine receptor (Karle, J. (291) 439)

Brain region
Vasopressin; Fos protein; Immunoreactivity; (Rat) (Wu, P.H. (281) 263)

Brain slice
Chloroethylclonidine; Estrogen; 5-Methyl urapidil; WB-4101 (Kow, L.-M. (282) 199)

Dexmedetomidine; Locus ceruleus; Intracellular recording; α_{2A}-Adrenoceptor (Chiu, T.-H. (285) 261)

Brattleboro rat
Desamino-8D-arginine vasopressin; Vasopressin; Angiotensin; Noradrenaline; Hemorrhage (Laycock, J.F. (271) 193)

Brefeldin A
Bradykinin B_1 receptor; Cycloheximide; Tunicamycin; Receptor upregulation; Aorta, isolated, rabbit (Audet, R. (271) 551)

Bretazenil
Benzodiazepine; $GABA_A$ receptor, diazepam-insensitive; Drug discrimination; Flumazenil; Ro 19-0528; GABA (γ-aminobutyric acid); (Receptor partial agonist); (Pigeon) (Acri, J.B. (278) 213)

Bromocriptine
Dopamine; D_1 receptor; Protein kinase C; Fenoldopam (Kansra, V. (289) 391)

Bronchial blood flow
Cyclooxygenase inhibitor; Hemodynamics; Ibuprofen; Smoke inhalation injury (Abdi, S. (293) 475)

Bronchial hyperreactivity
Phosphodiesterase inhibitor; Airway inflammation; Early and late asthmatic reaction; (Guinea pig, allergic) (Santing, R.E. (275) 75)

Bronchial hyperresponsiveness
Eosinophilia; Adhesion molecule; VLA-4 integrin (Milne, A.A.Y. (282) 243)

Asthma; TNF-α (tumor necrosis factor-α); Cytokine; Electrical field stimulation; Airway, human (Anticevich, S.Z. (284) 221)

Lipoxygenase metabolites; PAF (platelet-activating factor); Eosinophil infiltration (Seeds, E.A.-M. (293) 369)

Bronchial myocyte, human
Simvastatin; Mevalonate; Geranylgeraniol; Cell proliferation (Viganò, T. (291) 201)

Bronchoconstriction
Trimellitic anhydride; Mucus secretion; Asthma; Occupational asthma (Hayes, J.P. (292) 127)

Bronchoconstrictive response
Immunoglobulin E; Hyperresponsiveness; Ovalbumin; Allergic asthma; (Mouse) (Hessel, E.M. (293) 401)

Bronchodilation
Asthma; Cardiovascular; Central nervous system, dog; Emesis; Phosphodiesterase; Rolipram (Heaslip, R.J. (286) 281)

Bronchoprotection
Urodilatin; Natriuretic peptide, type A; Acetylcholine; Lung function, rat (Flüge, T. (271) 395)

Bronchospasm
(±)-CP96,345; MEN10,627; Neurokinin A; PAF (platelet-activating factor); Substance P; Tachykinin (Perretti, F. (273) 129)

Bronchus
HOE 140; Pulmonary artery; Umbilical artery; Umbilical vein; (Human) (Félétou, M. (274) 57)

Airway hyperresponsiveness; Ca^{2+} channel, voltage-dependent and receptor-operated; Inositol 1,4,5-trisphosphate; Acetylcholine; (Rat) (Chiba, Y. (278) 79)

Bronchus, human
Contraction; Histamine; Protein kinase C; GF 109203X; Phorbol ester (Yang, K.X.F. (275) 283)

Endothelin-1; Endothelin-3; Phosphatidylinositol hydrolysis; Protein kinase C (Nally, J.E. (288) 53)

Bronchus, main, guinea pig
β_2-Adrenoceptor; β_3-Adrenoceptor; Electrical field stimulation; Cholinergic contraction; NANC (non-adrenergic non-cholinergic) contraction (Ten Berge, R.E.J. (275) 199)

Brown adipocyte
Endothelin-1; Endothelin-3; Lipoprotein lipase; Gene expression; Endothelin ET_A receptor (Uchida, Y. (291) 33)

Bufodienolide
Na^+,K^+-ATPase; Marinobufagenin; Ouabain; Smooth muscle, vascular; Vasoconstriction (Bagrov, A.Y. (274) 151)

[^{125}I]α-Bungarotoxin
α_7 Nicotinic acetylcholine receptor subunit; HEK-293 (Human embryonic kidney 293 cell); Ion channel, ligand-gated; Cholinergic pharmacology (Gopalakrishnan, M. (290) 237)

Bupropion
6-Hydroxydopamine; H_2O_2; R56865; Cytotoxicity; Cytoprotection; Chromaffin cell (Abad, F. (293) 55)

Burying behavior
Flumazenil; Allopregnanolone; Anxiety (Fernández-Guasti, A. (281) 113)

Buspirone
Animal model; Anxiety; Diazepam; One-way avoidance; Successive negative contrast (Torres, C. (280) 277)

Butein
EDRF (endothelium-derived relaxing factor); Phosphodiesterase; cAMP; cGMP; Thoracic aorta, rat (Yu, S.-M. (280) 69)

Butorphanol
Opioid tolerance; Morphine; Protein kinase A; Protein kinase C (Narita, M. (271) 543)

Chronic opioid treatment; Protein kinase C; Phorbol ester binding; Morphine (Narita, M. (271) 547)

Opioid dependence; Central nervous system; Ca^{2+} channel; Diltiazem; Protein kinase C; Morphine (Tokuyama, S. (279) 93)

Opioid; Physical dependence; Protein kinase; Morphine; H-7; H-8 (Tokuyama, S. (284) 101)

***t*-Butyl hydroperoxide**
Free radical; Sinoatrial node; Atrioventricular node; Reperfusion arrhythmia; Lipid peroxidation (Satoh, N. (272) 233)

(2-[4-[4,4-bis(4-fluorophenyl)Butyl]-1-piperazinyl]-*N*-methyl-3-pyridinecarboxamide
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5891; FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester; FG5909 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-hydroxy-pyridine; Reuptake; Release; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline (Pettersson, E. (282) 131)

Butyramidine
Nitric oxide, NO; Amidine; Blood pressure; Shock; Inflammation; Endothelium; Endotoxin; Isothiourea (Southan, G.J. (291) 311)

γ-Butyrolactone bicyclic
Pentylenetetrazol; $GABA_A$ receptor-ionophore complex; Convulsant (picrotoxin) site; [^{35}S]TBPS binding; Benzodiazepine sites (Maksay, G. (288) 61)

BW A868C
DP receptor; 572C85; Intraocular pressure; (Rabbit); (Cat) (Matsugi, T. (275) 245)

Prostanoid DP receptor; Myometrium, human; Prostaglandin D_2; Smooth muscle (Fernandes, B. (283) 73)

BW373U86
δ-Opioid receptor agonist; Allodynia; Hyperalgesia; Rhesus monkey (Butelman, E.R. (277) 285)

572C85
DP receptor; BW A868C; Intraocular pressure; (Rabbit); (Cat) (Matsugi, T. (275) 245)

Ca^{2+}
Brain edema; Carrageenan; Kallikrein-kinin; Neurotropin; Particle-induced X-ray emission (Sprumont, P. (274) 95)

Tetrandrine; Hypertrophy; Dihydropyridine; DOCA (deoxycorticosterone acetate); (Receptor) (Xu, Y. (278) 1)

Renal kallikrein secretion; K^+; Ca^{2+} channel antagonist; Ouabain; Vanadium (Bompart, G. (278) 225)

Ca^{2+} channel antagonist; SR 33805; Smooth muscle cell; Proliferation (Dol, F. (280) 135)

Ca^{2+} channel antagonist; Ro 40-5967; Verapamil; 1,4-Dihydropyridine; Diltiazem; SR 33557 (Rutledge, A. (280) 155)

Genistein; Erbstatin analog (Helmeste, D.M. (280) R5)

Bradykinin; Uterus, rat; Vas deferens, rat; Trachea, guinea pig; Ileum, guinea pig; Urinary bladder, guinea pig; G protein; Protein kinase C (Calixto, J.B. (281) 279)

Bradykinin; Trachea, guinea-pig; Epithelium; Bradykinin B_2 receptor; Relaxation; Ryanodine; Apamin; HOE 140; NPC 17761 (Schlemper, V. (282) 177)

Ba^{2+}; Sr^{2+}; Nitric oxide (NO); Coronary artery, porcine; Diltiazem (Ohashi, K. (285) 165)

Genistein; Erbstatin analog (Helmeste, D.M. (286) 113)

Loop of Henle; Bradykinin; Ion transport (Grider, J. (287) 101)

Daphnoretin; Neutrophil (rat); Respiratory burst; Staurosporine; Protein kinase C; [^{3}H]Phorbol-12,13-dibutyrate binding (Wang, J.-P. (288) 341)

5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Calmodulin; Platelet; Thrombin (Helmeste, D.M. (288) 373)

Nitrite; Na^+,K^+-ATPase; Digitalis (Ikeda, U. (288) 379)

TRH (Thyrotropin-releasing hormone); TSH (Thyroid stimulating hormone); Triiodo-L-thyronine; Hypophysis; (Rat) (Roussel, J.-P. (289) 205)

Felbamate; NMDA (*N*-methyl-D-aspartate); Epilepsy (Taylor, L.A. (289) 229)

5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Calmodulin; Platelet; Thrombin (Helmeste, D.M. (290) 173)

Smooth muscle; Protein kinase C; Protein kinase C; (vascular); (cytosolic); (particulate) (Bazan, E. (290) 253)

Protein kinase C; Airway smooth muscle (Hoiting, B.H. (290) R5)

Neutrophil; Degranulation; cAMP; cGMP; Protein kinase C; Tolfenamic acid (Kankaanranta, H. (291) 17)

Corticotropin releasing factor; Ca^{2+} channel; Pertussis toxin; inositol trisphosphate; Epithelium (Kiang, J.G. (291) 107)

Arachidonic acid; Glutamate; Transport; Synaptosome (Lundy, D.F. (291) 273)

Nitric oxide (NO); Airway epithelium; Bradykinin; ATP (Sakai, A. (291) 375)

Gastric cell; Damage; Oxidative stress; Nitric oxide (NO) (Tepperman, B.L. (293) 259)

$[Ca^{2+}]_i$
Intimal hyperplasia; Hyperreactivity; Myosin light chain phosphorylation; Protein kinase inhibitor; HA1077 (Seto, M. (276) 27)

AMPA receptor; Cyclothiazide; Receptor desensitization; Ca^{2+} uptake; Cerebellar granule neuron; Cortical neuron; Primary culture (Cebers, G. (290) 105)

$[Ca^{2+}]_i$ transient
Cardiac myocyte; σ Receptor; Contractility (Novakova, M. (286) 19)

Ca^{2+}-activated K^+ channel
Smooth muscle cell, vascular; Tyrosine kinase; Genistein (Xiong, Z. (290) 117)

Ca^{2+}-ATPase
Ca^{2+} influx, store-dependent; Second messenger-operated channel; Ca^{2+} store; IP_3 receptor; Ryanodine receptor (Clementi, E. (289) 23)

Protein kinase C; Protein kinase A; Calmodulin; Megakaryocyte, rat; Patch-clamp (Uneyama, C. (291) 381)

Ca^{2+}-calmodulin
Blood pressure; Dopamine; Epilepsy; (El mouse) (Sutoo, D. (278) 33)

Ca^{2+} channel
ω-Conotoxin GVIA; ω-Conotoxin MVIIC; ω-Conotoxin MVIIA; ω-Agatoxin IVA; Sympathetic neurotransmission; Heart (Vega, T. (276) 231)

Diabetes mellitus; Phorbol ester; Protein kinase C; Ca^{2+}, extracellular; Aorta, rat (Hattori, Y. (279) 51)

Opioid dependence; Central nervous system; Diltiazem; Protein kinase C; Morphine; Butorphanol (Tokuyama, S. (279) 93)

Pregnancy; Vasoconstriction; Aortic ring; Nifedipine; Bay K 8644 (Roy, B. (280) 1)

Skin, toad; Diazepam; Tolerance (Norris, B. (280) 221)

Cryptolepine (5-methylquindoline); Vasodilation; Kidney, rat; G-protein; K^+ channel; Pertussis toxin (Oyekan, A.O. (285) 1)

Endothelial cell; Bradykinin; Fura-2; Nitric oxide (NO); Anesthetic, volatile; Sevoflurane; A23187; D-Arg-[Hyp^3, Thi^{5,8}, D-Phe^7] bradykinin; Des-Arg^9-[Leu^8] bradykinin (Az-ma, T. (289) 33)

Corticotropin releasing factor; Ca^{2+}; Pertussis toxin; inositol trisphosphate; Epithelium (Kiang, J.G. (291) 107)

Cadmium ion; Vasoconstriction; Contractile protein; Aorta, rat (Wakabayashi, I. (293) 133)

Ca^{2+} channel agonist
Peptaibol; Cardiac muscle (Huang, Q. (271) R5)

Ca^{2+} channel antagonist
Renal kallikrein secretion; Ca^{2+}; K^+; Ouabain; Vanadium (Bompart, G. (278) 225)

Ca^{2+}; SR 33805; Smooth muscle cell; Proliferation (Dol, F. (280) 135)

Ca^{2+}; Ro 40-5967; Verapamil; 1,4-Dihydropyridine; Diltiazem; SR 33557 (Rutledge, A. (280) 155)

Kidney; Autoregulation (Huang, C. (282) 1)

Elgodipine; Conductance vessel; Resistance vessel; (Rabbit); (Sheep) (Chulia, T. (285) 115)

Mitochondrial Ca^{2+}; Adrenal medulla (Uceda, G. (289) 73)

Ca^{2+} channel antagonist receptor
MPC-1304; Receptor occupation; Spontaneously hypertensive rat (SHR) (Nozawa, Y. (287) 191)

Ca^{2+} channel blocker
Veratridine; Na^+ channel; β-Adrenoceptor antagonist; Dilazep; Ca^{2+}, cytosolic (Hashizume, H. (271) 1)

Ca^{2+} channel, L-type, voltage-sensitive
Glutamate; Excitotoxicity; NMDA receptor; AMPA/Kainate receptor; Neuroprotection (Prehn, J.H.M. (292) 179)

Ca^{2+} channel, P-type
Motor endplate; ω-Agatoxin-IVA; Acetylcholine release (Wessler, I. (278) 83)

Ca^{2+} channel, voltage-dependent and receptor-operated
Airway hyperresponsiveness; Bronchus; Inositol 1,4,5-trisphosphate; Acetylcholine; (Rat) (Chiba, Y. (278) 79)

Ca^{2+} chelation
Blood platelet; 5-HT (Serotonin) uptake; EGTA (Ethyleneglycol-tetraacetic acid); BAPTA-AM (acetoxymethyl bis(*O*-aminophenoxy)ethane-*N*,*N*,*N*′,*N*′-tetraacetate); Ca^{2+} storage pool (Nishio, H. (288) 149)

Ca^{2+} concentration
Neuropeptide Y; U46619 (9,11-dideoxy-11α,9α-epoxymethano prostaglandin $F_{2\alpha}$); Basilar artery; Cytosolic; Ca^{2+} influx; Ca^{2+} sensitivity (Tanaka, Y. (289) 59)

Ca^{2+} concentration, intracellular
Methylmercury; Cytotoxicity; Thymocyte; Membrane potential (Oyama, Y. (293) 101)

Ca^{2+} conductance
Galantide; Galanin; Parasympathetic neuron; K^+ conductance (Mulvaney, J.M. (287) 97)

Ca^{2+} current
Antiarrhythmic; Action potential; K^+ current; Oxime; Cardiac myocyte (Karhu, S. (279) 7)

Ethanol; Heart; Na^+ current; Voltage clamp (Habuchi, Y. (292) 143)

Capsaicin; K^+ current; Smooth muscle cell (Lo, Y.-C. (292) 321)

Free radical; Myocyte; Cardiac (Gill, J.S. (292) 337)

Ca^{2+} current, L-type
Endothelin-1; Cardiac myocyte; β-Adrenoceptor agonist; (Guinea-pig) (Delpech, N. (285) 217)

Verapamil; Binding site; Ventricular myocyte, rat; Patch-clamp technique (Wegener, J.W. (287) 89)

Inactivation, Ca^{2+}-dependent; Ca^{2+} release, IP_3-mediated; α_1-Adrenoceptor (England, S. (288) 355)

Ca^{2+}, cytosolic
Veratridine; Na^+ channel; β-Adrenoceptor antagonist; Ca^{2+} channel blocker; Dilazep (Hashizume, H. (271) 1)

Endothelial cells, human; Isradipine; Fura-2; Histamine (Iouzalen, L. (289) 189)

Ca^{2+}-dependent Cl^- channel
Smooth muscle cell; Trachea; Caffeine; Sarcoplasmic reticulum; Ca^{2+} pump (Henmi, S. (282) 219)

Ca^{2+}-dependent release
Exocytosis; Ba^{2+}; Calmodulin; Okadaic acid; Phosphatase (Verhage, M. (291) 387)

Ca^{2+}, extracellular
Diabetes mellitus; Phorbol ester; Protein kinase C; Ca^{2+} channel; Aorta, rat (Hattori, Y. (279) 51)

Ca^{2+} homeostasis
Staurosporine; Adrenal chromaffin cell; Catecholamine release; Fura-2 (Maurer, J.A. (288) 163)

Nitric oxide (NO); Nitric oxide synthase; PC12 cell; cGMP (Clementi, E. (289) 113)

Ca^{2+}-induced Ca^{2+} release
Triphenyltin-induced contracture; Diaphragm; Na^+-channel activation (Liu, S.-H. (292) 95)

Ca^{2+} influx
Neuropeptide Y; U46619 (9,11-dideoxy-11α,9α-epoxymethano prostaglandin $F_{2\alpha}$); Basilar artery; Ca^{2+} concentration; Cytosolic; Ca^{2+} sensitivity (Tanaka, Y. (289) 59)

Endothelin; Endothelin receptor; Ca^{2+} release; Ca^{2+} sensitivity; Smooth muscle, vascular (Sudjarwo, S.A. (289) 197)

Vasorelaxation; Pyridine (Hsu, K.-S. (292) 265)

Ca^{2+} influx, store-dependent
Second messenger-operated channel; Ca^{2+} store; Ca^{2+} ATPase; IP_3 receptor; Ryanodine receptor (Clementi, E. (289) 23)

Ca^{2+}, intracellular
Neuropeptide Y; Neuropeptide Y Y_1 receptor antagonist; Blood pressure; Spontaneously hypertensive rat (SHR) (Tseng, A. (271) 265)

Chromaffin cell; Muscarinic receptor; Phosphatidylinositol hydrolysis; Cation channel, non-selective; (Guinea-pig) (Inoue, M. (276) 123)

Macrophage; Bradykinin receptor; Phospholipase C (Böckmann, S. (291) 159)

Ca^{2+} ionophore
Enterochromaffin-like cell; Stomach, rat; Histamine; Patch-clamp; K^+ channel (Sakai, H. (291) 153)

Ca^{2+} mobilization
Aortic endothelial cell; Cl^-, extracellular; Fura-2; Thapsigargin; Cyclopiazonic acid (Hosoki, E. (288) 131)

Ca^{2+} overload
Ischemia/reperfusion; Lidocaine; Mexiletine; Na^+ overload (Kamiyama, T. (272) 151)

Ca^{2+} pump
Smooth muscle cell; Trachea; Caffeine; Ca^{2+}-dependent Cl^- channel; Sarcoplasmic reticulum (Henmi, S. (282) 219)

Ca^{2+} release
Sarcoplasmic reticulum; Caffeine; Ryanodine (Takahashi, Y. (288) 285)

Endothelin; Endothelin receptor; Ca^{2+} influx; Ca^{2+} sensitivity; Smooth muscle, vascular (Sudjarwo, S.A. (289) 197)

Ca^{2+} release, IP_3-mediated
Ca^{2+} current, L-type; Inactivation, Ca^{2+}-dependent; α_1-Adrenoceptor (England, S. (288) 355)

Ca^{2+} sensitivity
Neuropeptide Y; U46619 (9,11-dideoxy-11α,9α-epoxymethano prostaglandin $F_{2\alpha}$); Basilar artery; Ca^{2+} concentration; Cytosolic; Ca^{2+} influx (Tanaka, Y. (289) 59)

Endothelin; Endothelin receptor; Ca^{2+} influx; Ca^{2+} release; Smooth muscle, vascular (Sudjarwo, S.A. (289) 197)

Ca^{2+} sensitization
α_1-Adrenoceptor subtype; Thoracic aorta; Myosin light chain phosphorylation; Botulinum C_3-sensitive GTP-binding protein (Kokubu, N. (290) 19)

Ca^{2+} sensitizer
Regulatory protein; Motility assay, in vitro; Pimobendan (Sata, M. (290) 55)

Ca^{2+} signal
Vascular smooth muscle cell; Caffeine (Alexander, P.B. (288) 79)

Ca^{2+} spike
Spontaneously epileptic rat (SER); Hippocampus; CA3 neuron; Nicardipine (Momiyama, T. (280) 119)

Ca^{2+} storage pool
Blood platelet; 5-HT (Serotonin) uptake; Ca^{2+} chelation; EGTA (Ethyleneglycoltetraacetic acid); BAPTA-AM (acetoxymethyl bis(*O*-aminophenoxy)ethane-*N*,*N*,*N*′,*N*′-tetraacetate) (Nishio, H. (288) 149)

Ca^{2+} store
Caffeine; Carbachol; Inositol 1,4,5-trisphosphate; Ryanodine; Smooth muscle, intestinal (Komori, S. (277) 173)

Ca^{2+} influx, store-dependent; Second messenger-operated channel; Ca^{2+} ATPase; IP_3 receptor; Ryanodine receptor (Clementi, E. (289) 23)

Ca^{2+} store refilling
Tyrosine kinase inhibitor; Aorta, rat; Contraction; Vanadate (Filipeanu, C.M. (281) 29)

Ca^{2+}, transient signal
Fura-2; Heart, guinea-pig; Isoproterenol; Dihydroouabain (Hotta, Y. (282) 121)

Ca^{2+} uptake
Cerebral endothelium; Endothelin; Signal transduction (Stanimirovic, D.B. (288) 1)

Cerebral endothelium; Endothelin; Signal transduction (Stanimirovic, D.B. (289) 409)

AMPA receptor; Cyclothiazide; Receptor desensitization; $[Ca^{2+}]_i$; Cerebellar granule neuron; Cortical neuron; Primary culture (Cebers, G. (290) 105)

Caco-2
Pristinamycin; Intestinal absorption; Intestinal epithelium; P-glycoprotein (Phung-Ba, V. (288) 187)

Cadmium ion
Vasoconstriction; Ca^{2+} channel; Contractile protein; Aorta, rat (Wakabayashi, I. (293) 133)

Caffeine
(−)-DS121; Dopamine autoreceptor antagonist; Dopamine D_3 receptor; D-Amphetamine; Cocaine; Drug discrimination (Clark, D. (275) 67)

Ca^{2+} store; Carbachol; Inositol 1,4,5-trisphosphate; Ryanodine; Smooth muscle, intestinal (Komori, S. (277) 173)

Smooth muscle cell; Trachea; Ca^{2+}-dependent Cl^- channel; Sarcoplasmic reticulum; Ca^{2+} pump (Henmi, S. (282) 219)

Ca^{2+} signal; Vascular smooth muscle cell (Alexander, P.B. (288) 79)

Ca^{2+} release; Sarcoplasmic reticulum; Ryanodine (Takahashi, Y. (288) 285)

Chromaffin cell; Acetylcholine receptor (Liu, P.-S. (291) 265)

Ag^+-induced contracture; Procaine; Dithiothreitol; Skeletal muscle; (Frog) (Oba, T. (292) 301)

Caged-ATP
Smooth muscle; ATP; Hypertrophy; Urinary bladder (Sjuve, R. (276) 137)

Calcification
ATP release; Noradrenaline; α_1-Adrenoceptor; Arteriosclerosis; Caudal artery, rat (Shinozuka, K. (292) 115)

Calcitonin
Hypothalamus-pituitary-adrenocortical axis; Opioid receptor mechanism (Milanés, M.V. (271) 103)

NMDA (*N*-methyl-D-aspartate); Aversive behavior; β-Adrenoceptor; 5-HT receptor; GABA receptor (Maeda, Y. (275) 163)

Calmodulin
5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Ca^{2+}; Platelet; Thrombin (Helmeste, D.M. (288) 373)

5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Ca^{2+}; Platelet; Thrombin (Helmeste, D.M. (290) 173)

Ca^{2+}-ATPase; Protein kinase C; Protein kinase A; Megakaryocyte, rat; Patch-clamp (Uneyama, C. (291) 381)

Exocytosis; Ba^{2+}; Ca^{2+}-dependent release; Okadaic acid; Phosphatase (Verhage, M. (291) 387)

Calmodulin antagonism
Vinca alkaloid; Bis-indol; Navelbine; Vinblastine; Vincristine; Tubulin; Anti-mitotic drug (Molnár, A. (291) 73)

Calmodulin antagonist
Pentamidine; AZT (3′-azido-2′,3′-dideoxythymidine); Nitric oxide (NO); Neuronal NO synthase (Kitamura, Y. (289) 299)

Calyculin A
Neutrophil; Respiratory burst; Okadaic acid; Protein phosphatase (Djerdjouri, B. (288) 193)

Muscarinic receptor; Agonists dual effect; Receptor theory, modified (Järv, J. (291) 43)

L-Canavanine
Lipopolysaccharide; Nitric oxide (NO); Nitric oxide (NO) synthase; Hypotension; N^G-Nitro-L-arginine methyl ester (Teale, D.M. (271) 87)

Cancer
Endotoxin; Nitric oxide (NO) synthase; Chemotherapy; Cytotoxicity; Anti-cancer drug (Hattori, Y. (291) 83)

CA3 neuron
Spontaneously epileptic rat (SER); Hippocampus; Ca^{2+} spike; Nicardipine (Momiyama, T. (280) 119)

Cannabinoid
Opioid; Noradrenaline; β,γ-Methylene-L-ATP; Vas deferens, mouse; Tolerance (Pertwee, R.G. (272) 67)

Phenylmethylsulphonyl fluoride; Anandamide; *R*-(+)-Arachidonyl-1′-hydroxy-2′-propylamide; Vas deferens, mouse; Myenteric plexus preparation, guinea-pig (Pertwee, R.G. (272) 73)

Blood pressure; Anandamide; CB_1 cannabinoid receptor antagonist (Varga, K. (278) 279)

Basal ganglia; Substantia nigra; Cannabinoid receptor; Motor system; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole (Miller, A.S. (279) 179)

Cannabinoid receptor antagonist; SR141716A; Vas deferens, mouse; 1-Pentyl-2-methyl-3-(1-naphthoyl)indole; 1-Pentyl-3-(1-naphthoyl)pyrrole; 1-Heptyl-3-(1-naphthoyl)indole (Pertwee, R.G. (284) 241)

Cannabinoid receptor
Basal ganglia; Cannabinoid; Substantia nigra; Motor system; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole (Miller, A.S. (279) 179)

Adenylate cyclase; Anandamide; GTP-binding protein (Barg, J. (287) 145)

Cannabinoid receptor antagonist
Cannabinoid; SR141716A; Vas deferens, mouse; 1-Pentyl-2-methyl-3-(1-naphthoyl)indole; 1-Pentyl-3-(1-naphthoyl)pyrrole; 1-Heptyl-3-(1-naphthoyl)indole (Pertwee, R.G. (284) 241)

Capillary density
Polyol pathway; Galactosemia; Nerve conduction; Ischemic resistance; Vasodilator treatment (Dines, K.C. (281) 303)

Capillary electrophoresis
Cicletanine; Sulfate; Kidney; Cell membrane; Ion transport; Natriuresis; Diuresis; Na^+ transport (Garay, R.P. (274) 175)

Capillary permeability
Diabetic vasculopathy; Neutral endopeptidase; Streptozotocin (Chakir, M. (285) 11)

Capsaicin
Diabetes; Sensory fiber; Urinary bladder; Epithelium (Pinna, C. (271) 151)

Spinal cord slice; Prostaglandin E_2 release; Capsazepine; Cyclooxygenase inhibition (Malmberg, A.B. (271) 293)

Diabetes; Sensory fibres; Stomach fundus; Ileum (Pinna, C. (276) 61)

Evan's blue; Pulmonary response (Bolser, D.C. (276) R1)

Tachykinin; Tachykinin NK_3 receptor; Tachykinin receptor antagonist; SR 142801 (Patacchini, R. (278) 17)

Bradykinin; Thromboxane A_2; Smooth muscle, airway (Molimard, M. (278) 49)

Sensory nerve; Neurogenic inflammation; (Prejunctional); (Postjunctional) (Parlani, M. (278) 117)

Gastrin-17; CCK (cholecystokinin); Gastroprotection; Stomach; Nitric oxide (NO) (Konturek, S.J. (278) 203)

Vasodilator nerve; Nitric oxide (NO); Mesenteric artery, guinea pig; CGRP (calcitonin gene-related peptide); Nitro-L-arginine; Zinc protoporphyrin IX (Gyoda, Y. (279) 83)

Nitric oxide (NO); Endotoxin; Gastric damage; Gastric defense; Stress (Barrachina, M.D. (280) 339)

Airway hyperresponsiveness; Sensory nerve; Inflammation; (Rabbit) (Herd, C.M. (282) 111)

TNF-α (tumor necrosis factor-α); Cutaneous hyperemia; Afferent nerve stimulation; CGRP (calcitonin gene-related peptide); Bradykinin (Herbert, M.K. (286) 273)

Vanilloid receptor; Vanilnoid, endogenous; Resiniferatoxin binding; Proton; Positive cooperativity; Non-competitive inhibition; Desensitization (Szallasi, A. (289) 181)

Ca^{2+} current; K^+ current; Smooth muscle cell (Lo, Y.-C. (292) 321)

Ethanol; 5-HT_3 receptor; Bezold-Jarisch reflex (Malinowska, B. (293) 71)

Capsazepine
Spinal cord slice; Prostaglandin E_2 release; Capsaicin; Cyclooxygenase inhibition (Malmberg, A.B. (271) 293)

Captopril
des-Asp-angiotensin I; Aortic ring; Indomethacin (Sim, M.K. (278) 175)

Angiotensin AT_1 receptor antagonist; Angiotensin converting enzyme inhibitor; Renal function; (Anesthetized dog) (Clark, K.L. (280) 195)

Iloprost; Nitric oxide (NO); Acute inflammation; Hypertension; (2K-1C rat) (Medeiros, M.V. (285) 109)

L-163,491; Pulmonary vascular bed, cat; Angiotensin receptor-mediated response; PD 123319; DuP 532 (Kaye, A.D. (287) 163)

CA1 pyramidal cell
trans-ACPD ((±)-*trans*-1-aminocyclopentane-1,3-dicarboxylic acid); Metabotropic glutamate receptor; Inhibitory postsynaptic potential; Hippocampus (Jouvenceau, A. (281) 131)

Carazolol
β-Adrenoceptor antagonist; β_3-Adrenoceptor agonist; Adenylyl cyclase; Lipolyse (Méjean, A. (291) 359)

Carbachol
Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; L-Arginine; Diarrhea; Intestinal secretion; Small intestinal transit (Izzo, A.A. (271) 31)

Substance P; Neurokinin A; Tachykinin receptor; Trachea, rat; 5-HT (5-hydroxytryptamine, serotonin) (Joos, G.F. (271) 47)

Turning behavior; Dopaminergic/cholinergic receptor interaction; Nucleus accumbens; Ventrolateral striatum; Turning pattern (Saigusa, T. (274) 213)

Ca^{2+} store; Caffeine; Inositol 1,4,5-trisphosphate; Ryanodine; Smooth muscle, intestinal (Komori, S. (277) 173)

Phospholipid metabolism; U50,488; Ethylketocyclazocine; Norepinephrine; Renal cortex (Mosaddeghi, M. (289) 411)

α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor; Arachidonic acid; Cyclothiazide; Kainate receptor; Striatal neuron (Petitet, F. (291) 143)

Carbamazepine anticonvulsant
GABA (γ-aminobutyric acid) uptake inhibitor; Nipecotic acid; Tiagabine; Epilepsy (Smith, S.E. (273) 259)

β-Carboline
$GABA_A$ receptor; Photoaffinity label (Zezula, J. (281) 93)

Carbonic anhydrase
Lidocaine; Spectrin; ATPase, vascular type; Erythrocyte membrane, human (Nishiguchi, E. (286) 1)

Carbon monoxide (CO)
Alveolar macrophage; Nitric oxide (NO); Heme oxygenase; Cyclic GMP; Superoxide anion (Fukushima, T. (289) 103)

Carbon tetrachloride
Endothelin; Endothelin receptor antagonist; Bosentan; Hepatotoxicity; Acute liver dysfunction (Hocher, B. (293) 361)

5-Carboxamidotryptamine
DOCA-salt (deoxycorticosterone acetate-salt) hypertensive rat; Blood pressure; Baroreflex sensitivity; (Chronic i.v. infusion) (Balasubramaniam, G. (276) 183)

Carboxypeptidase Y, urinary
Ebelactone B; Kininogen-deficient rat; Deoxycorticosterone acetate-salt hypertension; Na^+ excretion (Majima, M. (284) 1)

Cardiac
Free radical; Ca^{2+} current; Myocyte (Gill, J.S. (292) 337)

Cardiac action potential
α_1-Adrenoceptor; Muscarinic acetylcholine receptor; Positive inotropic effect; Protein kinase C; Arachidonic acid metabolism (Arreola, J. (271) 309)

Cardiac contractility
Isoprenaline; Diazepam; Forskolin; cAMP (Martinez, E. (282) 169)

Amiloride; EIPA (5-(*N*-ethyl-*N*-isopropyl)amiloride); Ouabain; Na^+/Ca^{2+} exchange; Na^+/H^+ exchange (Cargnelli, G. (292) 103)

Cardiac efficiency
Hypertrophy; L-Carnitine; Fatty acid (Schönekess, B.O. (286) 155)

Cardiac electropharmacology
Mechanism of arrhythmia; Antiarrhythmic drug (Lee, J.H. (285) 25)

Cardiac function
Propionyl-l-carnitine; Pressure overload; Cardiac hypertrophy; Enalapril (Micheletti, R. (286) 147)

Cardiac hypertrophy
Volume overload; Losartan; Angiotensin II; Endothelin-1; FR139317 (Ishiye, M. (280) 11)

Propionyl-l-carnitine; Pressure overload; Enalapril; Cardiac function (Micheletti, R. (286) 147)

Cardiac insufficiency
Toxic metabolite; Vasodepression; Hyperapnea; (*Ptychodiscus brevis*) (Koley, J. (293) 483)

Cardiac muscle
Peptaibol; Ca^{2+} channel agonist (Huang, Q. (271) R5)

Cardiac myocyte
Antiarrhythmic; Action potential; Ca^{2+} current; K^+ current; Oxime (Karhu, S. (279) 7)

Endothelin-1; L-type Ca^{2+} current; β-Adrenoceptor agonist; (Guinea-pig) (Delpech, N. (285) 217)

K_{ATP} channel; Imidazoline; (Guinea-pig) (Lee, K. (285) 309)

σ Receptor; Contractility; $[Ca^{2+}]_i$ transient (Novakova, M. (286) 19)

PACAP (pituitary adenylate cyclase-activating peptide); VIP (vasoactive intestinal polypeptide); cAMP; CDD/ANP-(99–126) (Bäsler, I. (291) 335)

Cardiocyte
Lidocaine; α_1-Adrenoceptor; Up-regulation; Culture (Mizuki, T. (277) 133)

Cardiomyocyte
SPM3672; Nitric oxide (NO) donor; Nitric oxide (NO); Heart muscle, contractility (Kojda, G. (284) 315)

Cardiomyopathy
Propionyl-L-carnitine; Papillary muscle; (Hamster) (Maresca, P. (287) 303)

β-adrenoceptor subtype; Coupling efficiency; Adenylyl cyclase; Hamster; Age-dependent (Witte, K. (290) 1)

Cardiovascular
Nucleus tractus solitarii; Neuropeptide Y receptor; α_2-Adrenoceptor; Receptor autoradiography (Yang, S.-N. (271) 201)

Non-steroidal anti-inflammatory drug; Nitric oxide (NO); Endotoxic shock, acute; Gastrointestinal; Ulcer; Prostaglandin (Wallace, J.L. (280) 63)

Asthma; Bronchodilation; Central nervous system, dog; Emesis; Phosphodiesterase; Rolipram (Heaslip, R.J. (286) 281)

L-Carnitine
Hypertrophy; Fatty acid; Cardiac efficiency (Schönekess, B.O. (286) 155)

β-Carotene
Morphine; Analgesia (Penn, N.W. (284) 191)

Carotid vascular resistance
Sumatriptan; Plasma protein extravasation; Trigeminal ganglion stimulation; Dura mater; Blood pressure (Spokes, R.A. (281) 75)

Carrageenan
Brain edema; Calcium; Kallikrein-kinin; Neurotropin; Particle-induced X-ray emission (Sprumont, P. (274) 95)

Carrageenin edema
Nitric oxide (NO); Prostaglandin (Sautebin, L. (286) 219)

Carrageenin, inflammation
c-Fos expression; Indomethacin; Nociception (Honoré, P. (272) 249)

Castration
Sexual behavior; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_2 receptor agonist; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Testosterone; Puberty (Padoin, M.J. (277) 1)

Catalepsy
Dopamine receptor antagonist; 5-HT_{1A} receptor agonist; Climbing; Stereotyped behavior; Grooming (Protais, P. (271) 167)

Cocaine; SCH23390; Haloperidol; Supersensitivity; Subsensitivity; (Mouse) (Ushijima, I. (285) 55)

Remoxipride; Antinociception; Rotarod; (Sheep) (Main, D.C.J. (287) 221)

Catecholamine
Dopamine; Dopamine receptor, agonist, antagonist; Protein kinase inhibitor; Ouabain; Ionic mechanism; Voltage clamp; Neuron; (Snail) (Emaduddin, M. (283) 113)

Monoamine oxidase A; Estrogen receptor; Neural cell; Estrogen (Ma, Z.-Q. (284) 171)

Adrenal; Glycine; Microdialysis; Polymerase chain reaction; Strychnine (Yadid, G. (288) 399)

β_1-Adrenoceptor; Transcriptional regulation; Corticosteroid; Thyroid hormone; (Sheep) (Tseng, Y.T. (289) 353)

Catecholamine, depression
Depression, animal model; Catechol-*O*-methyltransferase, inhibitor (Männistö, P.T. (274) 229)

Catecholamine homeostasis
Salsolinol; Neurotoxicity (Willets, J.M. (293) 319)

Catecholamine overflow
Noradrenaline; Adrenaline; Exercise; β_2-Adrenoceptor, prejunctional; (Freely moving rat) (Coppes, R.P. (274) 33)

Catecholamine release
Renal blood flow; Angiotensin II; Renal nerve; Prazosin; α-Adrenoceptor (Chen, K. (284) 281)

Staurosporine; Adrenal chromaffin cell; Ca^{2+} homeostasis; Fura-2 (Maurer, J.A. (288) 163)

Catecholamine, synthesis
Dopamine; Dopamine receptor agonist; DOPA (3,4-dihydroxyphenylalanine), accumulation; Adrenal medulla (Kujacic, M. (278) 9)

PAMP (proadrenomedullin N-terminal 20 peptide); Tyrosine hydroxylase; Nicotinic receptor; Adrenal medulla (Niina, H. (286) 95)

Catechol-*O*-methyltransferase inhibition
Dopamine; Microdialysis; L-DOPA (3,4-dihydroxyphenyl-L-alanine); Tolcapone (Napolitano, A. (273) 215)

Catechol-*O*-methyltransferase, inhibitor
Catecholamine, depression; Depression, animal model (Männistö, P.T. (274) 229)

Cation channel, non-selective
Chromaffin cell; Muscarinic receptor; Phosphatidylinositol hydrolysis; Ca^{2+}, intracellular; (Guinea-pig) (Inoue, M. (276) 123)

Caudal artery, rat
Melatonin receptor; Adrenergic nerve; Contraction (Krause, D.N. (276) 207)

ATP release; Noradrenaline; α_1-Adrenoceptor; Calcification; Arteriosclerosis (Shinozuka, K. (292) 115)

Caudal epididymis, rat
-Aminopyridine; α-Adrenoceptor; Contraction, phasic; K^+ channel (Huang, Y. (280) 231)

Caudate putamen
1-(*m*-Chlorophenyl)-biguanide; [^{3}H]GBR-12935; 5-HT_3 receptor; Dopamine transporter; Nucleus accumbens; (Rat) (Campbell, A.D. (290) 157)

Cavernous artery
Nitric oxide (NO); SIN-1 (3-morpholino-sydnonimine); VIP (vasoactive intestinal polypeptide); Smooth muscle, cavernosal; (Human) (Hempelmann, R.G. (276) 277)

CB_1 cannabinoid receptor antagonist
Cannabinoid; Blood pressure; Anandamide (Varga, K. (278) 279)

CCG (2-(Carboxycyclopropyl)glycine)
Human glutamate transporter (hGluT-1); COS-7 cell; Transfection (Yamashita, H. (289) 387)

CCK (cholecystokinin)
CCK receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin); Zero-maze; Anxiety; (Rat) (Bickerdike, M.J. (271) 403)

CCK receptor; Cytoprotection; Stomach; Gastric hyperemia (Konturek, S.J. (273) 57)

Cerebral cortex; Glutamate; NMDA receptor; Seizure (Bandopadhyay, R. (275) 53)

Gastrin-17; Gastroprotection; Stomach; Capsaicin; Nitric oxide (NO) (Konturek, S.J. (278) 203)

Enkephalin catabolism inhibitor; Enkephalin, endogenous; RB 101; PD-134,308; Tail-flick; Hot-plate; Antinociception; CCK_B receptor antagonist; Tolerance (Valverde, O. (286) 79)

CCK_B receptor; Gastrin; GTPγS (Lallement, J.-C. (290) 61)

CCK receptor
CCK (cholecystokinin); Cytoprotection; Stomach; Gastric hyperemia (Konturek, S.J. (273) 57)

Pancreatic hypertrophy; Bethanechol; Pentagastrin; Muscarinic receptor; CR1505 (Kato, M. (292) 47)

CCK_A receptor
CCK_B receptor; $CCK_{A/B}$ receptor antagonist, mixed; Radioligand binding; Gall bladder, guinea pig; Anxiolytic (Singh, L. (286) 185)

CCK_B receptor
CCK_A receptor; $CCK_{A/B}$ receptor antagonist, mixed; Radioligand binding; Gall bladder, guinea pig; Anxiolytic (Singh, L. (286) 185)

Cholecystokinin; Gastrin; GTPγS (Lallement, J.-C. (290) 61)

CCK receptor antagonist
Cholecystokinin; 5-HT (5-hydroxytryptamine, serotonin); Zero-maze; Anxiety; (Rat) (Bickerdike, M.J. (271) 403)

CCK_B receptor antagonist
RB 101 (mixed enkephalin-degrading enzyme inhibitor); Morphine; Formalin test; Naloxone; Naltrindole; (Mouse) (Noble, F. (273) 145)

Enkephalin catabolism inhibitor; Enkephalin, endogenous; CCK (cholecystokinin); RB 101; PD-134,308; Tail-flick; Hot-plate; Antinociception; Tolerance (Valverde, O. (286) 79)

$CCK_{A/B}$ receptor antagonist, mixed
CCK_A receptor; CCK_B receptor; Radioligand binding; Gall bladder, guinea pig; Anxiolytic (Singh, L. (286) 185)

CD11b
Sialidase; Fucoidin; β_2-Integrin; Interleukin-8; Interleukin-1 (Harris, J.G. (279) 149)

CDD/ANP-(99–126)
PACAP (pituitary adenylate cyclase-activating peptide); VIP (vasoactive intestinal polypeptide); cAMP; Cardiac myocyte (Bäsler, I. (291) 335)

Cecal ligation and puncture
N-Acetyl-L-cysteine; Allopurinol; Xanthine oxidase; Sepsis; Free radicals (Villa, P. (292) 341)

Cell culture
β-Amyloid peptide; Fura-2 (Korotzer, A.R. (288) 125)

Cell death
Flupirtine; Triaminopyridine; NMDA (*N*-methyl-D-aspartate); NMDA receptor; Neuron; HIV-1; gp120 (Perovic, S. (288) 27)

Cell growth
CV-11974; TCV-116; Smooth muscle cell; Vascular; c-*fos* (Flesch, M. (289) 399)

Cell membrane
Cicletanine; Sulfate; Kidney; Ion transport; Natriuresis; Diuresis; Na^+ transport; Capillary electrophoresis (Garay, R.P. (274) 175)

Nitrendipine; MDCK cell; K^+ flux; Rb^+ flux; Na^+, K^+, Cl^- cotransport; K^+ channel; Red blood cell (López-Burillo, S. (289) 259)

Cell proliferation
Benzodiazepine; Lung; (Chinese hamster) (Camins, A. (272) 289)

Smooth muscle, airway; Asthma; Glucocorticoid; β-Adrenoceptor agonist, cell culture (Young, P.G. (273) 137)

Receptor ligand; Mammary carcinoma cell; Colon carcinoma cell; Melanoma cell (Brent, P.J. (278) 151)

Human bronchial myocyte; Simvastatin; Mevalonate; Geranylgeraniol (Viganò, T. (291) 201)

Cell proliferation, human
5-HT_{1A} receptor; 5-HT_{1D} receptor; 5-HT receptor antagonist (Cattaneo, M.G. (291) 209)

Central nervous system
α-Adrenoceptor; Blood pressure; RG20 gene; (Rat) (Nunes, J.P. (278) 183)

Opioid dependence; Ca^{2+} channel; Diltiazem; Protein kinase C; Morphine; Butorphanol (Tokuyama, S. (279) 93)

Central nervous system, dog
Asthma; Bronchodilation; Cardiovascular; Emesis; Phosphodiesterase; Rolipram (Heaslip, R.J. (286) 281)

Cerebellar granule cell
L-AP4 (L(+)-2-amino-4-phosphonobutyric acid); Metabotropic glutamate receptor; Neurotrophic (Graham, M.E. (288) 115)

Cerebellar granule neuron
AMPA receptor; Cyclothiazide; Receptor desensitization; Ca^{2+} uptake; $[Ca^{2+}]_i$; Cortical neuron; Primary culture (Cebers, G. (290) 105)

Cerebellar nuclei
Somatostatin; Receptor; sstr1 receptor; Autoradiography (Bucharles, C. (271) 79)

Cerebellum
Dopamine D_2 receptor; Dopamine D_3 receptor; [^{125}I]Iodosulpiride; Receptor autoradiography; Striatum; (Rat) (Levant, B. (278) 243)

Ro 15-4513; $GABA_A$ receptor; Diazepam-insensitive; Alcohol sensitivity; Benzodiazepine; Imidazoquinoxaline; Imidazoquinazoline; Cyclopyrrolone (Wong, G. (289) 335)

Cerebral artery, canine
PACAP (pituitary adenylate cyclase-activating polypeptide); Blood flow, vertebral artery; VIP (vasoactive intestinal peptide); Vasodilation (Seki, Y. (275) 259)

PACAP (pituitary adenylate cyclase activating polypeptide); Intracerebral arteriole, rat; Endothelium-derived contracting factor; Prostaglandin $F_{2\alpha}$ (Anzai, M. (285) 173)

Cerebral blood flow autoregulation
Doxazosin; α-Adrenoceptor; Hemorrhagic hypotension; Spontaneously hypertensive rat (SHR) (Cai, H. (286) 249)

Cerebral cortex
Ultrasonic distress call; Lesion; Anxiolytic mechanism; Diazepam; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide) (Naito, H. (272) 261)

GABA (γ-aminobutyric acid); Release; Epidural cup; Modafinil; 5-HT (5-hydroxytryptamine, serotonin) (Tanganelli, S. (273) 63)

CCK (cholecystokinin); Glutamate; NMDA receptor; Seizure (Bandopadhyay, R. (275) 53)

Atropine; α-Adrenoceptor; Aorta; (Rat) (Chang, K.C. (284) 331)

Cerebral cortex, rat
[^{3}H]YM060 ([methyl-^{3}H]-(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride); $5\text{-}HT_3$ receptor (Akuzawa, S. (281) 37)

$GABA_A$ receptor; Benzodiazepine BZ_1 site; Benzodiazepine BZ_2 site; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate) binding; Ontogenesis; Flunitrazepam; CL 218,872; Zolpidem (Giorgi, O. (290) 37)

Cerebral endothelium
Endothelin; Ca^{2+} uptake; Signal transduction (Stanimirovic, D.B. (288) 1)

Endothelin; Ca^{2+} uptake; Signal transduction (Stanimirovic, D.B. (289) 409)

Cerebral ischemia
Rolipram; cAMP; Phosphodiesterase; Hippocampus; (Gerbil) (Kato, H. (272) 107)

Glycine; MAP2 (microtubule-associated protein 2); Receptor autoradiography; Immunohistochemistry (Araki, T. (278) 91)

JO 1784 (igmesine hydrochloride); Hippocampus; Neuroprotection; Nitric oxide (NO) synthase; (Gerbil) (O'Neill, M. (283) 217)

Hippocampus; Lipid peroxidation; N^G-Nitro-L-arginine methyl ester; (Gerbil) (Caldwell, M. (285) 203)

Cerebral vasospasm
BQ-123; Endothelin; Nitric oxide (NO); Subarachnoid hemorrhage (Hirose, H. (277) 77)

BQ-123; Endothelin; Nitric oxide (NO); Subarachnoid hemorrhage (Hirose, H. (284) 335)

C-fiber
Histamine H_3 receptor; Lung, rabbit; Acetylcholine; Neuropeptide; Edema (Delaunois, A. (277) 243)

CFTR (cystic fibrosis transmembrane conductance regulator)
Opiate; Antidiarrheal agent; Ion conductance; P-glycoprotein (Callaghan, R. (291) 183)

C_6 glioma cell
Phosphoinositide turnover; Protein kinase A; Endothelin; (ATP) (Lin, W.W. (291) 1)

CGP 35348
$GABA_B$ receptor antagonist; Pyramidal tract neuron; Transcallosal response, cat; Motor cortex (Chowdhury, S.A. (285) 99)

CGP 37849
Epilepsy; NMDA receptor antagonist; CGP 39551; MK-801; Spatial learning (Ylinen, A. (274) 159)

Working memory; Reference memory; NMDA receptor (Deacon, R.M.J. (280) 239)

CGP 39551
Epilepsy; NMDA receptor antagonist; CGP 37849; MK-801; Spatial learning (Ylinen, A. (274) 159)

CGP 42112A
Angiotensin II; Losartan; DuP 532; PD 123319; Smooth muscle, portal vein (Pelet, C. (279) 15)

CGRP-(8–37)
CGRP (calcitonin gene-related peptide); Renal blood flow; Renal conductance; Na^+ excretion; K^+ excretion; [Tyr^0]CGRP-(28–37) (Elhawary, A.M. (286) 255)

[Tyr^0]CGRP-(28–37)
CGRP (calcitonin gene-related peptide); Renal blood flow; Renal conductance; Na^+ excretion; K^+ excretion; CGRP-(8–37) (Elhawary, A.M. (286) 255)

CGRP (calcitonin gene-related peptide)
K^+ channel opener; Longitudinal muscle; K^+ channel, ATP-sensitive (Sun, Y.-D. (271) 453)

Endothelin-1; Inflammation (Lopez-Belmonte, J. (271) R15)

Adrenomedullin; Vascular bed, intestinal; Vasoactive peptide; (Six-membered ring structure) (Santiago, J.A. (272) 115)

Cisplatin; Peripheral neuropathy; 5-HT_3 antagonist (Whitaker-Azmitia, P.M. (275) 139)

Vasodilator nerve; Nitric oxide (NO); Mesenteric artery, guinea pig; Capsaicin; Nitro-L-arginine; Zinc protoporphyrin IX (Gyoda, Y. (279) 83)

Histamine; Paw edema; Neurogenic inflammation (Amann, R. (279) 227)

Renal blood flow; Renal conductance; Na^+ excretion; K^+ excretion; CGRP-(8–37); [Tyr^0]CGRP-(28–37) (Elhawary, A.M. (286) 255)

TNF-α (tumor necrosis factor-α); Capsaicin; Cutaneous hyperemia; Afferent nerve stimulation; Bradykinin (Herbert, M.K. (286) 273)

Forskolin; Adenylate cyclase; Guinea-pig ureter; K^+ channel (Santicioli, P. (289) 17)

UV-B irradiation; Neurogenic inflammation; Cutaneous vasodilatation; Laser Doppler; Substance P; Nitric oxide (NO) (Benrath, J. (293) 87)

α-CGRP (calcitonin gene-related peptide)
Arteriovenous anastomose; Dihydroergotamine; Heart; Migraine, pig; Sumatriptan (Van Gelderen, E.M. (284) 51)

CGRP receptor
Adrenomedullin; Kidney, rat; Anesthetized rat (Haynes, J.M. (280) 91)

CGS16949A
Fadrozole hydrochloride; Aromatase inhibitor; MCF-7; T47D (Yano, S. (289) 217)

Channel inhibition, pH dependent
Patch clamp; Antiarrhythmic, class Ia; Disopyramide; Skeletal muscle; K_{ATP} channel (Moser, C. (284) 35)

Charybdotoxin
Lemakalim; Glibenclamide; ATP-sensitive Ca^{2+} channel; Apamin; Nitric oxide (NO) (Franck, H. (271) 379)

Vas deferens, rat; α_2-Adrenoceptor; Xylazine; 4-Aminopyridine; Tetraethylammonium; Phorbol dibutyrate; Bay K 8644 (Docherty, J.R. (287) 287)

Chemical modification
Muscarinic receptor; Alcuronium; Methylscopolamine; Allosteric interaction (Jakubík, J. (289) 311)

Chemiluminescence
Oxygen radical; Neutrophil; Corticosteroid; Ozone; Allergen (Stevens, W.H.M. (293) 251)

Chemiluminescence, luminol-dependent
Eosinophil; K^+ channel (Saito, M. (291) 217)

Chemoprotection
Hepatotoxicity; Lobenzarit; Paracetamol; Molecular mechanism (Remirez, D. (293) 301)

Chemoreflex
Anesthesia; Urethane; Reticulospinal vasomotor neuron; Rostral ventrolateral medulla; (Rats) (Sun, M.-K. (293) 237)

Chemotactic factor
Macrophage inflammatory protein 2; Allergic inflammation; Dexamethasone (Tanabe, J.-i. (284) 257)

Chemotherapy
Endotoxin; Nitric oxide (NO) synthase; Cytotoxicity; Cancer; Anti-cancer drug (Hattori, Y. (291) 83)

Chiral analog
Melatonin; Binding site; Melanophore, *Xenopus laevis* (Sugden, D. (287) 239)

Chloramine-T
Na^+ current; Disopyramide; Use-dependent block; Activation gate; (Fast inactivation gate) (Koumi, S.-i. (277) 165)

Chlorethylclonidine
α_1-adrenoceptor subtype; SZL-49; [^{3}H]prazosin binding (Pimoule, C. (290) 49)

Chloride ion
Local anesthetic; Hippocampal neuron; Patch-clamp technique; GABA (γ-aminobutyric acid); Glycine (Hara, M. (283) 83)

Chlormethiazole
$GABA_A$ receptor; Flunitrazepam binding; Alphaxalone; Propofol; (+)-Etomidate; Etazolate (Slany, A. (291) 99)

***p*-Chloroamphetamine**
Dextromethorphan; Neurotoxicity; σ Receptor; 5-HT (5-hydroxytryptamine, serotonin); Brain (Narita, N. (293) 277)

Chloroethylclonidine
Brain slice; Estrogen; 5-Methyl urapidil; WB-4101 (Kow, L.-M. (282) 199)

***p*-Chlorophenylalanine treatment**
Tetrahydroaminoacridine; Nicotine; Nucleus basalis lesion; Alzheimer's disease (Riekkinen Jr., P. (279) 65)

***m*-Chlorophenylbiguanide**
Sleep; Waking; 5-HT_3 receptor; MDL 72222; Dopamine; (+)-SCH 23390; YM-09151-2 (Ponzoni, A. (278) 111)

1-(*m*-Chlorophenyl)-biguanide
[^{3}H]GBR-12935; 5-HT_3 receptor; Dopamine transporter; Nucleus accumbens; Caudate putamen; (Rat) (Campbell, A.D. (290) 157)

Chloroprocaine
Drug discrimination; Local anesthetic; Dopamine; Cocaine; Dimethocaine; Procaine; SCH 39166; Raclopride; (Squirrel monkey) (Mansbach, R.S. (274) 167)

Chlorzoxazone
Cytochrome P450; Cytochrome P450 2E1; V79 Chinese hamster cell; *p*-Nitrophenol; *N*-Nitrosodimethylamine (Schmalix, W.A. (293) 123)

CHO (Chinese hamster ovary) cell
α_{1B}-Adrenoceptor; Radioligand binding studies; Concentration, cytosolic Ca^{2+}; Receptor occupancy-response relationship (Horie, K. (288) 303)

Muscarinic receptor; Pertussis toxin; G proteins; [^{3}H]*N*-methylscopolamine; [^{35}S]guanosine 5′-*O*-(3-thiotriphosphate) (Burford, N.T. (289) 343)

Muscarinic receptors; Binding affinity; Stereoselectivity; Pirenzepine (Barbier, P. (290) 125)

Muscarinic acetylcholine receptor; Nitric oxide (NO) (Wang, S.Z. (291) R1)

Cholera toxin
G-protein; Opiate; U-50488H; U-69593; PD 117302; Hypothermia; Gut motility; Pertussis toxin (Shukla, V.K. (292) 293)

Cholesterol synthesis
Hypocholesterolemic drug; Liver; Intestine; Dual isotope blood ratio method; Occupancy principle; (RICO rat) (Hajri, T. (286) 131)

Choline
Acetylcholine; 3,4-Diaminopyridine; Microdialysis (Buyukuysal, R.L. (281) 179)

Cholinergic activation
Colonic; Epithelia; Ion transport; Muscarinic receptor; [^{3}H]*N*-Methylscopolamine (O'Malley, K.E. (275) 83)

Cholinergic contraction
β_2-Adrenoceptor; β_3-Adrenoceptor; Electrical field stimulation; NANC (non-adrenergic non-cholinergic) contraction; Bronchus, main, guinea pig (Ten Berge, R.E.J. (275) 199)

Cholinergic neuronal system
Dynorphin A-(1–13); CO (carbon monoxide); Delayed amnesia; Learning; Nor-binaltorphimine; κ-Opioid receptor; Passive avoidance (Hiramatsu, M. (282) 185)

Cholinergic neurotransmission
Lipoxin A_4; Nitric oxide (NO); Smooth muscle, airway (Tamaoki, J. (287) 233)

Cholinergic pharmacology
α_7 Nicotinic acetylcholine receptor subunit; [^{125}I]α-bungarotoxin; HEK-293 (Human embryonic kidney 293 cell); Ion channel, ligand-gated (Gopalakrishnan, M. (290) 237)

Cholinergic system
Methamphetamine; Scopolamine; Behavioral sensitization; Drug conditioning; Low-frequency tone (Yui, K. (279) 135)

Cholinesterase
MDL 73,745; Microdialysis; Acetylcholine; Norepinephrine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Zhu, X.-d. (276) 93)

Chorda tympani
Neuroimmunomodulation; Cyclosporine; Stress; Sympathetic nervous system; Parasympathetic nervous system; Submaxillary lymph node; Superior cervical ganglion (Esquifino, A.I. (285) 143)

Chromaffin cell
Muscarinic receptor; Phosphatidylinositol hydrolysis; Ca^{2+}, intracellular; Cation channel, non-selective; (Guinea-pig) (Inoue, M. (276) 123)

Anatoxin-a; Nicotinic acetylcholine receptor, neuronal type; Nicotinic receptor agonist; Mecamylamine; Noradrenaline release; Adrenaline release (Molloy, L. (289) 447)

Caffeine; Acetylcholine receptor (Liu, P.-S. (291) 265)

6-Hydroxydopamine; H_2O_2; Bupropion; R56865; Cytotoxicity; Cytoprotection (Abad, F. (293) 55)

Chronic CGP 39551
NMDA receptor; [^{3}H]Noradrenaline release; Quinolinic acid neurotoxicity; Hippocampus; Autoradiography (Mennini, T. (271) 93)

Chronic chlordiazepoxide
Behavior; EEG (electroencephalographic); Tolerance; Dependence; (Rat) (Sala, M. (273) 35)

Chronic opioid treatment
Protein kinase C; Phorbol ester binding; Morphine; Butorphanol (Narita, M. (271) 547)

Chronic variate stress
Foot-shock stress, acute; β-Adrenoceptor; 5-HT_{1A} receptor; 5-HT_2 receptor; Amitriptyline; Open-field; Brain cortex, rat (Ferretti, C. (280) 19)

Chronopharmacokinetics
Acetylsalicylic acid; Chronopharmacology; Chronotoxicity (Ohdo, S. (293) 151)

Chronopharmacology
Acetylsalicylic acid; Chronotoxicity; Chronopharmacokinetics (Ohdo, S. (293) 151)

Sodium valproate; Embryotoxicity (Ohdo, S. (293) 281)

Chronotoxicity
Acetylsalicylic acid; Chronopharmacology; Chronopharmacokinetics (Ohdo, S. (293) 151)

Chymostatin
Endothelin-1; Red blood cell; Staphylococcal α-toxin; Phosphoramidon; Pepstatin A; Leupeptin (Tippler, B. (271) 131)

CI977
κ-Opioid receptor; Excitatory amino acid; Epilepsy; Na^+ channel (Millan, M.H. (279) 75)

Cicaprost
Prostacyclin receptor; Non-prostanoid prostacyclin mimetic; Neutrophil, rat; Colon, rat (Wise, H. (278) 265)

Cicletanine
Sulfate; Kidney; Cell membrane; Ion transport; Natriuresis; Diuresis; Na^+ transport; Capillary electrophoresis (Garay, R.P. (274) 175)

Cilia
Formoterol; Terbutaline; Trachea; Maxillary sinus; Mucociliary clearance (Lindberg, S. (285) 275)

Cimetidine
Islets of Langerhans; Endocrine pancreas; Imidazoline receptor; Imidazoline I_1 site; Moxonidine; Efaroxan; Diazoxide; Insulin secretion (Tsoli, E. (284) 199)

Cirazoline
Imidazoline site; α-Adrenoceptor (Le Rouzic, M. (278) 261)

Circling
Dopamine; Microinjection; MK-801; Potentiation; Striatum, rat; 6-Hydroxydopamine (St-Pierre, J.-A. (272) 123)

Circling behavior
Muscimol; Δ^9-Tetrahydrocannabinol; Substantia nigra, pars reticulata; Contralateral circling; Drug interaction (Wickens, A.P. (282) 251)

Circular dichroism spectrum
Mast cell; Neuropeptide Y; Heterotrimeric G protein; Benzalkonium chloride; Pertussis toxin; (Rat); (Human) (Mousli, M. (289) 125)

Cisplatin
Peripheral neuropathy; CGRP (calcitonin gene-related peptide); 5-HT_3 antagonist (Whitaker-Azmitia, P.M. (275) 139)

Vagal depolarization; Vagus nerve; 5-HT (5-hydroxytryptamine, serotonin); Dexamethasone; (Rat); (Grease gap) (Woods, A.J. (278) 275)

CL 218,872
$GABA_A$ receptor; Benzodiazepine BZ_1 site; Benzodiazepine BZ_2 site; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate) binding; Ontogenesis; Flunitrazepam; Zolpidem; Cerebral cortex, rat (Giorgi, O. (290) 37)

Cl^- channel
Colon, rat; K^+ channel, Ca^{2+}; Prostaglandin; Enteric nervous system (Strabel, D. (274) 181)

Patch clamp; GABA receptor; Bicuculline; Retina; Bipolar cell; Rod pathway (Feigenspan, A. (288) 97)

Cl^-, extracellular
Aortic endothelial cell; Ca^{2+} mobilization; Fura-2; Thapsigargin; Cyclopiazonic acid (Hosoki, E. (288) 131)

Clenbuterol
β-Adrenoceptor agonist; Taurine; Urinary marker; Protein synthesis (Waterfield, C.J. (293) 141)

Climbing
Dopamine receptor antagonist; 5-HT_{1A} receptor agonist; Stereotyped behavior; Grooming; Catalepsy (Protais, P. (271) 167)

Clocinnamox
Morphine; Opioid receptor antagonist; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U69,593; Opioid receptor alkylation; Opioid receptor binding; mRNA; Solution hybridization; Analgesia; (Irreversible antagonist) (Chan, K. (287) 135)

Clomipramine
Fluoxetine; Imipramine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Extrapyramidal symptom; Antidepressant; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (281) 255)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); *m*-CPP (*m*-chlorophenylpiperazine); Depression, genetic model; Clorgyline; Imipramine (Aulakh, C.S. (282) 65)

Clonazepam
Diazepam; Ro 5-4864; Kidney, isolated, perfused; Renal function; Renal vasculature; (Rat) (Monasterolo, L.A. (276) 201)

Cloned receptor
NS-49; Oxymetazoline; α_1-Adrenoceptor subtype; Radioligand binding study; Cytosolic Ca^{2+} concentration (Obika, K. (291) 327)

Clonidine
Imidazoline; Idazoxan; Brain, human; Binding, specific (Greney, H. (271) 533)

DAMGO ([D-Ala^2,MePhe^4,Gly(ol)^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Nalorphine; U50,488; Xylazine (Paul, D. (272) 111)

Rostral ventrolateral medulla; Vasomotor neuron; Sympathoexcitatory neuron; GABA (γ-aminobutyric acid) (Sun, M.-K. (276) 291)

Hypothalamus; Pituitary; α_2-Adrenoceptor; Growth hormone; Oxymetazoline; α_2-Adrenoceptor antagonist; α_{2A}-Adrenoceptor subtype; α_{2B}-Adrenoceptor subtype (Makara, G.B. (287) 43)

Clonidine-induced mydriasis
DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); α_2-Adrenoceptor, postsynaptic; Brain, rat; [^{3}H]RX 821002 binding; α_{2D}-Adrenoceptor (Heal, D.J. (277) 215)

Cloning
Nitric oxide(NO); Nitric oxide synthase; Expression; Baculovirus; Endotoxic shock (Moss, D.W. (289) 41)

Clorgyline
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); *m*-CPP (*m*-chlorophenylpiperazine); Depression, genetic model; Imipramine; Clomipramine (Aulakh, C.S. (282) 65)

Clozapine
Haloperidol; Fos protein; Tolerance; Nucleus accumbens; Striatum; Amygdala; (Long-term treatment) (Sebens, J.B. (273) 175)

Prefrontal cortex; 5-HT_2 receptor; Microdialysis; Antipsychotic (Schmidt, C.J. (273) 273)

Dopamine D_4 receptor; Pyridobenzodiazepine (Liégeois, J.-F. (273) R1)

Dopamine D_3 receptor; Core temperature; Thermoregulation; Antipsychotic (Millan, M.J. (280) 225)

5-HT_{2A} receptor; Phencyclidine (Maurel-Remy, S. (280) R9)

Dopamine receptor agonist; Dopamine D_1 receptor; Dopamine D_2 receptor; Quinpirole; Antipsychotic, atypical; Scopolamine; SKF38393; (Rat) (Jackson, D.M. (282) 137)

CNQX (6-cyano-7-nitroquinoxaline-2,3-dione)
Glutamate; MK-801; Inflammation; Pain; Analgesia (Jackson, D.L. (284) 321)

Cocaine
Drug discrimination; Local anesthetic; Dopamine; Dimethocaine; Procaine; Chloroprocaine; SCH 39166; Raclopride; (Squirrel monkey) (Mansbach, R.S. (274) 167)

Amphetamine; Locomotor activity; Microdialysis, in vivo; Opioid receptor antagonist; Dopamine; Striatum; Nucleus accumbens (Schad, C.A. (275) 9)

(−)-DS121; Dopamine autoreceptor antagonist; Dopamine D_3 receptor; D-Amphetamine; Drug discrimination; Caffeine (Clark, D. (275) 67)

Naltrindole; Enkephalin; δ-Opioid receptor; Cocaine-induced sensitization (Shippenberg, T.S. (280) 55)

5-HT (5-hydroxytryptamine, serotonin); Fenfluramine; Corticosterone, presynaptic (Baumann, M.H. (282) 87)

SCH 23390; Sulpiride; Eticlopride; Ontogeny (Pruitt, D.L. (283) 125)

Apomorphine; Deoxyglucose; Brain metabolism; Nucleus accumbens (Pontieri, F.E. (284) 205)

SCH23390; Haloperidol; Catalepsy; Supersensitivity; Subsensitivity; (Mouse) (Ushijima, I. (285) 55)

ACTH (adrenocorticotropic hormone); Corticosterone; Hypothalamus-pituitary-adrenal axis (Schmidt, E.D. (285) 317)

Cytochrome P450; Hepatotoxicity; Coumarin 7-hydroxylase; Hepatotoxin (Pellinen, P. (292) 57)

Cocaine-induced sensitization
Cocaine; Naltrindole; Enkephalin; δ-Opioid receptor (Shippenberg, T.S. (280) 55)

CO (carbon monoxide)
Dynorphin A-(1–13); Cholinergic neuronal system; Delayed amnesia; Learning; Nor-binaltorphimine; κ-Opioid receptor; Passive avoidance (Hiramatsu, M. (282) 185)

Codeine
Noncompetitive agonist; Sensitization (Storch, A. (290) 207)

Cognition
Antipsychotic; Delay non-match to position; (Rat) (Didriksen, M. (281) 241)

Cold water tail-flick test
Antisense oligodeoxynucleotide; Analgesia; μ-Opioid receptor; (Rat) (Chen, X.-H. (275) 105)

Collagenase
Inflammation; Kinin; Nitric oxide (NO); Serine protease inhibitor; Platelet (Souza Pinto, J.C. (274) 101)

Colon
Epithelium; Ion transport; Histamine; Secretion; (Human) (Keely, S.J. (279) 203)

Colon carcinoma cell
Receptor ligand; Cell proliferation; Mammary carcinoma cell; Melanoma cell (Brent, P.J. (278) 151)

Colon, guinea pig
5-HT receptor; Gastrointestinal motility; Enteric nerve; Relaxation (Briejer, M.R. (279) 123)

Colonic
Cholinergic activation; Epithelia; Ion transport; Muscarinic receptor; [^{3}H]*N*-Methylscopolamine (O'Malley, K.E. (275) 83)

Colonic hypersensibility
Fedotozine; Visceral pain; κ-Opioid receptor; μ-Opioid receptor Langlois, A. (271) 245)

Colonic mucosa
Nicotine; Cytokine (Van Dijk, J.P.M. (278) R11)

Colon, rat
Cl^- channel; K^+ channel, Ca^{2+}; Prostaglandin; Enteric nervous system (Strabel, D. (274) 181)

Neurotensin; Neurotensin receptor; Gastrointestinal motility (Mulè, F. (275) 131)

Prostacyclin receptor; Cicaprost; Non-prostanoid prostacyclin mimetic; Neutrophil, rat (Wise, H. (278) 265)

Complex I
Manganese; Manganism; PC12 cell; Parkinson-like disease (Galvani, P. (293) 377)

Compound 48/80
Acetylshikonin; Hind-paw edema; Cutaneous anaphylaxis, passive; Neurogenic inflammation; Vascular permeability; [Thi^{5,8},D-Phe^7]Bradykinin; [D-Pro^2,D-Trp^{7,9}]Substance P (Wang, J.-P. (272) 87)

Abruquinone A; Paw edema; Neurogenic inflammation; Passive cutaneous anaphylaxis; Vascular permeability; Mast cell degranulation (Wang, J.-P. (273) 73)

Scratching; Itch; Pain; Substance P; Histamine (Kuraishi, Y. (275) 229)

Concanavalin A
TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Dioxin; Immunotoxicity; Interleukin; Thymus; Spleen; T lymphocyte; B lymphocyte; Macrophage; (Rat) (Badesha, J.S. (293) 429)

Concentration, cytosolic Ca^{2+}
α_{1B}-Adrenoceptor; Chinese hamster ovary (CHO) cell; Radioligand binding studies; Receptor occupancy-response relationship (Horie, K. (288) 303)

Conditioned fear stress
Conditioned suppression; Dopamine D_1 receptor; Dopamine D_2 receptor; Motor suppression (Kamei, H. (273) 229)

Conditioned place preference
Genetic selection; Locomotor activity; Nicotine; (Mouse) (Schechter, M.D. (279) 59)

Morphine; Diazepam; (Mouse) (Suzuki, T. (280) 327)

Conditioned suppression
Conditioned fear stress; Dopamine D_1 receptor; Dopamine D_2 receptor; Motor suppression (Kamei, H. (273) 229)

Conditioning
Morphine; 7-OH-DPAT (7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Place preference; Dopamine; Dopamine D_3 receptor; (Rat) (De Fonseca, F.R. (274) 47)

Conductance vessel
Elgodipine; Ca^{2+} channel antagonist; Resistance vessel; (Rabbit); (Sheep) (Chulia, T. (285) 115)

Conduction interval
Semotiadil; Diltiazem; Amlodipine; Nifedipine; Refractoriness (Stark, G. (286) 71)

Conflict
5-HT_{1A} receptor; Ipsapirone; (*S*)-WAY 100135; Punishment; Anxiolytic activity (Cervo, L. (284) 249)

ω-Conotoxin GVIA
ω-Conotoxin MVIIC; ω-Conotoxin MVIIA; ω-Agatoxin IVA; Sympathetic neurotransmission; Ca^{2+} channel; Heart (Vega, T. (276) 231)

ω-Conotoxin MVIIA
ω-Conotoxin GVIA; ω-Conotoxin MVIIC; ω-Agatoxin IVA; Sympathetic neurotransmission; Ca^{2+} channel; Heart (Vega, T. (276) 231)

ω-Conotoxin MVIIC
ω-Conotoxin GVIA; ω-Conotoxin MVIIA; ω-Agatoxin IVA; Sympathetic neurotransmission; Ca^{2+} channel; Heart (Vega, T. (276) 231)

Contact hypersensitivity
Ultraviolet irradiation; Neuropeptide release; Neurogenic immunomodulation; Langerhans cell (Gillardon, F. (293) 395)

Contractile force
Morphine; Opioid receptor; Aorta, rat (Parra, L. (277) 99)

Contractile protein
Cadmium ion; Vasoconstriction; Ca^{2+} channel; Aorta, rat (Wakabayashi, I. (293) 133)

Contractile response
Urinary bladder, rabbit; Muscarinic receptor subtype; Acetylcholine release; Muscarinic receptor antagonist (Tobin, G. (281) 1)

Contractility
Cardiac myocyte; σ Receptor; $[Ca^{2+}]_i$ transient (Novakova, M. (286) 19)

Contraction
Airway human; Leukotriene; Anti-immunoglobulin E; Cysteinyl leukotriene receptor antagonist (Gorenne, I. (275) 207)

Histamine; Bronchus, human; Protein kinase C; GF 109203X; Phorbol ester (Yang, K.X.F. (275) 283)

Melatonin receptor; Caudal artery, rat; Adrenergic nerve (Krause, D.N. (276) 207)

Pelanserin; 5-HT receptor antagonist; Methoxamine; Spontaneously hypertensive rat (SHR) (Villalobos-Molina, R. (277) 181)

Tyrosine kinase inhibitor; Aorta, rat; Ca^{2+} store refilling; Vanadate (Filipeanu, C.M. (281) 29)

Isoprostane; Myometrium, human; Prostanoid TP receptor; U46619 (Crankshaw, D. (285) 151)

Contraction, force of
Atrium, rat; Aortic ring; Relaxation; cGMP-dependent protein kinase; Acetylcholine (Bäumner, D. (273) 295)

Contraction, phasic
4-Aminopyridine; α-Adrenoceptor; K^+ channel; Caudal epididymis, rat (Huang, Y. (280) 231)

Contralateral circling
Muscimol; Δ^9-Tetrahydrocannabinol; Substantia nigra, pars reticulata; Circling behavior; Drug interaction (Wickens, A.P. (282) 251)

Contralateral turning
NMDA receptor; Non-NMDA receptor; Strionigral pathway (Ossowska, K. (273) 89)

Convulsant (picrotoxin) site
Pentylenetetrazol; γ-Butyrolactone bicyclic; $GABA_A$ receptor-ionophore complex; [^{35}S]TBPS binding; Benzodiazepine sites (Maksay, G. (288) 61)

Convulsion
AMPA ((*RS*)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid); NMDA (*N*-methyl-D-aspartate); ATPA ((*RS*)-2-amino-3-(3-hydroxy-5-*tert*-butylisoxazol-4-yl)propionic acid); Cue; Glutamate receptor; (Rat); (Mouse) (Arnt, J. (285) 289)

Core temperature
Dopamine D_3 receptor; Thermoregulation; Clozapine; Antipsychotic (Millan, M.J. (280) 225)

Coronary artery
Nitroglycerin bioactivation; Glutathione-*S*-transferase; Cytochrome *P*-450; Cultivated smooth muscle cell; cGMP (Braun, M. (276) 239)

Coronary artery, human
[Arg^8]Vasopressin; Vasopressin V_1 receptor; OPC-21268; OPC-31260; SR 49059; (Human) (Bax, W.A. (285) 199)

Coronary artery, porcine
Ca^{2+}; Ba^{2+}; Sr^{2+}; Nitric oxide (NO); Diltiazem (Ohashi, K. (285) 165)

Coronary artery, rat
Histamine; Artery, small; Histamine receptor; Nitric oxide (NO) (Van de Voorde, J. (271) 17)

Coronary flow
Endothelin receptor antagonist; Endothelin-1; Endothelin ET_A receptor; Endothelin ET_B receptor; Nitric oxide (NO); Vasoconstriction (Wang, Q.-D. (271) 25)

Coronary occlusion
Adenosine release; Reperfusion arrhythmia; Lidocaine; Quinidine; Gallopamil (Bernauer, W. (283) 91)

Cortex
Striatum; Rotenone; MPP^+ (1-methyl-4-phenylpyridinium ion); Dopaminergic system (Bougria, M. (291) 407)

Cortex, rat
Efaroxan; α_2-Adrenoceptor antagonist; Microdialysis; Acetylcholine release (Tellez, S. (277) 113)

Cortical culture
Toxicity; Antioxidant; Free radical; NMDA receptor (Eshhar, N. (283) 19)

K^+-induced depolarization; Hypoxia; Glutamate; Extracellular; Glutamate receptor; Serum-free culture (Uchiyama-Tsuyuki, Y. (293) 245)

Cortical neuron
Vinpocetine; Phenytoin; Na^+ channel, voltage-gated; Anticonvulsant; Neuroprotection; (Rat) (Molnár, P. (273) 303)

AMPA receptor; Cyclothiazide; Receptor desensitization; Ca^{2+} uptake; $[Ca^{2+}]_i$; Cerebellar granule neuron; Primary culture (Cebers, G. (290) 105)

Cortical wedge
Remacemide hydrochloride; FPL 12495AA; NMDA receptor (Hu, R.Q. (287) 251)

Corticosteroid
Adrenalectomy; Dopamine; Limbic forebrain; Locomotor activity; Nicotine; Sensitization; (Rat) (Johnson, D.H. (276) 155)

β_1-Adrenoceptor; Catecholamine; Transcriptional regulation; Thyroid hormone; (Sheep) (Tseng, Y.T. (289) 353)

Oxygen radical; Chemiluminescence; Neutrophil; Ozone; Allergen (Stevens, W.H.M. (293) 251)

Corticosterone
Social defeat; $5\text{-}HT_{1A}$ receptor; Subsensitivity (Korte, S.M. (272) 45)

Diurnal alteration; Opioid mechanism; ACTH (adrenocorticotrophin); Prolactin (Kiem, D.T. (272) 145)

$5\text{-}HT_{1A}$ receptor; Glucose; 5-HT (5-hydroxytryptamine, serotonin); Behavioral syndrome; (S)-UH301; Flesinoxan (Groenink, L. (272) 177)

5-HT (5-hydroxytryptamine, serotonin); ACTH (adrenocorticotropin); Prolactin; Renin; Blood pressure; Heart rate (Levy, A.D. (274) 141)

Apomorphine; 5-HT (5-hydroxytryptamine, serotonin); Grooming, excessive; Penile erection; Oxytocin; Prolactin; $5\text{-}HT_{2C}$ receptor; m-CPP (1-3-chlorophenylpiperazine); Hypothalamic paraventricular nucleus (Bagdy, G. (275) 301)

$5\text{-}HT_{1A}$ receptor; Glucose; Prolactin; Flesinoxan; Defensive burying; Anxiety (Groenink, L. (280) 185)

Learned helplessness; Antidepressant; $5\text{-}HT_2$ receptor (Nankai, M. (281) 123)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Ethanol tolerance; Ethanol withdrawal; 5-HT (5-hydroxytryptamine, serotonin) syndrome (Kleven, M. (281) 219)

ACTH (adrenocorticotropic hormone); Cocaine; Hypothalamus-pituitary-adrenal axis (Schmidt, E.D. (285) 317)

Corticosterone, presynaptic
5-HT (5-hydroxytryptamine, serotonin); Cocaine; Fenfluramine (Baumann, M.H. (282) 87)

Corticotropin releasing factor
Ca^{2+}; Ca^{2+} channel; Pertussis toxin; inositol trisphosphate; Epithelium (Kiang, J.G. (291) 107)

COS-7 cell
α_1-Adrenoceptor subtype; Radioligand binding study; Benign prostatic hypertrophy (Foglar, R. (288) 201)

Human glutamate transporter (hGluT-1); CCG (2-(Carboxycyclopropyl)-glycine); Transfection (Yamashita, H. (289) 387)

COS-7 cell, transient expression
Brain, chicken; G-protein-coupled receptor; Recombinant P_{2Y1} purinoceptor; *Xenopus* oocyte expression; Inositol 1,4,5-trisphosphate, formation (Simon, J. (291) 281)

Cotransmission
Endothelin receptor; Vas deferens; Endothelin-3; BQ-123; Sarafotoxin S6c; (Guinea-pig) (Mutafova-Yambolieva, V.N. (285) 213)

Cough
Antitussive; Antihistamine; (Guinea pig) (Bolser, D.C. (277) 159)

Coumarin 7-hydroxylase
Cytochrome P450; Cocaine; Hepatotoxicity; Hepatotoxin (Pellinen, P. (292) 57)

Coupling efficiency
Cardiomyopathy; β-adrenoceptor subtype; Adenylyl cyclase; Hamster; Age-dependent (Witte, K. (290) 1)

Covalent bond
Skeletal muscle actin; 5-HT (5-hydroxytryptamine, serotonin); Dopamine; 5-HT (5-hydroxytryptamine, serotonin) binding protein; Iron (Velez Pardo, C. (288) 209)

CP 55,940
Anandamide; Drug discrimination; Δ^9-Tetrahydrocannabinol (Wiley, J. (276) 49)

(±)-CP96,345
Bronchospasm; MEN10,627; Neurokinin A; PAF (platelet-activating factor); Substance P; Tachykinin (Perretti, F. (273) 129)

CP 99,994
CRF (corticotropin-releasing factor); Plasma extravasation; Antigen challenge; Neurogenic inflammation, guinea pig; Substance P (Yoshihara, S. (280) 113)

CP-122,288
Sumatriptan; 5-HT receptor; Vasoconstriction (Beattie, D.T. (276) 271)

CPP ((±)-3(2-carboxypiperazin-4-yl)-propyl-1-phosphonoic acid)
Somatostatin; Hippocampus; Muscarinic M_1 receptor; Pirenzepine; NMDA receptor; Working memory (Ohno, M. (271) 557)

m-CPP (1-3-chlorophenylpiperazine)
Apomorphine; 5-HT (5-hydroxytryptamine, serotonin); Grooming, excessive; Penile erection; Oxytocin; Prolactin; Corticosterone; 5-HT_{2C} receptor; Hypothalamic paraventricular nucleus (Bagdy, G. (275) 301)

***m*-CPP (*m*-chlorophenylpiperazine)**
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Depression, genetic model; Clorgyline; Imipramine; Clomipramine (Aulakh, C.S. (282) 65)

CR1505
Pancreatic hypertrophy; Bethanechol; Pentagastrin; Muscarinic receptor; CCK receptor (Kato, M. (292) 47)

CRF (corticotropin-releasing factor)
Interleukin-1; Nitric oxide (NO); Neuroimmunology; N^G-Nitro-L-arginine; Hemoglobin; Indomethacin; Prostaglandin (Sandi, C. (274) 17)

Interleukin-1; Interleukin-1 receptor antagonist; α-MSH (α-melanocyte-stimulating hormone); α-Helical CRF-(9–41); Morphine withdrawal (Katsumata, S. (278) 143)

CP 99,994; Plasma extravasation; Antigen challenge; Neurogenic inflammation, guinea pig; Substance P (Yoshihara, S. (280) 113)

Cromakalim
Nicorandil; cGMP; Detrusor muscle, rat; Femoral artery, rat; K^+ channel (Zhou, Q. (273) 153)

K^+ channel opener; NIP-121; Epithelium; Trachea, guinea-pig; Methylene blue; Phosphoramidon (Shikada, K.-i. (282) 193)

RP 49356; Myometrium; $^{42}K^+$ efflux; $^{86}Rb^+$ efflux; K^+ channel (Piper, I.T. (283) 1)

K_{ATP} channel opener; Pinacidil; Morphine; Intestinal transit; Diarrhea (Poggioli, R. (287) 207)

Crop emptying
Omeprazole; Medium chain triacylglycerol; Long chain triacylglycerol; Acid; (Chick) (Mabayo, R.T. (273) 161)

Cross-tolerance
γ-Hydroxybutyric acid (GHBA); Ethanol; Motor-impairing effect; (Rat) (Colombo, G. (273) 235)

Cryptolepine (5-methylquindoline)
Vasodilation; Kidney, rat; G-protein; K^+ channel; Ca^{2+} channel; Pertussis toxin (Oyekan, A.O. (285) 1)

CS-866
Angiotensin II; Nonpeptide; Angiotensin receptor antagonist; Angiotensin AT_1 receptor, selective (Mizuno, M. (285) 181)

Cue
AMPA ((*RS*)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid); NMDA (*N*-methyl-D-aspartate); ATPA ((*RS*)-2-amino-3-(3-hydroxy-5-*tert*-butylisoxazol-4-yl)propionic acid); Convulsion; Glutamate receptor; (Rat); (Mouse) (Arnt, J. (285) 289)

Cultivated smooth muscle cell
Nitroglycerin bioactivation; Glutathione-*S*-transferase; Cytochrome *P*-450; Coronary artery; cGMP (Braun, M. (276) 239)

Culture
Lidocaine; α_1-Adrenoceptor; Up-regulation; Cardiocyte (Mizuki, T. (277) 133)

Cultured neuron
Oxcarbazepine; 10-Monohydroxy metabolite; Na^+-dependent action potential; Maximal electroshock (Wamil, A.W. (271) 301)

Neurotoxicity; Excitatory amino acid; Glutamate; Glutamate receptor subtype; Motoneuron (Estevez, A.G. (280) 47)

Current clamp
Ischemia; Reperfusion; Skeletal muscle; Phosphocreatine disodium salt; Phosphocreatine di-L-arginine salt; L-Arginine; Electrophysiology (Tricarico, D. (287) 17)

Cutaneous anaphylaxis, passive
Acetylshikonin; Hind-paw edema; Neurogenic inflammation; Vascular permeability; Compound 48/80; [Thi^{5,8},D-Phe^7]Bradykinin; [D-Pro^2,D-Trp^{7,9}]Substance P (Wang, J.-P. (272) 87)

Cutaneous hyperemia
TNF-α (tumor necrosis factor-α); Capsaicin; Afferent nerve stimulation; CGRP (calcitonin gene-related peptide); Bradykinin (Herbert, M.K. (286) 273)

Cutaneous vasodilatation
UV-B irradiation; Neurogenic inflammation; Laser Doppler; CGRP (calcitonin gene-related peptide); Substance P; Nitric oxide (NO) (Benrath, J. (293) 87)

CV-11974
TCV-116; Smooth muscle cell; Vascular; Cell growth; c-*fos* (Flesch, M. (289) 399)

6-Cyano-7-nitroquinoxaline-2,3-dione
AMPA/kainate receptor; Desensitizing current, fast; GAMS (γ-D-glutamylaminomethylsulfonic acid); Hippocampal neuron, rat (Wilsch, V.W. (284) 141)

(±)-Cyanopindolol
Hyperphagia; Neuropeptide Y; *d*-Fenfluramine; Paraventricular nucleus of the hypothalamus; 5-HT receptor (Grignaschi, G. (274) 221)

Cyclazosin
α_1-Adrenoceptor antagonist; Prazosin-related antagonist; α_1-Adrenoceptor subtype (Giardinà, D. (287) 13)

Cyclic nucleotide
Gastric fundus; NANC (non-adrenergic, non-cholinergic); Phosphodiesterase (Barbier, A.J. (276) 41)

Pulmonary vein, sheep; Vasodilatation; 5-HT (5-hydroxytryptamine, serotonin); Endothelium (Zhang, L. (280) 335)

Cyclic nucleotide phosphodiesterase
Mesangial cell, rat; cyclic GMP; cyclic AMP; ANF-(1–28) (Atrial natriuretic factor-(1–28); E4021 (Ahn, H.-S. (289) 49)

Cycloheximide
Bradykinin B_1 receptor; Brefeldin A; Tunicamycin; Receptor upregulation; Aorta, isolated, rabbit (Audet, R. (271) 551)

Cyclohexyladenosine
Morphine; Antinociception; Tolerance; Adenosine receptor; (Rat) (Tao, P.-L. (278) 233)

Cyclooxygenase
Ulcer; NSAID (non-steroidal anti-inflammatory drug); Inflammation; Leukotriene (Wallace, J.L. (271) 525)

Cyclooxygenase inhibition
Spinal cord slice; Prostaglandin E_2 release; Capsaicin; Capsazepine (Malmberg, A.B. (271) 293)

Cyclooxygenase inhibitor
Bronchial blood flow; Hemodynamics; Ibuprofen; Smoke inhalation injury (Abdi, S. (293) 475)

Cyclo-oxygenase product
PAF (platelet-activating factor); Nitric oxide (NO); Vascular reactivity; L-NMMA (N^G-monomethyl-L-arginine); Indomethacin (Shiga, T. (282) 151)

Cyclophosphamide
Taurine; Niacin; Lung injury antioxidant; Membrane stabilizer (Venkatesan, N. (292) 75)

Cyclopiazonic acid
Skinned fiber; Sarcoplasmic reticulum; Development; Skeletal muscle (Huchet, C. (271) 141)

Aortic endothelial cell; Ca^{2+} mobilization; Cl^-, extracellular; Fura-2; Thapsigargin (Hosoki, E. (288) 131)

Cyclopyrrolone
Ro 15-4513; $GABA_A$ receptor; Diazepam-insensitive; Cerebellum; Alcohol sensitivity; Benzodiazepine; Imidazoquinoxaline; Imidazoquinazoline (Wong, G. (289) 335)

D-Cycloserine
Oxiracetam; Aniracetam; NMDA receptor; Noradrenaline release; Kynurenic acid (Pittaluga, A. (272) 203)

Cyclosporin
Neuroimmunomodulation; Stress; Sympathetic nervous system; Parasympathetic nervous system; Submaxillary lymph node; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (285) 143)

Substance P (tachykinin NK_1) receptor antagonist; Neuroimmunomodulation (Gitter, B.D. (289) 439)

Cyclothiazide
AMPA receptor; Receptor desensitization; Ca^{2+} uptake; $[Ca^{2+}]_i$; Cerebellar granule neuron; Cortical neuron; Primary culture (Cebers, G. (290) 105)

α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor; Arachidonic acid; Carbachol; Kainate receptor; Striatal neuron (Petitet, F. (291) 143)

CYP2A
Aflatoxin B_1; *Saccharomyces cerevisiae*; Metabolic activation (Pelkonen, P. (292) 67)

Cysteinyl leukotriene receptor antagonist
Airway human; Leukotriene; Anti-immunoglobulin E; Contraction (Gorenne, I. (275) 207)

Cystic fibrosis
Nitric oxide (NO); Asthma; Inflammation; Cytokine (Belvisi, M. (283) 255)

Cystometrogram
GYKI 52466; MK-801; Urethral sphincter, external; Bladder reflex (Yoshiyama, M. (287) 73)

Cytochrome P450
Nitroglycerin bioactivation; Glutathione-*S*-transferase; Coronary artery; Cultivated smooth muscle cell; cGMP (Braun, M. (276) 239)

Lipopolysaccharide; Arachidonic acid; Nitric oxide (NO) (Oyekan, A.O. (277) 123)

Cocaine; Hepatotoxicity; Coumarin 7-hydroxylase; Hepatotoxin (Pellinen, P. (292) 57)

Dexamethasone; Interleukin-2; Liver; TNF (tumor necrosis factor); Xanthine oxidase (Cantoni, L. (292) 257)

Cytochrome P450 2E1; V79 Chinese hamster cell; *p*-Nitrophenol; Chlorzoxazone; *N*-Nitrosodimethylamine (Schmalix, W.A. (293) 123)

Anesthesia, general; Anesthetics, general; Aniline hydroxylase (LaBella, F.S. (293) 231)

Zucker rat; Enzyme induction; Obesity (Irizar, A. (293) 385)

Cytochrome P450 3A4
Heterologous expression; V79 Chinese hamster cell; Testosterone; Ergot derivative (Rauschenbach, R. (293) 183)

Cytochrome P450 3A4, human
NIH/3T3 cell; Biotransformation; lacZ' shuttle vector; Mutagenicity (De Groene, E.M. (293) 47)

Cytochrome P450 2E1
Cytochrome P450; V79 Chinese hamster cell; *p*-Nitrophenol; Chlorzoxazone; *N*-Nitrosodimethylamine (Schmalix, W.A. (293) 123)

Cytokine
Lipopolysaccharide; Mitogen; Nitric oxide (NO); Prostaglandin (Akarasereenont, P. (273) 121)

Nicotine; Colonic mucosa (Van Dijk, J.P.M. (278) R11)

Bradykinin; Bradykinin analog; Bradykinin receptor antagonist; HOE 140; Mononuclear cell; Interleukine (Paegelow, I. (279) 211)

TNF (tumor necrosis factor); Interleukin-1; Elastase; Neutrophil (Klemm, P. (281) 69)

Nitric oxide (NO); Asthma; Cystic fibrosis; Inflammation (Belvisi, M. (283) 255)

Asthma; TNF-α (tumor necrosis factor-α); Bronchial hyperresponsiveness; Electrical field stimulation; Airway, human (Anticevich, S.Z. (284) 221)

Cytomegalovirus
Immunotoxicity testing; Ultraviolet light; Bis(tri-*n*-butyltin)oxide (Garssen, J. (292) 223)

Cytoprotection
CCK (cholecystokinin); CCK receptor; Stomach; Gastric hyperemia (Konturek, S.J. (273) 57)

6-Hydroxydopamine; H_2O_2; Bupropion; R56865; Cytotoxicity; Chromaffin cell (Abad, F. (293) 55)

Cytosolic
Neuropeptide Y; U46619 (9,11-dideoxy-11α,9α-epoxymethano prostaglandin $F_{2\alpha}$); Basilar artery; Ca^{2+} concentration; Ca^{2+} influx; Ca^{2+} sensitivity (Tanaka, Y. (289) 59)

Cytosolic Ca^{2+} concentration
NS-49; Oxymetazoline; α_1-Adrenoceptor subtype; Cloned receptor; Radioligand binding study (Obika, K. (291) 327)

Cytotoxicity
Endotoxin; Nitric oxide (NO) synthase; Chemotherapy; Cancer; Anticancer drug (Hattori, Y. (291) 83)

Hydrogen peroxide; L-Histidine; DNA single/double-strand break; Poly(ADP-ribose)polymerase (Palomba, L. (291) 167)

6-Hydroxydopamine; H_2O_2; Bupropion; R56865; Cytoprotection; Chromaffin cell (Abad, F. (293) 55)

Methylmercury; Thymocyte; Membrane potential; Ca^{2+} concentration, intracellular (Oyama, Y. (293) 101)

Damage
Ca^{2+}; Gastric cell; Oxidative stress; Nitric oxide (NO) (Tepperman, B.L. (293) 259)

DAMGO ([D-Ala^2,MePhe^4,Gly(ol)^5]enkephalin)
DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Naltrindole; ICI174864; 5-HT (5-hydroxytryptamine, serotonin); Spinal cord (Monroe, P.J. (272) 51)

DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Nalorphine; U50,488; Xylazine; Clonidine (Paul, D. (272) 111)

Clocinnamox; Morphine; Opioid receptor antagonist; DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U69,593; Opioid receptor alkylation; Opioid receptor binding; mRNA; Solution hybridization; Analgesia; (Irreversible antagonist) (Chan, K. (287) 135)

Daphnoretin
Neutrophil (rat); Respiratory burst; Staurosporine; Protein kinase C; Ca^{2+}; [^{3}H]Phorbol-12,13-dibutyrate binding (Wang, J.-P. (288) 341)

DDT$_1$ MF-2 smooth muscle cell
G$\beta\gamma$ subunit; Phospholipase C (Dickenson, J.M. (288) 393)

Histamine H_1 receptor; Inositol 1,3,4,5-tetrakisphosphate; Intracellular Ca^{2+} store (Van der Zee, L. (289) 463)

DDT (1,1,1-trichloro-2,2-bis(*p*-chlorophenyl)-ethane)
Neurotoxicity; Pyrethroid; Interaction; Behavior; Acetylcholine receptor (Johansson, U. (293) 159)

Decerebrate rigidity
Muscle relaxant, centrally acting; NK433; Straub tail reaction; γ-Activity (Sakitama, K. (273) 47)

Decongestive nose drops
Anti-oxidant; Hydroxyl radical scavenging; Lipid peroxidation; Nasal inflammation; Reactive oxygen species (Westerveld, G.-J. (291) 27)

De-endothelialization
Endothelin-1; Atherosclerosis; Atherogenic diet; (Tissue distribution) (Kurata, C. (293) 109)

Defensive burying
5-HT_{1A} receptor; Corticosterone; Glucose; Prolactin; Flesinoxan; Anxiety (Groenink, L. (280) 185)

Degranulation
Neutrophil; Ca^{2+}; cAMP; cGMP; Protein kinase C; Tolfenamic acid (Kankaanranta, H. (291) 17)

Delayed amnesia
Dynorphin A-(1–13); Cholinergic neuronal system; CO (carbon monoxide); Learning; Nor-binaltorphimine; κ-Opioid receptor; Passive avoidance (Hiramatsu, M. (282) 185)

Delayed-type hypersensitivity
Vascular permeability; Pulmonary inflammation; Airway hyperreactivity, mouse; LCB 2183 (Buckley, T.L. (282) 103)

Delay non-match to position
Antipsychotic; Cognition; (Rat) (Didriksen, M. (281) 241)

Denopamine
Adrenoceptor subtype; Blood vessel (Fujimoto, S. (280) 143)

Dental pulp
Afferent nerve; Blood flow; 5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindole acetic acid); Dopamine; Gingiva; Sympathetic nerve; (Rat) (Kerezoudis, N.P. (275) 191)

Dentate gyrus
Long-term potentiation; Hippocampus; Neural plasticity; Metabotropic glutamate receptor; NMDA (*N*-methyl-D-aspartate) (Bordi, F. (273) 291)

Urethane (ethyl carbamate); Perforant path; Evoked potential; GABAergic inhibition (Shirasaka, Y. (282) 11)

Deoxycorticosterone acetate-salt hypertension
Ebelactone B; Carboxypeptidase Y, urinary; Kininogen-deficient rat; Na^+ excretion (Majima, M. (284) 1)

Deoxyglucose
Cocaine; Apomorphine; Brain metabolism; Nucleus accumbens (Pontieri, F.E. (284) 205)

2-Deoxyglucose
Morphine; Ischemia; κ-Opioid receptor; Hippocampal slice; Tolerance (Shibata, S. (279) 197)

[1-^{14}C]Deoxyglucose
δ-Opioid receptor agonist; DPDPE ([D-Pen^2,D-Pen^5]enkephalin; (Brain site) (Ableitner, A. (271) 213)

2-Deoxy-D-glucose
Hyperphagia, experimentally induced; Anorectic drug; Insulin; Sodium mercaptoacetate; Neural circuit (Garosi, V.L. (276) 285)

Insulin secretion; Glucagon secretion; Neuroglycopenia; Nitric oxide (NO); Nitric oxide synthase; N^G-Nitro-L-arginine methyl ester; N^G-Nitro-L-arginine; (Mouse) (Ahrén, B. (280) 27)

2-Deoxyglucose uptake
Ischemia; Glutathione; Hippocampus; Presynaptic potential; Neuroprotection (Shibata, S. (273) 191)

Dependence
Chronic chlordiazepoxide; Behavior; EEG (electroencephalographic); Tolerance; (Rat) (Sala, M. (273) 35)

Depression
Forced swimming; 5-HT_{1A} receptor; S 14506; S 14671; (+)-WAY 100,135 (Schreiber, R. (271) 537)

Depression, animal model
Catecholamine, depression; Catechol-*O*-methyltransferase, inhibitor (Männistö, P.T. (274) 229)

Depression, genetic model
DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); *m*-CPP (*m*-chlorophenylpiperazine); Clorgyline; Imipramine; Clomipramine (Aulakh, C.S. (282) 65)

Dermorphine
Neurotransmission; Opiate; Dynorphin-A; Morphine; Motor nerve (Lavidis, N.A. (276) 71)

Desamino-8D-arginine vasopressin
Brattleboro rat; Vasopressin; Angiotensin; Noradrenaline; Hemorrhage (Laycock, J.F. (271) 193)

Descending inhibition
Neuro-neuronal transmission; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_3 receptor antagonism (Messori, E. (286) 205)

Desenkephalin-γ-endorphin
Endorphin receptor, γ-type; Apomorphine; Nucleus accumbens; Neuroleptic-like action; Antibody; Anti-idiotype antibody; Behavioral effect (Van Ree, J.M. (279) 187)

Desensitization
Prostaglandin E_2; Iloprost; Indomethacin; cAMP; Vasorelaxation (Parfenova, H. (278) 133)

Antisense oligodeoxynucleotide; δ-Opioid receptor; Antinociception (Narita, M. (284) 185)

Phosphoinositide-specific phospholipase C; Inositol 1,4,5-trisphosphate; Protein kinase A; Protein kinase C; Phosphatidylinositol 4,5-bisphosphate (Fisher, S.K. (288) 231)

Vanilloid receptor; Vanilnoid, endogenous; Resiniferatoxin binding; Capsaicin; Proton; Positive cooperativity; Non-competitive inhibition (Szallasi, A. (289) 181)

β-Adrenoceptor agonists; Adipocyte; Phosphodiesterase; β-Adrenoceptor subtypes; Lipolysis (Bousquet-Mélou, A. (289) 235)

Phospholipase C; G-proteins; P_{2Y} purinoceptors; Protein kinase C (Galas, M.-C. (291) 175)

Kainate; Glycoprotein; *Xenopus* oocyte (Yue, K.-T. (291) 229)

Desensitizing current, fast
AMPA/kainate receptor; GAMS (γ-D-glutamylaminomethylsulfonic acid); 6-Cyano-7-nitroquinoxaline-2,3-dione; Hippocampal neuron, rat (Wilsch, V.W. (284) 141)

Desipramine
Antidepressant drug; Fluoxetine; Maprotiline; Moclobemide; Trimipramine; 2-Methyl-5-hydroxytryptamine; 5-HT (5-hydroxytryptamine, serotonin); Reuptake inhibition; Hippocampus; Presynaptic modulation (Mongeau, R. (271) 121)

Apomorphine; Development; Nomifensine; Stereotypy; Zimelidine (Hilakivi, I. (271) 223)

Prenatal diazepam; Forced swimming test; Alprazolam (Cannizzaro, C. (273) 239)

Detrusor muscle, rat
Nicorandil; Cromakalim; cGMP; Femoral artery, rat; K^+ channel (Zhou, Q. (273) 153)

Detrusor smooth muscle
Electrical response; Excitatory junctional potential; (Contraction) (Hashitani, H. (284) 177)

Development
Skinned fiber; Sarcoplasmic reticulum; Skeletal muscle; Cyclopiazonic acid (Huchet, C. (271) 141)

Apomorphine; Desipramine; Nomifensine; Stereotypy; Zimelidine (Hilakivi, I. (271) 223)

Polyamine; Spermine; NMDA (*N*-methyl-D-aspartate); Hippocampus; Mg^{2+} (Bowe, M.A. (278) 55)

Opioid; Growth; Brain; Liver; (Intracerebroventricular) (Bartolome, J.V. (284) 43)

Developmental toxicity
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Neurobehavioral effect; Reproduction effect; Endocrine effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Experimental animal; Human infant; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

Dexamethasone
TNF (tumor necrosis factor); Interleukin-6; Pentoxifylline; Fusidic acid; Pentamidine isethionate; Adenosine receptor agonist (Chen, Y.-L. (271) 319)

Vagal depolarization; Vagus nerve; 5-HT (5-hydroxytryptamine, serotonin); Cisplatin; (Rat); (Grease gap) (Woods, A.J. (278) 275)

5-HT (5-hydroxytryptamine, serotonin); Actinomycin-D; Mast cell; Nedocromil sodium; Paw edema, rat (Raud, J. (282) 207)

Macrophage inflammatory protein 2; Allergic inflammation; Chemotactic factor (Tanabe, J.-i. (284) 257)

Neuropeptide Y; Tyrosine hydroxylase; PC12 cell; Nerve growth factor; Pertussis toxin (McCullough, L.A. (287) 271)

PLC-PRF-5; Angiotensin AT_1 receptor; Hepatoma cell; Steroid; Glucocorticoid effect (Wintersgill, H.P. (288) 365)

β-Adrenoceptor agonist; DNA binding; Lung; (Rat) (Peters, M.J. (289) 275)

Cytochrome P-450; Interleukin-2; Liver; TNF (tumor necrosis factor); Xanthine oxidase (Cantoni, L. (292) 257)

Dexfenfluramine
Histamine; 5-HT (5-hydroxytryptamine, serotonin); Methysergide; Microdialysis; Hypothalamus (Laitinen, K.S.M. (285) 159)

Dexmedetomidine
Aspartate; Atipamezole; Glutamate; GABA (γ-aminobutyric acid); Microdialysis; Hippocampus (Valtonen, P. (285) 239)

Locus ceruleus; Brain slice; Intracellular recording; α_{2A}-Adrenoceptor (Chiu, T.-H. (285) 261)

Ethanol; α_2-Adrenoceptor; Atipamezole; Monoamine; Motor performance; (Mouse) (Idänpään-Heikkilä, J.J. (292) 191)

Dexniguldipine-HCl
P-glycoprotein; Allosteric interaction; Multidrug resistance (Malkhandi, J. (288) 105)

Dextromethorphan
Reserpine; Motor behavior; Dopamine D_1 receptor; Dopamine D_2 receptor; L-DOPA (L-3,4-dihydroxyphenylalanine); (Mouse) (Kaur, S. (280) 159)

p-Chloroamphetamine; Neurotoxicity; σ Receptor; 5-HT (5-hydroxytryptamine, serotonin); Brain (Narita, N. (293) 277)

2α-DHET
Muscarinic receptor; 2α-(2',2'-disubstituted-hydroxy-ethoxy)tropane; Allosteric interaction; Heart (Gao, Z.-g. (289) 369)

Diabetes
Sensory fiber; Capsaicin; Urinary bladder; Epithelium (Pinna, C. (271) 151)

Dihydroetorphine; Antinociceptive effect; Opioid receptor; (Mouse) (Kamei, J. (275) 109)

Sensory fibres; Capsaicin; Stomach fundus; Ileum (Pinna, C. (276) 61)

Formalin test; Aldose reductase; Polyol pathway; Pain; Diabetic neuropathy (Calcutt, N.A. (285) 189)

Diabetes mellitus
Phorbol ester; Protein kinase C; Ca^{2+}, extracellular; Ca^{2+} channel; Aorta, rat (Hattori, Y. (279) 51)

Benfluorex metabolite; Non insulin-dependent; Membrane fluidity; Hepatocyte, isolated; (Rat) (Orsière, T.G. (291) 237)

Diabetic neuropathy
Diabetes; Formalin test; Aldose reductase; Polyol pathway; Pain (Calcutt, N.A. (285) 189)

Diabetic vasculopathy
Capillary permeability; Neutral endopeptidase; Streptozotocin (Chakir, M. (285) 11)

Diadenosine hexaphosphate
ATP-sensitive K^+ channel; Heart (Jovanović, A. (286) R1)

2',3'-Dialdehyde ATP analog
P_2 purinoceptor; Vas deferens, guinea-pig; Periodate-oxidized nucleotide; ATP (Fedan, J.S. (281) 213)

3,4-Diaminopyridine
Acetylcholine; Choline; Microdialysis (Buyukuysal, R.L. (281) 179)

Diaphragm
Triphenyltin-induced contracture; Na^+-channel activation; Ca^{2+}-induced Ca^{2+} release (Liu, S.-H. (292) 95)

Diarrhea
Carbachol; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; L-Arginine; Intestinal secretion; Small intestinal transit (Izzo, A.A. (271) 31)

K_{ATP} channel opener; Pinacidil; Cromakalim; Morphine; Intestinal transit (Poggioli, R. (287) 207)

Diazepam
Ultrasonic distress call; Cerebral cortex; Lesion; Anxiolytic mechanism; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide) (Naito, H. (272) 261)

Clonazepam; Ro 5-4864; Kidney, isolated, perfused; Renal function; Renal vasculature; (Rat) (Monasterolo, L.A. (276) 201)

Skin, toad; Tolerance; Ca^{2+} channel (Norris, B. (280) 221)

Animal model; Anxiety; Buspirone; One-way avoidance; Successive negative contrast (Torres, C. (280) 277)

Morphine; Conditioned place preference; (Mouse) (Suzuki, T. (280) 327)

Cardiac contractility; Isoprenaline; Forskolin; cAMP (Martinez, E. (282) 169)

Ethanol withdrawal; NMDA receptor; $GABA_A$ receptor; Microdialysis; Dizocilpine (Rossetti, Z.L. (283) 177)

Diazepam-insensitive
Ro 15-4513; $GABA_A$ receptor; Cerebellum; Alcohol sensitivity; Benzodiazepine; Imidazoquinoxaline; Imidazoquinazoline; Cyclopyrrolone (Wong, G. (289) 335)

$GABA_A$ receptor, $\alpha 4$ subunit; Benzodiazepine (Yang, W. (291) 319)

Diazoxide
Islets of Langerhans; Endocrine pancreas; Imidazoline receptor; Imidazoline I_1 site; Moxonidine; Efaroxan; Cimetidine; Insulin secretion (Tsoli, E. (284) 199)

Diclofenac
Prostaglandin G/H synthase (cyclooxygenase); Whole blood, human; Etodolac; Naproxen; Tenidap (Glaser, K. (281) 107)

Diet, human
Nitrate; Nitrite; *N*-nitroso compound; Dietary intake; Endogenous synthesis; Metabolism; Toxicokinetics; Animal toxicology; Human effects (Gangolli, S.D. (292) 1)

Dietary intake
Nitrate; Nitrite; *N*-nitroso compound; Human diet; Endogenous synthesis; Metabolism; Toxicokinetics; Animal toxicology; Human effects (Gangolli, S.D. (292) 1)

Diethyldithiocarbamate
Kupffer cells; Hepatotoxicity; Liver slice preparation (Ishiyama, H. (292) 135)

Digitalis
Arrhythmia; Ouabain; Azepexole; B-HT 933 (Thomas, G.P. (276) 215)

Nitrite; Na^+,K^+-ATPase; Ca^{2+} (Ikeda, U. (288) 379)

Dihydroergotamine
Arteriovenous anastomose; α-CGRP (calcitonin gene-related peptide); Heart; Migraine, pig; Sumatriptan (Van Gelderen, E.M. (284) 51)

Dihydro-β-erythroidine
Nicotinic acetylcholine receptor antagonist; Erysodine; Pharmacokinetics (Decker, M.W. (280) 79)

Dihydroetorphine
Diabetes; Antinociceptive effect; Opioid receptor; (Mouse) (Kamei, J. (275) 109)

Morphine; Opioid receptor, cloned; Binding characteristic; cAMP (Katsumata, S. (291) 367)

Dihydroouabain
Fura-2; Ca^{2+}, transient signal; Heart, guinea-pig; Isoproterenol (Hotta, Y. (282) 121)

Dihydropyridine
Tetrandrine; Hypertrophy; Ca^{2+}; DOCA (deoxycorticosterone acetate); (Receptor) (Xu, Y. (278) 1)

Phenylalkylamine; Allosteric interaction; Structural determinant; Molecular modeling (Voigt, W. (291) 255)

1,4-Dihydropyridine
Ca^{2+}; Ca^{2+} channel antagonist; Ro 40-5967; Verapamil; Diltiazem; SR 33557 (Rutledge, A. (280) 155)

Diisopropylfluorophosphate
β-Eudesmol; Organophosphate intoxication; Anticholinesterase agent; Obidoxime; Neuromuscular transmission (Chiou, L.C. (292) 151)

Dilazep
Veratridine; Na^+ channel; β-Adrenoceptor antagonist; Ca^{2+} channel blocker; Ca^{2+}, cytosolic (Hashizume, H. (271) 1)

Diltiazem
Opioid dependence; Central nervous system; Ca^{2+} channel; Protein kinase C; Morphine; Butorphanol (Tokuyama, S. (279) 93)

Ca^{2+}; Ca^{2+} channel antagonist; Ro 40-5967; Verapamil; 1,4-Dihydropyridine; SR 33557 (Rutledge, A. (280) 155)

Ca^{2+}; Ba^{2+}; Sr^{2+}; Nitric oxide (NO); Coronary artery, porcine (Ohashi, K. (285) 165)

Semotiadil; Amlodipine; Nifedipine; Conduction interval; Refractoriness (Stark, G. (286) 71)

Dimethindene, enantiomer
Muscarinic M_2 receptor antagonist; Histamine H_1 receptor; Muscarinic receptor subtype; Enantioselectivity; Stereoselectivity, inverse; PET (positron emission tomography); Alzheimer's disease (Pfaff, O. (286) 229)

Dimethocaine
Drug discrimination; Local anesthetic; Dopamine; Cocaine; Procaine; Chloroprocaine; SCH 39166; Raclopride; (Squirrel monkey) (Mansbach, R.S. (274) 167)

Dioxin
TCDD (2,3,7,8-Tetrachlorodibenzo-*p*-dioxin); Portocaval anastomosis; Anorexia; Food intake; Vagotomy (Tuomisto, J. (292) 277)

Toxic equivalency; Risk evaluation; Acute toxicity; Strain difference (Pohjanvirta, R. (293) 341)

TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Concanavalin A; Immunotoxicity; Interleukin; Thymus; Spleen; T lymphocyte; B lymphocyte; Macrophage; (Rat) (Badesha, J.S. (293) 429)

Dipyrone
Ketorolac tromethamine; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester (Granados-Soto, V. (277) 281)

Disinhibition
GABA receptor; Hippocampus; Epilepsy; Synaptic inhibition (Stanford, I.M. (277) 229)

Disopyramide
Na^+ current; Chloramine-T; Use-dependent block; Activation gate; (Fast inactivation gate) (Koumi, S.-i. (277) 165)

Patch clamp; Antiarrhythmic, class Ia; Skeletal muscle; K_{ATP} channel; Channel inhibition, pH dependent (Moser, C. (284) 35)

Dissociation
Angiotensin receptor; Angiotensin AT_1 receptor antagonist; Kinetics; Association (Hara, M. (289) 267)

Dissociation kinetics
Allosterism; Gallamine; [^{3}H]*N*-methylscopolamine (Christopoulos, A. (290) 259)

Distal colon
5-HT_3 receptor; Enteric nervous system; Myenteric neuron; YM060 {(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-enzimidazole monohydrochloride}; (Guinea pig) (Ito, H. (283) 107)

Disulfiram
GABA (γ-aminobutyric acid); Glutamate; Neurotoxicity (Mamatha, R.K. (292) 89)

Diterpenoid alkaloid
Autonomic nerve; Blood pressure; Heart rate (Chiao, H. (283) 103)

Dithioerythritol
Dithiothreitol; Pentobarbital; Anesthesia reversal; Toxicity; (Rodents) (Gailis, L. (292) 39)

Dithiothreitol
Dithioerythritol; Pentobarbital; Anesthesia reversal; Toxicity; (Rodents) (Gailis, L. (292) 39)

Ag^+-induced contracture; Caffeine; Procaine; Skeletal muscle; (Frog) (Oba, T. (292) 301)

Diuresis
Cicletanine; Sulfate; Kidney; Cell membrane; Ion transport; Natriuresis; Na^+ transport; Capillary electrophoresis (Garay, R.P. (274) 175)

Diurnal alteration
Opioid mechanism; ACTH (adrenocorticotrophin); Corticosterone; Prolactin (Kiem, D.T. (272) 145)

Dizocilpine
Ethanol withdrawal; NMDA receptor; $GABA_A$ receptor; Microdialysis; Diazepam (Rossetti, Z.L. (283) 177)

Epilepsy; Kynurenate; Kynurenine; Excitotoxicity; Anticonvulsant action; Piriform cortex (Baran, H. (286) 167)

Tyrosine hydroxylase; Aromatic L-amino acid decarboxylase; Dopamine; Parkinson's disease (Hadjiconstantinou, M. (289) 97)

DNA binding
β-Adrenoceptor agonist; Dexamethasone; Lung; (Rat) (Peters, M.J. (289) 275)

DNA-binding drug
Human immunodeficiency virus type 1 (HIV-1); Automation; DNase I footprinting (Feriotto, G. (290) 85)

DNA fragmentation
Septic liver failure; Glycosylation inhibitor; Liver, mouse (Leist, M. (292) 201)

Hepatocyte; TNF-α (tumor necrosis factor-α); Nitric oxide (NO); Oxygen tension; (Acute phase response); (Tissue) (Ohno, K. (292) 205)

DNA single / double-strand break
Hydrogen peroxide; L-Histidine; Cytotoxicity; Poly(ADP-ribose)polymerase (Palomba, L. (291) 167)

DNA synthesis
Opioid; Naloxone binding site; Uterus, immature; (Rat) (Vértes, Z. (291) 115)

Angiotensin II; Angiotensin AT_1 receptor antagonist; Platelet-derived growth factor; Basic fibroblast growth factor (Itazaki, K. (291) 417)

DNase I footprinting
DNA-binding drug; Human immunodeficiency virus type 1 (HIV-1); Automation (Feriotto, G. (290) 85)

DOCA (deoxycorticosterone acetate)
Tetrandrine; Hypertrophy; Dihydropyridine; Ca^{2+}; (Receptor) (Xu, Y. (278) 1)

DOCA-salt (deoxycorticosterone acetate-salt) hypertensive rat
5-Carboxamidotryptamine; Blood pressure; Baroreflex sensitivity; (Chronic i.v. infusion) (Balasubramaniam, G. (276) 183)

DOCA-salt hypertension
Na^+,K^+-ATPase; α Isoforms of Na^+,K^+-ATPase; Heart; Brain; Skeletal muscle (Sahin-Erdemli, I. (292) 163)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane)
Sexual behavior; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_2 receptor agonist; Testosterone; Castration; Puberty (Padoin, M.J. (277) 1)

m-CPP (*m*-chlorophenylpiperazine); Depression, genetic model; Clorgyline; Imipramine; Clomipramine (Aulakh, C.S. (282) 65)

DOPA (3,4-dihydroxyphenylalanine), accumulation
Dopamine; Dopamine receptor agonist; Catecholamine, synthesis; Adrenal medulla (Kujacic, M. (278) 9)

L-DOPA (3,4-dihydroxyphenyl-L-alanine)
Dopamine; Microdialysis; Catechol-*O*-methyltransferase inhibition; Tolcapone (Napolitano, A. (273) 215)

Reserpine; Motor behavior; Dextromethorphan; Dopamine D_1 receptor; Dopamine D_2 receptor; (Mouse) (Kaur, S. (280) 159)

Dopamine
Emesis; α_2-Adrenoceptor; Area postrema; (Cat); (Intracerebroventricular injection) (Jovanović-Mićić, D. (272) 21)

NMDA (*N*-methyl-D-aspartate); TRH (thyrotropin-releasing hormone); Striatum; (Rabbit) (Popoli, P. (272) 119)

Microinjection; MK-801; Circling; Potentiation; Striatum, rat; 6-Hydroxydopamine (St-Pierre, J.-A. (272) 123)

NMDA (*N*-methyl-D-aspartate); Accumbens; Prepulse inhibition; Schizophrenia; (Rat) (Reijmers, L.G.J.E. (272) 131)

Nitric oxide (NO); Motor behavior; Reserpine; (Mouse) (Starr, M.S. (272) 211)

Electrophysiology; Neurokinin; Senktide; Substance P; Tachykinin; Ventral tegmental area (Seabrook, G.R. (273) 113)

Microdialysis; Catechol-*O*-methyltransferase inhibition; L-DOPA (3,4-dihydroxyphenyl-L-alanine); Tolcapone (Napolitano, A. (273) 215)

Dopamine receptor; Adrenaline; Heart; Plasma; Adrenal medulla; (Partial least squares regression) (Kujacic, M. (273) 247)

Morphine; 7-OH-DPAT (7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Place preference; Conditioning; Dopamine D_3 receptor; (Rat) (De Fonseca, F.R. (274) 47)

Drug discrimination; Local anesthetic; Cocaine; Dimethocaine; Procaine; Chloroprocaine; SCH 39166; Raclopride; (Squirrel monkey) (Mansbach, R.S. (274) 167)

σ Receptor ligand; Tyrosine hydroxylase; Turning; DTG (1,3-di-*o*-tolylguanidine) (Weiser, S.D. (275) 1)

Amphetamine; Cocaine; Locomotor activity; Microdialysis, in vivo; Opioid receptor antagonist; Striatum; Nucleus accumbens (Schad, C.A. (275) 9)

Afferent nerve; Blood flow; 5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindole acetic acid); Gingiva; Dental pulp; Sympathetic nerve; (Rat) (Kerezoudis, N.P. (275) 191)

Mammillary complex; Memory; Retention; Acetylcholine; Norepinephrine; NMDA (*N*-methyl-D-asparate); Nicotine; Neuropeptide Y; GABA (γ-aminobutyric acid); (Mouse) (Flood, J.F. (275) 223)

Dopamine D_3 receptor; Ventral tegmental area (Lejeune, F. (275) R7)

MDL 73,745; Microdialysis; Cholinesterase; Acetylcholine; Norepinephrine; 5-HT (5-hydroxytryptamine, serotonin) (Zhu, X.-d. (276) 93)

Adrenalectomy; Corticosteroid; Limbic forebrain; Locomotor activity; Nicotine; Sensitization; (Rat) (Johnson, D.H. (276) 155)

Dopamine receptor agonist; Catecholamine, synthesis; DOPA (3,4-dihydroxyphenylalanine), accumulation; Adrenal medulla (Kujacic, M. (278) 9)

Blood pressure; Ca^{2+}-calmodulin; Epilepsy; (El mouse) (Sutoo, D. (278) 33)

Sleep; Waking; *m*-Chlorophenylbiguanide; 5-HT_3 receptor; MDL 72222; (+)-SCH 23390; YM-09151-2 (Ponzoni, A. (278) 111)

Phencyclidine; Neurotensin; NMDA (*N*-methyl-D-aspartate); Striatum; Nucleus accumbens (Hanson, G.R. (278) 167)

Sexual satiety; Mating; Apomorphine (Mas, M. (280) 331)

Methylphenidate; *d-threo*-Methylphenidate; WIN 35,428; Dopamine transporter; PET (positron emission tomography); (Baboon); (Mouse) (Gatley, S.J. (281) 141)

Dopamine uptake inhibitor; [^{3}H]GBR12935 binding; Brain microdialysis; Stereotypy (Nakachi, N. (281) 195)

Fluoxetine; Clomipramine; Imipramine; 5-HT (5-hydroxytryptamine, serotonin); Extrapyramidal symptom; Antidepressant; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (281) 255)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5891; (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-*N*-methyl-3-pyridinecarboxamide; FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester; FG5909 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-hydroxypyridine; Reuptake; Release; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline (Pettersson, E. (282) 131)

Catecholamine; Dopamine receptor, agonist, antagonist; Protein kinase inhibitor; Ouabain; Ionic mechanism; Voltage clamp; Neuron; (Snail) (Emaduddin, M. (283) 113)

Yawning; Sprague-Dawley rat; F344 rat (Tang, A.H. (284) 13)

Striatum; GABA-ergic drug; Kainic acid (Smolders, I. (284) 83)

Substantia nigra; GABA (γ-aminobutyric acid); NMDA (*N*-methyl-D-aspartate); Pyrrolidinone (Shepard, P.D. (285) 79)

Amantadine; c-*fos*; NMDA (*N*-methyl-D-aspartate); Striatum (Tomitaka, S.-i. (285) 207)

Fenoldopam; Noradrenaline; Renal blood flow; Splanchnic blood flow; Oxygen demand; Oxygen supply; Oxygen extraction ratio (Schiffer, E.R. (286) 49)

(+)-Pentazocine; *N*-Allylnormetazocine; σ Receptor; Striatum; Microdialysis (Gudelsky, G.A. (286) 223)

R(+)-8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY 100,635 (*n*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*n*-(2-pyridinyl)-cyclohexanecarboxamide trihydrochloride); *d*-Amphetamine; 5-HT_{1A} receptor; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (287) 179)

5-HT_3 receptor; Granisetron; Morphine; Reward (Rompré, P.-P. (287) 263)

Skeletal muscle actin; 5-HT (5-hydroxytryptamine, serotonin); Covalent bond; 5-HT (5-hydroxytryptamine, serotonin) binding protein; Iron (Velez Pardo, C. (288) 209)

Dizocilpine; Tyrosine hydroxylase; Aromatic L-amino acid decarboxylase; Parkinson's disease (Hadjiconstantinou, M. (289) 97)

D_1 receptor; Protein kinase C; Fenoldopam; Bromocriptine (Kansra, V. (289) 391)

Dopamine autoreceptor antagonist
(−)-DS121; Dopamine D_3 receptor; D-Amphetamine; Cocaine; Drug discrimination; Caffeine (Clark, D. (275) 67)

Dopamine, endogenous
Dopamine uptake inhibitor; Dopamine receptor agonist; Frontal cortex; Nucleus accumbens; Striatum (Irifune, M. (272) 79)

Dopamine, mesocortical
Locomotor activity; Nucleus accumbens; Voltammetry; 6-Hydroxydopamine lesion (Banks, K.E. (282) 157)

Dopamine metabolism
Glycine; NMDA (*N*-methyl-D-aspartate); Schizophrenia; Stereotypy (Kretschmer, B.D. (280) 37)

Dopamine outflow
Substance P fragment; Striatum; Tachykinin receptor (Khan, S. (282) 229)

Dopamine receptor
Adrenaline; Heart; Plasma; Dopamine; Adrenal medulla; (Partial least squares regression) (Kujacic, M. (273) 247)

Morphine; Ambulation, mouse; Sensitization; μ-Opioid receptor (Kuribara, H. (275) 251)

Repetitive jaw movement; YM-14673; TRH (thyrotropin-releasing hormone); Nucleus accumbens; Striatum (Miwa, Y. (277) 63)

Antidepressant; Quinpirole; SKF 38393; Motor activity (Allison, K. (277) 139)

5-HT_2 receptor; α_1-Adrenoceptor; Hyperactivity; Amphetamine; (Rat) (Arnt, J. (283) 55)

Na^+-pump; Phosphoinositide hydrolysis; Pertussis toxin; Vascular tone (Rashed, S.M.K. (284) 289)

Schizophrenia; Dopamine D_4-like site (Seeman, P. (286) R3)

mRNA; Dopamine D_4 receptor; Antipsychotic drug; Neuroleptics; Haloperidol (Schoots, O. (289) 67)

Dopamine D_1 receptor
Conditioned fear stress; Conditioned suppression; Dopamine D_2 receptor; Motor suppression (Kamei, H. (273) 229)

Behavioral sensitization; Dopamine D_2 receptor; Nucleus accumbens; Ventral tegmental area; Drug addiction (Jeziorski, M. (275) 235)

Reserpine; Motor behavior; Dextromethorphan; Dopamine D_2 receptor; L-DOPA (L-3,4-dihydroxyphenylalanine); (Mouse) (Kaur, S. (280) 159)

Dopamine receptor agonist; Clozapine; Dopamine D_2 receptor; Quinpirole; Antipsychotic, atypical; Scopolamine; SKF38393; (Rat) (Jackson, D.M. (282) 137)

Nucleus accumbens, shell, core; Dopamine D_2 receptor; SKF 82958; Quinpirole; SCH 23390; (−)-Sulpiride; Jaw movement; (Rat) (Cools, A.R. (286) 41)

Dopamine; Protein kinase C; Fenoldopam; Bromocriptine (Kansra, V. (289) 391)

Dopamine D_2 receptor
Conditioned fear stress; Conditioned suppression; Dopamine D_1 receptor; Motor suppression (Kamei, H. (273) 229)

Behavioral sensitization; Dopamine D_1 receptor; Nucleus accumbens; Ventral tegmental area; Drug addiction (Jeziorski, M. (275) 235)

Dopamine D_3 receptor; Substantia nigra pars compacta; Autoreceptor; Single unit recording; 7-OH-DPAT ((±)-7-hydroxy-dipropylaminotetralin) (Kreiss, D.S. (277) 209)

Dopamine D_3 receptor; [^{125}I]Iodosulpiride; Receptor autoradiography; Striatum; Cerebellum; (Rat) (Levant, B. (278) 243)

Reserpine; Motor behavior; Dextromethorphan; Dopamine D_1 receptor; L-DOPA (L-3,4-dihydroxyphenylalanine); (Mouse) (Kaur, S. (280) 159)

Dopamine receptor agonist; Clozapine; Dopamine D_1 receptor; Quinpirole; Antipsychotic, atypical; Scopolamine; SKF38393; (Rat) (Jackson, D.M. (282) 137)

Nucleus accumbens, shell, core; Dopamine D_1 receptor; SKF 82958; Quinpirole; SCH 23390; (−)-Sulpiride; Jaw movement; (Rat) (Cools, A.R. (286) 41)

Remoxipride; cAMP; Striatum; Metabolite, remoxipride (Westlind-Danielsson, A. (288) 89)

Antipsychotic drug; Dopamine D_4 receptor; Nemonapride; Raclopride (Seeman, P. (291) 59)

Muscarinic acetylcholine receptor; $GABA_B$ receptor; GTPase; Receptor-G protein coupling; Striatum (Odagaki, Y. (291) 245)

7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin); Dopamine D_3 receptor (Gonzalez, A.M. (272) R1)

Dopamine D_3 receptor
Morphine; 7-OH-DPAT (7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Place preference; Conditioning; Dopamine; (Rat) (De Fonseca, F.R. (274) 47)

(−)-DS121; Dopamine autoreceptor antagonist; D-Amphetamine; Cocaine; Drug discrimination; Caffeine (Clark, D. (275) 67)

Ventral tegmental area; Dopamine (Lejeune, F. (275) R7)

7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propylaminotetralin); SKF 38393; Motor behavior; Reserpine; (Mouse) (Starr, M.S. (277) 151)

Dopamine D_2 receptor; Substantia nigra pars compacta; Autoreceptor; Single unit recording; 7-OH-DPAT ((±)-7-hydroxy-dipropylaminotetralin) (Kreiss, D.S. (277) 209)

Dopamine D_2 receptor; [^{125}I]Iodosulpiride; Receptor autoradiography; Striatum; Cerebellum; (Rat) (Levant, B. (278) 243)

Core temperature; Thermoregulation; Clozapine; Antipsychotic (Millan, M.J. (280) 225)

7-OH-DPAT (7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); (+)-PD 128907 (4*aR*,10*bR*-(+)-*trans*-3,4,4*a*,10*b*-tetrahydro-4-*n*-propyl-2*H*,5*H*[4,3-*b*]-1,4-oxazin-9-ol) (Acri, J.B. (281) R7)

7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propyl-2-aminotetralin); Dopamine D_2 receptor (Gonzalez, A.M. (272) R1)

Dopamine D_4-like site
Schizophrenia; Dopamine receptor (Seeman, P. (286) R3)

Dopamine D_4 receptor
Clozapine; Pyridobenzodiazepine (Liégeois, J.-F. (273) R1)

Schizophrenia; Antipsychotic (Reynolds, G.P. (281) R5)

Dopamine receptor; mRNA; Antipsychotic drug; Neuroleptics; Haloperidol (Schoots, O. (289) 67)

Antipsychotic drug; Dopamine D_2 receptor; Nemonapride; Raclopride (Seeman, P. (291) 59)

Dopamine $D_{4.2}$ receptor
Vaccinia virus; Adenylyl cyclase; (Functional expression) (Bouvier, C. (290) 11)

Dopamine receptor agonist
Dopamine uptake inhibitor; Dopamine, endogenous; Frontal cortex; Nucleus accumbens; Striatum (Irifune, M. (272) 79)

Dopamine; Catecholamine, synthesis; DOPA (3,4-dihydroxyphenylalanine), accumulation; Adrenal medulla (Kujacic, M. (278) 9)

Clozapine; Dopamine D_1 receptor; Dopamine D_2 receptor; Quinpirole; Antipsychotic, atypical; Scopolamine; SKF38393; (Rat) (Jackson, D.M. (282) 137)

Dopamine receptor, agonist, antagonist
Catecholamine; Dopamine; Protein kinase inhibitor; Ouabain; Ionic mechanism; Voltage clamp; Neuron; (Snail) (Emaduddin, M. (283) 113)

Dopamine receptor antagonist
5-HT_{1A} receptor agonist; Climbing; Stereotyped behavior; Grooming; Catalepsy (Protais, P. (271) 167)

Dopamine D_1 receptor antagonist
Phencyclidine; Dopamine D_2 receptor antagonist; Striatum, rat; Microdialysis (Yonezawa, Y. (285) 305)

Dopamine D_2 receptor antagonist
Phencyclidine; Dopamine D_1 receptor antagonist; Striatum, rat; Microdialysis (Yonezawa, Y. (285) 305)

Dopamine receptor subtype
Pramipexole (SND 919) (Mierau, J. (290) 29)

Dopamine release
Endothelin; Neurotoxicity; NMDA receptor; Striatal slice (Kataoka, Y. (273) 285)

Nicotine; Nornicotine; Anabaseine; Anabasine; *N*-Methylanabasine; Striatum (Dwoskin, L.P. (276) 195)

MPP^+ (1-methyl-4-phenylpyridinium); Rotenone; Striatum; Substantia nigra; (Rat) (Santiago, M. (280) 251)

Riluzole; Neuroprotection; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Bradykinesia; Rigidity; Parkinson's disease; (Rhesus monkey) (Benazzouz, A. (284) 299)

Vinconate; Muscarinic receptor; Striatum; Microdialysis (Iino, T. (286) 99)

Dopaminergic / cholinergic receptor interaction
Turning behavior; Nucleus accumbens; Ventrolateral striatum; Carbachol; Turning pattern (Saigusa, T. (274) 213)

Dopaminergic neurotransmission
α_1-Adrenoceptor; Blood pressure; Microdialysis; Prazosin (Sommermeyer, H. (276) 267)

Dopaminergic system
Striatum; Cortex; Rotenone; MPP^+ (1-methyl-4-phenylpyridinium ion) (Bougria, M. (291) 407)

Dopamine transporter
Methylphenidate; *d-threo*-Methylphenidate; WIN 35,428; Dopamine; PET (positron emission tomography); (Baboon); (Mouse) (Gatley, S.J. (281) 141)

1-(*m*-Chlorophenyl)-biguanide; [^{3}H]GBR-12935; 5-HT_3 receptor; Nucleus accumbens; Caudate putamen; (Rat) (Campbell, A.D. (290) 157)

Dopamine transporter, vesicular
Insecticide; Fungicide; Herbicide; Rotenone; Neurotoxin; Parkinsonism (Vaccari, A. (292) 309)

Dopamine uptake
Local anesthetic; Microdialysis (Woodward, J.J. (277) 7)

Dopamine uptake inhibitor
Dopamine receptor agonist; Dopamine, endogenous; Frontal cortex; Nucleus accumbens; Striatum (Irifune, M. (272) 79)

[^{3}H]GBR12935 binding; Brain microdialysis; Dopamine; Stereotypy (Nakachi, N. (281) 195)

Dorsal raphe
5-HT (5-hydroxytryptamine, serotonin); (Guinea-pig) (Craven, R. (271) R1)

Dorsal root ganglion
Antinociception; μ-Opioid receptor; Primary afferent neuron; Ribonuclease protection assay; β-Funaltrexamine (Schäfer, M. (279) 165)

Downregulation
Angiotensin II; Nitric oxide (NO); Angiotensin receptor; Portal hypertension (Cahill, P.A. (288) 219)

GABA ρ_1 receptor; Protein kinase C; *Xenopus* oocyte; Phorbol ester; Staurosporine (Kusama, T. (291) 431)

Doxapram
Bleomycin; Experimental hypoxemia; Prednisolone; Almitrine; TEI-7322 (Horiuchi, H. (287) 27)

Doxazosin
Cerebral blood flow autoregulation; α-Adrenoceptor; Hemorrhagic hypotension; Spontaneously hypertensive rat (SHR) (Cai, H. (286) 249)

DPDPE ([D-Pen^2,D-Pen^5]enkephalin)
[1-^{14}C]Deoxyglucose; δ-Opioid receptor agonist; (Brain site) (Ableitner, A. (271) 213)

DAMGO ([D-Ala^2,NMePhe^4,Gly-ol^5]enkephalin); Naltrindole; ICI-174864; 5-HT (5-hydroxytryptamine, serotonin); Spinal cord (Monroe, P.J. (272) 51)

DAMGO ([D-Ala^2,MePhe^4,Gly(ol)^5]enkephalin); Nalorphine; U50,488; Xylazine; Clonidine (Paul, D. (272) 111)

Clocinnamox; Morphine; Opioid receptor antagonist; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); U69,593; Opioid receptor alkylation; Opioid receptor binding; mRNA; Solution hybridization; Analgesia; (Irreversible antagonist) (Chan, K. (287) 135)

DP receptor
572C85; BW A868C; Intraocular pressure; (Rabbit); (Cat) (Matsugi, T. (275) 245)

Drinking behavior
Reinforcement schedule; 5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Obsessive-compulsive disorder (Roehr, J. (278) 75)

Drinking response
Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Losartan; PD 123177; Vasopressin (Höhle, S. (275) 277)

Drug addiction
Behavioral sensitization; Dopamine D_1 receptor; Dopamine D_2 receptor; Nucleus accumbens; Ventral tegmental area (Jeziorski, M. (275) 235)

Drug conditioning
Methamphetamine; Scopolamine; Cholinergic system; Behavioral sensitization; Low-frequency tone (Yui, K. (279) 135)

Drug dependence
Behavioral pharmacology; Schedule-controlled behavior; Receptor binding; Phencyclidine; Drug tolerance; Sex difference; (Rat) (Wessinger, W.D. (277) 107)

Drug discrimination
Local anesthetic; Dopamine; Cocaine; Dimethocaine; Procaine; Chloroprocaine; SCH 39166; Raclopride; (Squirrel monkey) (Mansbach, R.S. (274) 167)

(−)-DS121; Dopamine autoreceptor antagonist; Dopamine D_3 receptor; D-Amphetamine; Cocaine; Caffeine (Clark, D. (275) 67)

Anandamide; CP 55,940; Δ^9-Tetrahydrocannabinol (Wiley, J. (276) 49)

Benzodiazepine; $GABA_A$ receptor, diazepam-insensitive; Bretazenil; Flumazenil; Ro 19-0528; GABA (γ-aminobutyric acid); (Receptor partial agonist); (Pigeon) (Acri, J.B. (278) 213)

Flesinoxan; 5-HT_{1A} receptor; (*S*)-UH301, enantiomer; WAY-100635; Fentanyl (Gommans, J. (284) 135)

Morphine; μ_1-Opioid receptor (Suzuki, T. (284) 195)

p-Fluoroamphetamine; ^{3}H-Monoamine uptake inhibition; Microdialysis, in vivo, in freely moving rat (Marona-Lewicka, D. (287) 105)

Drug effect
Amlodipine; Felodipine; Smooth muscle, vascular; (Rat) (Videbæk, L.M. (274) 109)

Drug interaction
Muscimol; Δ^9-Tetrahydrocannabinol; Substantia nigra, pars reticulata; Circling behavior; Contralateral circling (Wickens, A.P. (282) 251)

Drug resistance
Ascorbic acid; Vincristine; Lung cancer (Song, E.-J. (292) 119)

Drug tolerance
Behavioral pharmacology; Schedule-controlled behavior; Receptor binding; Phencyclidine; Drug dependence; Sex difference; (Rat) (Wessinger, W.D. (277) 107)

DS-4574
Peptidoleukotriene receptor antagonist; Endotoxin; Small intestinal mucosal injury; Hemoconcentration; Plasma leakage (Tabuchi, Y. (273) 281)

(−)-DS121
Dopamine autoreceptor antagonist; Dopamine D_3 receptor; D-Amphetamine; Cocaine; Drug discrimination; Caffeine (Clark, D. (275) 67)

DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine)
α_2-Adrenoceptor, postsynaptic; Brain, rat; [^{3}H]RX 821002 binding; Clonidine-induced mydriasis; α_{2D}-Adrenoceptor (Heal, D.J. (277) 215)

Locus ceruleus; Methamphetamine; Striatal dopamine (Fornai, F. (283) 99)

DTG (1,3-di(2-tolyl)guanidine)
σ Receptor ligand; Tyrosine hydroxylase; Turning; Dopamine (Weiser, S.D. (275) 1)

σ Binding site, heterogeneity; Radioreceptor assay; (+)-Pentazocine; Brain; Spinal cord; (Mouse) (Kovács, K.J. (285) 127)

Dystonia; Haloperidol; σ Receptor; Red nucleus (Matsumoto, R.R. (280) 301)

[^{3}H]DTG ([^{3}H]1,3-di(2-tolyl)guanidine)
[^{3}H](+)-Pentazocine; σ Binding site, subtype (Hudkins, R.L. (271) 235)

Dual isotope blood ratio method
Hypocholesterolemic drug; Liver; Intestine; Cholesterol synthesis; Occupancy principle; (RICO rat) (Hajri, T. (286) 131)

Duodenum
Endothelin; Endothelin receptor subtype; IRL 1620; FR139317; RES-701-1; (Rat) (Irie, K. (275) 45)

DuP 532
Angiotensin II; Losartan; PD 123319; CGP 42112A; Smooth muscle, portal vein (Pelet, C. (279) 15)

L-163,491; Pulmonary vascular bed, cat; Angiotensin receptor-mediated response; Captopril; PD 123319 (Kaye, A.D. (287) 163)

Dura mater
Sumatriptan; Plasma protein extravasation; Trigeminal ganglion stimulation; Carotid vascular resistance; Blood pressure (Spokes, R.A. (281) 75)

Dynorphin
NMDA receptor; Glycine receptor; Endorphin (Dumont, M. (271) 241)

Dynorphin-A
Neurotransmission; Opiate; Morphine; Dermorphine; Motor nerve (Lavidis, N.A. (276) 71)

Dynorphin A-(1–13)
Scopolamine; Passive avoidance response; Memory; Amnesia; (Mouse) (Ukai, M. (274) 89)

Alternation performance, spontaneous; U-50,488H; κ-Opioid receptor; Mouse (Ukai, M. (281) 173)

Cholinergic neuronal system; CO (carbon monoxide); Delayed amnesia; Learning; Nor-binaltorphimine; κ-Opioid receptor; Passive avoidance (Hiramatsu, M. (282) 185)

Dystonia
Haloperidol; σ Receptor; Red nucleus; DTG (di-*o*-tolylguanidine) (Matsumoto, R.R. (280) 301)

E4021
Phosphodiesterase; cGMP-specific phosphodiesterase (phosphodiesterase V); Vasorelaxant; Aorta, human (Miyahara, M. (284) 25)

Mesangial cell, rat; Cyclic nucleotide phosphodiesterase; cyclic GMP; cyclic AMP; ANF-(1–28) (Atrial natriuretic factor-(1–28) (Ahn, H.-S. (289) 49)

E6123
Airway microvascular leakage; Airway inflammation; PAF (platelet-activating factor); Ozone; (Guinea-pig) (Kaneko, T. (292) 251)

Early and late asthmatic reaction
Phosphodiesterase inhibitor; Bronchial hyperreactivity; Airway inflammation; (Guinea pig, allergic) (Santing, R.E. (275) 75)

Eating
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; Ventromedial hypothalamic nucleus; Body weight; Appetite; (Rat) (Tuomisto, J.T. (293) 309)

Ebelactone B
Carboxypeptidase Y, urinary; Kininogen-deficient rat; Deoxycorticosterone acetate-salt hypertension; Na^+ excretion (Majima, M. (284) 1)

Ebselen
Ethanol; Gastric mucosal injury, murine; Gastric surface mucous cell line GSM06; Lipid peroxide; Peptidoleukotriene (Tabuchi, Y. (272) 195)

ECG (electrocardiogram)
Ischemic arrhythmia; Antiarrhythmic, class I; (Selectivity) (Barrett, T.D. (285) 229)

Ecstasy
MDMA (3,4-methylenedioxymethamphetamine); Neurodegeneration; PBN (α-phenyl-*N*-tert-butyl nitrone); Neuroprotection; Free radical (Colado, M.I. (280) 343)

Edema
Histamine H_3 receptor; Lung, rabbit; C-fiber; Acetylcholine; Neuropeptide (Delaunois, A. (277) 243)

Lipocortin 1; Neurogenic inflammation; Topical glucocorticoid (Ahluwalia, A. (283) 193)

EDHF (endothelium-derived hyperpolarizing factor)
Endothelium; N^G-Nitro-L-arginine; Acetylcholine; Aorta; (Rat) (Hatake, K. (274) 25)

EDRF (endothelium-derived relaxing factor)
Butein; Phosphodiesterase; cAMP; cGMP; Thoracic aorta, rat (Yu, S.-M. (280) 69)

EEG (electroencephalographic)
Chronic chlordiazepoxide; Behavior; Tolerance; Dependence; (Rat) (Sala, M. (273) 35)

Efaroxan
Imidazoline; Imidazoline site; Insulin secretion; Vessel; Pancreas; Idazoxan; (Rat) (Berdeu, D. (275) 91)

α_2-Adrenoceptor antagonist; Microdialysis; Acetylcholine release; Cortex, rat (Tellez, S. (277) 113)

Islets of Langerhans; Endocrine pancreas; Imidazoline receptor; Imidazoline I_1 site; Moxonidine; Cimetidine; Diazoxide; Insulin secretion (Tsoli, E. (284) 199)

Effect, human
Nitrate; Nitrite; *N*-nitroso compound; Human diet; Dietary intake; Endogenous synthesis; Metabolism; Toxicokinetics; Animal toxicology (Gangolli, S.D. (292) 1)

EGTA (ethyleneglycoltetraacetic acid)
Blood platelet; 5-HT (Serotonin) uptake; Ca^{2+} chelation; BAPTA-AM (acetoxymethyl bis(*O*-aminophenoxy)ethane-*N*,*N*,*N*′,*N*′-tetraacetate); Ca^{2+} storage pool (Nishio, H. (288) 149)

EIPA (5-(*N*-ethyl-*N*-isopropyl)amiloride)
Amiloride; Ouabain; Cardiac contractility; Na^+/Ca^{2+} exchange; Na^+/H^+ exchange (Cargnelli, G. (292) 103)

Elastase
Cytokine; TNF (tumor necrosis factor); Interleukin-1; Neutrophil (Klemm, P. (281) 69)

Electrical field stimulation
β_2-Adrenoceptor; β_3-Adrenoceptor; Cholinergic contraction; NANC (non-adrenergic non-cholinergic) contraction; Bronchus, main, guinea pig (Ten Berge, R.E.J. (275) 199)

Asthma; TNF-α (tumor necrosis factor-α); Cytokine; Bronchial hyperresponsiveness; Airway, human (Anticevich, S.Z. (284) 221)

Electrical response
Detrusor smooth muscle; Excitatory junctional potential; (Contraction) (Hashitani, H. (284) 177)

Electrical stimulation
Spinal cord, rat; [^{3}H]Noradrenaline; Histamine; Histamine H_3 receptor (Celuch, S.M. (287) 127)

Electrolyte transport
Pinacidil; Galanin; K^+ channel activator (Homaidan, F.R. (271) 561)

Electrophysiology
Dopamine; Neurokinin; Senktide; Substance P; Tachykinin; Ventral tegmental area (Seabrook, G.R. (273) 113)

Ischemia; Reperfusion; Skeletal muscle; Phosphocreatine disodium salt; Phosphocreatine di-L-arginine salt; L-Arginine; Current clamp (Tricarico, D. (287) 17)

Elgodipine
Ca^{2+} channel antagonist; Conductance vessel; Resistance vessel; (Rabbit); (Sheep) (Chulia, T. (285) 115)

Eliprodil
σ Receptor; Ifenprodil; Subtype; Receptor binding; Brain, rat (Hashimoto, K. (273) 307)

Embryotoxicity
Sodium valproate; Chronopharmacology (Ohdo, S. (293) 281)

Emesis
Dopamine; α_2-Adrenoceptor; Area postrema; (Cat); (Intracerebroventricular injection) (Jovanović-Mićić, D. (272) 21)

5-HT_3 receptor; GK-128; (*Suncus murinus*) (Ito, C. (285) 37)

Asthma; Bronchodilation; Cardiovascular; Central nervous system, dog; Phosphodiesterase; Rolipram (Heaslip, R.J. (286) 281)

Enalapril
Propionyl-l-carnitine; Pressure overload; Cardiac hypertrophy; Cardiac function (Micheletti, R. (286) 147)

Nitric oxide (NO); Hypertension; Renin-angiotensin system; Myocardial ischemia (Moreno, Jr., H. (287) 93)

Enantioselectivity
Dimethindene, enantiomer; Muscarinic M_2 receptor antagonist; Histamine H_1 receptor; Muscarinic receptor subtype; Stereoselectivity, inverse; PET (positron emission tomography); Alzheimer's disease (Pfaff, O. (286) 229)

Endocrine effect
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Neurobehavioral effect; Reproduction effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Experimental animal; Human infant; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

Endocrine pancreas
Benzoic acid; Insulin; Glucagon; Ruminant; (Sheep) (Mineo, H. (280) 149)

Islets of Langerhans; Imidazoline receptor; Imidazoline I_1 site; Moxonidine; Efaroxan; Cimetidine; Diazoxide; Insulin secretion (Tsoli, E. (284) 199)

Endogenous synthesis
Nitrate; Nitrite; *N*-nitroso compound; Human diet; Dietary intake; Metabolism; Toxicokinetics; Animal toxicology; Human effects (Gangolli, S.D. (292) 1)

Endorphin
Dynorphin; NMDA receptor; Glycine receptor (Dumont, M. (271) 241)

β-Endorphin
Morphine; Ontogenesis; Antinociception (Tseng, L.F. (277) 71)

Antinociception; δ_2-Opioid receptor; Naltriben; Tail-flick inhibition (Tseng, L.F. (277) 251)

Antisense oligodeoxynucleotide; δ-Opioid receptor; Antinociception (Tseng, L.F. (287) 169)

Pineal gland, bovine; δ-Opioid receptor; ε-Opioid receptor (Aloyo, V.J. (288) 295)

β-Endorphin-(10–16)
Prolyl-leucyl-glycinamide; TRH (thyrotropin-releasing hormone); Melatonin; Nucleus accumbens; Antidepressant (Hatta, K. (284) 327)

Endorphin receptor
Recombinant cell; Radioligand binding; cAMP; Adenylyl cyclase (Knapp, R.J. (291) 129)

Endorphin receptor, γ-type
Desenkephalin-γ-endorphin; Apomorphine; Nucleus accumbens; Neuroleptic-like action; Antibody; Anti-idiotype antibody; Behavioral effect (Van Ree, J.M. (279) 187)

Endosulfan
Body weight; Liver weight; Spontaneous motor activity; Rota-rod endurance time; Liver injury; Learning; Memory (Paul, V. (293) 355)

Endothelial cell
Bradykinin; Fura-2; Nitric oxide (NO); Anesthetic, volatile; Sevoflurane; A23187; D-Arg-[Hyp^3, Thi^{5,8}, D-Phe^7] bradykinin; Des-Arg^9-[Leu^8] bradykinin; Ca^{2+} channel (Az-ma, T. (289) 33)

Phosphodiesterase inhibitor; Nitric oxide; cAMP; cGMP (Kessler, T. (290) 163)

Angiotensin IV; Angiotensin IV receptor (Bernier, S.G. (291) 191)

Endothelial cell, human
Ca^{2+}, cytosolic; Isradipine; Fura-2; Histamine (Iouzalen, L. (289) 189)

Endothelin
α,β-Methylene ATP; Phosphoramidon; Suramin; Sympathetic co-transmission; Vas deferens, rat (Lau, W.A.K. (272) 31)

Neurotoxicity; NMDA receptor; Dopamine release; Striatal slice (Kataoka, Y. (273) 285)

Endothelin ET_A receptor; [^{3}H]BQ-123 (Ihara, M. (274) 1)

Endothelin receptor subtype; IRL 1620; FR139317; RES-701-1; Duodenum; (Rat) (Irie, K. (275) 45)

Big-endothelin; Endothelin-converting enzyme; Brain; Astrocyte; Phospholipase A_2 (Deschepper, C.F. (275) 61)

Sarafotoxin; Vas deferens; BQ-123; IRL 1620; BQ-788; Endothelin-converting enzyme; Phosphoramidon; Neurotransmission; (Mouse) (Maas, J. (276) 113)

BQ-123; Nitric oxide (NO); Cerebral vasospasm; Subarachnoid hemorrhage (Hirose, H. (277) 77)

Alanine analog; Receptor subtype; Ileum, guinea-pig; Sarafotoxin S6c; Tachyphylaxis (Miasiro, N. (278) 103)

Oxytocin; Pharmacomechanical coupling; GTP; Myometrium (Izumi, H. (278) 187)

Heart; Ischemia; Receptor displacement (Franco-Cereceda, A. (279) 105)

BQ-123; Nitric oxide (NO); Cerebral vasospasm; Subarachnoid hemorrhage (Hirose, H. (284) 335)

Endothelin ET_A receptor; Endothelin ET_A receptor selective antagonist; Myometrium, human (Héluy, V. (285) 89)

IRL1620; Endothelin receptor subtype; PD145065; BQ-123; Tachyphylaxis (Miasiro, N. (285) 247)

Sarafotoxin; BQ-123; Endothelin ET_A receptor; Saphenous vein, rabbit (Nishiyama, M. (286) 209)

Smooth muscle; Vascular; Endothelin receptor (Lodge, N.J. (287) 279)

Cerebral endothelium; Ca^{2+} uptake; Signal transduction (Stanimirovic, D.B. (288) 1)

Mast cell; Histamine; Staurosporine; IAP (islet-activating protein); Protein kinase (Yamamura, H. (288) 269)

Endothelin receptor; Ca^{2+} influx; Ca^{2+} release; Ca^{2+} sensitivity; Smooth muscle, vascular (Sudjarwo, S.A. (289) 197)

Cerebral endothelium; Ca^{2+} uptake; Signal transduction (Stanimirovic, D.B. (289) 409)

Phosphoinositide turnover; Protein kinase A; C_6 glioma cell; (ATP) (Lin, W.W. (291) 1)

Endothelin receptor antagonist; Bosentan; Carbon tetrachloride; Hepatotoxicity; Acute liver dysfunction (Hocher, B. (293) 361)

Endothelin-1
Endothelin receptor antagonist; Coronary flow; Endothelin ET_A receptor; Endothelin ET_B receptor; Nitric oxide (NO); Vasoconstriction (Wang, Q.-D. (271) 25)

Red blood cell; Staphylococcal α-toxin; Phosphoramidon; Pepstatin A; Chymostatin; Leupeptin (Tippler, B. (271) 131)

CGRP (calcitonin gene-related peptide); Inflammation (Lopez-Belmonte, J. (271) R15)

Neutrophil; Inflammation (Lopez-Belmonte, J. (278) R7)

Cardiac hypertrophy; Volume overload; Losartan; Angiotensin II; FR139317 (Ishiye, M. (280) 11)

Endothelin ET_A receptor; Nitric oxide (NO); FR139317; Nitro-L-arginine; Hypertension; (Rat) (Fujita, K. (280) 311)

IRL 1620; FR 139317; Prostacyclin; Nitric oxide (NO); Prostaglandin E_2; Endothelin receptor (Grassi-Kassisse, D.M. (282) 57)

Cardiac myocyte; L-type Ca^{2+} current; β-Adrenoceptor agonist; (Guinea-pig) (Delpech, N. (285) 217)

Endothelin-3; Phosphatidylinositol hydrolysis; Human bronchi; Protein kinase C (Nally, J.E. (288) 53)

Smooth muscle; Myosin light chain (Kodama, M. (288) 69)

Protein phosphorylation; Protein kinase C; Heart, rat (Gando, S. (289) 175)

Endothelin-3; Lipoprotein lipase; Gene expression; Brown adipocyte; Endothelin ET_A receptor (Uchida, Y. (291) 33)

Atherosclerosis; De-endothelialization; Atherogenic diet; (Tissue distribution) (Kurata, C. (293) 109)

Erythropoietin, recombinant human; Glomerular endothelial cell; Mesangial cell; Proliferation (Nitta, K. (293) 491)

Endothelin-3
Endothelin receptor; Cotransmission; Vas deferens; BQ-123; Sarafotoxin S6c; (Guinea-pig) (Mutafova-Yambolieva, V.N. (285) 213)

Endothelin-1; Phosphatidylinositol hydrolysis; Human bronchi; Protein kinase C (Nally, J.E. (288) 53)

Endothelin-1; Lipoprotein lipase; Gene expression; Brown adipocyte; Endothelin ET_A receptor (Uchida, Y. (291) 33)

Endothelin-converting enzyme
Endothelin; Big-endothelin; Brain; Astrocyte; Phospholipase A_2 (Deschepper, C.F. (275) 61)

Endothelin; Sarafotoxin; Vas deferens; BQ-123; IRL 1620; BQ-788; Phosphoramidon; Neurotransmission; (Mouse) (Maas, J. (276) 113)

Endothelin receptor
Endothelin-1; IRL 1620; FR 139317; Prostacyclin; Nitric oxide (NO); Prostaglandin E_2 (Grassi-Kassisse, D.M. (282) 57)

Cotransmission; Vas deferens; Endothelin-3; BQ-123; Sarafotoxin S6c; (Guinea-pig) (Mutafova-Yambolieva, V.N. (285) 213)

Endothelin; Smooth muscle; Vascular (Lodge, N.J. (287) 279)

Endothelin; Ca^{2+} influx; Ca^{2+} release; Ca^{2+} sensitivity; Smooth muscle, vascular (Sudjarwo, S.A. (289) 197)

Endothelin ET_A receptor
Endothelin receptor antagonist; Coronary flow; Endothelin-1; Endothelin ET_B receptor; Nitric oxide (NO); Vasoconstriction (Wang, Q.-D. (271) 25)

Endothelin; [^{3}H]BQ-123 (Ihara, M. (274) 1)

Endothelin-1; Nitric oxide (NO); FR139317; Nitro-L-arginine; Hypertension; (Rat) (Fujita, K. (280) 311)

Endothelin; Endothelin ET_A receptor selective antagonist; Myometrium, human (Héluy, V. (285) 89)

Endothelin; Sarafotoxin; BQ-123; Saphenous vein, rabbit (Nishiyama, M. (286) 209)

Endothelin-1; Endothelin-3; Lipoprotein lipase; Gene expression; Brown adipocyte (Uchida, Y. (291) 33)

Endothelin ET_A receptor selective antagonist
Endothelin; Endothelin ET_A receptor; Myometrium, human (Héluy, V. (285) 89)

Endothelin ET_B receptor
Endothelin receptor antagonist; Coronary flow; Endothelin-1; Endothelin ET_A receptor; Nitric oxide (NO); Vasoconstriction (Wang, Q.-D. (271) 25)

Endothelin receptor antagonist
Coronary flow; Endothelin-1; Endothelin ET_A receptor; Endothelin ET_B receptor; Nitric oxide (NO); Vasoconstriction (Wang, Q.-D. (271) 25)

Middle cerebral artery thrombosis; Modified tissue-type plasminogen activator; SUN9216; FR139317 (Umemura, K. (275) 17)

Endothelin; Bosentan; Carbon tetrachloride; Hepatotoxicity; Acute liver dysfunction (Hocher, B. (293) 361)

Endothelin receptor subtype
Endothelin; IRL 1620; FR139317; RES-701-1; Duodenum; (Rat) (Irie, K. (275) 45)

Endothelin; IRL1620; PD145065; BQ-123; Tachyphylaxis (Miasiro, N. (285) 247)

Endothelium
Isoprenaline-induced relaxation; cAMP; cGMP; Pre-contraction; Aorta, rat (Eckly, A.E. (271) 237)

Lipoprotein; Vasodilation; Nitric oxide (NO) (Galle, J. (273) 311)

β-Adrenoceptor; Vascular permeability; Protein extravasation; Salbutamol; Salmeterol (Allen, M.J. (274) 7)

N^G-Nitro-L-arginine; EDHF (endothelium-derived hyperpolarizing factor); Acetylcholine; Aorta; (Rat) (Hatake, K. (274) 25)

K^+ channel blocker; Acetylcholine; Uterine artery; Nitric oxide (NO) (Jovanović, A. (280) 95)

Pulmonary vein, sheep; Vasodilatation; 5-HT (5-hydroxytryptamine, serotonin); Cyclic nucleotide (Zhang, L. (280) 335)

Tachykinin; Tachykinin NK_1 receptor; Nitric oxide (NO); Jugular vein, rabbit (Patacchini, R. (283) 233)

Nitric oxide (NO); Microvasculature; Neurogenic inflammation; Substance P; 5-HT (5-hydroxytryptamine, serotonin); ATP (Ralevic, V. (284) 231)

Mesenteric arterial bed, rat; Streptozotocin diabetes; Sympathetic nerve (Ralevic, V. (286) 193)

Adrenomedullin; cAMP; (Receptors) (Kato, J. (289) 383)

Nitric oxide, NO; Amidine; Butyramidine; Blood pressure; Shock; Inflammation; Endotoxin; Isothiourea (Southan, G.J. (291) 311)

Endothelium-dependent contraction
Acetylcholine; Renal artery, rat; Arachidonic acid metabolite (Nishimura, Y. (275) 217)

Endothelium-dependent relaxation
Adenosine receptor; Femoral artery; Femoral vein; 2-Octynyladenosine; YT-146 (Abiru, T. (281) 9)

Endothelium-derived contracting factor
PACAP (pituitary adenylate cyclase activating polypeptide); Cerebral artery, canine; Intracerebral arteriole, rat; Prostaglandin $F_{2\alpha}$ (Anzai, M. (285) 173)

Endotoxic shock
Nitric oxide(NO); Nitric oxide synthase; Cloning; Expression; Baculovirus (Moss, D.W. (289) 41)

Endotoxic shock, acute
Non-steroidal anti-inflammatory drug; Nitric oxide (NO); Gastrointestinal; Ulcer; Prostaglandin; Cardiovascular (Wallace, J.L. (280) 63)

Endotoxin
Nitric oxide (NO); Aminoguanidine; Nitric oxide (NO) synthase; Microcirculation; Blood pressure (Laszlo, F. (272) 169)

DS-4574; Peptidoleukotriene receptor antagonist; Small intestinal mucosal injury; Hemoconcentration; Plasma leakage (Tabuchi, Y. (273) 281)

Hypotension; Bradykinin B_1 receptor antagonist; Bradykinin; Des-Arg^9-bradykinin (Tokumasu, T. (274) 225)

Nitric oxide (NO); Capsaicin; Gastric damage; Gastric defense; Stress (Barrachina, M.D. (280) 339)

Nitric oxide (NO); Muscle-derived nitric oxide (NO); L-Arginine; Nitrovasodilator; Tolerance (Tsuchida, S. (281) 251)

Nitric oxide (NO); Microcirculation; N^G-Nitro-L-arginine methyl ester; N^G-Monomethyl-L-arginine; Multiple organ failure; Sepsis (László, F. (283) 47)

Vascular permeability; Kininogen-deficient rat; Bradykinin; PAF (platelet-activating factor); PAF receptor antagonist (Ueno, A. (284) 211)

Nitric oxide (NO) synthase; Chemotherapy; Cytotoxicity; Cancer; Anticancer drug (Hattori, Y. (291) 83)

Nitric oxide, NO; Amidine; Butyramidine; Blood pressure; Shock; Inflammation; Endothelium; Isothiourea (Southan, G.J. (291) 311)

Endotoxin shock
G 619; TNF-α (tumor necrosis factor-α); cAMP (Altavilla, D. (286) 31)

End-plate potential
Alkylating derivative of hexadecamethonium; Acetylcholinesterase inhibitor (Danilov, A.F. (277) 15)

Enkephalin
Cocaine; Naltrindole; δ-Opioid receptor; Cocaine-induced sensitization (Shippenberg, T.S. (280) 55)

Enkephalin catabolism inhibitor
Enkephalin, endogenous; CCK (cholecystokinin); RB 101; PD-134,308; Tail-flick; Hot-plate; Antinociception; CCK_B receptor antagonist; Tolerance (Valverde, O. (286) 79)

Enkephalin, endogenous
Enkephalin catabolism inhibitor; CCK (cholecystokinin); RB 101; PD-134,308; Tail-flick; Hot-plate; Antinociception; CCK_B receptor antagonist; Tolerance (Valverde, O. (286) 79)

Enteric nerve
Noncholinergic slow synaptic potential; 5-HT receptor; Gastrointestinal pharmacology (Pan, H. (278) 67)

5-HT receptor; Colon, guinea pig; Gastrointestinal motility; Relaxation (Briejer, M.R. (279) 123)

Enteric nervous system
Colon, rat; Cl^- channel; K^+ channel, Ca^{2+}; Prostaglandin (Strabel, D. (274) 181)

5-HT_3 receptor; Myenteric neuron; Distal colon; YM060 [(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-enzimidazole monohydrochloride]; (Guinea pig) (Ito, H. (283) 107)

Enterochromaffin-like cell
Stomach, rat; Ca^{2+} ionophore; Histamine; Patch-clamp; K^+ channel (Sakai, H. (291) 153)

Entrainment
Suprachiasmatic nucleus; Bombesin; Gastrin-releasing peptide; Neuromedin B; Ionophoresis; Neurophysiology; (Hamster) (Piggins, H.D. (271) 413)

Environmental temperature
Lead level, tissue; Lead toxicity; (Mouse) (Martinez-Garcia, F. (293) 271)

Enzyme induction
Cytochrome P450; Zucker rat; Obesity (Irizar, A. (293) 385)

Nitric oxide synthase; Lipopolysaccharide; Kupffer cell; Liver, rat; (*Propionibacterium avidum*) (Dhouib, M. (293) 439)

Eosinophil
β-Adrenoceptor agonist; Allergy; Inflammation; Passive cutaneous anaphylactic reaction (Teixeira, M.M. (272) 185)

K^+ channel; Chemiluminescence, luminol-dependent (Saito, M. (291) 217)

Toxocara canis; Airway inflammation; Tracheal reactivity (Buijs, J. (293) 207)

Eosinophil cationic protein (ECP)
Interleukin-5; House dust mite; Fluticasone propionate, aquous nasal spray; Rhinitis (Garrelds, I.M. (275) 295)

Eosinophilia
Bronchial hyperresponsiveness; Adhesion molecule; VLA-4 integrin (Milne, A.A.Y. (282) 243)

Eosinophil infiltration
Lipoxygenase metabolites; PAF (platelet-activating factor); Bronchial hyperresponsiveness (Seeds, E.A.-M. (293) 369)

Epalon
Neuroactive steroid; $GABA_A$ receptor; [^{3}H]Muscimol; 3α-Hydroxy-5α-pregnan-20-one (Goodnough, D.B. (288) 157)

Epidemiology
Risk assessment (Gangolli, S.D. (292) 1)

Epidural cup
GABA (γ-aminobutyric acid); Release; Modafinil; 5-HT (5-hydroxytryptamine, serotonin); Cerebral cortex (Tanganelli, S. (273) 63)

Epilepsy
GABA (γ-aminobutyric acid); Alanine; Glutamate (Baran, H. (273) 197)

GABA (γ-aminobutyric acid) uptake inhibitor; Nipecotic acid; Tiagabine; Carbamazepine anticonvulsant (Smith, S.E. (273) 259)

Glutamate; Nitric oxide (NO); NMDA (*N*-methyl-D-aspartate); Ischemia (Rundfeldt, C. (274) 73)

NMDA receptor antagonist; CGP 39551; CGP 37849; MK-801; Spatial learning (Ylinen, A. (274) 159)

GABA receptor; Hippocampus; Synaptic inhibition; Disinhibition (Stanford, I.M. (277) 229)

Blood pressure; Ca^{2+}-calmodulin; Dopamine; (El mouse) (Sutoo, D. (278) 33)

κ-Opioid receptor; CI977; Excitatory amino acid; Na^+ channel (Millan, M.H. (279) 75)

Levetiracetam; ucb L059; Anticonvulsant; Receptor binding (Noyer, M. (286) 137)

Kynurenate; Kynurenine; Excitotoxicity; Anticonvulsant action; Dizocilpine; Piriform cortex (Baran, H. (286) 167)

Kindling; NMDA (*N*-methyl-D-aspartate); Seizure; Excitatory amino acid; Amygdala (Croucher, M.J. (286) 265)

Nitric oxide (NO); Nitric oxide (NO) synthase; 7-Nitro indazole; Pilocarpine; Seizure (Van Leeuwen, R. (287) 211)

Felbamate; Ca^{2+}; NMDA (*N*-methyl-D-aspartate) (Taylor, L.A. (289) 229)

Epileptiform bursting
Felbamate; Anticonvulsant (Domenici, M.R. (271) 259)

Epinephrine
Adrenoceptor; Ageing; Fatty acid; Phospholipid; Heart muscle; (Rat) (Benediktsdóttir, V.E. (289) 419)

Epithelium
Diabetes; Sensory fiber; Capsaicin; Urinary bladder (Pinna, C. (271) 151)

Cholinergic activation; Colonic; Ion transport; Muscarinic receptor; [^{3}H]*N*-Methylscopolamine (O'Malley, K.E. (275) 83)

Colon; Ion transport; Histamine; Secretion; (Human) (Keely, S.J. (279) 203)

K^+ channel opener; Trachea; Submucosal gland (Griffin, A. (280) 317)

Bradykinin; Trachea, guinea-pig; Bradykinin B_2 receptor; Relaxation; Ca^{2+}; Ryanodine; Apamin; HOE 140; NPC 17761 (Schlemper, V. (282) 177)

K^+ channel opener; NIP-121; Cromakalim; Trachea, guinea-pig; Methylene blue; Phosphoramidon (Shikada, K.-i. (282) 193)

Corticotropin releasing factor; Ca^{2+}; Ca^{2+} channel; Pertussis toxin; inositol trisphosphate (Kiang, J.G. (291) 107)

Erbstatin analog
Genistein; Ca^{2+} (Helmeste, D.M. (280) R5)

Genistein; Ca^{2+} (Helmeste, D.M. (286) 113)

Ergot derivative
Heterologous expression; Cytochrome P450 3A4; V79 Chinese hamster cell; Testosterone (Rauschenbach, R. (293) 183)

Erysodine
Nicotinic acetylcholine receptor antagonist; Dihydro-β-erythroidine; Pharmacokinetics (Decker, M.W. (280) 79)

Erythrocyte
Lazaroid; (Ca^{2+}, Mg^{2+})-ATPase; Lipid peroxidation; Iron; Antioxidant (Zaidi, A. (290) 133)

Erythrocyte membrane, human
Lidocaine; Spectrin; ATPase, vascular type; Carbonic anhydrase (Nishiguchi, E. (286) 1)

Erythromycin
Motilin; Motilin receptor antagonist; Receptor binding; Smooth muscle contraction; Motilide (Depoortere, I. (286) 241)

Erythropoietin, recombinant human
Glomerular endothelial cell; Mesangial cell; Endothelin-1; Proliferation (Nitta, K. (293) 491)

E-selectin
Splanchnic artery occlusion shock; Leukocyte accumulation (Altavilla, D. (272) 223)

Estrogen
μ-Opioid receptor; Progesterone; Medial preoptic area; Upregulation (Zhou, L. (278) 271)

Brain slice; Chloroethylclonidine; 5-Methyl urapidil; WB-4101 (Kow, L.-M. (282) 199)

Monoamine oxidase A; Estrogen receptor; Neural cell; Catecholamine (Ma, Z.-Q. (284) 171)

Estrogen receptor
Monoamine oxidase A; Neural cell; Catecholamine; Estrogen (Ma, Z.-Q. (284) 171)

Etazolate
$GABA_A$ receptor; Flunitrazepam binding; Alphaxalone; Propofol; Chlormethiazole; (+)-Etomidate (Slany, A. (291) 99)

Ethanol
Ebselen; Gastric mucosal injury, murine; Gastric surface mucous cell line GSM06; Lipid peroxide; Peptidoleukotriene (Tabuchi, Y. (272) 195)

γ-Hydroxybutyric acid (GHBA); Motor-impairing effect; Cross-tolerance; (Rat) (Colombo, G. (273) 235)

Heart; Ca^{2+} current; Na^+ current; Voltage clamp (Habuchi, Y. (292) 143)

Nicotine; Stress, cold-restraint; Gastric lesion; Mast cell; (Mini-osmotic pump); (Rat) (Wong, D. (292) 157)

α_2-Adrenoceptor; Atipamezole; Dexmedetomidine; Monoamine; Motor performance; (Mouse) (Idänpään-Heikkilä, J.J. (292) 191)

Microsome; Mitochondria; Lipid order; Membrane protein (Sanchez-Amate, M.C. (292) 215)

Na^+,K^+-ATPase; Ouabain; K^+; Synaptosome (Foley, T.D. (292) 287)

5-HT_3 receptor; Bezold-Jarisch reflex; Capsaicin (Malinowska, B. (293) 71)

Ethanol self-administration
Amygdala, extended; $GABA_A$ receptor (Hyytiä, P. (283) 151)

Ethanol tolerance
8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Ethanol withdrawal; 5-HT (5-hydroxytryptamine, serotonin) syndrome; Corticosterone (Kleven, M. (281) 219)

BDNF (brain-derived neurotrophic factor); Neurotrophin-3; Neurotrophin-4/5 (Szabó, G. (287) 35)

Ethanol withdrawal
8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Ethanol tolerance; 5-HT (5-hydroxytryptamine, serotonin) syndrome; Corticosterone (Kleven, M. (281) 219)

NMDA receptor; $GABA_A$ receptor; Microdialysis; Dizocilpine; Diazepam (Rossetti, Z.L. (283) 177)

Ethylketocyclazocine
Phospholipid metabolism; U50,488; Norepinephrine; Carbachol; Renal cortex (Mosaddeghi, M. (289) 411)

***N*-Ethylmaleimide**
$GABA_B$ receptor; Baclofen; Neocortical slice, rat; Aluminum fluoride; G-protein (Ong, J. (287) 197)

Eticlopride
Cocaine; SCH 23390; Sulpiride; Ontogeny (Pruitt, D.L. (283) 125)

Etodolac
Prostaglandin G/H synthase (cyclooxygenase); Whole blood, human; Naproxen; Diclofenac; Tenidap (Glaser, K. (281) 107)

(+)-Etomidate
$GABA_A$ receptor; Flunitrazepam binding; Alphaxalone; Propofol; Chlormethiazole; Etazolate (Slany, A. (291) 99)

Etonitazene
Morphine; Naloxone; Radial maze; Opioid; Memory (Braida, D. (271) 497)

***β*-Eudesmol**
Organophosphate intoxication; Anticholinesterase agent; Obidoxime; Diisopropylfluorophosphate; Neuromuscular transmission (Chiou, L.C. (292) 151)

Evans blue
Capsaicin; Pulmonary response (Bolser, D.C. (276) R1)

Evoked potential
Urethane (ethyl carbamate); Dentate gyrus; Perforant path; GABAergic inhibition (Shirasaka, Y. (282) 11)

Excitatory amino acid
Flupirtine; Muscle relaxant; NMDA (*N*-methyl-D-aspartate); Spasticity; Spinal reflex; (Rat) (Schwarz, M. (276) 247)

Respiratory activity; Ventrolateral nucleus of the tractus solitarius; NMDA receptor; Apneusis (Berger, I. (277) 195)

κ-Opioid receptor; CI977; Epilepsy; Na^+ channel (Millan, M.H. (279) 75)

Neurotoxicity; Glutamate; Glutamate receptor subtype; Motoneuron; Cultured neuron (Estevez, A.G. (280) 47)

Mediodorsal thalamic nucleus; Prefrontal cortex; Anesthesia (Pirot, S. (285) 45)

Kindling; NMDA (*N*-methyl-D-aspartate); Seizure; Epilepsy; Amygdala (Croucher, M.J. (286) 265)

Excitatory amino acid receptor antagonist
Retina; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid); NMDA (*N*-methyl-D-aspartate); Thiokynurenic acid; Rose bengal (Lombardi, G. (271) 489)

Ventrolateral medulla; Glutamate receptor; L-Glutamate uptake inhibitor; Respiratory function; Blood pressure; Heart rate (McManigle, J.E. (280) 257)

Excitatory junctional potential
Detrusor smooth muscle; Electrical response; (Contraction) (Hashitani, H. (284) 177)

Excitotoxicity
L-α-Aminoadipic acid; Kynurenic acid; Kynurenine; Microdialysis; Neurodegeneration (Wu, H.-Q. (281) 55)

NMDA receptor; NMDA (*N*-methyl-D-aspartate); Benzomorphan (Sawyer, D.C. (284) 309)

Epilepsy; Kynurenate; Kynurenine; Anticonvulsant action; Dizocilpine; Piriform cortex (Baran, H. (286) 167)

Glutamate; NMDA receptor; AMPA/Kainate receptor; Ca^{2+} channel, L-type, voltage-sensitive; Neuroprotection (Prehn, J.H.M. (292) 179)

Exercise
Noradrenaline; Adrenaline; Catecholamine overflow; β_2-Adrenoceptor, prejunctional; (Freely moving rat) (Coppes, R.P. (274) 33)

Exocytosis
Ba^{2+}; Ca^{2+}-dependent release; Calmodulin; Okadaic acid; Phosphatase (Verhage, M. (291) 387)

EXP 3174
Angiotensin AT_1 receptor antagonist; Angiotensin II-induced drinking; Losartan; LR-B/081 (Polidori, C. (277) 223)

Irbesartan (SR 47436/BMS-186295); SR 47155A; Losartan; Pithed rat; Angiotensin II (Christophe, B. (281) 161)

Experimental animal
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Neurobehavioral effect; Reproduction effect; Endocrine effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Human infant; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

Experimental hypoxemia
Bleomycin; Prednisolone; Doxapram; Almitrine; TEI-7322 (Horiuchi, H. (287) 27)

Expression
Nitric oxide(NO); Nitric oxide synthase; Cloning; Baculovirus; Endotoxic shock (Moss, D.W. (289) 41)

Extracellular
Cortical culture; K^+-induced depolarization; Hypoxia; Glutamate; Glutamate receptor; Serum-free culture (Uchiyama-Tsuyuki, Y. (293) 245)

Extrapyramidal symptom
Fluoxetine; Clomipramine; Imipramine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Antidepressant; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (281) 255)

Extravasation
Formalin test; Inflammation; Pain; Opioid receptor subtype; Peripheral analgesia (Hong, Y. (277) 21)

Fadrozole hydrochloride
CGS16949A; Aromatase inhibitor; MCF-7; T47D (Yano, S. (289) 217)

Fatty acid
Hypertrophy; L-Carnitine; Cardiac efficiency (Schönekess, B.O. (286) 155)

Adrenoceptor; Ageing; Epinephrine; Phospholipid; Heart muscle; (Rat) (Benediktsdóttir, V.E. (289) 419)

Fatty acid, free
TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Tryptophan, free; Albumin (Unkila, M. (293) 115)

Fatty alcohol
Insulin secretion; Islet of Langerhans; Pancreas (Damgé, C. (274) 133)

Fedotozine
Visceral pain; κ-Opioid receptor; μ-Opioid receptor; Colonic hypersensibility Langlois, A. (271) 245)

Feedback inhibition
Nitrergic nerve; Nitric oxide (NO); NANC (non-adrenergic noncholinergic); Gastric fundus; (Rat) (De Man, J.G. (285) 269)

Feeding behavior
Metformin; Zucker rat; Genetic obesity; Insulin; Neuropeptide Y (Rouru, J. (273) 99)

Felbamate
Anticonvulsant; Epileptiform bursting (Domenici, M.R. (271) 259)

Ca^{2+}; NMDA (*N*-methyl-D-aspartate); Epilepsy (Taylor, L.A. (289) 229)

Felodipine
Amlodipine; Smooth muscle, vascular; Drug effect; (Rat) (Videbæk, L.M. (274) 109)

Femoral artery
Neuropeptide Y; Angiotensin II; Vasoconstriction; Second messenger (Cressier, F. (272) 57)

Adenosine receptor; Endothelium-dependent relaxation; Femoral vein; 2-Octynyladenosine; YT-146 (Abiru, T. (281) 9)

Femoral artery, rat
Nicorandil; Cromakalim; cGMP; Detrusor muscle, rat; K^+ channel (Zhou, Q. (273) 153)

Femoral vein
Adenosine receptor; Endothelium-dependent relaxation; Femoral artery; 2-Octynyladenosine; YT-146 (Abiru, T. (281) 9)

Fenfluramine
5-HT (5-hydroxytryptamine, serotonin); Cocaine; Corticosterone, presynaptic (Baumann, M.H. (282) 87)

Neurotoxicity; Appetite (McCann, U.D. (283) R5)

***d*-Fenfluramine**
Hyperphagia; Neuropeptide Y; (±)-Cyanopindolol; Paraventricular nucleus of the hypothalamus; 5-HT receptor (Grignaschi, G. (274) 221)

Fenoldopam
Dopamine; Noradrenaline; Renal blood flow; Splanchnic blood flow; Oxygen demand; Oxygen supply; Oxygen extraction ratio (Schiffer, E.R. (286) 49)

Dopamine; D_1 receptor; Protein kinase C; Bromocriptine (Kansra, V. (289) 391)

Fentanyl
Flesinoxan; Drug discrimination; 5-HT_{1A} receptor; (*S*)-UH301, enantiomer; WAY-100635 (Gommans, J. (284) 135)

Fever
Lipocortin/annexin; Anti-inflammatory peptide; Interleukin-1β; Prostaglandin E_2 (Palmi, M. (281) 97)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide)
FG5891; (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-*N*-methyl-3-pyridinecarboxamide; FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester; FG5909 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-hydroxy-pyridine; Reuptake; Release; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline (Pettersson, E. (282) 131)

FG5891
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-*N*-methyl-3-pyridinecarboxamide; FG5893 (2-[4-[4,4-bis(4-fluorophenyl)-butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester; FG5909 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-hydroxy-pyridine; Reuptake; Release; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline (Pettersson, E. (282) 131)

FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5891; (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-*N*-methyl-3-pyridinecarboxamide; FG5909 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-hydroxy-pyridine; Reuptake; Release; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline (Pettersson, E. (282) 131)

FG5909 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-hydroxy-pyridine
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5891; (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-*N*-methyl-3-pyridinecarboxamide; FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester; Reuptake; Release; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline (Pettersson, E. (282) 131)

Firing pattern, modulation
Muscarinic receptor; Afterhyperpolarization; Neostriatum; Neuromodulation (Pineda, J.C. (281) 271)

FK409
TRK-100; Antiplatelet activity (Hirasawa, Y. (272) 39)

FR144420; Nitric oxide (NO) (Kita, Y. (275) 125)

FK453
Adenosine receptor; Atrium; Aorta; Binding assay (Terai, T. (279) 217)

Flesinoxan
5-HT_{1A} receptor; Corticosterone; Glucose; 5-HT (5-hydroxytryptamine, serotonin); Behavioral syndrome; (S)-UH301 (Groenink, L. (272) 177)

5-HT_{1A} receptor; Corticosterone; Glucose; Prolactin; Defensive burying; Anxiety (Groenink, L. (280) 185)

Drug discrimination; 5-HT_{1A} receptor; (*S*)-UH301, enantiomer; WAY-100635; Fentanyl (Gommans, J. (284) 135)

Flexor reflex
Inositol trisphosphate; Motoneuron; Neuropeptide Y; Nociception; Spinal cord (Xu, X.-J. (272) 219)

Flumazenil
Benzodiazepine; $GABA_A$ receptor, diazepam-insensitive; Drug discrimination; Bretazenil; Ro 19-0528; GABA (γ-aminobutyric acid); (Receptor partial agonist); (Pigeon) (Acri, J.B. (278) 213)

Allopregnanolone; Anxiety; Burying behavior (Fernández-Guasti, A. (281) 113)

Benzodiazepine receptor; Iomazenil; Steady state; K_d; Partition coefficient (Videbæk, C. (281) 117)

Flunitrazepam
$GABA_A$ receptor; Benzodiazepine BZ_1 site; Benzodiazepine BZ_2 site; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate) binding; Ontogenesis; CL 218,872; Zolpidem; Cerebral cortex, rat (Giorgi, O. (290) 37)

Triethyllead; Benzodiazepine receptor; $GABA_A$ receptor; Muscimol; (Rat); (Brain) (Komulainen, H. (293) 167)

Flunitrazepam binding
HEK (Human embryonic kidney) cell line 293; $GABA_A$ receptor; Peripheral benzodiazepine binding site; $GABA_A$ receptor subunit (Fuchs, K. (289) 87)

$GABA_A$ receptor; Alphaxalone; Propofol; Chlormethiazole; (+)-Etomidate; Etazolate (Slany, A. (291) 99)

***p*-Fluoroamphetamine**
Drug discrimination; ^{3}H-Monoamine uptake inhibition; Microdialysis, in vivo, in freely moving rat (Marona-Lewicka, D. (287) 105)

Fluoxetine
Antidepressant drug; Desipramine; Maprotiline; Moclobemide; Trimipramine; 2-Methyl-5-hydroxytryptamine; 5-HT (5-hydroxytryptamine, serotonin); Reuptake inhibition; Hippocampus; Presynaptic modulation (Mongeau, R. (271) 121)

Clomipramine; Imipramine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Extrapyramidal symptom; Antidepressant; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (281) 255)

5-HT (5-hydroxytryptamine, serotonin) uptake; Frontal cortex; Ventral hippocampus; Raphe nuclei; Microdialysis, in vivo (Malagié, I. (286) 213)

Fluoxetine, repeated administration
Frontal cortex; Spontaneously active neuron; (Rat) (Ceci, A. (271) 231)

Flupirtine
Excitatory amino acid; Muscle relaxant; NMDA (*N*-methyl-D-aspartate); Spasticity; Spinal reflex; (Rat) (Schwarz, M. (276) 247)

Triaminopyridine; NMDA (*N*-methyl-D-aspartate); NMDA receptor; Neuron; Cell death; HIV-1; gp120 (Perovic, S. (288) 27)

Flurazepam
Benzodiazepine type 1 receptor; [^{3}H]Zolpidem; Tolerance; Receptor down-regulation; Midazolam (Wu, Y. (278) 125)

Flurbiprofen
Nefopam; Nitric oxide (NO); Arterial relaxation; Platelet aggregation; Antinociception (Pallapies, D. (271) 335)

7-Nitro indazole; Antinociception; Nitric oxide (NO); Nitric oxide (NO) synthase; (Mouse) (Gaffen, Z. (271) 445)

Fluticasone propionate, aquous nasal spray
Interleukin-5; Eosinophil cationic protein (ECP); House dust mite; Rhinitis (Garrelds, I.M. (275) 295)

Fluvoxamine
Opioid dependence; Paroxetine; Place conditioning; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, specific; Morphine (Rafieian-Kopaei, M. (275) 185)

FMO1A1
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); *N*-oxygenation; FMO (recombinant rat liver flavin-containing monoxygenase) (Chiba, K. (293) 97)

FMO (recombinant rat liver flavin-containing monoxygenase)
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); *N*-oxygenation; FMO1A1 (Chiba, K. (293) 97)

Food
Metabolite; Methylation; Blood; Urine; Water (Vahter, M. (293) 455)

Food intake
Substance P; Nitric oxide (NO); Motor behavior (Mancuso, F. (271) 329)

Baclofen; $GABA_B$ receptor; Water intake; Palatable liquid diet (Ebenezer, I.S. (273) 183)

Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; 5-HT (5-hydroxytryptamine, serotonin); Anorexia; Gastric emptying (Hui, S.-C.G. (283) 141)

Dioxin; TCDD (2,3,7,8-Tetrachlorodibenzo-*p*-dioxin); Portocaval anastomosis; Anorexia; Vagotomy (Tuomisto, J. (292) 277)

Foot-shock stress, acute
Chronic variate stress; β-Adrenoceptor; $5\text{-}HT_{1A}$ receptor; $5\text{-}HT_2$ receptor; Amitriptyline; Open-field; Brain cortex, rat (Ferretti, C. (280) 19)

Forced swimming test
$5\text{-}HT_{1A}$ receptor; Depression; S 14506; S 14671; (+)-WAY 100,135 (Schreiber, R. (271) 537)

Prenatal diazepam; Desipramine; Alprazolam (Cannizzaro, C. (273) 239)

$5\text{-}HT_{1A}$ receptor; MKC-242 (5-{3-[((2*S*)-1,4-benzodioxan-2-ylmethyl)-amino]propoxy}-1,3-benzodioxole); Antidepressant activity; (Mouse) (Matsuda, T. (280) 235)

Formalin test
RB 101 (mixed enkephalin-degrading enzyme inhibitor); Morphine; CCK_B receptor antagonist; Naloxone; Naltrindole; (Mouse) (Noble, F. (273) 145)

Inflammation; Pain; Opioid receptor subtype; Peripheral analgesia; Extravasation (Hong, Y. (277) 21)

Antinociception; Adenosine; Methylxanthine; Pain mechanism (Doak, G.J. (281) 311)

Diabetes; Aldose reductase; Polyol pathway; Pain; Diabetic neuropathy (Calcutt, N.A. (285) 189)

Adenosine analgesia; Adenosine kinase; Stimulus intensity (Poon, A. (286) 177)

Formoterol
Cilia; Terbutaline; Trachea; Maxillary sinus; Mucociliary clearance (Lindberg, S. (285) 275)

Forskolin
Cardiac contractility; Isoprenaline; Diazepam; cAMP (Martinez, E. (282) 169)

ATP release, neuronal; Ouabain; Atrium, guinea-pig; W-7; Vinblastine; Okadaic acid (Katsuragi, T. (282) 213)

CGRP (Calcitonin gene-related peptide); Adenylate cyclase; Guinea-pig ureter; K^+ channel (Santicioli, P. (289) 17)

Phosphodiesterase inhibitor; Peripheral blood mononuclear cell; Arachidonate; cAMP; β_2-adrenoceptor agonist (Hichami, A. (291) 91)

c-fos
Amantadine; Dopamine; NMDA (*N*-metal-D-aspartate); Striatum (Tomitaka, S.-i. (285) 207)

CV-11974; TCV-116; Smooth muscle cell; Vascular; Cell growth (Flesch, M. (289) 399)

5-HT_2 receptor; 5-HT uptake inhibitor; Antidepressant (Tilakaratne, N. (290) 263)

c-Fos expression
Indomethacin; Nociception; Carrageenin, inflammation (Honoré, P. (272) 249)

Fos protein
Haloperidol; Clozapine; Tolerance; Nucleus accumbens; Striatum; Amygdala; (Long-term treatment) (Sebens, J.B. (273) 175)

Vasopressin; Immunoreactivity; Brain region; (Rat) (Wu, P.H. (281) 263)

FPL 12495AA
Remacemide hydrochloride; Cortical wedge; NMDA receptor (Hu, R.Q. (287) 251)

FR139317
Middle cerebral artery thrombosis; Modified tissue-type plasminogen activator; SUN9216; Endothelin receptor antagonist (Umemura, K. (275) 17)

Endothelin; Endothelin receptor subtype; IRL 1620; RES-701-1; Duodenum; (Rat) (Irie, K. (275) 45)

Cardiac hypertrophy; Volume overload; Losartan; Angiotensin II; Endothelin-1 (Ishiye, M. (280) 11)

Endothelin-1; Endothelin ET_A receptor; Nitric oxide (NO); Nitro-L-arginine; Hypertension; (Rat) (Fujita, K. (280) 311)

Endothelin-1; IRL 1620; Prostacyclin; Nitric oxide (NO); Prostaglandin E_2; Endothelin receptor (Grassi-Kassisse, D.M. (282) 57)

FR144420
FK409; Nitric oxide (NO) (Kita, Y. (275) 125)

F344 rat
Yawning; Sprague-Dawley rat; Dopamine (Tang, A.H. (284) 13)

Free radical
t-Butyl hydroperoxide; Sinoatrial node; Atrioventricular node; Reperfusion arrhythmia; Lipid peroxidation (Satoh, N. (272) 233)

MDMA (3,4-methylenedioxymethamphetamine); Ecstasy; Neurodegeneration; PBN (α-phenyl-*N*-tert-butyl nitrone); Neuroprotection (Colado, M.I. (280) 343)

Toxicity; Antioxidant; NMDA receptor; Cortical culture (Eshhar, N. (283) 19)

Ca^{2+} current; Myocyte; Cardiac (Gill, J.S. (292) 337)

N-Acetyl-L-cysteine; Allopurinol; Xanthine oxidase; Sepsis; Cecal ligation and puncture (Villa, P. (292) 341)

Free radical scavenger
Nitric oxide (NO) donor; Superoxide; Peroxynitrite; Gastric damage (Lamarque, D. (277) 187)

Frontal cortex
Fluoxetine, repeated administration; Spontaneously active neuron; (Rat) (Ceci, A. (271) 231)

Dopamine uptake inhibitor; Dopamine receptor agonist; Dopamine, endogenous; Nucleus accumbens; Striatum (Irifune, M. (272) 79)

5-HT (5-hydroxytryptamine, serotonin) uptake; Fluoxetine; Ventral hippocampus; Raphe nuclei; Microdialysis, in vivo (Malagié, I. (286) 213)

Frontoparietal cortex
Histamine; Somatostatin receptor; Adenylyl cyclase; (Rat) (Puebla, L. (289) 361)

Fucoidin
Sialidase; β_2-Integrin; CD11b; Interleukin-8; Interleukin-1 (Harris, J.G. (279) 149)

β-Funaltrexamine
Antinociception; μ-Opioid receptor; Dorsal root ganglion; Primary afferent neuron; Ribonuclease protection assay (Schäfer, M. (279) 165)

μ-Opioid receptor; Tyr-D-Arg-Phe-β-Ala-NH_2; Memory; Passive avoidance; Locomotor activity; (Mouse) (Ukai, M. (287) 245)

Fungicide
Dopamine transporter, vesicular; Insecticide; Herbicide; Rotenone; Neurotoxin; Parkinsonism (Vaccari, A. (292) 309)

Fura-2
Ca^{2+}, transient signal; Heart, guinea-pig; Isoproterenol; Dihydroouabain (Hotta, Y. (282) 121)

β-Amyloid peptide; Cell culture (Korotzer, A.R. (288) 125)

Aortic endothelial cell; Ca^{2+} mobilization; Cl^-, extracellular; Thapsigargin; Cyclopiazonic acid (Hosoki, E. (288) 131)

Staurosporine; Adrenal chromaffin cell; Ca^{2+} homeostasis; Catecholamine release (Maurer, J.A. (288) 163)

Endothelial cell; Bradykinin; Nitric oxide (NO); Anesthetic, volatile; Sevoflurane; A23187; D-Arg-[Hyp^3, $Thi^{5,8}$, D-Phe^7] bradykinin; Des-Arg^9-[Leu^8] bradykinin; Ca^{2+} channel (Az-ma, T. (289) 33)

Endothelial cells, human; Ca^{2+}, cytosolic; Isradipine; Histamine (Iouzalen, L. (289) 189)

Furosemide
Bradykinin; Thromboxane A_2 receptor; Smooth muscle; Airway (Molimard, M. (278) 253)

Fusidic acid
TNF (tumor necrosis factor); Interleukin-6; Dexamethasone; Pentoxifylline; Pentamidine isethionate; Adenosine receptor agonist (Chen, Y.-L. (271) 319)

G 619
TNF-α (tumor necrosis factor-α); Endotoxin shock; cAMP (Altavilla, D. (286) 31)

G_s
Vitamin B_{12} deficiency; Adenylyl cyclase; β-Adrenoceptor; Signal transduction (Hatta, S. (291) 351)

GABA (γ-aminobutyric acid)
Release; Epidural cup; Modafinil; 5-HT (5-hydroxytryptamine, serotonin); Cerebral cortex (Tanganelli, S. (273) 63)

Alanine; Glutamate; Epilepsy (Baran, H. (273) 197)

$GABA_B$ receptor; 2-Hydroxy-saclofen; Hippocampus; Presynaptic inhibition; (Inhibition) (Caddick, S.J. (274) 41)

Mammillary complex; Memory; Retention; Acetylcholine; Dopamine; Norepinephrine; NMDA (*N*-methyl-D-asparate); Nicotine; Neuropeptide Y; (Mouse) (Flood, J.F. (275) 223)

Clonidine; Rostral ventrolateral medulla; Vasomotor neuron; Sympathoexcitatory neuron (Sun, M.-K. (276) 291)

Benzodiazepine; $GABA_A$ receptor, diazepam-insensitive; Drug discrimination; Bretazenil; Flumazenil; Ro 19-0528; (Receptor partial agonist); (Pigeon) (Acri, J.B. (278) 213)

Local anesthetic; Hippocampal neuron; Chloride ion; Patch-clamp technique; Glycine (Hara, M. (283) 83)

Dopamine; Substantia nigra; NMDA (*N*-methyl-D-aspartate); Pyrrolidinone (Shepard, P.D. (285) 79)

Aspartate; Atipamezole; Dexmedetomidine; Glutamate; Microdialysis; Hippocampus (Valtonen, P. (285) 239)

Toluene; Microdialysis; Globus pallidus; Striatum (Stengård, K. (292) 43)

Disulfiram; Glutamate; Neurotoxicity (Mamatha, R.K. (292) 89)

GABA (γ-aminobutyric acid) derivative
Arylaminopyridazine; SR 95103; GABA receptor antagonist; (*Ascaris suum*) (Martin, R.J. (276) 9)

GABA (γ-aminobutyric acid) release
NMDA receptor subtype; Striatum; Acetylcholine release; Spermidine release (Nankai, M. (286) 61)

GABA (γ-aminobutyric acid) uptake inhibitor
Nipecotic acid; Tiagabine; Carbamazepine anticonvulsant; Epilepsy (Smith, S.E. (273) 259)

GABA receptor
Calcitonin; NMDA (*N*-methyl-D-aspartate); Aversive behavior; β-Adrenoceptor; 5-HT receptor (Maeda, Y. (275) 163)

Hippocampus; Epilepsy; Synaptic inhibition; Disinhibition (Stanford, I.M. (277) 229)

Patch clamp; Cl^- channel; Bicuculline; Retina; Bipolar cell; Rod pathway (Feigenspan, A. (288) 97)

GABA receptor antagonist
Antinociception, i.c.v., i.t.; Benzodiazepine; Nociceptive test; Opioid (Luger, T.J. (271) 421)

Arylaminopyridazine; GABA (γ-aminobutyric acid) derivative; SR 95103; (*Ascaris suum*) (Martin, R.J. (276) 9)

GABA receptor δ-subunit
Polyclonal antiserum (Quirk, K. (290) 175)

GABA release
Acetylcholine release; Noradrenaline release; Galantide (Akehira, K. (284) 149)

$GABA_A$ receptor
Gastric acid secretion; Muscimol (Lin, W.-C. (279) 43)

β-Carboline; Photoaffinity label (Zezula, J. (281) 93)

Ethanol self-administration; Amygdala, extended (Hyytiä, P. (283) 151)

Ethanol withdrawal; NMDA receptor; Microdialysis; Dizocilpine; Diazepam (Rossetti, Z.L. (283) 177)

Epalon; Neuroactive steroid; [^{3}H]Muscimol; 3α-Hydroxy-5α-pregnan-20-one (Goodnough, D.B. (288) 157)

HEK (Human embryonic kidney) cell line 293; Flunitrazepam binding; Peripheral benzodiazepine binding site; $GABA_A$ receptor subunit (Fuchs, K. (289) 87)

Thiomuscimol; Photoaffinity labeling; Brain, rat (Nielsen, M. (289) 109)

Ro 15-4513; Diazepam-insensitive; Cerebellum; Alcohol sensitivity; Benzodiazepine; Imidazoquinoxaline; Imidazoquinazoline; Cyclopyrrolone (Wong, G. (289) 335)

Benzodiazepine BZ_1 site; Benzodiazepine BZ_2 site; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate) binding; Ontogenesis; Flunitrazepam; CL 218,872; Zolpidem; Cerebral cortex, rat (Giorgi, O. (290) 37)

Flunitrazepam binding; Alphaxalone; Propofol; Chlormethiazole; (+)-Etomidate; Etazolate (Slany, A. (291) 99)

Antisense oligonucleotide; Receptor subunit; Benzodiazepine receptor; Brain, rat (Karle, J. (291) 439)

Triethyllead; Benzodiazepine receptor; Flunitrazepam; Muscimol; (Rat); (Brain) (Komulainen, H. (293) 167)

$GABA_A$ receptor, diazepam-insensitive
Benzodiazepine; Drug discrimination; Bretazenil; Flumazenil; Ro 19-0528; GABA (γ-aminobutyric acid); (Receptor partial agonist); (Pigeon) (Acri, J.B. (278) 213)

$GABA_A$ receptor, α4 subunit
Benzodiazepine; Diazepam-insensitive (Yang, W. (291) 319)

$GABA_A$ receptor, γ3 subunit
Benzodiazepine site (Hadingham, K.L. (291) 301)

$GABA_A$ receptor-ionophore complex
Pentylenetetrazol; γ-Butyrolactone bicyclic; Convulsant (picrotoxin) site; [^{35}S]TBPS binding; Benzodiazepine sites (Maksay, G. (288) 61)

$GABA_A$ receptor, recombinant
Neuroactive steroids; Patch clamp; (Ligand binding modulation) (Hauser, C.A.E. (289) 249)

$GABA_A$ receptor subunit
HEK (Human embryonic kidney) cell line 293; Flunitrazepam binding; $GABA_A$ receptor; Peripheral benzodiazepine binding site (Fuchs, K. (289) 87)

$GABA_B$ receptor
Baclofen; Food intake; Water intake; Palatable liquid diet (Ebenezer, I.S. (273) 183)

GABA (γ-aminobutyric acid); 2-Hydroxy-saclofen; Hippocampus; Presynaptic inhibition; (Inhibition) (Caddick, S.J. (274) 41)

(*RS*)-(±)-Baclofen; (*S*)-2-Hydroxysaclofen; (*R*)-2-Hydroxysaclofen; Ileum, guinea pig; Hippocampus, rat; Neocortex, rat (Kerr, D.I.B. (287) 185)

Baclofen; Neocortical slice, rat; *N*-Ethylmaleimide; Aluminum fluoride; G-protein (Ong, J. (287) 197)

Dopamine D_2 receptor; Muscarinic acetylcholine receptor; GTPase; Receptor-G protein coupling; Striatum (Odagaki, Y. (291) 245)

$GABA_B$ receptor antagonist
CGP 35348; Pyramidal tract neuron; Transcallosal response, cat; Motor cortex (Chowdhury, S.A. (285) 99)

GABA ρ_1 receptor
Protein kinase C; *Xenopus* oocyte; Down-regulation; Phorbol ester; Staurosporine (Kusama, T. (291) 431)

GABAergic drug
Dopamine; Striatum; Kainic acid (Smolders, I. (284) 83)

GABAergic inhibition
Urethane (ethyl carbamate); Dentate gyrus; Perforant path; Evoked potential (Shirasaka, Y. (282) 11)

Galactosemia
Polyol pathway; Nerve conduction; Ischemic resistance; Capillary density; Vasodilator treatment (Dines, K.C. (281) 303)

Galanin
Pinacidil; K^+ channel activator; Electrolyte transport (Homaidan, F.R. (271) 561)

Galantide; Parasympathetic neuron; K^+ conductance; Ca^{2+} conductance (Mulvaney, J.M. (287) 97)

Galanthamine
PC12; Patch-clamp; Nicotinic acetylcholine receptor; Physostigmine (Storch, A. (290) 207)

Galantide
Acetylcholine release; Noradrenaline release; GABA release (Akehira, K. (284) 149)

Galanin; Parasympathetic neuron; K^+ conductance; Ca^{2+} conductance (Mulvaney, J.M. (287) 97)

Gallamine
Allosterism; [^{3}H]*N*-methylscopolamine; Dissociation kinetics (Christopoulos, A. (290) 259)

Gallbladder
β_3-Adrenoceptor; Adipose tissue; Obesity; RNase protection; (Human) (Berkowitz, D.E. (289) 223)

Gallbladder, guinea-pig
Tachykinin NK_2 receptor; Tachykinin receptor antagonist; MEN 10,627; SR 48968; Proximal colon, guinea-pig (Patacchini, R. (271) 111)

CCK_A receptor; CCK_B receptor; $CCK_{A/B}$ receptor antagonist, mixed; Radioligand binding; Anxiolytic (Singh, L. (286) 185)

Gallopamil
Coronary occlusion; Adenosine release; Reperfusion arrhythmia; Lidocaine; Quinidine (Bernauer, W. (283) 91)

GAMS (γ-D-glutamylaminomethylsulfonic acid)
AMPA/kainate receptor; Desensitizing current, fast; 6-Cyano-7-nitroquinoxaline-2,3-dione; Hippocampal neuron, rat (Wilsch, V.W. (284) 141)

Gastric acid secretion
Histamine; *Helicobacter pylori*; Histamine chloramine (Asagoe, K. (275) 179)

Presynaptic α_2-adrenoceptor; α_2-Adrenoceptor subtype; Vagus nerve; (Rat) (Blandizzi, C. (278) 179)

Muscimol; $GABA_A$ receptor (Lin, W.-C. (279) 43)

α-Adrenoceptor; Interleukin-1β; Indomethacin; Sympatho-adrenomedullary system (Yokotani, K. (279) 233)

Gastric cell
Ca^{2+}; Damage; Oxidative stress; Nitric oxide (NO) (Tepperman, B.L. (293) 259)

Gastric damage
Nitric oxide (NO) donor; Superoxide; Peroxynitrite; Free radical scavenger (Lamarque, D. (277) 187)

Nitric oxide (NO); Endotoxin; Capsaicin; Gastric defense; Stress (Barrachina, M.D. (280) 339)

Gastric defense
Nitric oxide (NO); Endotoxin; Capsaicin; Gastric damage; Stress (Barrachina, M.D. (280) 339)

Gastric emptying
Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; 5-HT (5-hydroxytryptamine, serotonin); Anorexia; Food intake (Hui, S.-C.G. (283) 141)

Bombesin; Bombesin receptor subtype; Bombesin receptor antagonist (Varga, G. (286) 109)

Gastric fundus
NANC (non-adrenergic, non-cholinergic); Cyclic nucleotide; Phosphodiesterase (Barbier, A.J. (276) 41)

Feedback inhibition; Nitrergic nerve; Nitric oxide (NO); NANC (non-adrenergic non-cholinergic); (Rat) (De Man, J.G. (285) 269)

Gastric fundus, rat
Hemoglobin; Hydroxocobalamin; Nitric oxide (NO); N^G-Nitro-L-arginine; NANC (non-adrenergic, non-cholinergic) nerve; Nitrosothiol (Jenkinson, K.M. (275) 145)

Gastric hyperemia
CCK (cholecystokinin); CCK receptor; Cytoprotection; Stomach (Konturek, S.J. (273) 57)

Gastric lesion
YM638 ([[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio] acetic acid); Leukotriene D_4 receptor antagonist; Gastric mucosal protection (Miyata, K. (276) 165)

Nicotine; Stress, cold-restraint; Ethanol; Mast cell; (Mini-osmotic pump); (Rat) (Wong, D. (292) 157)

Gastric mucosa
Nitric oxide (NO); Lipopolysaccharide; (Stomach) (Brown, J.F. (292) 111)

Gastric mucosal injury
NSAID (non-steroidal anti-inflammatory drug); Nitric oxide (NO) (Barrachina, M.D. (281) R3)

Gastric mucosal injury, murine
Ebselen; Ethanol; Gastric surface mucous cell line GSM06; Lipid peroxide; Peptidoleukotriene (Tabuchi, Y. (272) 195)

Gastric mucosal protection
YM638 ([[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio] acetic acid); Leukotriene D_4 receptor antagonist; Gastric lesion (Miyata, K. (276) 165)

Gastric surface mucous cell line GSM06
Ebselen; Ethanol; Gastric mucosal injury, murine; Lipid peroxide; Peptidoleukotriene (Tabuchi, Y. (272) 195)

Gastrin
CCK_B receptor; Cholecystokinin; GTPγS (Lallement, J.-C. (290) 61)

Gastrin-17
CCK (cholecystokinin); Gastroprotection; Stomach; Capsaicin; Nitric oxide (NO) (Konturek, S.J. (278) 203)

Gastrin-releasing peptide
Suprachiasmatic nucleus; Entrainment; Bombesin; Neuromedin B; Ionophoresis; Neurophysiology; (Hamster) (Piggins, H.D. (271) 413)

Neuromedin B; Bombesin (Ladenheim, E.E. (271) R7)

Gastrointestinal
Non-steroidal anti-inflammatory drug; Nitric oxide (NO); Endotoxic shock, acute; Ulcer; Prostaglandin; Cardiovascular (Wallace, J.L. (280) 63)

Gastrointestinal motility
Neurotensin; Neurotensin receptor; Colon, rat (Mulè, F. (275) 131)

5-HT receptor; Colon, guinea pig; Enteric nerve; Relaxation (Briejer, M.R. (279) 123)

Gastrointestinal pharmacology
Enteric nerve; Noncholinergic slow synaptic potential; 5-HT receptor (Pan, H. (278) 67)

Gastrointestinal system, rat
8-OH-DPAT ((±)-8-hydroxy-2-(*n*-dipropylamino)tetralin); Adrenal gland; $5\text{-}HT_{1A}$ receptor; Acid (Gidener, S. (284) 19)

Gastroprotection
Gastrin-17; CCK (cholecystokinin); Stomach; Capsaicin; Nitric oxide (NO) (Konturek, S.J. (278) 203)

GBH (γ-hydroxybutyric acid)
Voluntary γ-hydroxybutyric acid intake; Alcoholism; (Rat) (Colombo, G. (285) 103)

[^{3}H]GBR-12935
1-(*m*-Chlorophenyl)-biguanide; $5\text{-}HT_3$ receptor; Dopamine transporter; Nucleus accumbens; Caudate putamen; (Rat) (Campbell, A.D. (290) 157)

[^{3}H]GBR-12935 binding
Dopamine uptake inhibitor; Brain microdialysis; Dopamine; Stereotypy (Nakachi, N. (281) 195)

$G_o\alpha$ subunit
G protein; Go isoform; Pregnancy; Myometrium; Human uterus (Zumbihl, R. (288) 9)

$G\beta\gamma$ subunit
DDT_1MF-2 cell; Smooth muscle cell; Phospholipase C (Dickenson, J.M. (288) 393)

Gene expression
Endothelin-1; Endothelin-3; Lipoprotein lipase; Brown adipocyte; Endothelin ET_A receptor (Uchida, Y. (291) 33)

Substance P receptor; Tachykinin NK_1 receptor; Polymerase chain reaction; Pituitary; AtT20 cell (Winkler, A. (291) 51)

Genetic obesity
Metformin; Zucker rat; Feeding behavior; Insulin; Neuropeptide Y (Rouru, J. (273) 99)

Genetics
Transgenic mouse; Superoxide dismutase; Opiate receptor; Antinociception (Elmer, G.I. (283) 227)

Genetic selection
Conditioned place preference; Locomotor activity; Nicotine; (Mouse) (Schechter, M.D. (279) 59)

Genistein
Erbstatin analog; Ca^{2+} (Helmeste, D.M. (280) R5)

Erbstatin analog; Ca^{2+} (Helmeste, D.M. (286) 113)

Ca^{2+}-activated K^+ channel; Smooth muscle cell, vascular; Tyrosine kinase (Xiong, Z. (290) 117)

Geranylgeraniol
Human bronchial myocyte; Simvastatin; Mevalonate; Cell proliferation (Viganò, T. (291) 201)

GFAP (glial fibrillary acidic protein)
Imidazoline; Imidazoline receptor; [^{3}H]Idazoxan; Astrocyte (Alemany, R. (280) 205)

GF 109203X
Contraction; Histamine; Bronchus, human; Protein kinase C; Phorbol ester (Yang, K.X.F. (275) 283)

Gingiva
Afferent nerve; Blood flow; 5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindole acetic acid); Dopamine; Dental pulp; Sympathetic nerve; (Rat) (Kerezoudis, N.P. (275) 191)

GK-128
$5\text{-}HT_3$ receptor; Emesis; (*Suncus murinus*) (Ito, C. (285) 37)

Glibenclamide
Lemakalim; ATP-sensitive Ca^{2+} channel; Apamin; Charybdotoxin; Nitric oxide (NO) (Franck, H. (271) 379)

K^+ channel; Levcromakalim; Myocardium; Hypoxia; (Guinea-pig) (Mellemkjær, S. (277) 51)

Aorta, rat; Sulfonylurea; Prostanoid; Prostaglandin $F_{2\alpha}$; Tolbutamide; Thromboxane A_2 (Delaey, C. (280) 179)

Binding site; Hypoglycemic agent; Liver; Sulfonylurea compound (Inoue, Y. (284) 77)

K_{ATP} channel; Myocardial ischemia; Glucose (Kamigaki, M. (287) 121)

Levcromakalim; Artery, subcutaneous; (Human) (Hüsken, B.C.P. (287) 313)

Globus pallidus
Toluene; GABA (γ-aminobutyric acid); Microdialysis; Striatum (Stengård, K. (292) 43)

Glomerular endothelial cell
Erythropoietin, recombinant human; Mesangial cell; Endothelin-1; Proliferation (Nitta, K. (293) 491)

Glucagon
Benzoic acid; Endocrine pancreas; Insulin; Ruminant; (Sheep) (Mineo, H. (280) 149)

Glucagon-related peptide
Acid secretion; Histamine; [^{14}C]aminopyrine accumulation (Gros, L. (288) 319)

Glucagon secretion
Insulin secretion; Neuroglycopenia; 2-Deoxy-D-glucose; Nitric oxide (NO); Nitric oxide synthase; N^G-Nitro-L-arginine methyl ester; N^G-Nitro-L-arginine; (Mouse) (Ahrén, B. (280) 27)

Glucocorticoid
Smooth muscle, airway; Asthma; β-Adrenoceptor agonist, cell culture; Cell proliferation (Young, P.G. (273) 137)

Peritoneal leukocyte; Respiratory burst; Activation, ex vivo; (Rat) (Røshol, H. (286) 9)

Lipopolysaccharide; Antioxidant; Vitamin E; Vitamin C; Allopurinol (Dimmeler, S. (287) 257)

Transcription; Nuclear receptor (Tanaka, H. (291) 121)

Glucocorticoid effect
PLC-PRF-5; Angiotensin AT_1 receptor; Hepatoma cell; Dexamethasone; Steroid (Wintersgill, H.P. (288) 365)

Glucose
5-HT_{1A} receptor; Corticosterone; 5-HT (5-hydroxytryptamine, serotonin); Behavioral syndrome; (S)-UH301; Flesinoxan (Groenink, L. (272) 177)

5-HT_{1A} receptor; Corticosterone; Prolactin; Flesinoxan; Defensive burying; Anxiety (Groenink, L. (280) 185)

K_{ATP} channel; Myocardial ischemia; Glibenclamide (Kamigaki, M. (287) 121)

Glucose tolerance
Spontaneously hypertensive rat (SHR); Blood pressure; Angiotensin converting enzyme inhibitor; Angiotensin AT_1 receptor antagonist (Chow, L. (282) 77)

Glucuronidation
PCB (polychlorinated biphenyl); TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Thyroid hormone (Van Birgelen, A.P.J.M. (293) 77)

mGlu receptor
NMDA receptor; NMDA (*N*-methyl-D-asparate); *t*-ACPD (*trans*-(±)-1-amino-1,3-cyclopentanedicarboxylic acid); L-AP-3 (L-2-amino-3-phosphono-propionate); Periaqueductal gray matter (Leyva, J. (285) 123)

cAMP; Phospholipase C; G-protein (Knöpfel, T. (288) 389)

Glutamate
GABA (γ-aminobutyric acid); Alanine; Epilepsy (Baran, H. (273) 197)

Nitric oxide (NO); NMDA (*N*-methyl-D-aspartate); Epilepsy; Ischemia (Rundfeldt, C. (274) 73)

CCK (cholecystokinin); Cerebral cortex; NMDA receptor; Seizure (Bandopadhyay, R. (275) 53)

Neurotoxicity; Excitatory amino acid; Glutamate receptor subtype; Motoneuron; Cultured neuron (Estevez, A.G. (280) 47)

Vitamin B_{12}; Ischemia; Hippocampus; Neuroprotection; Hypoxia/hypoglycemia (Yamamoto, Y. (281) 335)

Striatum; κ-Opioid receptor (Hill, M.P. (281) R1)

Presynaptic action; Grease-gap; Hippocampus; Autoreceptor; (D.C. potential) (Shew, T.R. (284) 93)

MK-801; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); Inflammation; Pain; Analgesia (Jackson, D.L. (284) 321)

Aspartate; Atipamezole; Dexmedetomidine; GABA (γ-aminobutyric acid); Microdialysis; Hippocampus (Valtonen, P. (285) 239)

Prepulse inhibition, rat; 5-HT (5-hydroxytryptamine, serotonin); Antipsychotic; Schizophrenia (Varty, G.B. (287) 201)

NMDA receptor; Glycine site antagonist; Allosteric interaction; Glycine (Grimwood, S. (290) 221)

Arachidonic acid; Transport; Synaptosome; Ca^{2+} (Lundy, D.F. (291) 273)

Disulfiram; GABA (γ-aminobutyric acid); Neurotoxicity (Mamatha, R.K. (292) 89)

Excitotoxicity; NMDA receptor; AMPA/Kainate receptor; Ca^{2+} channel, L-type, voltage-sensitive; Neuroprotection (Prehn, J.H.M. (292) 179)

Cortical culture; K^+-induced depolarization; Hypoxia; Extracellular; Glutamate receptor; Serum-free culture (Uchiyama-Tsuyuki, Y. (293) 245)

Glutamate neurotransmission
Ionizing irradiation; Neuroprotective; Na^+ channel blocker; Neuronal damage; (Rat) (Alaoui, F. (276) 55)

Glutamate receptor
Spinal cord; Nociception; Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester; L-N^5-(1-Iminoethyl)ornithine; *S*-Nitroso-*N*-penicillamine (Budai, D. (278) 39)

Ventrolateral medulla; L-Glutamate uptake inhibitor; Respiratory function; Excitatory amino acid receptor antagonist; Blood pressure; Heart rate (McManigle, J.E. (280) 257)

AMPA ((*RS*)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid); NMDA (*N*-methyl-D-aspartate); ATPA ((*RS*)-2-amino-3-(3-hydroxy-5-*tert*-butylisoxazol-4-yl)propionic acid); Cue; Convulsion; (Rat); (Mouse) (Arnt, J. (285) 289)

Cortical culture; K^+-induced depolarization; Hypoxia; Glutamate; Extracellular; Serum-free culture (Uchiyama-Tsuyuki, Y. (293) 245)

Glutamate receptor subtype
Neurotoxicity; Excitatory amino acid; Glutamate; Motoneuron; Cultured neuron (Estevez, A.G. (280) 47)

Glutamate release
Metabotropic glutamate receptor; Striatum; Synaptosome; Parkinson's disease; (Presynaptic) (East, S.J. (277) 117)

Adenosine A_{2A} receptor; Striatum; (Rat) (Popoli, P. (287) 215)

Glutamatergic synaptic transmission
β-Amyloid-(1–40); Long-term potentiation (Wu, J. (284) R1)

L-Glutamate uptake inhibitor
Ventrolateral medulla; Glutamate receptor; Respiratory function; Excitatory amino acid receptor antagonist; Blood pressure; Heart rate (McManigle, J.E. (280) 257)

Glutathione
Ischemia; Hippocampus; 2-Deoxyglucose uptake; Presynaptic potential; Neuroprotection (Shibata, S. (273) 191)

Zinc sulfate; *N*-acetylcysteine; Acetaminophen; Hepatotoxicity; Alanine aminotransferase; Malondialdehyde (Woo, P.C.Y. (293) 217)

Glutathione-*S*-transferase
Nitroglycerin bioactivation; Cytochrome *P*-450; Coronary artery; Cultivated smooth muscle cell; cGMP (Braun, M. (276) 239)

Glycine
Myoclonus; Hypoxia; NMDA (*N*-methyl-D-aspartate); Ischemia; HA-966; ACEA-1011; ACEA-1021 (Matsumoto, R.R. (275) 117)

Cerebral ischemia; MAP2 (microtubule-associated protein 2); Receptor autoradiography; Immunohistochemistry (Araki, T. (278) 91)

NMDA (*N*-methyl-D-aspartate); Schizophrenia; Dopamine metabolism; Stereotypy (Kretschmer, B.D. (280) 37)

Local anesthetic; Hippocampal neuron; Chloride ion; Patch-clamp technique; GABA (γ-aminobutyric acid) (Hara, M. (283) 83)

Adrenal; Catecholamine; Microdialysis; Polymerase chain reaction; Strychnine (Yadid, G. (288) 399)

NMDA receptor; Glycine site antagonist; Allosteric interaction; Glutamate (Grimwood, S. (290) 221)

Glycine receptor
Dynorphin; NMDA receptor; Endorphin (Dumont, M. (271) 241)

Glycine receptor, strychnine-insensitive
Anticonvulsant; Anxiolytic; Separation-induced vocalization; Audiogenic seizure; NMDA receptor; (DBA/2J mouse); (Rat pup) (Kehne, J.H. (284) 109)

ACPC (1-aminocyclopropanecarboxylic acid); NMDA receptor (Popik, P. (291) 221)

Glycine site antagonist
NMDA receptor; Allosteric interaction; Glutamate; Glycine (Grimwood, S. (290) 221)

Glycoprotein
Desensitization; Kainate; *Xenopus* oocyte (Yue, K.-T. (291) 229)

P-Glycoprotein
Dexniguldipine-HCl; Allosteric interaction; Multidrug resistance (Malkhandi, J. (288) 105)

Pristinamycin; Intestinal absorption; Intestinal epithelium; Caco-2 (Phung-Ba, V. (288) 187)

Opiate; Antidiarrheal agent; Ion conductance; CFTR (cystic fibrosis transmembrane conductance regulator) (Callaghan, R. (291) 183)

Glycosylation inhibitor
Septic liver failure; Liver, mouse; DNA fragmentation (Leist, M. (292) 201)

cGMP
Isoprenaline-induced relaxation; cAMP; Pre-contraction; Endothelium; Aorta, rat (Eckly, A.E. (271) 237)

Nicorandil; Cromakalim; Detrusor muscle, rat; Femoral artery, rat; K^+ channel (Zhou, Q. (273) 153)

Nitroglycerin bioactivation; Glutathione-*S*-transferase; Cytochrome *P*-450; Coronary artery; Cultivated smooth muscle cell (Braun, M. (276) 239)

Red nucleus; L-Arginine; Analgesia; Nitric oxide (NO) (Kumar, A. (279) 1)

Butein; EDRF (endothelium-derived relaxing factor); Phosphodiesterase; cAMP; Thoracic aorta, rat (Yu, S.-M. (280) 69)

Proximal duodenum, rat; Nitric oxide (NO); NANC (non-adrenergic, non-cholinergic) nerve; Smooth muscle relaxation; Apamin; K^+ channel (Martins, S.L.R. (284) 265)

Nipradilol; Nitric oxide (NO); Nitrite (Adachi, T. (286) 201)

Platelet inhibition; cAMP; Prostacyclin; Nitric oxide (NO); Protein phosphorylation (Grünberg, B. (288) 329)

Neutrophil; Migration; ANF (Atrial natriuretic factor) (Elferink, J.G.R. (288) 335)

Mesangial cell, rat; Cyclic nucleotide phosphodiesterase; cyclic AMP; ANF-(1–28) (Atrial natriuretic factor-(1–28); E4021 (Ahn, H.-S. (289) 49)

Alveolar macrophage; Carbon monoxide (CO); Nitric oxide (NO); Heme oxygenase; Superoxide anion (Fukushima, T. (289) 103)

Nitric oxide (NO); Nitric oxide synthase; PC12 cell; Ca^{2+} homeostasis (Clementi, E. (289) 113)

Platelet; Iloprost; cAMP; Synergism (Fisch, A. (289) 455)

Endothelial cell; Phosphodiesterase inhibitor; Nitric oxide; cAMP (Kessler, T. (290) 163)

Nitric oxide (NO) synthase; Methylene blue; LY83583; NADPH-diaphorase (Luo, D. (290) 247)

Neutrophil; Degranulation; Ca^{2+}; cAMP; Protein kinase C; Tolfenamic acid (Kankaanranta, H. (291) 17)

Aortic valve cusp, porcine; Nitric oxide (NO); Nitric oxide synthase, constitutive; Nitric oxide synthase, inducible; Thrombin (De Meyer, E. (291) 67)

cGMP-dependent protein kinase
Atrium, rat; Contraction, force of; Aortic ring; Relaxation; Acetylcholine (Bäumner, D. (273) 295)

cGMP-specific phosphodiesterase (phosphodiesterase V)
Phosphodiesterase; E4021; Vasorelaxant; Aorta, human (Miyahara, M. (284) 25)

Go isoform
G protein; $G_o\alpha$ subunit; Pregnancy; Myometrium; Human uterus (Zumbihl, R. (288) 9)

gp120
Flupirtine; Triaminopyridine; NMDA (*N*-methyl-D-aspartate); NMDA receptor; Neuron; Cell death; HIV-1 (Perovic, S. (288) 27)

GPIIb/IIIa
Humanized antibody; Thrombosis, photochemically induced; Microcirculation; Bleeding time; (Squirrel monkey) (Kaku, S. (279) 115)

G-protein
Mast cell, cutaneous; Neuropeptide Y; Mastoparan; Benzalkonium chloride; Pertussis toxin; Neuraminidase (Emadi-Khiav, B. (272) 97)

Bradykinin; Uterus, rat; Vas deferens, rat; Trachea, guinea pig; Ileum, guinea pig; Urinary bladder, guinea pig; Ca^{2+}; Protein kinase C (Calixto, J.B. (281) 279)

Cryptolepine (5-methylquindoline); Vasodilation; Kidney, rat; K^+ channel; Ca^{2+} channel; Pertussis toxin (Oyekan, A.O. (285) 1)

$GABA_B$ receptor; Baclofen; Neocortical slice, rat; *N*-Ethylmaleimide; Aluminum fluoride (Ong, J. (287) 197)

$G_o\alpha$ subunit; Go isoform; Pregnancy; Myometrium; Human uterus (Zumbihl, R. (288) 9)

$5\text{-}HT_{1A}$ receptor; $5\text{-}HT_{1A}$ receptor antagonist; Autoradiography, quantitative; [^{3}H]8-OH-DPAT ([^{3}H]8-hydroxy-2-(di-*n*-propylamino)tetralin); [^{3}H]WAY 100635 (Gozlan, H. (288) 173)

Muscarinic receptor; Mutation; Arginine (Jones, P.G. (288) 251)

$5\text{-}HT_{1A}$ receptor; GTP hydrolysis; Adenylyl cyclase; Hippocampus (Odagaki, Y. (288) 385)

cAMP; Phospholipase C; mGluR (Knöpfel, T. (288) 389)

Chinese hamster ovary cell; Muscarinic receptor; Pertussis toxin; [^{3}H]*N*-methylscopolamine; [^{35}S]guanosine 5′-*O*-(3-thiotriphosphate) (Burford, N.T. (289) 343)

Muscarinic receptor; Mutation; Aspartate (Page, K.M. (289) 429)

Desensitization; Phospholipase C; P_{2Y} purinoceptors; Protein kinase C (Galas, M.-C. (291) 175)

Opiate; U-50488H; U-69593; PD 117302; Hypothermia; Gut motility; Cholera toxin; Pertussis toxin (Shukla, V.K. (292) 293)

G-protein activation
Bradykinin; Adenylate cyclase (inhibition); Ileum; Guinea pig; Bradykinin receptor; (High-affinity binding site) (Liebmann, C. (288) 35)

G-protein-coupled receptor
Brain, chicken; Recombinant P_{2Y1} purinoceptor; *Xenopus* oocyte expression; COS-7 cell, transient expression; Inositol 1,4,5-trisphosphate, formation (Simon, J. (291) 281)

G-protein coupling
Angiotensin AT_{1A} receptor; Protein kinase C; Receptor internalization; Regulation (Balmforth, A.J. (291) 135)

GR55562
GR127935; Metergoline; Methiothepin; $5\text{-}HT_{1D\alpha}$ receptor; $5\text{-}HT_1D_\beta$ receptor (Walsh, D.M. (287) 79)

GR71251
Tachykinin receptor antagonist; GR82334; L-659,877; Substance P; Neurokinin A (Guo, J.-Z. (281) 49)

GR82334
Tachykinin receptor antagonist; GR71251; L-659,877; Substance P; Neurokinin A (Guo, J.-Z. (281) 49)

GR127935
Ketanserin; Saphenous vein, rabbit; Jugular vein, guinea-pig; $5\text{-}HT_{1D}$ receptor (Razzaque, Z. (283) 199)

GR55562; Metergoline; Methiothepin; $5\text{-}HT_{1D\alpha}$ receptor; $5\text{-}HT_1D_\beta$ receptor (Walsh, D.M. (287) 79)

$5\text{-}HT_{1A}$, $5\text{-}HT_{1D\alpha}$ and $5\text{-}HT_{1D\beta}$ receptors , cloned, human; $5\text{-}HT_{1B}$ receptor, opossum kidney; cAMP formation; $5\text{-}HT_{1D}$ receptor antagonist (Pauwels, P.J. (290) 95)

GR159897
Tachykinin receptor; Tachykinin NK_2 receptor; Neurokinin A (Beresford, I.J.M. (272) 241)

Granisetron
$5\text{-}HT_3$ receptor; Dopamine; Morphine; Reward (Rompré, P.-P. (287) 263)

Grease-gap
Presynaptic action; Glutamate; Hippocampus; Autoreceptor; (D.C. potential) (Shew, T.R. (284) 93)

Grooming
Dopamine receptor antagonist; $5\text{-}HT_{1A}$ receptor agonist; Climbing; Stereotyped behavior; Catalepsy (Protais, P. (271) 167)

Aging; ACTH (adrenocorticotropin); Melanocortin; Stretching; Yawning; Penile erection (Poggioli, R. (271) 253)

Grooming, excessive
Apomorphine; 5-HT (5-hydroxytryptamine, serotonin); Penile erection; Oxytocin; Prolactin; Corticosterone; $5\text{-}HT_{2C}$ receptor; m-CPP (1-3-chlorophenylpiperazine); Hypothalamic paraventricular nucleus (Bagdy, G. (275) 301)

Growth
Opioid; Development; Brain; Liver; (Intracerebroventricular) (Bartolome, J.V. (284) 43)

Growth hormone
Morphine; Antisense oligodeoxynucleotide; μ-Opioid receptor; δ-Opioid receptor; Prolactin (Idänpään-Heikkilä, J.J. (284) 227)

Psycholeine; Quadrigemine C; Somatostatin; Adenylate cyclase (Rasolonjanahary, R. (285) 19)

Tolerance; Morphine; Thyrotropin; Prolactin; Locomotor activity; Rectal temperature (Rauhala, P. (285) 69)

Hypothalamus; Pituitary; α_2-Adrenoceptor; Clonidine; Oxymetazoline; α_2-Adrenoceptor antagonist; α_{2A}-Adrenoceptor subtype; α_{2B}-Adrenoceptor subtype (Makara, G.B. (287) 43)

GRP (gastrin-releasing peptide)
Bombesin; Bombesin binding site; Lung, human; GRP-preferring bombesin receptor (Lach, E. (273) 313)

GRP-preferring bombesin receptor
Bombesin; GRP (gastrin-releasing peptide); Bombesin binding site; Lung, human (Lach, E. (273) 313)

GSH
Lipopolysaccharide; Melatonin; Liver; GSSG; Lipid peroxidation (Sewerynek, E. (293) 327)

GSSG
Lipopolysaccharide; Melatonin; Liver; GSH; Lipid peroxidation (Sewerynek, E. (293) 327)

GTP
Oxytocin; Endothelin; Pharmacomechanical coupling; Myometrium (Izumi, H. (278) 187)

GTPase
Dopamine D_2 receptor; Muscarinic acetylcholine receptor; $GABA_B$ receptor; Receptor-G protein coupling; Striatum (Odagaki, Y. (291) 245)

GTP-binding protein
Adenylate cyclase; Anandamide; Cannabinoid receptor (Barg, J. (287) 145)

GTPγS
CCK_B receptor; Cholecystokinin; Gastrin (Lallement, J.-C. (290) 61)

GTP hydrolysis
5-HT_{1A} receptor; G protein (GTP-binding protein); Adenylyl cyclase; Hippocampus (Odagaki, Y. (288) 385)

[^{35}S]Guanosine 5′-*O*-(3-thiotriphosphate)
Chinese hamster ovary cell; Muscarinic receptor; Pertussis toxin; G proteins; [^{3}H]*N*-methylscopolamine (Burford, N.T. (289) 343)

Guanylate cyclase
Allicin; Pulmonary vascular bed, rat; Pulmonary vascular bed, cat; Vasodilator response; N^{ω}-Nitro-L-arginine methyl ester; Methylene blue; Hypoxic pulmonary vasoconstriction (Kaye, A.D. (276) 21)

Gut motility
Morphine; Methylnaltrexone; Naloxone; Ileum, guinea-pig; Intestine, human, isolated (Yuan, C.-S. (276) 107)

G-protein; Opiate; U-50488H; U-69593; PD 117302; Hypothermia; Cholera toxin; Pertussis toxin (Shukla, V.K. (292) 293)

GYKI 52466
Anti-epileptic; Seizure (Borowicz, K.K. (281) 319)

MK-801; Cystometrogram; Urethral sphincter, external; Bladder reflex (Yoshiyama, M. (287) 73)

H-7
Opioid; Physical dependence; Protein kinase; Morphine; Butorphanol; H-8 (Tokuyama, S. (284) 101)

H-8
Opioid; Physical dependence; Protein kinase; Morphine; Butorphanol; H-7 (Tokuyama, S. (284) 101)

pH
Antiarrhythmic agent, class III; K^+ channel (Herzer, T. (291) 205)

HA-966
Myoclonus; Hypoxia; NMDA (*N*-methyl-D-aspartate); Ischemia; ACEA-1011; ACEA-1021; Glycine (Matsumoto, R.R. (275) 117)

HA1077
Intimal hyperplasia; Hyperreactivity; Myosin light chain phosphorylation; Protein kinase inhibitor; $[Ca^{2+}]_i$ (Seto, M. (276) 27)

Haloperidol
Oral dyskinesia; 6-Hydroxydopamine; Tardive dyskinesia (Huang, N.-Y. (271) 433)

Clozapine; Fos protein; Tolerance; Nucleus accumbens; Striatum; Amygdala; (Long-term treatment) (Sebens, J.B. (273) 175)

Dystonia; σ Receptor; Red nucleus; DTG (di-*o*-tolylguanidine) (Matsumoto, R.R. (280) 301)

Cocaine; SCH23390; Catalepsy; Supersensitivity; Subsensitivity; (Mouse) (Ushijima, I. (285) 55)

Dopamine receptor; mRNA; Dopamine D_4 receptor; Antipsychotic drug; Neuroleptics (Schoots, O. (289) 67)

Headache
5-HT (5-hydroxytryptamine, serotonin); Red wine; Platelet; Migraine (Pattichis, K. (292) 173)

Heart
Muscarinic receptor; Allosteric modulation; Alcuronium (Maaß, A. (272) 103)

Dopamine receptor; Adrenaline; Plasma; Dopamine; Adrenal medulla; (Partial least squares regression) (Kujacic, M. (273) 247)

ω-Conotoxin GVIA; ω-Conotoxin MVIIC; ω-Conotoxin MVIIA; ω-Agatoxin IVA; Sympathetic neurotransmission; Ca^{2+} channel (Vega, T. (276) 231)

Endothelin; Ischemia; Receptor displacement (Franco-Cereceda, A. (279) 105)

Arteriovenous anastomose; α-CGRP (calcitonin gene-related peptide); Dihydroergotamine; Migraine, pig; Sumatriptan (Van Gelderen, E.M. (284) 51)

Diadenosine hexaphosphate; ATP-sensitive K^+ channel (Jovanović, A. (286) R1)

Muscarinic receptor; 2α-DHET; 2α-(2′,2′-disubstituted-hydroxy-ethoxy)-tropane; Allosteric interaction (Gao, Z.-g. (289) 369)

Ethanol; Ca^{2+} current; Na^+ current; Voltage clamp (Habuchi, Y. (292) 143)

Na^+,K^+-ATPase; α Isoforms of Na^+,K^+-ATPase; DOCA-salt hypertension; Brain; Skeletal muscle (Sahin-Erdemli, I. (292) 163)

Heart, guinea-pig
Fura-2; Ca^{2+}, transient signal; Isoproterenol; Dihydroouabain (Hotta, Y. (282) 121)

Heart muscle
Adrenoceptor; Ageing; Epinephrine; Fatty acid; Phospholipid; (Rat) (Benediktsdóttir, V.E. (289) 419)

Heart muscle, contractility
SPM3672; Nitric oxide (NO) donor; Nitric oxide (NO); Cardiomyocyte (Kojda, G. (284) 315)

Heart, rat
α_1-Adrenoceptor; β-Adrenoceptor; Myocardial contractility; Protein phosphorylation (Hartmann, M. (287) 57)

Endothelin-1; Protein phosphorylation; Protein kinase C (Gando, S. (289) 175)

Mitochondria; Pravastatin; Simvastatin (Satoh, K. (292) 271)

Heart rate
5-HT (5-hydroxytryptamine, serotonin); ACTH (adrenocorticotropin); Corticosterone; Prolactin; Renin; Blood pressure (Levy, A.D. (274) 141)

Ventrolateral medulla; Glutamate receptor; L-Glutamate uptake inhibitor; Respiratory function; Excitatory amino acid receptor antagonist; Blood pressure (McManigle, J.E. (280) 257)

Diterpenoid alkaloid; Autonomic nerve; Blood pressure (Chiao, H. (283) 103)

UP 269-6; Losartan; Angiotensin II; Angiotensin II receptor antagonist; Blood pressure (Cazes, M. (284) 157)

HEK-293 (human embryonic kidney 293 cell)
Flunitrazepam binding; $GABA_A$ receptor; Peripheral benzodiazepine binding site; $GABA_A$ receptor subunit (Fuchs, K. (289) 87)

α_7 Nicotinic acetylcholine receptor subunit; [^{125}I]α-bungarotoxin; Ion channel, ligand-gated; Cholinergic pharmacology (Gopalakrishnan, M. (290) 237)

HEL 299 cell
Muscarinic receptor synthesis; Propylbenzilylcholine mustard; Receptor inactivation; Radioligand binding; cAMP accumulation (Haddad, E.-B. (290) 201)

α-Helical CRF-(9–41)
Interleukin-1; Interleukin-1 receptor antagonist; α-MSH (α-melanocyte-stimulating hormone); CRF (corticotropin-releasing factor); Morphine withdrawal (Katsumata, S. (278) 143)

Helicobacter pylori
Histamine; Histamine chloramine; Gastric acid secretion (Asagoe, K. (275) 179)

Heme oxygenase
Amnesia; Inhibitory avoidance; Hippocampus; Zinc protoporphyrin-9 (Fin, C. (271) 227)

Alveolar macrophage; Carbon monoxide (CO); Nitric oxide (NO); Cyclic GMP; Superoxide anion (Fukushima, T. (289) 103)

Hemocoagulation
Somatotropin; Somatostatin; Vitamin K-dependent coagulation factor (Negrev, N. (277) 145)

Hemoconcentration
DS-4574; Peptidoleukotriene receptor antagonist; Endotoxin; Small intestinal mucosal injury; Plasma leakage (Tabuchi, Y. (273) 281)

Hemodynamics
PAF (platelet activating factor); Blood flow, regional; PAF receptor antagonist; Microsphere (King, K.A. (281) 187)

Bronchial blood flow; Cyclooxygenase inhibitor; Ibuprofen; Smoke inhalation injury (Abdi, S. (293) 475)

Hemodynamics, regional
Adrenomedullin; Spontaneously hypertensive rat (SHR); Microsphere (He, H. (273) 209)

Hemoglobin
Interleukin-1; Nitric oxide (NO); CRF (corticotropin-releasing factor; Neuroimmunology; N^G-Nitro-L-arginine; Indomethacin; Prostaglandin (Sandi, C. (274) 17)

Gastric fundus, rat; Hydroxocobalamin; Nitric oxide (NO); N^G-Nitro-L-arginine; NANC (non-adrenergic, non-cholinergic) nerve; Nitrosothiol (Jenkinson, K.M. (275) 145)

Hemorrhage
Desamino-8D-arginine vasopressin; Brattleboro rat; Vasopressin; Angiotensin; Noradrenaline (Laycock, J.F. (271) 193)

Hemorrhagic hypotension
Cerebral blood flow autoregulation; Doxazosin; α-Adrenoceptor; Spontaneously hypertensive rat (SHR) (Cai, H. (286) 249)

Hemorrhagic shock
Hypovolemia; ACTH-(1–24); (Conscious rabbit) (Ludbrook, J. (275) 267)

Hypovolemia; Nitric oxide (NO); *N*-Nitro-L-arginine methyl ester; (Rabbit, conscious) (Ventura, S. (277) 265)

Hepatic focus
Polychlorinated biphenyl; Tumour promotion (Hemming, H. (292) 241)

Hepatocyte
α_1-Adrenoceptor; Liver; Tamsulosin (García-Sáinz, J.A. (289) 1)

TNF-α (tumor necrosis factor-α); DNA fragmentation; Nitric oxide (NO); Oxygen tension; (Acute phase response); (Tissue) (Ohno, K. (292) 205)

Hepatocyte, isolated
Benfluorex metabolite; Diabetes mellitus; Non insulin-dependent; Membrane fluidity; (Rat) (Orsière, T.G. (291) 237)

Hepatocyte membrane
α_1-Adrenoceptor subtype; Liver; α_{1A}-Adrenoceptor (García-Sáinz, J.A. (272) 139)

Hepatoma cell
PLC-PRF-5; Angiotensin AT_1 receptor; Dexamethasone; Steroid; Glucocorticoid effect (Wintersgill, H.P. (288) 365)

Hepatotoxicity
Cytochrome P450; Cocaine; Coumarin 7-hydroxylase; Hepatotoxin (Pellinen, P. (292) 57)

Diethyldithiocarbamate; Kupffer cells; Liver slice preparation (Ishiyama, H. (292) 135)

Zinc sulfate; *N*-acetylcysteine; Acetaminophen; Glutathione; Alanine aminotransferase; Malondialdehyde (Woo, P.C.Y. (293) 217)

Paracetamol; Mitochondrial ATPase; Mitochondrial particle, sonic; Arrhenius kinetics (Parmar, D.V. (293) 225)

Chemoprotection; Lobenzarit; Paracetamol; Molecular mechanism (Remirez, D. (293) 301)

Endothelin; Endothelin receptor antagonist; Bosentan; Carbon tetrachloride; Acute liver dysfunction (Hocher, B. (293) 361)

Hepatotoxin
Cytochrome P450; Cocaine; Hepatotoxicity; Coumarin 7-hydroxylase (Pellinen, P. (292) 57)

1-Heptyl-3-(1-naphthoyl)indole
Cannabinoid; Cannabinoid receptor antagonist; SR141716A; Vas deferens, mouse; 1-Pentyl-2-methyl-3-(1-naphthoyl)indole; 1-Pentyl-3-(1-naphthoyl)pyrrole (Pertwee, R.G. (284) 241)

Herbicide
Dopamine transporter, vesicular; Insecticide; Fungicide; Rotenone; Neurotoxin; Parkinsonism (Vaccari, A. (292) 309)

Heterologous expression
Cytochrome P450 3A4; V79 Chinese hamster cell; Testosterone; Ergot derivative (Rauschenbach, R. (293) 183)

Heterotrimeric G protein
Mast cell; Neuropeptide Y; Circular dichroism spectrum; Benzalkonium chloride; Pertussis toxin; (Rat); (Human) (Mousli, M. (289) 125)

Hexachlorobenzene
Hexafluorobenzene; Porphyria; Biotransformation; Mercapturic acid; Phenolic metabolite (Rietjens, I.M.C.M. (293) 293)

Hexafluorobenzene
Hexachlorobenzene; Porphyria; Biotransformation; Mercapturic acid; Phenolic metabolite (Rietjens, I.M.C.M. (293) 293)

HHSiD (*p*-fluorohexahydro-siladifenidol hydrochloride)
Acetylcholine; Atrium AF-DX 116, human; McN-A-343; Muscarinic receptor; Myocardial contractility; Pirenzepine; Ventricle (Du, X.Y. (284) 119)

5-HIAA (5-hydroxyindole acetic acid)
Afferent nerve; Blood flow; 5-HT (5-hydroxytryptamine, serotonin); Dopamine; Gingiva; Dental pulp; Sympathetic nerve; (Rat) (Kerezoudis, N.P. (275) 191)

Hind-paw edema
Acetylshikonin; Cutaneous anaphylaxis, passive; Neurogenic inflammation; Vascular permeability; Compound 48/80; [Thi^{5,8},D-Phe^{7}]Bradykinin; [D-Pro^{2},D-Trp^{7,9}]Substance P (Wang, J.-P. (272) 87)

Hippocampal CA3, rat
ucb L059; Bicuculline; Input-output curve; Paired-pulse inhibition (Margineanu, D.G. (286) 321)

Hippocampal neuron
Local anesthetic; Chloride ion; Patch-clamp technique; GABA (γ-aminobutyric acid); Glycine (Hara, M. (283) 83)

Hippocampal neuron, rat
AMPA/kainate receptor; Desensitizing current, fast; GAMS (γ-D-glutamylaminomethylsulfonic acid); 6-Cyano-7-nitroquinoxaline-2,3-dione (Wilsch, V.W. (284) 141)

Hippocampal slice
Morphine; Ischemia; κ-Opioid receptor; 2-Deoxyglucose; Tolerance (Shibata, S. (279) 197)

Hippocampus
Chronic CGP 39551; NMDA receptor; [^{3}H]Noradrenaline release; Quinolinic acid neurotoxicity; Autoradiography (Mennini, T. (271) 93)

Antidepressant drug; Desipramine; Fluoxetine; Maprotiline; Moclobemide; Trimipramine; 2-Methyl-5-hydroxytryptamine; 5-HT (5-hydroxytryptamine, serotonin); Reuptake inhibition; Presynaptic modulation (Mongeau, R. (271) 121)

Amnesia; Inhibitory avoidance; Heme oxygenase; Zinc protoporphyrin-9 (Fin, C. (271) 227)

Somatostatin; Muscarinic M_1 receptor; Pirenzepine; NMDA receptor; CPP ((±)-3(2-carboxypiperazin-4-yl)-propyl-1-phosphonoic acid); Working memory (Ohno, M. (271) 557)

Cerebral ischemia; Rolipram; cAMP; Phosphodiesterase; (Gerbil) (Kato, H. (272) 107)

Ischemia; Glutathione; 2-Deoxyglucose uptake; Presynaptic potential; Neuroprotection (Shibata, S. (273) 191)

Ischemia; Nitric oxide (NO); Presynaptic potential; Neuroprotection (Shibata, S. (273) 223)

Long-term potentiation; Dentate gyrus; Neural plasticity; Metabotropic glutamate receptor; NMDA (*N*-methyl-D-aspartate) (Bordi, F. (273) 291)

Long-term depression; Phospholipase A_2 (Stanton, P.K. (273) R7)

GABA (γ-aminobutyric acid); $GABA_B$ receptor; 2-Hydroxy-saclofen; Presynaptic inhibition; (Inhibition) (Caddick, S.J. (274) 41)

NMDA (*N*-methyl-D-aspartate); Aniracetam (Pizzi, M. (275) 311)

GABA receptor; Epilepsy; Synaptic inhibition; Disinhibition (Stanford, I.M. (277) 229)

Polyamine; Spermine; NMDA (*N*-methyl-D-aspartate); Mg^{2+}; Development (Bowe, M.A. (278) 55)

Spontaneously epileptic rat (SER); CA3 neuron; Ca^{2+} spike; Nicardipine (Momiyama, T. (280) 119)

trans-ACPD ((±)-*trans*-1-aminocyclopentane-1,3-dicarboxylic acid); Metabotropic glutamate receptor; Inhibitory postsynaptic potential; CA1 pyramidal cell (Jouvenceau, A. (281) 131)

Vitamin B_{12}; Ischemia; Neuroprotection; Glutamate; Hypoxia/hypoglycemia (Yamamoto, Y. (281) 335)

Spatial learning; Acetylcholine; Scopolamine; 5-HT_{1A} receptor; (*S*)-WAY 100135; Alzheimer disease; (Rat) (Carli, M. (283) 133)

Cerebral ischemia; JO 1784 (igmesine hydrochloride); Neuroprotection; Nitric oxide (NO) synthase; (Gerbil) (O'Neill, M. (283) 217)

Presynaptic action; Glutamate; Grease-gap; Autoreceptor; (D.C. potential) (Shew, T.R. (284) 93)

Cerebral ischemia; Lipid peroxidation; N^{G}-Nitro-L-arginine methyl ester; (Gerbil) (Caldwell, M. (285) 203)

5-HT_{1A} receptor; 5-HT_{1B} receptor; Scopolamine; Spatial memory; (Microinjection) (Buhot, M.-C. (285) 221)

Aspartate; Atipamezole; Dexmedetomidine; Glutamate; GABA (γ-aminobutyric acid); Microdialysis (Valtonen, P. (285) 239)

5-HT_{1A} receptor; GTP hydrolysis; G protein (GTP-binding protein); Adenylyl cyclase (Odagaki, Y. (288) 385)

Hippocampus, rat
$GABA_B$ receptor; (*RS*)-(±)-Baclofen; (*S*)-2-Hydroxysaclofen; (*R*)-2-Hydroxysaclofen; Ileum, guinea pig; Neocortex, rat (Kerr, D.I.B. (287) 185)

Histamine
Coronary artery, rat; Artery, small; Histamine receptor; Nitric oxide (NO) (Van de Voorde, J. (271) 17)

Prostaglandin E_2; Prostacyclin; Airway; (Human) (Knight, D.A. (272) 1)

Prostanoid; Airway; (Human) (Knight, D.A. (272) 13)

Helicobacter pylori; Histamine chloramine; Gastric acid secretion (Asagoe, K. (275) 179)

Scratching; Itch; Pain; Compound 48/80; Substance P (Kuraishi, Y. (275) 229)

Contraction; Bronchus, human; Protein kinase C; GF 109203X; Phorbol ester (Yang, K.X.F. (275) 283)

Colon; Epithelium; Ion transport; Secretion; (Human) (Keely, S.J. (279) 203)

Paw edema; Neurogenic inflammation; CGRP (calcitonin gene-related peptide) (Amann, R. (279) 227)

Nitric oxide (NO); Allergic conjunctivitis; Vascular permeability; N^G-Nitro-L-arginine methyl ester; Aminoguanidine; PAF (platelet-activating factor) (Meijer, F. (284) 61)

5-HT (5-hydroxytryptamine, serotonin); Dexfenfluramine; Methysergide; Microdialysis; Hypothalamus (Laitinen, K.S.M. (285) 159)

Noradrenaline; Atipamezole; α_2-Adrenoceptor antagonist; Microdialysis, in vivo; Hypothalamus (Laitinen, K.S.M. (285) 255)

Spinal cord, rat; [^{3}H]Noradrenaline; Electrical stimulation; Histamine H_3 receptor (Celuch, S.M. (287) 127)

Histamine H_2 receptor; U937 cell; cAMP; Homologous desensitization (Smit, M.J. (288) 17)

Mast cell; Endothelin; Staurosporine; IAP (islet-activating protein); Protein kinase (Yamamura, H. (288) 269)

Acid secretion; Glucagon-related peptides; [^{14}C]aminopyrine accumulation (Gros, L. (288) 319)

Endothelial cells, human; Ca^{2+}, cytosolic; Isradipine; Fura-2 (Iouzalen, L. (289) 189)

Somatostatin receptor; Adenylyl cyclase; Frontoparietal cortex; (Rat) (Puebla, L. (289) 361)

Phospholipase C; Protein kinase C; Phorbol ester; Staurosporine; Ro 31-8220; Adrenal chromaffin cell (Bunn, S.J. (290) 227)

Enterochromaffin-like cell; Stomach, rat; Ca^{2+} ionophore; Patch-clamp; K^+ channel (Sakai, H. (291) 153)

Histamine chloramine
Histamine; *Helicobacter pylori*; Gastric acid secretion (Asagoe, K. (275) 179)

Histamine liberation
Mast cell; Amphipathic α-helix; Magainin; Neuropeptide Y; Substance P; Liposome (Cross, L.J.M. (291) 291)

Histamine receptor
Coronary artery, rat; Histamine; Artery, small; Nitric oxide (NO) (Van de Voorde, J. (271) 17)

Histamine H_1 receptor
Dimethindene, enantiomer; Muscarinic M_2 receptor antagonist; Muscarinic receptor subtype; Enantioselectivity; Stereoselectivity, inverse; PET (positron emission tomography); Alzheimer's disease (Pfaff, O. (286) 229)

Phosphoinositide hydrolysis; Seizure; Soman; Metabotropic glutamate receptor (Bodjarian, N. (289) 291)

Inositol 1,3,4,5-tetrakisphosphate; Intracellular Ca^{2+} store; DDT_1 MF-2 smooth muscle cell (Van der Zee, L. (289) 463)

Histamine H_1 receptor antagonist, blocking effect
Neuropeptide; Achatin-I; (Snail) (Santos, D.E. (272) 231)

Histamine H_2 receptor
Antinociception; Restraint; Hot plate test (Wong, C.-L. (279) 109)

Histamine; U937 cell; cAMP; Homologous desensitization (Smit, M.J. (288) 17)

Histamine H_3 receptor
Substance P; Neurogenic inflammation (Ohkubo, T. (273) 83)

K^+ channel, ATP-sensitive; Prejunctional inhibition; Substance P (Ohkubo, T. (277) 45)

Lung, rabbit; C-fiber; Acetylcholine; Neuropeptide; Edema (Delaunois, A. (277) 243)

Spinal cord, rat; [^{3}H]Noradrenaline; Electrical stimulation; Histamine (Celuch, S.M. (287) 127)

Histamine H_3 receptor agonist
Neurogenic inflammation; Trigeminal ganglion; Sensory nerve; μ-Opioid receptor agonist; 5-HT_{1D} receptor agonist (Escott, K.J. (284) 69)

L-Histidine
Hydrogen peroxide; Cytotoxicity; DNA single/double-strand break; Poly(ADP-ribose)polymerase (Palomba, L. (291) 167)

Histogranin
NMDA receptor; Passive avoidance; Learning; Memory; (Mouse) (Maurice, T. (283) 251)

NMDA receptor; Passive avoidance; Learning; Memory; (Mouse) (Maurice, T. (287) 219)

HIV-1
Flupirtine; Triaminopyridine; NMDA (*N*-methyl-D-aspartate); NMDA receptor; Neuron; Cell death; gp120 (Perovic, S. (288) 27)

H_2O_2
6-Hydroxydopamine; Bupropion; R56865; Cytotoxicity; Cytoprotection; Chromaffin cell (Abad, F. (293) 55)

HOE 140
Pulmonary artery; Bronchus; Umbilical artery; Umbilical vein; (Human) (Félétou, M. (274) 57)

Bradykinin; Bradykinin analog; Bradykinin receptor antagonist; Mononuclear cell; Cytokine; Interleukine (Paegelow, I. (279) 211)

Bradykinin; Trachea, guinea-pig; Epithelium; Bradykinin B_2 receptor; Relaxation; Ca^{2+}; Ryanodine; Apamin; NPC 17761 (Schlemper, V. (282) 177)

Bradykinin; WIN 64338 (Wirth, K.J. (288) R1)

Homologous desensitization
Histamine; Histamine H_2 receptor; U937 cell; cAMP (Smit, M.J. (288) 17)

Hot-plate
Enkephalin catabolism inhibitor; Enkephalin, endogenous; CCK (cholecystokinin); RB 101; PD-134,308; Tail-flick; Antinociception; CCK_B receptor antagonist; Tolerance (Valverde, O. (286) 79)

Hot-plate test
Antinociception; Histamine H_2 receptor; Restraint (Wong, C.-L. (279) 109)

House dust mite
Interleukin-5; Eosinophil cationic protein (ECP); Fluticasone propionate, aquous nasal spray; Rhinitis (Garrelds, I.M. (275) 295)

HPLC (high-performance liquid chromatography)
PAF (platelet-activating factor); Septum, interventricular; Myocardial ischemia; (Rabbit) (Salinas, P. (293) 65)

HPMPC (1-(*S*)-(3-hydroxy-2-phosphonomethoxyethyl)cytosine)
Acyclic nucleotide analog; PMEA (9-(2-phosphomethoxyethyl)adenine); Antiarthritic effect; Adjuvant arthritis (Zídek, Z. (286) 307)

B-HT 933
Arrhythmia; Digitalis; Ouabain; Azepexole (Thomas, G.P. (276) 215)

5-HT (5-hydroxytryptamine, serotonin)
Substance P; Neurokinin A; Tachykinin receptor; Trachea, rat; Carbachol (Joos, G.F. (271) 47)

Antidepressant drug; Desipramine; Fluoxetine; Maprotiline; Moclobemide; Trimipramine; 2-Methyl-5-hydroxytryptamine; Reuptake inhibition; Hippocampus; Presynaptic modulation (Mongeau, R. (271) 121)

N-3389; 2-Methyl-5-HT; 5-HT_3 receptor; 5-HT_4 receptor (Hagihara, K. (271) 159)

Cholecystokinin; CCK receptor antagonist; Zero-maze; Anxiety; (Rat) (Bickerdike, M.J. (271) 403)

Nicotine; Sertraline; Self-administration; (Monkey) (Sannerud, C.A. (271) 461)

Dorsal raphe; (Guinea-pig) (Craven, R. (271) R1)

DAMGO ([D-Ala^2,NMePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Naltrindole; IC1174864; Spinal cord (Monroe, P.J. (272) 51)

5-HT_{1A} receptor; Corticosterone; Glucose; Behavioral syndrome; (S)-UH301; Flesinoxan (Groenink, L. (272) 177)

GABA (γ-aminobutyric acid); Release; Epidural cup; Modafinil; Cerebral cortex (Tanganelli, S. (273) 63)

ACTH (adrenocorticotropin); Corticosterone; Prolactin; Renin; Blood pressure; Heart rate (Levy, A.D. (274) 141)

Afferent nerve; Blood flow; 5-HIAA (5-hydroxyindole acetic acid); Dopamine; Gingiva; Dental pulp; Sympathetic nerve; (Rat) (Kerezoudis, N.P. (275) 191)

Apomorphine; Grooming, excessive; Penile erection; Oxytocin; Prolactin; Corticosterone; 5-HT_{2C} receptor; m-CPP (1-3-chlorophenylpiperazine); Hypothalamic paraventricular nucleus (Bagdy, G. (275) 301)

MDL 73,745; Microdialysis; Cholinesterase; Acetylcholine; Norepinephrine; Dopamine (Zhu, X.-d. (276) 93)

Sexual behavior; 5-HT_2 receptor agonist; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Testosterone; Castration; Puberty (Padoin, M.J. (277) 1)

Vagal depolarization; Vagus nerve; Cisplatin; Dexamethasone; (Rat); (Grease gap) (Woods, A.J. (278) 275)

Pulmonary vein, sheep; Vasodilatation; Endothelium; Cyclic nucleotide (Zhang, L. (280) 335)

MDMA (3,4-methylenedioxymethamphetamine); 5-HT_{1A} receptor (Aguirre, N. (281) 101)

Alcoholization; Receptor; mRNA; Binding; Autoradiography; (Rat) (Nevo, I. (281) 229)

Fluoxetine; Clomipramine; Imipramine; Dopamine; Extrapyramidal symptom; Antidepressant; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (281) 255)

Cocaine; Fenfluramine; Corticosterone, presynaptic (Baumann, M.H. (282) 87)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5891; (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-*N*-methyl-3-pyridinecarboxamide; FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester; FG5909 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-hydroxypyridine; Reuptake; Release; Dopamine; Noradrenaline (Pettersson, E. (282) 131)

Actinomycin-D; Dexamethasone; Mast cell; Nedocromil sodium; Paw edema, rat (Raud, J. (282) 207)

Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; Anorexia; Gastric emptying; Food intake (Hui, S.-C.G. (283) 141)

Nitric oxide (NO); Endothelium; Microvasculature; Neurogenic inflammation; Substance P; ATP (Ralevic, V. (284) 231)

Phosphoinositide hydrolysis; Immobilization stress; Imipramine (Okuyama, N. (285) 61)

Histamine; Dexfenfluramine; Methysergide; Microdialysis; Hypothalamus (Laitinen, K.S.M. (285) 159)

Neuro-neuronal transmission; 5-HT_3 receptor antagonism; Descending inhibition (Messori, E. (286) 205)

Micturition; Spinal cord; 5-HT_3 receptor (Espey, M.J. (287) 173)

Prepulse inhibition, rat; Glutamate; Antipsychotic; Schizophrenia (Varty, G.B. (287) 201)

α_1-Adrenoceptor; 5-HT_2 receptor; Aorta, rat; SDZ NVI-085; SK&F 89748-A (Van der Graaf, P.H. (287) 309)

Skeletal muscle actin; Dopamine; Covalent bond; 5-HT (5-hydroxytryptamine, serotonin) binding protein; Iron (Velez Pardo, C. (288) 209)

Inositol 1,4,5-trisphosphate; Noradrenaline; Smooth muscle, vascular (Murphy, T.V. (290) 141)

Red wine; Platelet; Migraine; Headache (Pattichis, K. (292) 173)

p-Chloroamphetamine; Dextromethorphan; Neurotoxicity; σ Receptor; Brain (Narita, N. (293) 277)

5-HT (5-hydroxytryptamine, serotonin) binding protein
Skeletal muscle actin; 5-HT (5-hydroxytryptamine, serotonin); Dopamine; Covalent bond; Iron (Velez Pardo, C. (288) 209)

5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, specific
Opioid dependence; Paroxetine; Fluvoxamine; Place conditioning; Morphine (Rafieian-Kopaei, M. (275) 185)

5-HT (5-hydroxytryptamine, serotonin) syndrome
8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Ethanol tolerance; Ethanol withdrawal; Corticosterone (Kleven, M. (281) 219)

5-HT (5-hydroxytryptamine, serotonin) uptake
Fluoxetine; Frontal cortex; Ventral hippocampus; Raphe nuclei; Microdialysis, in vivo (Malagié, I. (286) 213)

Blood platelet; Ca^{2+} chelation; EGTA (ethyleneglycoltetraacetic acid); BAPTA-AM (acetoxymethyl bis(*O*-aminophenoxy)ethane-*N,N,N',N'*-tetraacetate); Ca^{2+} storage pool (Nishio, H. (288) 149)

5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor
Reinforcement schedule; Drinking behavior; Obsessive-compulsive disorder (Roehr, J. (278) 75)

Calmodulin; Ca^{2+}; Platelet; Thrombin (Helmeste, D.M. (288) 373)

Calmodulin; Ca^{2+}; Platelet; Thrombin (Helmeste, D.M. (290) 173)

5-HT_2 receptor; c-*fos*; Antidepressant (Tilakaratne, N. (290) 263)

5-HT receptor
Hyperphagia; Neuropeptide Y; *d*-Fenfluramine; (±)-Cyanopindolol; Paraventricular nucleus of the hypothalamus (Grignaschi, G. (274) 221)

Calcitonin; NMDA (*N*-methyl-D-aspartate); Aversive behavior; β-Adrenoceptor; GABA receptor (Maeda, Y. (275) 163)

CP-122,288; Sumatriptan; Vasoconstriction (Beattie, D.T. (276) 271)

Enteric nerve; Noncholinergic slow synaptic potential; Gastrointestinal pharmacology (Pan, H. (278) 67)

Colon, guinea pig; Gastrointestinal motility; Enteric nerve; Relaxation (Briejer, M.R. (279) 123)

5-HT receptor antagonist
Pelanserin; Contraction; Methoxamine; Spontaneously hypertensive rat (SHR) (Villalobos-Molina, R. (277) 181)

5-HT_{1A} receptor; 5-HT_{1D} receptor; Cell proliferation, human (Cattaneo, M.G. (291) 209)

5-HT_1 receptor
5-HT_2 receptor; Neocortical high-voltage spindle, rat; Thalamocortical oscillation (Jäkälä, P. (282) 39)

5-HT_{1A} receptor
In vivo labeling; [^{3}H]WAY 100635; Brain, mouse (Laporte, A.-M. (271) 505)

WAY-100635; Brain, rat; Radioligand, in vivo; PET (positron emission tomography) (Hume, S.P. (271) 515)

Forced swimming; Depression; S 14506; S 14671; (+)-WAY 100,135 (Schreiber, R. (271) 537)

Social defeat; Corticosterone; Subsensitivity (Korte, S.M. (272) 45)

Corticosterone; Glucose; 5-HT (5-hydroxytryptamine, serotonin); Behavioral syndrome; (S)-UH301; Flesinoxan (Groenink, L. (272) 177)

Chronic variate stress; Foot-shock stress, acute; β-Adrenoceptor; 5-HT_2 receptor; Amitriptyline; Open-field; Brain cortex, rat (Ferretti, C. (280) 19)

Corticosterone; Glucose; Prolactin; Flesinoxan; Defensive burying; Anxiety (Groenink, L. (280) 185)

MKC-242 (5-{3-[((2*S*)-1,4-benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole); Forced swimming test; Antidepressant activity; (Mouse) (Matsuda, T. (280) 235)

WAY-100635; 5-HT_{1A} receptor antagonist (Forster, E.A. (281) 81)

MDMA (3,4-methylenedioxymethamphetamine); 5-HT (5-hydroxytryptamine, serotonin) (Aguirre, N. (281) 101)

5-HT_{1D} receptor; 5-HT_7 receptor (Waeber, C. (283) 31)

Spatial learning; Hippocampus; Acetylcholine; Scopolamine; (*S*)-WAY 100135; Alzheimer disease; (Rat) (Carli, M. (283) 133)

8-OH-DPAT ((±)-8-hydroxy-2-(*n*-dipropylamino)tetralin); Adrenal gland; Gastrointestinal system, rat; Acid (Gidener, S. (284) 19)

Flesinoxan; Drug discrimination; (*S*)-UH301, enantiomer; WAY-100635; Fentanyl (Gommans, J. (284) 135)

Ipsapirone; (*S*)-WAY 100135; Punishment; Conflict; Anxiolytic activity (Cervo, L. (284) 249)

5-HT_{1B} receptor; Hippocampus; Scopolamine; Spatial memory; (Microinjection) (Buhot, M.-C. (285) 221)

R(+)-8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY 100,635 (*n*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*n*-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride); *d*-Amphetamine; Dopamine; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (287) 179)

G-protein; 5-HT_{1A} receptor antagonist; Autoradiography, quantitative; [^{3}H]8-OH-DPAT ([^{3}H]8-hydroxy-2-(di-*n*-propylamino)tetralin); [^{3}H]-WAY 100635 (Gozlan, H. (288) 173)

GTP hydrolysis; G protein (GTP-binding protein); Adenylyl cyclase; Hippocampus (Odagaki, Y. (288) 385)

5-HT_{1D} receptor; Cell proliferation, human; 5-HT receptor antagonist (Cattaneo, M.G. (291) 209)

5-HT_{1A} receptor agonist
Dopamine receptor antagonist; Climbing; Stereotyped behavior; Grooming; Catalepsy (Protais, P. (271) 167)

5-HT_{1A} receptor antagonist
WAY-100135; NAN-190; Microdialysis (Routledge, C. (276) 281)

5-HT_{1A} receptor; WAY-100635 (Forster, E.A. (281) 81)

5-HT_{1A} receptor; G-protein; Autoradiography, quantitative; [^{3}H]8-OH-DPAT ([^{3}H]8-hydroxy-2-(di-*n*-propylamino)tetralin); [^{3}H]WAY 100635 (Gozlan, H. (288) 173)

5-HT_{1A} receptor, human
PET (positron emission tomography); [^{11}C]WAY-100635 (Pike, V.W. (283) R1)

5-HT_{1A}, 5-$HT_{1D\alpha}$ and 5-$HT_{1D\beta}$ receptors, cloned, human
GR 127,935; 5-HT_{1B} receptor, opossum kidney; cAMP formation; 5-HT_{1D} receptor antagonist (Pauwels, P.J. (290) 95)

5-HT_{1B} receptor
5-HT_{1A} receptor; Hippocampus; Scopolamine; Spatial memory; (Microinjection) (Buhot, M.-C. (285) 221)

5-HT_{1B} receptor, opossum kidney
GR 127,935; 5-HT_{1A}, 5-$HT_{1D\alpha}$ and 5-$HT_{1D\beta}$ receptors , cloned, human; cAMP formation; 5-HT_{1D} receptor antagonist (Pauwels, P.J. (290) 95)

5-HT_{1D} receptor
5-HT_{1A} receptor; 5-HT_7 receptor (Waeber, C. (283) 31)

Ketanserin; GR127935; Saphenous vein, rabbit; Jugular vein, guinea-pig (Razzaque, Z. (283) 199)

5-HT_{1A} receptor; Cell proliferation, human; 5-HT receptor antagonist (Cattaneo, M.G. (291) 209)

5-HT_{1D} receptor agonist
Neurogenic inflammation; Trigeminal ganglion; Sensory nerve; μ-Opioid receptor agonist; Histamine H_3 receptor agonist (Escott, K.J. (284) 69)

α_1-Adrenoceptor agonist; Hypothermia (Kalkman, H.O. (285) 313)

5-HT_{1D} receptor antagonist
GR 127,935; 5-HT_{1A}, 5-$HT_{1D\alpha}$ and 5-$HT_{1D\beta}$ receptors , cloned, human; 5-HT_{1B} receptor, opossum kidney; cAMP formation (Pauwels, P.J. (290) 95)

5-HT_{1D} receptor subtype, recombinant, human
Ketanserin; Ritanserin; 5-HT_{2A} receptor antagonist; Subtype selectivity; 5-$HT_{1D\alpha}$ receptor antagonist; cAMP (Zgombick, J.M. (291) 9)

5-$HT_{1D\alpha}$ receptor
GR127935; GR55562; Metergoline; Methiothepin; 5-HT_1D_β receptor (Walsh, D.M. (287) 79)

5-$HT_{1D\alpha}$ receptor antagonist
5-HT_{1D} receptor subtype, recombinant, human; Ketanserin; Ritanserin; 5-HT_{2A} receptor antagonist; Subtype selectivity; cAMP (Zgombick, J.M. (291) 9)

5-$HT_{1D\beta}$ receptor
GR127935; GR55562; Metergoline; Methiothepin; 5-$HT_{1D\alpha}$ receptor (Walsh, D.M. (287) 79)

5-HT_2 receptor
α-Adrenoceptor; Prostate, rat; Smooth muscle; Autoradiography (Killam, A.L. (273) 7)

Prefrontal cortex; Microdialysis; Clozapine; Antipsychotic (Schmidt, C.J. (273) 273)

Chronic variate stress; Foot-shock stress, acute; β-Adrenoceptor; 5-HT_{1A} receptor; Amitriptyline; Open-field; Brain cortex, rat (Ferretti, C. (280) 19)

Learned helplessness; Antidepressant; Corticosterone (Nankai, M. (281) 123)

5-HT_1 receptor; Neocortical high-voltage spindle, rat; Thalamocortical oscillation (Jäkälä, P. (282) 39)

Dopamine receptor; α_1-Adrenoceptor; Hyperactivity; Amphetamine; (Rat) (Arnt, J. (283) 55)

α_1-Adrenoceptor; 5-HT (5-hydroxytryptamine, serotonin); Aorta, rat; SDZ NVI-085; SK&F 89748-A (Van der Graaf, P.H. (287) 309)

5-HT uptake inhibitor; c-*fos*; Antidepressant (Tilakaratne, N. (290) 263)

5-HT_2 receptor agonist
Sexual behavior; 5-HT (5-hydroxytryptamine, serotonin); DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Testosterone; Castration; Puberty (Padoin, M.J. (277) 1)

5-HT_{2A} receptor
Phencyclidine; Clozapine (Maurel-Remy, S. (280) R9)

5-HT_{2A} receptor antagonist
5-HT_{1D} receptor subtype, recombinant, human; Ketanserin; Ritanserin; Subtype selectivity; 5-$HT_{1D\alpha}$ receptor antagonist; cAMP (Zgombick, J.M. (291) 9)

5-HT_{2C} receptor
Apomorphine; 5-HT (5-hydroxytryptamine, serotonin); Grooming, excessive; Penile erection; Oxytocin; Prolactin; Corticosterone; m-CPP (1-3-chlorophenylpiperazine); Hypothalamic paraventricular nucleus (Bagdy, G. (275) 301)

5-HT_3 antagonist
Cisplatin; Peripheral neuropathy; CGRP (calcitonin gene-related peptide) (Whitaker-Azmitia, P.M. (275) 139)

5-HT_3 receptor
N-3389; 5-HT (5-hydroxytryptamine, serotonin); 2-Methyl-5-HT; 5-HT_4 receptor (Hagihara, K. (271) 159)

Sleep; Waking; *m*-Chlorophenylbiguanide; MDL 72222; Dopamine; (+)-SCH 23390; YM-09151-2 (Ponzoni, A. (278) 111)

[^{3}H]YM060 ([methyl-^{3}H]-(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride); Cerebral cortex, rat (Akuzawa, S. (281) 37)

Enteric nervous system; Myenteric neuron; Distal colon; YM060 [(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-enzimidazole monohydrochloride]; (Guinea pig) (Ito, H. (283) 107)

GK-128; Emesis; (*Suncus murinus*) (Ito, C. (285) 37)

Micturition; Spinal cord; 5-HT (5-hydroxytryptamine, serotonin) (Espey, M.J. (287) 173)

Dopamine; Granisetron; Morphine; Reward (Rompré, P.-P. (287) 263)

1-(*m*-Chlorophenyl)-biguanide; [^{3}H]GBR-12935; Dopamine transporter; Nucleus accumbens; Caudate putamen; (Rat) (Campbell, A.D. (290) 157)

Ethanol; Bezold-Jarisch reflex; Capsaicin (Malinowska, B. (293) 71)

5-HT$_3$ receptor antagonism
Neuro-neuronal transmission; 5-HT (5-hydroxytryptamine, serotonin); Descending inhibition (Messori, E. (286) 205)

5-HT$_4$ receptor
N-3389; 5-HT (5-hydroxytryptamine, serotonin); 2-Methyl-5-HT; 5-HT$_3$ receptor (Hagihara, K. (271) 159)

5-HT$_7$ receptor
Ileum, guinea-pig; Smooth muscle relaxation (Carter, D. (280) 243)

5-HT$_{1D}$ receptor; 5-HT$_{1A}$ receptor (Waeber, C. (283) 31)

Human glutamate transporter (hGluT-1)
CCG (2-(Carboxycyclopropyl)glycine); COS-7 cell; Transfection (Yamashita, H. (289) 387)

Human immunodeficiency virus type 1 (HIV-1)
DNA-binding drug; Automation; DNase I footprinting (Feriotto, G. (290) 85)

Humanized antibody
GPIIb/IIIa; Thrombosis, photochemically induced; Microcirculation; Bleeding time; (Squirrel monkey) (Kaku, S. (279) 115)

Hydrogen peroxide
L-Histidine; Cytotoxicity; DNA single/double-strand break; Poly(ADP-ribose)polymerase (Palomba, L. (291) 167)

Hydroxocobalamin
Gastric fundus, rat; Hemoglobin; Nitric oxide (NO); N^G-Nitro-L-arginine; NANC (non-adrenergic, non-cholinergic) nerve; Nitrosothiol (Jenkinson, K.M. (275) 145)

N^G-Hydroxy-L-arginine
Bacterial lipopolysaccharide; Nitric oxide synthase, inducible (Hecker, M. (275) R1)

γ-Hydroxybutyric acid (GHBA)
Ethanol; Motor-impairing effect; Cross-tolerance; (Rat) (Colombo, G. (273) 235)

6-Hydroxydopamine
Blood pressure control; Sinoaortic denervation; Neostigmine; Prazosin; Yohimbine (Taira, C.A. (271) 9)

Haloperidol; Oral dyskinesia; Tardive dyskinesia (Huang, N.-Y. (271) 433)

Dopamine; Microinjection; MK-801; Circling; Potentiation; Striatum, rat (St-Pierre, J.-A. (272) 123)

Mitochondrial complex I; Mitochondrial complex IV; Neurotoxicity; Monoamine oxidase A; Monoamine oxidase B; Parkinson's disease (Glinka, Y.Y. (292) 329)

H_2O_2; Bupropion; R56865; Cytotoxicity; Cytoprotection; Chromaffin cell (Abad, F. (293) 55)

6-Hydroxydopamine lesion
Dopamine, mesocortical; Locomotor activity; Nucleus accumbens; Voltammetry (Banks, K.E. (282) 157)

Hydroxyl radical scavenging
Anti-oxidant; Decongestive nose drops; Lipid peroxidation; Nasal inflammation; Reactive oxygen species (Westerveld, G.-J. (291) 27)

3α-Hydroxy-5α-pregnan-20-one
Epalon; Neuroactive steroid; $GABA_A$ receptor; [^{3}H]Muscimol (Goodnough, D.B. (288) 157)

2-Hydroxysaclofen
GABA (γ-aminobutyric acid); $GABA_B$ receptor; Hippocampus; Presynaptic inhibition; (Inhibition) (Caddick, S.J. (274) 41)

(*R*)-2-Hydroxysaclofen
$GABA_B$ receptor; (*RS*)-(±)-Baclofen; (*S*)-2-Hydroxysaclofen; Ileum, guinea pig; Hippocampus, rat; Neocortex, rat (Kerr, D.I.B. (287) 185)

(*S*)-2-Hydroxysaclofen
$GABA_B$ receptor; (*RS*)-(±)-Baclofen; (*R*)-2-Hydroxysaclofen; Ileum, guinea pig; Hippocampus, rat; Neocortex, rat (Kerr, D.I.B. (287) 185)

Hyperactivity
Dopamine receptor; 5-HT$_2$ receptor; α_1-Adrenoceptor; Amphetamine; (Rat) (Arnt, J. (283) 55)

Hyperalgesia
Prostaglandin E_2; Phosphodiesterase; Rolipram; Sympathetically maintained pain (Ouseph, A.K. (273) 107)

BW373U86; δ-Opioid receptor agonist; Allodynia; Rhesus monkey (Butelman, E.R. (277) 285)

Neuropathy; Medetomidine; Atipamezole; Mustard oil (Mansikka, H. (281) 43)

Hyperapnea
Toxic metabolite; Vasodepression; Cardiac insufficiency; (*Ptychodiscus brevis*) (Koley, J. (293) 483)

Hyperemia
Blood vessel; Vascular control; K^+ channel (Kosmas, E.N. (274) 193)

Hyperphagia
Neuropeptide Y; *d*-Fenfluramine; (±)-Cyanopindolol; Paraventricular nucleus of the hypothalamus; 5-HT receptor (Grignaschi, G. (274) 221)

Hyperphagia, experimentally induced
Anorectic drug; 2-Deoxy-D-glucose; Insulin; Sodium mercaptoacetate; Neural circuit (Garosi, V.L. (276) 285)

Hyperreactivity
Intimal hyperplasia; Myosin light chain phosphorylation; Protein kinase inhibitor; HA1077; $[Ca^{2+}]_i$ (Seto, M. (276) 27)

Hyperresponsiveness
Immunoglobulin E; Bronchoconstrictive response; Ovalbumin; Allergic asthma; (Mouse) (Hessel, E.M. (293) 401)

Hypertension
Endothelin-1; Endothelin ET_A receptor; Nitric oxide (NO); FR139317; Nitro-L-arginine; (Rat) (Fujita, K. (280) 311)

Iloprost; Nitric oxide (NO); Acute inflammation; Captopril; (2K-1C rat) (Medeiros, M.V. (285) 109)

Nitric oxide (NO); Enalapril; Renin-angiotensin system; Myocardial ischemia (Moreno, Jr., H. (287) 93)

Hyperthermia
MDMA (3,4-methylenedioxymethamphetamine); Tryptophan hydroxylase; Hypothermia (Che, S. (293) 447)

Hypertrophy
Smooth muscle; ATP; Urinary bladder; Caged-ATP (Sjuve, R. (276) 137)

Tetrandrine; Dihydropyridine; Ca^{2+}; DOCA (deoxycorticosterone acetate); (Receptor) (Xu, Y. (278) 1)

LR-B/081; Angiotensin II; Smooth muscle cell; Inositol trisphosphate; Prostaglandin (Catalioto, R.-M. (280) 285)

L-Carnitine; Fatty acid; Cardiac efficiency (Schönekess, B.O. (286) 155)

Hypocholesterolemic drug
Liver; Intestine; Cholesterol synthesis; Dual isotope blood ratio method; Occupancy principle; (RICO rat) (Hajri, T. (286) 131)

Hypoglycemic agent
Binding site; Glibenclamide (Glyburide); Liver; Sulfonylurea compound (Inoue, Y. (284) 77)

Hypophysis
TRH (Thyrotropin-releasing hormone); TSH (Thyroid stimulating hormone); Triiodo-L-thyronine; Ca^{2+}; (Rat) (Roussel, J.-P. (289) 205)

Hypotension
Lipopolysaccharide; Nitric oxide (NO); Nitric oxide (NO) synthase; L-Canavanine; N^G-Nitro-L-arginine methyl ester (Teale, D.M. (271) 87)

Bradykinin B_1 receptor antagonist; Bradykinin; Des-Arg^9-bradykinin; Endotoxin (Tokumasu, T. (274) 225)

Morphine; Adenosine; Adenosine receptor (White, P.J. (286) 315)

Hypotensive activity
α_2-Adrenoceptor; Bradycardic activity; Imidazole derivative; Imidazoline derivative; Lipophilicity; Mydriatic activity (Nasal, A. (274) 125)

Hypothalamic paraventricular nucleus
Apomorphine; 5-HT (5-hydroxytryptamine, serotonin); Grooming, excessive; Penile erection; Oxytocin; Prolactin; Corticosterone; 5-HT_{2C} receptor; m-CPP (1-3-chlorophenylpiperazine) (Bagdy, G. (275) 301)

Hypothalamus
Histamine; 5-HT (5-hydroxytryptamine, serotonin); Dexfenfluramine; Methysergide; Microdialysis (Laitinen, K.S.M. (285) 159)

Histamine; Noradrenaline; Atipamezole; α_2-Adrenoceptor antagonist; Microdialysis, in vivo (Laitinen, K.S.M. (285) 255)

Pituitary; α_2-Adrenoceptor; Growth hormone; Clonidine; Oxymetazoline; α_2-Adrenoceptor antagonist; α_{2A}-Adrenoceptor subtype; α_{2B}-Adrenoceptor subtype (Makara, G.B. (287) 43)

Hypothalamus-pituitary-adrenal axis
ACTH (adrenocorticotropic hormone); Cocaine; Corticosterone (Schmidt, E.D. (285) 317)

Hypothalamus-pituitary-adrenocortical axis
Calcitonin; Opioid receptor mechanism (Milanés, M.V. (271) 103)

Hypothermia
α_1-Adrenoceptor agonist; 5-HT_{1D} receptor agonist (Kalkman, H.O. (285) 313)

G-protein; Opiate; U-50488H; U-69593; PD 117302; Gut motility; Cholera toxin; Pertussis toxin (Shukla, V.K. (292) 293)

MDMA (3,4-methylenedioxymethamphetamine); Tryptophan hydroxylase; Hyperthermia (Che, S. (293) 447)

Hypovolemia
ACTH-(1–24); Hemorrhagic shock; (Conscious rabbit) (Ludbrook, J. (275) 267)

Hemorrhagic shock; Nitric oxide (NO); *N*-Nitro-L-arginine methyl ester; (Rabbit, conscious) (Ventura, S. (277) 265)

Hypoxia
Myoclonus; NMDA (*N*-methyl-D-aspartate); Ischemia; HA-966; ACEA-1011; ACEA-1021; Glycine (Matsumoto, R.R. (275) 117)

K^+ channel; Levcromakalim; Glibenclamide; Myocardium; (Guinea-pig) (Mellemkjær, S. (277) 51)

Cortical culture; K^+-induced depolarization; Glutamate; Extracellular; Glutamate receptor; Serum-free culture (Uchiyama-Tsuyuki, Y. (293) 245)

Hypoxia / hypoglycemia
Vitamin B_{12}; Ischemia; Hippocampus; Neuroprotection; Glutamate (Yamamoto, Y. (281) 335)

Hypoxic pulmonary vasoconstriction
Allicin; Pulmonary vascular bed, rat; Pulmonary vascular bed, cat; Vasodilator response; N^{ω}-Nitro-L-arginine methyl ester; Methylene blue; Guanylate cyclase (Kaye, A.D. (276) 21)

IAP (islet-activating protein)
Mast cell; Histamine; Endothelin; Staurosporine; Protein kinase (Yamamura, H. (288) 269)

Ibogaine
σ Receptor; (Subtype selectivity) (Bowen, W.D. (279) R1)

Ibuprofen
Bronchial blood flow; Cyclooxygenase inhibitor; Hemodynamics; Smoke inhalation injury (Abdi, S. (293) 475)

IC1174864
DAMGO ([D-Ala^2,NMePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Naltrindole; 5-HT (5-hydroxytryptamine, serotonin); Spinal cord (Monroe, P.J. (272) 51)

IC1192,605
Bradykinin; Thromboxane; Airflow obstruction; WEB2086; OKY-046 (Kawikova, I. (280) 293)

Idazoxan
Imidazoline; Clonidine; Brain, human; Binding, specific (Greney, H. (271) 533)

Imidazoline; Imidazoline site; Insulin secretion; Vessel; Pancreas; Efaroxan; (Rat) (Berdeu, D. (275) 91)

[^{3}H]Idazoxan
Imidazoline; Imidazoline receptor; GFAP (glial fibrillary acidic protein); Astrocyte (Alemany, R. (280) 205)

Imidazoline receptor; α_{2A}-Adrenoceptor; α_{2B}-Adrenoceptor; Kidney, rat; [^{3}H]Rilmenidine; Autoradiography (King, P.R. (281) 341)

Ifenprodil
σ Receptor; Eliprodil; Subtype; Receptor binding; Brain, rat (Hashimoto, K. (273) 307)

Ileum
Diabetes; Sensory fibres; Capsaicin; Stomach fundus (Pinna, C. (276) 61)

Bradykinin; Adenylate cyclase (inhibition); Guinea pig; G protein activation; Bradykinin receptor; (High-affinity binding site) (Liebmann, C. (288) 35)

Ileum, guinea-pig
Morphine; Methylnaltrexone; Naloxone; Gut motility; Intestine, human, isolated (Yuan, C.-S. (276) 107)

Naloxone benzoylhydrazone; κ-Opioid receptor; Receptor binding (Berzetei-Gurske, I.P. (277) 257)

Endothelin; Alanine analog; Receptor subtype; Sarafotoxin S6c; Tachyphylaxis (Miasiro, N. (278) 103)

5-ht$_7$ receptor; Smooth muscle relaxation (Carter, D. (280) 243)

Bradykinin; Uterus, rat; Vas deferens, rat; Trachea, guinea pig; Urinary bladder, guinea pig; Ca^{2+}; G protein; Protein kinase C (Calixto, J.B. (281) 279)

$GABA_B$ receptor; (*RS*)-(±)-Baclofen; (*S*)-2-Hydroxysaclofen; (*R*)-2-Hydroxysaclofen; Hippocampus, rat; Neocortex, rat (Kerr, D.I.B. (287) 185)

Bradykinin receptor; Adenylate cyclase; Inhibitory B_2 receptor; Antagonist profile (unique) (Liebmann, C. (289) 403)

Ileum, rat
Somatostatin; Synaptosome; Acetylcholine; Presynaptic mechanism (Kurjak, M. (281) 295)

Iloprost
Prostaglandin E_2; Desensitization; Indomethacin; cAMP; Vasorelaxation (Parfenova, H. (278) 133)

Nitric oxide (NO); Acute inflammation; Captopril; Hypertension; (2K-1C rat) (Medeiros, M.V. (285) 109)

Platelet; cAMP; cGMP; Synergism (Fisch, A. (289) 455)

Imidazole derivative
α_2-Adrenoceptor; Bradycardic activity; Hypotensive activity; Imidazoline derivative; Lipophilicity; Mydriatic activity (Nasal, A. (274) 125)

Imidazoline
Clonidine; Idazoxan; Brain, human; Binding, specific (Greney, H. (271) 533)

Imidazoline site; Insulin secretion; Vessel; Pancreas; Efaroxan; Idazoxan; (Rat) (Berdeu, D. (275) 91)

Imidazoline receptor; GFAP (glial fibrillary acidic protein); [^{3}H]Idazoxan; Astrocyte (Alemany, R. (280) 205)

K_{ATP} channel; Cardiac myocyte; (Guinea-pig) (Lee, K. (285) 309)

Imidazoline derivative
α_2-Adrenoceptor; Bradycardic activity; Hypotensive activity; Imidazole derivative; Lipophilicity; Mydriatic activity (Nasal, A. (274) 125)

Imidazoline I_1 site
Islets of Langerhans; Endocrine pancreas; Imidazoline receptor; Moxonidine; Efaroxan; Cimetidine; Diazoxide; Insulin secretion (Tsoli, E. (284) 199)

Imidazoline receptor
Imidazoline; GFAP (glial fibrillary acidic protein); [^{3}H]Idazoxan; Astrocyte (Alemany, R. (280) 205)

α_{2A}-Adrenoceptor; α_{2B}-Adrenoceptor; Kidney, rat; [^{3}H]Rilmenidine; [^{3}H]Idazoxan; Autoradiography (King, P.R. (281) 341)

α_2-Adrenoceptor; Sympathoinhibition; Presynaptic inhibition; Moxonidine; UK 14304 (Urban, R. (282) 19)

α_2-Adrenoceptor; Presynaptic inhibition; Moxonidine; Rilmenidine; UK 14304 (Urban, R. (282) 29)

Islets of Langerhans; Endocrine pancreas; Imidazoline I_1 site; Moxonidine; Efaroxan; Cimetidine; Diazoxide; Insulin secretion (Tsoli, E. (284) 199)

Imidazoline site
Imidazoline; Insulin secretion; Vessel; Pancreas; Efaroxan; Idazoxan; (Rat) (Berdeu, D. (275) 91)

Cirazoline; α-Adrenoceptor (Le Rouzic, M. (278) 261)

Imidazoquinazoline
Ro 15-4513; $GABA_A$ receptor; Diazepam-insensitive; Cerebellum; Alcohol sensitivity; Benzodiazepine; Imidazoquinoxaline; Cyclopyrrolone (Wong, G. (289) 335)

Imidazoquinoxaline
Ro 15-4513; $GABA_A$ receptor; Diazepam-insensitive; Cerebellum; Alcohol sensitivity; Benzodiazepine; Imidazoquinazoline; Cyclopyrrolone (Wong, G. (289) 335)

L-N^5-(1-Iminoethyl)ornithine
Spinal cord; Nociception; Glutamate receptor; Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester; *S*-Nitroso-*N*-penicillamine (Budai, D. (278) 39)

Imipramine
Fluoxetine; Clomipramine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Extrapyramidal symptom; Antidepressant; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (281) 255)

DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); *m*-CPP (*m*-chlorophenylpiperazine); Depression, genetic model; Clorgyline; Clomipramine (Aulakh, C.S. (282) 65)

Phosphoinositide hydrolysis; Immobilization stress; 5-HT (5-hydroxytryptamine, serotonin) (Okuyama, N. (285) 61)

Immobilization stress
Phosphoinositide hydrolysis; 5-HT (5-hydroxytryptamine, serotonin); Imipramine (Okuyama, N. (285) 61)

Immunoglobulin E
Bronchoconstrictive response; Hyperresponsiveness; Ovalbumin; Allergic asthma; (Mouse) (Hessel, E.M. (293) 401)

Immunohistochemistry
Cerebral ischemia; Glycine; MAP2 (microtubule-associated protein 2); Receptor autoradiography (Araki, T. (278) 91)

Immunoreactivity
Vasopressin; Fos protein; Brain region; (Rat) (Wu, P.H. (281) 263)

Immunotoxicity
TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Dioxin; Concanavalin A; Interleukin; Thymus; Spleen; T lymphocyte; B lymphocyte; Macrophage; (Rat) (Badesha, J.S. (293) 429)

Immunotoxicity testing
Cytomegalovirus; Ultraviolet light; Bis(tri-*n*-butyltin)oxide (Garssen, J. (292) 223)

Inactivation, Ca^{2+}-dependent
Ca^{2+} current, L-type; Ca^{2+} release, IP_3-mediated; α_1-Adrenoceptor (England, S. (288) 355)

Indomethacin
c-Fos expression; Nociception; Carrageenin, inflammation (Honoré, P. (272) 249)

Vascular permeability; PAF (platelet-activating factor); Nitric oxide (NO); (Skin); (Mouse) (Fujii, E. (273) 267)

Interleukin-1; Nitric oxide (NO); CRF (corticotropin-releasing factor; Neuroimmunology; N^G-Nitro-L-arginine; Hemoglobin; Prostaglandin (Sandi, C. (274) 17)

Prostaglandin E_2; Iloprost; Desensitization; cAMP; Vasorelaxation (Parfenova, H. (278) 133)

des-Asp-angiotensin I; Aortic ring; Captopril (Sim, M.K. (278) 175)

α-Adrenoceptor; Gastric acid secretion; Interleukin-1β; Sympatho-adrenomedullary system (Yokotani, K. (279) 233)

PAF (platelet-activating factor); Nitric oxide (NO); Cyclo-oxygenase product; Vascular reactivity; L-NMMA (N^G-monomethyl-L-arginine) (Shiga, T. (282) 151)

Infant, human
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Neurobehavioral effect; Reproduction effect; Endocrine effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Experimental animal; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

Infarct
Myocardial ischemia; Reperfusion injury; Adenosine A_1 receptor agonist (Lee, Y.-M. (279) 251)

Inflammation
Vein; Somatostatin receptor; Peripheral nervous system; Substance P (Reubi, J.C. (271) 371)

Ulcer; NSAID (non-steroidal anti-inflammatory drug); Cyclooxygenase; Leukotriene (Wallace, J.L. (271) 525)

CGRP (calcitonin gene-related peptide); Endothelin-1 (Lopez-Belmonte, J. (271) R15)

Eosinophil; β-Adrenoceptor agonist; Allergy; Passive cutaneous anaphylactic reaction (Teixeira, M.M. (272) 185)

Nitric oxide (NO); Aminoguanidine; (Rat) (Connor, J.R. (273) 15)

Collagenase; Kinin; Nitric oxide (NO); Serine protease inhibitor; Platelet (Souza Pinto, J.C. (274) 101)

Formalin test; Pain; Opioid receptor subtype; Peripheral analgesia; Extravasation (Hong, Y. (277) 21)

Endothelin-1; Neutrophil (Lopez-Belmonte, J. (278) R7)

Airway hyperresponsiveness; Capsaicin; Sensory nerve; (Rabbit) (Herd, C.M. (282) 111)

Nitric oxide (NO); Asthma; Cystic fibrosis; Cytokine (Belvisi, M. (283) 255)

Glutamate; MK-801; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); Pain; Analgesia (Jackson, D.L. (284) 321)

Nitric oxide, NO; Amidine; Butyramidine; Blood pressure; Shock; Endothelium; Endotoxin; Isothiourea (Southan, G.J. (291) 311)

Inflammatory bowel disease
5-Aminosalicylic acid; Nitric oxide (NO) (Pallapies, D. (282) 145)

Inhibitory avoidance
Amnesia; Heme oxygenase; Hippocampus; Zinc protoporphyrin-9 (Fin, C. (271) 227)

Inhibitory postsynaptic potential
trans-ACPD ((±)-*trans*-1-aminocyclopentane-1,3-dicarboxylic acid); Metabotropic glutamate receptor; Hippocampus; CA1 pyramidal cell (Jouvenceau, A. (281) 131)

Inhibitory B_2 receptor
Bradykinin receptor; Ileum, guinea pig; Adenylate cyclase; Antagonist profile (unique) (Liebmann, C. (289) 403)

Inositol phosphate
Adrenoceptor; Norepinephrine; Receptor reserve; Spare receptor (Esbenshade, T.A. (289) 305)

Thrombin; Phospholipase C inhibitor; Pertussis toxin; Atrium, rat; Noradrenaline (Woodcock, E.A. (291) 213)

Inositol 1,3,4,5-tetrakisphosphate
Histamine H_1 receptor; Intracellular Ca^{2+} store; DDT_1 MF-2 smooth muscle cell (Van der Zee, L. (289) 463)

Inositol trisphosphate
Flexor reflex; Motoneuron; Neuropeptide Y; Nociception; Spinal cord (Xu, X.-J. (272) 219)

LR-B/081; Angiotensin II; Smooth muscle cell; Prostaglandin; Hypertrophy (Catalioto, R.-M. (280) 285)

α_1-Adrenoceptor; Protein kinase C; Na^+,K^+-ATPase; Second messenger; Renal proximal tubule (Gopalakrishnan, S.M. (288) 139)

Corticotropin releasing factor; Ca^{2+}; Ca^{2+} channel; Pertussis toxin; Epithelium (Kiang, J.G. (291) 107)

Inositol 1,4,5-trisphosphate
Ca^{2+} store; Caffeine; Carbachol; Ryanodine; Smooth muscle, intestinal (Komori, S. (277) 173)

Airway hyperresponsiveness; Bronchus; Ca^{2+} channel, voltage-dependent and receptor-operated; Acetylcholine; (Rat) (Chiba, Y. (278) 79)

Phosphoinositide-specific phospholipase C; Desensitization; Protein kinase A; Protein kinase C; Phosphatidylinositol 4,5-bisphosphate (Fisher, S.K. (288) 231)

α_1-Adrenoceptor; Uterine artery; Pregnancy (Zhang, L. (289) 375)

5-HT (5-Hydroxytryptamine, serotonin); Noradrenaline; Smooth muscle, vascular (Murphy, T.V. (290) 141)

Inositol 1,4,5-trisphosphate, formation
Brain, chicken; G-protein-coupled receptor; Recombinant P_{2Y1} purinoceptor; *Xenopus* oocyte expression; COS-7 cell, transient expression (Simon, J. (291) 281)

Input-output curve
ucb L059; Bicuculline; Hippocampal CA3, rat; Paired-pulse inhibition (Margineanu, D.G. (286) 321)

Insecticide
Dopamine transporter, vesicular; Fungicide; Herbicide; Rotenone; Neurotoxin; Parkinsonism (Vaccari, A. (292) 309)

In situ hybridization
Somatostatin; SS-2 binding site; SRIF-2 binding site; Recombinant SSTR-1 receptor; Adenylate cyclase; Receptor autoradiography (Hoyer, D. (289) 151)

Somatostatin; SS-1 binding site; SRIF-1 binding site; Recombinant SSTR-2 receptor; Adenylate cyclase; Receptor autoradiography (Schoeffter, P. (289) 163)

Insulin
Metformin; Zucker rat; Genetic obesity; Feeding behavior; Neuropeptide Y (Rouru, J. (273) 99)

Hyperphagia, experimentally induced; Anorectic drug; 2-Deoxy-D-glucose; Sodium mercaptoacetate; Neural circuit (Garosi, V.L. (276) 285)

Benzoic acid; Endocrine pancreas; Glucagon; Ruminant; (Sheep) (Mineo, H. (280) 149)

Insulin secretion
Fatty alcohol; Islet of Langerhans; Pancreas (Damgé, C. (274) 133)

Imidazoline; Imidazoline site; Vessel; Pancreas; Efaroxan; Idazoxan; (Rat) (Berdeu, D. (275) 91)

M16209; Aldose reductase inhibitor; Antihyperglycemic effect; Streptozotocin-induced diabetes (Nakayama, K. (276) 77)

M16209; Aldose reductase inhibitor; Pancreas, perfused; K^+ channel, ATP-sensitive (Nakayama, K. (276) 85)

Glucagon secretion; Neuroglycopenia; 2-Deoxy-D-glucose; Nitric oxide (NO); Nitric oxide synthase; N^G-Nitro-L-arginine methyl ester; N^G-Nitro-L-arginine; (Mouse) (Ahrén, B. (280) 27)

Islets of Langerhans; Endocrine pancreas; Imidazoline receptor; Imidazoline I_1 site; Moxonidine; Efaroxan; Cimetidine; Diazoxide (Tsoli, E. (284) 199)

β_2-Integrin
Sialidase; Fucoidin; CD11b; Interleukin-8; Interleukin-1 (Harris, J.G. (279) 149)

Interaction
Neurotoxicity; DDT (1,1,1-trichloro-2,2-bis(*p*-chlorophenyl)-ethane); Pyrethroid; Behavior; Acetylcholine receptor (Johansson, U. (293) 159)

Interleukin
Bradykinin; Bradykinin analog; Bradykinin receptor antagonist; HOE 140; Mononuclear cell; Cytokine (Paegelow, I. (279) 211)

TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Dioxin; Concanavalin A; Immunotoxicity; Thymus; Spleen; T lymphocyte; B lymphocyte; Macrophage; (Rat) (Badesha, J.S. (293) 429)

Interleukin-1
Nitric oxide (NO); CRF (corticotropin-releasing factor; Neuroimmunology; N^G-Nitro-L-arginine; Hemoglobin; Indomethacin; Prostaglandin (Sandi, C. (274) 17)

Interleukin-1 receptor antagonist; Prostaglandin E_2; 5-Lipoxygenase; Stomach, rat (Montuschi, P. (275) 31)

Interleukin-1 receptor antagonist; α-MSH (α-melanocyte-stimulating hormone); α-Helical CRF-(9–41); CRF (corticotropin-releasing factor); Morphine withdrawal (Katsumata, S. (278) 143)

Sialidase; Fucoidin; β_2-Integrin; CD11b; Interleukin-8 (Harris, J.G. (279) 149)

Cytokine; TNF (tumor necrosis factor); Elastase; Neutrophil (Klemm, P. (281) 69)

Interleukin-1 receptor antagonist; Prostaglandin E_2; 5-Lipoxygenase; Stomach, rat (Montuschi, P. (282) 263)

Nitrite; Nitric oxide (NO) synthase (Ikeda, U. (290) 69)

Interleukin-1 receptor antagonist
Interleukin-1; Prostaglandin E_2; 5-Lipoxygenase; Stomach, rat (Montuschi, P. (275) 31)

Interleukin-1; α-MSH (α-melanocyte-stimulating hormone); α-Helical CRF-(9–41); CRF (corticotropin-releasing factor); Morphine withdrawal (Katsumata, S. (278) 143)

Interleukin-1; Prostaglandin E_2; 5-Lipoxygenase; Stomach, rat (Montuschi, P. (282) 263)

Interleukin-1β
α-Adrenoceptor; Gastric acid secretion; Indomethacin; Sympatho-adrenomedullary system (Yokotani, K. (279) 233)

Lipocortin/annexin; Anti-inflammatory peptide; Fever; Prostaglandin E_2 (Palmi, M. (281) 97)

Interleukin-2
Cytochrome P-450; Dexamethasone; Liver; TNF (tumor necrosis factor); Xanthine oxidase (Cantoni, L. (292) 257)

Interleukin-5
Eosinophil cationic protein (ECP); House dust mite; Fluticasone propionate, aquous nasal spray; Rhinitis (Garrelds, I.M. (275) 295)

Interleukin-6
TNF (tumor necrosis factor); Dexamethasone; Pentoxifylline; Fusidic acid; Pentamidine isethionate; Adenosine receptor agonist (Chen, Y.-L. (271) 319)

Interleukin-8
Sialidase; Fucoidin; β_2-Integrin; CD11b; Interleukin-1 (Harris, J.G. (279) 149)

Lipocortin 1; RU486; Adrenalectomy; PAF (platelet-activating factor) (Harris, J.G. (283) 9)

Intestinal absorption
Pristinamycin; Intestinal epithelium; Caco-2; P-glycoprotein (Phung-Ba, V. (288) 187)

Intestinal epithelium
Pristinamycin; Intestinal absorption; Caco-2; P-glycoprotein (Phung-Ba, V. (288) 187)

Intestinal secretion
Carbachol; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; L-Arginine; Diarrhea; Small intestinal transit (Izzo, A.A. (271) 31)

Intestinal transit
K_{ATP} channel opener; Pinacidil; Cromakalim; Morphine; Diarrhea (Poggioli, R. (287) 207)

Intestine
Hypocholesterolemic drug; Liver; Cholesterol synthesis; Dual isotope blood ratio method; Occupancy principle; (RICO rat) (Hajri, T. (286) 131)

Intestine, human, isolated
Morphine; Methylnaltrexone; Naloxone; Gut motility; Ileum, guinea-pig (Yuan, C.-S. (276) 107)

Intimal hyperplasia
Hyperreactivity; Myosin light chain phosphorylation; Protein kinase inhibitor; HA1077; $[Ca^{2+}]_i$ (Seto, M. (276) 27)

Intracardiac ganglion
Sino-atrial node, rat; Na^+,K^+,Cl^- cotransport; Loop diuretic (Harper, A.A. (286) 299)

Intracellular Ca^{2+} store
Histamine H_1 receptor; Inositol 1,3,4,5-tetrakisphosphate; DDT_1 MF-2 smooth muscle cell (Van der Zee, L. (289) 463)

Intracellular recording
Dexmedetomidine; Locus ceruleus; Brain slice; α_{2A}-Adrenoceptor (Chiu, T.-H. (285) 261)

Intracerebral arteriole, rat
PACAP (pituitary adenylate cyclase activating polypeptide); Cerebral artery, canine; Endothelium-derived contracting factor; Prostaglandin $F_{2\alpha}$ (Anzai, M. (285) 173)

Intraocular pressure
DP receptor; 572C85; BW A868C; (Rabbit); (Cat) (Matsugi, T. (275) 245)

Intrinsic activity
Mitogenesis; cAMP formation (Griffon, N. (282) R3)

Adenosine receptor; Adenosine; 8-Alkylaminoadenosine analogue; Theophylline-7-riboside and derivative; Affinity (Van der Wenden, E.M. (290) 189)

In utero exposure
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Neurobehavioral effect; Reproduction effect; Endocrine effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Experimental animal; Human infant; Lactational exposure (Seegal, R.F. (293) 1)

Invertebrate immunocyte
Morphine; Lipopolysaccharide; Phagocytosis (Ottaviani, E. (276) 35)

In vivo labeling
5-HT_{1A} receptor; [^{3}H]WAY 100635; Brain, mouse (Laporte, A.-M. (271) 505)

[^{125}I]Iodosulpiride
Dopamine D_2 receptor; Dopamine D_3 receptor; Receptor autoradiography; Striatum; Cerebellum; (Rat) (Levant, B. (278) 243)

Iomazenil
Benzodiazepine receptor; Flumazenil; Steady state; K_d; Partition coefficient (Videbæk, C. (281) 117)

Ion channel
Pyrantel; Acetylcholine; *Ascaris*, muscle; Anthelmintic; Parasitic nematode (Robertson, S.J. (271) 273)

Ion channel, ligand-gated
α_7 Nicotinic acetylcholine receptor subunit; [^{125}I]α-bungarotoxin; HEK-293 (Human embryonic kidney 293 cell); Cholinergic pharmacology (Gopalakrishnan, M. (290) 237)

Ion conductance
Opiate; Antidiarrheal agent; P-glycoprotein; CFTR (cystic fibrosis transmembrane conductance regulator) (Callaghan, R. (291) 183)

Ion current, potentiation, inhibition
Nicotinic acetylcholine receptor, neuronal; *Xenopus* oocyte; Metal ion, divalent; Voltage clamp (Zwart, R. (291) 399)

Ionic mechanism
Catecholamine; Dopamine; Dopamine receptor, agonist, antagonist; Protein kinase inhibitor; Ouabain; Voltage clamp; Neuron; (Snail) (Emaduddin, M. (283) 113)

Ionizing irradiation
Neuroprotective; Glutamate neurotransmission; Na^+ channel blocker; Neuronal damage; (Rat) (Alaoui, F. (276) 55)

Ionophoresis
Suprachiasmatic nucleus; Entrainment; Bombesin; Gastrin-releasing peptide; Neuromedin B; Neurophysiology; (Hamster) (Piggins, H.D. (271) 413)

Ion transport
Cicletanine; Sulfate; Kidney; Cell membrane; Natriuresis; Diuresis; Na^+ transport; Capillary electrophoresis (Garay, R.P. (274) 175)

Cholinergic activation; Colonic; Epithelia; Muscarinic receptor; [^{3}H]*N*-Methylscopolamine (O'Malley, K.E. (275) 83)

Colon; Epithelium; Histamine; Secretion; (Human) (Keely, S.J. (279) 203)

Loop of Henle; Bradykinin; Ca^{2+} (Grider, J. (287) 101)

IP_3 receptor
Ca^{2+} influx, store-dependent; Second messenger-operated channel; Ca^{2+} store; Ca^{2+} ATPase; Ryanodine receptor (Clementi, E. (289) 23)

Ipsapirone
5-HT_{1A} receptor; (*S*)-WAY 100135; Punishment; Conflict; Anxiolytic activity (Cervo, L. (284) 249)

Irbesartan (SR 47436/BMS-186295)
SR 47155A; Losartan; EXP 3174; Pithed rat; Angiotensin II (Christophe, B. (281) 161)

IRL 1620
Endothelin; Endothelin receptor subtype; FR139317; RES-701-1; Duodenum; (Rat) (Irie, K. (275) 45)

Endothelin; Sarafotoxin; Vas deferens; BQ-123; BQ-788; Endothelin-converting enzyme; Phosphoramidon; Neurotransmission; (Mouse) (Maas, J. (276) 113)

Endothelin-1; FR 139317; Prostacyclin; Nitric oxide (NO); Prostaglandin E_2; Endothelin receptor (Grassi-Kassisse, D.M. (282) 57)

Endothelin; Endothelin receptor subtype; PD145065; BQ-123; Tachyphylaxis (Miasiro, N. (285) 247)

Iron
Skeletal muscle actin; 5-HT (5-hydroxytryptamine, serotonin); Dopamine; Covalent bond; 5-HT (5-hydroxytryptamine, serotonin) binding protein (Velez Pardo, C. (288) 209)

Lazaroid; (Ca^{2+}, Mg^{2+})-ATPase; Lipid peroxidation; Antioxidant; Erythrocyte (Zaidi, A. (290) 133)

Ischemia
Glutathione; Hippocampus; 2-Deoxyglucose uptake; Presynaptic potential; Neuroprotection (Shibata, S. (273) 191)

Nitric oxide (NO); Hippocampus; Presynaptic potential; Neuroprotection (Shibata, S. (273) 223)

Glutamate; Nitric oxide (NO); NMDA (*N*-methyl-D-aspartate); Epilepsy (Rundfeldt, C. (274) 73)

Myoclonus; Hypoxia; NMDA (*N*-methyl-D-aspartate); HA-966; ACEA-1011; ACEA-1021; Glycine (Matsumoto, R.R. (275) 117)

Endothelin; Heart; Receptor displacement (Franco-Cereceda, A. (279) 105)

Morphine; κ-Opioid receptor; 2-Deoxyglucose; Hippocampal slice; Tolerance (Shibata, S. (279) 197)

Vitamin B_{12}; Hippocampus; Neuroprotection; Glutamate; Hypoxia/hypoglycemia (Yamamoto, Y. (281) 335)

Metabotropic glutamate receptor; AP-3 (2-amino-3-phosphonopropionate) (Maginn, M. (282) 259)

Reperfusion; Skeletal muscle; Phosphocreatine disodium salt; Phosphocreatine di-L-arginine salt; L-Arginine; Current clamp; Electrophysiology (Tricarico, D. (287) 17)

Adenosine; Adenosine receptor; Therapy; (Gerbil) (Von Lubitz, D.K.J.E. (287) 295)

Ischemia / reperfusion
Ca^{2+} overload; Lidocaine; Mexiletine; Na^+ overload (Kamiyama, T. (272) 151)

Ischemic arrhythmia
Antiarrhythmic, class I; ECG (electrocardiogram); (Selectivity) (Barrett, T.D. (285) 229)

Ischemic resistance
Polyol pathway; Galactosemia; Nerve conduction; Capillary density; Vasodilator treatment (Dines, K.C. (281) 303)

Islet of Langerhans
Fatty alcohol; Insulin secretion; Pancreas (Damgé, C. (274) 133)

Endocrine pancreas; Imidazoline receptor; Imidazoline I_1 site; Moxonidine; Efaroxan; Cimetidine; Diazoxide; Insulin secretion (Tsoli, E. (284) 199)

α Isoforms of Na^+,K^+-ATPase
Na^+,K^+-ATPase; DOCA-salt hypertension; Heart; Brain; Skeletal muscle (Sahin-Erdemli, I. (292) 163)

Isolation rearing
Place preference; *d*-Amphetamine; (Rat) (Wongwitdecha, N. (279) 99)

Isoprenaline
Cardiac contractility; Diazepam; Forskolin; cAMP (Martinez, E. (282) 169)

Isoprenaline-induced relaxation
cAMP; cGMP; Pre-contraction; Endothelium; Aorta, rat (Eckly, A.E. (271) 237)

Isoprostane
Myometrium, human; Contraction; Prostanoid TP receptor; U46619 (Crankshaw, D. (285) 151)

Isoproterenol
Fura-2; Ca^{2+}, transient signal; Heart, guinea-pig; Dihydroouabain (Hotta, Y. (282) 121)

Isothiourea
Nitric oxide, NO; Amidine; Butyramidine; Blood pressure; Shock; Inflammation; Endothelium; Endotoxin (Southan, G.J. (291) 311)

Isradipine
Endothelial cells, human; Ca^{2+}, cytosolic; Fura-2; Histamine (Iouzalen, L. (289) 189)

Itch
Scratching; Pain; Compound 48/80; Substance P; Histamine (Kuraishi, Y. (275) 229)

Jaw movement
Nucleus accumbens, shell, core; Dopamine D_1 receptor; Dopamine D_2 receptor; SKF 82958; Quinpirole; SCH 23390; (−)-Sulpiride; (Rat) (Cools, A.R. (286) 41)

JO 1784 (igmesine hydrochloride)
Cerebral ischemia; Hippocampus; Neuroprotection; Nitric oxide (NO) synthase; (Gerbil) (O'Neill, M. (283) 217)

JTP-2942 (*Nα*-((1*S*,2*R*)-2-methyl-4-oxocyclopentylcarbonyl)-L-histidyl-L-prolinamide monohydrate)
TRH (thyrotropin-releasing hormone) analog; Acetylcholine turnover (Matsushita, M. (276) 177)

Jugular vein, guinea-pig
Ketanserin; GR127935; Saphenous vein, rabbit; 5-HT_{1D} receptor (Razzaque, Z. (283) 199)

Jugular vein, rabbit
Tachykinin; Tachykinin NK_1 receptor; Endothelium; Nitric oxide (NO) (Patacchini, R. (283) 233)

K^+
Renal kallikrein secretion; Ca^{2+}; Ca^{2+} channel antagonist; Ouabain; Vanadium (Bompart, G. (278) 225)

Na^+,K^+-ATPase; Ethanol; Ouabain; Synaptosome (Foley, T.D. (292) 287)

K^+ channel
Nicorandil; Cromakalim; cGMP; Detrusor muscle, rat; Femoral artery, rat (Zhou, Q. (273) 153)

Blood vessel; Hyperemia; Vascular control (Kosmas, E.N. (274) 193)

Levcromakalim; Glibenclamide; Myocardium; Hypoxia; (Guinea-pig) (Mellemkjær, S. (277) 51)

4-Aminopyridine; α-Adrenoceptor; Contraction, phasic; Caudal epididymis, rat (Huang, Y. (280) 231)

Cromakalim; RP 49356; Myometrium; $^{42}K^+$ efflux; $^{86}Rb^+$ efflux (Piper, I.T. (283) 1)

Proximal duodenum, rat; Nitric oxide (NO); NANC (non-adrenergic, non-cholinergic) nerve; Smooth muscle relaxation; Apamin; cGMP (Martins, S.L.R. (284) 265)

Cryptolepine (5-methylquindoline); Vasodilation; Kidney, rat; G-protein; Ca^{2+} channel; Pertussis toxin (Oyekan, A.O. (285) 1)

Myometrium; Pregnancy; Ritodrine hydrochloride; β-Adrenoceptor agonist (Hamada, Y. (288) 45)

CGRP (Calcitonin gene-related peptide); Forskolin; Adenylate cyclase; Guinea-pig ureter (Santicioli, P. (289) 17)

Nitrendipine; MDCK cell; K^+ flux; Rb^+ flux; Cell membrane; Na^+, K^+, Cl^- cotransport; Red blood cell (López-Burillo, S. (289) 259)

Enterochromaffin-like cell; Stomach, rat; Ca^{2+} ionophore; Histamine; Patch-clamp (Sakai, H. (291) 153)

Antiarrhythmic agent, class III; pH (Herzer, T. (291) 205)

Eosinophil; Chemiluminescence, luminol-dependent (Saito, M. (291) 217)

K^+ channel activator
Pinacidil; Galanin; Electrolyte transport (Homaidan, F.R. (271) 561)

K^+ channel, ATP-sensitive
K^+ channel opener; Longitudinal muscle; CGRP (calcitonin gene-related peptide) (Sun, Y.-D. (271) 453)

M16209; Aldose reductase inhibitor; Insulin secretion; Pancreas, perfused (Nakayama, K. (276) 85)

Histamine H_3 receptor; Prejunctional inhibition; Substance P (Ohkubo, T. (277) 45)

Myocardial ischemia; Preconditioning (Grover, G.J. (277) 271)

K^+ channel blocker
Action potential; Langendorff; Refractory period; (Rat); (Guinea-pig) (D'Alonzo, A.J. (272) 269)

Acetylcholine; Uterine artery; Endothelium; Nitric oxide (NO) (Jovanović, A. (280) 95)

K^+ channel, Ca^{2+}
Colon, rat; Cl^- channel; Prostaglandin; Enteric nervous system (Strabel, D. (274) 181)

K^+ channel, cloned
$K_{V1.2}$; $K_{V1.4}$; Antiarrhythmic drug; Bradycardic drug (Yamagishi, T. (281) 151)

K^+ channel opener
Longitudinal muscle; CGRP (calcitonin gene-related peptide); K^+ channel, ATP-sensitive (Sun, Y.-D. (271) 453)

Uterus, human; Rubidium; Levcromakalim; P1060 (Criddle, D.N. (272) 293)

Trachea; Submucosal gland; Epithelium (Griffin, A. (280) 317)

NIP-121; Cromakalim; Epithelium; Trachea, guinea-pig; Methylene blue; Phosphoramidon (Shikada, K.-i. (282) 193)

K^+ conductance
Galantide; Galanin; Parasympathetic neuron; Ca^{2+} conductance (Mulvaney, J.M. (287) 97)

K^+ current
Antiarrhythmic; Action potential; Ca^{2+} current; Oxime; Cardiac myocyte (Karhu, S. (279) 7)

Capsaicin; Ca^{2+} current; Smooth muscle cell (Lo, Y.-C. (292) 321)

K^+ excretion
CGRP (calcitonin gene-related peptide); Renal blood flow; Renal conductance; Na^+ excretion; CGRP-(8–37); [Tyr^0]CGRP-(28–37) (Elhawary, A.M. (286) 255)

K^+ flux
Nitrendipine; MDCK cell; Rb^+ flux; Cell membrane; Na^+, K^+, Cl^- cotransport; K^+ channel; Red blood cell (López-Burillo, S. (289) 259)

K^+-induced depolarization
Cortical culture; Hypoxia; Glutamate; Extracellular; Glutamate receptor; Serum-free culture (Uchiyama-Tsuyuki, Y. (293) 245)

$^{42}K^+$ efflux
Cromakalim; RP 49356; Myometrium; $^{86}Rb^+$ efflux; K^+ channel (Piper, I.T. (283) 1)

K_d
Benzodiazepine receptor; Iomazenil; Flumazenil; Steady state; Partition coefficient (Videbæk, C. (281) 117)

$K_{V1.2}$
K^+ channel, cloned; $K_{V1.4}$; Antiarrhythmic drug; Bradycardic drug (Yamagishi, T. (281) 151)

$K_{V1.4}$
K^+ channel, cloned; $K_{V1.2}$; Antiarrhythmic drug; Bradycardic drug (Yamagishi, T. (281) 151)

Kainate
Desensitization; Glycoprotein; *Xenopus* oocyte (Yue, K.-T. (291) 229)

Kainate receptor
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor; Arachidonic acid; Carbachol; Cyclothiazide; Striatal neuron (Petitet, F. (291) 143)

Kainic acid
Dopamine; Striatum; GABA-ergic drug (Smolders, I. (284) 83)

Kallikrein-kinin
Brain edema; Carrageenan; Calcium; Neurotropin; Particle-induced X-ray emission (Sprumont, P. (274) 95)

K_{ATP} channel
Patch clamp; Antiarrhythmic, class Ia; Disopyramide; Skeletal muscle; Channel inhibition, pH dependent (Moser, C. (284) 35)

Imidazoline; Cardiac myocyte; (Guinea-pig) (Lee, K. (285) 309)

Myocardial ischemia; Glucose; Glibenclamide (Kamigaki, M. (287) 121)

K_{ATP} channel opener
Pinacidil; Cromakalim; Morphine; Intestinal transit; Diarrhea (Poggioli, R. (287) 207)

Ketanserin
GR127935; Saphenous vein, rabbit; Jugular vein, guinea-pig; 5-HT_{1D} receptor (Razzaque, Z. (283) 199)

5-HT_{1D} receptor subtype, recombinant, human; Ritanserin; 5-HT_{2A} receptor antagonist; Subtype selectivity; 5-$HT_{1D\alpha}$ receptor antagonist; cAMP (Zgombick, J.M. (291) 9)

Ketorolac tromethamine
Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; Dipyrone (Granados-Soto, V. (277) 281)

κ-Opioid receptor; Antinociception; (Intracerebroventricular administration) (Tripathi, A. (278) 27)

Kidney
Cicletanine; Sulfate; Cell membrane; Ion transport; Natriuresis; Diuresis; Na^+ transport; Capillary electrophoresis (Garay, R.P. (274) 175)

Autoregulation; Ca^{2+} channel antagonist (Huang, C. (282) 1)

Kidney, isolated, perfused
Diazepam; Clonazepam; Ro 5-4864; Renal function; Renal vasculature; (Rat) (Monasterolo, L.A. (276) 201)

Kidney, rat
Adrenomedullin; CGRP receptor; Anesthetized rat (Haynes, J.M. (280) 91)

Imidazoline receptor; α_{2A}-Adrenoceptor; α_{2B}-Adrenoceptor; [^{3}H]Rilmenidine; [^{3}H]Idazoxan; Autoradiography (King, P.R. (281) 341)

Cryptolepine (5-methylquindoline); Vasodilation; G-protein; K^+ channel; Ca^{2+} channel; Pertussis toxin (Oyekan, A.O. (285) 1)

Kidney, SHR (spontaneously hypertensive rat) and WKY (Wistar-Kyoto rat)
α_2-Adrenoceptor; Noradrenaline release (Bohmann, C. (271) 283)

Kindling
NMDA (*N*-methyl-D-aspartate); Seizure; Epilepsy; Excitatory amino acid; Amygdala (Croucher, M.J. (286) 265)

Kinetics
Angiotensin receptor; Angiotensin AT_1 receptor antagonist; Association; Dissociation (Hara, M. (289) 267)

Kinin
Collagenase; Inflammation; Nitric oxide (NO); Serine protease inhibitor; Platelet (Souza Pinto, J.C. (274) 101)

Kininogen-deficient rat
Ebelactone B; Carboxypeptidase Y, urinary; Deoxycorticosterone acetate-salt hypertension; Na^+ excretion (Majima, M. (284) 1)

Endotoxin; Vascular permeability; Bradykinin; PAF (platelet-activating factor); PAF receptor antagonist (Ueno, A. (284) 211)

Kupffer cell
Diethyldithiocarbamate; Hepatotoxicity; Liver slice preparation (Ishiyama, H. (292) 135)

Nitric oxide synthase; Enzyme induction; Lipopolysaccharide; Liver, rat; (*Propionibacterium avidum*) (Dhouib, M. (293) 439)

Kynurenate
NMDA (*N*-methyl-D-aspartate); Nootropic (Hamelin, S.M. (281) R11)

Epilepsy; Kynurenine; Excitotoxicity; Anticonvulsant action; Dizocilpine; Piriform cortex (Baran, H. (286) 167)

Kynurenic acid
D-Cycloserine; Oxiracetam; Aniracetam; NMDA receptor; Noradrenaline release (Pittaluga, A. (272) 203)

L-α-Aminoadipic acid; Excitotoxicity; Kynurenine; Microdialysis; Neurodegeneration (Wu, H.-Q. (281) 55)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Nucleus tractus solitarii; Lateral tegmental field; Muscimol (Vayssettes-Courchay, C. (285) 299)

Kynurenine
L-α-Aminoadipic acid; Excitotoxicity; Kynurenic acid; Microdialysis; Neurodegeneration (Wu, H.-Q. (281) 55)

Epilepsy; Kynurenate; Excitotoxicity; Anticonvulsant action; Dizocilpine; Piriform cortex (Baran, H. (286) 167)

L-163,491
Pulmonary vascular bed, cat; Angiotensin receptor-mediated response; Captopril; PD 123319; DuP 532 (Kaye, A.D. (287) 163)

L-659,877
Tachykinin receptor antagonist; GR82334; GR71251; Substance P; Neurokinin A (Guo, J.-Z. (281) 49)

Labyrinthectomy, unilateral
Vestibular compensation; Methylprednisolone; Steroid (Jerram, A.H. (275) 291)

Lactational exposure
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Neurobehavioral effect; Reproduction effect; Endocrine effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Experimental animal; Human infant; In utero exposure (Seegal, R.F. (293) 1)

Lamotrigine
Parkinson's disease; Animal model (Löschmann, P.-A. (284) 129)

Langendorff
Action potential; K^+ channel blocker; Refractory period; (Rat); (Guinea-pig) (D'Alonzo, A.J. (272) 269)

Langerhans cell
Ultraviolet irradiation; Neuropeptide release; Neurogenic immunomodulation; Contact hypersensitivity (Gillardon, F. (293) 395)

Laser Doppler
UV-B irradiation; Neurogenic inflammation; Cutaneous vasodilatation; CGRP (calcitonin gene-related peptide); Substance P; Nitric oxide (NO) (Benrath, J. (293) 87)

Lateral tegmental field
8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Nucleus tractus solitarii; Muscimol; Kynurenic acid (Vayssettes-Courchay, C. (285) 299)

Lazaroid
(Ca^{2+}, Mg^{2+})-ATPase; Lipid peroxidation; Iron; Antioxidant; Erythrocyte (Zaidi, A. (290) 133)

LCB 2183
Delayed-type hypersensitivity; Vascular permeability; Pulmonary inflammation; Airway hyperreactivity, mouse (Buckley, T.L. (282) 103)

Lead level, tissue
Environmental temperature; Lead toxicity; (Mouse) (Martinez-Garcia, F. (293) 271)

Lead poisoning
Benzodiazepine receptor, peripheral; Benzodiazepine receptor, central; PK 11195; Ro 15-1788; Liver (Fonia, O. (293) 335)

Lead toxicity
Environmental temperature; Lead level, tissue; (Mouse) (Martinez-Garcia, F. (293) 271)

Learned helplessness
Antidepressant; 5-HT_2 receptor; Corticosterone (Nankai, M. (281) 123)

Learning
Nitric oxide (NO); Locomotor activity; Startle response; Psychophysiological status (Sandi, C. (277) 89)

Dynorphin A-(1–13); Cholinergic neuronal system; CO (carbon monoxide); Delayed amnesia; Nor-binaltorphimine; κ-Opioid receptor; Passive avoidance (Hiramatsu, M. (282) 185)

Histogranin; NMDA receptor; Passive avoidance; Memory; (Mouse) (Maurice, T. (283) 251)

Histogranin; NMDA receptor; Passive avoidance; Memory; (Mouse) (Maurice, T. (287) 219)

Endosulfan; Body weight; Liver weight; Spontaneous motor activity; Rota-rod endurance time; Liver injury; Memory (Paul, V. (293) 355)

Learning and memory
TRH (thyrotropin-releasing hormone); Sustained release formulation; Senescence-accelerated mouse (SAM); Neophobia; Anxiety (Miyamoto, M. (271) 357)

Leiomyosarcoma cell, human
Na^+ channel, fast; Na^+ current, fast; Smooth muscle cell, uterine; Whole-cell voltage clamp; Veratridine effect (Kusaka, M. (271) 387)

Lemakalim
Glibenclamide; ATP-sensitive Ca^{2+} channel; Apamin; Charybdotoxin; Nitric oxide (NO) (Franck, H. (271) 379)

Lesion
Ultrasonic distress call; Cerebral cortex; Anxiolytic mechanism; Diazepam; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide) (Naito, H. (272) 261)

Leukocyte accumulation
E-selectin; Splanchnic artery occlusion shock (Altavilla, D. (272) 223)

Leukotriene
Ulcer; NSAID (non-steroidal anti-inflammatory drug); Inflammation; Cyclooxygenase (Wallace, J.L. (271) 525)

Airway human; Anti-immunoglobulin E; Contraction; Cysteinyl leukotriene receptor antagonist (Gorenne, I. (275) 207)

Nitric oxide (NO); Tracheal hyperresponsiveness; (Guinea pig) (Folkerts, G. (285) R1)

Leukotriene receptor
SK&F 104353; Leukotriene C_4; Leukotriene D_4 (Norman, P. (271) 73)

Leukotriene C_4
Leukotriene receptor; SK&F 104353; Leukotriene D_4 (Norman, P. (271) 73)

Leukotriene D_4
Leukotriene receptor; SK&F 104353; Leukotriene C_4 (Norman, P. (271) 73)

Leukotriene D_4 receptor antagonist
YM638 ([[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio] acetic acid); Gastric mucosal protection; Gastric lesion (Miyata, K. (276) 165)

Leupeptin
Endothelin-1; Red blood cell; Staphylococcal α-toxin; Phosphoramidon; Pepstatin A; Chymostatin (Tippler, B. (271) 131)

Levcromakalim
Uterus, human; Rubidium; K^+ channel opener; P1060 (Criddle, D.N. (272) 293)

K^+ channel; Glibenclamide; Myocardium; Hypoxia; (Guinea-pig) (Mellemkjær, S. (277) 51)

P1060; Saphenous vein, human; Rubidium ion (Criddle, D.N. (286) 123)

Glibenclamide; Artery, subcutaneous; (Human) (Hüsken, B.C.P. (287) 313)

Levetiracetam
ucb L059; Epilepsy; Anticonvulsant; Receptor binding (Noyer, M. (286) 137)

Lidocaine
Ca^{2+} overload; Ischemia/reperfusion; Mexiletine; Na^+ overload (Kamiyama, T. (272) 151)

α_1-Adrenoceptor; Up-regulation; Cardiocyte; Culture (Mizuki, T. (277) 133)

Coronary occlusion; Adenosine release; Reperfusion arrhythmia; Quinidine; Gallopamil (Bernauer, W. (283) 91)

Spectrin; ATPase, vascular type; Carbonic anhydrase; Erythrocyte membrane, human (Nishiguchi, E. (286) 1)

Ligand binding
α_2-Adrenoceptor subtype; cAMP level; (*Autographa californica* nuclear polyhedrosis virus); (*Spodoptera frugiperda*) (Jansson, C.C. (290) 75)

Limbic forebrain
Adrenalectomy; Corticosteroid; Dopamine; Locomotor activity; Nicotine; Sensitization; (Rat) (Johnson, D.H. (276) 155)

Lipid order
Ethanol; Microsome; Mitochondria; Membrane protein (Sanchez-Amate, M.C. (292) 215)

Lipid peroxidation
Free radical; *t*-Butyl hydroperoxide; Sinoatrial node; Atrioventricular node; Reperfusion arrhythmia (Satoh, N. (272) 233)

Cerebral ischemia; Hippocampus; N^G-Nitro-L-arginine methyl ester; (Gerbil) (Caldwell, M. (285) 203)

Lazaroid; (Ca^{2+}, Mg^{2+})-ATPase; Iron; Antioxidant; Erythrocyte (Zaidi, A. (290) 133)

Anti-oxidant; Decongestive nose drops; Hydroxyl radical scavenging; Nasal inflammation; Reactive oxygen species (Westerveld, G.-J. (291) 27)

Lipopolysaccharide; Melatonin; Liver; GSH; GSSG (Sewerynek, E. (293) 327)

Lipid peroxide
Ebselen; Ethanol; Gastric mucosal injury, murine; Gastric surface mucous cell line GSM06; Peptidoleukotriene (Tabuchi, Y. (272) 195)

Lipocortin 1
RU486; Interleukin-8; Adrenalectomy; PAF (platelet-activating factor) (Harris, J.G. (283) 9)

Neurogenic inflammation; Edema; Topical glucocorticoid (Ahluwalia, A. (283) 193)

Lipocortin / annexin
Anti-inflammatory peptide; Interleukin-1β; Fever; Prostaglandin E_2 (Palmi, M. (281) 97)

Lipolyse
Carazolol; β-Adrenoceptor antagonist; β_3-Adrenoceptor agonist; Adenylyl cyclase (Méjean, A. (291) 359)

Lipolysis
Desensitization; β-Adrenoceptor agonists; Adipocyte; Phosphodiesterase; β-Adrenoceptor subtypes (Bousquet-Mélou, A. (289) 235)

Lipophilicity
α_2-Adrenoceptor; Bradycardic activity; Hypotensive activity; Imidazole derivative; Imidazoline derivative; Mydriatic activity (Nasal, A. (274) 125)

Lipopolysaccharide
Nitric oxide (NO); Nitric oxide (NO) synthase; Hypotension; L-Canavanine; N^G-Nitro-L-arginine methyl ester (Teale, D.M. (271) 87)

Adrenergic nerve; Nitric oxide (NO); Tail artery, rat; Sepsis (Takakura, K. (271) 367)

Cytokine; Mitogen; Nitric oxide (NO); Prostaglandin (Akarasereenont, P. (273) 121)

Morphine; Phagocytosis; Invertebrate immunocyte (Ottaviani, E. (276) 35)

Cytochrome *P*-450; Arachidonic acid; Nitric oxide (NO) (Oyekan, A.O. (277) 123)

Acetylcholine; Aminoguanidine; Mesenteric arterial bed; N^G-Nitro-L-arginine methyl ester; Portal vein ligation; (Portal hypertensive rat) (Heinemann, A. (278) 87)

Antioxidant; Vitamin E; Vitamin C; Allopurinol; Glucocorticoid (Dimmeler, S. (287) 257)

Nitric oxide (NO); Gastric mucosa; (Stomach) (Brown, J.F. (292) 111)

Melatonin; Liver; GSH; GSSG; Lipid peroxidation (Sewerynek, E. (293) 327)

Nitric oxide synthase; Enzyme induction; Kupffer cell; Liver, rat; (*Propionibacterium avidum*) (Dhouib, M. (293) 439)

Lipoprotein
Vasodilation; Nitric oxide (NO); Endothelium (Galle, J. (273) 311)

Lipoprotein lipase
Endothelin-1; Endothelin-3; Gene expression; Brown adipocyte; Endothelin ET_A receptor (Uchida, Y. (291) 33)

Liposome
PAF (platelet-activating factor); Smooth muscle, trachea (Costuleanu, M. (281) 89)

α-Trinositol (D-*myo*-inositol 1,2,6-trisphosphate); Smooth muscle, aortic, vascular (Brailoiu, E. (281) 209)

Mast cell; Histamine liberation; Amphipathic α-helix; Magainin; Neuropeptide Y; Substance P (Cross, L.J.M. (291) 291)

Lipoxin A_4
Cholinergic neurotransmission; Nitric oxide (NO); Smooth muscle, airway (Tamaoki, J. (287) 233)

Lipoxygenase metabolite
PAF (platelet-activating factor); Bronchial hyperresponsiveness; Eosinophil infiltration (Seeds, E.A.-M. (293) 369)

5-Lipoxygenase
Interleukin-1 receptor antagonist; Interleukin-1; Prostaglandin E_2; Stomach, rat (Montuschi, P. (275) 31)

Interleukin-1 receptor antagonist; Interleukin-1; Prostaglandin E_2; Stomach, rat (Montuschi, P. (282) 263)

5-Lipoxygenase inhibitor
Nitric oxide (NO); Microvascular injury (László, F. (277) R1)

Liver
α_1-Adrenoceptor subtype; Hepatocyte membrane; α_{1A}-Adrenoceptor (García-Sáinz, J.A. (272) 139)

Opioid; Growth; Development; Brain; (Intracerebroventricular) (Bartolome, J.V. (284) 43)

Binding site; Glibenclamide (Glyburide); Hypoglycemic agent; Sulfonylurea compound (Inoue, Y. (284) 77)

Hypocholesterolemic drug; Intestine; Cholesterol synthesis; Dual isotope blood ratio method; Occupancy principle; (RICO rat) (Hajri, T. (286) 131)

α_1-Adrenoceptor; Hepatocyte; Tamsulosin (García-Sáinz, J.A. (289) 1)

Cytochrome P-450; Dexamethasone; Interleukin-2; TNF (tumor necrosis factor); Xanthine oxidase (Cantoni, L. (292) 257)

Lipopolysaccharide; Melatonin; GSH; GSSG; Lipid peroxidation (Sewerynek, E. (293) 327)

Benzodiazepine receptor, peripheral; Benzodiazepine receptor, central; PK 11195; Ro 15-1788; Lead poisoning (Fonia, O. (293) 335)

Liver, human
α_1-Adrenoceptor; α_{1A}-Adrenoceptor (García-Sáinz, J.A. (289) 81)

Liver injury
Endosulfan; Body weight; Liver weight; Spontaneous motor activity; Rota-rod endurance time; Learning; Memory (Paul, V. (293) 355)

Liver, mouse
Septic liver failure; Glycosylation inhibitor; DNA fragmentation (Leist, M. (292) 201)

Liver, rat
Nitric oxide synthase; Enzyme induction; Lipopolysaccharide; Kupffer cell; (*Propionibacterium avidum*) (Dhouib, M. (293) 439)

Liver slice preparation
Diethyldithiocarbamate; Kupffer cells; Hepatotoxicity (Ishiyama, H. (292) 135)

Liver weight
Endosulfan; Body weight; Spontaneous motor activity; Rota-rod endurance time; Liver injury; Learning; Memory (Paul, V. (293) 355)

LOAEL (lowest observable adverse effect level)
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Neurobehavioral effect; Reproduction effect; Endocrine effect; TEF (toxic equivalency factor); Experimental animal; Human infant; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

Lobenzarit
Chemoprotection; Hepatotoxicity; Paracetamol; Molecular mechanism (Remirez, D. (293) 301)

Local anesthetic
Drug discrimination; Dopamine; Cocaine; Dimethocaine; Procaine; Chloroprocaine; SCH 39166; Raclopride; (Squirrel monkey) (Mansbach, R.S. (274) 167)

Dopamine uptake; Microdialysis (Woodward, J.J. (277) 7)

Hippocampal neuron; Chloride ion; Patch-clamp technique; GABA (γ-aminobutyric acid); Glycine (Hara, M. (283) 83)

Localisation
α_1-Adrenoceptor; β-Adrenoceptor; Myocardium, rat; Noradrenaline; Uptake blocker (Dybvik, T. (281) 21)

Locomotion
Phencyclidine; Nitric oxide (NO) synthase inhibitor; Ataxia; (Mouse) (Noda, Y. (286) 291)

Locomotor activity
Amphetamine; Cocaine; Microdialysis, in vivo; Opioid receptor antagonist; Dopamine; Striatum; Nucleus accumbens (Schad, C.A. (275) 9)

Methamphetamine; Sensitization; Nitric oxide (NO); N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester; NMDA receptor (Ohno, M. (275) 39)

Adrenalectomy; Corticosteroid; Dopamine; Limbic forebrain; Nicotine; Sensitization; (Rat) (Johnson, D.H. (276) 155)

Nitric oxide (NO); Startle response; Psychophysiological status; Learning (Sandi, C. (277) 89)

Conditioned place preference; Genetic selection; Nicotine; (Mouse) (Schechter, M.D. (279) 59)

LY326325; NBQX (6-nitro-7-sulfamoylbenzo(*f*)quinoxaline-2,3-(1*H*,4*H*dione); AMPA receptor antagonist; Anxiety; Plus maze; (Mouse) (Karcz-Kubicha, M. (279) 171)

Dopamine, mesocortical; Nucleus accumbens; Voltammetry; 6-Hydroxydopamine lesion (Banks, K.E. (282) 157)

Tolerance; Morphine; Thyrotropin; Prolactin; Growth hormone; Rectal temperature (Rauhala, P. (285) 69)

μ-Opioid receptor; Tyr-D-Arg-Phe-β-Ala-NH_2; β-Funaltrexamine; Memory; Passive avoidance; (Mouse) (Ukai, M. (287) 245)

Locus ceruleus
Methamphetamine; Striatal dopamine; DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine) (Fornai, F. (283) 99)

Dexmedetomidine; Brain slice; Intracellular recording; α_{2A}-Adrenoceptor (Chiu, T.-H. (285) 261)

Long chain triacylglycerol
Omeprazole; Crop emptying; Medium chain triacylglycerol; Acid; (Chick) (Mabayo, R.T. (273) 161)

Longitudinal muscle
K^+ channel opener; CGRP (calcitonin gene-related peptide); K^+ channel, ATP-sensitive (Sun, Y.-D. (271) 453)

Long-term depression
Hippocampus; Phospholipase A_2 (Stanton, P.K. (273) R7)

Long-term potentiation
Hippocampus; Dentate gyrus; Neural plasticity; Metabotropic glutamate receptor; NMDA (*N*-methyl-D-aspartate) (Bordi, F. (273) 291)

β-Amyloid-(1–40); Glutamatergic synaptic transmission (Wu, J. (284) R1)

Loop diuretic
Sino-atrial node, rat; Na^+,K^+,Cl^- cotransport; Intracardiac ganglion (Harper, A.A. (286) 299)

Loop of Henle
Bradykinin; Ion transport; Ca^{2+} (Grider, J. (287) 101)

Losartan
ME3221; Angiotensin AT_1 receptor antagonist, surmountable; Antihypertensive drug; Telemetry (Nagura, J. (274) 201)

Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; PD 123177; Vasopressin; Drinking response (Höhle, S. (275) 277)

Angiotensin AT_1 receptor antagonist; Angiotensin II-induced drinking; EXP3174; LR-B/081 (Polidori, C. (277) 223)

Angiotensin II; DuP 532; PD 123319; CGP 42112A; Smooth muscle, portal vein (Pelet, C. (279) 15)

Cardiac hypertrophy; Volume overload; Angiotensin II; Endothelin-1; FR139317 (Ishiye, M. (280) 11)

Irbesartan (SR 47436/BMS-186295); SR 47155A; EXP 3174; Pithed rat; Angiotensin II (Christophe, B. (281) 161)

UP 269-6; Angiotensin II; Angiotensin II receptor antagonist; Blood pressure; Heart rate (Cazes, M. (284) 157)

Des-Asp-angiotensin I; PD123319; Pulmonary artery, rabbit; Transmural stimulation; (Superfusion) (Sim, M.K. (284) 215)

Angiotensin II; Angiotensin AT_1 receptor antagonist; LR-B/081; Receptor binding studies (Renzetti, A.R. (290) 151)

Low-frequency tone
Methamphetamine; Scopolamine; Cholinergic system; Behavioral sensitization; Drug conditioning (Yui, K. (279) 135)

LR-B/081
Angiotensin AT_1 receptor antagonist; Angiotensin II-induced drinking; Losartan; EXP3174 (Polidori, C. (277) 223)

Angiotensin II; Smooth muscle cell; Inositol trisphosphate; Prostaglandin; Hypertrophy (Catalioto, R.-M. (280) 285)

Angiotensin II; Angiotensin AT_1 receptor antagonist; Losartan; Receptor binding studies (Renzetti, A.R. (290) 151)

Lung
Benzodiazepine; Cell proliferation; (Chinese hamster) (Camins, A. (272) 289)

β-Adrenoceptor agonist; Dexamethasone; DNA binding; (Rat) (Peters, M.J. (289) 275)

Lung cancer
Ascorbic acid; Drug resistance; Vincristine (Song, E.-J. (292) 119)

Lung function, rat
Urodilatin; Natriuretic peptide, type A; Bronchoprotection; Acetylcholine (Flüge, T. (271) 395)

Lung, human
Bombesin; GRP (gastrin-releasing peptide); Bombesin binding site; GRP-preferring bombesin receptor (Lach, E. (273) 313)

Lung injury antioxidant
Cyclophosphamide; Taurine; Niacin; Membrane stabilizer (Venkatesan, N. (292) 75)

Lung, rabbit
Histamine H_3 receptor; C-fiber; Acetylcholine; Neuropeptide; Edema (Delaunois, A. (277) 243)

LY83583
Nitric oxide (NO) synthase; Methylene blue; cGMP; NADPH-diaphorase (Luo, D. (290) 247)

LY326325
NBQX (6-nitro-7-sulfamoylbenzo(*f*)quinoxaline-2,3-(1*H*,4*H*dione); AMPA receptor antagonist; Anxiety; Plus maze; Locomotor activity; (Mouse) (Karcz-Kubicha, M. (279) 171)

M16209
Aldose reductase inhibitor; Antihyperglycemic effect; Streptozotocin-induced diabetes; Insulin secretion (Nakayama, K. (276) 77)

Aldose reductase inhibitor; Insulin secretion; Pancreas, perfused; K^+ channel, ATP-sensitive (Nakayama, K. (276) 85)

Macrophage
Opiate receptor; Morphine 6-glucuronide (Makman, M.H. (273) R5)

Thromboxane; Azelastine; Airway hyperresponsiveness (Tamaoki, J. (278) 161)

Bradykinin receptor; Phospholipase C; Ca^{2+}, intracellular (Böckmann, S. (291) 159)

TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Dioxin; Concanavalin A; Immunotoxicity; Interleukin; Thymus; Spleen; T lymphocyte; B lymphocyte; (Rat) (Badesha, J.S. (293) 429)

Macrophage inflammatory protein 2
Allergic inflammation; Dexamethasone; Chemotactic factor (Tanabe, J.-i. (284) 257)

Magainin
Mast cell; Histamine liberation; Amphipathic α-helix; Neuropeptide Y; Substance P; Liposome (Cross, L.J.M. (291) 291)

Malignant melanoma
Melanocortin receptor; Antibody (Xia, Y. (288) 277)

Malondialdehyde
Zinc sulfate; *N*-acetylcysteine; Acetaminophen; Hepatotoxicity; Glutathione; Alanine aminotransferase (Woo, P.C.Y. (293) 217)

Mammary carcinoma cell
Receptor ligand; Cell proliferation; Colon carcinoma cell; Melanoma cell (Brent, P.J. (278) 151)

Mammillary complex
Memory; Retention; Acetylcholine; Dopamine; Norepinephrine; NMDA (*N*-methyl-D-asparate); Nicotine; Neuropeptide Y; GABA (γ-aminobutyric acid); (Mouse) (Flood, J.F. (275) 223)

Manganese
Manganism; Complex I; PC12 cell; Parkinson-like disease (Galvani, P. (293) 377)

Manganism
Manganese; Complex I; PC12 cell; Parkinson-like disease (Galvani, P. (293) 377)

MAP2 (microtubule-associated protein 2)
Cerebral ischemia; Glycine; Receptor autoradiography; Immunohistochemistry (Araki, T. (278) 91)

Maprotiline
Antidepressant drug; Desipramine; Fluoxetine; Moclobemide; Trimipramine; 2-Methyl-5-hydroxytryptamine; 5-HT (5-hydroxytryptamine, serotonin); Reuptake inhibition; Hippocampus; Presynaptic modulation (Mongeau, R. (271) 121)

Marijuana
Basal ganglia; Cannabinoid; Substantia nigra; Cannabinoid receptor; Motor system; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole (Miller, A.S. (279) 179)

Withdrawal; Tetrahydrocannabinol (Tsou, K. (280) R13)

Marine product
2-Polyprenyl-1,4-hydroquinone; Phospholipase A_2; Neutrophil, human; Anti-inflammatory drug (Gil, B. (285) 281)

Marinobufagenin
Na^+,K^+-ATPase; Bufodienolide; Ouabain; Smooth muscle, vascular; Vasoconstriction (Bagrov, A.Y. (274) 151)

Mast cell
5-HT (5-hydroxytryptamine, serotonin); Actinomycin-D; Dexamethasone; Nedocromil sodium; Paw edema, rat (Raud, J. (282) 207)

Histamine; Endothelin; Staurosporine; IAP (islet-activating protein); Protein kinase (Yamamura, H. (288) 269)

Neuropeptide Y; Circular dichroism spectrum; Heterotrimeric G protein; Benzalkonium chloride; Pertussis toxin; (Rat); (Human) (Mousli, M. (289) 125)

Histamine liberation; Amphipathic α-helix; Magainin; Neuropeptide Y; Substance P; Liposome (Cross, L.J.M. (291) 291)

Nicotine; Stress, cold-restraint; Ethanol; Gastric lesion; (Mini-osmotic pump); (Rat) (Wong, D. (292) 157)

Mast cell, cutaneous
Neuropeptide Y; Mastoparan; G-protein; Benzalkonium chloride; Pertussis toxin; Neuraminidase (Emadi-Khiav, B. (272) 97)

Mast cell degranulation
Abruquinone A; Paw edema; Neurogenic inflammation; Passive cutaneous anaphylaxis; Vascular permeability; Compound 48/80 (Wang, J.-P. (273) 73)

Mastoparan
Mast cell, cutaneous; Neuropeptide Y; G-protein; Benzalkonium chloride; Pertussis toxin; Neuraminidase (Emadi-Khiav, B. (272) 97)

Mating
Sexual satiety; Apomorphine; Dopamine (Mas, M. (280) 331)

Maxillary sinus
Cilia; Formoterol; Terbutaline; Trachea; Mucociliary clearance (Lindberg, S. (285) 275)

Maximal electroshock
Oxcarbazepine; 10-Monohydroxy metabolite; Na^+-dependent action potential; Cultured neuron (Wamil, A.W. (271) 301)

[^{3}H]Mazindol binding
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Autoradiography; Basal ganglion; Motor recovery; (Marmoset) (Gnanalingham, K.K. (277) 235)

MCF-7
CGS16949A; Fadrozole hydrochloride; Aromatase inhibitor; T47D (Yano, S. (289) 217)

McN-A-343
Acetylcholine; Atrium AF-DX 116, human; HHSiD (*p*-fluorohexahydro-siladifenidol hydrochloride); Muscarinic receptor; Myocardial contractility; Pirenzepine; Ventricle (Du, X.Y. (284) 119)

MCPG ((RS)-α-methyl-4-carboxyphenylglycine)
L-AP3 (L-2-amino-3-phosphonopropionic acid); Metabotropic glutamate receptor; Phosphatidyl inositide hydrolysis; *Xenopus* oocyte (Saugstad, J.A. (289) 395)

MDCK cell
Nitrendipine; K^+ flux; Rb^+ flux; Cell membrane; Na^+, K^+, Cl^- cotransport; K^+ channel; Red blood cell (López-Burillo, S. (289) 259)

MDL 72222
Sleep; Waking; *m*-Chlorophenylbiguanide; 5-HT_3 receptor; Dopamine; (+)-SCH 23390; YM-09151-2 (Ponzoni, A. (278) 111)

MDL 73,745
Microdialysis; Cholinesterase; Acetylcholine; Norepinephrine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Zhu, X.-d. (276) 93)

MDMA (3,4-methylenedioxymethamphetamine)
Ecstasy; Neurodegeneration; PBN (α-phenyl-*N*-tert-butyl nitrone); Neuroprotection; Free radical (Colado, M.I. (280) 343)

5-HT (5-hydroxytryptamine, serotonin); 5-HT_{1A} receptor (Aguirre, N. (281) 101)

Tryptophan hydroxylase; Hyperthermia; Hypothermia (Che, S. (293) 447)

ME3221
Angiotensin AT_1 receptor antagonist, surmountable; Antihypertensive drug; Losartan; Telemetry (Nagura, J. (274) 201)

Mecamylamine
Anatoxin-a; Chromaffin cell; Nicotinic acetylcholine receptor, neuronal type; Nicotinic receptor agonist; Noradrenaline release; Adrenaline release (Molloy, L. (289) 447)

Mechanism of arrhythmia
Cardiac electropharmacology; Antiarrhythmic drug (Lee, J.H. (285) 25)

Medetomidine
Neuropathy; Hyperalgesia; Atipamezole; Mustard oil (Mansikka, H. (281) 43)

Medial preoptic area
μ-Opioid receptor; Estrogen; Progesterone; Upregulation (Zhou, L. (278) 271)

Mediodorsal thalamic nucleus
Prefrontal cortex; Anesthesia; Excitatory amino acid (Pirot, S. (285) 45)

Medium chain triacylglycerol
Omeprazole; Crop emptying; Long chain triacylglycerol; Acid; (Chick) (Mabayo, R.T. (273) 161)

Megakaryocyte, rat
Ca^{2+}-ATPase; Protein kinase C; Protein kinase A; Calmodulin; Patch-clamp (Uneyama, C. (291) 381)

Melanocortin
Aging; ACTH (adrenocorticotropin); Grooming; Stretching; Yawning; Penile erection (Poggioli, R. (271) 253)

Melanocortin receptor
Antibody; Malignant melanoma (Xia, Y. (288) 277)

Melanocortin receptor subtype
[^{125}I][Nle^4, D-Phe^7]α-MSH ligand binding; MSH (melanocyte stimulating hormone) peptide selectivity; Phosphoramidon (Schiöth, H.B. (288) 311)

Melanoma cell
Receptor ligand; Cell proliferation; Mammary carcinoma cell; Colon carcinoma cell (Brent, P.J. (278) 151)

Melanophore, *Xenopus laevis*
Melatonin; Chiral analog; Binding site (Sugden, D. (287) 239)

Melatonin
Napping; Polysomnographic recording (Nave, R. (275) 213)

β-Endorphin-(10–16); Prolyl-leucyl-glycinamide; TRH (thyrotropin-releasing hormone); Nucleus accumbens; Antidepressant (Hatta, K. (284) 327)

Chiral analog; Binding site; Melanophore, *Xenopus laevis* (Sugden, D. (287) 239)

Lipopolysaccharide; Liver; GSH; GSSG; Lipid peroxidation (Sewerynek, E. (293) 327)

Melatonin receptor
Caudal artery, rat; Adrenergic nerve; Contraction (Krause, D.N. (276) 207)

Melittin
Aminoglycoside; Spermine; Phosphatidylinositol; Membrane aggregation; Membrane fusion (Van Bambeke, F. (289) 321)

Memantine
Nucleus basalis magnocellularis; Acetylcholine; Neuroprotection; (+)-MK-801; Amantadine; Ataxia; Stereotypy; (Rat) (Wenk, G.L. (293) 267)

Membrane aggregation
Aminoglycoside; Spermine; Melittin; Phosphatidylinositol; Membrane fusion (Van Bambeke, F. (289) 321)

Membrane fluidity
Benfluorex metabolite; Diabetes mellitus; Non insulin-dependent; Hepatocyte, isolated; (Rat) (Orsière, T.G. (291) 237)

Membrane fusion
Aminoglycoside; Spermine; Melittin; Phosphatidylinositol; Membrane aggregation (Van Bambeke, F. (289) 321)

Membrane potential
Methylmercury; Cytotoxicity; Thymocyte; Ca^{2+} concentration, intracellular (Oyama, Y. (293) 101)

Membrane protein
Ethanol; Microsome; Mitochondria; Lipid order (Sanchez-Amate, M.C. (292) 215)

Membrane stabilizer
Cyclophosphamide; Taurine; Niacin; Lung injury antioxidant (Venkatesan, N. (292) 75)

Memory
Etonitazene; Morphine; Naloxone; Radial maze; Opioid (Braida, D. (271) 497)

Dynorphin A-(1–13); Scopolamine; Passive avoidance response; Amnesia; (Mouse) (Ukai, M. (274) 89)

Mammillary complex; Retention; Acetylcholine; Dopamine; Norepinephrine; NMDA (*N*-methyl-D-asparate); Nicotine; Neuropeptide Y; GABA (γ-aminobutyric acid); (Mouse) (Flood, J.F. (275) 223)

Histogranin; NMDA receptor; Passive avoidance; Learning; (Mouse) (Maurice, T. (283) 251)

Histogranin; NMDA receptor; Passive avoidance; Learning; (Mouse) (Maurice, T. (287) 219)

μ-Opioid receptor; Tyr-D-Arg-Phe-β-Ala-NH_2; β-Funaltrexamine; Passive avoidance; Locomotor activity; (Mouse) (Ukai, M. (287) 245)

Endosulfan; Body weight; Liver weight; Spontaneous motor activity; Rota-rod endurance time; Liver injury; Learning (Paul, V. (293) 355)

MEN 10,627
Tachykinin NK_2 receptor; Tachykinin receptor antagonist; SR 48968; Gallbladder, guinea-pig; Proximal colon, guinea-pig (Patacchini, R. (271) 111)

Bronchospasm; (±)-CP96,345; Neurokinin A; PAF (platelet-activating factor); Substance P; Tachykinin (Perretti, F. (273) 129)

Meningitis
Nitric oxide (NO); Blood-cerebrospinal fluid barrier; Aminoguanidine (Boje, K.M.K. (272) 297)

Mercapturic acid
Hexafluorobenzene; Hexachlorobenzene; Porphyria; Biotransformation; Phenolic metabolite (Rietjens, I.M.C.M. (293) 293)

Mesangial cell
Tranilast; PDGF (platelet-derived growth factor); Nitric oxide (NO) (Hishikawa, K. (291) 435)

Erythropoietin, recombinant human; Glomerular endothelial cell; Endothelin-1; Proliferation (Nitta, K. (293) 491)

Mesangial cell, rat
Cyclic nucleotide phosphodiesterase; cyclic GMP; cyclic AMP; ANF-(1–28) (Atrial natriuretic factor-(1–28); E4021 (Ahn, H.-S. (289) 49)

Mesenteric arterial bed
Acetylcholine; Aminoguanidine; Lipopolysaccharide; N^G-Nitro-L-arginine methyl ester; Portal vein ligation; (Portal hypertensive rat) (Heinemann, A. (278) 87)

Mesenteric arterial bed, rat
Endothelium; Streptozotocin diabetes; Sympathetic nerve (Ralevic, V. (286) 193)

Mesenteric artery, guinea pig
Vasodilator nerve; Nitric oxide (NO); CGRP (calcitonin gene-related peptide); Capsaicin; Nitro-L-arginine; Zinc protoporphyrin IX (Gyoda, Y. (279) 83)

Messenger RNA regulation
Muscarinic receptor; Polymerase chain reaction; Primary neuronal culture (Brusa, R. (289) 9)

Metabolic activation
Aflatoxin B_1; *Saccharomyces cerevisiae*; CYP2A (Pelkonen, P. (292) 67)

Metabolism
Nitrate; Nitrite; *N*-nitroso compound; Human diet; Dietary intake; Endogenous synthesis; Toxicokinetics; Animal toxicology; Human effects (Gangolli, S.D. (292) 1)

Metabolite
Methylation; Blood; Urine; Water; Food (Vahter, M. (293) 455)

Metabolite, remoxipride
Remoxipride; cAMP; Striatum; Dopamine D_2 receptor (Westlind-Danielsson, A. (288) 89)

Metabotropic glutamate receptor
Long-term potentiation; Hippocampus; Dentate gyrus; Neural plasticity; NMDA (*N*-methyl-D-aspartate) (Bordi, F. (273) 291)

Glutamate release; Striatum; Synaptosome; Parkinson's disease; (Presynaptic) (East, S.J. (277) 117)

trans-ACPD ((±)-*trans*-1-aminocyclopentane-1,3-dicarboxylic acid); Inhibitory postsynaptic potential; Hippocampus; CA1 pyramidal cell (Jouvenceau, A. (281) 131)

AP-3 (2-amino-3-phosphonopropionate); Ischemia (Maginn, M. (282) 259)

Adenosine A_2 receptor; Basal ganglia; Striatum; Subthalamic nucleus (Feeley Kearney, J.A. (287) 115)

L-AP4 (L(+)-2-amino-4-phosphonobutyric acid); Cerebellar granule cell; Neurotrophic (Graham, M.E. (288) 115)

Phosphoinositide hydrolysis; Seizure; Soman; Histamine H_1 receptor (Bodjarian, N. (289) 291)

L-AP3 (L-2-amino-3-phosphonopropionic acid); MCPG ((RS)-α-methyl-4-carboxyphenylglycine); Phosphatidyl inositide hydrolysis; *Xenopus* oocyte (Saugstad, J.A. (289) 395)

$MGlu_{4a}$ receptor antagonist; L-2-amino-4-phosphonobutanoic acid (Johansen, P.A. (290) R1)

Metal ion, divalent
Nicotinic acetylcholine receptor, neuronal; *Xenopus* oocyte; Voltage clamp; Ion current, potentiation, inhibition (Zwart, R. (291) 399)

Metergoline
Morphine tolerance; Methysergide; Ritanserin; Mianserin; Antinociception (Zarrindast, M.-R. (273) 203)

GR127935; GR55562; Methiothepin; $5\text{-}HT_{1D\alpha}$ receptor; $5\text{-}HT_1D_\beta$ receptor (Walsh, D.M. (287) 79)

Metformin
Zucker rat; Genetic obesity; Feeding behavior; Insulin; Neuropeptide Y (Rouru, J. (273) 99)

Methamphetamine
Locomotor activity; Sensitization; Nitric oxide (NO); N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester; NMDA receptor (Ohno, M. (275) 39)

Scopolamine; Cholinergic system; Behavioral sensitization; Drug conditioning; Low-frequency tone (Yui, K. (279) 135)

Locus ceruleus; Striatal dopamine; DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine) (Fornai, F. (283) 99)

Methanol
Nitric oxide (NO) synthase; Brain; N^{ω}-Nitro-L-arginine methyl ester metabolism; Mitochondrial toxin (Brouillet, E. (293) 487)

Methiothepin
GR127935; GR55562; Metergoline; $5\text{-}HT_{1D\alpha}$ receptor; $5\text{-}HT_1D_\beta$ receptor (Walsh, D.M. (287) 79)

Methoxamine
Pelanserin; 5-HT receptor antagonist; Contraction; Spontaneously hypertensive rat (SHR) (Villalobos-Molina, R. (277) 181)

***N*-Methyl-actinodaphnine**
α-Adrenoceptor antagonist; α_1-Adrenoceptor subtype; (*Illigera luzonensis*) (Guh, J.-H. (279) 33)

***N*-Methylanabasine**
Nicotine; Nornicotine; Anabaseine; Anabasine; Dopamine release; Striatum (Dwoskin, L.P. (276) 195)

Methylation
Metabolite; Blood; Urine; Water; Food (Vahter, M. (293) 455)

Methylation inhibitor
Benzodiazepine binding; *S*-Adenosylhomocysteine; 5'-Methylthioadenosine; (Rat) (Tsvetnitsky, V. (282) 255)

α,β-Methylene ATP
Endothelin; Phosphoramidon; Suramin; Sympathetic co-transmission; Vas deferens, rat (Lau, W.A.K. (272) 31)

β,γ-Methylene-L-ATP
Cannabinoid; Opioid; Noradrenaline; Vas deferens, mouse; Tolerance (Pertwee, R.G. (272) 67)

Methylene blue
Allicin; Pulmonary vascular bed, rat; Pulmonary vascular bed, cat; Vasodilator response; N^{ω}-Nitro-L-arginine methyl ester; Hypoxic pulmonary vasoconstriction; Guanylate cyclase (Kaye, A.D. (276) 21)

K^+ channel opener; NIP-121; Cromakalim; Epithelium; Trachea, guinea-pig; Phosphoramidon (Shikada, K.-i. (282) 193)

Nitric oxide (NO) synthase; LY83583; cGMP; NADPH-diaphorase (Luo, D. (290) 247)

2-Methyl-5-hydroxytryptamine
Antidepressant drug; Desipramine; Fluoxetine; Maprotiline; Moclobemide; Trimipramine; 5-HT (5-hydroxytryptamine, serotonin); Reuptake inhibition; Hippocampus; Presynaptic modulation (Mongeau, R. (271) 121)

N-3389; 5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_3$ receptor; $5\text{-}HT_4$ receptor (Hagihara, K. (271) 159)

Methylmercury
Cytotoxicity; Thymocyte; Membrane potential; Ca^{2+} concentration, intracellular (Oyama, Y. (293) 101)

Methylnaltrexone
Morphine; Naloxone; Gut motility; Ileum, guinea-pig; Intestine, human, isolated (Yuan, C.-S. (276) 107)

Methylphenidate
d-threo-Methylphenidate; WIN 35,428; Dopamine; Dopamine transporter; PET (positron emission tomography); (Baboon); (Mouse) (Gatley, S.J. (281) 141)

***d-threo*-Methylphenidate**
Methylphenidate; WIN 35,428; Dopamine; Dopamine transporter; PET (positron emission tomography); (Baboon); (Mouse) (Gatley, S.J. (281) 141)

Methylprednisolone
Vestibular compensation; Steroid; Labyrinthectomy, unilateral (Jerram, A.H. (275) 291)

Methylscopolamine
Muscarinic receptor; Alcuronium; Allosteric interaction; Chemical modification (Jakubík, J. (289) 311)

[^{3}H]*N*-Methylscopolamine
Cholinergic activation; Colonic; Epithelia; Ion transport; Muscarinic receptor (O'Malley, K.E. (275) 83)

Chinese hamster ovary cell; Muscarinic receptor; Pertussis toxin; G proteins; [^{35}S]guanosine 5'-*O*-(3-thiotriphosphate) (Burford, N.T. (289) 343)

Allosterism; Gallamine; Dissociation kinetics (Christopoulos, A. (290) 259)

5'-Methylthioadenosine
Methylation inhibitor; Benzodiazepine binding; *S*-Adenosylhomocysteine; (Rat) (Tsvetnitsky, V. (282) 255)

5-Methyl urapidil
Brain slice; Chloroethylclonidine; Estrogen; WB-4101 (Kow, L.-M. (282) 199)

Methylxanthine
Formalin test; Antinociception; Adenosine; Pain mechanism (Doak, G.J. (281) 311)

Methysergide
Morphine tolerance; Metergoline; Ritanserin; Mianserin; Antinociception (Zarrindast, M.-R. (273) 203)

Histamine; 5-HT (5-hydroxytryptamine, serotonin); Dexfenfluramine; Microdialysis; Hypothalamus (Laitinen, K.S.M. (285) 159)

Mevalonate
Human bronchial myocyte; Simvastatin; Geranylgeraniol; Cell proliferation (Viganò, T. (291) 201)

Mexiletine
Ca^{2+} overload; Ischemia/reperfusion; Lidocaine; Na^{+} overload (Kamiyama, T. (272) 151)

Mg^{2+}
Polyamine; Spermine; NMDA (*N*-methyl-D-aspartate); Hippocampus; Development (Bowe, M.A. (278) 55)

$MGlu_{4a}$ receptor antagonist
Metabotropic glutamate receptor; L-2-amino-4-phosphonobutanoic acid (Johansen, P.A. (290) R1)

Mianserin
Morphine tolerance; Methysergide; Metergoline; Ritanserin; Antinociception (Zarrindast, M.-R. (273) 203)

Microcirculation
Nitric oxide (NO); Aminoguanidine; Nitric oxide (NO) synthase; Blood pressure; Endotoxin (Laszlo, F. (272) 169)

Humanized antibody; GPIIb/IIIa; Thrombosis, photochemically induced; Bleeding time; (Squirrel monkey) (Kaku, S. (279) 115)

Nitric oxide (NO); Endotoxin; N^{G}-Nitro-L-arginine methyl ester; N^{G}-Monomethyl-L-arginine; Multiple organ failure; Sepsis (László, F. (283) 47)

Microdialysis
Dopamine; Catechol-*O*-methyltransferase inhibition; L-DOPA (3,4-dihydroxyphenyl-L-alanine); Tolcapone (Napolitano, A. (273) 215)

Prefrontal cortex; 5-HT_2 receptor; Clozapine; Antipsychotic (Schmidt, C.J. (273) 273)

MDL 73,745; Cholinesterase; Acetylcholine; Norepinephrine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Zhu, X.-d. (276) 93)

α_1-Adrenoceptor; Blood pressure; Dopaminergic neurotransmission; Prazosin (Sommermeyer, H. (276) 267)

5-HT_{1A} receptor antagonist; WAY-100135; NAN-190 (Routledge, C. (276) 281)

Local anesthetic; Dopamine uptake (Woodward, J.J. (277) 7)

Efaroxan; α_2-Adrenoceptor antagonist; Acetylcholine release; Cortex, rat (Tellez, S. (277) 113)

L-α-Aminoadipic acid; Excitotoxicity; Kynurenic acid; Kynurenine; Neurodegeneration (Wu, H.-Q. (281) 55)

Acetylcholine; Choline; 3,4-Diaminopyridine (Buyukuysal, R.L. (281) 179)

Ethanol withdrawal; NMDA receptor; $GABA_A$ receptor; Dizocilpine; Diazepam (Rossetti, Z.L. (283) 177)

Histamine; 5-HT (5-hydroxytryptamine, serotonin); Dexfenfluramine; Methysergide; Hypothalamus (Laitinen, K.S.M. (285) 159)

Aspartate; Atipamezole; Dexmedetomidine; Glutamate; GABA (γ-aminobutyric acid); Hippocampus (Valtonen, P. (285) 239)

Phencyclidine; Dopamine D_1 receptor antagonist; Dopamine D_2 receptor antagonist; Striatum, rat (Yonezawa, Y. (285) 305)

Vinconate; Dopamine release; Muscarinic receptor; Striatum (Iino, T. (286) 99)

(+)-Pentazocine; *N*-Allylnormetazocine; σ Receptor; Dopamine; Striatum (Gudelsky, G.A. (286) 223)

Adrenal; Catecholamine; Glycine; Polymerase chain reaction; Strychnine (Yadid, G. (288) 399)

Toluene; GABA (γ-aminobutyric acid); Globus pallidus; Striatum (Stengård, K. (292) 43)

Microdialysis, in vivo
Amphetamine; Cocaine; Locomotor activity; Opioid receptor antagonist; Dopamine; Striatum; Nucleus accumbens (Schad, C.A. (275) 9)

Fluoxetine; Clomipramine; Imipramine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Extrapyramidal symptom; Antidepressant; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (281) 255)

Histamine; Noradrenaline; Atipamezole; α_2-Adrenoceptor antagonist; Hypothalamus (Laitinen, K.S.M. (285) 255)

5-HT (5-hydroxytryptamine, serotonin) uptake; Fluoxetine; Frontal cortex; Ventral hippocampus; Raphe nuclei (Malagié, I. (286) 213)

R(+)-8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY 100,635 (*n*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*n*-(2-pyridinyl)-cyclohexanecarboxamide trihydrochloride); *d*-Amphetamine; Dopamine; 5-HT_{1A} receptor; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (287) 179)

Microdialysis, in vivo, in freely moving rat
p-Fluoroamphetamine; Drug discrimination; ^{3}H-Monoamine uptake inhibition (Marona-Lewicka, D. (287) 105)

Microinjection
Dopamine; MK-801; Circling; Potentiation; Striatum, rat; 6-Hydroxydopamine (St-Pierre, J.-A. (272) 123)

Microsome
Ethanol; Mitochondria; Lipid order; Membrane protein (Sanchez-Amate, M.C. (292) 215)

Microsphere
Adrenomedullin; Hemodynamics, regional; Spontaneously hypertensive rat (SHR) (He, H. (273) 209)

PAF (platelet activating factor); Hemodynamics; Blood flow, regional; PAF receptor antagonist (King, K.A. (281) 187)

Microvascular injury
5-Lipoxygenase inhibitor; Nitric oxide (NO) (László, F. (277) R1)

Microvasculature
Nitric oxide (NO); Endothelium; Neurogenic inflammation; Substance P; 5-HT (5-hydroxytryptamine, serotonin); ATP (Ralevic, V. (284) 231)

Micturition
Spinal cord; 5-HT_3 receptor; 5-HT (5-hydroxytryptamine, serotonin) (Espey, M.J. (287) 173)

Midazolam
Benzodiazepine type I receptor; [^{3}H]Zolpidem; Tolerance; Receptor down-regulation; Flurazepam (Wu, Y. (278) 125)

Middle cerebral artery thrombosis
Modified tissue-type plasminogen activator; SUN9216; Endothelin receptor antagonist; FR139317 (Umemura, K. (275) 17)

Migraine
5-HT (5-hydroxytryptamine, serotonin); Red wine; Platelet; Headache (Pattichis, K. (292) 173)

Migraine, pig
Arteriovenous anastomose; α-CGRP (calcitonin gene-related peptide); Dihydroergotamine; Heart; Sumatriptan (Van Gelderen, E.M. (284) 51)

Migration
Neutrophil; cGMP; ANF (Atrial natriuretic factor) (Elferink, J.G.R. (288) 335)

Mitochondria
Steroidogenesis; Brain, rat; Benzodiazepine receptor, peripheral (McCauley, L.D. (276) 145)

Ethanol; Microsome; Lipid order; Membrane protein (Sanchez-Amate, M.C. (292) 215)

Heart (rat); Pravastatin; Simvastatin (Satoh, K. (292) 271)

Aging; *N*-Acetylcysteine; Thiol (Miquel, J. (292) 333)

Mitochondrial ATPase
Paracetamol; Hepatotoxicity; Mitochondrial particle, sonic; Arrhenius kinetics (Parmar, D.V. (293) 225)

Mitochondrial Ca^{2+}
Ca^{2+} channel antagonist; Adrenal medulla (Uceda, G. (289) 73)

Mitochondrial complex I
Mitochondrial complex IV; 6-Hydroxydopamine; Neurotoxicity; Monoamine oxidase A; Monoamine oxidase B; Parkinson's disease (Glinka, Y.Y. (292) 329)

Mitochondrial complex IV
Mitochondrial complex I; 6-Hydroxydopamine; Neurotoxicity; Monoamine oxidase A; Monoamine oxidase B; Parkinson's disease (Glinka, Y.Y. (292) 329)

Mitochondrial particle, sonic
Paracetamol; Hepatotoxicity; Mitochondrial ATPase; Arrhenius kinetics (Parmar, D.V. (293) 225)

Mitochondrial toxin
Nitric oxide (NO) synthase; Brain; N^{ω}-Nitro-L-arginine methyl ester metabolism; Methanol (Brouillet, E. (293) 487)

Mitogen
Cytokine; Lipopolysaccharide; Nitric oxide (NO); Prostaglandin (Akarasereenont, P. (273) 121)

Mitogenesis
cAMP formation; Intrinsic activity (Griffon, N. (282) R3)

Mitosis
ATP; ATP receptor; Smooth muscle cell (Erlinge, D. (289) 135)

MK-801
Dopamine; Microinjection; Circling; Potentiation; Striatum, rat; 6-Hydroxydopamine (St-Pierre, J.-A. (272) 123)

Epilepsy; NMDA receptor antagonist; CGP 39551; CGP 37849; Spatial learning (Ylinen, A. (274) 159)

Glutamate; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); Inflammation; Pain; Analgesia (Jackson, D.L. (284) 321)

GYKI 52466; Cystometrogram; Urethral sphincter, external; Bladder reflex (Yoshiyama, M. (287) 73)

(+)-MK-801
Nucleus basalis magnocellularis; Acetylcholine; Neuroprotection; Memantine; Amantadine; Ataxia; Stereotypy; (Rat) (Wenk, G.L. (293) 267)

[^{3}H]MK912
α_2-Adrenoceptor subtype; [^{3}H]RX821002; (Pig) (Wikberg-Matsson, A. (284) 271)

MKC-242 (5-{3-[((2*S*)-1,4-benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole)
5-HT_{1A} receptor; Forced swimming test; Antidepressant activity; (Mouse) (Matsuda, T. (280) 235)

Moclobemide
Antidepressant drug; Desipramine; Fluoxetine; Maprotiline; Trimipramine; 2-Methyl-5-hydroxytryptamine; 5-HT (5-hydroxytryptamine, serotonin); Reuptake inhibition; Hippocampus; Presynaptic modulation (Mongeau, R. (271) 121)

Modafinil
GABA (γ-aminobutyric acid); Release; Epidural cup; 5-HT (5-hydroxytryptamine, serotonin); Cerebral cortex (Tanganelli, S. (273) 63)

Modified tissue-type plasminogen activator
Middle cerebral artery thrombosis; SUN9216; Endothelin receptor antagonist; FR139317 (Umemura, K. (275) 17)

Molecular mechanism
Chemoprotection; Hepatotoxicity; Lobenzarit; Paracetamol (Remirez, D. (293) 301)

Molecular modeling
Dihydropyridine; Phenylalkylamine; Allosteric interaction; Structural determinant (Voigt, W. (291) 255)

Monoamine
Monoamine transporter; Vesicle; Tetrabenazine (Kilbourn, M. (278) 249)

Ethanol; α_2-Adrenoceptor; Atipamezole; Dexmedetomidine; Motor performance; (Mouse) (Idänpään-Heikkilä, J.J. (292) 191)

Monoamine oxidase A
Estrogen receptor; Neural cell; Catecholamine; Estrogen (Ma, Z.-Q. (284) 171)

Mitochondrial complex I; Mitochondrial complex IV; 6-Hydroxydopamine; Neurotoxicity; Monoamine oxidase B; Parkinson's disease (Glinka, Y.Y. (292) 329)

Monoamine oxidase B
Mitochondrial complex I; Mitochondrial complex IV; 6-Hydroxydopamine; Neurotoxicity; Monoamine oxidase A; Parkinson's disease (Glinka, Y.Y. (292) 329)

Monoamine transporter
Monoamine; Vesicle; Tetrabenazine (Kilbourn, M. (278) 249)

[^{3}H]Monoamine uptake inhibition
p-Fluoroamphetamine; Drug discrimination; Microdialysis, in vivo, in freely moving rat (Marona-Lewicka, D. (287) 105)

Monoclonal antibody
Neutralization; Tetrodotoxin (Matsumura, K. (293) 41)

10-Monohydroxy metabolite
Oxcarbazepine; Na^+-dependent action potential; Cultured neuron; Maximal electroshock (Wamil, A.W. (271) 301)

N^G-Monomethyl-L-arginine
Nitric oxide (NO); Endotoxin; Microcirculation; N^G-Nitro-L-arginine methyl ester; Multiple organ failure; Sepsis (László, F. (283) 47)

Mononeuropathic rat
Paw pressure; κ-Opioid receptor agonist (ICI 204448); Peripheral antinociception (Keïta, H. (277) 275)

Mononuclear cell
Bradykinin; Bradykinin analog; Bradykinin receptor antagonist; HOE 140; Cytokine; Interleukine (Paegelow, I. (279) 211)

Monosynaptic reflex
TRH (thyrotropin-releasing hormone); Spinal cord; TRH analog; (Neonatal rat) (Deshpande, S.B. (271) 439)

Morphine
Etonitazene; Naloxone; Radial maze; Opioid; Memory (Braida, D. (271) 497)

Opioid tolerance; Butorphanol; Protein kinase A; Protein kinase C (Narita, M. (271) 543)

Chronic opioid treatment; Protein kinase C; Phorbol ester binding; Butorphanol (Narita, M. (271) 547)

RB 101 (mixed enkephalin-degrading enzyme inhibitor); CCK_B receptor antagonist; Formalin test; Naloxone; Naltrindole; (Mouse) (Noble, F. (273) 145)

7-OH-DPAT (7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Place preference; Conditioning; Dopamine; Dopamine D_3 receptor; (Rat) (De Fonseca, F.R. (274) 47)

Opioid dependence; Paroxetine; Fluvoxamine; Place conditioning; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, specific (Rafieian-Kopaei, M. (275) 185)

Ambulation, mouse; Sensitization; μ-Opioid receptor; Dopamine receptor (Kuribara, H. (275) 251)

Lipopolysaccharide; Phagocytosis; Invertebrate immunocyte (Ottaviani, E. (276) 35)

Neurotransmission; Opiate; Dynorphin-A; Dermorphine; Motor nerve (Lavidis, N.A. (276) 71)

Methylnaltrexone; Naloxone; Gut motility; Ileum, guinea-pig; Intestine, human, isolated (Yuan, C.-S. (276) 107)

β-Endorphin; Ontogenesis; Antinociception (Tseng, L.F. (277) 71)

Opioid receptor; Aorta, rat; Contractile force (Parra, L. (277) 99)

Antinociception; Tolerance; Adenosine receptor; Cyclohexyladenosine; (Rat) (Tao, P.-L. (278) 233)

Opioid dependence; Central nervous system; Ca^{2+} channel; Diltiazem; Protein kinase C; Butorphanol (Tokuyama, S. (279) 93)

Ischemia; κ-Opioid receptor; 2-Deoxyglucose; Hippocampal slice; Tolerance (Shibata, S. (279) 197)

Diazepam; Conditioned place preference; (Mouse) (Suzuki, T. (280) 327)

Acetylcholine release; Striatum; Nucleus accumbens; Opioid receptor; Sensitization (Tjon, G.H.K. (283) 169)

Opioid; Physical dependence; Protein kinase; Butorphanol; H-7; H-8 (Tokuyama, S. (284) 101)

β-Carotene; Analgesia (Penn, N.W. (284) 191)

Drug discrimination; μ_1-Opioid receptor (Suzuki, T. (284) 195)

Antisense oligodeoxynucleotide; μ-Opioid receptor; δ-Opioid receptor; Growth hormone; Prolactin (Idänpään-Heikkilä, J.J. (284) 227)

Tolerance; Thyrotropin; Prolactin; Growth hormone; Locomotor activity; Rectal temperature (Rauhala, P. (285) 69)

Nitric oxide (NO); Nitric oxide (NO) synthase; Brain (Leza, J.-C. (285) 95)

Acetylcholine; Muscarinic receptor; Striatum (Schoffelmeer, A.N.M. (286) 311)

Adenosine; Hypotension; Adenosine receptor (White, P.J. (286) 315)

Clocinnamox; Opioid receptor antagonist; DAMGO ([D-Ala^2,MePhe^4, Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U69,593; Opioid receptor alkylation; Opioid receptor binding; mRNA; Solution hybridization; Analgesia; (Irreversible antagonist) (Chan, K. (287) 135)

K_{ATP} channel opener; Pinacidil; Cromakalim; Intestinal transit; Diarrhea (Poggioli, R. (287) 207)

5-HT_3 receptor; Dopamine; Granisetron; Reward (Rompré, P.-P. (287) 263)

Dihydroetorphine; Opioid receptor, cloned; Binding characteristic; cAMP (Katsumata, S. (291) 367)

Morphine 6-glucuronide
Opiate receptor; Macrophage (Makman, M.H. (273) R5)

Morphine tolerance
NMDA receptor/glycine site antagonist; Tail flick test; (CD-1 mouse) (Lutfy, K. (273) 187)

Methysergide; Metergoline; Ritanserin; Mianserin; Antinociception (Zarrindast, M.-R. (273) 203)

Morphine withdrawal
Interleukin-1; Interleukin-1 receptor antagonist; α-MSH (α-melanocyte-stimulating hormone); α-Helical CRF-(9–41); CRF (corticotropin-releasing factor) (Katsumata, S. (278) 143)

Motilide
Motilin; Motilin receptor antagonist; Receptor binding; Smooth muscle contraction; Erythromycin (Depoortere, I. (286) 241)

Motilin
Motilin receptor antagonist; Receptor binding; Smooth muscle contraction; Erythromycin; Motilide (Depoortere, I. (286) 241)

Motilin receptor antagonist
Motilin; Receptor binding; Smooth muscle contraction; Erythromycin; Motilide (Depoortere, I. (286) 241)

Motility assay, in vitro
Ca^{2+} sensitizer; Regulatory protein; Pimobendan (Sata, M. (290) 55)

Motoneuron
Flexor reflex; Inositol trisphosphate; Neuropeptide Y; Nociception; Spinal cord (Xu, X.-J. (272) 219)

Neurotoxicity; Excitatory amino acid; Glutamate; Glutamate receptor subtype; Cultured neuron (Estevez, A.G. (280) 47)

Motor activity
NMDA (*N*-methyl-D-aspartate); Theophylline; Reserpine; (Mouse) (Giménez-Llort, L. (275) 171)

Antidepressant; Dopamine receptor; Quinpirole; SKF 38393 (Allison, K. (277) 139)

Motor behavior
Substance P; Nitric oxide (NO); Food intake (Mancuso, F. (271) 329)

Nitric oxide (NO); Dopamine; Reserpine; (Mouse) (Starr, M.S. (272) 211)

Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propylaminotetralin); SKF 38393; Reserpine; (Mouse) (Starr, M.S. (277) 151)

Reserpine; Dextromethorphan; Dopamine D_1 receptor; Dopamine D_2 receptor; L-DOPA (L-3,4-dihydroxyphenylalanine); (Mouse) (Kaur, S. (280) 159)

Motor cortex
NS 1619; BK_{Ca} channel; Niflumic acid (Lee, K. (280) 215)

$GABA_B$ receptor antagonist; CGP 35348; Pyramidal tract neuron; Transcallosal response, cat (Chowdhury, S.A. (285) 99)

Motor endplate
ω-Agatoxin-IVA; Ca^{2+} channel, P-type; Acetylcholine release (Wessler, I. (278) 83)

Motor-impairing effect
γ-Hydroxybutyric acid (GHBA); Ethanol; Cross-tolerance; (Rat) (Colombo, G. (273) 235)

Motor nerve
Neurotransmission; Opiate; Dynorphin-A; Morphine; Dermorphine (Lavidis, N.A. (276) 71)

Motor performance
Ethanol; α_2-Adrenoceptor; Atipamezole; Dexmedetomidine; Monoamine; (Mouse) (Idänpään-Heikkilä, J.J. (292) 191)

Motor recovery
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); [^{3}H]Mazindol binding; Autoradiography; Basal ganglion; (Marmoset) (Gnanalingham, K.K. (277) 235)

Motor suppression
Conditioned fear stress; Conditioned suppression; Dopamine D_1 receptor; Dopamine D_2 receptor (Kamei, H. (273) 229)

Motor system
Basal ganglia; Cannabinoid; Substantia nigra; Cannabinoid receptor; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole (Miller, A.S. (279) 179)

Mouse
Alternation performance, spontaneous; Dynorphin A-(1–13); U-50,488H; κ-Opioid receptor (Ukai, M. (281) 173)

Moxonidine
α_2-Adrenoceptor; Imidazoline receptor; Sympathoinhibition; Presynaptic inhibition; UK 14304 (Urban, R. (282) 19)

α_2-Adrenoceptor; Imidazoline receptor; Presynaptic inhibition; Rilmenidine; UK 14304 (Urban, R. (282) 29)

Islets of Langerhans; Endocrine pancreas; Imidazoline receptor; Imidazoline I_1 site; Efaroxan; Cimetidine; Diazoxide; Insulin secretion (Tsoli, E. (284) 199)

MPC-1304
Ca^{2+} channel antagonist receptor; Receptor occupation; Spontaneously hypertensive rat (SHR) (Nozawa, Y. (287) 191)

MPP^+ (1-methyl-4-phenylpyridinium)
Dopamine release; Rotenone; Striatum; Substantia nigra; (Rat) (Santiago, M. (280) 251)

Striatum; Cortex; Rotenone; Dopaminergic system (Bougria, M. (291) 407)

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
[^{3}H]Mazindol binding; Autoradiography; Basal ganglion; Motor recovery; (Marmoset) (Gnanalingham, K.K. (277) 235)

Riluzole; Neuroprotection; Bradykinesia; Rigidity; Dopamine release; Parkinson's disease; (Rhesus monkey) (Benazzouz, A. (284) 299)

N-oxygenation; FMO (recombinant rat liver flavin-containing monooxygenase); FMO1A1 (Chiba, K. (293) 97)

MSH (melanocyte stimulating hormone) peptide selectivity
Melanocortin receptor subtype; [^{125}I][Nle^4, D-Phe^7]α-MSH ligand binding; Phosphoramidon (Schiöth, H.B. (288) 311)

α-MSH (α-melanocyte-stimulating hormone)
Interleukin-1; Interleukin-1 receptor antagonist; α-Helical CRF-(9–41); CRF (corticotropin-releasing factor); Morphine withdrawal (Katsumata, S. (278) 143)

[^{125}I][Nle^4, D-Phe^7]α-MSH ligand binding
Melanocortin receptor subtype; MSH (melanocyte stimulating hormone) peptide selectivity; Phosphoramidon (Schiöth, H.B. (288) 311)

Mucociliary clearance
Cilia; Formoterol; Terbutaline; Trachea; Maxillary sinus (Lindberg, S. (285) 275)

Mucus secretion
Trimellitic anhydride; Bronchoconstriction; Asthma; Occupational asthma (Hayes, J.P. (292) 127)

Multidrug resistance
Dexniguldipine-HCl; P-glycoprotein; Allosteric interaction (Malkhandi, J. (288) 105)

Multiple organ failure
Nitric oxide (NO); Endotoxin; Microcirculation; N^G-Nitro-L-arginine methyl ester; N^G-Monomethyl-L-arginine; Sepsis (László, F. (283) 47)

Muscarinic acetylcholine receptor
α_1-Adrenoceptor; Cardiac action potential; Positive inotropic effect; Protein kinase C; Arachidonic acid metabolism (Arreola, J. (271) 309)

Dopamine D_2 receptor; $GABA_B$ receptor; GTPase; Receptor-G protein coupling; Striatum (Odagaki, Y. (291) 245)

Chinese hamster ovary (CHO) cell; Nitric oxide (NO) (Wang, S.Z. (291) R1)

Muscarinic receptor
Allosteric modulation; Alcuronium; Heart (Maaß, A. (272) 103)

Cholinergic activation; Colonic; Epithelia; Ion transport; [^{3}H]*N*-Methylscopolamine (O'Malley, K.E. (275) 83)

Chromaffin cell; Phosphatidylinositol hydrolysis; Ca^{2+}, intracellular; Cation channel, non-selective; (Guinea-pig) (Inoue, M. (276) 123)

β-Adrenoceptor; Receptor alkylation, irreversible (Watson, N. (278) 195)

Firing pattern, modulation; Afterhyperpolarization; Neostriatum; Neuromodulation (Pineda, J.C. (281) 271)

Acetylcholine; Atrium AF-DX 116, human; HHSiD (*p*-fluorohexahydro-siladifenidol hydrochloride); McN-A-343; Myocardial contractility; Pirenzepine; Ventricle (Du, X.Y. (284) 119)

Vinconate; Dopamine release; Striatum; Microdialysis (Iino, T. (286) 99)

Morphine; Acetylcholine; Striatum (Schoffelmeer, A.N.M. (286) 311)

G-protein; Mutation; Arginine (Jones, P.G. (288) 251)

Messenger RNA regulation; Polymerase chain reaction; Primary neuronal culture (Brusa, R. (289) 9)

Alcuronium; Methylscopolamine; Allosteric interaction; Chemical modification (Jakubík, J. (289) 311)

Chinese hamster ovary cell; Pertussis toxin; G proteins; [^{3}H]*N*-methylscopolamine; [^{35}S]guanosine 5′-*O*-(3-thiotriphosphate) (Burford, N.T. (289) 343)

2α-DHET; 2α-(2′,2′-disubstituted-hydroxy-ethoxy)tropane; Allosteric interaction; Heart (Gao, Z.-g. (289) 369)

G-protein; Mutation; Aspartate (Page, K.M. (289) 429)

Binding affinity; Stereoselectivity; CHO (Chinese hamster ovary) cells; Pirenzepine (Barbier, P. (290) 125)

Ca^{2+} mobilization; Agonists dual effect; Receptor theory, modified (Järv, J. (291) 43)

Pancreatic hypertrophy; Bethanechol; Pentagastrin; CCK receptor; CR1505 (Kato, M. (292) 47)

Muscarinic receptor antagonist
Urinary bladder, rabbit; Muscarinic receptor subtype; Contractile response; Acetylcholine release (Tobin, G. (281) 1)

Muscarinic receptor, heart
Alcuronium; Allosteric interaction; Positive allostericity (Hejnová, L. (291) 427)

Muscarinic receptor subtype
Urinary bladder, rabbit; Contractile response; Acetylcholine release; Muscarinic receptor antagonist (Tobin, G. (281) 1)

Zamifenacin (Watson, N. (285) 135)

Dimethindene, enantiomer; Muscarinic M_2 receptor antagonist; Histamine H_1 receptor; Enantioselectivity; Stereoselectivity, inverse; PET (positron emission tomography); Alzheimer's disease (Pfaff, O. (286) 229)

Muscarinic receptor synthesis
Propylbenzilylcholine mustard; HEL 299 cell; Receptor inactivation; Radioligand binding; cAMP accumulation (Haddad, E.-B. (290) 201)

Muscarinic M_1 receptor
Somatostatin; Hippocampus; Pirenzepine; NMDA receptor; CPP ((±)-3(2-carboxypiperazin-4-yl)-propyl-1-phosphonoic acid); Working memory (Ohno, M. (271) 557)

Muscarinic M_2 receptor
β-Adrenoceptor-mediated relaxation; Smooth muscle, human, bronchial (Watson, N. (275) 307)

Muscarinic M_2 receptor antagonist
Dimethindene, enantiomer; Histamine H_1 receptor; Muscarinic receptor subtype; Enantioselectivity; Stereoselectivity, inverse; PET (positron emission tomography); Alzheimer's disease (Pfaff, O. (286) 229)

Muscimol
Gastric acid secretion; $GABA_A$ receptor (Lin, W.-C. (279) 43)

Δ^9-Tetrahydrocannabinol; Substantia nigra, pars reticulata; Circling behavior; Contralateral circling; Drug interaction (Wickens, A.P. (282) 251)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Nucleus tractus solitarii; Lateral tegmental field; Kynurenic acid (Vayssettes-Courchay, C. (285) 299)

Triethyllead; Benzodiazepine receptor; $GABA_A$ receptor; Flunitrazepam; (Rat); (Brain) (Komulainen, H. (293) 167)

[^{3}H]Muscimol
Epalon; Neuroactive steroid; $GABA_A$ receptor; 3α-Hydroxy-5α-pregnan-20-one (Goodnough, D.B. (288) 157)

Muscle-derived nitric oxide (NO)
Nitric oxide (NO); Endotoxin; L-Arginine; Nitrovasodilator; Tolerance (Tsuchida, S. (281) 251)

Muscle fiber
7-Oxo-prostacyclin; Na^+/K^+ pump (Stankovičová, T. (276) 101)

Muscle hyperalgesia, referred
Spasmolytic and/or non-steroidal antiinflammatory treatment; Ureteral calculosis, artificial; (Rat) (Giamberardino, M.A. (278) 97)

Muscle relaxant
Excitatory amino acid; Flupirtine; NMDA (*N*-methyl-D-aspartate); Spasticity; Spinal reflex; (Rat) (Schwarz, M. (276) 247)

Muscle relaxant, centrally acting
NK433; Decerebrate rigidity; Straub tail reaction; γ-Activity (Sakitama, K. (273) 47)

Muscle relaxation
β-Adrenoceptor, atypical; Taenia caecum, guinea-pig; Noradrenaline (Koike, K. (279) 159)

Mustard oil
Neuropathy; Hyperalgesia; Medetomidine; Atipamezole (Mansikka, H. (281) 43)

Mutagenicity
Cytochrome P450-3A4, human; NIH/3T3 cell; Biotransformation; lacZ' shuttle vector (De Groene, E.M. (293) 47)

Activation; Benzylic alcohol; Sulfotransferase; (*Salmonella typhimurium*) (Glatt, H. (293) 173)

Mutation
Muscarinic receptor; G-protein; Arginine (Jones, P.G. (288) 251)

Muscarinic receptor; G-protein; Aspartate (Page, K.M. (289) 429)

Mydriatic activity
$α_2$-Adrenoceptor; Bradycardic activity; Hypotensive activity; Imidazole derivative; Imidazoline derivative; Lipophilicity (Nasal, A. (274) 125)

Myeloperoxidase
Tetramethylbenzidine; Polymorphonucleocyte; Renal ischemia/reperfusion; Adhesion molecule (Laight, D.W. (292) 81)

Myenteric neuron
5-HT_3 receptor; Enteric nervous system; Distal colon; YM060 {(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-enzimidazole monohydrochloride}; (Guinea pig) (Ito, H. (283) 107)

Myenteric plexus preparation, guinea-pig
Cannabinoid; Phenylmethylsulphonyl fluoride; Anandamide; *R*-(+)-Arachidonyl-1'-hydroxy-2'-propylamide; Vas deferens, mouse (Pertwee, R.G. (272) 73)

Myocardial contractility
Acetylcholine; Atrium AF-DX 116, human; HHSiD (*p*-fluorohexahydrosiladifenidol hydrochloride); McN-A-343; Muscarinic receptor; Pirenzepine; Ventricle (Du, X.Y. (284) 119)

Heart, rat; $α_1$-Adrenoceptor; β-Adrenoceptor; Protein phosphorylation (Hartmann, M. (287) 57)

Myocardial ischemia
Thromboxane receptor antagonist; Reperfusion injury; Aspirin (Gomoll, A.W. (271) 471)

K^+ channel, ATP-sensitive; Preconditioning (Grover, G.J. (277) 271)

Reperfusion injury; Adenosine A_1 receptor agonist; Infarct (Lee, Y.-M. (279) 251)

Nitric oxide (NO); Hypertension; Enalapril; Renin-angiotensin system (Moreno, Jr., H. (287) 93)

K_{ATP} channel; Glucose; Glibenclamide (Kamigaki, M. (287) 121)

PAF (platelet-activating factor); Septum, interventricular; HPLC (high-performance liquid chromatography); (Rabbit) (Salinas, P. (293) 65)

Myocardium
K^+ channel; Levcromakalim; Glibenclamide; Hypoxia; (Guinea-pig) (Mellemkjær, S. (277) 51)

Myocardium, rat
$α_1$-Adrenoceptor; β-Adrenoceptor; Localisation; Noradrenaline; Uptake blocker (Dybvik, T. (281) 21)

Myoclonus
Hypoxia; NMDA (*N*-methyl-D-aspartate); Ischemia; HA-966; ACEA-1011; ACEA-1021; Glycine (Matsumoto, R.R. (275) 117)

Myocyte
Free radical; Ca^{2+} current; Cardiac (Gill, J.S. (292) 337)

Myometrial receptor
Oxytocin; Vasopressin; OPC-21268; Vasopressin receptor antagonist (Atke, A. (281) 63)

Myometrium
Oxytocin; Endothelin; Pharmacomechanical coupling; GTP (Izumi, H. (278) 187)

Cromakalim; RP 49356; $^{42}K^+$ efflux; $^{86}Rb^+$ efflux; K^+ channel (Piper, I.T. (283) 1)

G protein; $G_o α$ subunit; Go isoform; Pregnancy; Human uterus (Zumbihl, R. (288) 9)

Pregnancy; K^+ channel; Ritodrine hydrochloride; β-Adrenoceptor agonist (Hamada, Y. (288) 45)

Myometrium, human
Prostanoid DP receptor; Prostaglandin D_2; BW A868C; Smooth muscle (Fernandes, B. (283) 73)

Endothelin; Endothelin ET_A receptor; Endothelin ET_A receptor selective antagonist (Héluy, V. (285) 89)

Isoprostane; Contraction; Prostanoid TP receptor; U46619 (Crankshaw, D. (285) 151)

Myosin light chain
Endothelin-1; Smooth muscle (Kodama, M. (288) 69)

Myosin light chain phosphorylation
Intimal hyperplasia; Hyperreactivity; Protein kinase inhibitor; HA1077; $[Ca^{2+}]_i$ (Seto, M. (276) 27)

$α_1$-Adrenoceptor subtype; Thoracic aorta; Ca^{2+}-sensitization; Botulinum C_3-sensitive GTP-binding protein (Kokubu, N. (290) 19)

N-3389
5-HT (5-hydroxytryptamine, serotonin); 2-Methyl-5-HT; 5-HT_3 receptor; 5-HT_4 receptor (Hagihara, K. (271) 159)

Na^+ channel
Veratridine; β-Adrenoceptor antagonist; Ca^{2+} channel blocker; Dilazep; Ca^{2+}, cytosolic (Hashizume, H. (271) 1)

κ-Opioid receptor; CI977; Excitatory amino acid; Epilepsy (Millan, M.H. (279) 75)

Na^+ channel activation
Triphenyltin-induced contracture; Diaphragm; Ca^{2+}-induced Ca^{2+} release (Liu, S.-H. (292) 95)

Na^+ channel blocker
Ionizing irradiation; Neuroprotective; Glutamate neurotransmission; Neuronal damage; (Rat) (Alaoui, F. (276) 55)

Na^+ channel, fast
Na^+ current, fast; Leiomyosarcoma cell, human; Smooth muscle cell, uterine; Whole-cell voltage clamp; Veratridine effect (Kusaka, M. (271) 387)

Na^+ channel, voltage-gated
Vinpocetine; Phenytoin; Anticonvulsant; Neuroprotection; Cortical neuron; (Rat) (Molnár, P. (273) 303)

Na^+ current
Disopyramide; Chloramine-T; Use-dependent block; Activation gate; (Fast inactivation gate) (Koumi, S.-i. (277) 165)

Ethanol; Heart; Ca^{2+} current; Voltage clamp (Habuchi, Y. (292) 143)

Na^+ current, fast
Na^+ channel, fast; Leiomyosarcoma cell, human; Smooth muscle cell, uterine; Whole-cell voltage clamp; Veratridine effect (Kusaka, M. (271) 387)

Na^+-dependent action potential
Oxcarbazepine; 10-Monohydroxy metabolite; Cultured neuron; Maximal electroshock (Wamil, A.W. (271) 301)

Na^+ excretion
Ebelactone B; Carboxypeptidase Y, urinary; Kininogen-deficient rat; Deoxycorticosterone acetate-salt hypertension (Majima, M. (284) 1)

CGRP (calcitonin gene-related peptide); Renal blood flow; Renal conductance; K^+ excretion; CGRP-(8–37); [Tyr^0]CGRP-(28–37) (Elhawary, A.M. (286) 255)

Na^+ overload
Ca^{2+} overload; Ischemia/reperfusion; Lidocaine; Mexiletine (Kamiyama, T. (272) 151)

Na^+ pump
Dopamine receptor; Phosphoinositide hydrolysis; Pertussis toxin; Vascular tone (Rashed, S.M.K. (284) 289)

Na^+ transport
Cicletanine; Sulfate; Kidney; Cell membrane; Ion transport; Natriuresis; Diuresis; Capillary electrophoresis (Garay, R.P. (274) 175)

Na^+/Ca^{2+} exchange
Amiloride; EIPA (5-(*N*-ethyl-*N*-isopropyl)amiloride); Ouabain; Cardiac contractility; Na^+/H^+ exchange (Cargnelli, G. (292) 103)

Na^+/H^+ exchange
Amiloride; EIPA (5-(*N*-ethyl-*N*-isopropyl)amiloride); Ouabain; Cardiac contractility; Na^+/Ca^{2+} exchange (Cargnelli, G. (292) 103)

Na^+,K^+-ATPase
Bufodienolide; Marinobufagenin; Ouabain; Smooth muscle, vascular; Vasoconstriction (Bagrov, A.Y. (274) 151)

α_1-Adrenoceptor; Inositol triphosphate; Protein kinase C; Second messenger; Renal proximal tubule (Gopalakrishnan, S.M. (288) 139)

Nitrite; Ca^{2+}; Digitalis (Ikeda, U. (288) 379)

α Isoforms of Na^+,K^+-ATPase; DOCA-salt hypertension; Heart; Brain; Skeletal muscle (Sahin-Erdemli, I. (292) 163)

Ethanol; Ouabain; K^+; Synaptosome (Foley, T.D. (292) 287)

Na^+,K^+,Cl^- cotransport
Sino-atrial node, rat; Loop diuretic; Intracardiac ganglion (Harper, A.A. (286) 299)

Nitrendipine; MDCK cell; K^+ flux; Rb^+ flux; Cell membrane; K^+ channel; Red blood cell (López-Burillo, S. (289) 259)

Na^+/K^+ pump
7-Oxo-prostacyclin; Muscle fiber (Stankovičová, T. (276) 101)

NADPH-diaphorase
Nitric oxide (NO) synthase; Methylene blue; LY83583; cGMP (Luo, D. (290) 247)

Nalorphine
DAMGO ([D-Ala^2,$MePhe^4$,$Gly(ol)^5$]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U50,488; Xylazine; Clonidine (Paul, D. (272) 111)

Naloxone
Etonitazene; Morphine; Radial maze; Opioid; Memory (Braida, D. (271) 497)

RB 101 (mixed enkephalin-degrading enzyme inhibitor); Morphine; CCK_B receptor antagonist; Formalin test; Naltrindole; (Mouse) (Noble, F. (273) 145)

Morphine; Methylnaltrexone; Gut motility; Ileum, guinea-pig; Intestine, human, isolated (Yuan, C.-S. (276) 107)

Naloxone benzoylhydrazone
Ileum, guinea pig; κ-Opioid receptor; Receptor binding (Berzetei-Gurske, I.P. (277) 257)

Naloxone binding site
Opioid; DNA synthesis; Uterus, immature; (Rat) (Vértes, Z. (291) 115)

Naltriben
β-Endorphin; Antinociception; δ_2-Opioid receptor; Tail-flick inhibition (Tseng, L.F. (277) 251)

Naltriben diabetes
TAN-67; Antinociception; δ-Opioid receptor; 7-Benzylidenenaltrexone (Kamei, J. (276) 131)

TAN-67; Antinociception; δ-Opioid receptor; 7-Benzylidenenaltrexone (Kamei, J. (280) 347)

Naltrindole
DAMGO ([D-Ala^2,NMePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); ICI174864; 5-HT (5-hydroxytryptamine, serotonin); Spinal cord (Monroe, P.J. (272) 51)

RB 101 (mixed enkephalin-degrading enzyme inhibitor); Morphine; CCK_B receptor antagonist; Formalin test; Naloxone; (Mouse) (Noble, F. (273) 145)

Cocaine; Enkephalin; δ-Opioid receptor; Cocaine-induced sensitization (Shippenberg, T.S. (280) 55)

NAN-190
$5\text{-}HT_{1A}$ receptor antagonist; WAY-100135; Microdialysis (Routledge, C. (276) 281)

NANC (non-adrenergic, non-cholinergic)
Gastric fundus; Cyclic nucleotide; Phosphodiesterase (Barbier, A.J. (276) 41)

Feedback inhibition; Nitrergic nerve; Nitric oxide (NO); Gastric fundus; (Rat) (De Man, J.G. (285) 269)

NANC (non-adrenergic, non-cholinergic) contraction
β_2-Adrenoceptor; β_3-Adrenoceptor; Electrical field stimulation; Cholinergic contraction; Bronchus, main, guinea pig (Ten Berge, R.E.J. (275) 199)

NANC (non-adrenergic, non-cholinergic) nerve
Gastric fundus, rat; Hemoglobin; Hydroxocobalamin; Nitric oxide (NO); N^G-Nitro-L-arginine; Nitrosothiol (Jenkinson, K.M. (275) 145)

Proximal duodenum, rat; Nitric oxide (NO); Smooth muscle relaxation; Apamin; K^+ channel; cGMP (Martins, S.L.R. (284) 265)

Napping
Polysomnographic recording; Melatonin (Nave, R. (275) 213)

Naproxen
Prostaglandin G/H synthase (cyclooxygenase); Whole blood, human; Etodolac; Diclofenac; Tenidap (Glaser, K. (281) 107)

Nasal inflammation
Anti-oxidant; Decongestive nose drops; Hydroxyl radical scavenging; Lipid peroxidation; Reactive oxygen species (Westerveld, G.-J. (291) 27)

Natriuresis
Cicletanine; Sulfate; Kidney; Cell membrane; Ion transport; Diuresis; Na^+ transport; Capillary electrophoresis (Garay, R.P. (274) 175)

Natriuretic peptide, type A
Urodilatin; Bronchoprotection; Acetylcholine; Lung function, rat (Flüge, T. (271) 395)

Navelbine
Vinca alkaloid; Bis-indol; Vinblastine; Vincristine; Calmodulin antagonism; Tubulin; Anti-mitotic drug (Molnár, A. (291) 73)

NBQX (6-nitro-7-sulfamoylbenzo(*f*)quinoxaline-2,3-(1*H*,4*H*dione)
LY326325; AMPA receptor antagonist; Anxiety; Plus maze; Locomotor activity; (Mouse) (Karcz-Kubicha, M. (279) 171)

Nedocromil sodium
5-HT (5-hydroxytryptamine, serotonin); Actinomycin-D; Dexamethasone; Mast cell; Paw edema, rat (Raud, J. (282) 207)

Nefopam
Flurbiprofen; Nitric oxide (NO); Arterial relaxation; Platelet aggregation; Antinociception (Pallapies, D. (271) 335)

Nemonapride
Antipsychotic drug; Dopamine D_2 receptor; Dopamine D_4 receptor; Raclopride (Seeman, P. (291) 59)

Neocortex, rat
$GABA_B$ receptor; (*RS*)-(±)-Baclofen; (*S*)-2-Hydroxysaclofen; (*R*)-2-Hydroxysaclofen; Ileum, guinea pig; Hippocampus, rat (Kerr, D.I.B. (287) 185)

Neocortical high-voltage spindle, rat
$5\text{-}HT_1$ receptor; $5\text{-}HT_2$ receptor; Thalamocortical oscillation (Jäkälä, P. (282) 39)

Neocortical slice, rat
$GABA_B$ receptor; Baclofen; *N*-Ethylmaleimide; Aluminum fluoride; G-protein (Ong, J. (287) 197)

Neointimal thickening
Adenosine A_2 receptor agonist; YT-146; (Rat) (Takiguchi, Y. (281) 205)

Neophobia
TRH (thyrotropin-releasing hormone); Sustained release formulation; Senescence-accelerated mouse (SAM); Learning and memory; Anxiety (Miyamoto, M. (271) 357)

Neostigmine
Blood pressure control; Sinoaortic denervation; 6-Hydroxydopamine; Prazosin; Yohimbine (Taira, C.A. (271) 9)

Neostriatum
Muscarinic receptor; Firing pattern, modulation; Afterhyperpolarization; Neuromodulation (Pineda, J.C. (281) 271)

Nerve conduction
Polyol pathway; Galactosemia; Ischemic resistance; Capillary density; Vasodilator treatment (Dines, K.C. (281) 303)

Nerve growth factor
Neuropeptide Y; Tyrosine hydroxylase; PC12 cell; Dexamethasone; Pertussis toxin (McCullough, L.A. (287) 271)

Neural cell
Monoamine oxidase A; Estrogen receptor; Catecholamine; Estrogen (Ma, Z.-Q. (284) 171)

Neural circuit
Hyperphagia, experimentally induced; Anorectic drug; 2-Deoxy-D-glucose; Insulin; Sodium mercaptoacetate (Garosi, V.L. (276) 285)

Neural plasticity
Long-term potentiation; Hippocampus; Dentate gyrus; Metabotropic glutamate receptor; NMDA (*N*-methyl-D-aspartate) (Bordi, F. (273) 291)

Neuraminidase
Mast cell, cutaneous; Neuropeptide Y; Mastoparan; G-protein; Benzalkonium chloride; Pertussis toxin (Emadi-Khiav, B. (272) 97)

Neuroactive steroid
Epalon; $GABA_A$ receptor; [^{3}H]Muscimol; 3α-Hydroxy-5α-pregnan-20-one (Goodnough, D.B. (288) 157)

$GABA_A$ receptor, recombinant; Patch clamp; (Ligand binding modulation) (Hauser, C.A.E. (289) 249)

Neurobehavioral effect
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Reproduction effect; Endocrine effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Experimental animal; Human infant; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

Neurodegeneration
MDMA (3,4-methylenedioxymethamphetamine); Ecstasy; PBN (α-phenyl-*N*-tert-butyl nitrone); Neuroprotection; Free radical (Colado, M.I. (280) 343)

L-α-Aminoadipic acid; Excitotoxicity; Kynurenic acid; Kynurenine; Microdialysis (Wu, H.-Q. (281) 55)

Neurogenic immunomodulation
Ultraviolet irradiation; Neuropeptide release; Langerhans cell; Contact hypersensitivity (Gillardon, F. (293) 395)

Neurogenic inflammation
Acetylshikonin; Hind-paw edema; Cutaneous anaphylaxis, passive; Vascular permeability; Compound 48/80; [Thi^{5,8},D-Phe^{7}]Bradykinin; [D-Pro^{2},D-Trp^{7,9}]Substance P (Wang, J.-P. (272) 87)

Abruquinone A; Paw edema; Passive cutaneous anaphylaxis; Vascular permeability; Compound 48/80; Mast cell degranulation (Wang, J.-P. (273) 73)

Substance P; Histamine H_3 receptor (Ohkubo, T. (273) 83)

Sensory nerve; Capsaicin; (Prejunctional); (Postjunctional) (Parlani, M. (278) 117)

Histamine; Paw edema; CGRP (calcitonin gene-related peptide) (Amann, R. (279) 227)

Lipocortin 1; Edema; Topical glucocorticoid (Ahluwalia, A. (283) 193)

Trigeminal ganglion; Sensory nerve; μ-Opioid receptor agonist; 5-HT_{1D} receptor agonist; Histamine H_3 receptor agonist (Escott, K.J. (284) 69)

Nitric oxide (NO); Endothelium; Microvasculature; Substance P; 5-HT (5-hydroxytryptamine, serotonin); ATP (Ralevic, V. (284) 231)

UV-B irradiation; Cutaneous vasodilatation; Laser Doppler; CGRP (calcitonin gene-related peptide); Substance P; Nitric oxide (NO) (Benrath, J. (293) 87)

Neurogenic inflammation, guinea pig
CRF (corticotropin-releasing factor); CP 99,994; Plasma extravasation; Antigen challenge; Substance P (Yoshihara, S. (280) 113)

Neuroglycopenia
Insulin secretion; Glucagon secretion; 2-Deoxy-D-glucose; Nitric oxide (NO); Nitric oxide synthase; N^G-Nitro-L-arginine methyl ester; N^G-Nitro-L-arginine; (Mouse) (Ahrén, B. (280) 27)

Neuroimmunology
Interleukin-1; Nitric oxide (NO); CRF (corticotropin-releasing factor; N^G-Nitro-L-arginine; Hemoglobin; Indomethacin; Prostaglandin (Sandi, C. (274) 17)

Neuroimmunomodulation
Cyclosporine; Stress; Sympathetic nervous system; Parasympathetic nervous system; Submaxillary lymph node; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (285) 143)

Cyclosporin; Substance P (tachykinin NK_1) receptor antagonist (Gitter, B.D. (289) 439)

Neurokinin
Nociception; Analgesic; Substance P; Spinal cord (Smith, G. (271) 481)

Dopamine; Electrophysiology; Senktide; Substance P; Tachykinin; Ventral tegmental area (Seabrook, G.R. (273) 113)

Neurokinin A
Substance P; Tachykinin receptor; Trachea, rat; Carbachol; 5-HT (5-hydroxytryptamine, serotonin) (Joos, G.F. (271) 47)

Tachykinin receptor; Tachykinin NK_2 receptor; GR159897 (Beresford, I.J.M. (272) 241)

Bronchospasm; (±)-CP96,345; MEN10,627; PAF (platelet-activating factor); Substance P; Tachykinin (Perretti, F. (273) 129)

Tachykinin receptor antagonist; GR82334; GR71251; L-659,877; Substance P (Guo, J.-Z. (281) 49)

Neuroleptic-like action
Desenkephalin-γ-endorphin; Endorphin receptor, γ-type; Apomorphine; Nucleus accumbens; Antibody; Anti-idiotype antibody; Behavioral effect (Van Ree, J.M. (279) 187)

Neuroleptic
Dopamine receptor; mRNA; Dopamine D_4 receptor; Antipsychotic drug; Haloperidol (Schoots, O. (289) 67)

Neuromedin B
Suprachiasmatic nucleus; Entrainment; Bombesin; Gastrin-releasing peptide; Ionophoresis; Neurophysiology; (Hamster) (Piggins, H.D. (271) 413)

Gastrin-releasing peptide; Bombesin (Ladenheim, E.E. (271) R7)

Neuromodulation
Muscarinic receptor; Firing pattern, modulation; Afterhyperpolarization; Neostriatum (Pineda, J.C. (281) 271)

Neuromuscular transmission
β-Eudesmol; Organophosphate intoxication; Anticholinesterase agent; Obidoxime; Diisopropylfluorophosphate (Chiou, L.C. (292) 151)

Neuron
Catecholamine; Dopamine; Dopamine receptor, agonist, antagonist; Protein kinase inhibitor; Ouabain; Ionic mechanism; Voltage clamp; (Snail) (Emaduddin, M. (283) 113)

Flupirtine; Triaminopyridine; NMDA (*N*-methyl-D-aspartate); NMDA receptor; Cell death; HIV-1; gp120 (Perovic, S. (288) 27)

Neuronal damage
Ionizing irradiation; Neuroprotective; Glutamate neurotransmission; Na^+ channel blocker; (Rat) (Alaoui, F. (276) 55)

Neuronal NO synthase
Pentamidine; AZT (3′-azido-2′,3′-dideoxythymidine); Nitric oxide (NO); Calmodulin antagonist (Kitamura, Y. (289) 299)

Neuro-neuronal transmission
5-HT (5-hydroxytryptamine, serotonin); 5-HT_3 receptor antagonism; Descending inhibition (Messori, E. (286) 205)

Neuropathy
Hyperalgesia; Medetomidine; Atipamezole; Mustard oil (Mansikka, H. (281) 43)

Neuropeptide
Histamine H_1 receptor antagonist, blocking effect; Achatin-I; (Snail) (Santos, D.E. (272) 231)

Histamine H_3 receptor; Lung, rabbit; C-fiber; Acetylcholine; Edema (Delaunois, A. (277) 243)

Neuropeptide FF release
Anti-opioid; Spinal cord slice; NMDA (*N*-methyl-D-aspartate); Opioid tolerance (Devillers, J.-P. (271) 185)

Neuropeptide release
Ultraviolet irradiation; Neurogenic immunomodulation; Langerhans cell; Contact hypersensitivity (Gillardon, F. (293) 395)

Neuropeptide Y
Neuropeptide Y Y_1 receptor antagonist; Blood pressure; Ca^{2+}, intracellular; Spontaneously hypertensive rat (SHR) (Tseng, A. (271) 265)

Neuropeptide Y Y_1 receptor antagonist; BIBP3226 (Rudolf, K. (271) R11)

Angiotensin II; Vasoconstriction; Second messenger; Femoral artery (Cressier, F. (272) 57)

Mast cell, cutaneous; Mastoparan; G-protein; Benzalkonium chloride; Pertussis toxin; Neuraminidase (Emadi-Khiav, B. (272) 97)

Flexor reflex; Inositol trisphosphate; Motoneuron; Nociception; Spinal cord (Xu, X.-J. (272) 219)

Metformin; Zucker rat; Genetic obesity; Feeding behavior; Insulin (Rouru, J. (273) 99)

Hyperphagia; *d*-Fenfluramine; (±)-Cyanopindolol; Paraventricular nucleus of the hypothalamus; 5-HT receptor (Grignaschi, G. (274) 221)

Mammillary complex; Memory; Retention; Acetylcholine; Dopamine; Norepinephrine; NMDA (*N*-methyl-D-asparate); Nicotine; GABA (γ-aminobutyric acid); (Mouse) (Flood, J.F. (275) 223)

SK-N-MC cell; Radioligand binding; BIBP3226 (Entzeroth, M. (278) 239)

Neuropeptide Y_1, Y_2 and Y_3 receptor bioassay; Neuropeptide Y Y_1 receptor antagonist, non-peptide (Jacques, D. (278) R3)

Tyrosine hydroxylase; PC12 cell; Nerve growth factor; Dexamethasone; Pertussis toxin (McCullough, L.A. (287) 271)

Adenylylcyclase; β-Adrenoceptor (Rocha-Singh, K.J. (288) 349)

U46619 (9,11-dideoxy-11α,9α-epoxymethano prostaglandin $F_{2\alpha}$); Basilar artery; Ca^{2+} concentration; Cytosolic; Ca^{2+} influx; Ca^{2+} sensitivity (Tanaka, Y. (289) 59)

Mast cell; Circular dichroism spectrum; Heterotrimeric G protein; Benzalkonium chloride; Pertussis toxin; (Rat); (Human) (Mousli, M. (289) 125)

Mast cell; Histamine liberation; Amphipathic α-helix; Magainin; Substance P; Liposome (Cross, L.J.M. (291) 291)

Neuropeptide Y receptor
Nucleus tractus solitarii; α_2-Adrenoceptor; Receptor autoradiography; Cardiovascular (Yang, S.-N. (271) 201)

Neuropeptide Y Y_1 receptor
Acetylcholine release; Noradrenaline release; Neuropeptide Y Y_2 receptor (Sawa, T. (276) 223)

Neuropeptide Y Y_1 receptor antagonist
Neuropeptide Y; Blood pressure; Ca^{2+}, intracellular; Spontaneously hypertensive rat (SHR) (Tseng, A. (271) 265)

Neuropeptide Y; BIBP3226 (Rudolf, K. (271) R11)

Neuropeptide Y_1, Y_2 and Y_3 receptor bioassay
Neuropeptide Y; Neuropeptide Y Y_1 receptor antagonist, non-peptide (Jacques, D. (278) R3)

Neuropeptide Y Y_1 receptor antagonist, non-peptide
Neuropeptide Y; Neuropeptide Y_1, Y_2 and Y_3 receptor bioassay (Jacques, D. (278) R3)

Neuropeptide Y Y_2 receptor
Acetylcholine release; Noradrenaline release; Neuropeptide Y Y_1 receptor (Sawa, T. (276) 223)

Neurophysiology
Suprachiasmatic nucleus; Entrainment; Bombesin; Gastrin-releasing peptide; Neuromedin B; Ionophoresis; (Hamster) (Piggins, H.D. (271) 413)

Neuroprotection
Ischemia; Glutathione; Hippocampus; 2-Deoxyglucose uptake; Presynaptic potential (Shibata, S. (273) 191)

Ischemia; Nitric oxide (NO); Hippocampus; Presynaptic potential (Shibata, S. (273) 223)

Vinpocetine; Phenytoin; Na^+ channel, voltage-gated; Anticonvulsant; Cortical neuron; (Rat) (Molnár, P. (273) 303)

MDMA (3,4-methylenedioxymethamphetamine); Ecstasy; Neurodegeneration; PBN (α-phenyl-*N*-tert-butyl nitrone); Free radical (Colado, M.I. (280) 343)

Vitamin B_{12}; Ischemia; Hippocampus; Glutamate; Hypoxia/hypoglycemia (Yamamoto, Y. (281) 335)

Cerebral ischemia; JO 1784 (igmesine hydrochloride); Hippocampus; Nitric oxide (NO) synthase; (Gerbil) (O'Neill, M. (283) 217)

Riluzole; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Bradykinesia; Rigidity; Dopamine release; Parkinson's disease; (Rhesus monkey) (Benazzouz, A. (284) 299)

Glutamate; Excitotoxicity; NMDA receptor; AMPA/Kainate receptor; Ca^{2+} channel, L-type, voltage-sensitive (Prehn, J.H.M. (292) 179)

Nucleus basalis magnocellularis; Acetylcholine; Memantine; (+)-MK-801; Amantadine; Ataxia; Stereotypy; (Rat) (Wenk, G.L. (293) 267)

Neuroprotective
Ionizing irradiation; Glutamate neurotransmission; Na^+ channel blocker; Neuronal damage; (Rat) (Alaoui, F. (276) 55)

Neurotensin
Neurotensin receptor; Gastrointestinal motility; Colon, rat (Mulè, F. (275) 131)

Phencyclidine; NMDA (*N*-methyl-D-aspartate); Dopamine; Striatum; Nucleus accumbens (Hanson, G.R. (278) 167)

Neurotensin receptor
Neurotensin; Gastrointestinal motility; Colon, rat (Mulè, F. (275) 131)

Neurotoxicity
Endothelin; NMDA receptor; Dopamine release; Striatal slice (Kataoka, Y. (273) 285)

Excitatory amino acid; Glutamate; Glutamate receptor subtype; Motoneuron; Cultured neuron (Estevez, A.G. (280) 47)

Fenfluramine; Appetite (McCann, U.D. (283) R5)

Disulfiram; GABA (γ-aminobutyric acid); Glutamate (Mamatha, R.K. (292) 89)

Mitochondrial complex I; Mitochondrial complex IV; 6-Hydroxydopamine; Monoamine oxidase A; Monoamine oxidase B; Parkinson's disease (Glinka, Y.Y. (292) 329)

DDT (1,1,1-trichloro-2,2-bis(*p*-chlorophenyl)-ethane); Pyrethroid; Interaction; Behavior; Acetylcholine receptor (Johansson, U. (293) 159)

p-Chloroamphetamine; Dextromethorphan; σ Receptor; 5-HT (5-hydroxytryptamine, serotonin); Brain (Narita, N. (293) 277)

Salsolinol; Catecholamine homeostasis (Willets, J.M. (293) 319)

Neurotoxin
Dopamine transporter, vesicular; Insecticide; Fungicide; Herbicide; Rotenone; Parkinsonism (Vaccari, A. (292) 309)

Neurotransmission
Opiate; Dynorphin-A; Morphine; Dermorphine; Motor nerve (Lavidis, N.A. (276) 71)

Endothelin; Sarafotoxin; Vas deferens; BQ-123; IRL 1620; BQ-788; Endothelin-converting enzyme; Phosphoramidon; (Mouse) (Maas, J. (276) 113)

Neurotrophic
L-AP4 (L(+)-2-amino-4-phosphonobutyric acid); Metabotropic glutamate receptor; Cerebellar granule cell (Graham, M.E. (288) 115)

Neurotrophin-3
Ethanol tolerance; BDNF (brain-derived neurotrophic factor); Neurotrophin-4/5 (Szabó, G. (287) 35)

Neurotrophin-4/5
Ethanol tolerance; BDNF (brain-derived neurotrophic factor); Neurotrophin-3 (Szabó, G. (287) 35)

Neurotropin
Brain edema; Carrageenan; Calcium; Kallikrein-kinin; Particle-induced X-ray emission (Sprumont, P. (274) 95)

Neutral endopeptidase
Diabetic vasculopathy; Capillary permeability; Streptozotocin (Chakir, M. (285) 11)

Neutralization
Monoclonal antibody; Tetrodotoxin (Matsumura, K. (293) 41)

Neutrophil
Endothelin-1; Inflammation (Lopez-Belmonte, J. (278) R7)

Cytokine; TNF (tumor necrosis factor); Interleukin-1; Elastase (Klemm, P. (281) 69)

Respiratory burst; Calyculin A; Okadaic acid; Protein phosphatase (Djerdjouri, B. (288) 193)

Migration; cGMP; ANF (Atrial natriuretic factor) (Elferink, J.G.R. (288) 335)

Degranulation; Ca^{2+}; cAMP; cGMP; Protein kinase C; Tolfenamic acid (Kankaanranta, H. (291) 17)

Oxygen radical; Chemiluminescence; Corticosteroid; Ozone; Allergen (Stevens, W.H.M. (293) 251)

Neutrophil, human
2-Polyprenyl-1,4-hydroquinone; Marine product; Phospholipase A_2; Anti-inflammatory drug (Gil, B. (285) 281)

Neutrophil, rat
Prostacyclin receptor; Cicaprost; Non-prostanoid prostacyclin mimetic; Colon, rat (Wise, H. (278) 265)

Daphnoretin; Respiratory burst; Staurosporine; Protein kinase C; Ca^{2+}; [^{3}H]Phorbol-12,13-dibutyrate binding (Wang, J.-P. (288) 341)

Niacin
Cyclophosphamide; Taurine; Lung injury antioxidant; Membrane stabilizer (Venkatesan, N. (292) 75)

Nicardipine
Spontaneously epileptic rat (SER); Hippocampus; CA3 neuron; Ca^{2+} spike (Momiyama, T. (280) 119)

Nicorandil
Cromakalim; cGMP; Detrusor muscle, rat; Femoral artery, rat; K^+ channel (Zhou, Q. (273) 153)

Nicotine
Sertraline; 5-HT (5-hydroxytryptamine, serotonin); Self-administration; (Monkey) (Sannerud, C.A. (271) 461)

Mammillary complex; Memory; Retention; Acetylcholine; Dopamine; Norepinephrine; NMDA (*N*-methyl-D-asparate); Neuropeptide Y; GABA (γ-aminobutyric acid); (Mouse) (Flood, J.F. (275) 223)

Adrenalectomy; Corticosteroid; Dopamine; Limbic forebrain; Locomotor activity; Sensitization; (Rat) (Johnson, D.H. (276) 155)

Nornicotine; Anabaseine; Anabasine; *N*-Methylanabasine; Dopamine release; Striatum (Dwoskin, L.P. (276) 195)

Colonic mucosa; Cytokine (Van Dijk, J.P.M. (278) R11)

Conditioned place preference; Genetic selection; Locomotor activity; (Mouse) (Schechter, M.D. (279) 59)

Tetrahydroaminoacridine; Nucleus basalis lesion; *p*-Chlorophenylalanine treatment; Alzheimer's disease (Riekkinen Jr., P. (279) 65)

Stress, cold-restraint; Ethanol; Gastric lesion; Mast cell; (Mini-osmotic pump); (Rat) (Wong, D. (292) 157)

Nicotinic acetylcholine receptor
Brain imaging; Alzheimer's disease (London, E.D. (278) R1)

PC12; Patch-clamp; Physostigmine; Galanthamine (Storch, A. (290) 207)

Nicotinic acetylcholine receptor antagonist
Erysodine; Dihydro-β-erythroidine; Pharmacokinetics (Decker, M.W. (280) 79)

Nicotinic acetylcholine receptor, neuronal type
Anatoxin-a; Chromaffin cell; Nicotinic receptor agonist; Mecamylamine; Noradrenaline release; Adrenaline release (Molloy, L. (289) 447)

Xenopus oocyte; Metal ion, divalent; Voltage clamp; Ion current, potentiation, inhibition (Zwart, R. (291) 399)

α_7 Nicotinic acetylcholine receptor subunit
[^{125}I]α-bungarotoxin; HEK-293 (Human embryonic kidney 293 cell); Ion channel, ligand-gated; Cholinergic pharmacology (Gopalakrishnan, M. (290) 237)

Nicotinic autoreceptor
Adenosine receptor, presynaptic; Adenosine, endogenous; Nicotinic receptor desensitization; [^{3}H]Acetylcholine release; Phrenic motor nerve ending (Correia-de-Sá, P. (271) 349)

Nicotinic receptor
PAMP (proadrenomedullin N-terminal 20 peptide); Catecholamine synthesis; Tyrosine hydroxylase; Adrenal medulla (Niina, H. (286) 95)

Nicotinic receptor agonist
Anatoxin-a; Chromaffin cell; Nicotinic acetylcholine receptor, neuronal type; Mecamylamine; Noradrenaline release; Adrenaline release (Molloy, L. (289) 447)

Nicotinic receptor desensitization
Adenosine receptor, presynaptic; Adenosine, endogenous; Nicotinic autoreceptor; [^{3}H]Acetylcholine release; Phrenic motor nerve ending (Correia-de-Sá, P. (271) 349)

Nifedipine
Ca^{2+} channel; Pregnancy; Vasoconstriction; Aortic ring; Bay K 8644 (Roy, B. (280) 1)

Semotiadil; Diltiazem; Amlodipine; Conduction interval; Refractoriness (Stark, G. (286) 71)

Niflumic acid
NS 1619; BK_{Ca} channel; Motor cortex (Lee, K. (280) 215)

NIH / 3T3 cell
Cytochrome P450-3A4, human; Biotransformation; lacZ′ shuttle vector; Mutagenicity (De Groene, E.M. (293) 47)

NIP-121
K^+ channel opener; Cromakalim; Epithelium; Trachea, guinea-pig; Methylene blue; Phosphoramidon (Shikada, K.-i. (282) 193)

Nipecotic acid
GABA (γ-aminobutyric acid) uptake inhibitor; Tiagabine; Carbamazepine anticonvulsant; Epilepsy (Smith, S.E. (273) 259)

Nipradilol
Nitric oxide (NO); Nitrite; cGMP (Adachi, T. (286) 201)

Nitrate
Nitrite; *N*-nitroso compound; Human diet; Dietary intake; Endogenous synthesis; Metabolism; Toxicokinetics; Animal toxicology; Human effects (Gangolli, S.D. (292) 1)

Nitrendipine
MDCK cell; K^+ flux; Rb^+ flux; Cell membrane; Na^+, K^+, Cl^- cotransport; K^+ channel; Red blood cell (López-Burillo, S. (289) 259)

Nitrergic nerve
Feedback inhibition; Nitric oxide (NO); NANC (non-adrenergic non-cholinergic); Gastric fundus; (Rat) (De Man, J.G. (285) 269)

Nitric oxide (NO)
Coronary artery, rat; Histamine; Artery, small; Histamine receptor (Van de Voorde, J. (271) 17)

Endothelin receptor antagonist; Coronary flow; Endothelin-1; Endothelin ET_A receptor; Endothelin ET_B receptor; Vasoconstriction (Wang, Q.-D. (271) 25)

Carbachol; N^G-Nitro-L-arginine methyl ester; L-Arginine; Diarrhea; Intestinal secretion; Small intestinal transit (Izzo, A.A. (271) 31)

Lipopolysaccharide; Nitric oxide (NO) synthase; Hypotension; L-Canavanine; N^G-Nitro-L-arginine methyl ester (Teale, D.M. (271) 87)

Substance P; Motor behavior; Food intake (Mancuso, F. (271) 329)

Flurbiprofen; Nefopam; Arterial relaxation; Platelet aggregation; Antinociception (Pallapies, D. (271) 335)

Adrenergic nerve; Lipopolysaccharide; Tail artery, rat; Sepsis (Takakura, K. (271) 367)

Lemakalim; Glibenclamide; ATP-sensitive Ca^{2+} channel; Apamin; Charybdotoxin (Franck, H. (271) 379)

7-Nitro indazole; Flurbiprofen; Antinociception; Nitric oxide (NO) synthase; (Mouse) (Gaffen, Z. (271) 445)

Aminoguanidine; Nitric oxide (NO) synthase; Microcirculation; Blood pressure; Endotoxin (Laszlo, F. (272) 169)

Dopamine; Motor behavior; Reserpine; (Mouse) (Starr, M.S. (272) 211)

Meningitis; Blood-cerebrospinal fluid barrier; Aminoguanidine (Boje, K.M.K. (272) 297)

Inflammation; Aminoguanidine; (Rat) (Connor, J.R. (273) 15)

Cytokine; Lipopolysaccharide; Mitogen; Prostaglandin (Akarasereenont, P. (273) 121)

Nitric oxide synthase, inhibition; Portal vein ligation, rat; Portal hypertension (Michielsen, P.P. (273) 167)

Ischemia; Hippocampus; Presynaptic potential; Neuroprotection (Shibata, S. (273) 223)

Vascular permeability; PAF (platelet-activating factor); Indomethacin; (Skin); (Mouse) (Fujii, E. (273) 267)

Lipoprotein; Vasodilation; Endothelium (Galle, J. (273) 311)

Interleukin-1; CRF (corticotropin-releasing factor; Neuroimmunology; N^G-Nitro-L-arginine; Hemoglobin; Indomethacin; Prostaglandin (Sandi, C. (274) 17)

Glutamate; NMDA (*N*-methyl-D-aspartate); Epilepsy; Ischemia (Rundfeldt, C. (274) 73)

Collagenase; Inflammation; Kinin; Serine protease inhibitor; Platelet (Souza Pinto, J.C. (274) 101)

Methamphetamine; Locomotor activity; Sensitization; N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester; NMDA receptor (Ohno, M. (275) 39)

Pancreatic islet; Pancreas transplantation; Nitric oxide (NO) synthase; Blood flow regulation (Svensson, A.M. (275) 99)

FR144420; FK409 (Kita, Y. (275) 125)

Gastric fundus, rat; Hemoglobin; Hydroxocobalamin; N^G-Nitro-L-arginine; NANC (non-adrenergic, non-cholinergic) nerve; Nitrosothiol (Jenkinson, K.M. (275) 145)

Adenosine release; Ventral striatum, rat (Fischer, H. (275) R5)

SIN-1 (3-morpholino-sydnonimine); VIP (vasoactive intestinal polypeptide); Cavernous artery; Smooth muscle, cavernosal; (Human) (Hempelmann, R.G. (276) 277)

BQ-123; Endothelin; Cerebral vasospasm; Subarachnoid hemorrhage (Hirose, H. (277) 77)

Locomotor activity; Startle response; Psychophysiological status; Learning (Sandi, C. (277) 89)

Lipopolysaccharide; Cytochrome *P*-450; Arachidonic acid (Oyekan, A.O. (277) 123)

Hypovolemia; Hemorrhagic shock; *N*-Nitro-L-arginine methyl ester; (Rabbit, conscious) (Ventura, S. (277) 265)

Ketorolac tromethamine; N^G-Nitro-L-arginine methyl ester; Dipyrone (Granados-Soto, V. (277) 281)

5-Lipoxygenase inhibitor; Microvascular injury (László, F. (277) R1)

Spinal cord; Nociception; Glutamate receptor; N^{ω}-Nitro-L-arginine methyl ester; L-N^5-(1-Iminoethyl)ornithine; *S*-Nitroso-*N*-penicillamine (Budai, D. (278) 39)

Gastrin-17; CCK (cholecystokinin); Gastroprotection; Stomach; Capsaicin (Konturek, S.J. (278) 203)

Red nucleus; L-Arginine; Analgesia; cGMP (Kumar, A. (279) 1)

Vasodilator nerve; Mesenteric artery, guinea pig; CGRP (calcitonin gene-related peptide); Capsaicin; Nitro-L-arginine; Zinc protoporphyrin IX (Gyoda, Y. (279) 83)

Insulin secretion; Glucagon secretion; Neuroglycopenia; 2-Deoxy-D-glucose; Nitric oxide synthase; N^G-Nitro-L-arginine methyl ester; N^G-Nitro-L-arginine; (Mouse) (Ahrén, B. (280) 27)

Non-steroidal anti-inflammatory drug; Endotoxic shock, acute; Gastrointestinal; Ulcer; Prostaglandin; Cardiovascular (Wallace, J.L. (280) 63)

K^+ channel blocker; Acetylcholine; Uterine artery; Endothelium (Jovanović, A. (280) 95)

Endothelin-1; Endothelin ET_A receptor; FR139317; Nitro-L-arginine; Hypertension; (Rat) (Fujita, K. (280) 311)

Endotoxin; Capsaicin; Gastric damage; Gastric defense; Stress (Barrachina, M.D. (280) 339)

Muscle-derived nitric oxide (NO); Endotoxin; L-Arginine; Nitrovasodilator; Tolerance (Tsuchida, S. (281) 251)

NSAID (non-steroidal anti-inflammatory drug); Gastric mucosal injury (Barrachina, M.D. (281) R3)

Endothelin-1; IRL 1620; FR 139317; Prostacyclin; Prostaglandin E_2; Endothelin receptor (Grassi-Kassisse, D.M. (282) 57)

5-Aminosalicylic acid; Inflammatory bowel disease (Pallapies, D. (282) 145)

PAF (platelet-activating factor); Cyclo-oxygenase product; Vascular reactivity; L-NMMA (N^G-monomethyl-L-arginine); Indomethacin (Shiga, T. (282) 151)

Angiotensin II; Bradykinin; Vasopressin; Pulmonary artery; Pulmonary vein; Prostaglandin I_2 (Sai, Y. (282) 235)

Endotoxin; Microcirculation; N^G-Nitro-L-arginine methyl ester; N^G-Monomethyl-L-arginine; Multiple organ failure; Sepsis (László, F. (283) 47)

N^G-Nitro-L-arginine methyl ester; 5-HT (5-hydroxytryptamine, serotonin); Anorexia; Gastric emptying; Food intake (Hui, S.-C.G. (283) 141)

Tachykinin; Tachykinin NK_1 receptor; Endothelium; Jugular vein, rabbit (Patacchini, R. (283) 233)

Asthma; Cystic fibrosis; Inflammation; Cytokine (Belvisi, M. (283) 255)

Allergic conjunctivitis; Vascular permeability; N^G-Nitro-L-arginine methyl ester; Aminoguanidine; Histamine; PAF (platelet-activating factor) (Meijer, F. (284) 61)

Endothelium; Microvasculature; Neurogenic inflammation; Substance P; 5-HT (5-hydroxytryptamine, serotonin); ATP (Ralevic, V. (284) 231)

Proximal duodenum, rat; NANC (non-adrenergic, non-cholinergic) nerve; Smooth muscle relaxation; Apamin; K^+ channel; cGMP (Martins, S.L.R. (284) 265)

SPM3672; Nitric oxide (NO) donor; Cardiomyocyte; Heart muscle, contractility (Kojda, G. (284) 315)

BQ-123; Endothelin; Cerebral vasospasm; Subarachnoid hemorrhage (Hirose, H. (284) 335)

Morphine; Nitric oxide (NO) synthase; Brain (Leza, J.-C. (285) 95)

Iloprost; Acute inflammation; Captopril; Hypertension; (2K-1C rat) (Medeiros, M.V. (285) 109)

Ca^{2+}; Ba^{2+}; Sr^{2+}; Coronary artery, porcine; Diltiazem (Ohashi, K. (285) 165)

Feedback inhibition; Nitrergic nerve; NANC (non-adrenergic non-cholinergic); Gastric fundus; (Rat) (De Man, J.G. (285) 269)

Tracheal hyperresponsiveness; Leukotriene; (Guinea pig) (Folkerts, G. (285) R1)

Nipradilol; Nitrite; cGMP (Adachi, T. (286) 201)

Carrageenin edema; Prostaglandin (Sautebin, L. (286) 219)

N^G-Nitro-L-arginine; Pressor response; Sympathetic nervous system; Renin-angiotensin system; (Dog) (Nakahara, T. (287) 49)

Hypertension; Enalapril; Renin-angiotensin system; Myocardial ischemia (Moreno, Jr., H. (287) 93)

Epilepsy; Nitric oxide (NO) synthase; 7-Nitro indazole; Pilocarpine; Seizure (Van Leeuwen, R. (287) 211)

Lipoxin A_4; Cholinergic neurotransmission; Smooth muscle, airway (Tamaoki, J. (287) 233)

Angiotensin II; Angiotensin receptor; Downregulation; Portal hypertension (Cahill, P.A. (288) 219)

Platelet inhibition; cAMP; cGMP; Prostacyclin; Protein phosphorylation (Grünberg, B. (288) 329)

Endothelial cell; Bradykinin; Fura-2; Anesthetic, volatile; Sevoflurane; A23187; D-Arg-[Hyp^3, Thi^{5,8}, D-Phe^7] bradykinin; Des-Arg^9-[Leu^8] bradykinin; Ca^{2+} channel (Az-ma, T. (289) 33)

Nitric oxide synthase; Cloning; Expression; Baculovirus; Endotoxic shock (Moss, D.W. (289) 41)

Alveolar macrophage; Carbon monoxide (CO); Heme oxygenase; Cyclic GMP; Superoxide anion (Fukushima, T. (289) 103)

Nitric oxide synthase; PC12 cell; Ca^{2+} homeostasis; cGMP (Clementi, E. (289) 113)

Pentamidine; AZT (3'-azido-2',3'-dideoxythymidine); Neuronal NO synthase; Calmodulin antagonist (Kitamura, Y. (289) 299)

Endothelial cell; Phosphodiesterase inhibitor; cAMP; cGMP (Kessler, T. (290) 163)

Aortic valve cusp, porcine; Cyclic GMP; Nitric oxide synthase, constitutive; Nitric oxide synthase, inducible; Thrombin (De Meyer, E. (291) 67)

Amidine; Butyramidine; Blood pressure; Shock; Inflammation; Endothelium; Endotoxin; Isothiourea (Southan, G.J. (291) 311)

Ca^{2+}; Airway epithelium; Bradykinin; ATP (Sakai, A. (291) 375)

Tranilast; PDGF (platelet-derived growth factor); Mesangial cell (Hishikawa, K. (291) 435)

Muscarinic acetylcholine receptor; Chinese hamster ovary (CHO) cell (Wang, S.Z. (291) R1)

Gastric mucosa; Lipopolysaccharide; (Stomach) (Brown, J.F. (292) 111)

Hepatocyte; TNF-α (tumor necrosis factor-α); DNA fragmentation; Oxygen tension; (Acute phase response); (Tissue) (Ohno, K. (292) 205)

Paraquat; Superoxide anion; Acetylcholine; A23187 (Hsu, K.-S. (292) 315)

UV-B irradiation; Neurogenic inflammation; Cutaneous vasodilatation; Laser Doppler; CGRP (calcitonin gene-related peptide); Substance P (Benrath, J. (293) 87)

Ca^{2+}; Gastric cell; Damage; Oxidative stress (Tepperman, B.L. (293) 259)

Ozone; Nitric oxide (NO) synthase; mRNA (Haddad, E.-B. (293) 287)

Nitric oxide (NO) donor
Superoxide; Peroxynitrite; Free radical scavenger; Gastric damage (Lamarque, D. (277) 187)

SPM3672; Nitric oxide (NO); Cardiomyocyte; Heart muscle, contractility (Kojda, G. (284) 315)

Nitric oxide (NO) synthase
Lipopolysaccharide; Nitric oxide (NO); Hypotension; L-Canavanine; N^G-Nitro-L-arginine methyl ester (Teale, D.M. (271) 87)

7-Nitro indazole; Flurbiprofen; Antinociception; Nitric oxide (NO); (Mouse) (Gaffen, Z. (271) 445)

Nitric oxide (NO); Aminoguanidine; Microcirculation; Blood pressure; Endotoxin (Laszlo, F. (272) 169)

Pancreatic islet; Pancreas transplantation; Nitric oxide (NO); Blood flow regulation (Svensson, A.M. (275) 99)

Insulin secretion; Glucagon secretion; Neuroglycopenia; 2-Deoxy-D-glucose; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; N^G-Nitro-L-arginine; (Mouse) (Ahrén, B. (280) 27)

Cerebral ischemia; JO 1784 (igmesine hydrochloride); Hippocampus; Neuroprotection; (Gerbil) (O'Neill, M. (283) 217)

Morphine; Nitric oxide (NO); Brain (Leza, J.-C. (285) 95)

Epilepsy; Nitric oxide (NO); 7-Nitro indazole; Pilocarpine; Seizure (Van Leeuwen, R. (287) 211)

Nitric oxide (NO); Cloning; Expression; Baculovirus; Endotoxic shock (Moss, D.W. (289) 41)

Nitric oxide (NO); PC12 cell; Ca^{2+} homeostasis; cGMP (Clementi, E. (289) 113)

Interleukin-1; Nitrite (Ikeda, U. (290) 69)

Methylene blue; LY83583; cGMP; NADPH-diaphorase (Luo, D. (290) 247)

Endotoxin; Chemotherapy; Cytotoxicity; Cancer; Anti-cancer drug (Hattori, Y. (291) 83)

Nitric oxide (NO); Ozone; mRNA (Haddad, E.-B. (293) 287)

Enzyme induction; Lipopolysaccharide; Kupffer cell; Liver, rat; (*Propionibacterium avidum*) (Dhouib, M. (293) 439)

Brain; N^{ω}-Nitro-L-arginine methyl ester metabolism; Methanol; Mitochondrial toxin (Brouillet, E. (293) 487)

Nitric oxide (NO) synthase, constitutive
Aortic valve cusp, porcine; Nitric oxide (NO); Cyclic GMP; Nitric oxide synthase, inducible; Thrombin (De Meyer, E. (291) 67)

Nitric oxide (NO) synthase, inducible
Bacterial lipopolysaccharide; N^G-Hydroxy-L-arginine (Hecker, M. (275) R1)

Aortic valve cusp, porcine; Nitric oxide (NO); Cyclic GMP; Nitric oxide synthase, constitutive; Thrombin (De Meyer, E. (291) 67)

Nitric oxide (NO) synthase, inhibition
Nitric oxide (NO); Portal vein ligation, rat; Portal hypertension (Michielsen, P.P. (273) 167)

Nitric oxide (NO) synthase inhibitor
Phencyclidine; Ataxia; Locomotion; (Mouse) (Noda, Y. (286) 291)

Nitrite
Nipradilol; Nitric oxide (NO); cGMP (Adachi, T. (286) 201)

Na^+,K^+-ATPase; Ca^{2+}; Digitalis (Ikeda, U. (288) 379)

Interleukin-1; Nitric oxide (NO) synthase (Ikeda, U. (290) 69)

Nitrate; *N*-nitroso compound; Human diet; Dietary intake; Endogenous synthesis; Metabolism; Toxicokinetics; Animal toxicology; Human effects (Gangolli, S.D. (292) 1)

Nitro-L-arginine
Vasodilator nerve; Nitric oxide (NO); Mesenteric artery, guinea pig; CGRP (calcitonin gene-related peptide); Capsaicin; Zinc protoporphyrin IX (Gyoda, Y. (279) 83)

Endothelin-1; Endothelin ET_A receptor; Nitric oxide (NO); FR139317; Hypertension; (Rat) (Fujita, K. (280) 311)

N^G-Nitro-L-arginine
Interleukin-1; Nitric oxide (NO); CRF (corticotropin-releasing factor; Neuroimmunology; Hemoglobin; Indomethacin; Prostaglandin (Sandi, C. (274) 17)

Endothelium; EDHF (endothelium-derived hyperpolarizing factor); Acetylcholine; Aorta; (Rat) (Hatake, K. (274) 25)

Methamphetamine; Locomotor activity; Sensitization; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; NMDA receptor (Ohno, M. (275) 39)

Gastric fundus, rat; Hemoglobin; Hydroxocobalamin; Nitric oxide (NO); NANC (non-adrenergic, non-cholinergic) nerve; Nitrosothiol (Jenkinson, K.M. (275) 145)

Insulin secretion; Glucagon secretion; Neuroglycopenia; 2-Deoxy-D-glucose; Nitric oxide (NO); Nitric oxide synthase; N^G-Nitro-L-arginine methyl ester; (Mouse) (Ahrén, B. (280) 27)

Nitric oxide (NO); Pressor response; Sympathetic nervous system; Renin-angiotensin system; (Dog) (Nakahara, T. (287) 49)

***N*-Nitro-L-arginine methyl ester**
Hypovolemia; Hemorrhagic shock; Nitric oxide (NO); (Rabbit, conscious) (Ventura, S. (277) 265)

N^G-Nitro-L-arginine methyl ester
Carbachol; Nitric oxide (NO); L-Arginine; Diarrhea; Intestinal secretion; Small intestinal transit (Izzo, A.A. (271) 31)

Lipopolysaccharide; Nitric oxide (NO); Nitric oxide (NO) synthase; Hypotension; L-Canavanine (Teale, D.M. (271) 87)

Methamphetamine; Locomotor activity; Sensitization; Nitric oxide (NO); N^G-Nitro-L-arginine; NMDA receptor (Ohno, M. (275) 39)

Ketorolac tromethamine; Nitric oxide (NO); Dipyrone (Granados-Soto, V. (277) 281)

Acetylcholine; Aminoguanidine; Lipopolysaccharide; Mesenteric arterial bed; Portal vein ligation; (Portal hypertensive rat) (Heinemann, A. (278) 87)

Insulin secretion; Glucagon secretion; Neuroglycopenia; 2-Deoxy-D-glucose; Nitric oxide (NO); Nitric oxide synthase; N^G-Nitro-L-arginine; (Mouse) (Ahrén, B. (280) 27)

Nitric oxide (NO); Endotoxin; Microcirculation; N^G-Monomethyl-L-arginine; Multiple organ failure; Sepsis (László, F. (283) 47)

Nitric oxide (NO); 5-HT (5-hydroxytryptamine, serotonin); Anorexia; Gastric emptying; Food intake (Hui, S.-C.G. (283) 141)

Nitric oxide (NO); Allergic conjunctivitis; Vascular permeability; Aminoguanidine; Histamine; PAF (platelet-activating factor) (Meijer, F. (284) 61)

Cerebral ischemia; Hippocampus; Lipid peroxidation; (Gerbil) (Caldwell, M. (285) 203)

N^{ω}-Nitro-L-arginine methyl ester
Allicin; Pulmonary vascular bed, rat; Pulmonary vascular bed, cat; Vasodilator response; Methylene blue; Hypoxic pulmonary vasoconstriction; Guanylate cyclase (Kaye, A.D. (276) 21)

Spinal cord; Nociception; Glutamate receptor; Nitric oxide (NO); L-N^5-(1-Iminoethyl)ornithine; *S*-Nitroso-*N*-penicillamine (Budai, D. (278) 39)

N^{ω}-Nitro-L-arginine methyl ester metabolism
Nitric oxide (NO) synthase; Brain; Methanol; Mitochondrial toxin (Brouillet, E. (293) 487)

Nitroglycerin bioactivation
Glutathione-*S*-transferase; Cytochrome *P*-450; Coronary artery; Cultivated smooth muscle cell; cGMP (Braun, M. (276) 239)

7-Nitro indazole
Flurbiprofen; Antinociception; Nitric oxide (NO); Nitric oxide (NO) synthase; (Mouse) (Gaffen, Z. (271) 445)

Epilepsy; Nitric oxide (NO); Nitric oxide (NO) synthase; Pilocarpine; Seizure (Van Leeuwen, R. (287) 211)

***p*-Nitrophenol**
Cytochrome P450; Cytochrome P450 2E1; V79 Chinese hamster cell; Chlorzoxazone; *N*-Nitrosodimethylamine (Schmalix, W.A. (293) 123)

***N*-Nitroso compound**
Nitrate; Nitrite; Human diet; Dietary intake; Endogenous synthesis; Metabolism; Toxicokinetics; Animal toxicology; Human effects (Gangolli, S.D. (292) 1)

***N*-Nitrosodimethylamine**
Cytochrome P450; Cytochrome P450 2E1; V79 Chinese hamster cell; *p*-Nitrophenol; Chlorzoxazone (Schmalix, W.A. (293) 123)

***S*-Nitroso-*N*-penicillamine**
Spinal cord; Nociception; Glutamate receptor; Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester; L-N^5-(1-Iminoethyl)ornithine (Budai, D. (278) 39)

Nitrosothiol
Gastric fundus, rat; Hemoglobin; Hydroxocobalamin; Nitric oxide (NO); N^G-Nitro-L-arginine; NANC (non-adrenergic, non-cholinergic) nerve (Jenkinson, K.M. (275) 145)

Nitrovasodilator
Nitric oxide (NO); Muscle-derived nitric oxide (NO); Endotoxin; L-Arginine; Tolerance (Tsuchida, S. (281) 251)

NK433
Muscle relaxant, centrally acting; Decerebrate rigidity; Straub tail reaction; γ-Activity (Sakitama, K. (273) 47)

NMDA (*N*-methyl-D-asparate)
Anti-opioid; Neuropeptide FF release; Spinal cord slice; Opioid tolerance (Devillers, J.-P. (271) 185)

Retina; Excitatory amino acid receptor antagonist; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid); Thiokynurenic acid; Rose bengal (Lombardi, G. (271) 489)

TRH (thyrotropin-releasing hormone); Dopamine; Striatum; (Rabbit) (Popoli, P. (272) 119)

Dopamine; Accumbens; Prepulse inhibition; Schizophrenia; (Rat) (Reijmers, L.G.J.E. (272) 131)

Long-term potentiation; Hippocampus; Dentate gyrus; Neural plasticity; Metabotropic glutamate receptor (Bordi, F. (273) 291)

Glutamate; Nitric oxide (NO); Epilepsy; Ischemia (Rundfeldt, C. (274) 73)

Myoclonus; Hypoxia; Ischemia; HA-966; ACEA-1011; ACEA-1021; Glycine (Matsumoto, R.R. (275) 117)

Calcitonin; Aversive behavior; β-Adrenoceptor; 5-HT receptor; GABA receptor (Maeda, Y. (275) 163)

Theophylline; Motor activity; Reserpine; (Mouse) (Giménez-Llort, L. (275) 171)

Mammillary complex; Memory; Retention; Acetylcholine; Dopamine; Norepinephrine; Nicotine; Neuropeptide Y; GABA (γ-aminobutyric acid); (Mouse) (Flood, J.F. (275) 223)

Aniracetam; Hippocampus (Pizzi, M. (275) 311)

Excitatory amino acid; Flupirtine; Muscle relaxant; Spasticity; Spinal reflex; (Rat) (Schwarz, M. (276) 247)

Polyamine; Spermine; Hippocampus; Mg^{2+}; Development (Bowe, M.A. (278) 55)

Phencyclidine; Neurotensin; Dopamine; Striatum; Nucleus accumbens (Hanson, G.R. (278) 167)

Glycine; Schizophrenia; Dopamine metabolism; Stereotypy (Kretschmer, B.D. (280) 37)

Kynurenate; Nootropic (Hamelin, S.M. (281) R11)

NMDA receptor; Benzomorphan; Excitotoxicity (Sawyer, D.C. (284) 309)

Dopamine; Substantia nigra; GABA (γ-aminobutyric acid); Pyrrolidinone (Shepard, P.D. (285) 79)

NMDA receptor; mGlu receptor; *t*-ACPD (*trans*-(±)-1-amino-1,3-cyclopentanedicarboxylic acid); L-AP-3 (L-2-amino-3-phosphono-propionate); Periaqueductal gray matter (Leyva, J. (285) 123)

Amantadine; c-*fos*; Dopamine; Striatum (Tomitaka, S.-i. (285) 207)

AMPA ((*RS*)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid); ATPA ((*RS*)-2-amino-3-(3-hydroxy-5-*tert*-butylisoxazol-4-yl)propionic acid); Cue; Convulsion; Glutamate receptor; (Rat); (Mouse) (Arnt, J. (285) 289)

Kindling; Seizure; Epilepsy; Excitatory amino acid; Amygdala (Croucher, M.J. (286) 265)

Flupirtine; Triaminopyridine; NMDA receptor; Neuron; Cell death; HIV-1; gp120 (Perovic, S. (288) 27)

Felbamate; Ca^{2+}; Epilepsy (Taylor, L.A. (289) 229)

NMDA receptor

Chronic CGP 39551; [^{3}H]Noradrenaline release; Quinolinic acid neurotoxicity; Hippocampus; Autoradiography (Mennini, T. (271) 93)

Dynorphin; Glycine receptor; Endorphin (Dumont, M. (271) 241)

Somatostatin; Hippocampus; Muscarinic M_1 receptor; Pirenzepine; CPP ((±)-3(2-carboxypiperazin-4-yl)-propyl-1-phosphonoic acid); Working memory (Ohno, M. (271) 557)

D-Cycloserine; Oxiracetam; Aniracetam; Noradrenaline release; Kynurenic acid (Pittaluga, A. (272) 203)

Non-NMDA receptor; Contralateral turning; Strionigral pathway (Ossowska, K. (273) 89)

Endothelin; Neurotoxicity; Dopamine release; Striatal slice (Kataoka, Y. (273) 285)

Methamphetamine; Locomotor activity; Sensitization; Nitric oxide (NO); N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester (Ohno, M. (275) 39)

CCK (cholecystokinin); Cerebral cortex; Glutamate; Seizure (Bandopadhyay, R. (275) 53)

Excitatory amino acid; Respiratory activity; Ventrolateral nucleus of the tractus solitarius; Apneusis (Berger, I. (277) 195)

CGP 37849; Working memory; Reference memory (Deacon, R.M.J. (280) 239)

Toxicity; Antioxidant; Free radical; Cortical culture (Eshhar, N. (283) 19)

Ethanol withdrawal; $GABA_A$ receptor; Microdialysis; Dizocilpine; Diazepam (Rossetti, Z.L. (283) 177)

Adenosine A_1 receptor; Seizure; Alzheimer's disease; (Mouse) (Von Lubitz, D.K.J.E. (283) 185)

Histogranin; Passive avoidance; Learning; Memory; (Mouse) (Maurice, T. (283) 251)

Anticonvulsant; Anxiolytic; Separation-induced vocalization; Audiogenic seizure; Glycine receptor, strychnine-insensitive; (DBA/2J mouse); (Rat pup) (Kehne, J.H. (284) 109)

NMDA (*N*-methyl-D-aspartate); Benzomorphan; Excitotoxicity (Sawyer, D.C. (284) 309)

mGlu receptor; NMDA (*N*-methyl-D-asparate); *t*-ACPD (*trans*-(±)-1-amino-1,3-cyclopentanedicarboxylic acid); L-AP-3 (L-2-amino-3-phosphono-propionate); Periaqueductal gray matter (Leyva, J. (285) 123)

Histogranin; Passive avoidance; Learning; Memory; (Mouse) (Maurice, T. (287) 219)

Remacemide hydrochloride; FPL 12495AA; Cortical wedge (Hu, R.Q. (287) 251)

Flupirtine; Triaminopyridine; NMDA (*N*-methyl-D-aspartate); Neuron; Cell death; HIV-1; gp120 (Perovic, S. (288) 27)

Photoaffinity; Polyamine (Foucaud, B. (289) 471)

Glycine site antagonist; Allosteric interaction; Glutamate; Glycine (Grimwood, S. (290) 221)

ACPC (1-aminocyclopropanecarboxylic acid); Glycine receptor, strychnine-insensitive (Popik, P. (291) 221)

Glutamate; Excitotoxicity; AMPA/Kainate receptor; Ca^{2+} channel, L-type, voltage-sensitive; Neuroprotection (Prehn, J.H.M. (292) 179)

NMDA receptor antagonist
Amygdala kindling; Strychnine-insensitive glycine site; Anticonvulsant; (DBA/2 mouse) (Chapman, A.G. (274) 83)

Epilepsy; CGP 39551; CGP 37849; MK-801; Spatial learning (Ylinen, A. (274) 159)

AMPA receptor antagonist; Seizure (Czuczwar, S.J. (281) 327)

NMDA receptor/glycine site antagonist
Morphine tolerance; Tail flick test; (CD-1 mouse) (Lutfy, K. (273) 187)

NMDA receptor subtype
Striatum; GABA (γ-aminobutyric acid) release; Acetylcholine release; Spermidine release (Nankai, M. (286) 61)

L-NMMA (N^G-monomethyl-L-arginine)
PAF (platelet-activating factor); Nitric oxide (NO); Cyclo-oxygenase product; Vascular reactivity; Indomethacin (Shiga, T. (282) 151)

Nociception
Analgesic; Neurokinin; Substance P; Spinal cord (Smith, G. (271) 481)

Flexor reflex; Inositol trisphosphate; Motoneuron; Neuropeptide Y; Spinal cord (Xu, X.-J. (272) 219)

c-Fos expression; Indomethacin; Carrageenin, inflammation (Honoré, P. (272) 249)

Spinal cord; Glutamate receptor; Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester; L-N^5-(1-Iminoethyl)ornithine; *S*-Nitroso-*N*-penicillamine (Budai, D. (278) 39)

Nociceptive test
GABA receptor antagonist; Antinociception, i.c.v., i.t.; Benzodiazepine; Opioid (Luger, T.J. (271) 421)

Antinociception; Benzodiazepine; Opioid; (Intracerebroventricular); (Intrathecal) (Luger, T.J. (275) 153)

Nomifensine
Apomorphine; Desipramine; Development; Stereotypy; Zimelidine (Hilakivi, I. (271) 223)

Non-cholinergic slow synaptic potential
Enteric nerve; 5-HT receptor; Gastrointestinal pharmacology (Pan, H. (278) 67)

Non-competitive agonist
Codeine; Sensitization (Storch, A. (290) 207)

Non-competitive inhibition
Vanilloid receptor; Vanilnoid, endogenous; Resiniferatoxin binding; Capsaicin; Proton; Positive cooperativity; Desensitization (Szallasi, A. (289) 181)

Non-insulin-dependent
Benfluorex metabolite; Diabetes mellitus; Membrane fluidity; Hepatocyte, isolated; (Rat) (Orsière, T.G. (291) 237)

Non-NMDA receptor
NMDA receptor; Contralateral turning; Strionigral pathway (Ossowska, K. (273) 89)

Non-peptide
Angiotensin II; CS-866; Angiotensin receptor antagonist; Angiotensin AT_1 receptor, selective (Mizuno, M. (285) 181)

Non-prostanoid prostacyclin mimetic
Prostacyclin receptor; Cicaprost; Neutrophil, rat; Colon, rat (Wise, H. (278) 265)

Non-steroidal anti-inflammatory drug
Nitric oxide (NO); Endotoxic shock, acute; Gastrointestinal; Ulcer; Prostaglandin; Cardiovascular (Wallace, J.L. (280) 63)

Nootropic
NMDA (*N*-methyl-D-aspartate); Kynurenate (Hamelin, S.M. (281) R11)

Noradrenaline
Desamino-8D-arginine vasopressin; Brattleboro rat; Vasopressin; Angiotensin; Hemorrhage (Laycock, J.F. (271) 193)

Cannabinoid; Opioid; β,γ-Methylene-L-ATP; Vas deferens, mouse; Tolerance (Pertwee, R.G. (272) 67)

Vas deferens, human; Phenoxybenzamine; α-Adrenoceptor agonist; α-Adrenoceptor antagonist (Amobi, N. (273) 25)

Adrenaline; Catecholamine overflow; Exercise; β_2-Adrenoceptor, prejunctional; (Freely moving rat) (Coppes, R.P. (274) 33)

β-Adrenoceptor, atypical; Taenia caecum, guinea-pig; Muscle relaxation (Koike, K. (279) 159)

α_1-Adrenoceptor; β-Adrenoceptor; Localisation; Myocardium, rat; Uptake blocker (Dybvik, T. (281) 21)

Adrenoceptor; Umbilical artery, human; Smooth muscle, vascular (Bodelsson, G. (282) 95)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5891; (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-*N*-methyl-3-pyridinecarboxamide; FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester; FG5909 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-hydroxypyridine; Reuptake; Release; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Pettersson, E. (282) 131)

Histamine; Atipamezole; α_2-Adrenoceptor antagonist; Microdialysis, in vivo; Hypothalamus (Laitinen, K.S.M. (285) 255)

Dopamine; Fenoldopam; Renal blood flow; Splanchnic blood flow; Oxygen demand; Oxygen supply; Oxygen extraction ratio (Schiffer, E.R. (286) 49)

Inositol 1,4,5-trisphosphate; 5-HT (5-Hydroxytryptamine, serotonin); Smooth muscle, vascular (Murphy, T.V. (290) 141)

Thrombin; Inositol phosphate; Phospholipase C inhibitor; Pertussis toxin; Atrium, rat (Woodcock, E.A. (291) 213)

ATP release; α_1-Adrenoceptor; Calcification; Arteriosclerosis; Caudal artery, rat (Shinozuka, K. (292) 115)

[^{3}H]Noradrenaline
Spinal cord, rat; Electrical stimulation; Histamine; Histamine H_3 receptor (Celuch, S.M. (287) 127)

Noradrenaline release
α_2-Adrenoceptor; Kidney, SHR (spontaneously hypertensive rat) and WKY (Wistar-Kyoto rat) (Bohmann, C. (271) 283)

D-Cycloserine; Oxiracetam; Aniracetam; NMDA receptor; Kynurenic acid (Pittaluga, A. (272) 203)

Acetylcholine release; Neuropeptide Y Y_1 receptor; Neuropeptide Y Y_2 receptor (Sawa, T. (276) 223)

Acetylcholine release; GABA release; Galantide (Akehira, K. (284) 149)

Anatoxin-a; Chromaffin cell; Nicotinic acetylcholine receptor, neuronal type; Nicotinic receptor agonist; Mecamylamine; Adrenaline release (Molloy, L. (289) 447)

[^{3}H]Noradrenaline release
Chronic CGP 39551; NMDA receptor; Quinolinic acid neurotoxicity; Hippocampus; Autoradiography (Mennini, T. (271) 93)

Noradrenaline release, spontaneous
Aging; Vasoconstrictor; Potentiation (Glenn, T.C. (276) 191)

Nor-binaltorphimine
Dynorphin A-(1–13); Cholinergic neuronal system; CO (carbon monoxide); Delayed amnesia; Learning; κ-Opioid receptor; Passive avoidance (Hiramatsu, M. (282) 185)

Norepinephrine
Mammillary complex; Memory; Retention; Acetylcholine; Dopamine; NMDA (*N*-methyl-D-asparate); Nicotine; Neuropeptide Y; GABA (γ-aminobutyric acid); (Mouse) (Flood, J.F. (275) 223)

MDL 73,745; Microdialysis; Cholinesterase; Acetylcholine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin) (Zhu, X.-d. (276) 93)

Adrenoceptor; Inositol phosphate; Receptor reserve; Spare receptor (Esbenshade, T.A. (289) 305)

Phospholipid metabolism; U50,488; Ethylketocyclazocine; Carbachol; Renal cortex (Mosaddeghi, M. (289) 411)

Nornicotine
Nicotine; Anabaseine; Anabasine; *N*-Methylanabasine; Dopamine release; Striatum (Dwoskin, L.P. (276) 195)

NPC 17761
Bradykinin; Trachea, guinea-pig; Epithelium; Bradykinin B_2 receptor; Relaxation; Ca^{2+}; Ryanodine; Apamin; HOE 140 (Schlemper, V. (282) 177)

NS-49
Oxymetazoline; α_1-Adrenoceptor subtype; Cloned receptor; Radioligand binding study; Cytosolic Ca^{2+} concentration (Obika, K. (291) 327)

NS 1619
BK_{Ca} channel; Niflumic acid; Motor cortex (Lee, K. (280) 215)

NSAID (non-steroidal anti-inflammatory drug)
Ulcer; Inflammation; Cyclooxygenase; Leukotriene (Wallace, J.L. (271) 525)

Gastric mucosal injury; Nitric oxide (NO) (Barrachina, M.D. (281) R3)

N4TG1 cell
δ-Opioid receptor; TIPP (H-Tyr-Tic-Phe-Phe-OH); [Tyr(3′-I)^1]TIPP; Brain, rat; Vas deferens, mouse (Lee, P.H.K. (280) 211)

Nuclear receptor
Glucocorticoid; Transcription (Tanaka, H. (291) 121)

Nucleus accumbens
Dopamine uptake inhibitor; Dopamine receptor agonist; Dopamine, endogenous; Frontal cortex; Striatum (Irifune, M. (272) 79)

Haloperidol; Clozapine; Fos protein; Tolerance; Striatum; Amygdala; (Long-term treatment) (Sebens, J.B. (273) 175)

Turning behavior; Dopaminergic/cholinergic receptor interaction; Ventrolateral striatum; Carbachol; Turning pattern (Saigusa, T. (274) 213)

Amphetamine; Cocaine; Locomotor activity; Microdialysis, in vivo; Opioid receptor antagonist; Dopamine; Striatum (Schad, C.A. (275) 9)

Behavioral sensitization; Dopamine D_1 receptor; Dopamine D_2 receptor; Ventral tegmental area; Drug addiction (Jeziorski, M. (275) 235)

Repetitive jaw movement; YM-14673; TRH (thyrotropin-releasing hormone); Striatum; Dopamine receptor (Miwa, Y. (277) 63)

Phencyclidine; Neurotensin; NMDA (*N*-methyl-D-aspartate); Dopamine; Striatum (Hanson, G.R. (278) 167)

Desenkephalin-γ-endorphin; Endorphin receptor, γ-type; Apomorphine; Neuroleptic-like action; Antibody; Anti-idiotype antibody; Behavioral effect (Van Ree, J.M. (279) 187)

Fluoxetine; Clomipramine; Imipramine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Extrapyramidal symptom; Antidepressant; Microdialysis, in vivo; Striatum; (Rat) (Ichikawa, J. (281) 255)

Dopamine, mesocortical; Locomotor activity; Voltammetry; 6-Hydroxydopamine lesion (Banks, K.E. (282) 157)

Acetylcholine release; Striatum; Morphine; Opioid receptor; Sensitization (Tjon, G.H.K. (283) 169)

Cocaine; Apomorphine; Deoxyglucose; Brain metabolism (Pontieri, F.E. (284) 205)

β-Endorphin-(10–16); Prolyl-leucyl-glycinamide; TRH (thyrotropin-releasing hormone); Melatonin; Antidepressant (Hatta, K. (284) 327)

R(+)-8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY 100,635 (*n*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*n*-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride); *d*-Amphetamine; Dopamine; 5-HT_{1A} receptor; Microdialysis, in vivo; Striatum; (Rat) (Ichikawa, J. (287) 179)

1-(*m*-Chlorophenyl)-biguanide; [^{3}H]GBR-12935; 5-HT_3 receptor; Dopamine transporter; Caudate putamen; (Rat) (Campbell, A.D. (290) 157)

Nucleus accumbens, shell, core
Dopamine D_1 receptor; Dopamine D_2 receptor; SKF 82958; Quinpirole; SCH 23390; (−)-Sulpiride; Jaw movement; (Rat) (Cools, A.R. (286) 41)

Nucleus basalis lesion
Tetrahydroaminoacridine; Nicotine; *p*-Chlorophenylalanine treatment; Alzheimer's disease (Riekkinen Jr., P. (279) 65)

Nucleus basalis magnocellularis
Acetylcholine; Neuroprotection; Memantine; (+)-MK-801; Amantadine; Ataxia; Stereotypy; (Rat) (Wenk, G.L. (293) 267)

Nucleus tractus solitarii
Neuropeptide Y receptor; α_2-Adrenoceptor; Receptor autoradiography; Cardiovascular (Yang, S.-N. (271) 201)

[^{3}H]Sumatriptan; Autoradiography; Trigeminal nucleus caudalis; (Cat) (Mills, A. (280) 175)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); Lateral tegmental field; Muscimol; Kynurenic acid (Vayssettes-Courchay, C. (285) 299)

Obesity
β_3-Adrenoceptor; Adipose tissue; Gallbladder; RNase protection; (Human) (Berkowitz, D.E. (289) 223)

Cytochrome P450; Zucker rat; Enzyme induction (Irizar, A. (293) 385)

Obidoxime
β-Eudesmol; Organophosphate intoxication; Anticholinesterase agent; Diisopropylfluorophosphate; Neuromuscular transmission (Chiou, L.C. (292) 151)

Obsessive-compulsive disorder
Reinforcement schedule; Drinking behavior; 5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor (Roehr, J. (278) 75)

Occupancy principle
Hypocholesterolemic drug; Liver; Intestine; Cholesterol synthesis; Dual isotope blood ratio method; (RICO rat) (Hajri, T. (286) 131)

Occupational asthma
Trimellitic anhydride; Mucus secretion; Bronchoconstriction; Asthma (Hayes, J.P. (292) 127)

2-Octynyladenosine
Adenosine receptor; Endothelium-dependent relaxation; Femoral artery; Femoral vein; YT-146 (Abiru, T. (281) 9)

7-OH-DPAT (7-hydroxy-2-(di-*n*-propylamino)tetralin)
Dopamine D_2 receptor; Dopamine D_3 receptor (Gonzalez, A.M. (272) R1)

Morphine; Place preference; Conditioning; Dopamine; Dopamine D_3 receptor; (Rat) (De Fonseca, F.R. (274) 47)

Dopamine D_3 receptor; SKF 38393; Motor behavior; Reserpine; (Mouse) (Starr, M.S. (277) 151)

Dopamine D_2 receptor; Dopamine D_3 receptor; Substantia nigra pars compacta; Autoreceptor; Single unit recording (Kreiss, D.S. (277) 209)

Dopamine D_3 receptor; (+)-PD 128907 (4*aR*,10*bR*-(+)-*trans*-3,4,4*a*,10*b*-tetrahydro-4-*n*-propyl-2*H*,5*H*[4,3-*b*]-1,4-oxazin-9-ol) (Acri, J.B. (281) R7)

8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin)
Ultrasonic distress call; Cerebral cortex; Lesion; Anxiolytic mechanism; Diazepam (Naito, H. (272) 261)

Ethanol tolerance; Ethanol withdrawal; 5-HT (5-hydroxytryptamine, serotonin) syndrome; Corticosterone (Kleven, M. (281) 219)

Adrenal gland; Gastrointestinal system, rat; 5-HT_{1A} receptor; Acid (Gidener, S. (284) 19)

Nucleus tractus solitarii; Lateral tegmental field; Muscimol; Kynurenic acid (Vayssettes-Courchay, C. (285) 299)

[^{3}H]8-OH-DPAT ([^{3}H]8-hydroxy-2-(di-*n*-propylamino)tetralin)
5-HT_{1A} receptor; G-protein; 5-HT_{1A} receptor antagonist; Autoradiography, quantitative; [^{3}H]WAY 100635 (Gozlan, H. (288) 173)

***R*(+)-8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin)**
WAY 100,635 (*n*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*n*-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride); *d*-Amphetamine; Dopamine; 5-HT_{1A} receptor; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (287) 179)

Okadaic acid
ATP release, neuronal; Forskolin; Ouabain; Atrium, guinea-pig; W-7; Vinblastine (Katsuragi, T. (282) 213)

Neutrophil; Respiratory burst; Calyculin A; Protein phosphatase (Djerdjouri, B. (288) 193)

Exocytosis; Ba^{2+}; Ca^{2+}-dependent release; Calmodulin; Phosphatase (Verhage, M. (291) 387)

OKY-046
Bradykinin; Thromboxane; Airflow obstruction; WEB2086; ICI192,605 (Kawikova, I. (280) 293)

Olanzapine
Risperidone; Seroquel; Ziprasidone; Amperozide; Schizophrenia; Ventral tegmental area; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (281) 289)

Olfactory bulbectomy
Benzodiazepine receptor, peripheral type; Thymus; Spleen; Adrenal; Antidepressant (Dennis, T. (272) 279)

Omeprazole
Crop emptying; Medium chain triacylglycerol; Long chain triacylglycerol; Acid; (Chick) (Mabayo, R.T. (273) 161)

One-way avoidance
Animal model; Anxiety; Buspirone; Diazepam; Successive negative contrast (Torres, C. (280) 277)

Ontogenesis
β-Endorphin; Morphine; Antinociception (Tseng, L.F. (277) 71)

$GABA_A$ receptor; Benzodiazepine BZ_1 site; Benzodiazepine BZ_2 site; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate) binding; Flunitrazepam; CL 218,872; Zolpidem; Cerebral cortex, rat (Giorgi, O. (290) 37)

Ontogeny
Cocaine; SCH 23390; Sulpiride; Eticlopride (Pruitt, D.L. (283) 125)

OPC-21268
Oxytocin; Vasopressin; Myometrial receptor; Vasopressin receptor antagonist (Atke, A. (281) 63)

[Arg^8]Vasopressin; Coronary artery, human; Vasopressin V_1 receptor; OPC-31260; SR 49059; (Human) (Bax, W.A. (285) 199)

OPC-31260
[Arg^8]Vasopressin; Coronary artery, human; Vasopressin V_1 receptor; OPC-21268; SR 49059; (Human) (Bax, W.A. (285) 199)

Open-field
Chronic variate stress; Foot-shock stress, acute; β-Adrenoceptor; 5-HT_{1A} receptor; 5-HT_2 receptor; Amitriptyline; Brain cortex, rat (Ferretti, C. (280) 19)

Opiate
Neurotransmission; Dynorphin-A; Morphine; Dermorphine; Motor nerve (Lavidis, N.A. (276) 71)

Analgesia; δ-Opioid receptor antagonist; Opioid withdrawal; Abstinence (Fundytus, M.E. (286) 105)

Antidiarrheal agent; Ion conductance; P-glycoprotein; CFTR (cystic fibrosis transmembrane conductance regulator) (Callaghan, R. (291) 183)

G-protein; U-50488H; U-69593; PD 117302; Hypothermia; Gut motility; Cholera toxin; Pertussis toxin (Shukla, V.K. (292) 293)

Opiate receptor
Macrophage; Morphine 6-glucuronide (Makman, M.H. (273) R5)

Transgenic mouse; Superoxide dismutase; Antinociception; Genetics (Elmer, G.I. (283) 227)

Opioid
GABA receptor antagonist; Antinociception, i.c.v., i.t.; Benzodiazepine; Nociceptive test (Luger, T.J. (271) 421)

Etonitazene; Morphine; Naloxone; Radial maze; Memory (Braida, D. (271) 497)

Cannabinoid; Noradrenaline; β,γ-Methylene-L-ATP; Vas deferens, mouse; Tolerance (Pertwee, R.G. (272) 67)

Antinociception; Benzodiazepine; Nociceptive test; (Intracerebroventricular); (Intrathecal) (Luger, T.J. (275) 153)

Social behavior; Play behavior; μ-Opioid receptor; δ-Opioid receptor; κ-Opioid receptor (Vanderschuren, L.J.M.J. (276) 257)

σ Receptor; Phenylmorphan; (Subtype selectivity) (Bowen, W.D. (278) 257)

Growth; Development; Brain; Liver; (Intracerebroventricular) (Bartolome, J.V. (284) 43)

Physical dependence; Protein kinase; Morphine; Butorphanol; H-7; H-8 (Tokuyama, S. (284) 101)

Naloxone binding site; DNA synthesis; Uterus, immature; (Rat) (Vértes, Z. (291) 115)

Opioid dependence
Paroxetine; Fluvoxamine; Place conditioning; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, specific; Morphine (Rafieian-Kopaei, M. (275) 185)

Central nervous system; Ca^{2+} channel; Diltiazem; Protein kinase C; Morphine; Butorphanol (Tokuyama, S. (279) 93)

Opioid mechanism
Diurnal alteration; ACTH (adrenocorticotrophin); Corticosterone; Prolactin (Kiem, D.T. (272) 145)

Opioid, pharmacology
Adenosine, pharmacology; Antinociception; Spinal cord; (Mouse) (Keil, II, G.J. (271) 37)

Opioid receptor
Dihydroetorphine; Diabetes; Antinociceptive effect; (Mouse) (Kamei, J. (275) 109)

Morphine; Aorta, rat; Contractile force (Parra, L. (277) 99)

Acetylcholine release; Striatum; Nucleus accumbens; Morphine; Sensitization (Tjon, G.H.K. (283) 169)

Opioid receptor alkylation
Clocinnamox; Morphine; Opioid receptor antagonist; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U69,593; Opioid receptor binding; mRNA; Solution hybridization; Analgesia; (Irreversible antagonist) (Chan, K. (287) 135)

Opioid receptor antagonist
Amphetamine; Cocaine; Locomotor activity; Microdialysis, in vivo; Dopamine; Striatum; Nucleus accumbens (Schad, C.A. (275) 9)

Clocinnamox; Morphine; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U69,593; Opioid receptor alkylation; Opioid receptor binding; mRNA; Solution hybridization; Analgesia; (Irreversible antagonist) (Chan, K. (287) 135)

Opioid receptor binding
Clocinnamox; Morphine; Opioid receptor antagonist; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U69,593; Opioid receptor alkylation; mRNA; Solution hybridization; Analgesia; (Irreversible antagonist) (Chan, K. (287) 135)

Opioid receptor, cloned
Dihydroetorphine; Morphine; Binding characteristic; cAMP (Katsumata, S. (291) 367)

Opioid receptor mechanism
Calcitonin; Hypothalamus-pituitary-adrenocortical axis (Milanés, M.V. (271) 103)

Opioid receptor subtype
Formalin test; Inflammation; Pain; Peripheral analgesia; Extravasation (Hong, Y. (277) 21)

Opioid tolerance
Anti-opioid; Neuropeptide FF release; Spinal cord slice; NMDA (*N*-methyl-D-aspartate) (Devillers, J.-P. (271) 185)

Morphine; Butorphanol; Protein kinase A; Protein kinase C (Narita, M. (271) 543)

Protein kinase A; Protein kinase C (Narita, M. (280) R1)

Opioid withdrawal
Analgesia; Opiate; δ-Opioid receptor antagonist; Abstinence (Fundytus, M.E. (286) 105)

δ-Opioid receptor
TAN-67; Antinociception; 7-Benzylidenenaltrexone; Naltriben diabetes (Kamei, J. (276) 131)

Opioid; Social behavior; Play behavior; μ-Opioid receptor; κ-Opioid receptor (Vanderschuren, L.J.M.J. (276) 257)

Cocaine; Naltrindole; Enkephalin; Cocaine-induced sensitization (Shippenberg, T.S. (280) 55)

TIPP (H-Tyr-Tic-Phe-Phe-OH); [Tyr(3'-I)^1]TIPP; Brain, rat; N4TG1 cell; Vas deferens, mouse (Lee, P.H.K. (280) 211)

TAN-67; Antinociception; 7-Benzylidenenaltrexone; Naltriben diabetes (Kamei, J. (280) 347)

Antisense oligodeoxynucleotide; Desensitization; Antinociception (Narita, M. (284) 185)

Morphine; Antisense oligodeoxynucleotide; μ-Opioid receptor; Growth hormone; Prolactin (Idänpään-Heikkilä, J.J. (284) 227)

Antisense oligodeoxynucleotide; β-Endorphin; Antinociception (Tseng, L.F. (287) 169)

Pineal gland, bovine; β-endorphin; ε-Opioid receptor (Aloyo, V.J. (288) 295)

δ-Opioid receptor agonist
[1-^{14}C]Deoxyglucose; DPDPE ([D-Pen^2,D-Pen^5]enkephalin; (Brain site) (Ableitner, A. (271) 213)

BW373U86; Allodynia; Hyperalgesia; Rhesus monkey (Butelman, E.R. (277) 285)

δ-Opioid receptor antagonist
Analgesia; Opiate; Opioid withdrawal; Abstinence (Fundytus, M.E. (286) 105)

δ_2-Opioid receptor
β-Endorphin; Antinociception; Naltriben; Tail-flick inhibition (Tseng, L.F. (277) 251)

ε-Opioid receptor
Pineal gland, bovine; β-endorphin; δ-Opioid receptor (Aloyo, V.J. (288) 295)

κ-Opioid receptor
μ-Opioid receptor; Antinociception; Visceral pain (Diop, L. (271) 65)

Fedotozine; Visceral pain; μ-Opioid receptor; Colonic hypersensibility Langlois, A. (271) 245)

Opioid; Social behavior; Play behavior; μ-Opioid receptor; δ-Opioid receptor (Vanderschuren, L.J.M.J. (276) 257)

Naloxone benzoylhydrazone; Ileum, guinea pig; Receptor binding (Berzetei-Gurske, I.P. (277) 257)

Ketorolac tromethamine; Antinociception; (Intracerebroventricular administration) (Tripathi, A. (278) 27)

CI977; Excitatory amino acid; Epilepsy; Na^+ channel (Millan, M.H. (279) 75)

Morphine; Ischemia; 2-Deoxyglucose; Hippocampal slice; Tolerance (Shibata, S. (279) 197)

Alternation performance, spontaneous; Dynorphin A-(1–13); U-50,488H; Mouse (Ukai, M. (281) 173)

Striatum; Glutamate (Hill, M.P. (281) R1)

Dynorphin A-(1–13); Cholinergic neuronal system; CO (carbon monoxide); Delayed amnesia; Learning; Nor-binaltorphimine; Passive avoidance (Hiramatsu, M. (282) 185)

κ-Opioid receptor agonist (ICI 204448)
Mononeuropathic rat; Paw pressure; Peripheral antinociception (Keïta, H. (277) 275)

μ-Opioid receptor
κ-Opioid receptor; Antinociception; Visceral pain (Diop, L. (271) 65)

Fedotozine; Visceral pain; κ-Opioid receptor; Colonic hypersensibility Langlois, A. (271) 245)

Antisense oligodeoxynucleotide; Analgesia; Cold water tail-flick test; (Rat) (Chen, X.-H. (275) 105)

Morphine; Ambulation, mouse; Sensitization; Dopamine receptor (Kuribara, H. (275) 251)

Opioid; Social behavior; Play behavior; δ-Opioid receptor; κ-Opioid receptor (Vanderschuren, L.J.M.J. (276) 257)

Estrogen; Progesterone; Medial preoptic area; Upregulation (Zhou, L. (278) 271)

Antinociception; Dorsal root ganglion; Primary afferent neuron; Ribonuclease protection assay; β-Funaltrexamine (Schäfer, M. (279) 165)

Morphine; Antisense oligodeoxynucleotide; δ-Opioid receptor; Growth hormone; Prolactin (Idänpään-Heikkilä, J.J. (284) 227)

Tyr-D-Arg-Phe-β-Ala-NH_2; β-Funaltrexamine; Memory; Passive avoidance; Locomotor activity; (Mouse) (Ukai, M. (287) 245)

μ-Opioid receptor agonist
Neurogenic inflammation; Trigeminal ganglion; Sensory nerve; 5-HT_{1D} receptor agonist; Histamine H_3 receptor agonist (Escott, K.J. (284) 69)

μ_1-Opioid receptor
Morphine; Drug discrimination (Suzuki, T. (284) 195)

Oral absorption
Renin inhibitor; Spontaneously hypertensive rat (SHR); Renin, recombinant human; Pressor response; Bioavailability (Shibasaki, M. (271) 341)

Oral administration
TRH (thyrotropin-releasing hormone); TA-0910 (TRH analog); Ataxia (Kinoshita, K. (274) 65)

Oral dyskinesia
Haloperidol; 6-Hydroxydopamine; Tardive dyskinesia (Huang, N.-Y. (271) 433)

Organophosphate intoxication
β-Eudesmol; Anticholinesterase agent; Obidoxime; Diisopropylfluorophosphate; Neuromuscular transmission (Chiou, L.C. (292) 151)

Ouabain
Na^+,K^+-ATPase; Bufodienolide; Marinobufagenin; Smooth muscle, vascular; Vasoconstriction (Bagrov, A.Y. (274) 151)

Arrhythmia; Digitalis; Azepexole; B-HT 933 (Thomas, G.P. (276) 215)

Renal kallikrein secretion; Ca^{2+}; K^+; Ca^{2+} channel antagonist; Vanadium (Bompart, G. (278) 225)

ATP release, neuronal; Forskolin; Atrium, guinea-pig; W-7; Vinblastine; Okadaic acid (Katsuragi, T. (282) 213)

Catecholamine; Dopamine; Dopamine receptor, agonist, antagonist; Protein kinase inhibitor; Ionic mechanism; Voltage clamp; Neuron; (Snail) (Emaduddin, M. (283) 113)

Amiloride; EIPA (5-(*N*-ethyl-*N*-isopropyl)amiloride); Cardiac contractility; Na^+/Ca^{2+} exchange; Na^+/H^+ exchange (Cargnelli, G. (292) 103)

Na^+,K^+-ATPase; Ethanol; K^+; Synaptosome (Foley, T.D. (292) 287)

Ovalbumin
Immunoglobulin E; Bronchoconstrictive response; Hyperresponsiveness; Allergic asthma; (Mouse) (Hessel, E.M. (293) 401)

Oxcarbazepine
10-Monohydroxy metabolite; Na^+-dependent action potential; Cultured neuron; Maximal electroshock (Wamil, A.W. (271) 301)

Oxidative stress
Streptozotocin; Acetyl-L-carnitine; Brain; Alzheimer's disease (Terwel, D. (287) 65)

Ca^{2+}; Gastric cell; Damage; Nitric oxide (NO) (Tepperman, B.L. (293) 259)

Oxime
Antiarrhythmic; Action potential; Ca^{2+} current; K^+ current; Cardiac myocyte (Karhu, S. (279) 7)

Oxiracetam
D-Cycloserine; Aniracetam; NMDA receptor; Noradrenaline release; Kynurenic acid (Pittaluga, A. (272) 203)

7-Oxo-prostacyclin
Na^+/K^+ pump; Muscle fiber (Stankovičová, T. (276) 101)

***N*-Oxygenation**
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); FMO (recombinant rat liver flavin-containing monoxygenase); FMO1A1 (Chiba, K. (293) 97)

Oxygen demand
Dopamine; Fenoldopam; Noradrenaline; Renal blood flow; Splanchnic blood flow; Oxygen supply; Oxygen extraction ratio (Schiffer, E.R. (286) 49)

Oxygen extraction ratio
Dopamine; Fenoldopam; Noradrenaline; Renal blood flow; Splanchnic blood flow; Oxygen demand; Oxygen supply (Schiffer, E.R. (286) 49)

Oxygen radical
Chemiluminescence; Neutrophil; Corticosteroid; Ozone; Allergen (Stevens, W.H.M. (293) 251)

Oxygen supply
Dopamine; Fenoldopam; Noradrenaline; Renal blood flow; Splanchnic blood flow; Oxygen demand; Oxygen extraction ratio (Schiffer, E.R. (286) 49)

Oxygen tension
Hepatocyte; TNF-α (tumor necrosis factor-α); DNA fragmentation; Nitric oxide (NO); (Acute phase response); (Tissue) (Ohno, K. (292) 205)

Oxymetazoline
Hypothalamus; Pituitary; α_2-Adrenoceptor; Growth hormone; Clonidine; α_2-Adrenoceptor antagonist; α_{2A}-Adrenoceptor subtype; α_{2B}-Adrenoceptor subtype (Makara, G.B. (287) 43)

NS-49; α_1-Adrenoceptor subtype; Cloned receptor; Radioligand binding study; Cytosolic Ca^{2+} concentration (Obika, K. (291) 327)

Oxytocin
Apomorphine; 5-HT (5-hydroxytryptamine, serotonin); Grooming, excessive; Penile erection; Prolactin; Corticosterone; 5-HT_{2C} receptor; m-CPP (1-3-chlorophenylpiperazine); Hypothalamic paraventricular nucleus (Bagdy, G. (275) 301)

Endothelin; Pharmacomechanical coupling; GTP; Myometrium (Izumi, H. (278) 187)

Vasopressin; Myometrial receptor; OPC-21268; Vasopressin receptor antagonist (Atke, A. (281) 63)

Ozone
Airway microvascular leakage; Airway inflammation; PAF (platelet-activating factor); E6123; (Guinea-pig) (Kaneko, T. (292) 251)

Oxygen radical; Chemiluminescence; Neutrophil; Corticosteroid; Allergen (Stevens, W.H.M. (293) 251)

Nitric oxide (NO); Nitric oxide (NO) synthase; mRNA (Haddad, E.-B. (293) 287)

P1060
Uterus, human; Rubidium; K^+ channel opener; Levcromakalim (Criddle, D.N. (272) 293)

Levcromakalim; Saphenous vein, human; Rubidium ion (Criddle, D.N. (286) 123)

PACAP (pituitary adenylate cyclase-activating polypeptide)
Blood flow, vertebral artery; Cerebral artery, canine; VIP (vasoactive intestinal peptide); Vasodilation (Seki, Y. (275) 259)

Cerebral artery, canine; Intracerebral arteriole, rat; Endothelium-derived contracting factor; Prostaglandin $F_{2\alpha}$ (Anzai, M. (285) 173)

VIP (vasoactive intestinal polypeptide); cAMP; Cardiac myocyte; CDD/ANP-(99–126) (Bäsler, I. (291) 335)

PACAP (pituitary adenylate cyclase-activating polypeptide) analog
Recombinant PACAP receptor (Gourlet, P. (287) 7)

PACAP type I receptor
Recombinant receptors; Alternative splicing (Ciccarelli, E. (288) 259)

Pacing-induced heart failure
Protein kinase C; Polymyxin B; α-Adrenoceptor; Smooth muscle, vascular (Forster, C. (283) 241)

PAF (platelet-activiting factor)
Bronchospasm; (±)-CP96,345; MEN10,627; Neurokinin A; Substance P; Tachykinin (Perretti, F. (273) 129)

Vascular permeability; Nitric oxide (NO); Indomethacin; (Skin); (Mouse) (Fujii, E. (273) 267)

Liposome; Smooth muscle, trachea (Costuleanu, M. (281) 89)

Hemodynamics; Blood flow, regional; PAF receptor antagonist; Microsphere (King, K.A. (281) 187)

Nitric oxide (NO); Cyclo-oxygenase product; Vascular reactivity; L-NMMA (N^G-monomethyl-L-arginine); Indomethacin (Shiga, T. (282) 151)

Lipocortin 1; RU486; Interleukin-8; Adrenalectomy (Harris, J.G. (283) 9)

Nitric oxide (NO); Allergic conjunctivitis; Vascular permeability; N^G-Nitro-L-arginine methyl ester; Aminoguanidine; Histamine (Meijer, F. (284) 61)

Endotoxin; Vascular permeability; Kininogen-deficient rat; Bradykinin; PAF receptor antagonist (Ueno, A. (284) 211)

PCA-4248; Phosphoinositides; Protein phosphorylation; Platelets (Catalán, R.E. (290) 183)

Airway microvascular leakage; Airway inflammation; Ozone; E6123; (Guinea-pig) (Kaneko, T. (292) 251)

Septum, interventricular; Myocardial ischemia; HPLC (high-performance liquid chromatography); (Rabbit) (Salinas, P. (293) 65)

Lipoxygenase metabolites; Bronchial hyperresponsiveness; Eosinophil infiltration (Seeds, E.A.-M. (293) 369)

PAF receptor antagonist
PAF (platelet activating factor); Hemodynamics; Blood flow, regional; Microsphere (King, K.A. (281) 187)

Endotoxin; Vascular permeability; Kininogen-deficient rat; Bradykinin; PAF (platelet-activating factor) (Ueno, A. (284) 211)

Pain
Scratching; Itch; Compound 48/80; Substance P; Histamine (Kuraishi, Y. (275) 229)

Formalin test; Inflammation; Opioid receptor subtype; Peripheral analgesia; Extravasation (Hong, Y. (277) 21)

Glutamate; MK-801; CNQX (6-cyano-7-nitroquinoxaline-2,3-dione); Inflammation; Analgesia (Jackson, D.L. (284) 321)

Diabetes; Formalin test; Aldose reductase; Polyol pathway; Diabetic neuropathy (Calcutt, N.A. (285) 189)

Pain mechanism
Formalin test; Antinociception; Adenosine; Methylxanthine (Doak, G.J. (281) 311)

Paired-pulse inhibition
ucb L059; Bicuculline; Hippocampal CA3, rat; Input-output curve (Margineanu, D.G. (286) 321)

Palatable liquid diet
Baclofen; $GABA_B$ receptor; Food intake; Water intake (Ebenezer, I.S. (273) 183)

PAMP (proadrenomedullin N-terminal 20 peptide)
Catecholamine synthesis; Tyrosine hydroxylase; Nicotinic receptor; Adrenal medulla (Niina, H. (286) 95)

Pancreas
Fatty alcohol; Insulin secretion; Islet of Langerhans (Damgé, C. (274) 133)

Imidazoline; Imidazoline site; Insulin secretion; Vessel; Efaroxan; Idazoxan; (Rat) (Berdeu, D. (275) 91)

Pancreas, perfused
M16209; Aldose reductase inhibitor; Insulin secretion; K^+ channel, ATP-sensitive (Nakayama, K. (276) 85)

Pancreas transplantation
Pancreatic islet; Nitric oxide (NO) synthase; Nitric oxide (NO); Blood flow regulation (Svensson, A.M. (275) 99)

Pancreatic hypertrophy
Bethanechol; Pentagastrin; Muscarinic receptor; CCK receptor; CR1505 (Kato, M. (292) 47)

Pancreatic islet
Pancreas transplantation; Nitric oxide (NO) synthase; Nitric oxide (NO); Blood flow regulation (Svensson, A.M. (275) 99)

Papillary muscle
Propionyl-L-carnitine; Cardiomyopathy; (Hamster) (Maresca, P. (287) 303)

Paracetamol
Hepatotoxicity; Mitochondrial ATPase; Mitochondrial particle, sonic; Arrhenius kinetics (Parmar, D.V. (293) 225)

Chemoprotection; Hepatotoxicity; Lobenzarit; Molecular mechanism (Remirez, D. (293) 301)

Paraquat
Superoxide anion; Nitric oxide (NO); Acetylcholine; A23187 (Hsu, K.-S. (292) 315)

Parasitic nematode
Pyrantel; Acetylcholine; Ion channel; *Ascaris*, muscle; Anthelmintic (Robertson, S.J. (271) 273)

Parasympathetic nervous system
Neuroimmunomodulation; Cyclosporine; Stress; Sympathetic nervous system; Submaxillary lymph node; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (285) 143)

Parasympathetic neuron
Galantide; Galanin; K^+ conductance; Ca^{2+} conductance (Mulvaney, J.M. (287) 97)

Parasympathetic reflex
Pentylenetetrazole; Vasodilatation (Izumi, H. (273) 299)

Paraventricular nucleus of the hypothalamus
Hyperphagia; Neuropeptide Y; *d*-Fenfluramine; (±)-Cyanopindolol; 5-HT receptor (Grignaschi, G. (274) 221)

Parkinson-like disease
Manganese; Manganism; Complex I; PC12 cell (Galvani, P. (293) 377)

Parkinson's disease
Metabotropic glutamate receptor; Glutamate release; Striatum; Synaptosome; (Presynaptic) (East, S.J. (277) 117)

Animal model; Lamotrigine (Löschmann, P.-A. (284) 129)

Riluzole; Neuroprotection; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Bradykinesia; Rigidity; Dopamine release; (Rhesus monkey) (Benazzouz, A. (284) 299)

Dizocilpine; Tyrosine hydroxylase; Aromatic L-amino acid decarboxylase; Dopamine (Hadjiconstantinou, M. (289) 97)

Dopamine transporter, vesicular; Insecticide; Fungicide; Herbicide; Rotenone; Neurotoxin (Vaccari, A. (292) 309)

Mitochondrial complex I; Mitochondrial complex IV; 6-Hydroxydopamine; Neurotoxicity; Monoamine oxidase A; Monoamine oxidase B (Glinka, Y.Y. (292) 329)

Paroxetine
Opioid dependence; Fluvoxamine; Place conditioning; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, specific; Morphine (Rafieian-Kopaei, M. (275) 185)

Particle-induced X-ray emission
Brain edema; Carrageenan; Calcium; Kallikrein-kinin; Neurotropin (Sprumont, P. (274) 95)

Partition coefficient
Benzodiazepine receptor; Iomazenil; Flumazenil; Steady state; K_d (Videbæk, C. (281) 117)

Passive avoidance
Dynorphin A-(1–13); Cholinergic neuronal system; CO (carbon monoxide); Delayed amnesia; Learning; Nor-binaltorphimine; κ-Opioid receptor (Hiramatsu, M. (282) 185)

Histogranin; NMDA receptor; Learning; Memory; (Mouse) (Maurice, T. (283) 251)

Histogranin; NMDA receptor; Learning; Memory; (Mouse) (Maurice, T. (287) 219)

μ-Opioid receptor; Tyr-D-Arg-Phe-β-Ala-NH_2; β-Funaltrexamine; Memory; Locomotor activity; (Mouse) (Ukai, M. (287) 245)

Passive avoidance response
Dynorphin A-(1–13); Scopolamine; Memory; Amnesia; (Mouse) (Ukai, M. (274) 89)

Passive cutaneous anaphylactic reaction
Eosinophil; β-Adrenoceptor agonist; Allergy; Inflammation (Teixeira, M.M. (272) 185)

Passive cutaneous anaphylaxis
Abruquinone A; Paw edema; Neurogenic inflammation; Vascular permeability; Compound 48/80; Mast cell degranulation (Wang, J.-P. (273) 73)

Patch clamp
Antiarrhythmic, class Ia; Disopyramide; Skeletal muscle; K_{ATP} channel; Channel inhibition, pH dependent (Moser, C. (284) 35)

GABA receptor; Cl^- channel; Bicuculline; Retina; Bipolar cell; Rod pathway (Feigenspan, A. (288) 97)

$GABA_A$ receptor, recombinant; Neuroactive steroids; (Ligand binding modulation) (Hauser, C.A.E. (289) 249)

PC12; Nicotinic acetylcholine receptor; Physostigmine; Galanthamine (Storch, A. (290) 207)

Enterochromaffin-like cell; Stomach, rat; Ca^{2+} ionophore; Histamine; K^+ channel (Sakai, H. (291) 153)

Ca^{2+}-ATPase; Protein kinase C; Protein kinase A; Calmodulin; Megakaryocyte, rat (Uneyama, C. (291) 381)

Patch-clamp technique
Local anesthetic; Hippocampal neuron; Chloride ion; GABA (γ-aminobutyric acid); Glycine (Hara, M. (283) 83)

Ca^{2+} current, L-type; Verapamil; Binding site; Ventricular myocyte, rat (Wegener, J.W. (287) 89)

Paw edema
Abruquinone A; Neurogenic inflammation; Passive cutaneous anaphylaxis; Vascular permeability; Compound 48/80; Mast cell degranulation (Wang, J.-P. (273) 73)

Phospholipase A_2; Thielocin A1β; Anti-inflammatory drug (Tanaka, K. (279) 143)

Histamine; Neurogenic inflammation; CGRP (calcitonin gene-related peptide) (Amann, R. (279) 227)

Paw edema, rat
5-HT (5-hydroxytryptamine, serotonin); Actinomycin-D; Dexamethasone; Mast cell; Nedocromil sodium (Raud, J. (282) 207)

Paw pressure
Mononeuropathic rat; κ-Opioid receptor agonist (ICI 204448); Peripheral antinociception (Keïta, H. (277) 275)

PBN (α-phenyl-*N*-tert-butyl nitrone)
MDMA (3,4-methylenedioxymethamphetamine); Ecstasy; Neurodegeneration; Neuroprotection; Free radical (Colado, M.I. (280) 343)

PC12
Patch-clamp; Nicotinic acetylcholine receptor; Physostigmine; Galanthamine (Storch, A. (290) 207)

PC12 cell
Neuropeptide Y; Tyrosine hydroxylase; Nerve growth factor; Dexamethasone; Pertussis toxin (McCullough, L.A. (287) 271)

Nitric oxide (NO); Nitric oxide synthase; Ca^{2+} homeostasis; cGMP (Clementi, E. (289) 113)

Manganese; Manganism; Complex I; Parkinson-like disease (Galvani, P. (293) 377)

PCA-4248
PAF (platelet activating factor); Phosphoinositides; Protein phosphorylation; Platelets (Catalán, R.E. (290) 183)

PCB (polychlorinated biphenyl)
PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Neurobehavioral effect; Reproduction effect; Endocrine effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Experimental animal; Human infant; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Glucuronidation; Thyroid hormone (Van Birgelen, A.P.J.M. (293) 77)

Aryl hydrocarbon receptor; 2,3,7,8-TCDD; Reporter gene; Biomarker; (Interaction) (Aarts, J.M.M.J.G. (293) 463)

PCDD (polychlorinated dibenzo-*p*-dioxin)
PCB (polychlorinated biphenyl); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Neurobehavioral effect; Reproduction effect; Endocrine effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Experimental animal; Human infant; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

PCDF (polychlorinated dibenzofuran)
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Neurobehavioral effect; Reproduction effect; Endocrine effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Experimental animal; Human infant; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

PD 117302
G-protein; Opiate; U-50488H; U-69593; Hypothermia; Gut motility; Cholera toxin; Pertussis toxin (Shukla, V.K. (292) 293)

PD 123177
Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Losartan; Vasopressin; Drinking response (Höhle, S. (275) 277)

PD 123319
Angiotensin II; Losartan; DuP 532; CGP 42112A; Smooth muscle, portal vein (Pelet, C. (279) 15)

Des-Asp-angiotensin I; Losartan; Pulmonary artery, rabbit; Transmural stimulation; (Superfusion) (Sim, M.K. (284) 215)

L-163,491; Pulmonary vascular bed, cat; Angiotensin receptor-mediated response; Captopril; DuP 532 (Kaye, A.D. (287) 163)

PD-134,308
Enkephalin catabolism inhibitor; Enkephalin, endogenous; CCK (cholecystokinin); RB 101; Tail-flick; Hot-plate; Antinociception; CCK_B receptor antagonist; Tolerance (Valverde, O. (286) 79)

PD145065
Endothelin; IRL1620; Endothelin receptor subtype; BQ-123; Tachyphylaxis (Miasiro, N. (285) 247)

PDGF (platelet-derived growth factor)
Tranilast; Mesangial cell; Nitric oxide (NO) (Hishikawa, K. (291) 435)

Pelanserin
5-HT receptor antagonist; Contraction; Methoxamine; Spontaneously hypertensive rat (SHR) (Villalobos-Molina, R. (277) 181)

Penile erection
Aging; ACTH (adrenocorticotropin); Melanocortin; Grooming; Stretching; Yawning (Poggioli, R. (271) 253)

Apomorphine; 5-HT (5-hydroxytryptamine, serotonin); Grooming, excessive; Oxytocin; Prolactin; Corticosterone; $5\text{-}HT_{2C}$ receptor; m-CPP (1-3-chlorophenylpiperazine); Hypothalamic paraventricular nucleus (Bagdy, G. (275) 301)

Pentagastrin
Pancreatic hypertrophy; Bethanechol; Muscarinic receptor; CCK receptor; CR1505 (Kato, M. (292) 47)

Pentamidine
AZT (3′-azido-2′,3′-dideoxythymidine); Nitric oxide (NO); Neuronal NO synthase; Calmodulin antagonist (Kitamura, Y. (289) 299)

Pentamidine isethionate
TNF (tumor necrosis factor); Interleukin-6; Dexamethasone; Pentoxifylline; Fusidic acid; Adenosine receptor agonist (Chen, Y.-L. (271) 319)

(+)-Pentazocine
σ Binding site, heterogeneity; Radioreceptor assay; DTG (1,3-di(2-tolyl)guanidine); Brain; Spinal cord; (Mouse) (Kovács, K.J. (285) 127)

N-Allylnormetazocine; σ Receptor; Dopamine; Striatum; Microdialysis (Gudelsky, G.A. (286) 223)

[^{3}H](+)-Pentazocine
[^{3}H]DTG ([^{3}H]1,3-di(2-tolyl)guanidine); σ Binding site, subtype (Hudkins, R.L. (271) 235)

Pentobarbital
Dithiothreitol; Dithioerythritol; Anesthesia reversal; Toxicity; (Rodents) (Gailis, L. (292) 39)

Pentoxifylline
TNF (tumor necrosis factor); Interleukin-6; Dexamethasone; Fusidic acid; Pentamidine isethionate; Adenosine receptor agonist (Chen, Y.-L. (271) 319)

Pentylenetetrazole
Parasympathetic reflex; Vasodilatation (Izumi, H. (273) 299)

γ-Butyrolactone bicyclic; $GABA_A$ receptor-ionophore complex; Convulsant (picrotoxin) site; [^{35}S]TBPS binding; Benzodiazepine sites (Maksay, G. (288) 61)

1-Pentyl-2-methyl-3-(1-naphthoyl)indole
Cannabinoid; Cannabinoid receptor antagonist; SR141716A; Vas deferens, mouse; 1-Pentyl-3-(1-naphthoyl)pyrrole; 1-Heptyl-3-(1-naphthoyl)indole (Pertwee, R.G. (284) 241)

1-Pentyl-3-(1-naphthoyl)pyrrole
Cannabinoid; Cannabinoid receptor antagonist; SR141716A; Vas deferens, mouse; 1-Pentyl-2-methyl-3-(1-naphthoyl)indole; 1-Heptyl-3-(1-naphthoyl)indole (Pertwee, R.G. (284) 241)

Pepstatin A
Endothelin-1; Red blood cell; Staphylococcal α-toxin; Phosphoramidon; Chymostatin; Leupeptin (Tippler, B. (271) 131)

Peptaibol
Ca^{2+} channel agonist; Cardiac muscle (Huang, Q. (271) R5)

Peptidoleukotriene
Ebselen; Ethanol; Gastric mucosal injury, murine; Gastric surface mucous cell line GSM06; Lipid peroxide (Tabuchi, Y. (272) 195)

Peptidoleukotriene receptor antagonist
DS-4574; Endotoxin; Small intestinal mucosal injury; Hemoconcentration; Plasma leakage (Tabuchi, Y. (273) 281)

Perforant path
Urethane (ethyl carbamate); Dentate gyrus; Evoked potential; GABAergic inhibition (Shirasaka, Y. (282) 11)

Periaqueductal gray matter
NMDA receptor; mGlu receptor; NMDA (*N*-methyl-D-asparate); *t*-ACPD (*trans*-(±)-1-amino-1,3-cyclopentanedicarboxylic acid); L-AP-3 (L-2-amino-3-phosphono-propionate) (Leyva, J. (285) 123)

Periodate-oxidized nucleotide
P_2 purinoceptor; Vas deferens, guinea-pig; ATP; 2′,3′-Dialdehyde ATP analog (Fedan, J.S. (281) 213)

Peripheral analgesia
Formalin test; Inflammation; Pain; Opioid receptor subtype; Extravasation (Hong, Y. (277) 21)

Peripheral antinociception
Mononeuropathic rat; Paw pressure; κ-Opioid receptor agonist (ICI 204448) (Keïta, H. (277) 275)

Peripheral benzodiazepine binding site
HEK (Human embryonic kidney) cell line 293; Flunitrazepam binding; $GABA_A$ receptor; $GABA_A$ receptor subunit (Fuchs, K. (289) 87)

Peripheral blood mononuclear cell
Phosphodiesterase inhibitor; Arachidonate; cAMP; Forskolin; β_2-adrenoceptor agonist (Hichami, A. (291) 91)

Peripheral nervous system
Vein; Inflammation; Somatostatin receptor; Substance P (Reubi, J.C. (271) 371)

Peripheral neuropathy
Cisplatin; CGRP (calcitonin gene-related peptide); $5\text{-}HT_3$ antagonist (Whitaker-Azmitia, P.M. (275) 139)

Peritoneal leukocyte
Glucocorticoid; Respiratory burst; Activation, ex vivo; (Rat) (Røshol, H. (286) 9)

Peroxynitrite
Nitric oxide (NO) donor; Superoxide; Free radical scavenger; Gastric damage (Lamarque, D. (277) 187)

Pertussis toxin
Mast cell, cutaneous; Neuropeptide Y; Mastoparan; G-protein; Benzalkonium chloride; Neuraminidase (Emadi-Khiav, B. (272) 97)

Na^+-pump; Dopamine receptor; Phosphoinositide hydrolysis; Vascular tone (Rashed, S.M.K. (284) 289)

Cryptolepine (5-methylquindoline); Vasodilation; Kidney, rat; G-protein; K^+ channel; Ca^{2+} channel (Oyekan, A.O. (285) 1)

Neuropeptide Y; Tyrosine hydroxylase; PC12 cell; Nerve growth factor; Dexamethasone (McCullough, L.A. (287) 271)

Mast cell; Neuropeptide Y; Circular dichroism spectrum; Heterotrimeric G protein; Benzalkonium chloride; (Rat); (Human) (Mousli, M. (289) 125)

Chinese hamster ovary cell; Muscarinic receptor; G proteins; [^{3}H]*N*-methylscopolamine; [^{35}S]guanosine 5′-*O*-(3-thiotriphosphate) (Burford, N.T. (289) 343)

Corticotropin releasing factor; Ca^{2+}; Ca^{2+} channel; inositol trisphosphate; Epithelium (Kiang, J.G. (291) 107)

Thrombin; Inositol phosphate; Phospholipase C inhibitor; Atrium, rat; Noradrenaline (Woodcock, E.A. (291) 213)

G-protein; Opiate; U-50488H; U-69593; PD 117302; Hypothermia; Gut motility; Cholera toxin (Shukla, V.K. (292) 293)

PET (positron emission tomography)
WAY-100635; 5-HT_{1A} receptor; Brain, rat; Radioligand, in vivo (Hume, S.P. (271) 515)

Receptor imaging; β-Adrenoceptor; Radioligand (Van Waarde, A. (272) 159)

Methylphenidate; *d-threo*-Methylphenidate; WIN 35,428; Dopamine; Dopamine transporter; (Baboon); (Mouse) (Gatley, S.J. (281) 141)

5-HT_{1A} receptor, human; [^{11}C]WAY-100635 (Pike, V.W. (283) R1)

Dimethindene, enantiomer; Muscarinic M_2 receptor antagonist; Histamine H_1 receptor; Muscarinic receptor subtype; Enantioselectivity; Stereoselectivity, inverse; Alzheimer's disease (Pfaff, O. (286) 229)

Phagocytosis
Morphine; Lipopolysaccharide; Invertebrate immunocyte (Ottaviani, E. (276) 35)

Pharmacokinetics
Nicotinic acetylcholine receptor antagonist; Erysodine; Dihydro-β-erythroidine (Decker, M.W. (280) 79)

Pharmacomechanical coupling
Oxytocin; Endothelin; GTP; Myometrium (Izumi, H. (278) 187)

Phencyclidine
Behavioral pharmacology; Schedule-controlled behavior; Receptor binding; Drug dependence; Drug tolerance; Sex difference; (Rat) (Wessinger, W.D. (277) 107)

Neurotensin; NMDA (*N*-methyl-D-aspartate); Dopamine; Striatum; Nucleus accumbens (Hanson, G.R. (278) 167)

5-HT_{2A} receptor; Clozapine (Maurel-Remy, S. (280) R9)

Dopamine D_1 receptor antagonist; Dopamine D_2 receptor antagonist; Striatum, rat; Microdialysis (Yonezawa, Y. (285) 305)

Nitric oxide (NO) synthase inhibitor; Ataxia; Locomotion; (Mouse) (Noda, Y. (286) 291)

Phenolic metabolite
Hexafluorobenzene; Hexachlorobenzene; Porphyria; Biotransformation; Mercapturic acid (Rietjens, I.M.C.M. (293) 293)

Phenoxybenzamine
Vas deferens, human; Noradrenaline; α-Adrenoceptor agonist; α-Adrenoceptor antagonist (Amobi, N. (273) 25)

Phenylalkylamine
Dihydropyridine; Allosteric interaction; Structural determinant; Molecular modeling (Voigt, W. (291) 255)

Phenylephrine
α_1-Adrenoceptor; Renal function; Prazosin (Chen, C. (287) 1)

Phenylmethylsulphonyl fluoride
Cannabinoid; Anandamide; *R*-(+)-Arachidonyl-1′-hydroxy-2′-propylamide; Vas deferens, mouse; Myenteric plexus preparation, guinea-pig (Pertwee, R.G. (272) 73)

Phenylmorphan
σ Receptor; Opioid; (Subtype selectivity) (Bowen, W.D. (278) 257)

Phenytoin
Vinpocetine; Na^+ channel, voltage-gated; Anticonvulsant; Neuroprotection; Cortical neuron; (Rat) (Molnár, P. (273) 303)

Phorbol dibutyrate
Vas deferens, rat; α_2-Adrenoceptor; Xylazine; 4-Aminopyridine; Tetraethylammonium; Charybdotoxin; Bay K 8644 (Docherty, J.R. (287) 287)

[^{3}H]Phorbol-12,13-dibutyrate binding
Daphnoretin; Neutrophil (rat); Respiratory burst; Staurosporine; Protein kinase C; Ca^{2+} (Wang, J.-P. (288) 341)

Phorbol ester
Contraction; Histamine; Bronchus, human; Protein kinase C; GF 109203X (Yang, K.X.F. (275) 283)

Diabetes mellitus; Protein kinase C; Ca^{2+}, extracellular; Ca^{2+} channel; Aorta, rat (Hattori, Y. (279) 51)

Histamine; Phospholipase C; Protein kinase C; Staurosporine; Ro 31-8220; Adrenal chromaffin cell (Bunn, S.J. (290) 227)

GABA ρ_1 receptor; Protein kinase C; *Xenopus* oocyte; Down-regulation; Staurosporine (Kusama, T. (291) 431)

Phorbol ester binding
Chronic opioid treatment; Protein kinase C; Morphine; Butorphanol (Narita, M. (271) 547)

Phosphatase
Exocytosis; Ba^{2+}; Ca^{2+}-dependent release; Calmodulin; Okadaic acid (Verhage, M. (291) 387)

Phosphatidic acid
Phosphodiesterase; Phospholipid; Rolipram; U937; cAMP (DiSanto, M.E. (290) 169)

Phosphatidyl inositide hydrolysis
L-AP3 (L-2-amino-3-phosphonopropionic acid); MCPG ((RS)-α-methyl-4-carboxyphenylglycine); Metabotropic glutamate receptor; *Xenopus* oocyte (Saugstad, J.A. (289) 395)

Phosphatidylinositol
Aminoglycoside; Spermine; Melittin; Membrane aggregation; Membrane fusion (Van Bambeke, F. (289) 321)

Phosphatidylinositol 4,5-bisphosphate
Phosphoinositide-specific phospholipase C; Inositol 1,4,5-trisphosphate; Desensitization; Protein kinase A; Protein kinase C (Fisher, S.K. (288) 231)

Phosphatidylinositol hydrolysis
Chromaffin cell; Muscarinic receptor; Ca^{2+}, intracellular; Cation channel, non-selective; (Guinea-pig) (Inoue, M. (276) 123)

Endothelin-1; Endothelin-3; Human bronchi; Protein kinase C (Nally, J.E. (288) 53)

Phosphocreatine di-L-arginine salt
Ischemia; Reperfusion; Skeletal muscle; Phosphocreatine disodium salt; L-Arginine; Current clamp; Electrophysiology (Tricarico, D. (287) 17)

Phosphocreatine disodium salt
Ischemia; Reperfusion; Skeletal muscle; Phosphocreatine di-L-arginine salt; L-Arginine; Current clamp; Electrophysiology (Tricarico, D. (287) 17)

Phosphodiesterase
Cerebral ischemia; Rolipram; cAMP; Hippocampus; (Gerbil) (Kato, H. (272) 107)

Hyperalgesia; Prostaglandin E_2; Rolipram; Sympathetically maintained pain (Ouseph, A.K. (273) 107)

Gastric fundus; NANC (non-adrenergic, non-cholinergic); Cyclic nucleotide (Barbier, A.J. (276) 41)

Butein; EDRF (endothelium-derived relaxing factor); cAMP; cGMP; Thoracic aorta, rat (Yu, S.-M. (280) 69)

Tardive dyskinesia, rat; cAMP; Rolipram; Ageing (Sasaki, H. (282) 71)

cGMP-specific phosphodiesterase (phosphodiesterase V); E4021; Vasorelaxant; Aorta, human (Miyahara, M. (284) 25)

Asthma; Bronchodilation; Cardiovascular; Central nervous system, dog; Emesis; Rolipram (Heaslip, R.J. (286) 281)

Desensitization; β-Adrenoceptor agonists; Adipocyte; β-Adrenoceptor subtypes; Lipolysis (Bousquet-Mélou, A. (289) 235)

Phosphatidic acid; Phospholipid; Rolipram; U937; cAMP (DiSanto, M.E. (290) 169)

Phosphodiesterase inhibitor
Bronchial hyperreactivity; Airway inflammation; Early and late asthmatic reaction; (Guinea pig, allergic) (Santing, R.E. (275) 75)

Endothelial cell; Nitric oxide; cAMP; cGMP (Kessler, T. (290) 163)

Peripheral blood mononuclear cell; Arachidonate; cAMP; Forskolin; β_2-adrenoceptor agonist (Hichami, A. (291) 91)

Phosphoinositide
PAF (platelet activating factor); PCA-4248; Protein phosphorylation; Platelets (Catalán, R.E. (290) 183)

Phosphoinositide hydrolysis
Na^+-pump; Dopamine receptor; Pertussis toxin; Vascular tone (Rashed, S.M.K. (284) 289)

Immobilization stress; 5-HT (5-hydroxytryptamine, serotonin); Imipramine (Okuyama, N. (285) 61)

Seizure; Soman; Histamine H_1 receptor; Metabotropic glutamate receptor (Bodjarian, N. (289) 291)

Phosphoinositide-specific phospholipase C
Inositol 1,4,5-trisphosphate; Desensitization; Protein kinase A; Protein kinase C; Phosphatidylinositol 4,5-bisphosphate (Fisher, S.K. (288) 231)

Phosphoinositide turnover
Protein kinase A; Endothelin; C_6 glioma cell; (ATP) (Lin, W.W. (291) 1)

Phospholipase A_2
Hippocampus; Long-term depression (Stanton, P.K. (273) R7)

Endothelin; Big-endothelin; Endothelin-converting enzyme; Brain; Astrocyte (Deschepper, C.F. (275) 61)

Thielocin A1β; Paw edema; Anti-inflammatory drug (Tanaka, K. (279) 143)

2-Polyprenyl-1,4-hydroquinone; Marine product; Neutrophil, human; Anti-inflammatory drug (Gil, B. (285) 281)

Biscoclaurine alkaloid; Arachidonic acid; Platelet (Akiba, S. (291) 343)

Phospholipase C
cAMP; G-protein; mGluR (Knöpfel, T. (288) 389)

DDT_1MF-2 cell; Smooth muscle cell; Gβγ subunit (Dickenson, J.M. (288) 393)

Histamine; Protein kinase C; Phorbol ester; Staurosporine; Ro 31-8220; Adrenal chromaffin cell (Bunn, S.J. (290) 227)

Macrophage; Bradykinin receptor; Ca^{2+}, intracellular (Böckmann, S. (291) 159)

Desensitization; G-proteins; P_{2Y} purinoceptors; Protein kinase C (Galas, M.-C. (291) 175)

Phospholipase C inhibitor
Thrombin; Inositol phosphate; Pertussis toxin; Atrium, rat; Noradrenaline (Woodcock, E.A. (291) 213)

Phospholipase D
α_2-Adrenoceptor; Tyrosine kinase inhibitor (Jinsi, A. (277) 29)

α_2-Adrenoceptor; Protein kinase C; Smooth muscle, vascular (Aburto, T. (277) 35)

Phospholipid
Adrenoceptor; Ageing; Epinephrine; Fatty acid; Heart muscle; (Rat) (Benediktsdóttir, V.E. (289) 419)

Phosphatidic acid; Phosphodiesterase; Rolipram; U937; cAMP (DiSanto, M.E. (290) 169)

Phospholipid metabolism
U50,488; Ethylketocyclazocine; Norepinephrine; Carbachol; Renal cortex (Mosaddeghi, M. (289) 411)

Phosphoramidon
Endothelin-1; Red blood cell; Staphylococcal α-toxin; Pepstatin A; Chymostatin; Leupeptin (Tippler, B. (271) 131)

α,β-Methylene ATP; Endothelin; Suramin; Sympathetic co-transmission; Vas deferens, rat (Lau, W.A.K. (272) 31)

Endothelin; Sarafotoxin; Vas deferens; BQ-123; IRL 1620; BQ-788; Endothelin-converting enzyme; Neurotransmission; (Mouse) (Maas, J. (276) 113)

K^+ channel opener; NIP-121; Cromakalim; Epithelium; Trachea, guinea-pig; Methylene blue (Shikada, K.-i. (282) 193)

Melanocortin receptor subtype; [^{125}I][Nle^4, D-Phe^7]α-MSH ligand binding; MSH (melanocyte stimulating hormone) peptide selectivity (Schiöth, H.B. (288) 311)

Photoaffinity
Polyamine; NMDA receptor (Foucaud, B. (289) 471)

Photoaffinity label
$GABA_A$ receptor; β-Carboline (Zezula, J. (281) 93)

Thiomuscimol; $GABA_A$ receptor; Brain, rat (Nielsen, M. (289) 109)

Phrenic motor nerve ending
Adenosine receptor, presynaptic; Adenosine, endogenous; Nicotinic autoreceptor; Nicotinic receptor desensitization; [^{3}H]Acetylcholine release (Correia-de-Sá, P. (271) 349)

Physical dependence
Opioid; Protein kinase; Morphine; Butorphanol; H-7; H-8 (Tokuyama, S. (284) 101)

Physostigmine
Yawning; Atropine; Adenosine receptor agonist; Adenosine receptor antagonist; (Rat) (Zarrindast, M.-R. (276) 3)

PC12; Patch-clamp; Nicotinic acetylcholine receptor; Galanthamine (Storch, A. (290) 207)

Pilocarpine
Epilepsy; Nitric oxide (NO); Nitric oxide (NO) synthase; 7-Nitro indazole; Seizure (Van Leeuwen, R. (287) 211)

Pimobendan
Ca^{2+} sensitizer; Regulatory protein; Motility assay, in vitro (Sata, M. (290) 55)

Pinacidil
Galanin; K^+ channel activator; Electrolyte transport (Homaidan, F.R. (271) 561)

K_{ATP} channel opener; Cromakalim; Morphine; Intestinal transit; Diarrhea (Poggioli, R. (287) 207)

Pineal gland, bovine
β-endorphin; δ-Opioid receptor; ε-Opioid receptor (Aloyo, V.J. (288) 295)

Pirenzepine
Somatostatin; Hippocampus; Muscarinic M_1 receptor; NMDA receptor; CPP ((±)-3(2-carboxypiperazin-4-yl)-propyl-1-phosphonoic acid); Working memory (Ohno, M. (271) 557)

Acetylcholine; Atrium AF-DX 116, human; HHSiD (*p*-fluorohexahydrosiladifenidol hydrochloride); McN-A-343; Muscarinic receptor; Myocardial contractility; Ventricle (Du, X.Y. (284) 119)

Muscarinic receptors; Binding affinity; Stereoselectivity; CHO (Chinese hamster ovary) cells (Barbier, P. (290) 125)

Piriform cortex
Epilepsy; Kynurenate; Kynurenine; Excitotoxicity; Anticonvulsant action; Dizocilpine (Baran, H. (286) 167)

Pithed rat
Irbesartan (SR 47436/BMS-186295); SR 47155A; Losartan; EXP 3174; Angiotensin II (Christophe, B. (281) 161)

Pituitary
Hypothalamus; α_2-Adrenoceptor; Growth hormone; Clonidine; Oxymetazoline; α_2-Adrenoceptor antagonist; α_{2A}-Adrenoceptor subtype; α_{2B}-Adrenoceptor subtype (Makara, G.B. (287) 43)

Substance P receptor; Tachykinin NK_1 receptor; Gene expression; Polymerase chain reaction; AtT20 cell (Winkler, A. (291) 51)

PK 11195
Benzodiazepine receptor, peripheral; Benzodiazepine receptor, central; Ro 15-1788; Lead poisoning; Liver (Fonia, O. (293) 335)

Place conditioning
Opioid dependence; Paroxetine; Fluvoxamine; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, specific; Morphine (Rafiean-Kopaei, M. (275) 185)

Place preference
Morphine; 7-OH-DPAT (7-hydroxy-2-(*N*,*N*-di-*n*-propylamino)tetralin); Conditioning; Dopamine; Dopamine D_3 receptor; (Rat) (De Fonseca, F.R. (274) 47)

Isolation rearing; *d*-Amphetamine; (Rat) (Wongwitdecha, N. (279) 99)

Plasma
Dopamine receptor; Adrenaline; Heart; Dopamine; Adrenal medulla; (Partial least squares regression) (Kujacic, M. (273) 247)

Plasma extravasation
CRF (corticotropin-releasing factor); CP 99,994; Antigen challenge; Neurogenic inflammation, guinea pig; Substance P (Yoshihara, S. (280) 113)

Plasma leakage
DS-4574; Peptidoleukotriene receptor antagonist; Endotoxin; Small intestinal mucosal injury; Hemoconcentration (Tabuchi, Y. (273) 281)

Plasma protein extravasation
Sumatriptan; Trigeminal ganglion stimulation; Dura mater; Carotid vascular resistance; Blood pressure (Spokes, R.A. (281) 75)

Platelet
Collagenase; Inflammation; Kinin; Nitric oxide (NO); Serine protease inhibitor (Souza Pinto, J.C. (274) 101)

5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Calmodulin; Ca^{2+}; Thrombin (Helmeste, D.M. (288) 373)

Iloprost; cAMP; cGMP; Synergism (Fisch, A. (289) 455)

5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Calmodulin; Ca^{2+}; Thrombin (Helmeste, D.M. (290) 173)

PAF (platelet activating factor); PCA-4248; Phosphoinositides; Protein phosphorylation (Catalán, R.E. (290) 183)

Biscoclaurine alkaloid; Phospholipase A_2; Arachidonic acid (Akiba, S. (291) 343)

5-HT (5-hydroxytryptamine, serotonin); Red wine; Migraine; Headache (Pattichis, K. (292) 173)

Platelet aggregation
Flurbiprofen; Nefopam; Nitric oxide (NO); Arterial relaxation; Antinociception (Pallapies, D. (271) 335)

Platelet-derived growth factor
Angiotensin II; Angiotensin AT_1 receptor antagonist; Basic fibroblast growth factor; DNA synthesis (Itazaki, K. (291) 417)

Platelet inhibition
cAMP; cGMP; Prostacyclin; Nitric oxide (NO); Protein phosphorylation (Grünberg, B. (288) 329)

Play behavior
Opioid; Social behavior; μ-Opioid receptor; δ-Opioid receptor; κ-Opioid receptor (Vanderschuren, L.J.M.J. (276) 257)

PLC-PRF-5
Angiotensin AT_1 receptor; Hepatoma cell; Dexamethasone; Steroid; Glucocorticoid effect (Wintersgill, H.P. (288) 365)

Plus maze
LY326325; NBQX (6-nitro-7-sulfamoylbenzo(*f*)quinoxaline-2,3-(1*H*,4*H*dione); AMPA receptor antagonist; Anxiety; Locomotor activity; (Mouse) (Karcz-Kubicha, M. (279) 171)

PMEA (9-(2-phosphomethoxyethyl)adenine)
Acyclic nucleotide analog; HPMPC (1-(*S*)-(3-hydroxy-2-phosphonomethoxyethyl)cytosine); Antiarthritic effect; Adjuvant arthritis (Zídek, Z. (286) 307)

Poly(ADP-ribose)polymerase
Hydrogen peroxide; L-Histidine; Cytotoxicity; DNA single/double-strand break (Palomba, L. (291) 167)

Polyamine
Spermine; NMDA (*N*-methyl-D-aspartate); Hippocampus; Mg^{2+}; Development (Bowe, M.A. (278) 55)

Photoaffinity; NMDA receptor (Foucaud, B. (289) 471)

Polychlorinated biphenyl
Hepatic focus; Tumour promotion (Hemming, H. (292) 241)

Polyclonal antiserum
GABA receptor δ-subunit (Quirk, K. (290) 175)

Polymerase chain reaction
Adrenal; Catecholamine; Glycine; Microdialysis; Strychnine (Yadid, G. (288) 399)

Muscarinic receptor; Messenger RNA regulation; Primary neuronal culture (Brusa, R. (289) 9)

Substance P receptor; Tachykinin NK_1 receptor; Gene expression; Pituitary; AtT20 cell (Winkler, A. (291) 51)

Polymorphonucleocyte
Myeloperoxidase; Tetramethylbenzidine; Renal ischemia/reperfusion; Adhesion molecule (Laight, D.W. (292) 81)

Polymyxin B
Pacing-induced heart failure; Protein kinase C; α-Adrenoceptor; Smooth muscle, vascular (Forster, C. (283) 241)

Polyol pathway
Galactosemia; Nerve conduction; Ischemic resistance; Capillary density; Vasodilator treatment (Dines, K.C. (281) 303)

Diabetes; Formalin test; Aldose reductase; Pain; Diabetic neuropathy (Calcutt, N.A. (285) 189)

2-Polyprenyl-1,4-hydroquinone
Marine product; Phospholipase A_2; Neutrophil, human; Anti-inflammatory drug (Gil, B. (285) 281)

Polysomnographic recording
Napping; Melatonin (Nave, R. (275) 213)

Porphyria
Hexafluorobenzene; Hexachlorobenzene; Biotransformation; Mercapturic acid; Phenolic metabolite (Rietjens, I.M.C.M. (293) 293)

Portal hypertension
Nitric oxide (NO); Nitric oxide synthase, inhibition; Portal vein ligation, rat (Michielsen, P.P. (273) 167)

Angiotensin II; Nitric oxide (NO); Angiotensin receptor; Downregulation (Cahill, P.A. (288) 219)

Portal vein
Visnagin; Aorta, rat (Duarte, J. (286) 115)

Portal vein ligation
Acetylcholine; Aminoguanidine; Lipopolysaccharide; Mesenteric arterial bed; N^G-Nitro-L-arginine methyl ester; (Portal hypertensive rat) (Heinemann, A. (278) 87)

Portal vein ligation, rat
Nitric oxide (NO); Nitric oxide synthase, inhibition; Portal hypertension (Michielsen, P.P. (273) 167)

Portocaval anastomosis
Dioxin; TCDD (2,3,7,8-Tetrachlorodibenzo-*p*-dioxin); Anorexia; Food intake; Vagotomy (Tuomisto, J. (292) 277)

Positive allosteric ity
Muscarinic receptor, heart; Alcuronium; Allosteric interaction (Hejnová, L. (291) 427)

Positive cooperativity
Vanilloid receptor; Vanilnoid, endogenous; Resiniferatoxin binding; Capsaicin; Proton; Non-competitive inhibition; Desensitization (Szallasi, A. (289) 181)

Positive inotropic effect
α_1-Adrenoceptor; Muscarinic acetylcholine receptor; Cardiac action potential; Protein kinase C; Arachidonic acid metabolism (Arreola, J. (271) 309)

Potentiation
Dopamine; Microinjection; MK-801; Circling; Striatum, rat; 6-Hydroxydopamine (St-Pierre, J.-A. (272) 123)

Aging; Noradrenaline release, spontaneous; Vasoconstrictor (Glenn, T.C. (276) 191)

PPADS (pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid)
P_1 purinoceptor; P_{2Y} purinoceptor; Taenia caeci, guinea-pig; Suramin; Adenosine 5′-triphosphate (Piper, A.S. (280) 125)

P_1 purinoceptor
P_{2Y} purinoceptor; Taenia caeci, guinea-pig; Suramin; Adenosine 5′-triphosphate; PPADS (pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid) (Piper, A.S. (280) 125)

P_2 purinoceptor
Vas deferens, guinea-pig; Periodate-oxidized nucleotide; ATP; 2′,3′-Dialdehyde ATP analog (Fedan, J.S. (281) 213)

P_{2X} purinoceptor
Tail artery, rat; Sympathetic nerve stimulation; Purinergic transmission; Suramin (McLaren, G.J. (277) 57)

P_{2Y} purinoceptor
P_1 purinoceptor; Taenia caeci, guinea-pig; Suramin; Adenosine 5′-triphosphate; PPADS (pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid) (Piper, A.S. (280) 125)

Desensitization; Phospholipase C; G-proteins; Protein kinase C (Galas, M.-C. (291) 175)

Pramipexole (SND 919)
Dopamine receptor subtype (Mierau, J. (290) 29)

Pravastatin
Heart (rat); Mitochondria; Simvastatin (Satoh, K. (292) 271)

Prazosin
Blood pressure control; Sinoaortic denervation; Neostigmine; 6-Hydroxydopamine; Yohimbine (Taira, C.A. (271) 9)

α_1-Adrenoceptor; Blood pressure; Dopaminergic neurotransmission; Microdialysis (Sommermeyer, H. (276) 267)

Renal blood flow; Catecholamine release; Angiotensin II; Renal nerve; α-Adrenoceptor (Chen, K. (284) 281)

α_1-Adrenoceptor; Renal function; Phenylephrine (Chen, C. (287) 1)

[^{3}H]Prazosin binding
α_1-adrenoceptor subtype; Chlorethylclonidine; SZL-49 (Pimoule, C. (290) 49)

Prazosin-related antagonist
Cyclazosin; α_1-Adrenoceptor antagonist; α_1-Adrenoceptor subtype (Giardinà, D. (287) 13)

Precipitated withdrawal
Δ^9-Tetrahydrocannabinol; SR 141716A, (*N*-(piperidin-1-yl)-5-(4-chlorophenyl)-1(2,4-dichloro-phenyl)-4-methyl-1*H*-pyrazole carboxamide · HCl) (Aceto, M.D. (282) R1)

Preconditioning
Myocardial ischemia; K^+ channel, ATP-sensitive (Grover, G.J. (277) 271)

Pre-contraction
Isoprenaline-induced relaxation; cAMP; cGMP; Endothelium; Aorta, rat (Eckly, A.E. (271) 237)

Prednisolone
Bleomycin; Experimental hypoxemia; Doxapram; Almitrine; TEI-7322 (Horiuchi, H. (287) 27)

Prefrontal cortex
5-HT_2 receptor; Microdialysis; Clozapine; Antipsychotic (Schmidt, C.J. (273) 273)

Mediodorsal thalamic nucleus; Anesthesia; Excitatory amino acid (Pirot, S. (285) 45)

Pregnancy
Ca^{2+} channel; Vasoconstriction; Aortic ring; Nifedipine; Bay K 8644 (Roy, B. (280) 1)

Uterine artery; Vasopressin receptor; Arginine vasopressin; (Guinea-pig) (Jovanović, A. (280) 101)

G protein; $G_o\alpha$ subunit; Go isoform; Myometrium; Human uterus (Zumbihl, R. (288) 9)

Myometrium; K^+ channel; Ritodrine hydrochloride; β-Adrenoceptor agonist (Hamada, Y. (288) 45)

α_1-Adrenoceptor; Inositol 1,4,5-trisphosphate; Uterine artery (Zhang, L. (289) 375)

Prejunctional inhibition
K^+ channel, ATP-sensitive; Histamine H_3 receptor; Substance P (Ohkubo, T. (277) 45)

Prenatal diazepam
Forced swimming test; Desipramine; Alprazolam (Cannizzaro, C. (273) 239)

Prepulse inhibition
Dopamine; NMDA (*N*-methyl-D-aspartate); Accumbens; Schizophrenia; (Rat) (Reijmers, L.G.J.E. (272) 131)

Prepulse inhibition, rat
5-HT (5-hydroxytryptamine, serotonin); Glutamate; Antipsychotic; Schizophrenia (Varty, G.B. (287) 201)

Pressor response
Renin inhibitor; Spontaneously hypertensive rat (SHR); Renin, recombinant human; Oral absorption; Bioavailability (Shibasaki, M. (271) 341)

Nitric oxide (NO); N^G-Nitro-L-arginine; Sympathetic nervous system; Renin-angiotensin system; (Dog) (Nakahara, T. (287) 49)

Pressure overload
Propionyl-l-carnitine; Cardiac hypertrophy; Enalapril; Cardiac function (Micheletti, R. (286) 147)

Presynaptic α_2-adrenoceptor
α_2-Adrenoceptor subtype; Gastric acid secretion; Vagus nerve; (Rat) (Blandizzi, C. (278) 179)

Presynaptic action
Glutamate; Grease-gap; Hippocampus; Autoreceptor; (D.C. potential) (Shew, T.R. (284) 93)

Presynaptic inhibition
GABA (γ-aminobutyric acid); $GABA_B$ receptor; 2-Hydroxy-saclofen; Hippocampus; (Inhibition) (Caddick, S.J. (274) 41)

α_2-Adrenoceptor; Imidazoline receptor; Sympathoinhibition; Moxonidine; UK 14304 (Urban, R. (282) 19)

α_2-Adrenoceptor; Imidazoline receptor; Moxonidine; Rilmenidine; UK 14304 (Urban, R. (282) 29)

Presynaptic mechanism
Somatostatin; Synaptosome; Ileum, rat; Acetylcholine (Kurjak, M. (281) 295)

Presynaptic modulation
Antidepressant drug; Desipramine; Fluoxetine; Maprotiline; Moclobemide; Trimipramine; 2-Methyl-5-hydroxytryptamine; 5-HT (5-hydroxytryptamine, serotonin); Reuptake inhibition; Hippocampus (Mongeau, R. (271) 121)

Presynaptic potential
Ischemia; Glutathione; Hippocampus; 2-Deoxyglucose uptake; Neuroprotection (Shibata, S. (273) 191)

Ischemia; Nitric oxide (NO); Hippocampus; Neuroprotection (Shibata, S. (273) 223)

Primary afferent neuron
Antinociception; μ-Opioid receptor; Dorsal root ganglion; Ribonuclease protection assay; β-Funaltrexamine (Schäfer, M. (279) 165)

Primary culture
AMPA receptor; Cyclothiazide; Receptor desensitization; Ca^{2+} uptake; $[Ca^{2+}]_i$; Cerebellar granule neuron; Cortical neuron (Cebers, G. (290) 105)

Primary neuronal culture
Muscarinic receptor; Messenger RNA regulation; Polymerase chain reaction (Brusa, R. (289) 9)

Pristinamycin
Intestinal absorption; Intestinal epithelium; Caco-2; P-glycoprotein (Phung-Ba, V. (288) 187)

Procaine
Drug discrimination; Local anesthetic; Dopamine; Cocaine; Dimethocaine; Chloroprocaine; SCH 39166; Raclopride; (Squirrel monkey) (Mansbach, R.S. (274) 167)

Ag^+-induced contracture; Caffeine; Dithiothreitol; Skeletal muscle; (Frog) (Oba, T. (292) 301)

Progesterone
μ-Opioid receptor; Estrogen; Medial preoptic area; Upregulation (Zhou, L. (278) 271)

Prolactin
Diurnal alteration; Opioid mechanism; ACTH (adrenocorticotrophin); Corticosterone (Kiem, D.T. (272) 145)

5-HT (5-hydroxytryptamine, serotonin); ACTH (adrenocorticotropin); Corticosterone; Renin; Blood pressure; Heart rate (Levy, A.D. (274) 141)

Apomorphine; 5-HT (5-hydroxytryptamine, serotonin); Grooming, excessive; Penile erection; Oxytocin; Corticosterone; $5\text{-}HT_{2C}$ receptor; m-CPP (1-3-chlorophenylpiperazine); Hypothalamic paraventricular nucleus (Bagdy, G. (275) 301)

$5\text{-}HT_{1A}$ receptor; Corticosterone; Glucose; Flesinoxan; Defensive burying; Anxiety (Groenink, L. (280) 185)

Morphine; Antisense oligodeoxynucleotide; μ-Opioid receptor; δ-Opioid receptor; Growth hormone (Idänpään-Heikkilä, J.J. (284) 227)

Tolerance; Morphine; Thyrotropin; Growth hormone; Locomotor activity; Rectal temperature (Rauhala, P. (285) 69)

Proliferation
Ca^{2+}; Ca^{2+} channel antagonist; SR 33805; Smooth muscle cell (Dol, F. (280) 135)

Erythropoietin, recombinant human; Glomerular endothelial cell; Mesangial cell; Endothelin-1 (Nitta, K. (293) 491)

Prolyl-leucyl-glycinamide
β-Endorphin-(10–16); TRH (thyrotropin-releasing hormone); Melatonin; Nucleus accumbens; Antidepressant (Hatta, K. (284) 327)

Propionyl-L-carnitine
Pressure overload; Cardiac hypertrophy; Enalapril; Cardiac function (Micheletti, R. (286) 147)

Papillary muscle; Cardiomyopathy; (Hamster) (Maresca, P. (287) 303)

Propofol
$GABA_A$ receptor; Flunitrazepam binding; Alphaxalone; Chlormethiazole; (+)-Etomidate; Etazolate (Slany, A. (291) 99)

Propylbenzilylcholine mustard
Muscarinic receptor synthesis; HEL 299 cell; Receptor inactivation; Radioligand binding; cAMP accumulation (Haddad, E.-B. (290) 201)

Prostacyclin
Histamine; Prostaglandin E_2; Airway; (Human) (Knight, D.A. (272) 1)

Endothelin-1; IRL 1620; FR 139317; Nitric oxide (NO); Prostaglandin E_2; Endothelin receptor (Grassi-Kassisse, D.M. (282) 57)

Platelet inhibition; cAMP; cGMP; Nitric oxide (NO); Protein phosphorylation (Grünberg, B. (288) 329)

Prostacyclin receptor
Cicaprost; Non-prostanoid prostacyclin mimetic; Neutrophil, rat; Colon, rat (Wise, H. (278) 265)

Prostaglandin
Cytokine; Lipopolysaccharide; Mitogen; Nitric oxide (NO) (Akarasereenont, P. (273) 121)

Interleukin-1; Nitric oxide (NO); CRF (corticotropin-releasing factor; Neuroimmunology; N^G-Nitro-L-arginine; Hemoglobin; Indomethacin (Sandi, C. (274) 17)

Colon, rat; Cl^- channel; K^+ channel, Ca^{2+}; Enteric nervous system (Strabel, D. (274) 181)

Non-steroidal anti-inflammatory drug; Nitric oxide (NO); Endotoxic shock, acute; Gastrointestinal; Ulcer; Cardiovascular (Wallace, J.L. (280) 63)

LR-B/081; Angiotensin II; Smooth muscle cell; Inositol trisphosphate; Hypertrophy (Catalioto, R.-M. (280) 285)

Carrageenin edema; Nitric oxide (NO) (Sautebin, L. (286) 219)

Prostaglandin D_2
Prostanoid DP receptor; Myometrium, human; BW A868C; Smooth muscle (Fernandes, B. (283) 73)

Prostaglandin E_2
Histamine; Prostacyclin; Airway; (Human) (Knight, D.A. (272) 1)

Hyperalgesia; Phosphodiesterase; Rolipram; Sympathetically maintained pain (Ouseph, A.K. (273) 107)

Interleukin-1 receptor antagonist; Interleukin-1; 5-Lipoxygenase; Stomach, rat (Montuschi, P. (275) 31)

Iloprost; Desensitization; Indomethacin; cAMP; Vasorelaxation (Parfenova, H. (278) 133)

Lipocortin/annexin; Anti-inflammatory peptide; Interleukin-1β; Fever (Palmi, M. (281) 97)

Endothelin-1; IRL 1620; FR 139317; Prostacyclin; Nitric oxide (NO); Endothelin receptor (Grassi-Kassisse, D.M. (282) 57)

Interleukin-1 receptor antagonist; Interleukin-1; 5-Lipoxygenase; Stomach, rat (Montuschi, P. (282) 263)

Prostaglandin E_2 release
Spinal cord slice; Capsaicin; Capsazepine; Cyclooxygenase inhibition (Malmberg, A.B. (271) 293)

Prostaglandin $F_{2\alpha}$
Aorta, rat; Sulfonylurea; Prostanoid; Glibenclamide; Tolbutamide; Thromboxane A_2 (Delaey, C. (280) 179)

PACAP (pituitary adenylate cyclase activating polypeptide); Cerebral artery, canine; Intracerebral arteriole, rat; Endothelium-derived contracting factor (Anzai, M. (285) 173)

Prostaglandin G/H synthase (cyclooxygenase)
Whole blood, human; Etodolac; Naproxen; Diclofenac; Tenidap (Glaser, K. (281) 107)

Prostaglandin I_2
Angiotensin II; Bradykinin; Vasopressin; Pulmonary artery; Pulmonary vein; Nitric oxide (NO) (Sai, Y. (282) 235)

Prostanoid
Histamine; Airway; (Human) (Knight, D.A. (272) 13)

Aorta, rat; Sulfonylurea; Prostaglandin $F_{2\alpha}$; Glibenclamide; Tolbutamide; Thromboxane A_2 (Delaey, C. (280) 179)

Prostanoid DP receptor
Myometrium, human; Prostaglandin D_2; BW A868C; Smooth muscle (Fernandes, B. (283) 73)

Prostanoid TP receptor
Isoprostane; Myometrium, human; Contraction; U46619 (Crankshaw, D. (285) 151)

Prostate, rat
5-HT_2 receptor; α-Adrenoceptor; Smooth muscle; Autoradiography (Killam, A.L. (273) 7)

Protection
Seizure; Adenosine A_3 receptor; (Mouse) (Von Lubitz, D.K.J.E. (275) 23)

Protein extravasation
β-Adrenoceptor; Endothelium; Vascular permeability; Salbutamol; Salmeterol (Allen, M.J. (274) 7)

Protein kinase
Opioid; Physical dependence; Morphine; Butorphanol; H-7; H-8 (Tokuyama, S. (284) 101)

Mast cell; Histamine; Endothelin; Staurosporine; IAP (islet-activating protein) (Yamamura, H. (288) 269)

Protein kinase A
Opioid tolerance; Morphine; Butorphanol; Protein kinase C (Narita, M. (271) 543)

Protein kinase C; Opioid tolerance (Narita, M. (280) R1)

Phosphoinositide-specific phospholipase C; Inositol 1,4,5-trisphosphate; Desensitization; Protein kinase C; Phosphatidylinositol 4,5-bisphosphate (Fisher, S.K. (288) 231)

Phosphoinositide turnover; Endothelin; C_6 glioma cell; (ATP) (Lin, W.W. (291) 1)

Ca^{2+}-ATPase; Protein kinase C; Calmodulin; Megakaryocyte, rat; Patch-clamp (Uneyama, C. (291) 381)

Protein kinase C
α_1-Adrenoceptor; Muscarinic acetylcholine receptor; Cardiac action potential; Positive inotropic effect; Arachidonic acid metabolism (Arreola, J. (271) 309)

Opioid tolerance; Morphine; Butorphanol; Protein kinase A (Narita, M. (271) 543)

Chronic opioid treatment; Phorbol ester binding; Morphine; Butorphanol (Narita, M. (271) 547)

Contraction; Histamine; Bronchus, human; GF 109203X; Phorbol ester (Yang, K.X.F. (275) 283)

α_2-Adrenoceptor; Smooth muscle, vascular; Phospholipase D (Aburto, T. (277) 35)

Diabetes mellitus; Phorbol ester; Ca^{2+}, extracellular; Ca^{2+} channel; Aorta, rat (Hattori, Y. (279) 51)

Opioid dependence; Central nervous system; Ca^{2+} channel; Diltiazem; Morphine; Butorphanol (Tokuyama, S. (279) 93)

Protein kinase A; Opioid tolerance (Narita, M. (280) R1)

Bradykinin; Uterus, rat; Vas deferens, rat; Trachea, guinea pig; Ileum, guinea pig; Urinary bladder, guinea pig; Ca^{2+}; G protein (Calixto, J.B. (281) 279)

Pacing-induced heart failure; Polymyxin B; α-Adrenoceptor; Smooth muscle, vascular (Forster, C. (283) 241)

Endothelin-1; Endothelin-3; Phosphatidylinositol hydrolysis; Human bronchi (Nally, J.E. (288) 53)

α_1-Adrenoceptor; Inositol triphosphate; Na^+,K^+-ATPase; Second messenger; Renal proximal tubule (Gopalakrishnan, S.M. (288) 139)

Phosphoinositide-specific phospholipase C; Inositol 1,4,5-trisphosphate; Desensitization; Protein kinase A; Phosphatidylinositol 4,5-bisphosphate (Fisher, S.K. (288) 231)

Daphnoretin; Neutrophil (rat); Respiratory burst; Staurosporine; Ca^{2+}; [^{3}H]Phorbol-12,13-dibutyrate binding (Wang, J.-P. (288) 341)

Endothelin-1; Protein phosphorylation; Heart, rat (Gando, S. (289) 175)

Dopamine; D_1 receptor; Fenoldopam; Bromocriptine (Kansra, V. (289) 391)

Histamine; Phospholipase C; Phorbol ester; Staurosporine; Ro 31-8220; Adrenal chromaffin cell (Bunn, S.J. (290) 227)

Smooth muscle; Ca^{2+}; Protein kinase C; (vascular); (cytosolic); (particulate) (Bazan, E. (290) 253)

Smooth muscle; Ca^{2+}; Protein kinase C; (vascular); (cytosolic); (particulate) (Bazan, E. (290) 253)

Ca^{2+}; Airway smooth muscle (Hoiting, B.H. (290) R5)

Neutrophil; Degranulation; Ca^{2+}; cAMP; cGMP; Tolfenamic acid (Kankaanranta, H. (291) 17)

Angiotensin AT_{1A} receptor; Receptor internalization; G-protein coupling; Regulation (Balmforth, A.J. (291) 135)

Desensitization; Phospholipase C; G-proteins; P_{2Y} purinoceptors (Galas, M.-C. (291) 175)

Ca^{2+}-ATPase; Protein kinase A; Calmodulin; Megakaryocyte, rat; Patch-clamp (Uneyama, C. (291) 381)

GABA ρ_1 receptor; *Xenopus* oocyte; Down-regulation; Phorbol ester; Staurosporine (Kusama, T. (291) 431)

Protein kinase inhibitor
Intimal hyperplasia; Hyperreactivity; Myosin light chain phosphorylation; HA1077; $[Ca^{2+}]_i$ (Seto, M. (276) 27)

Catecholamine; Dopamine; Dopamine receptor, agonist, antagonist; Ouabain; Ionic mechanism; Voltage clamp; Neuron; (Snail) (Emaduddin, M. (283) 113)

Protein phosphatase
Neutrophil; Respiratory burst; Calyculin A; Okadaic acid (Djerdjouri, B. (288) 193)

Protein phosphorylation
Heart, rat; α_1-Adrenoceptor; β-Adrenoceptor; Myocardial contractility (Hartmann, M. (287) 57)

Platelet inhibition; cAMP; cGMP; Prostacyclin; Nitric oxide (NO) (Grünberg, B. (288) 329)

Endothelin-1; Protein kinase C; Heart, rat (Gando, S. (289) 175)

PAF (platelet activating factor); PCA-4248; Phosphoinositides; Platelets (Catalán, R.E. (290) 183)

Protein synthesis
β-Adrenoceptor agonist; Clenbuterol; Taurine; Urinary marker (Waterfield, C.J. (293) 141)

Proton
Vanilloid receptor; Vanilnoid, endogenous; Resiniferatoxin binding; Capsaicin; Positive cooperativity; Non-competitive inhibition; Desensitization (Szallasi, A. (289) 181)

Proximal colon, guinea-pig
Tachykinin NK_2 receptor; Tachykinin receptor antagonist; MEN 10,627; SR 48968; Gallbladder, guinea-pig (Patacchini, R. (271) 111)

Proximal duodenum, rat
Nitric oxide (NO); NANC (non-adrenergic, non-cholinergic) nerve; Smooth muscle relaxation; Apamin; K^+ channel; cGMP (Martins, S.L.R. (284) 265)

Psycholeine
Quadrigemine C; Somatostatin; Growth hormone; Adenylate cyclase (Rasolonjanahary, R. (285) 19)

Psychophysiological status
Nitric oxide (NO); Locomotor activity; Startle response; Learning (Sandi, C. (277) 89)

Puberty
Sexual behavior; 5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_2$ receptor agonist; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Testosterone; Castration (Padoin, M.J. (277) 1)

Pulmonary artery
HOE 140; Bronchus; Umbilical artery; Umbilical vein; (Human) (Félétou, M. (274) 57)

Angiotensin II; Bradykinin; Vasopressin; Pulmonary vein; Nitric oxide (NO); Prostaglandin I_2 (Sai, Y. (282) 235)

Pulmonary artery, rabbit
Des-Asp-angiotensin I; Losartan; PD123319; Transmural stimulation; (Superfusion) (Sim, M.K. (284) 215)

Pulmonary inflammation
Delayed-type hypersensitivity; Vascular permeability; Airway hyperreactivity, mouse; LCB 2183 (Buckley, T.L. (282) 103)

Pulmonary response
Evan's blue; Capsaicin (Bolser, D.C. (276) R1)

Pulmonary vascular bed, cat
Allicin; Pulmonary vascular bed, rat; Vasodilator response; N^{ω}-Nitro-L-arginine methyl ester; Methylene blue; Hypoxic pulmonary vasoconstriction; Guanylate cyclase (Kaye, A.D. (276) 21)

L-163,491; Angiotensin receptor-mediated response; Captopril; PD 123319; DuP 532 (Kaye, A.D. (287) 163)

Pulmonary vascular bed, rat
Allicin; Pulmonary vascular bed, cat; Vasodilator response; N^{ω}-Nitro-L-arginine methyl ester; Methylene blue; Hypoxic pulmonary vasoconstriction; Guanylate cyclase (Kaye, A.D. (276) 21)

Pulmonary vein
Angiotensin II; Bradykinin; Vasopressin; Pulmonary artery; Nitric oxide (NO); Prostaglandin I_2 (Sai, Y. (282) 235)

Pulmonary vein, sheep
Vasodilatation; 5-HT (5-hydroxytryptamine, serotonin); Endothelium; Cyclic nucleotide (Zhang, L. (280) 335)

Punishment
$5\text{-}HT_{1A}$ receptor; Ipsapirone; (*S*)-WAY 100135; Conflict; Anxiolytic activity (Cervo, L. (284) 249)

Purinergic transmission
Tail artery, rat; Sympathetic nerve stimulation; P_{2X} purinoceptor; Suramin (McLaren, G.J. (277) 57)

Pyramidal tract neuron
$GABA_B$ receptor antagonist; CGP 35348; Transcallosal response, cat; Motor cortex (Chowdhury, S.A. (285) 99)

Pyrantel
Acetylcholine; Ion channel; *Ascaris*, muscle; Anthelmintic; Parasitic nematode (Robertson, S.J. (271) 273)

Pyrethroid
Neurotoxicity; DDT (1,1,1-trichloro-2,2-bis(*p*-chlorophenyl)-ethane); Interaction; Behavior; Acetylcholine receptor (Johansson, U. (293) 159)

Pyridine
Vasorelaxation; Ca^{2+} influx (Hsu, K.-S. (292) 265)

Pyridobenzodiazepine
Dopamine D_4 receptor; Clozapine (Liégeois, J.-F. (273) R1)

Pyrrolidinone
Dopamine; Substantia nigra; GABA (γ-aminobutyric acid); NMDA (*N*-methyl-D-aspartate) (Shepard, P.D. (285) 79)

Quadrigemine C
Psycholeine; Somatostatin; Growth hormone; Adenylate cyclase (Rasolonjanahary, R. (285) 19)

Quinidine
Coronary occlusion; Adenosine release; Reperfusion arrhythmia; Lidocaine; Gallopamil (Bernauer, W. (283) 91)

Quinolinic acid neurotoxicity
Chronic CGP 39551; NMDA receptor; [^{3}H]Noradrenaline release; Hippocampus; Autoradiography (Mennini, T. (271) 93)

Quinpirole
Antidepressant; Dopamine receptor; SKF 38393; Motor activity (Allison, K. (277) 139)

Dopamine receptor agonist; Clozapine; Dopamine D_1 receptor; Dopamine D_2 receptor; Antipsychotic, atypical; Scopolamine; SKF38393; (Rat) (Jackson, D.M. (282) 137)

Nucleus accumbens, shell, core; Dopamine D_1 receptor; Dopamine D_2 receptor; SKF 82958; SCH 23390; (−)-Sulpiride; Jaw movement; (Rat) (Cools, A.R. (286) 41)

R56865
6-Hydroxydopamine; H_2O_2; Bupropion; Cytotoxicity; Cytoprotection; Chromaffin cell (Abad, F. (293) 55)

Raclopride
Drug discrimination; Local anesthetic; Dopamine; Cocaine; Dimethocaine; Procaine; Chloroprocaine; SCH 39166; (Squirrel monkey) (Mansbach, R.S. (274) 167)

Antipsychotic drug; Dopamine D_2 receptor; Dopamine D_4 receptor; Nemonapride (Seeman, P. (291) 59)

Radial maze
Etonitazene; Morphine; Naloxone; Opioid; Memory (Braida, D. (271) 497)

Radioligand
PET (positron emission tomography); Receptor imaging; β-Adrenoceptor (Van Waarde, A. (272) 159)

Radioligand binding
Neuropeptide Y; SK-N-MC cell; BIBP3226 (Entzeroth, M. (278) 239)

CCK_A receptor; CCK_B receptor; $CCK_{A/B}$ receptor antagonist, mixed; Gall bladder, guinea pig; Anxiolytic (Singh, L. (286) 185)

α_1-Adrenoceptor subtype; COS-7 cells; Benign prostatic hypertrophy (Foglar, R. (288) 201)

α_{1B}-Adrenoceptor; Chinese hamster ovary (CHO) cell; Concentration, cytosolic Ca^{2+}; Receptor occupancy-response relationship (Horie, K. (288) 303)

Muscarinic receptor synthesis; Propylbenzilylcholine mustard; HEL 299 cell; Receptor inactivation; cAMP accumulation (Haddad, E.-B. (290) 201)

Endorphin receptor; Recombinant cell; cAMP; Adenylyl cyclase (Knapp, R.J. (291) 129)

NS-49; Oxymetazoline; α_1-Adrenoceptor subtype; Cloned receptor; Cytosolic Ca^{2+} concentration (Obika, K. (291) 327)

Radioligand, in vivo
WAY-100635; $5\text{-}HT_{1A}$ receptor; Brain, rat; PET (positron emission tomography) (Hume, S.P. (271) 515)

Radioreceptor assay
σ Binding site, heterogeneity; DTG (1,3-di(2-tolyl)guanidine); (+)-Pentazocine; Brain; Spinal cord; (Mouse) (Kovács, K.J. (285) 127)

Raphe nuclei
5-HT (5-hydroxytryptamine, serotonin) uptake; Fluoxetine; Frontal cortex; Ventral hippocampus; Microdialysis, in vivo (Malagié, I. (286) 213)

$^{86}Rb^+$ efflux
Cromakalim; RP 49356; Myometrium; $^{42}K^+$ efflux; K^+ channel (Piper, I.T. (283) 1)

Rb^+ flux
Nitrendipine; MDCK cell; K^+ flux; Cell membrane; Na^+, K^+, Cl^- cotransport; K^+ channel; Red blood cell (López-Burillo, S. (289) 259)

RB 101 (mixed enkephalin-degrading enzyme inhibitor)
Morphine; CCK_B receptor antagonist; Formalin test; Naloxone; Naltrindole; (Mouse) (Noble, F. (273) 145)

Enkephalin catabolism inhibitor; Enkephalin, endogenous; CCK (cholecystokinin); PD-134,308; Tail-flick; Hot-plate; Antinociception; CCK_B receptor antagonist; Tolerance (Valverde, O. (286) 79)

Reactive oxygen species
Anti-oxidant; Decongestive nose drops; Hydroxyl radical scavenging; Lipid peroxidation; Nasal inflammation (Westerveld, G.-J. (291) 27)

Receptor
Somatostatin; sstr1 receptor; Cerebellar nuclei; Autoradiography (Bucharles, C. (271) 79)

Alcoholization; 5-HT (5-hydroxytryptamine, serotonin); mRNA; Binding; Autoradiography; (Rat) (Nevo, I. (281) 229)

Receptor alkylation, irreversible
Muscarinic receptor; β-Adrenoceptor (Watson, N. (278) 195)

Receptor autoradiography
Nucleus tractus solitarii; Neuropeptide Y receptor; α_2-Adrenoceptor; Cardiovascular (Yang, S.-N. (271) 201)

Cerebral ischemia; Glycine; MAP2 (microtubule-associated protein 2); Immunohistochemistry (Araki, T. (278) 91)

Dopamine D_2 receptor; Dopamine D_3 receptor; [^{125}I]Iodosulpiride; Striatum; Cerebellum; (Rat) (Levant, B. (278) 243)

Somatostatin; SS-2 binding site; SRIF-2 binding site; Recombinant SSTR-1 receptor; Adenylate cyclase; In situ hybridization (Hoyer, D. (289) 151)

Somatostatin; SS-1 binding site; SRIF-1 binding site; Recombinant SSTR-2 receptor; Adenylate cyclase; In situ hybridization (Schoeffter, P. (289) 163)

Receptor binding
σ Receptor; Ifenprodil; Eliprodil; Subtype; Brain, rat (Hashimoto, K. (273) 307)

Behavioral pharmacology; Schedule-controlled behavior; Phencyclidine; Drug dependence; Drug tolerance; Sex difference; (Rat) (Wessinger, W.D. (277) 107)

Naloxone benzoylhydrazone; Ileum, guinea pig; κ-Opioid receptor (Berzetei-Gurske, I.P. (277) 257)

Benzodiazepine; Spinal cord; Alpidem-insensitive site (Maguire, P.A. (280) 167)

Levetiracetam; ucb L059; Epilepsy; Anticonvulsant (Noyer, M. (286) 137)

Motilin; Motilin receptor antagonist; Smooth muscle contraction; Erythromycin; Motilide (Depoortere, I. (286) 241)

Angiotensin II; Angiotensin AT_1 receptor antagonist; LR-B/081; Losartan (Renzetti, A.R. (290) 151)

Receptor desensitization
Airway hyperreactivity; β-Adrenoceptor agonist; Salbutamol; β-Adrenoceptor; (Guinea pig) (Buchheit, K.-H. (287) 85)

AMPA receptor; Cyclothiazide; Ca^{2+} uptake; $[Ca^{2+}]_i$; Cerebellar granule neuron; Cortical neuron; Primary culture (Cebers, G. (290) 105)

Receptor displacement
Endothelin; Heart; Ischemia (Franco-Cereceda, A. (279) 105)

Receptor down-regulation
Benzodiazepine type I receptor; [^{3}H]Zolpidem; Tolerance; Midazolam; Flurazepam (Wu, Y. (278) 125)

Receptor-G protein coupling
Dopamine D_2 receptor; Muscarinic acetylcholine receptor; $GABA_B$ receptor; GTPase; Striatum (Odagaki, Y. (291) 245)

Receptor imaging
PET (positron emission tomography); β-Adrenoceptor; Radioligand (Van Waarde, A. (272) 159)

Receptor inactivation
Muscarinic receptor synthesis; Propylbenzilylcholine mustard; HEL 299 cell; Radioligand binding; cAMP accumulation (Haddad, E.-B. (290) 201)

Receptor internalization
Angiotensin AT_{1A} receptor; Protein kinase C; G-protein coupling; Regulation (Balmforth, A.J. (291) 135)

Receptor ligand
Cell proliferation; Mammary carcinoma cell; Colon carcinoma cell; Melanoma cell (Brent, P.J. (278) 151)

Receptor occupancy-response relationship
α_{1B}-Adrenoceptor; Chinese hamster ovary (CHO) cell; Radioligand binding studies; Concentration, cytosolic Ca^{2+} (Horie, K. (288) 303)

Receptor occupation
MPC-1304; Ca^{2+} channel antagonist receptor; Spontaneously hypertensive rat (SHR) (Nozawa, Y. (287) 191)

Receptor reserve
Adrenoceptor; Norepinephrine; Inositol phosphate; Spare receptor (Esbenshade, T.A. (289) 305)

Receptor subtype
Endothelin; Alanine analog; Ileum, guinea-pig; Sarafotoxin S6c; Tachyphylaxis (Miasiro, N. (278) 103)

Receptor subunit
$GABA_A$ receptor; Antisense oligonucleotide; Benzodiazepine receptor; Brain, rat (Karle, J. (291) 439)

Receptor theory, modified
Muscarinic receptor; Ca^{2+} mobilization; Agonists dual effect (Järv, J. (291) 43)

Receptor upregulation
Bradykinin B_1 receptor; Cycloheximide; Brefeldin A; Tunicamycin; Aorta, isolated, rabbit (Audet, R. (271) 551)

β-Adrenoceptor; Ageing; β-Adrenoceptor blockade; cAMP; (Rat) (Conlon, D. (289) 283)

σ Receptor
Ifenprodil; Eliprodil; Subtype; Receptor binding; Brain, rat (Hashimoto, K. (273) 307)

Phenylmorphan; Opioid; (Subtype selectivity) (Bowen, W.D. (278) 257)

Ibogaine; (Subtype selectivity) (Bowen, W.D. (279) R1)

Dystonia; Haloperidol; Red nucleus; DTG (di-*o*-tolylguanidine) (Matsumoto, R.R. (280) 301)

Cardiac myocyte; Contractility; $[Ca^{2+}]_i$ transient (Novakova, M. (286) 19)

(+)-Pentazocine; *N*-Allylnormetazocine; Dopamine; Striatum; Microdialysis (Gudelsky, G.A. (286) 223)

p-Chloroamphetamine; Dextromethorphan; Neurotoxicity; 5-HT (5-hydroxytryptamine, serotonin); Brain (Narita, N. (293) 277)

σ Receptor ligand
Tyrosine hydroxylase; Turning; Dopamine; DTG (1,3-di-*o*-tolylguanidine) (Weiser, S.D. (275) 1)

Recombinant cell
Endorphin receptor; Radioligand binding; cAMP; Adenylyl cyclase (Knapp, R.J. (291) 129)

Recombinant P_{2Y1} purinoceptor
Brain, chicken; G-protein-coupled receptor; *Xenopus* oocyte expression; COS-7 cell, transient expression; Inositol 1,4,5-trisphosphate, formation (Simon, J. (291) 281)

Recombinant PACAP receptor
PACAP (pituitary adenylate cyclase activating polypeptide) analog (Gourlet, P. (287) 7)

Recombinant receptor
PACAP type I receptors; Alternative splicing (Ciccarelli, E. (288) 259)

Recombinant SSTR-1 receptor
Somatostatin; SS-2 binding site; SRIF-2 binding site; Adenylate cyclase; Receptor autoradiography; In situ hybridization (Hoyer, D. (289) 151)

Recombinant SSTR-2 receptor
Somatostatin; SS-1 binding site; SRIF-1 binding site; Adenylate cyclase; Receptor autoradiography; In situ hybridization (Schoeffter, P. (289) 163)

Rectal temperature
Tolerance; Morphine; Thyrotropin; Prolactin; Growth hormone; Locomotor activity (Rauhala, P. (285) 69)

Red blood cell
Endothelin-1; Staphylococcal α-toxin; Phosphoramidon; Pepstatin A; Chymostatin; Leupeptin (Tippler, B. (271) 131)

Nitrendipine; MDCK cell; K^+ flux; Rb^+ flux; Cell membrane; Na^+, K^+, Cl^- cotransport; K^+ channel (López-Burillo, S. (289) 259)

Red nucleus
L-Arginine; Analgesia; Nitric oxide (NO); cGMP (Kumar, A. (279) 1)

Dystonia; Haloperidol; σ Receptor; DTG (di-*o*-tolylguanidine) (Matsumoto, R.R. (280) 301)

Red wine
5-HT (5-hydroxytryptamine, serotonin); Platelet; Migraine; Headache (Pattichis, K. (292) 173)

Reference memory
CGP 37849; Working memory; NMDA receptor (Deacon, R.M.J. (280) 239)

Refractoriness
Semotiadil; Diltiazem; Amlodipine; Nifedipine; Conduction interval (Stark, G. (286) 71)

Refractory period
Action potential; K^+ channel blocker; Langendorff; (Rat); (Guinea-pig) (D'Alonzo, A.J. (272) 269)

Regulation
Angiotensin AT_{1A} receptor; Protein kinase C; Receptor internalization; G-protein coupling (Balmforth, A.J. (291) 135)

Regulatory protein
Ca^{2+} sensitizer; Motility assay, in vitro; Pimobendan (Sata, M. (290) 55)

Reinforcement schedule
Drinking behavior; 5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Obsessive-compulsive disorder (Roehr, J. (278) 75)

Relaxation
Atrium, rat; Contraction, force of; Aortic ring; cGMP-dependent protein kinase; Acetylcholine (Bäumner, D. (273) 295)

5-HT receptor; Colon, guinea pig; Gastrointestinal motility; Enteric nerve (Briejer, M.R. (279) 123)

Bradykinin; Trachea, guinea-pig; Epithelium; Bradykinin B_2 receptor; Ca^{2+}; Ryanodine; Apamin; HOE 140; NPC 17761 (Schlemper, V. (282) 177)

Release
GABA (γ-aminobutyric acid); Epidural cup; Modafinil; 5-HT (5-hydroxytryptamine, serotonin); Cerebral cortex (Tanganelli, S. (273) 63)

FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5891; (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-*N*-methyl-3-pyridinecarboxamide; FG5893 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester; FG5909 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-hydroxypyridine; Reuptake; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline (Pettersson, E. (282) 131)

Remacemide hydrochloride
FPL 12495AA; Cortical wedge; NMDA receptor (Hu, R.Q. (287) 251)

Remoxipride
Antinociception; Catalepsy; Rotarod; (Sheep) (Main, D.C.J. (287) 221)

cAMP; Striatum; Dopamine D_2 receptor; Metabolite, remoxipride (Westlind-Danielsson, A. (288) 89)

Renal artery, rat
Acetylcholine; Endothelium-dependent contraction; Arachidonic acid metabolite (Nishimura, Y. (275) 217)

Renal blood flow
Catecholamine release; Angiotensin II; Renal nerve; Prazosin; α-Adrenoceptor (Chen, K. (284) 281)

Dopamine; Fenoldopam; Noradrenaline; Splanchnic blood flow; Oxygen demand; Oxygen supply; Oxygen extraction ratio (Schiffer, E.R. (286) 49)

CGRP (calcitonin gene-related peptide); Renal conductance; Na^+ excretion; K^+ excretion; CGRP-(8–37); [Tyr^0]CGRP-(28–37) (Elhawary, A.M. (286) 255)

Renal conductance
CGRP (calcitonin gene-related peptide); Renal blood flow; Na^+ excretion; K^+ excretion; CGRP-(8–37); [Tyr^0]CGRP-(28–37) (Elhawary, A.M. (286) 255)

Renal cortex
Phospholipid metabolism; U50,488; Ethylketocyclazocine; Norepinephrine; Carbachol (Mosaddeghi, M. (289) 411)

Renal function
Diazepam; Clonazepam; Ro 5-4864; Kidney, isolated, perfused; Renal vasculature; (Rat) (Monasterolo, L.A. (276) 201)

Angiotensin AT_1 receptor antagonist; Captopril; Angiotensin converting enzyme inhibitor; (Anesthetized dog) (Clark, K.L. (280) 195)

α_1-Adrenoceptor; Phenylephrine; Prazosin (Chen, C. (287) 1)

Renal ischemia / reperfusion
Myeloperoxidase; Tetramethylbenzidine; Polymorphonucleocyte; Adhesion molecule (Laight, D.W. (292) 81)

Renal kallikrein secretion
Ca^{2+}; K^+; Ca^{2+} channel antagonist; Ouabain; Vanadium (Bompart, G. (278) 225)

Renal nerve
Renal blood flow; Catecholamine release; Angiotensin II; Prazosin; α-Adrenoceptor (Chen, K. (284) 281)

Renal proximal tubule
α_1-Adrenoceptor; Inositol triphosphate; Protein kinase C; Na^+,K^+-ATPase; Second messenger (Gopalakrishnan, S.M. (288) 139)

Renal vasculature
Diazepam; Clonazepam; Ro 5-4864; Kidney, isolated, perfused; Renal function; (Rat) (Monasterolo, L.A. (276) 201)

Renin
5-HT (5-hydroxytryptamine, serotonin); ACTH (adrenocorticotropin); Corticosterone; Prolactin; Blood pressure; Heart rate (Levy, A.D. (274) 141)

Renin-angiotensin system
Angiotensin IV; (Receptor) (Bernier, S.G. (271) 55)

Nitric oxide (NO); N^G-Nitro-L-arginine; Pressor response; Sympathetic nervous system; (Dog) (Nakahara, T. (287) 49)

Nitric oxide (NO); Hypertension; Enalapril; Myocardial ischemia (Moreno, Jr., H. (287) 93)

Renin inhibitor
Spontaneously hypertensive rat (SHR); Renin, recombinant human; Pressor response; Oral absorption; Bioavailability (Shibasaki, M. (271) 341)

Renin, recombinant human
Renin inhibitor; Spontaneously hypertensive rat (SHR); Pressor response; Oral absorption; Bioavailability (Shibasaki, M. (271) 341)

Reperfusion
Ischemia; Skeletal muscle; Phosphocreatine disodium salt; Phosphocreatine di-L-arginine salt; L-Arginine; Current clamp; Electrophysiology (Tricarico, D. (287) 17)

Reperfusion arrhythmia
Free radical; *t*-Butyl hydroperoxide; Sinoatrial node; Atrioventricular node; Lipid peroxidation (Satoh, N. (272) 233)

Coronary occlusion; Adenosine release; Lidocaine; Quinidine; Gallopamil (Bernauer, W. (283) 91)

Reperfusion injury
Thromboxane receptor antagonist; Myocardial ischemia; Aspirin (Gomoll, A.W. (271) 471)

Myocardial ischemia; Adenosine A_1 receptor agonist; Infarct (Lee, Y.-M. (279) 251)

Repetitive jaw movement
YM-14673; TRH (thyrotropin-releasing hormone); Nucleus accumbens; Striatum; Dopamine receptor (Miwa, Y. (277) 63)

Reporter gene
Aryl hydrocarbon receptor; PCB; 2,3,7,8-TCDD; Biomarker; (Interaction) (Aarts, J.M.M.J.G. (293) 463)

Reproduction effect
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Neurobehavioral effect; Endocrine effect; LOAEL (lowest observable adverse effect level); TEF (toxic equivalency factor); Experimental animal; Human infant; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

RES-701-1
Endothelin; Endothelin receptor subtype; IRL 1620; FR139317; Duodenum; (Rat) (Irie, K. (275) 45)

Reserpine
Nitric oxide (NO); Dopamine; Motor behavior; (Mouse) (Starr, M.S. (272) 211)

NMDA (*N*-methyl-D-aspartate); Theophylline; Motor activity; (Mouse) (Giménez-Llort, L. (275) 171)

Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propylaminotetralin); SKF 38393; Motor behavior; (Mouse) (Starr, M.S. (277) 151)

Motor behavior; Dextromethorphan; Dopamine D_1 receptor; Dopamine D_2 receptor; L-DOPA (L-3,4-dihydroxyphenylalanine); (Mouse) (Kaur, S. (280) 159)

Resiniferatoxin binding
Vanilloid receptor; Vanilnoid, endogenous; Capsaicin; Proton; Positive cooperativity; Non-competitive inhibition; Desensitization (Szallasi, A. (289) 181)

Resistance vessel
Elgodipine; Ca^{2+} channel antagonist; Conductance vessel; (Rabbit); (Sheep) (Chulia, T. (285) 115)

Respiratory activity
Excitatory amino acid; Ventrolateral nucleus of the tractus solitarius; NMDA receptor; Apneusis (Berger, I. (277) 195)

Respiratory burst
Glucocorticoid; Peritoneal leukocyte; Activation, ex vivo; (Rat) (Røshol, H. (286) 9)

Neutrophil; Calyculin A; Okadaic acid; Protein phosphatase (Djerdjouri, B. (288) 193)

Daphnoretin; Neutrophil (rat); Staurosporine; Protein kinase C; Ca^{2+}; [^{3}H]Phorbol-12,13-dibutyrate binding (Wang, J.-P. (288) 341)

Respiratory function
Ventrolateral medulla; Glutamate receptor; L-Glutamate uptake inhibitor; Excitatory amino acid receptor antagonist; Blood pressure; Heart rate (McManigle, J.E. (280) 257)

Restraint
Antinociception; Histamine H_2 receptor; Hot plate test (Wong, C.-L. (279) 109)

Retention
Mammillary complex; Memory; Acetylcholine; Dopamine; Norepinephrine; NMDA (*N*-methyl-D-asparate); Nicotine; Neuropeptide Y; GABA (γ-aminobutyric acid); (Mouse) (Flood, J.F. (275) 223)

Reticulospinal vasomotor neuron
Anesthesia; Urethane; Chemoreflex; Rostral ventrolateral medulla; (Rats) (Sun, M.-K. (293) 237)

Retina
Excitatory amino acid receptor antagonist; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid); NMDA (*N*-methyl-D-aspartate); Thiokynurenic acid; Rose bengal (Lombardi, G. (271) 489)

Patch clamp; GABA receptor; Cl^- channel; Bicuculline; Bipolar cell; Rod pathway (Feigenspan, A. (288) 97)

Reuptake
FG5865 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide); FG5891; (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-*N*-methyl-3-pyridinecarboxamide; FG5893 (2-[4-[4,4-bis(4-

fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester; FG5909 (2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-hydroxypyridine; Release; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Noradrenaline (Pettersson, E. (282) 131)

Reuptake inhibition
Antidepressant drug; Desipramine; Fluoxetine; Maprotiline; Moclobemide; Trimipramine; 2-Methyl-5-hydroxytryptamine; 5-HT (5-hydroxytryptamine, serotonin); Hippocampus; Presynaptic modulation (Mongeau, R. (271) 121)

Reward
5-HT_3 receptor; Dopamine; Granisetron; Morphine (Rompré, P.-P. (287) 263)

RG20 gene
α-Adrenoceptor; Blood pressure; Central nervous system; (Rat) (Nunes, J.P. (278) 183)

Rhesus monkey
BW373U86; δ-Opioid receptor agonist; Allodynia; Hyperalgesia (Butelman, E.R. (277) 285)

Rhinitis
Interleukin-5; Eosinophil cationic protein (ECP); House dust mite; Fluticasone propionate, aquous nasal spray (Garrelds, I.M. (275) 295)

Ribonuclease protection assay
Antinociception; μ-Opioid receptor; Dorsal root ganglion; Primary afferent neuron; β-Funaltrexamine (Schäfer, M. (279) 165)

Rigidity
Riluzole; Neuroprotection; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Bradykinesia; Dopamine release; Parkinson's disease; (Rhesus monkey) (Benazzouz, A. (284) 299)

Rilmenidine
α_2-Adrenoceptor; Imidazoline receptor; Presynaptic inhibition; Moxonidine; UK 14304 (Urban, R. (282) 29)

[^{3}H]Rilmenidine
Imidazoline receptor; α_{2A}-Adrenoceptor; α_{2B}-Adrenoceptor; Kidney, rat; [^{3}H]Idazoxan; Autoradiography (King, P.R. (281) 341)

Riluzole
Neuroprotection; MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine); Bradykinesia; Rigidity; Dopamine release; Parkinson's disease; (Rhesus monkey) (Benazzouz, A. (284) 299)

Risk assessment
Epidemiology (Gangolli, S.D. (292) 1)

Risk evaluation
Dioxin; Toxic equivalency; Acute toxicity; Strain difference (Pohjanvirta, R. (293) 341)

Risperidone
Olanzapine; Seroquel; Ziprasidone; Amperozide; Schizophrenia; Ventral tegmental area; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (281) 289)

Ritanserin
Morphine tolerance; Methysergide; Metergoline; Mianserin; Antinociception (Zarrindast, M.-R. (273) 203)

5-HT_{1D} receptor subtype, recombinant, human; Ketanserin; 5-HT_{2A} receptor antagonist; Subtype selectivity; 5-$HT_{1D\alpha}$ receptor antagonist; cAMP (Zgombick, J.M. (291) 9)

Ritodrine hydrochloride
Myometrium; Pregnancy; K^+ channel; β-Adrenoceptor agonist (Hamada, Y. (288) 45)

mRNA
Alcoholization; 5-HT (5-hydroxytryptamine, serotonin); Receptor; Binding; Autoradiography; (Rat) (Nevo, I. (281) 229)

Clocinnamox; Morphine; Opioid receptor antagonist; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U69,593; Opioid receptor alkylation; Opioid receptor binding; Solution hybridization; Analgesia; (Irreversible antagonist) (Chan, K. (287) 135)

Dopamine receptor; Dopamine D_4 receptor; Antipsychotic drug; Neuroleptics; Haloperidol (Schoots, O. (289) 67)

Nitric oxide (NO); Ozone; Nitric oxide (NO) synthase (Haddad, E.-B. (293) 287)

RNase protection
β_3-Adrenoceptor; Adipose tissue; Gallbladder; Obesity; (Human) (Berkowitz, D.E. (289) 223)

Ro 5-4864
Diazepam; Clonazepam; Kidney, isolated, perfused; Renal function; Renal vasculature; (Rat) (Monasterolo, L.A. (276) 201)

Ro 15-1788
Benzodiazepine receptor, peripheral; Benzodiazepine receptor, central; PK 11195; Lead poisoning; Liver (Fonia, O. (293) 335)

Ro 15-4513
$GABA_A$ receptor; Diazepam-insensitive; Cerebellum; Alcohol sensitivity; Benzodiazepine; Imidazoquinoxaline; Imidazoquinazoline; Cyclopyrrolone (Wong, G. (289) 335)

Ro 19-0528
Benzodiazepine; $GABA_A$ receptor, diazepam-insensitive; Drug discrimination; Bretazenil; Flumazenil; GABA (γ-aminobutyric acid); (Receptor partial agonist); (Pigeon) (Acri, J.B. (278) 213)

Ro 31-8220
Histamine; Phospholipase C; Protein kinase C; Phorbol ester; Staurosporine; Adrenal chromaffin cell (Bunn, S.J. (290) 227)

Ro 40-5967
Ca^{2+}; Ca^{2+} channel antagonist; Verapamil; 1,4-Dihydropyridine; Diltiazem; SR 33557 (Rutledge, A. (280) 155)

Rod pathway
Patch clamp; GABA receptor; Cl^- channel; Bicuculline; Retina; Bipolar cell (Feigenspan, A. (288) 97)

Rolipram
Cerebral ischemia; cAMP; Phosphodiesterase; Hippocampus; (Gerbil) (Kato, H. (272) 107)

Hyperalgesia; Prostaglandin E_2; Phosphodiesterase; Sympathetically maintained pain (Ouseph, A.K. (273) 107)

Tardive dyskinesia, rat; cAMP; Phosphodiesterase; Ageing (Sasaki, H. (282) 71)

Asthma; Bronchodilation; Cardiovascular; Central nervous system, dog; Emesis; Phosphodiesterase (Heaslip, R.J. (286) 281)

Phosphatidic acid; Phosphodiesterase; Phospholipid; U937; cAMP (DiSanto, M.E. (290) 169)

Rose bengal
Retina; Excitatory amino acid receptor antagonist; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid); NMDA (*N*-methyl-D-aspartate); Thiokynurenic acid (Lombardi, G. (271) 489)

Rostral ventrolateral medulla
Clonidine; Vasomotor neuron; Sympathoexcitatory neuron; GABA (γ-aminobutyric acid) (Sun, M.-K. (276) 291)

Anesthesia; Urethane; Chemoreflex; Reticulospinal vasomotor neuron; (Rats) (Sun, M.-K. (293) 237)

Rotarod
Remoxipride; Antinociception; Catalepsy; (Sheep) (Main, D.C.J. (287) 221)

Rotarod endurance time
Endosulfan; Body weight; Liver weight; Spontaneous motor activity; Liver injury; Learning; Memory (Paul, V. (293) 355)

Rotenone
Dopamine release; MPP^+ (1-methyl-4-phenylpyridinium); Striatum; Substantia nigra; (Rat) (Santiago, M. (280) 251)

Striatum; Cortex; MPP^+ (1-methyl-4-phenylpyridinium ion); Dopaminergic system (Bougria, M. (291) 407)

Dopamine transporter, vesicular; Insecticide; Fungicide; Herbicide; Neurotoxin; Parkinsonism (Vaccari, A. (292) 309)

RP 49356
Cromakalim; Myometrium; $^{42}K^+$ efflux; $^{86}Rb^+$ efflux; K^+ channel (Piper, I.T. (283) 1)

RU486
Lipocortin 1; Interleukin-8; Adrenalectomy; PAF (platelet-activating factor) (Harris, J.G. (283) 9)

Rubidium
Uterus, human; K^+ channel opener; Levcromakalim; P1060 (Criddle, D.N. (272) 293)

Levcromakalim; P1060; Saphenous vein, human (Criddle, D.N. (286) 123)

Ruminant
Benzoic acid; Endocrine pancreas; Insulin; Glucagon; (Sheep) (Mineo, H. (280) 149)

[^{3}H]RX 821002
α_2-Adrenoceptor subtype; [^{3}H]MK912; (Pig) (Wikberg-Matsson, A. (284) 271)

[^{3}H]RX 821002 binding
DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine); α_2-Adrenoceptor, postsynaptic; Brain, rat; Clonidine-induced mydriasis; α_{2D}-Adrenoceptor (Heal, D.J. (277) 215)

Ryanodine
Ca^{2+} store; Caffeine; Carbachol; Inositol 1,4,5-trisphosphate; Smooth muscle, intestinal (Komori, S. (277) 173)

Bradykinin; Trachea, guinea-pig; Epithelium; Bradykinin B_2 receptor; Relaxation; Ca^{2+}; Apamin; HOE 140; NPC 17761 (Schlemper, V. (282) 177)

Ca^{2+} release; Sarcoplasmic reticulum; Caffeine (Takahashi, Y. (288) 285)

Ryanodine receptor
Ca^{2+} influx, store-dependent; Second messenger-operated channel; Ca^{2+} store; Ca^{2+} ATPase; IP_3 receptor (Clementi, E. (289) 23)

S 14506
Forced swimming; 5-HT_{1A} receptor; Depression; S 14671; (+)-WAY 100,135 (Schreiber, R. (271) 537)

S 14671
Forced swimming; 5-HT_{1A} receptor; Depression; S 14506; (+)-WAY 100,135 (Schreiber, R. (271) 537)

Saccharomyces cerevisiae
Aflatoxin B_1; CYP2A; Metabolic activation (Pelkonen, P. (292) 67)

Salbutamol
β-Adrenoceptor; Endothelium; Vascular permeability; Protein extravasation; Salmeterol (Allen, M.J. (274) 7)

Airway hyperreactivity; β-Adrenoceptor agonist; β-Adrenoceptor; Receptor desensitisation; (Guinea pig) (Buchheit, K.-H. (287) 85)

Salmeterol
β-Adrenoceptor; Endothelium; Vascular permeability; Protein extravasation; Salbutamol (Allen, M.J. (274) 7)

Salsolinol
Neurotoxicity; Catecholamine homeostasis (Willets, J.M. (293) 319)

Saphenous vein, human
Levcromakalim; P1060; Rubidium ion (Criddle, D.N. (286) 123)

Saphenous vein, rabbit
Ketanserin; GR127935; Jugular vein, guinea-pig; 5-HT_{1D} receptor (Razzaque, Z. (283) 199)

Endothelin; Sarafotoxin; BQ-123; Endothelin ET_A receptor (Nishiyama, M. (286) 209)

Sarafotoxin
Endothelin; Vas deferens; BQ-123; IRL 1620; BQ-788; Endothelin-converting enzyme; Phosphoramidon; Neurotransmission; (Mouse) (Maas, J. (276) 113)

Endothelin; BQ-123; Endothelin ET_A receptor; Saphenous vein, rabbit (Nishiyama, M. (286) 209)

Sarafotoxin S6c
Endothelin; Alanine analog; Receptor subtype; Ileum, guinea-pig; Tachyphylaxis (Miasiro, N. (278) 103)

Endothelin receptor; Cotransmission; Vas deferens; Endothelin-3; BQ-123; (Guinea-pig) (Mutafova-Yambolieva, V.N. (285) 213)

Sarcoplasmic reticulum
Skinned fiber; Development; Skeletal muscle; Cyclopiazonic acid (Huchet, C. (271) 141)

Smooth muscle cell; Trachea; Caffeine; Ca^{2+}-dependent Cl^- channel; Ca^{2+} pump (Henmi, S. (282) 219)

Ca^{2+} release; Caffeine; Ryanodine (Takahashi, Y. (288) 285)

SB 203220
Angiotensin II; SK&F 108566; Angiotensin AT_1 receptor; (In vitro and in vivo pharmacology) (Aiyar, N. (283) 63)

SCH 23390
Cocaine; Sulpiride; Eticlopride; Ontogeny (Pruitt, D.L. (283) 125)

Cocaine; Haloperidol; Catalepsy; Supersensitivity; Subsensitivity; (Mouse) (Ushijima, I. (285) 55)

Nucleus accumbens, shell, core; Dopamine D_1 receptor; Dopamine D_2 receptor; SKF 82958; Quinpirole; (−)-Sulpiride; Jaw movement; (Rat) (Cools, A.R. (286) 41)

(+)-SCH 23390
Sleep; Waking; *m*-Chlorophenylbiguanide; 5-HT_3 receptor; MDL 72222; Dopamine; YM-09151-2 (Ponzoni, A. (278) 111)

SCH 39166
Drug discrimination; Local anesthetic; Dopamine; Cocaine; Dimethocaine; Procaine; Chloroprocaine; Raclopride; (Squirrel monkey) (Mansbach, R.S. (274) 167)

Schedule-controlled behavior
Behavioral pharmacology; Receptor binding; Phencyclidine; Drug dependence; Drug tolerance; Sex difference; (Rat) (Wessinger, W.D. (277) 107)

Schizophrenia
Dopamine; NMDA (*N*-methyl-D-aspartate); Accumbens; Prepulse inhibition; (Rat) (Reijmers, L.G.J.E. (272) 131)

Glycine; NMDA (*N*-methyl-D-aspartate); Dopamine metabolism; Stereotypy (Kretschmer, B.D. (280) 37)

Risperidone; Olanzapine; Seroquel; Ziprasidone; Amperozide; Ventral tegmental area; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (281) 289)

Dopamine D_4 receptor; Antipsychotic (Reynolds, G.P. (281) R5)

Dopamine receptor; Dopamine D_4-like site (Seeman, P. (286) R3)

Prepulse inhibition, rat; 5-HT (5-hydroxytryptamine, serotonin); Glutamate; Antipsychotic (Varty, G.B. (287) 201)

Scopolamine
Dynorphin A-(1–13); Passive avoidance response; Memory; Amnesia; (Mouse) (Ukai, M. (274) 89)

Methamphetamine; Cholinergic system; Behavioral sensitization; Drug conditioning; Low-frequency tone (Yui, K. (279) 135)

Dopamine receptor agonist; Clozapine; Dopamine D_1 receptor; Dopamine D_2 receptor; Quinpirole; Antipsychotic, atypical; SKF38393; (Rat) (Jackson, D.M. (282) 137)

Spatial learning; Hippocampus; Acetylcholine; 5-HT_{1A} receptor; (*S*)-WAY 100135; Alzheimer disease; (Rat) (Carli, M. (283) 133)

5-HT_{1A} receptor; 5-HT_{1B} receptor; Hippocampus; Spatial memory; (Microinjection) (Buhot, M.-C. (285) 221)

Scratching
Itch; Pain; Compound 48/80; Substance P; Histamine (Kuraishi, Y. (275) 229)

SDZ NVI-085
α_1-Adrenoceptor; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_2 receptor; Aorta, rat; SK&F 89748-A (Van der Graaf, P.H. (287) 309)

Second messenger
Neuropeptide Y; Angiotensin II; Vasoconstriction; Femoral artery (Cressier, F. (272) 57)

α_1-Adrenoceptor; Inositol triphosphate; Protein kinase C; Na^+,K^+-ATPase; Renal proximal tubule (Gopalakrishnan, S.M. (288) 139)

Second messenger-operated channel
Ca^{2+} influx, store-dependent; Ca^{2+} store; Ca^{2+} ATPase; IP_3 receptor; Ryanodine receptor (Clementi, E. (289) 23)

Secretion
Colon; Epithelium; Ion transport; Histamine; (Human) (Keely, S.J. (279) 203)

Seizure
Adenosine A_3 receptor; Protection; (Mouse) (Von Lubitz, D.K.J.E. (275) 23)

CCK (cholecystokinin); Cerebral cortex; Glutamate; NMDA receptor (Bandopadhyay, R. (275) 53)

Anti-epileptic; GYKI 52466 (Borowicz, K.K. (281) 319)

AMPA receptor antagonist; NMDA receptor antagonist (Czuczwar, S.J. (281) 327)

Adenosine A_1 receptor; NMDA receptor; Alzheimer's disease; (Mouse) (Von Lubitz, D.K.J.E. (283) 185)

Kindling; NMDA (*N*-methyl-D-aspartate); Epilepsy; Excitatory amino acid; Amygdala (Croucher, M.J. (286) 265)

Epilepsy; Nitric oxide (NO); Nitric oxide (NO) synthase; 7-Nitro indazole; Pilocarpine (Van Leeuwen, R. (287) 211)

Phosphoinositide hydrolysis; Soman; Histamine H_1 receptor; Metabotropic glutamate receptor (Bodjarian, N. (289) 291)

Self-administration
Nicotine; Sertraline; 5-HT (5-hydroxytryptamine, serotonin); (Monkey) (Sannerud, C.A. (271) 461)

Semotiadil
Diltiazem; Amlodipine; Nifedipine; Conduction interval; Refractoriness (Stark, G. (286) 71)

Senescence-accelerated mouse (SAM)
TRH (thyrotropin-releasing hormone); Sustained release formulation; Neophobia; Learning and memory; Anxiety (Miyamoto, M. (271) 357)

Senktide
Dopamine; Electrophysiology; Neurokinin; Substance P; Tachykinin; Ventral tegmental area (Seabrook, G.R. (273) 113)

Sensitization
Methamphetamine; Locomotor activity; Nitric oxide (NO); N^G-Nitro-L-arginine; N^G-Nitro-L-arginine methyl ester; NMDA receptor (Ohno, M. (275) 39)

Morphine; Ambulation, mouse; μ-Opioid receptor; Dopamine receptor (Kuribara, H. (275) 251)

Adrenalectomy; Corticosteroid; Dopamine; Limbic forebrain; Locomotor activity; Nicotine; (Rat) (Johnson, D.H. (276) 155)

Acetylcholine release; Striatum; Nucleus accumbens; Morphine; Opioid receptor (Tjon, G.H.K. (283) 169)

Codeine; Noncompetitive agonist (Storch, A. (290) 207)

Sensory fiber
Diabetes; Capsaicin; Urinary bladder; Epithelium (Pinna, C. (271) 151)

Diabetes; Capsaicin; Stomach fundus; Ileum (Pinna, C. (276) 61)

Sensory nerve
Neurogenic inflammation; Capsaicin; (Prejunctional); (Postjunctional) (Parlani, M. (278) 117)

Airway hyperresponsiveness; Capsaicin; Inflammation; (Rabbit) (Herd, C.M. (282) 111)

Neurogenic inflammation; Trigeminal ganglion; μ-Opioid receptor agonist; 5-HT_{1D} receptor agonist; Histamine H_3 receptor agonist (Escott, K.J. (284) 69)

Separation-induced vocalization
Anticonvulsant; Anxiolytic; Audiogenic seizure; Glycine receptor, strychnine-insensitive; NMDA receptor; (DBA/2J mouse); (Rat pup) (Kehne, J.H. (284) 109)

Sepsis
Adrenergic nerve; Nitric oxide (NO); Lipopolysaccharide; Tail artery, rat (Takakura, K. (271) 367)

Nitric oxide (NO); Endotoxin; Microcirculation; N^G-Nitro-L-arginine methyl ester; N^G-Monomethyl-L-arginine; Multiple organ failure (László, F. (283) 47)

N-Acetyl-L-cysteine; Allopurinol; Xanthine oxidase; Free radicals; Cecal ligation and puncture (Villa, P. (292) 341)

Septic liver failure
Glycosylation inhibitor; Liver, mouse; DNA fragmentation (Leist, M. (292) 201)

Septum, interventricular
PAF (platelet-activating factor); Myocardial ischemia; HPLC (high-performance liquid chromatography); (Rabbit) (Salinas, P. (293) 65)

Serine protease inhibitor
Collagenase; Inflammation; Kinin; Nitric oxide (NO); Platelet (Souza Pinto, J.C. (274) 101)

Seroquel
Risperidone; Olanzapine; Ziprasidone; Amperozide; Schizophrenia; Ventral tegmental area; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (281) 289)

Sertraline
Nicotine; 5-HT (5-hydroxytryptamine, serotonin); Self-administration; (Monkey) (Sannerud, C.A. (271) 461)

Serum-free culture
Cortical culture; K^+-induced depolarization; Hypoxia; Glutamate; Extracellular; Glutamate receptor (Uchiyama-Tsuyuki, Y. (293) 245)

Sevoflurane
Endothelial cell; Bradykinin; Fura-2; Nitric oxide (NO); Anesthetic, volatile; A23187; D-Arg-[Hyp^3, $Thi^{5,8}$, D-Phe^7] bradykinin; Des-Arg^9-[Leu^8] bradykinin; Ca^{2+} channel (Az-ma, T. (289) 33)

Sex difference
Behavioral pharmacology; Schedule-controlled behavior; Receptor binding; Phencyclidine; Drug dependence; Drug tolerance; (Rat) (Wessinger, W.D. (277) 107)

Sexual behavior
5-HT (5-hydroxytryptamine, serotonin); 5-HT_2 receptor agonist; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Testosterone; Castration; Puberty (Padoin, M.J. (277) 1)

Sexual satiety
Mating; Apomorphine; Dopamine (Mas, M. (280) 331)

Shock
Nitric oxide, NO; Amidine; Butyramidine; Blood pressure; Inflammation; Endothelium; Endotoxin; Isothiourea (Southan, G.J. (291) 311)

Sialidase
Fucoidin; β_2-Integrin; CD11b; Interleukin-8; Interleukin-1 (Harris, J.G. (279) 149)

Signal transduction
Cerebral endothelium; Endothelin; Ca^{2+} uptake (Stanimirovic, D.B. (288) 1)

Cerebral endothelium; Endothelin; Ca^{2+} uptake (Stanimirovic, D.B. (289) 409)

Vitamin B_{12} deficiency; Adenylyl cyclase; β-Adrenoceptor; G_s (Hatta, S. (291) 351)

Simvastatin
Human bronchial myocyte; Mevalonate; Geranylgeraniol; Cell proliferation (Viganò, T. (291) 201)

Heart (rat); Mitochondria; Pravastatin (Satoh, K. (292) 271)

Single unit recording
Dopamine D_2 receptor; Dopamine D_3 receptor; Substantia nigra pars compacta; Autoreceptor; 7-OH-DPAT ((±)-7-hydroxy-dipropylaminotetralin) (Kreiss, D.S. (277) 209)

SIN-1 (3-morpholino-sydnonimine)
Nitric oxide (NO); VIP (vasoactive intestinal polypeptide); Cavernous artery; Smooth muscle, cavernosal; (Human) (Hempelmann, R.G. (276) 277)

Sinoaortic denervation
Blood pressure control; Neostigmine; 6-Hydroxydopamine; Prazosin; Yohimbine (Taira, C.A. (271) 9)

Sinoatrial node
Free radical; *t*-Butyl hydroperoxide; Atrioventricular node; Reperfusion arrhythmia; Lipid peroxidation (Satoh, N. (272) 233)

Sinoatrial node, rat
Na^+,K^+,Cl^- cotransport; Loop diuretic; Intracardiac ganglion (Harper, A.A. (286) 299)

Sinus rate
Bradykinin; Bradykinin B_2 receptor; Atrium, guinea pig (Tesfamariam, B. (281) 17)

Skeletal muscle
Skinned fiber; Sarcoplasmic reticulum; Development; Cyclopiazonic acid (Huchet, C. (271) 141)

Patch clamp; Antiarrhythmic, class Ia; Disopyramide; K_{ATP} channel; Channel inhibition, pH dependent (Moser, C. (284) 35)

Ischemia; Reperfusion; Phosphocreatine disodium salt; Phosphocreatine di-L-arginine salt; L-Arginine; Current clamp; Electrophysiology (Tricarico, D. (287) 17)

Na^+,K^+-ATPase; α Isoforms of Na^+,K^+-ATPase; DOCA-salt hypertension; Heart; Brain (Sahin-Erdemli, I. (292) 163)

Ag^+-induced contracture; Caffeine; Procaine; Dithiothreitol; (Frog) (Oba, T. (292) 301)

Skeletal muscle actin
5-HT (5-hydroxytryptamine, serotonin); Dopamine; Covalent bond; 5-HT (5-hydroxytryptamine, serotonin) binding protein; Iron (Velez Pardo, C. (288) 209)

SKF 38393
Antidepressant; Dopamine receptor; Quinpirole; Motor activity (Allison, K. (277) 139)

Dopamine D_3 receptor; 7-OH-DPAT (7-hydroxy-*N*,*N*-di-*n*-propylaminotetralin); Motor behavior; Reserpine; (Mouse) (Starr, M.S. (277) 151)

Dopamine receptor agonist; Clozapine; Dopamine D_1 receptor; Dopamine D_2 receptor; Quinpirole; Antipsychotic, atypical; Scopolamine; (Rat) (Jackson, D.M. (282) 137)

SKF 82958
Nucleus accumbens, shell, core; Dopamine D_1 receptor; Dopamine D_2 receptor; Quinpirole; SCH 23390; (−)-Sulpiride; Jaw movement; (Rat) (Cools, A.R. (286) 41)

SKF 89748-A
α_1-Adrenoceptor; 5-HT (5-hydroxytryptamine, serotonin); 5-HT_2 receptor; Aorta, rat; SDZ NVI-085 (Van der Graaf, P.H. (287) 309)

SKF 104353
Leukotriene receptor; Leukotriene C_4; Leukotriene D_4 (Norman, P. (271) 73)

SKF 108566
SB 203220; Angiotensin II; Angiotensin AT_1 receptor; (In vitro and in vivo pharmacology) (Aiyar, N. (283) 63)

Skin, human
Autoradiography; Bradykinin receptor (Schremmer-Danninger, E. (283) 207)

Skin, toad
Diazepam; Tolerance; Ca^{2+} channel (Norris, B. (280) 221)

Skinned fiber
Sarcoplasmic reticulum; Development; Skeletal muscle; Cyclopiazonic acid (Huchet, C. (271) 141)

SK-N-MC cell
Neuropeptide Y; Radioligand binding; BIBP3226 (Entzeroth, M. (278) 239)

Sleep
Waking; *m*-Chlorophenylbiguanide; 5-HT_3 receptor; MDL 72222; Dopamine; (+)-SCH 23390; YM-09151-2 (Ponzoni, A. (278) 111)

Small intestinal mucosal injury
DS-4574; Peptidoleukotriene receptor antagonist; Endotoxin; Hemoconcentration; Plasma leakage (Tabuchi, Y. (273) 281)

Small intestinal transit
Carbachol; Nitric oxide (NO); N^G-Nitro-L-arginine methyl ester; L-Arginine; Diarrhea; Intestinal secretion (Izzo, A.A. (271) 31)

Smoke inhalation injury
Bronchial blood flow; Cyclooxygenase inhibitor; Hemodynamics; Ibuprofen (Abdi, S. (293) 475)

Smooth muscle
5-HT_2 receptor; α-Adrenoceptor; Prostate, rat; Autoradiography (Killam, A.L. (273) 7)

ATP; Hypertrophy; Urinary bladder; Caged-ATP (Sjuve, R. (276) 137)

Bradykinin; Furosemide; Thromboxane A_2 receptor; Airway (Molimard, M. (278) 253)

Prostanoid DP receptor; Myometrium, human; Prostaglandin D_2; BW A868C (Fernandes, B. (283) 73)

Endothelin; Vascular; Endothelin receptor (Lodge, N.J. (287) 279)

Endothelin-1; Myosin light chain (Kodama, M. (288) 69)

Ca^{2+}; Protein kinase C; Protein kinase C; (vascular); (cytosolic); (particulate) (Bazan, E. (290) 253)

Smooth muscle, airway
Asthma; Glucocorticoid; β-Adrenoceptor agonist, cell culture; Cell proliferation (Young, P.G. (273) 137)

Bradykinin; Capsaicin; Thromboxane A_2 (Molimard, M. (278) 49)

Lipoxin A_4; Cholinergic neurotransmission; Nitric oxide (NO) (Tamaoki, J. (287) 233)

Smooth muscle, aortic, vascular
α-Trinositol (D-*myo*-inositol 1,2,6-trisphosphate); Liposome (Brailoiu, E. (281) 209)

Smooth muscle, cavernosal
Nitric oxide (NO); SIN-1 (3-morpholino-sydnonimine); VIP (vasoactive intestinal polypeptide); Cavernous artery; (Human) (Hempelmann, R.G. (276) 277)

Smooth muscle cell
Ca^{2+}; Ca^{2+} channel antagonist; SR 33805; Proliferation (Dol, F. (280) 135)

LR-B/081; Angiotensin II; Inositol trisphosphate; Prostaglandin; Hypertrophy (Catalioto, R.-M. (280) 285)

Trachea; Caffeine; Ca^{2+}-dependent Cl^- channel; Sarcoplasmic reticulum; Ca^{2+} pump (Henmi, S. (282) 219)

DDT_1MF-2 cell; $G\beta\gamma$ subunit; Phospholipase C (Dickenson, J.M. (288) 393)

ATP; Mitosis; ATP receptor (Erlinge, D. (289) 135)

CV-11974; TCV-116; Vascular; Cell growth; c-*fos* (Flesch, M. (289) 399)

Capsaicin; Ca^{2+} current; K^+ current (Lo, Y.-C. (292) 321)

Smooth muscle cell, uterine
Na^+ channel, fast; Na^+ current, fast; Leiomyosarcoma cell, human; Whole-cell voltage clamp; Veratridine effect (Kusaka, M. (271) 387)

Smooth muscle cell, vascular
Ca^{2+} signal; Caffeine (Alexander, P.B. (288) 79)

Ca^{2+}-activated K^+ channel; Tyrosine kinase; Genistein (Xiong, Z. (290) 117)

Smooth muscle contraction
Motilin; Motilin receptor antagonist; Receptor binding; Erythromycin; Motilide (Depoortere, I. (286) 241)

Smooth muscle, human, bronchial
Muscarinic M_2 receptor; β-Adrenoceptor-mediated relaxation (Watson, N. (275) 307)

Smooth muscle, intestinal
Ca^{2+} store; Caffeine; Carbachol; Inositol 1,4,5-trisphosphate; Ryanodine (Komori, S. (277) 173)

Smooth muscle, portal vein
Angiotensin II; Losartan; DuP 532; PD 123319; CGP 42112A (Pelet, C. (279) 15)

Smooth muscle relaxation
Ileum, guinea-pig; 5-ht_7 receptor (Carter, D. (280) 243)

Proximal duodenum, rat; Nitric oxide (NO); NANC (non-adrenergic, non-cholinergic) nerve; Apamin; K^+ channel; cGMP (Martins, S.L.R. (284) 265)

Smooth muscle, trachea
PAF (platelet-activating factor); Liposome (Costuleanu, M. (281) 89)

Smooth muscle, vascular
Amlodipine; Felodipine; Drug effect; (Rat) (Videbæk, L.M. (274) 109)

Na^+,K^+-ATPase; Bufodienolide; Marinobufagenin; Ouabain; Vasoconstriction (Bagrov, A.Y. (274) 151)

α_2-Adrenoceptor; Protein kinase C; Phospholipase D (Aburto, T. (277) 35)

Adrenoceptor; Noradrenaline; Umbilical artery, human (Bodelsson, G. (282) 95)

Pacing-induced heart failure; Protein kinase C; Polymyxin B; α-Adrenoceptor (Forster, C. (283) 241)

Endothelin; Endothelin receptor; Ca^{2+} influx; Ca^{2+} release; Ca^{2+} sensitivity (Sudjarwo, S.A. (289) 197)

Inositol 1,4,5-trisphosphate; 5-HT (5-Hydroxytryptamine, serotonin); Noradrenaline (Murphy, T.V. (290) 141)

Social behavior
Opioid; Play behavior; μ-Opioid receptor; δ-Opioid receptor; κ-Opioid receptor (Vanderschuren, L.J.M.J. (276) 257)

Social defeat
Corticosterone; 5-HT_{1A} receptor; Subsensitivity (Korte, S.M. (272) 45)

Sodium mercaptoacetate
Hyperphagia, experimentally induced; Anorectic drug; 2-Deoxy-D-glucose; Insulin; Neural circuit (Garosi, V.L. (276) 285)

Sodium valproate
Embryotoxicity; Chronopharmacology (Ohdo, S. (293) 281)

Solution hybridization
Clocinnamox; Morphine; Opioid receptor antagonist; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); U69,593; Opioid receptor alkylation; Opioid receptor binding; mRNA; Analgesia; (Irreversible antagonist) (Chan, K. (287) 135)

Soman
Phosphoinositide hydrolysis; Seizure; Histamine H_1 receptor; Metabotropic glutamate receptor (Bodjarian, N. (289) 291)

Somatostatin
Receptor; sstr1 receptor; Cerebellar nuclei; Autoradiography (Bucharles, C. (271) 79)

Hippocampus; Muscarinic M_1 receptor; Pirenzepine; NMDA receptor; CPP ((±)-3(2-carboxypiperazin-4-yl)-propyl-1-phosphonoic acid); Working memory (Ohno, M. (271) 557)

Somatotropin; Hemocoagulation; Vitamin K-dependent coagulation factor (Negrev, N. (277) 145)

Synaptosome; Ileum, rat; Acetylcholine; Presynaptic mechanism (Kurjak, M. (281) 295)

Psycholeine; Quadrigemine C; Growth hormone; Adenylate cyclase (Rasolonjanahary, R. (285) 19)

SS-2 binding site; SRIF-2 binding site; Recombinant SSTR-1 receptor; Adenylate cyclase; Receptor autoradiography; In situ hybridization (Hoyer, D. (289) 151)

SS-1 binding site; SRIF-1 binding site; Recombinant SSTR-2 receptor; Adenylate cyclase; Receptor autoradiography; In situ hybridization (Schoeffter, P. (289) 163)

Somatostatin analog
Vapreotide; Substance P; Tachykinin NK_1 receptor; Tachykinin NK_2 receptor; Airway; Binding (Bétoin, F. (279) 241)

Somatostatin receptor
Vein; Inflammation; Peripheral nervous system; Substance P (Reubi, J.C. (271) 371)

Histamine; Adenylyl cyclase; Frontoparietal cortex; (Rat) (Puebla, L. (289) 361)

Somatotropin
Somatostatin; Hemocoagulation; Vitamin K-dependent coagulation factor (Negrev, N. (277) 145)

Spare receptor
Adrenoceptor; Norepinephrine; Inositol phosphate; Receptor reserve (Esbenshade, T.A. (289) 305)

Spasmolytic and/or non-steroidal antiinflammatory treatment
Ureteral calculosis, artificial; Muscle hyperalgesia, referred; (Rat) (Giamberardino, M.A. (278) 97)

Spasticity
Excitatory amino acid; Flupirtine; Muscle relaxant; NMDA (*N*-methyl-D-aspartate); Spinal reflex; (Rat) (Schwarz, M. (276) 247)

Spatial learning
Epilepsy; NMDA receptor antagonist; CGP 39551; CGP 37849; MK-801 (Ylinen, A. (274) 159)

Hippocampus; Acetylcholine; Scopolamine; 5-HT_{1A} receptor; (*S*)-WAY 100135; Alzheimer disease; (Rat) (Carli, M. (283) 133)

Spatial memory
5-HT_{1A} receptor; 5-HT_{1B} receptor; Hippocampus; Scopolamine; (Microinjection) (Buhot, M.-C. (285) 221)

Spectrin
Lidocaine; ATPase, vascular type; Carbonic anhydrase; Erythrocyte membrane, human (Nishiguchi, E. (286) 1)

Spermidine release
NMDA receptor subtype; Striatum; GABA (γ-aminobutyric acid) release; Acetylcholine release (Nankai, M. (286) 61)

Spermine
Polyamine; NMDA (*N*-methyl-D-aspartate); Hippocampus; Mg^{2+}; Development (Bowe, M.A. (278) 55)

Aminoglycoside; Melittin; Phosphatidylinositol; Membrane aggregation; Membrane fusion (Van Bambeke, F. (289) 321)

Spinal cord
Adenosine, pharmacology; Opioid, pharmacology; Antinociception; (Mouse) (Keil, II, G.J. (271) 37)

TRH (thyrotropin-releasing hormone); Monosynaptic reflex; TRH analog; (Neonatal rat) (Deshpande, S.B. (271) 439)

Nociception; Analgesic; Neurokinin; Substance P (Smith, G. (271) 481)

DAMGO ([D-Ala^2,NMePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Naltrindole; ICI174864; 5-HT (5-hydroxytryptamine, serotonin) (Monroe, P.J. (272) 51)

Flexor reflex; Inositol trisphosphate; Motoneuron; Neuropeptide Y; Nociception (Xu, X.-J. (272) 219)

Nociception; Glutamate receptor; Nitric oxide (NO); N^{ω}-Nitro-L-arginine methyl ester; L-N^5-(1-Iminoethyl)ornithine; *S*-Nitroso-*N*-penicillamine (Budai, D. (278) 39)

Benzodiazepine; Receptor binding; Alpidem-insensitive site (Maguire, P.A. (280) 167)

σ Binding site, heterogeneity; Radioreceptor assay; DTG (1,3-di(2-tolyl)guanidine); (+)-Pentazocine; Brain; (Mouse) (Kovács, K.J. (285) 127)

Micturition; 5-HT_3 receptor; 5-HT (5-hydroxytryptamine, serotonin) (Espey, M.J. (287) 173)

Spinal cord, rat
[^{3}H]Noradrenaline; Electrical stimulation; Histamine; Histamine H_3 receptor (Celuch, S.M. (287) 127)

Spinal cord slice
Anti-opioid; Neuropeptide FF release; NMDA (*N*-methyl-D-aspartate); Opioid tolerance (Devillers, J.-P. (271) 185)

Prostaglandin E_2 release; Capsaicin; Capsazepine; Cyclooxygenase inhibition (Malmberg, A.B. (271) 293)

Spinal reflex
Excitatory amino acid; Flupirtine; Muscle relaxant; NMDA (*N*-methyl-D-aspartate); Spasticity; (Rat) (Schwarz, M. (276) 247)

Splanchnic artery occlusion shock
E-selectin; Leukocyte accumulation (Altavilla, D. (272) 223)

Splanchnic blood flow
Dopamine; Fenoldopam; Noradrenaline; Renal blood flow; Oxygen demand; Oxygen supply; Oxygen extraction ratio (Schiffer, E.R. (286) 49)

Spleen
Benzodiazepine receptor, peripheral type; Olfactory bulbectomy; Thymus; Adrenal; Antidepressant (Dennis, T. (272) 279)

TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Dioxin; Concanavalin A; Immunotoxicity; Interleukin; Thymus; T lymphocyte; B lymphocyte; Macrophage; (Rat) (Badesha, J.S. (293) 429)

SPM3672
Nitric oxide (NO) donor; Nitric oxide (NO); Cardiomyocyte; Heart muscle, contractility (Kojda, G. (284) 315)

Spontaneously active neuron
Fluoxetine, repeated administration; Frontal cortex; (Rat) (Ceci, A. (271) 231)

Spontaneously epileptic rat (SER)
Hippocampus; CA3 neuron; Ca^{2+} spike; Nicardipine (Momiyama, T. (280) 119)

Spontaneously hypertensive rat (SHR)
Neuropeptide Y; Neuropeptide Y Y_1 receptor antagonist; Blood pressure; Ca^{2+}, intracellular (Tseng, A. (271) 265)

Renin inhibitor; Renin, recombinant human; Pressor response; Oral absorption; Bioavailability (Shibasaki, M. (271) 341)

Adrenomedullin; Hemodynamics, regional; Microsphere (He, H. (273) 209)

Pelanserin; 5-HT receptor antagonist; Contraction; Methoxamine (Villalobos-Molina, R. (277) 181)

Glucose tolerance; Blood pressure; Angiotensin converting enzyme inhibitor; Angiotensin AT_1 receptor antagonist (Chow, L. (282) 77)

Cerebral blood flow autoregulation; Doxazosin; α-Adrenoceptor; Hemorrhagic hypotension (Cai, H. (286) 249)

MPC-1304; Ca^{2+} channel antagonist receptor; Receptor occupation (Nozawa, Y. (287) 191)

Spontaneous motor activity
Endosulfan; Body weight; Liver weight; Rota-rod endurance time; Liver injury; Learning; Memory (Paul, V. (293) 355)

Sr^{2+}
Ca^{2+}; Ba^{2+}; Nitric oxide (NO); Coronary artery, porcine; Diltiazem (Ohashi, K. (285) 165)

SR 33557
Ca^{2+}; Ca^{2+} channel antagonist; Ro 40-5967; Verapamil; 1,4-Dihydropyridine; Diltiazem (Rutledge, A. (280) 155)

SR 33589
Amiodarone; Antiarrhythmic (class III); Anti-adrenoceptor activity (Hodeige, D. (279) 25)

SR 33805
Ca^{2+}; Ca^{2+} channel antagonist; Smooth muscle cell; Proliferation (Dol, F. (280) 135)

SR 47155A
Irbesartan (SR 47436/BMS-186295); Losartan; EXP 3174; Pithed rat; Angiotensin II (Christophe, B. (281) 161)

SR 48968
Tachykinin NK_2 receptor; Tachykinin receptor antagonist; MEN 10,627; Gallbladder, guinea-pig; Proximal colon, guinea-pig (Patacchini, R. (271) 111)

SR 49059
[Arg^8]Vasopressin; Coronary artery, human; Vasopressin V_1 receptor; OPC-21268; OPC-31260; (Human) (Bax, W.A. (285) 199)

SR 95103
Arylaminopyridazine; GABA (γ-aminobutyric acid) derivative; GABA receptor antagonist; (*Ascaris suum*) (Martin, R.J. (276) 9)

SR 141716A (*N*-(piperidin-1-yl)-5-(4-chlorophenyl)-1(2,4-dichlorophenyl)-4-methyl-1*H*-pyrazole carboxamide · HCl)
Δ^9-Tetrahydrocannabinol; Precipitated withdrawal (Aceto, M.D. (282) R1)

Cannabinoid; Cannabinoid receptor antagonist; Vas deferens, mouse; 1-Pentyl-2-methyl-3-(1-naphthoyl)indole; 1-Pentyl-3-(1-naphthoyl)pyrrole; 1-Heptyl-3-(1-naphthoyl)indole (Pertwee, R.G. (284) 241)

SR 142801
Tachykinin; Tachykinin NK_3 receptor; Capsaicin; Tachykinin receptor antagonist (Patacchini, R. (278) 17)

SRIF-1 binding site
Somatostatin; SS-1 binding site; Recombinant SSTR-2 receptor; Adenylate cyclase; Receptor autoradiography; In situ hybridization (Schoeffter, P. (289) 163)

SRIF-2 binding site
Somatostatin; SS-2 binding site; Recombinant SSTR-1 receptor; Adenylate cyclase; Receptor autoradiography; In situ hybridization (Hoyer, D. (289) 151)

SS-1 binding site
Somatostatin; SRIF-1 binding site; Recombinant SSTR-2 receptor; Adenylate cyclase; Receptor autoradiography; In situ hybridization (Schoeffter, P. (289) 163)

SS-2 binding site
Somatostatin; SRIF-2 binding site; Recombinant SSTR-1 receptor; Adenylate cyclase; Receptor autoradiography; In situ hybridization (Hoyer, D. (289) 151)

sstr1 receptor
Somatostatin; Receptor; Cerebellar nuclei; Autoradiography (Bucharles, C. (271) 79)

Staphylococcal α-toxin
Endothelin-1; Red blood cell; Phosphoramidon; Pepstatin A; Chymostatin; Leupeptin (Tippler, B. (271) 131)

Startle response
Nitric oxide (NO); Locomotor activity; Psychophysiological status; Learning (Sandi, C. (277) 89)

Staurosporine
Adrenal chromaffin cell; Ca^{2+} homeostasis; Catecholamine release; Fura-2 (Maurer, J.A. (288) 163)

Mast cell; Histamine; Endothelin; IAP (islet-activating protein); Protein kinase (Yamamura, H. (288) 269)

Daphnoretin; Neutrophil (rat); Respiratory burst; Protein kinase C; Ca^{2+}; [^{3}H]Phorbol-12,13-dibutyrate binding (Wang, J.-P. (288) 341)

Histamine; Phospholipase C; Protein kinase C; Phorbol ester; Ro 31-8220; Adrenal chromaffin cell (Bunn, S.J. (290) 227)

GABA ρ_1 receptor; Protein kinase C; *Xenopus* oocyte; Down-regulation; Phorbol ester (Kusama, T. (291) 431)

Steady state
Benzodiazepine receptor; Iomazenil; Flumazenil; K_d; Partition coefficient (Videbæk, C. (281) 117)

Stereoselectivity
Muscarinic receptors; Binding affinity; CHO (Chinese hamster ovary) cells; Pirenzepine (Barbier, P. (290) 125)

Stereoselectivity, inverse
Dimethindene, enantiomer; Muscarinic M_2 receptor antagonist; Histamine H_1 receptor; Muscarinic receptor subtype; Enantioselectivity; PET (positron emission tomography); Alzheimer's disease (Pfaff, O. (286) 229)

Stereotyped behavior
Dopamine receptor antagonist; 5-HT_{1A} receptor agonist; Climbing; Grooming; Catalepsy (Protais, P. (271) 167)

Stereotypy
Apomorphine; Desipramine; Development; Nomifensine; Zimelidine (Hilakivi, I. (271) 223)

Glycine; NMDA (*N*-methyl-D-aspartate); Schizophrenia; Dopamine metabolism (Kretschmer, B.D. (280) 37)

Dopamine uptake inhibitor; [^{3}H]GBR12935 binding; Brain microdialysis; Dopamine (Nakachi, N. (281) 195)

Nucleus basalis magnocellularis; Acetylcholine; Neuroprotection; Memantine; (+)-MK-801; Amantadine; Ataxia; (Rat) (Wenk, G.L. (293) 267)

Steroid
Vestibular compensation; Methylprednisolone; Labyrinthectomy, unilateral (Jerram, A.H. (275) 291)

PLC-PRF-5; Angiotensin AT_1 receptor; Hepatoma cell; Dexamethasone; Glucocorticoid effect (Wintersgill, H.P. (288) 365)

Steroidogenesis
Brain, rat; Benzodiazepine receptor, peripheral; Mitochondrion (McCauley, L.D. (276) 145)

Stimulus intensity
Formalin test; Adenosine analgesia; Adenosine kinase (Poon, A. (286) 177)

Stomach
CCK (cholecystokinin); CCK receptor; Cytoprotection; Gastric hyperemia (Konturek, S.J. (273) 57)

Gastrin-17; CCK (cholecystokinin); Gastroprotection; Capsaicin; Nitric oxide (NO) (Konturek, S.J. (278) 203)

Stomach fundus
Diabetes; Sensory fibres; Capsaicin; Ileum (Pinna, C. (276) 61)

Stomach, rat
Interleukin-1 receptor antagonist; Interleukin-1; Prostaglandin E_2; 5-Lipoxygenase (Montuschi, P. (275) 31)

Interleukin-1 receptor antagonist; Interleukin-1; Prostaglandin E_2; 5-Lipoxygenase (Montuschi, P. (282) 263)

Enterochromaffin-like cell; Ca^{2+} ionophore; Histamine; Patch-clamp; K^+ channel (Sakai, H. (291) 153)

Strain difference
Dioxin; Toxic equivalency; Risk evaluation; Acute toxicity (Pohjanvirta, R. (293) 341)

Straub tail reaction
Muscle relaxant, centrally acting; NK433; Decerebrate rigidity; γ-Activity (Sakitama, K. (273) 47)

Streptozotocin
Diabetic vasculopathy; Capillary permeability; Neutral endopeptidase (Chakir, M. (285) 11)

Acetyl-L-carnitine; Brain; Alzheimer's disease; Oxidative stress (Terwel, D. (287) 65)

Streptozotocin-induced diabetes
M16209; Aldose reductase inhibitor; Antihyperglycemic effect; Insulin secretion (Nakayama, K. (276) 77)

Endothelium; Mesenteric arterial bed, rat; Sympathetic nerve (Ralevic, V. (286) 193)

Stress
Nitric oxide (NO); Endotoxin; Capsaicin; Gastric damage; Gastric defense (Barrachina, M.D. (280) 339)

Neuroimmunomodulation; Cyclosporine; Sympathetic nervous system; Parasympathetic nervous system; Submaxillary lymph node; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (285) 143)

Stress, cold-restraint
Nicotine; Ethanol; Gastric lesion; Mast cell; (Mini-osmotic pump); (Rat) (Wong, D. (292) 157)

Stretching
Aging; ACTH (adrenocorticotropin); Melanocortin; Grooming; Yawning; Penile erection (Poggioli, R. (271) 253)

Striatal dopamine
Locus ceruleus; Methamphetamine; DSP-4 (*N*-(2-chloroethyl)-*N*-ethyl-2-bromobenzylamine) (Fornai, F. (283) 99)

Striatal neuron
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor; Arachidonic acid; Carbachol; Cyclothiazide; Kainate receptor (Petitet, F. (291) 143)

Striatal slice
Endothelin; Neurotoxicity; NMDA receptor; Dopamine release (Kataoka, Y. (273) 285)

Striatum
Dopamine uptake inhibitor; Dopamine receptor agonist; Dopamine, endogenous; Frontal cortex; Nucleus accumbens (Irifune, M. (272) 79)

NMDA (*N*-methyl-D-aspartate); TRH (thyrotropin-releasing hormone); Dopamine; (Rabbit) (Popoli, P. (272) 119)

Haloperidol; Clozapine; Fos protein; Tolerance; Nucleus accumbens; Amygdala; (Long-term treatment) (Sebens, J.B. (273) 175)

Amphetamine; Cocaine; Locomotor activity; Microdialysis, in vivo; Opioid receptor antagonist; Dopamine; Nucleus accumbens (Schad, C.A. (275) 9)

Nicotine; Nornicotine; Anabaseine; Anabasine; *N*-Methylanabasine; Dopamine release (Dwoskin, L.P. (276) 195)

Repetitive jaw movement; YM-14673; TRH (thyrotropin-releasing hormone); Nucleus accumbens; Dopamine receptor (Miwa, Y. (277) 63)

Metabotropic glutamate receptor; Glutamate release; Synaptosome; Parkinson's disease; (Presynaptic) (East, S.J. (277) 117)

Phencyclidine; Neurotensin; NMDA (*N*-methyl-D-aspartate); Dopamine; Nucleus accumbens (Hanson, G.R. (278) 167)

Dopamine D_2 receptor; Dopamine D_3 receptor; [^{125}I]Iodosulpiride; Receptor autoradiography; Cerebellum; (Rat) (Levant, B. (278) 243)

Dopamine release; MPP^+ (1-methyl-4-phenylpyridinium); Rotenone; Substantia nigra; (Rat) (Santiago, M. (280) 251)

Fluoxetine; Clomipramine; Imipramine; Dopamine; 5-HT (5-hydroxytryptamine, serotonin); Extrapyramidal symptom; Antidepressant; Microdialysis, in vivo; Nucleus accumbens; (Rat) (Ichikawa, J. (281) 255)

Glutamate; κ-Opioid receptor (Hill, M.P. (281) R1)

Substance P fragment; Dopamine outflow; Tachykinin receptor (Khan, S. (282) 229)

Acetylcholine release; Nucleus accumbens; Morphine; Opioid receptor; Sensitization (Tjon, G.H.K. (283) 169)

Dopamine; GABA-ergic drug; Kainic acid (Smolders, I. (284) 83)

Amantadine; c-*fos*; Dopamine; NMDA (*N*-methyl-D-aspartate) (Tomitaka, S.-i. (285) 207)

NMDA receptor subtype; GABA (γ-aminobutyric acid) release; Acetylcholine release; Spermidine release (Nankai, M. (286) 61)

Vinconate; Dopamine release; Muscarinic receptor; Microdialysis (Iino, T. (286) 99)

(+)-Pentazocine; *N*-Allylnormetazocine; σ Receptor; Dopamine; Microdialysis (Gudelsky, G.A. (286) 223)

Morphine; Acetylcholine; Muscarinic receptor (Schoffelmeer, A.N.M. (286) 311)

Adenosine A_2 receptor; Basal ganglia; Metabotropic glutamate receptor; Subthalamic nucleus (Feeley Kearney, J.A. (287) 115)

R(+)-8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); WAY 100,635 (*n*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*n*-(2-pyridinyl) cyclohexanecarboxamide trihydrochloride); *d*-Amphetamine; Dopamine; 5-HT_{1A} receptor; Microdialysis, in vivo; Nucleus accumbens; (Rat) (Ichikawa, J. (287) 179)

Adenosine A_{2A} receptor; Glutamate release; (Rat) (Popoli, P. (287) 215)

Remoxipride; cAMP; Dopamine D_2 receptor; Metabolite, remoxipride (Westlind-Danielsson, A. (288) 89)

Dopamine D_2 receptor; Muscarinic acetylcholine receptor; $GABA_B$ receptor; GTPase; Receptor-G protein coupling (Odagaki, Y. (291) 245)

Cortex; Rotenone; MPP^+ (1-methyl-4-phenylpyridinium ion); Dopaminergic system (Bougria, M. (291) 407)

Toluene; GABA (γ-aminobutyric acid); Microdialysis; Globus pallidus (Stengård, K. (292) 43)

Striatum, rat
Dopamine; Microinjection; MK-801; Circling; Potentiation; 6-Hydroxydopamine (St-Pierre, J.-A. (272) 123)

Phencyclidine; Dopamine D_1 receptor antagonist; Dopamine D_2 receptor antagonist; Microdialysis (Yonezawa, Y. (285) 305)

Strionigral pathway
NMDA receptor; Non-NMDA receptor; Contralateral turning (Ossowska, K. (273) 89)

Structural determinant
Dihydropyridine; Phenylalkylamine; Allosteric interaction; Molecular modeling (Voigt, W. (291) 255)

Strychnine
Adrenal; Catecholamine; Glycine; Microdialysis; Polymerase chain reaction (Yadid, G. (288) 399)

Strychnine-insensitive glycine site
Amygdala kindling; NMDA receptor antagonist; Anticonvulsant; (DBA/2 mouse) (Chapman, A.G. (274) 83)

Subarachnoid hemorrhage
BQ-123; Endothelin; Nitric oxide (NO); Cerebral vasospasm (Hirose, H. (277) 77)

BQ-123; Endothelin; Nitric oxide (NO); Cerebral vasospasm (Hirose, H. (284) 335)

Submaxillary lymph node
Neuroimmunomodulation; Cyclosporine; Stress; Sympathetic nervous system; Parasympathetic nervous system; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (285) 143)

Submucosal gland
K^+ channel opener; Trachea; Epithelium (Griffin, A. (280) 317)

Subsensitivity
Social defeat; Corticosterone; $5\text{-}HT_{1A}$ receptor (Korte, S.M. (272) 45)

Cocaine; SCH23390; Haloperidol; Catalepsy; Supersensitivity; (Mouse) (Ushijima, I. (285) 55)

Substance P
Neurokinin A; Tachykinin receptor; Trachea, rat; Carbachol; 5-HT (5-hydroxytryptamine, serotonin) (Joos, G.F. (271) 47)

Nitric oxide (NO); Motor behavior; Food intake (Mancuso, F. (271) 329)

Vein; Inflammation; Somatostatin receptor; Peripheral nervous system (Reubi, J.C. (271) 371)

Nociception; Analgesic; Neurokinin; Spinal cord (Smith, G. (271) 481)

Histamine H_3 receptor; Neurogenic inflammation (Ohkubo, T. (273) 83)

Dopamine; Electrophysiology; Neurokinin; Senktide; Tachykinin; Ventral tegmental area (Seabrook, G.R. (273) 113)

Bronchospasm; (±)-CP96,345; MEN10,627; Neurokinin A; PAF (platelet-activating factor); Tachykinin (Perretti, F. (273) 129)

Scratching; Itch; Pain; Compound 48/80; Histamine (Kuraishi, Y. (275) 229)

K^+ channel, ATP-sensitive; Histamine H_3 receptor; Prejunctional inhibition (Ohkubo, T. (277) 45)

Vapreotide; Somatostatin analog; Tachykinin NK_1 receptor; Tachykinin NK_2 receptor; Airway; Binding (Bétoin, F. (279) 241)

CRF (corticotropin-releasing factor); CP 99,994; Plasma extravasation; Antigen challenge; Neurogenic inflammation, guinea pig (Yoshihara, S. (280) 113)

Tachykinin receptor antagonist; GR82334; GR71251; L-659,877; Neurokinin A (Guo, J.-Z. (281) 49)

Nitric oxide (NO); Endothelium; Microvasculature; Neurogenic inflammation; 5-HT (5-hydroxytryptamine, serotonin); ATP (Ralevic, V. (284) 231)

Mast cell; Histamine liberation; Amphipathic α-helix; Magainin; Neuropeptide Y; Liposome (Cross, L.J.M. (291) 291)

UV-B irradiation; Neurogenic inflammation; Cutaneous vasodilatation; Laser Doppler; CGRP (calcitonin gene-related peptide); Nitric oxide (NO) (Benrath, J. (293) 87)

[D-Pro^2,D-Trp^{7,9}]Substance P
Acetylshikonin; Hind-paw edema; Cutaneous anaphylaxis, passive; Neurogenic inflammation; Vascular permeability; Compound 48/80; [Thi^{5,8},D-Phe^7]Bradykinin (Wang, J.-P. (272) 87)

Substance P fragment
Striatum; Dopamine outflow; Tachykinin receptor (Khan, S. (282) 229)

Substance P receptor
Tachykinin NK_1 receptor; Gene expression; Polymerase chain reaction; Pituitary; AtT20 cell (Winkler, A. (291) 51)

Substance P (tachykinin NK_1) receptor antagonist
Cyclosporin; Neuroimmunomodulation (Gitter, B.D. (289) 439)

Substantia nigra
Basal ganglia; Cannabinoid; Cannabinoid receptor; Motor system; Marijuana; Tetrahydrocannabinol; WIN 55,212-2; Aminoalkylindole (Miller, A.S. (279) 179)

Dopamine release; MPP^+ (1-methyl-4-phenylpyridinium); Rotenone; Striatum; (Rat) (Santiago, M. (280) 251)

Dopamine; GABA (γ-aminobutyric acid); NMDA (*N*-methyl-D-aspartate); Pyrrolidinone (Shepard, P.D. (285) 79)

Substantia nigra, pars compacta
Dopamine D_2 receptor; Dopamine D_3 receptor; Autoreceptor; Single unit recording; 7-OH-DPAT ((±)-7-hydroxy-dipropylaminotetralin) (Kreiss, D.S. (277) 209)

Risperidone; Olanzapine; Seroquel; Ziprasidone; Amperozide; Schizophrenia; Ventral tegmental area; (Rat) (Skarsfeldt, T. (281) 289)

Substantia nigra, pars reticulata
Muscimol; Δ^9-Tetrahydrocannabinol; Circling behavior; Contralateral circling; Drug interaction (Wickens, A.P. (282) 251)

Subthalamic nucleus
Adenosine A_2 receptor; Basal ganglia; Metabotropic glutamate receptor; Striatum (Feeley Kearney, J.A. (287) 115)

Subtype
σ Receptor; Ifenprodil; Eliprodil; Receptor binding; Brain, rat (Hashimoto, K. (273) 307)

Subtype selectivity
5-HT_{1D} receptor subtype, recombinant, human; Ketanserin; Ritanserin; 5-HT_{2A} receptor antagonist; 5-$HT_{1D\alpha}$ receptor antagonist; cAMP (Zgombick, J.M. (291) 9)

Successive negative contrast
Animal model; Anxiety; Buspirone; Diazepam; One-way avoidance (Torres, C. (280) 277)

Sulfate
Cicletanine; Kidney; Cell membrane; Ion transport; Natriuresis; Diuresis; Na^+ transport; Capillary electrophoresis (Garay, R.P. (274) 175)

Sulfonylurea
Aorta, rat; Prostanoid; Prostaglandin $F_{2\alpha}$; Glibenclamide; Tolbutamide; Thromboxane A_2 (Delaey, C. (280) 179)

Binding site; Glibenclamide (Glyburide); Hypoglycemic agent; Liver (Inoue, Y. (284) 77)

Sulfotransferase
Activation; Benzylic alcohol; Mutagenicity; (*Salmonella typhimurium*) (Glatt, H. (293) 173)

Sulpiride
Cocaine; SCH 23390; Eticlopride; Ontogeny (Pruitt, D.L. (283) 125)

(−)-Sulpiride
Nucleus accumbens, shell, core; Dopamine D_1 receptor; Dopamine D_2 receptor; SKF 82958; Quinpirole; SCH 23390; Jaw movement; (Rat) (Cools, A.R. (286) 41)

Sumatriptan
CP-122,288; 5-HT receptor; Vasoconstriction (Beattie, D.T. (276) 271)

Plasma protein extravasation; Trigeminal ganglion stimulation; Dura mater; Carotid vascular resistance; Blood pressure (Spokes, R.A. (281) 75)

Arteriovenous anastomose; α-CGRP (calcitonin gene-related peptide); Dihydroergotamine; Heart; Migraine, pig (Van Gelderen, E.M. (284) 51)

[^{3}H]Sumatriptan
Autoradiography; Trigeminal nucleus caudalis; Nucleus tractus solitarius; (Cat) (Mills, A. (280) 175)

SUN9216
Middle cerebral artery thrombosis; Modified tissue-type plasminogen activator; Endothelin receptor antagonist; FR139317 (Umemura, K. (275) 17)

Superior cervical ganglion
Neuroimmunomodulation; Cyclosporine; Stress; Sympathetic nervous system; Parasympathetic nervous system; Submaxillary lymph node; Chorda tympani (Esquifino, A.I. (285) 143)

Superoxide
Nitric oxide (NO) donor; Peroxynitrite; Free radical scavenger; Gastric damage (Lamarque, D. (277) 187)

Superoxide anion
Alveolar macrophage; Carbon monoxide (CO); Nitric oxide (NO); Heme oxygenase; Cyclic GMP (Fukushima, T. (289) 103)

Paraquat; Nitric oxide (NO); Acetylcholine; A23187 (Hsu, K.-S. (292) 315)

Superoxide dismutase
Transgenic mouse; Opiate receptor; Antinociception; Genetics (Elmer, G.I. (283) 227)

Supersensitivity
Cocaine; SCH23390; Haloperidol; Catalepsy; Subsensitivity; (Mouse) (Ushijima, I. (285) 55)

Suprachiasmatic nucleus
Entrainment; Bombesin; Gastrin-releasing peptide; Neuromedin B; Ionophoresis; Neurophysiology; (Hamster) (Piggins, H.D. (271) 413)

Suramin
α,β-Methylene ATP; Endothelin; Phosphoramidon; Sympathetic co-transmission; Vas deferens, rat (Lau, W.A.K. (272) 31)

Tail artery, rat; Sympathetic nerve stimulation; Purinergic transmission; P_{2X} purinoceptor (McLaren, G.J. (277) 57)

P_1 purinoceptor; P_{2Y} purinoceptor; Taenia caeci, guinea-pig; Adenosine 5′-triphosphate; PPADS (pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid) (Piper, A.S. (280) 125)

Sustained release formulation
TRH (thyrotropin-releasing hormone); Senescence-accelerated mouse (SAM); Neophobia; Learning and memory; Anxiety (Miyamoto, M. (271) 357)

Sympathetically maintained pain
Hyperalgesia; Prostaglandin E_2; Phosphodiesterase; Rolipram (Ouseph, A.K. (273) 107)

Sympathetic co-transmission
α,β-Methylene ATP; Endothelin; Phosphoramidon; Suramin; Vas deferens, rat (Lau, W.A.K. (272) 31)

Sympathetic nerve
Afferent nerve; Blood flow; 5-HT (5-hydroxytryptamine, serotonin); 5-HIAA (5-hydroxyindole acetic acid); Dopamine; Gingiva; Dental pulp; (Rat) (Kerezoudis, N.P. (275) 191)

Endothelium; Mesenteric arterial bed, rat; Streptozotocin diabetes (Ralevic, V. (286) 193)

Sympathetic nerve stimulation
Tail artery, rat; Purinergic transmission; P_{2X} purinoceptor; Suramin (McLaren, G.J. (277) 57)

Sympathetic nervous system
Neuroimmunomodulation; Cyclosporine; Stress; Parasympathetic nervous system; Submaxillary lymph node; Superior cervical ganglion; Chorda tympani (Esquifino, A.I. (285) 143)

Nitric oxide (NO); N^G-Nitro-L-arginine; Pressor response; Renin-angiotensin system; (Dog) (Nakahara, T. (287) 49)

Sympathetic neurotransmission
ω-Conotoxin GVIA; ω-Conotoxin MVIIC; ω-Conotoxin MVIIA; ω-Agatoxin IVA; Ca^{2+} channel; Heart (Vega, T. (276) 231)

Sympatho-adrenomedullary system
α-Adrenoceptor; Gastric acid secretion; Interleukin-1β; Indomethacin (Yokotani, K. (279) 233)

Sympathoexcitatory neuron
Clonidine; Rostral ventrolateral medulla; Vasomotor neuron; GABA (γ-aminobutyric acid) (Sun, M.-K. (276) 291)

Sympatholnhibition
α_2-Adrenoceptor; Imidazoline receptor; Presynaptic inhibition; Moxonidine; UK 14304 (Urban, R. (282) 19)

Synaptic inhibition
GABA receptor; Hippocampus; Epilepsy; Disinhibition (Stanford, I.M. (277) 229)

Synaptosome
Metabotropic glutamate receptor; Glutamate release; Striatum; Parkinson's disease; (Presynaptic) (East, S.J. (277) 117)

Somatostatin; Ileum, rat; Acetylcholine; Presynaptic mechanism (Kurjak, M. (281) 295)

Arachidonic acid; Glutamate; Transport; Ca^{2+} (Lundy, D.F. (291) 273)

Na^+,K^+-ATPase; Ethanol; Ouabain; K^+ (Foley, T.D. (292) 287)

Synergism
Platelet; Iloprost; cAMP; cGMP (Fisch, A. (289) 455)

SZL-49
α_1-adrenoceptor subtype; Chlorethylclonidine; [^{3}H]prazosin binding (Pimoule, C. (290) 49)

Tachykinin
Dopamine; Electrophysiology; Neurokinin; Senktide; Substance P; Ventral tegmental area (Seabrook, G.R. (273) 113)

Bronchospasm; (±)-CP96,345; MEN10,627; Neurokinin A; PAF (platelet-activating factor); Substance P (Perretti, F. (273) 129)

Tachykinin NK_3 receptor; Capsaicin; Tachykinin receptor antagonist; SR 142801 (Patacchini, R. (278) 17)

Tachykinin NK_1 receptor; Endothelium; Nitric oxide (NO); Jugular vein, rabbit (Patacchini, R. (283) 233)

Tachykinin receptor
Substance P; Neurokinin A; Trachea, rat; Carbachol; 5-HT (5-hydroxytryptamine, serotonin) (Joos, G.F. (271) 47)

Tachykinin NK_2 receptor; Neurokinin A; GR159897 (Beresford, I.J.M. (272) 241)

Substance P fragment; Striatum; Dopamine outflow (Khan, S. (282) 229)

Tachykinin receptor antagonist
Tachykinin NK_2 receptor; MEN 10,627; SR 48968; Gallbladder, guinea-pig; Proximal colon, guinea-pig (Patacchini, R. (271) 111)

Tachykinin; Tachykinin NK_3 receptor; Capsaicin; SR 142801 (Patacchini, R. (278) 17)

GR82334; GR71251; L-659,877; Substance P; Neurokinin A (Guo, J.-Z. (281) 49)

Tachykinin NK_1 receptor
Vapreotide; Somatostatin analog; Substance P; Tachykinin NK_2 receptor; Airway; Binding (Bétoin, F. (279) 241)

Tachykinin; Endothelium; Nitric oxide (NO); Jugular vein, rabbit (Patacchini, R. (283) 233)

Substance P receptor; Gene expression; Polymerase chain reaction; Pituitary; AtT20 cell (Winkler, A. (291) 51)

Tachykinin NK_2 receptor
Tachykinin receptor; Neurokinin A; GR159897 (Beresford, I.J.M. (272) 241)

Vapreotide; Somatostatin analog; Substance P; Tachykinin NK_1 receptor; Airway; Binding (Bétoin, F. (279) 241)

Tachykinin receptor antagonist; MEN 10,627; SR 48968; Gallbladder, guinea-pig; Proximal colon, guinea-pig (Patacchini, R. (271) 111)

Tachykinin NK_3 receptor
Tachykinin; Capsaicin; Tachykinin receptor antagonist; SR 142801 (Patacchini, R. (278) 17)

Tachyphylaxis
Endothelin; Alanine analog; Receptor subtype; Ileum, guinea-pig; Sarafotoxin S6c (Miasiro, N. (278) 103)

Endothelin; IRL1620; Endothelin receptor subtype; PD145065; BQ-123 (Miasiro, N. (285) 247)

Taenia caeci, guinea-pig
β-Adrenoceptor, atypical; Muscle relaxation; Noradrenaline (Koike, K. (279) 159)

P_1 purinoceptor; P_{2Y} purinoceptor; Suramin; Adenosine 5'-triphosphate; PPADS (pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid) (Piper, A.S. (280) 125)

Tail artery, rat
Adrenergic nerve; Nitric oxide (NO); Lipopolysaccharide; Sepsis (Takakura, K. (271) 367)

Sympathetic nerve stimulation; Purinergic transmission; P_{2X} purinoceptor; Suramin (McLaren, G.J. (277) 57)

Tail-flick
Enkephalin catabolism inhibitor; Enkephalin, endogenous; CCK (cholecystokinin); RB 101; PD-134,308; Hot-plate; Antinociception; CCK_B receptor antagonist; Tolerance (Valverde, O. (286) 79)

Tail-flick inhibition
β-Endorphin; Antinociception; δ_2-Opioid receptor; Naltriben (Tseng, L.F. (277) 251)

Tail-flick test
Morphine tolerance; NMDA receptor/glycine site antagonist; (CD-1 mouse) (Lutfy, K. (273) 187)

Tamsulosin
α_1-Adrenoceptor; Liver; Hepatocyte (García-Sáinz, J.A. (289) 1)

TAN-67
Antinociception; δ-Opioid receptor; 7-Benzylidenenaltrexone; Naltriben diabetes (Kamei, J. (276) 131)

Antinociception; δ-Opioid receptor; 7-Benzylidenenaltrexone; Naltriben diabetes (Kamei, J. (280) 347)

Tardive dyskinesia
Haloperidol; Oral dyskinesia; 6-Hydroxydopamine (Huang, N.-Y. (271) 433)

Tardive dyskinesia, rat
cAMP; Phosphodiesterase; Rolipram; Ageing (Sasaki, H. (282) 71)

TA-0910 (TRH analog)
TRH (thyrotropin-releasing hormone); Oral administration; Ataxia (Kinoshita, K. (274) 65)

Taurine
Cyclophosphamide; Niacin; Lung injury antioxidant; Membrane stabilizer (Venkatesan, N. (292) 75)

β-Adrenoceptor agonist; Clenbuterol; Urinary marker; Protein synthesis (Waterfield, C.J. (293) 141)

[^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate) binding
Pentylenetetrazol; γ-Butyrolactone bicyclic; $GABA_A$ receptor-ionophore complex; Convulsant (picrotoxin) site; Benzodiazepine sites (Maksay, G. (288) 61)

$GABA_A$ receptor; Benzodiazepine BZ_1 site; Benzodiazepine BZ_2 site; Ontogenesis; Flunitrazepam; CL 218,872; Zolpidem; Cerebral cortex, rat (Giorgi, O. (290) 37)

TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin)
Dioxin; Portocaval anastomosis; Anorexia; Food intake; Vagotomy (Tuomisto, J. (292) 277)

PCB (polychlorinated biphenyl); Glucuronidation; Thyroid hormone (Van Birgelen, A.P.J.M. (293) 77)

Tryptophan, free; Fatty acid, free; Albumin (Unkila, M. (293) 115)

Ventromedial hypothalamic nucleus; Body weight; Appetite; Eating; (Rat) (Tuomisto, J.T. (293) 309)

Thymocyte selection; Arylhydrocarbon receptor; Apoptosis; Bcl-2; Thymus organ culture, mouse fetal (Kremer, J. (293) 413)

Dioxin; Concanavalin A; Immunotoxicity; Interleukin; Thymus; Spleen; T lymphocyte; B lymphocyte; Macrophage; (Rat) (Badesha, J.S. (293) 429)

Aryl hydrocarbon receptor; PCB; Reporter gene; Biomarker; (Interaction) (Aarts, J.M.M.J.G. (293) 463)

TCV-116
CV-11974; Smooth muscle cell; Vascular; Cell growth; c-*fos* (Flesch, M. (289) 399)

T47D
CGS16949A; Fadrozole hydrochloride; Aromatase inhibitor; MCF-7 (Yano, S. (289) 217)

TEF (toxic equivalency factor)
PCB (polychlorinated biphenyl); PCDD (polychlorinated dibenzo-*p*-dioxin); PCDF (polychlorinated dibenzofuran); Ah (aryl hydrocarbon) receptor; Developmental toxicity; Neurobehavioral effect; Reproduction effect; Endocrine effect; LOAEL (lowest observable adverse effect level); Experimental animal; Human infant; Lactational exposure; In utero exposure (Seegal, R.F. (293) 1)

TEI-7322
Bleomycin; Experimental hypoxemia; Prednisolone; Doxapram; Almitrine (Horiuchi, H. (287) 27)

Telemetry
ME3221; Angiotensin AT_1 receptor antagonist, surmountable; Antihypertensive drug; Losartan (Nagura, J. (274) 201)

Tenidap
Prostaglandin G/H synthase (cyclooxygenase); Whole blood, human; Etodolac; Naproxen; Diclofenac (Glaser, K. (281) 107)

Terbutaline
Cilia; Formoterol; Trachea; Maxillary sinus; Mucociliary clearance (Lindberg, S. (285) 275)

Testosterone
Sexual behavior; 5-HT (5-hydroxytryptamine, serotonin); $5\text{-}HT_2$ receptor agonist; DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane); Castration; Puberty (Padoin, M.J. (277) 1)

Heterologous expression; Cytochrome P450 3A4; V79 Chinese hamster cell; Ergot derivative (Rauschenbach, R. (293) 183)

Tetrabenazine
Monoamine transporter; Monoamine; Vesicle (Kilbourn, M. (278) 249)

Tetraethylammonium
Vas deferens, rat; α_2-Adrenoceptor; Xylazine; 4-Aminopyridine; Charybdotoxin; Phorbol dibutyrate; Bay K 8644 (Docherty, J.R. (287) 287)

Tetrahydroaminoacridine
Nicotine; Nucleus basalis lesion; *p*-Chlorophenylalanine treatment; Alzheimer's disease (Riekkinen Jr., P. (279) 65)

Tetrahydrocannabinol
Basal ganglia; Cannabinoid; Substantia nigra; Cannabinoid receptor; Motor system; Marijuana; WIN 55,212-2; Aminoalkylindole (Miller, A.S. (279) 179)

Marijuana; Withdrawal (Tsou, K. (280) R13)

Δ^9-Tetrahydrocannabinol
Anandamide; CP 55,940; Drug discrimination (Wiley, J. (276) 49)

Muscimol; Substantia nigra, pars reticulata; Circling behavior; Contralateral circling; Drug interaction (Wickens, A.P. (282) 251)

Precipitated withdrawal; SR 141716A, (*N*-(piperidin-1-yl)-5-(4-chlorophenyl)-1(2,4-dichloro-phenyl)-4-methyl-1*H*-pyrazole carboxamide · HCl) (Aceto, M.D. (282) R1)

Tetramethylbenzidine
Myeloperoxidase; Polymorphonucleocyte; Renal ischemia/reperfusion; Adhesion molecule (Laight, D.W. (292) 81)

Tetrandrine
Hypertrophy; Dihydropyridine; Ca^{2+}; DOCA (deoxycorticosterone acetate); (Receptor) (Xu, Y. (278) 1)

Tetrodotoxin
Monoclonal antibody; Neutralization (Matsumura, K. (293) 41)

Thalamocortical oscillation
$5\text{-}HT_1$ receptor; $5\text{-}HT_2$ receptor; Neocortical high-voltage spindle, rat (Jäkälä, P. (282) 39)

Thapsigargin
Aortic endothelial cell; Ca^{2+} mobilization; Cl^-, extracellular; Fura-2; Cyclopiazonic acid (Hosoki, E. (288) 131)

Theophylline
NMDA (*N*-methyl-D-aspartate); Motor activity; Reserpine; (Mouse) (Giménez-Llort, L. (275) 171)

Theophylline-7-riboside and derivative
Adenosine receptor; Adenosine; 8-Alkylaminoadenosine analogue; Affinity; Intrinsic activity (Van der Wenden, E.M. (290) 189)

Therapy
Adenosine; Ischemia; Adenosine receptor; (Gerbil) (Von Lubitz, D.K.J.E. (287) 295)

Thermoregulation
Dopamine D_3 receptor; Core temperature; Clozapine; Antipsychotic (Millan, M.J. (280) 225)

Thielocin A1β
Phospholipase A_2; Paw edema; Anti-inflammatory drug (Tanaka, K. (279) 143)

Thiokynurenic acid
Retina; Excitatory amino acid receptor antagonist; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid); NMDA (*N*-methyl-D-aspartate); Rose bengal (Lombardi, G. (271) 489)

Thiol
Aging; Mitochondria; *N*-Acetylcysteine (Miquel, J. (292) 333)

Thiomuscimol
Photoaffinity labeling; $GABA_A$ receptor; Brain, rat (Nielsen, M. (289) 109)

Thoracic aorta
α_1-Adrenoceptor subtype; Ca^{2+}-sensitization; Myosin light chain phosphorylation; Botulinum C_3-sensitive GTP-binding protein (Kokubu, N. (290) 19)

Thoracic aorta, rat
Butein; EDRF (endothelium-derived relaxing factor); Phosphodiesterase; cAMP; cGMP (Yu, S.-M. (280) 69)

Thrombin
5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Calmodulin; Ca^{2+}; Platelet (Helmeste, D.M. (288) 373)

5-HT (5-hydroxytryptamine, serotonin) uptake inhibitor; Calmodulin; Ca^{2+}; Platelet (Helmeste, D.M. (290) 173)

Aortic valve cusp, porcine; Nitric oxide (NO); Cyclic GMP; Nitric oxide synthase, constitutive; Nitric oxide synthase, inducible (De Meyer, E. (291) 67)

Inositol phosphate; Phospholipase C inhibitor; Pertussis toxin; Atrium, rat; Noradrenaline (Woodcock, E.A. (291) 213)

Thrombosis, photochemically induced
Humanized antibody; GPIIb/IIIa; Microcirculation; Bleeding time; (Squirrel monkey) (Kaku, S. (279) 115)

Thromboxane
Macrophage; Azelastine; Airway hyperresponsiveness (Tamaoki, J. (278) 161)

Bradykinin; Airflow obstruction; WEB2086; ICI192,605; OKY-046 (Kawikova, I. (280) 293)

Thromboxane receptor antagonist
Myocardial ischemia; Reperfusion injury; Aspirin (Gomoll, A.W. (271) 471)

Thromboxane A_2
Bradykinin; Capsaicin; Smooth muscle, airway (Molimard, M. (278) 49)

Aorta, rat; Sulfonylurea; Prostanoid; Prostaglandin $F_{2\alpha}$; Glibenclamide; Tolbutamide (Delaey, C. (280) 179)

Thromboxane A_2 receptor
Bradykinin; Furosemide; Smooth muscle; Airway (Molimard, M. (278) 253)

Thymocyte
Methylmercury; Cytotoxicity; Membrane potential; Ca^{2+} concentration, intracellular (Oyama, Y. (293) 101)

Thymocyte selection
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; Arylhydrocarbon receptor; Apoptosis; Bcl-2; Thymus organ culture, mouse fetal (Kremer, J. (293) 413)

Thymus
Benzodiazepine receptor, peripheral type; Olfactory bulbectomy; Spleen; Adrenal; Antidepressant (Dennis, T. (272) 279)

TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Dioxin; Concanavalin A; Immunotoxicity; Interleukin; Spleen; T lymphocyte; B lymphocyte; Macrophage; (Rat) (Badesha, J.S. (293) 429)

Thymus organ culture, mouse fetal
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; Thymocyte selection; Arylhydrocarbon receptor; Apoptosis; Bcl-2 (Kremer, J. (293) 413)

Thyroid hormone
β_1-Adrenoceptor; Catecholamine; Transcriptional regulation; Corticosteroid; (Sheep) (Tseng, Y.T. (289) 353)

PCB (polychlorinated biphenyl); TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Glucuronidation (Van Birgelen, A.P.J.M. (293) 77)

Thyrotropin
Tolerance; Morphine; Prolactin; Growth hormone; Locomotor activity; Rectal temperature (Rauhala, P. (285) 69)

Tiagabine
GABA (γ-aminobutyric acid) uptake inhibitor; Nipecotic acid; Carbamazepine anticonvulsant; Epilepsy (Smith, S.E. (273) 259)

TIPP (H-Tyr-Tic-Phe-Phe-OH)
δ-Opioid receptor; [Tyr(3′-I)^1]TIPP; Brain, rat; N4TG1 cell; Vas deferens, mouse (Lee, P.H.K. (280) 211)

[Tyr(3′-I)^1]TIPP
δ-Opioid receptor; TIPP (H-Tyr-Tic-Phe-Phe-OH); Brain, rat; N4TG1 cell; Vas deferens, mouse (Lee, P.H.K. (280) 211)

T lymphocyte
TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Dioxin; Concanavalin A; Immunotoxicity; Interleukin; Thymus; Spleen; B lymphocyte; Macrophage; (Rat) (Badesha, J.S. (293) 429)

TNF (tumor necrosis factor)
Interleukin-6; Dexamethasone; Pentoxifylline; Fusidic acid; Pentamidine isethionate; Adenosine receptor agonist (Chen, Y.-L. (271) 319)

Cytokine; Interleukin-1; Elastase; Neutrophil (Klemm, P. (281) 69)

Cytochrome P-450; Dexamethasone; Interleukin-2; Liver; Xanthine oxidase (Cantoni, L. (292) 257)

TNF-α (tumor necrosis factor-α)
Asthma; Cytokine; Bronchial hyperresponsiveness; Electrical field stimulation; Airway, human (Anticevich, S.Z. (284) 221)

G 619; Endotoxin shock; cAMP (Altavilla, D. (286) 31)

Capsaicin; Cutaneous hyperemia; Afferent nerve stimulation; CGRP (calcitonin gene-related peptide); Bradykinin (Herbert, M.K. (286) 273)

Hepatocyte; DNA fragmentation; Nitric oxide (NO); Oxygen tension; (Acute phase response); (Tissue) (Ohno, K. (292) 205)

Tolbutamide
Aorta, rat; Sulfonylurea; Prostanoid; Prostaglandin $F_{2\alpha}$; Glibenclamide; Thromboxane A_2 (Delaey, C. (280) 179)

Tolcapone
Dopamine; Microdialysis; Catechol-*O*-methyltransferase inhibition; L-DOPA (3,4-dihydroxyphenyl-L-alanine) (Napolitano, A. (273) 215)

Tolerance
Cannabinoid; Opioid; Noradrenaline; β,γ-Methylene-L-ATP; Vas deferens, mouse (Pertwee, R.G. (272) 67)

Chronic chlordiazepoxide; Behavior; EEG (electroencephalographic); Dependence; (Rat) (Sala, M. (273) 35)

Haloperidol; Clozapine; Fos protein; Nucleus accumbens; Striatum; Amygdala; (Long-term treatment) (Sebens, J.B. (273) 175)

Benzodiazepine type I receptor; [^{3}H]Zolpidem; Receptor down-regulation; Midazolam; Flurazepam (Wu, Y. (278) 125)

Morphine; Antinociception; Adenosine receptor; Cyclohexyladenosine; (Rat) (Tao, P.-L. (278) 233)

Morphine; Ischemia; κ-Opioid receptor; 2-Deoxyglucose; Hippocampal slice (Shibata, S. (279) 197)

Skin, toad; Diazepam; Ca^{2+} channel (Norris, B. (280) 221)

Nitric oxide (NO); Muscle-derived nitric oxide (NO); Endotoxin; L-Arginine; Nitrovasodilator (Tsuchida, S. (281) 251)

Morphine; Thyrotropin; Prolactin; Growth hormone; Locomotor activity; Rectal temperature (Rauhala, P. (285) 69)

Enkephalin catabolism inhibitor; Enkephalin, endogenous; CCK (cholecystokinin); RB 101; PD-134,308; Tail-flick; Hot-plate; Antinociception; CCK_B receptor antagonist (Valverde, O. (286) 79)

Tolfenamic acid
Neutrophil; Degranulation; Ca^{2+}; cAMP; cGMP; Protein kinase C (Kankaanranta, H. (291) 17)

Toluene
GABA (γ-aminobutyric acid); Microdialysis; Globus pallidus; Striatum (Stengård, K. (292) 43)

Topical glucocorticoid
Lipocortin 1; Neurogenic inflammation; Edema (Ahluwalia, A. (283) 193)

Toxic equivalency
Dioxin; Risk evaluation; Acute toxicity; Strain difference (Pohjanvirta, R. (293) 341)

Toxicity
Antioxidant; Free radical; NMDA receptor; Cortical culture (Eshhar, N. (283) 19)

Dithiothreitol; Dithioerythritol; Pentobarbital; Anesthesia reversal; (Rodents) (Gailis, L. (292) 39)

Toxic metabolite
Vasodepression; Hyperapnea; Cardiac insufficiency; (*Ptychodiscus brevis*) (Koley, J. (293) 483)

Toxicokinetics
Nitrate; Nitrite; *N*-nitroso compound; Human diet; Dietary intake; Endogenous synthesis; Metabolism; Animal toxicology; Human effects (Gangolli, S.D. (292) 1)

Toxocara canis
Airway inflammation; Eosinophil; Tracheal reactivity (Buijs, J. (293) 207)

Trachea
K^+ channel opener; Submucosal gland; Epithelium (Griffin, A. (280) 317)

Smooth muscle cell; Caffeine; Ca^{2+}-dependent Cl^- channel; Sarcoplasmic reticulum; Ca^{2+} pump (Henmi, S. (282) 219)

Cilia; Formoterol; Terbutaline; Maxillary sinus; Mucociliary clearance (Lindberg, S. (285) 275)

Trachea, guinea pig
Bradykinin; Uterus, rat; Vas deferens, rat; Ileum, guinea pig; Urinary bladder, guinea pig; Ca^{2+}; G protein; Protein kinase C (Calixto, J.B. (281) 279)

Bradykinin; Epithelium; Bradykinin B_2 receptor; Relaxation; Ca^{2+}; Ryanodine; Apamin; HOE 140; NPC 17761 (Schlemper, V. (282) 177)

K^+ channel opener; NIP-121; Cromakalim; Epithelium; Methylene blue; Phosphoramidon (Shikada, K.-i. (282) 193)

Trachea, rat
Substance P; Neurokinin A; Tachykinin receptor; Carbachol; 5-HT (5-hydroxytryptamine, serotonin) (Joos, G.F. (271) 47)

Tracheal hyperresponsiveness
Nitric oxide (NO); Leukotriene; (Guinea pig) (Folkerts, G. (285) R1)

Tracheal reactivity
Toxocara canis; Airway inflammation; Eosinophil (Buijs, J. (293) 207)

Tranilast
PDGF (platelet-derived growth factor); Mesangial cell; Nitric oxide (NO) (Hishikawa, K. (291) 435)

Transcallosal response, cat
$GABA_B$ receptor antagonist; CGP 35348; Pyramidal tract neuron; Motor cortex (Chowdhury, S.A. (285) 99)

Transcription
Glucocorticoid; Nuclear receptor (Tanaka, H. (291) 121)

Transcriptional regulation
β_1-Adrenoceptor; Catecholamine; Corticosteroid; Thyroid hormone; (Sheep) (Tseng, Y.T. (289) 353)

Transfection
Human glutamate transporter (hGluT-1); CCG (2-(Carboxycyclopropyl)-glycine); COS-7 cell (Yamashita, H. (289) 387)

Transgenic mouse
Superoxide dismutase; Opiate receptor; Antinociception; Genetics (Elmer, G.I. (283) 227)

Transmural stimulation
Des-Asp-angiotensin I; Losartan; PD123319; Pulmonary artery, rabbit; (Superfusion) (Sim, M.K. (284) 215)

Transport
Arachidonic acid; Glutamate; Synaptosome; Ca^{2+} (Lundy, D.F. (291) 273)

TRH (thyrotropin-releasing hormone)
Sustained release formulation; Senescence-accelerated mouse (SAM); Neophobia; Learning and memory; Anxiety (Miyamoto, M. (271) 357)

Monosynaptic reflex; Spinal cord; TRH analog; (Neonatal rat) (Deshpande, S.B. (271) 439)

NMDA (*N*-methyl-D-aspartate); Dopamine; Striatum; (Rabbit) (Popoli, P. (272) 119)

TA-0910 (TRH analog); Oral administration; Ataxia (Kinoshita, K. (274) 65)

Repetitive jaw movement; YM-14673; Nucleus accumbens; Striatum; Dopamine receptor (Miwa, Y. (277) 63)

β-Endorphin-(10–16); Prolyl-leucyl-glycinamide; Melatonin; Nucleus accumbens; Antidepressant (Hatta, K. (284) 327)

TSH (Thyroid stimulating hormone); Triiodo-L-thyronine; Ca^{2+}; Hypophysis; (Rat) (Roussel, J.-P. (289) 205)

TRH (thyrotropin-releasing hormone) analog
TRH (thyrotropin-releasing hormone); Monosynaptic reflex; Spinal cord; (Neonatal rat) (Deshpande, S.B. (271) 439)

JTP-2942 (*Nα*-((1*S*,2*R*)-2-methyl-4-oxocyclopentylcarbonyl)-L-histidyl-L-prolinamide monohydrate); Acetylcholine turnover (Matsushita, M. (276) 177)

Triaminopyridine
Flupirtine; NMDA (*N*-methyl-D-aspartate); NMDA receptor; Neuron; Cell death; HIV-1; gp120 (Perovic, S. (288) 27)

Triethyllead
Benzodiazepine receptor; $GABA_A$ receptor; Flunitrazepam; Muscimol; (Rat); (Brain) (Komulainen, H. (293) 167)

Trigeminal ganglion
Neurogenic inflammation; Sensory nerve; μ-Opioid receptor agonist; $5\text{-}HT_{1D}$ receptor agonist; Histamine H_3 receptor agonist (Escott, K.J. (284) 69)

Trigeminal ganglion stimulation
Sumatriptan; Plasma protein extravasation; Dura mater; Carotid vascular resistance; Blood pressure (Spokes, R.A. (281) 75)

Trigeminal nucleus caudalis
[^{3}H]Sumatriptan; Autoradiography; Nucleus tractus solitarius; (Cat) (Mills, A. (280) 175)

Triiodo-L-thyronine
TRH (Thyrotropin-releasing hormone); TSH (Thyroid stimulating hormone); Ca^{2+}; Hypophysis; (Rat) (Roussel, J.-P. (289) 205)

Trimellitic anhydride
Mucus secretion; Bronchoconstriction; Asthma; Occupational asthma (Hayes, J.P. (292) 127)

Trimipramine
Antidepressant drug; Desipramine; Fluoxetine; Maprotiline; Moclobemide; 2-Methyl-5-hydroxytryptamine; 5-HT (5-hydroxytryptamine, serotonin); Reuptake inhibition; Hippocampus; Presynaptic modulation (Mongeau, R. (271) 121)

α-Trinositol (D-*myo*-inositol 1,2,6-trisphosphate)
Liposome; Smooth muscle, aortic, vascular (Brailoiu, E. (281) 209)

Triphenyltin-induced contracture
Diaphragm; Na^+-channel activation; Ca^{2+}-induced Ca^{2+} release (Liu, S.-H. (292) 95)

TRK-100
FK409; Antiplatelet activity (Hirasawa, Y. (272) 39)

Tryptophan, free
TCDD (2,3,7,8-tetrachlorodibenzo-*p*-dioxin); Fatty acid, free; Albumin (Unkila, M. (293) 115)

Tryptophan hydroxylase
MDMA (3,4-methylenedioxymethamphetamine); Hyperthermia; Hypothermia (Che, S. (293) 447)

TSH (thyroid-stimulating hormone)
TRH (thyrotropin-releasing hormone); Triiodo-L-thyronine; Ca^{2+}; Hypophysis; (Rat) (Roussel, J.-P. (289) 205)

Tubulin
Vinca alkaloid; Bis-indol; Navelbine; Vinblastine; Vincristine; Calmodulin antagonism; Anti-mitotic drug (Molnár, A. (291) 73)

Tumor promotion
Polychlorinated biphenyl; Hepatic focus (Hemming, H. (292) 241)

Tunicamycin
Bradykinin B_1 receptor; Cycloheximide; Brefeldin A; Receptor upregulation; Aorta, isolated, rabbit (Audet, R. (271) 551)

Turning
σ Receptor ligand; Tyrosine hydroxylase; Dopamine; DTG (1,3-di-*o*-tolylguanidine) (Weiser, S.D. (275) 1)

Turning behavior
Dopaminergic/cholinergic receptor interaction; Nucleus accumbens; Ventrolateral striatum; Carbachol; Turning pattern (Saigusa, T. (274) 213)

Turning pattern
Turning behavior; Dopaminergic/cholinergic receptor interaction; Nucleus accumbens; Ventrolateral striatum; Carbachol (Saigusa, T. (274) 213)

Tyr-D-Arg-Phe-β-Ala-NH_2
μ-Opioid receptor; β-Funaltrexamine; Memory; Passive avoidance; Locomotor activity; (Mouse) (Ukai, M. (287) 245)

Tyrosine hydroxylase
σ Receptor ligand; Turning; Dopamine; DTG (1,3-di-*o*-tolylguanidine) (Weiser, S.D. (275) 1)

PAMP (proadrenomedullin N-terminal 20 peptide); Catecholamine synthesis; Nicotinic receptor; Adrenal medulla (Niina, H. (286) 95)

Neuropeptide Y; PC12 cell; Nerve growth factor; Dexamethasone; Pertussis toxin (McCullough, L.A. (287) 271)

Dizocilpine; Aromatic L-amino acid decarboxylase; Dopamine; Parkinson's disease (Hadjiconstantinou, M. (289) 97)

Tyrosine kinase
Ca^{2+}-activated K^+ channel; Smooth muscle cell, vascular; Genistein (Xiong, Z. (290) 117)

Tyrosine kinase inhibitor
α_2-Adrenoceptor; Phospholipase D (Jinsi, A. (277) 29)

Aorta, rat; Contraction; Ca^{2+} store refilling; Vanadate (Filipeanu, C.M. (281) 29)

U937
Phosphatidic acid; Phosphodiesterase; Phospholipid; Rolipram; cAMP (DiSanto, M.E. (290) 169)

U937 cell
Histamine; Histamine H_2 receptor; cAMP; Homologous desensitization (Smit, M.J. (288) 17)

U46619 (9,11-dideoxy-11α,9α-epoxymethano prostaglandin $F_{2\alpha}$)
Isoprostane; Myometrium, human; Contraction; Prostanoid TP receptor (Crankshaw, D. (285) 151)

Neuropeptide Y; Basilar artery; Ca^{2+} concentration; Cytosolic; Ca^{2+} influx; Ca^{2+} sensitivity (Tanaka, Y. (289) 59)

U50,488
DAMGO ([D-Ala^2,MePhe^4,Gly(ol)^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Nalorphine; Xylazine; Clonidine (Paul, D. (272) 111)

Phospholipid metabolism; Ethylketocyclazocine; Norepinephrine; Carbachol; Renal cortex (Mosaddeghi, M. (289) 411)

U50,488H
Alternation performance, spontaneous; Dynorphin A-(1–13); κ-Opioid receptor; Mouse (Ukai, M. (281) 173)

G-protein; Opiate; U-69593; PD 117302; Hypothermia; Gut motility; Cholera toxin; Pertussis toxin (Shukla, V.K. (292) 293)

U69,593
Clocinnamox; Morphine; Opioid receptor antagonist; DAMGO ([D-Ala^2,MePhe^4,Gly-ol^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Opioid receptor alkylation; Opioid receptor binding; mRNA; Solution hybridization; Analgesia; (Irreversible antagonist) (Chan, K. (287) 135)

G-protein; Opiate; U-50488H; PD 117302; Hypothermia; Gut motility; Cholera toxin; Pertussis toxin (Shukla, V.K. (292) 293)

ucb L059
Levetiracetam; Epilepsy; Anticonvulsant; Receptor binding (Noyer, M. (286) 137)

Bicuculline; Hippocampal CA3, rat; Input-output curve; Paired-pulse inhibition (Margineanu, D.G. (286) 321)

(*S*)-UH301
5-HT_{1A} receptor; Corticosterone; Glucose; 5-HT (5-hydroxytryptamine, serotonin); Behavioral syndrome; Flesinoxan (Groenink, L. (272) 177)

(*S*)-UH301, enantiomer
Flesinoxan; Drug discrimination; 5-HT_{1A} receptor; WAY-100635; Fentanyl (Gommans, J. (284) 135)

UK 14304
α_2-Adrenoceptor; Imidazoline receptor; Sympathoinhibition; Presynaptic inhibition; Moxonidine (Urban, R. (282) 19)

α_2-Adrenoceptor; Imidazoline receptor; Presynaptic inhibition; Moxonidine; Rilmenidine (Urban, R. (282) 29)

Ulcer
NSAID (non-steroidal anti-inflammatory drug); Inflammation; Cyclooxygenase; Leukotriene (Wallace, J.L. (271) 525)

Non-steroidal anti-inflammatory drug; Nitric oxide (NO); Endotoxic shock, acute; Gastrointestinal; Prostaglandin; Cardiovascular (Wallace, J.L. (280) 63)

Ultrasonic distress call
Cerebral cortex; Lesion; Anxiolytic mechanism; Diazepam; 8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide) (Naito, H. (272) 261)

Ultraviolet light
Cytomegalovirus; Immunotoxicity testing; Bis(tri-*n*-butyltin)oxide (Garssen, J. (292) 223)

UV-B irradiation; Neurogenic inflammation; Cutaneous vasodilatation; Laser Doppler; CGRP (calcitonin gene-related peptide); Substance P; Nitric oxide (NO) (Benrath, J. (293) 87)

Neuropeptide release; Neurogenic immunomodulation; Langerhans cell; Contact hypersensitivity (Gillardon, F. (293) 395)

Umbilical artery
HOE 140; Pulmonary artery; Bronchus; Umbilical vein; (Human) (Félétou, M. (274) 57)

Umbilical artery, human
Adrenoceptor; Noradrenaline; Smooth muscle, vascular (Bodelsson, G. (282) 95)

Umbilical vein
HOE 140; Pulmonary artery; Bronchus; Umbilical artery; (Human) (Félétou, M. (274) 57)

UP 269-6
Losartan; Angiotensin II; Angiotensin II receptor antagonist; Blood pressure; Heart rate (Cazes, M. (284) 157)

Up-regulation
Lidocaine; α_1-Adrenoceptor; Cardiocyte; Culture (Mizuki, T. (277) 133)

μ-Opioid receptor; Estrogen; Progesterone; Medial preoptic area (Zhou, L. (278) 271)

Uptake blocker
α_1-Adrenoceptor; β-Adrenoceptor; Localisation; Myocardium, rat; Noradrenaline (Dybvik, T. (281) 21)

Ureter, guinea-pig
CGRP (Calcitonin gene-related peptide); Forskolin; Adenylate cyclase; K^+ channel (Santicioli, P. (289) 17)

Ureteral calculosis, artificial
Spasmolytic and/or non-steroidal antiinflammatory treatment; Muscle hyperalgesia, referred; (Rat) (Giamberardino, M.A. (278) 97)

Urethane
Anesthesia; Chemoreflex; Reticulospinal vasomotor neuron; Rostral ventrolateral medulla; (Rats) (Sun, M.-K. (293) 237)

Urethane (ethyl carbamate)
Dentate gyrus; Perforant path; Evoked potential; GABAergic inhibition (Shirasaka, Y. (282) 11)

Urethra
α_1-Adrenoceptor; Aorta (Auguet, M. (287) 153)

Urethral sphincter, external
GYKI 52466; MK-801; Cystometrogram; Bladder reflex (Yoshiyama, M. (287) 73)

Urinary bladder
Diabetes; Sensory fiber; Capsaicin; Epithelium (Pinna, C. (271) 151)

Smooth muscle; ATP; Hypertrophy; Caged-ATP (Sjuve, R. (276) 137)

Urinary bladder, guinea pig
Bradykinin; Uterus, rat; Vas deferens, rat; Trachea, guinea pig; Ileum, guinea pig; Ca^{2+}; G protein; Protein kinase C (Calixto, J.B. (281) 279)

Urinary bladder, rabbit
Muscarinic receptor subtype; Contractile response; Acetylcholine release; Muscarinic receptor antagonist (Tobin, G. (281) 1)

Urinary marker
β-Adrenoceptor agonist; Clenbuterol; Taurine; Protein synthesis (Waterfield, C.J. (293) 141)

Urine
Metabolite; Methylation; Blood; Water; Food (Vahter, M. (293) 455)

Urodilatin
Natriuretic peptide, type A; Bronchoprotection; Acetylcholine; Lung function, rat (Flüge, T. (271) 395)

Use-dependent block
Na^+ current; Disopyramide; Chloramine-T; Activation gate; (Fast inactivation gate) (Koumi, S.-i. (277) 165)

Uterine artery
K^+ channel blocker; Acetylcholine; Endothelium; Nitric oxide (NO) (Jovanović, A. (280) 95)

Pregnancy; Vasopressin receptor; Arginine vasopressin; (Guinea-pig) (Jovanović, A. (280) 101)

α_1-Adrenoceptor; Inositol 1,4,5-trisphosphate; Pregnancy (Zhang, L. (289) 375)

Uterus, human
Rubidium; K^+ channel opener; Levcromakalim; P1060 (Criddle, D.N. (272) 293)

G. protein; $G_o\alpha$ subunit; Go isoform; Pregnancy; Myometrium (Zumbihl, R. (288) 9)

Uterus, immature
Opioid; Naloxone binding site; DNA synthesis; (Rat) (Vértes, Z. (291) 115)

Uterus, rat
Bradykinin; Vas deferens, rat; Trachea, guinea pig; Ileum, guinea pig; Urinary bladder, guinea pig; Ca^{2+}; G protein; Protein kinase C (Calixto, J.B. (281) 279)

Vaccinia virus
Dopamine $D_{4.2}$ receptor; Adenylyl cyclase; (Functional expression) (Bouvier, C. (290) 11)

Vagal depolarization
Vagus nerve; 5-HT (5-hydroxytryptamine, serotonin); Cisplatin; Dexamethasone; (Rat); (Grease gap) (Woods, A.J. (278) 275)

Vagotomy
Dioxin; TCDD (2,3,7,8-Tetrachlorodibenzo-*p*-dioxin); Portocaval anastomosis; Anorexia; Food intake (Tuomisto, J. (292) 277)

Vagus nerve
Presynaptic α_2-adrenoceptor; α_2-Adrenoceptor subtype; Gastric acid secretion; (Rat) (Blandizzi, C. (278) 179)

Vagal depolarization; 5-HT (5-hydroxytryptamine, serotonin); Cisplatin; Dexamethasone; (Rat); (Grease gap) (Woods, A.J. (278) 275)

Vanadate
Tyrosine kinase inhibitor; Aorta, rat; Contraction; Ca^{2+} store refilling (Filipeanu, C.M. (281) 29)

Vanadium
Renal kallikrein secretion; Ca^{2+}; K^+; Ca^{2+} channel antagonist; Ouabain (Bompart, G. (278) 225)

Vanilloid receptor
Vanilnoid, endogenous; Resiniferatoxin binding; Capsaicin; Proton; Positive cooperativity; Non-competitive inhibition; Desensitization (Szallasi, A. (289) 181)

Vanilnoid, endogenous
Vanilloid receptor; Resiniferatoxin binding; Capsaicin; Proton; Positive cooperativity; Non-competitive inhibition; Desensitization (Szallasi, A. (289) 181)

Vapreotide
Somatostatin analog; Substance P; Tachykinin NK_1 receptor; Tachykinin NK_2 receptor; Airway; Binding (Bétoin, F. (279) 241)

Vascular
Endothelin; Smooth muscle; Endothelin receptor (Lodge, N.J. (287) 279)

CV-11974; TCV-116; Smooth muscle cell; Cell growth; c-*fos* (Flesch, M. (289) 399)

Vascular bed, intestinal
Adrenomedullin; Vasoactive peptide; CGRP (calcitonin gene-related peptide); (Six-membered ring structure) (Santiago, J.A. (272) 115)

Vascular control
Blood vessel; Hyperemia; K^+ channel (Kosmas, E.N. (274) 193)

Vascular permeability
Acetylshikonin; Hind-paw edema; Cutaneous anaphylaxis, passive; Neurogenic inflammation; Compound 48/80; [Thi^{5,8},D-Phe^7]Bradykinin; [D-Pro^2,D-Trp^{7,9}]Substance P (Wang, J.-P. (272) 87)

Abruquinone A; Paw edema; Neurogenic inflammation; Passive cutaneous anaphylaxis; Compound 48/80; Mast cell degranulation (Wang, J.-P. (273) 73)

PAF (platelet-activating factor); Nitric oxide (NO); Indomethacin; (Skin); (Mouse) (Fujii, E. (273) 267)

β-Adrenoceptor; Endothelium; Protein extravasation; Salbutamol; Salmeterol (Allen, M.J. (274) 7)

Delayed-type hypersensitivity; Pulmonary inflammation; Airway hyperreactivity, mouse; LCB 2183 (Buckley, T.L. (282) 103)

Nitric oxide (NO); Allergic conjunctivitis; N^G-Nitro-L-arginine methyl ester; Aminoguanidine; Histamine; PAF (platelet-activating factor) (Meijer, F. (284) 61)

Endotoxin; Kininogen-deficient rat; Bradykinin; PAF (platelet-activating factor); PAF receptor antagonist (Ueno, A. (284) 211)

Vascular reactivity
PAF (platelet-activating factor); Nitric oxide (NO); Cyclo-oxygenase product; L-NMMA (N^G-monomethyl-L-arginine); Indomethacin (Shiga, T. (282) 151)

Vascular tone
Na^+-pump; Dopamine receptor; Phosphoinositide hydrolysis; Pertussis toxin (Rashed, S.M.K. (284) 289)

Vas deferens
Endothelin; Sarafotoxin; BQ-123; IRL 1620; BQ-788; Endothelin-converting enzyme; Phosphoramidon; Neurotransmission; (Mouse) (Maas, J. (276) 113)

Endothelin receptor; Cotransmission; Endothelin-3; BQ-123; Sarafotoxin S6c; (Guinea-pig) (Mutafova-Yambolieva, V.N. (285) 213)

Vas deferens, guinea-pig
P_2 purinoceptor; Periodate-oxidized nucleotide; ATP; 2′,3′-Dialdehyde ATP analog (Fedan, J.S. (281) 213)

Vas deferens, human
Noradrenaline; Phenoxybenzamine; α-Adrenoceptor agonist; α-Adrenoceptor antagonist (Amobi, N. (273) 25)

Vas deferens, mouse
Cannabinoid; Opioid; Noradrenaline; β,γ-Methylene-L-ATP; Tolerance (Pertwee, R.G. (272) 67)

Cannabinoid; Phenylmethylsulphonyl fluoride; Anandamide; *R*-(+)-Arachidonyl-1′-hydroxy-2′-propylamide; Myenteric plexus preparation, guinea-pig (Pertwee, R.G. (272) 73)

δ-Opioid receptor; TIPP (H-Tyr-Tic-Phe-Phe-OH); [Tyr(3′-I)^1]TIPP; Brain, rat; N4TG1 cell (Lee, P.H.K. (280) 211)

Cannabinoid; Cannabinoid receptor antagonist; SR141716A; 1-Pentyl-2-methyl-3-(1-naphthoyl)indole; 1-Pentyl-3-(1-naphthoyl)pyrrole; 1-Heptyl-3-(1-naphthoyl)indole (Pertwee, R.G. (284) 241)

Vas deferens, rat
α,β-Methylene ATP; Endothelin; Phosphoramidon; Suramin; Sympathetic co-transmission (Lau, W.A.K. (272) 31)

Bradykinin; Uterus, rat; Trachea, guinea pig; Ileum, guinea pig; Urinary bladder, guinea pig; Ca^{2+}; G protein; Protein kinase C (Calixto, J.B. (281) 279)

α_2-Adrenoceptor; Xylazine; 4-Aminopyridine; Tetraethylammonium; Charybdotoxin; Phorbol dibutyrate; Bay K 8644 (Docherty, J.R. (287) 287)

Vasoactive peptide
Adrenomedullin; Vascular bed, intestinal; CGRP (calcitonin gene-related peptide); (Six-membered ring structure) (Santiago, J.A. (272) 115)

Vasoconstriction
Endothelin receptor antagonist; Coronary flow; Endothelin-1; Endothelin ET_A receptor; Endothelin ET_B receptor; Nitric oxide (NO) (Wang, Q.-D. (271) 25)

Neuropeptide Y; Angiotensin II; Second messenger; Femoral artery (Cressier, F. (272) 57)

Na^+,K^+-ATPase; Bufodienolide; Marinobufagenin; Ouabain; Smooth muscle, vascular (Bagrov, A.Y. (274) 151)

CP-122,288; Sumatriptan; 5-HT receptor (Beattie, D.T. (276) 271)

Ca^{2+} channel; Pregnancy; Aortic ring; Nifedipine; Bay K 8644 (Roy, B. (280) 1)

Cadmium ion; Ca^{2+} channel; Contractile protein; Aorta, rat (Wakabayashi, I. (293) 133)

Vasoconstrictor
Aging; Noradrenaline release, spontaneous; Potentiation (Glenn, T.C. (276) 191)

Vasodepression
Toxic metabolite; Hyperapnea; Cardiac insufficiency; (*Ptychodiscus brevis*) (Koley, J. (293) 483)

Vasodilation
Pentylenetetrazole; Parasympathetic reflex (Izumi, H. (273) 299)

Lipoprotein; Nitric oxide (NO); Endothelium (Galle, J. (273) 311)

PACAP (pituitary adenylate cyclase-activating polypeptide); Blood flow, vertebral artery; Cerebral artery, canine; VIP (vasoactive intestinal peptide) (Seki, Y. (275) 259)

Pulmonary vein, sheep; 5-HT (5-hydroxytryptamine, serotonin); Endothelium; Cyclic nucleotide (Zhang, L. (280) 335)

Cryptolepine (5-methylquindoline); Kidney, rat; G-protein; K^+ channel; Ca^{2+} channel; Pertussis toxin (Oyekan, A.O. (285) 1)

Vasodilator nerve
Nitric oxide (NO); Mesenteric artery, guinea pig; CGRP (calcitonin gene-related peptide); Capsaicin; Nitro-L-arginine; Zinc protoporphyrin IX (Gyoda, Y. (279) 83)

Vasodilator response
Allicin; Pulmonary vascular bed, rat; Pulmonary vascular bed, cat; N^{ω}-Nitro-L-arginine methyl ester; Methylene blue; Hypoxic pulmonary vasoconstriction; Guanylate cyclase (Kaye, A.D. (276) 21)

Vasodilator treatment
Polyol pathway; Galactosemia; Nerve conduction; Ischemic resistance; Capillary density (Dines, K.C. (281) 303)

Vasomotor neuron
Clonidine; Rostral ventrolateral medulla; Sympathoexcitatory neuron; GABA (γ-aminobutyric acid) (Sun, M.-K. (276) 291)

Vasopressin
Desamino-8D-arginine vasopressin; Brattleboro rat; Angiotensin; Noradrenaline; Hemorrhage (Laycock, J.F. (271) 193)

Angiotensin AT_1 receptor; Angiotensin AT_2 receptor; Losartan; PD 123177; Drinking response (Höhle, S. (275) 277)

Oxytocin; Myometrial receptor; OPC-21268; Vasopressin receptor antagonist (Atke, A. (281) 63)

Fos protein; Immunoreactivity; Brain region; (Rat) (Wu, P.H. (281) 263)

Angiotensin II; Bradykinin; Pulmonary artery; Pulmonary vein; Nitric oxide (NO); Prostaglandin I_2 (Sai, Y. (282) 235)

[Arg^8]Vasopressin
Coronary artery, human; Vasopressin V_1 receptor; OPC-21268; OPC-31260; SR 49059; (Human) (Bax, W.A. (285) 199)

Vasopressin receptor
Uterine artery; Pregnancy; Arginine vasopressin; (Guinea-pig) (Jovanović, A. (280) 101)

Vasopressin receptor antagonist
Oxytocin; Vasopressin; Myometrial receptor; OPC-21268 (Atke, A. (281) 63)

Vasopressin V_1 receptor
[Arg^8]Vasopressin; Coronary artery, human; OPC-21268; OPC-31260; SR 49059; (Human) (Bax, W.A. (285) 199)

Vasorelaxant
Phosphodiesterase; cGMP-specific phosphodiesterase (phosphodiesterase V); E4021; Aorta, human (Miyahara, M. (284) 25)

Vasorelaxation
Prostaglandin E_2; Iloprost; Desensitization; Indomethacin; cAMP (Parfenova, H. (278) 133)

Pyridine; Ca^{2+} influx (Hsu, K.-S. (292) 265)

V79 Chinese hamster cell
Cytochrome P450; Cytochrome P450 2E1; *p*-Nitrophenol; Chlorzoxazone; *N*-Nitrosodimethylamine (Schmalix, W.A. (293) 123)

Heterologous expression; Cytochrome P450 3A4; Testosterone; Ergot derivative (Rauschenbach, R. (293) 183)

Vein
Inflammation; Somatostatin receptor; Peripheral nervous system; Substance P (Reubi, J.C. (271) 371)

Ventral hippocampus
5-HT (5-hydroxytryptamine, serotonin) uptake; Fluoxetine; Frontal cortex; Raphe nuclei; Microdialysis, in vivo (Malagié, I. (286) 213)

Ventral striatum, rat
Nitric oxide (NO); Adenosine release (Fischer, H. (275) R5)

Ventral tegmental area
Dopamine; Electrophysiology; Neurokinin; Senktide; Substance P; Tachykinin (Seabrook, G.R. (273) 113)

Behavioral sensitization; Dopamine D_1 receptor; Dopamine D_2 receptor; Nucleus accumbens; Drug addiction (Jeziorski, M. (275) 235)

Dopamine D_3 receptor; Dopamine (Lejeune, F. (275) R7)

Risperidone; Olanzapine; Seroquel; Ziprasidone; Amperozide; Schizophrenia; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (281) 289)

Ventricle
Acetylcholine; Atrium AF-DX 116, human; HHSiD (*p*-fluorohexahydrosiladifenidol hydrochloride); McN-A-343; Muscarinic receptor; Myocardial contractility; Pirenzepine (Du, X.Y. (284) 119)

Ventricular myocyte, rat
Ca^{2+} current, L-type; Verapamil; Binding site; Patch-clamp technique (Wegener, J.W. (287) 89)

Ventrolateral medulla
Glutamate receptor; L-Glutamate uptake inhibitor; Respiratory function; Excitatory amino acid receptor antagonist; Blood pressure; Heart rate (McManigle, J.E. (280) 257)

Ventrolateral nucleus of the tractus solitarius
Excitatory amino acid; Respiratory activity; NMDA receptor; Apneusis (Berger, I. (277) 195)

Ventrolateral striatum
Turning behavior; Dopaminergic/cholinergic receptor interaction; Nucleus accumbens; Carbachol; Turning pattern (Saigusa, T. (274) 213)

Ventromedial hypothalamic nucleus
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin; Body weight; Appetite; Eating; (Rat) (Tuomisto, J.T. (293) 309)

Verapamil
Ca^{2+}; Ca^{2+} channel antagonist; Ro 40-5967; 1,4-Dihydropyridine; Diltiazem; SR 33557 (Rutledge, A. (280) 155)

Ca^{2+} current, L-type; Binding site; Ventricular myocyte, rat; Patch-clamp technique (Wegener, J.W. (287) 89)

Veratridine
Na^+ channel; β-Adrenoceptor antagonist; Ca^{2+} channel blocker; Dilazep; Ca^{2+}, cytosolic (Hashizume, H. (271) 1)

Veratridine effect
Na^+ channel, fast; Na^+ current, fast; Leiomyosarcoma cell, human; Smooth muscle cell, uterine; Whole-cell voltage clamp (Kusaka, M. (271) 387)

Vesicle
Monoamine transporter; Monoamine; Tetrabenazine (Kilbourn, M. (278) 249)

Vessel
Imidazoline; Imidazoline site; Insulin secretion; Pancreas; Efaroxan; Idazoxan; (Rat) (Berdeu, D. (275) 91)

Vestibular compensation
Methylprednisolone; Steroid; Labyrinthectomy, unilateral (Jerram, A.H. (275) 291)

Vinblastine
ATP release, neuronal; Forskolin; Ouabain; Atrium, guinea-pig; W-7; Okadaic acid (Katsuragi, T. (282) 213)

Vinca alkaloid; Bis-indol; Navelbine; Vincristine; Calmodulin antagonism; Tubulin; Anti-mitotic drug (Molnár, A. (291) 73)

Vinca alkaloid
Bis-indol; Navelbine; Vinblastine; Vincristine; Calmodulin antagonism; Tubulin; Anti-mitotic drug (Molnár, A. (291) 73)

Vinconate
Dopamine release; Muscarinic receptor; Striatum; Microdialysis (Iino, T. (286) 99)

Vincristine
Vinca alkaloid; Bis-indol; Navelbine; Vinblastine; Calmodulin antagonism; Tubulin; Anti-mitotic drug (Molnár, A. (291) 73)

Ascorbic acid; Drug resistance; Lung cancer (Song, E.-J. (292) 119)

Vinpocetine
Phenytoin; Na^+ channel, voltage-gated; Anticonvulsant; Neuroprotection; Cortical neuron; (Rat) (Molnár, P. (273) 303)

VIP (vasoactive intestinal peptide)
PACAP (pituitary adenylate cyclase-activating polypeptide); Blood flow, vertebral artery; Cerebral artery, canine; Vasodilation (Seki, Y. (275) 259)

Nitric oxide (NO); SIN-1 (3-morpholino-sydnonimine); Cavernous artery; Smooth muscle, cavernosal; (Human) (Hempelmann, R.G. (276) 277)

PACAP (pituitary adenylate cyclase-activating peptide); cAMP; Cardiac myocyte; CDD/ANP-(99–126) (Bäsler, I. (291) 335)

Visceral pain
μ-Opioid receptor; κ-Opioid receptor; Antinociception (Diop, L. (271) 65)

Fedotozine; κ-Opioid receptor; μ-Opioid receptor; Colonic hypersensibility Langlois, A. (271) 245)

Visnagin
Aorta, rat; Portal vein (Duarte, J. (286) 115)

Vitamin B_{12}
Ischemia; Hippocampus; Neuroprotection; Glutamate; Hypoxia/hypoglycemia (Yamamoto, Y. (281) 335)

Vitamin B_{12} deficiency
Adenylyl cyclase; β-Adrenoceptor; G_s; Signal transduction (Hatta, S. (291) 351)

Vitamin C
Lipopolysaccharide; Antioxidant; Vitamin E; Allopurinol; Glucocorticoid (Dimmeler, S. (287) 257)

Vitamin E
Lipopolysaccharide; Antioxidant; Vitamin C; Allopurinol; Glucocorticoid (Dimmeler, S. (287) 257)

Vitamin K-dependent coagulation factor
Somatotropin; Somatostatin; Hemocoagulation (Negrev, N. (277) 145)

VLA-4 integrin
Bronchial hyperresponsiveness; Eosinophilia; Adhesion molecule (Milne, A.A.Y. (282) 243)

Voltage clamp
Catecholamine; Dopamine; Dopamine receptor, agonist, antagonist; Protein kinase inhibitor; Ouabain; Ionic mechanism; Neuron; (Snail) (Emaduddin, M. (283) 113)

Nicotinic acetylcholine receptor, neuronal; *Xenopus* oocyte; Metal ion, divalent; Ion current, potentiation, inhibition (Zwart, R. (291) 399)

Ethanol; Heart; Ca^{2+} current; Na^+ current (Habuchi, Y. (292) 143)

Voltammetry
Dopamine, mesocortical; Locomotor activity; Nucleus accumbens; 6-Hydroxydopamine lesion (Banks, K.E. (282) 157)

Volume overload
Cardiac hypertrophy; Losartan; Angiotensin II; Endothelin-1; FR139317 (Ishiye, M. (280) 11)

Voluntary γ-hydroxybutyric acid intake
GBH (γ-hydroxybutyric acid); Alcoholism; (Rat) (Colombo, G. (285) 103)

W-7
ATP release, neuronal; Forskolin; Ouabain; Atrium, guinea-pig; Vinblastine; Okadaic acid (Katsuragi, T. (282) 213)

Waking
Sleep; *m*-Chlorophenylbiguanide; 5-HT_3 receptor; MDL 72222; Dopamine; (+)-SCH 23390; YM-09151-2 (Ponzoni, A. (278) 111)

Water
Metabolite; Methylation; Blood; Urine; Food (Vahter, M. (293) 455)

Water intake
Baclofen; $GABA_B$ receptor; Food intake; Palatable liquid diet (Ebenezer, I.S. (273) 183)

WAY-100,135
5-HT_{1A} receptor antagonist; NAN-190; Microdialysis (Routledge, C. (276) 281)

(+)-WAY-100,135
Forced swimming; 5-HT_{1A} receptor; Depression; S 14506; S 14671 (Schreiber, R. (271) 537)

(*S*)-WAY-100,135
Spatial learning; Hippocampus; Acetylcholine; Scopolamine; 5-HT_{1A} receptor; Alzheimer disease; (Rat) (Carli, M. (283) 133)

5-HT_{1A} receptor; Ipsapirone; Punishment; Conflict; Anxiolytic activity (Cervo, L. (284) 249)

WAY-100,635 (*n*-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-*n*-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride)
5-HT_{1A} receptor; Brain, rat; Radioligand, in vivo; PET (positron emission tomography) (Hume, S.P. (271) 515)

5-HT_{1A} receptor; 5-HT_{1A} receptor antagonist (Forster, E.A. (281) 81)

Flesinoxan; Drug discrimination; 5-HT_{1A} receptor; (*S*)-UH301, enantiomer; Fentanyl (Gommans, J. (284) 135)

R(+)-8-OH-DPAT (8-hydroxy-2-(di-*n*-propylamino)tetralin); *d*-Amphetamine; Dopamine; 5-HT_{1A} receptor; Microdialysis, in vivo; Nucleus accumbens; Striatum; (Rat) (Ichikawa, J. (287) 179)

[^{11}C]WAY-100,635
5-HT_{1A} receptor, human; PET (positron emission tomography) (Pike, V.W. (283) R1)

[^{3}H]WAY-100,635
5-HT_{1A} receptor; In vivo labeling; Brain, mouse (Laporte, A.-M. (271) 505)

5-HT_{1A} receptor; G-protein; 5-HT_{1A} receptor antagonist; Autoradiography, quantitative; [^{3}H]8-OH-DPAT ([^{3}H]8-hydroxy-2-(di-*n*-propylamino)tetralin) (Gozlan, H. (288) 173)

WB-4101
Brain slice; Chloroethylclonidine; Estrogen; 5-Methyl urapidil (Kow, L.-M. (282) 199)

WEB2086
Bradykinin; Thromboxane; Airflow obstruction; IC1192,605; OKY-046 (Kawikova, I. (280) 293)

Whole blood, human
Prostaglandin G/H synthase (cyclooxygenase); Etodolac; Naproxen; Diclofenac; Tenidap (Glaser, K. (281) 107)

Whole-cell voltage clamp
Na^+ channel, fast; Na^+ current, fast; Leiomyosarcoma cell, human; Smooth muscle cell, uterine; Veratridine effect (Kusaka, M. (271) 387)

WIN 35,428
Methylphenidate; *d-threo*-Methylphenidate; Dopamine; Dopamine transporter; PET (positron emission tomography); (Baboon); (Mouse) (Gatley, S.J. (281) 141)

WIN 55,212-2
Basal ganglia; Cannabinoid; Substantia nigra; Cannabinoid receptor; Motor system; Marijuana; Tetrahydrocannabinol; Aminoalkylindole (Miller, A.S. (279) 179)

WIN 64,338
Bradykinin; HOE 140 (Wirth, K.J. (288) R1)

Withdrawal
Marijuana; Tetrahydrocannabinol (Tsou, K. (280) R13)

Working memory
Somatostatin; Hippocampus; Muscarinic M_1 receptor; Pirenzepine; NMDA receptor; CPP ((±)-3(2-carboxypiperazin-4-yl)-propyl-1-phosphonoic acid) (Ohno, M. (271) 557)

CGP 37849; Reference memory; NMDA receptor (Deacon, R.M.J. (280) 239)

Xanthine oxidase
Cytochrome P-450; Dexamethasone; Interleukin-2; Liver; TNF (tumor necrosis factor) (Cantoni, L. (292) 257)

N-Acetyl-L-cysteine; Allopurinol; Sepsis; Free radicals; Cecal ligation and puncture (Villa, P. (292) 341)

***Xenopus* oocyte**
L-AP3 (L-2-amino-3-phosphonopropionic acid); MCPG ((RS)-α-methyl-4-carboxyphenylglycine); Metabotropic glutamate receptor; Phosphatidyl inositide hydrolysis (Saugstad, J.A. (289) 395)

Desensitization; Kainate; Glycoprotein (Yue, K.-T. (291) 229)

Nicotinic acetylcholine receptor, neuronal; Metal ion, divalent; Voltage clamp; Ion current, potentiation, inhibition (Zwart, R. (291) 399)

GABA ρ_1 receptor; Protein kinase C; Down-regulation; Phorbol ester; Staurosporine (Kusama, T. (291) 431)

***Xenopus* oocyte expression**
Brain, chicken; G-protein-coupled receptor; Recombinant P_{2Y1} purinoceptor; COS-7 cell, transient expression; Inositol 1,4,5-trisphosphate, formation (Simon, J. (291) 281)

Xylazine
DAMGO ([D-Ala^2,MePhe^4,Gly(ol)^5]enkephalin); DPDPE ([D-Pen^2,D-Pen^5]enkephalin); Nalorphine; U50,488; Clonidine (Paul, D. (272) 111)

Vas deferens, rat; α_2-Adrenoceptor; 4-Aminopyridine; Tetraethylammonium; Charybdotoxin; Phorbol dibutyrate; Bay K 8644 (Docherty, J.R. (287) 287)

Yawning
Aging; ACTH (adrenocorticotropin); Melanocortin; Grooming; Stretching; Penile erection (Poggioli, R. (271) 253)

Physostigmine; Atropine; Adenosine receptor agonist; Adenosine receptor antagonist; (Rat) (Zarrindast, M.-R. (276) 3)

Sprague-Dawley rat; F344 rat; Dopamine (Tang, A.H. (284) 13)

YM-060 {(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-enzimidazole monohydrochloride}
5-HT_3 receptor; Enteric nervous system; Myenteric neuron; Distal colon; (Guinea pig) (Ito, H. (283) 107)

[^{3}H]YM-060 ([methyl-^{3}H]-(−)-(*R*)-5-[(1-methyl-1*H*-indol-3-yl)carbonyl]-4,5,6,7-tetrahydro-1*H*-benzimidazole monohydrochloride)
5-HT_3 receptor; Cerebral cortex, rat (Akuzawa, S. (281) 37)

YM-638 ([[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio] acetic acid)
Leukotriene D_4 receptor antagonist; Gastric mucosal protection; Gastric lesion (Miyata, K. (276) 165)

YM-14673
Repetitive jaw movement; TRH (thyrotropin-releasing hormone); Nucleus accumbens; Striatum; Dopamine receptor (Miwa, Y. (277) 63)

YM-09151-2
Sleep; Waking; *m*-Chlorophenylbiguanide; 5-HT_3 receptor; MDL 72222; Dopamine; (+)-SCH 23390 (Ponzoni, A. (278) 111)

Yohimbine
Blood pressure control; Sinoaortic denervation; Neostigmine; 6-Hydroxydopamine; Prazosin (Taira, C.A. (271) 9)

YT-146
Adenosine receptor; Endothelium-dependent relaxation; Femoral artery; Femoral vein; 2-Octynyladenosine (Abiru, T. (281) 9)

Adenosine A_2 receptor agonist; Neointimal thickening; (Rat) (Takiguchi, Y. (281) 205)

Zamifenacin
Muscarinic receptor subtype (Watson, N. (285) 135)

Zero-maze
Cholecystokinin; CCK receptor antagonist; 5-HT (5-hydroxytryptamine, serotonin); Anxiety; (Rat) (Bickerdike, M.J. (271) 403)

Zimelidine
Apomorphine; Desipramine; Development; Nomifensine; Stereotypy (Hilakivi, I. (271) 223)

Zinc protoporphyrin-9
Amnesia; Inhibitory avoidance; Heme oxygenase; Hippocampus (Fin, C. (271) 227)

Vasodilator nerve; Nitric oxide (NO); Mesenteric artery, guinea pig; CGRP (calcitonin gene-related peptide); Capsaicin; Nitro-L-arginine (Gyoda, Y. (279) 83)

Zinc sulfate
N-acetylcysteine; Acetaminophen; Hepatotoxicity; Glutathione; Alanine aminotransferase; Malondialdehyde (Woo, P.C.Y. (293) 217)

Ziprasidone
Risperidone; Olanzapine; Seroquel; Amperozide; Schizophrenia; Ventral tegmental area; Substantia nigra pars compacta; (Rat) (Skarsfeldt, T. (281) 289)

Zolpidem
$GABA_A$ receptor; Benzodiazepine BZ_1 site; Benzodiazepine BZ_2 site; [^{35}S]TBPS ([^{35}S]*t*-butylbicyclophosphorothionate) binding; Ontogenesis; Flunitrazepam; CL 218,872; Cerebral cortex, rat (Giorgi, O. (290) 37)

[^{3}H]Zolpidem
Benzodiazepine type 1 receptor; Tolerance; Receptor down-regulation; Midazolam; Flurazepam (Wu, Y. (278) 125)

lacZ′ shuttle vector
Cytochrome P450-3A4, human; NIH/3T3 cell; Biotransformation; Mutagenicity (De Groene, E.M. (293) 47)

Zucker rat
Metformin; Genetic obesity; Feeding behavior; Insulin; Neuropeptide Y (Rouru, J. (273) 99)

Cytochrome P450; Enzyme induction; Obesity (Irizar, A. (293) 385)

European Journal of Pharmacology

GENERAL INSTRUCTIONS

Complete instructions are given in the 'Notice to authors' (Vol. 295, No. 1, page vii) or available as reprint, free on request. The 'Notice' must be followed to the letter so that papers conform to the style of the *European Journal of Pharmacology*.

The original and 3 copies, complete with 4 sets of figures and tables should be sent to:

The Editorial Office, European Journal of Pharmacology, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands

(telephone: +31.30.2538833, telefax: +31.30.2539033).

Acceptability of rapid communications will be decided by the editors, who will be advised by a member of the editorial board or by one of the consultants. Full length manuscripts, short communications and short reviews are generally submitted to two referees who are chosen for their ability to evaluate the work. Authors may request that certain referees not be chosen. Members of the editorial board will usually be called upon for advice when there is disagreement among referees or between referees and authors, or when the editors believe that the manuscript has not received adequate consideration from the referees. In order to reduce mailing costs, manuscripts will not be returned to the authors. Only the decision of the editors, together with the advise of the referees will be sent to the author(s). When authors submit a revised manuscript, they should reply to the comments of the referees, indicating which comments they have incorporated and their reasons for disregarding any suggestions considered unacceptable. Revised manuscripts should be returned in duplicate to the editorial office. A revised manuscript should be received at the editorial office not later than 5 weeks (minor revision) or 10 weeks (extensive revision) after the editorial decision was postmarked to the author(s). Revised manuscripts received later than this will be processed as a new manuscript. Handwritten additions or corrections are not acceptable. Pages affected by revision must be retyped.

The preferred medium of final submission to the accepting editor is on disk with the accompanying reviewed and revised manuscript (see 'Electronic manuscripts' below). Manuscripts submitted by facsimile transmission will not be considered. Manuscripts should be typewritten or printed with double spacing (at least 6 mm between lines) and with wide margins (not more than 26 lines per page). The possibility that accepted manuscripts will be processed by electronic scanning makes it essential that the typing/printing be of the highest quality. A laser-type or similar quality printer or a high-quality typewriter with a black carbon ribbon should be used to ensure proper contrast for the original. A standard, at least 12-point (0.0138 inch), type face, neither distorted nor reduced or enlarged, is to be used. Manuscripts printed with low-quality printers will be returned for retyping with an acceptable type face. Manuscripts should be written in English. Accepted manuscripts will, if necessary, have English style and language corrected. Manuscripts with extensive changes will be returned to the authors for retyping. Submission of a paper in clear, grammatical English will, therefore, shorten publication time considerably.

1. Electronic manuscripts

Electronic manuscripts have the advantage that there is no need for the rekeying of text, thereby avoiding the possibility of introducing errors and resulting in reliable and fast delivery of proofs. The preferred storage medium is a $5\frac{1}{4}$ or $3\frac{1}{2}$ inch disk in MS-DOS format, although other systems are welcome, e.g., NEC and Macintosh (in this case, save your file in the usual manner, do not use the option 'save in MS-DOS format'). Please do not split the article into separate files (title page as one file, text as another, etc.). Ensure that the letter 'l' and digit '1' (also letter 'O' and digit '0') have been used properly, and structure your article (tabs, indents, etc.) consistently. Characters not available on your wordprocessor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter α). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your wordprocessor to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the wordprocessor format. If your wordprocessor features the option to save files 'in flat ASCII', please do not use it. Format your disk correctly and ensure that only the relevant file (one complete article only) is on the disk. Also, specify the type of computer and wordprocessing package used and label the disk with your name and the name of the file on the disk. After final acceptance, your disk plus one, final, printed and exactly matching version (as a printout) should be submitted together to the accepting editor. It is important that the file on disk and the printout are identical. Both will then be forwarded by the editor to Elsevier. Further information may be obtained from the Publisher.

2. Rapid communications

(a) Reports on exciting new results within the scope of the journal can be submitted for publication in the rapid communications section.

(b) A rapid communication should not exceed 700 words and should contain no or only one simple table or figure of not more than 8.4 cm = 1 column width.

(c) A maximum of 8 references may be used.

(d) The rapid communication should be typewritten, lines double spaced, with wide margins, without any subheadings, and preferably accompanied by a floppy disk (see section 1). The manuscript should be arranged in the following order: title (not exceeding 85 characters including spaces between words); surname(s) of author(s), preceded by one name spelled out in full; name and address of the establishment where the work was done (all on 1 page); abstract (max. 75 words) and keywords (indexing terms, max. 3 items); text; acknowledgement(s); references; figure legend and figure; table (colour figures will delay publication). Name, full postal address, telephone and telefax numbers of author to whom correspondence is to be sent should be mentioned on the title page.

(e) Rapid communications have priority at the editorial office and publisher.

(f) All proofreading will be done by the editorial staff of the publisher; no proofs will be sent to the author(s).

(g) Upon acceptance of a rapid communication a reprint order form will be sent to the author(s).

3. Full length manuscripts

(a) The manuscript should be arranged as follows. First page: title (not exceeding 85 characters including spaces between words); surname(s) of author(s), preceded by one name spelled out in full; name and address of the establishment where the work was done; name, full postal address, telephone and telefax numbers of author to whom proofs and other correspondence should be sent. Next page (2): abstract and keywords (indexing terms: normally 3–6 items). Pages 3 to end: 1. Introduction; 2. Materials and methods; 3. Results; 4. Discussion; Acknowledgements; References; figure legends and figures; tables. Both sections and their subdivisions should be numbered (2.1., 2.2., 2.3. etc.).

(b) Abstract and keywords: an abstract not exceeding 150 words and stating what was done, what was found, and what was concluded should be typed on a separate sheet. Below the abstract, type 3–6 keywords or short phrases suitable for indexing. These terms will be printed at the end of the abstract. If possible, keywords should be selected from *Index Medicus* or *Excerpta Medica Index*. First category keywords (e.g. Hyperphagia; G-Strophantidin; Fiber shortening) will all be listed and cross-indexed. Second category keywords (e.g. Rat, Cold, Metabolite) will only be listed under the index entry for the first category keywords. If the editors feel that keywords should be adjusted to the standards of the journal this will be done without consultation of the author(s).

(c) Standard nomenclature should be used throughout. Avoid unnecessary abbreviations and symbols (see extensive 'Notice to authors', Vol. 295, No. 1, p. vii). Words at the end of a line should not be divided. Use of hyphens, capital letters, numbers written or spelled out (e.g. 8 or eight) should be consistent throughout the manuscript.

(d) Legends of illustrations and footnotes should be typed on separate sheets, lines double spaced. Footnotes, to be numbered consecutively in superscript throughout the text, should be used as little as possible.
(e) Drugs: generic names should be used. Trade names may be mentioned in parentheses the first time the name of the drug appears in the text. The form of the drug used should be indicated.

4. Short communications should be prepared as described under 3, except for the following:
(a) The average length of a short communication should not exceed 4 pages in print (approx. 2000–2300 words including abstract, captions and references). A maximum of 2 illustrations (figures and tables) is allowed.
(b) An abstract of not more than 100 words should be provided and 3–6 keywords should be listed immediately below the abstract.
(c) All proofreading will be done by the editorial staff of the publisher; no proofs will be sent to the author(s).
(d) Upon acceptance of a short communication a reprint order form will be sent to the author(s).

5. References
References in the text to literature cited should be given by the name of the author(s), followed by the year of publication in parentheses, e.g.: Downie and Larsson (1990) or (Hicks et al., 1988, 1989; Seeman et al., 1990; Stoof and Kebabian, 1991a,b,c). For three or more authors the name of the first author followed by et al. should be used. Journal names should be abbreviated according to the *List of Serial Title Word Abbreviations* (available from the International Serials Data System, 20 Rue Bachaumont, 75002 Paris, France; ISBN 2-904938-02-8). References should be listed alphabetically. Citations of the literature in the list of references should include the full title of the article referred to. Personal communications and unpublished data should not appear in the list of references. Sample references:

Periodicals:
Harrison, J.K., W.R. Pearson and K.R. Lynch, 1991, Molecular characterization of α_1- and α_2-adrenoceptors, Trends Pharmacol. Sci. 12, 62.

Books:
De Graan, P.N.E., P. Schotman and D.H.G. Versteeg, 1990, Neural mechanisms of action of neuropeptides: macromolecules and neurotransmitters, in: Neuropeptides: Basics and Perspectives, ed. D. De Wied (Elsevier, Amsterdam) p. 139.
Appenzeller, O., 1990, The Autonomic Nervous System (Elsevier, Amsterdam) p. 419.

6. Illustrations, graphs and tables (see Notice to authors, Vol. 295, No. 1, p. vii)
(a) Either the original drawings plus 3 good photographs, or 4 good photographs of the drawings (on glossy paper and unmounted) or 4 high-quality computer printouts should be submitted. Illustrations may be submitted in electronic format as well, but must always be accompanied by reproducible paper printouts. Photocopies may not be used. The photographs should be of adequate definition and contrast. The number of illustrations should be limited to the essential.
(b) It is important to allow for reduction to fit a single column, 8.4 cm wide, or at most a double column, maximally 17.6 cm wide. Illustrations, especially photomicrographs, should be submitted in their final size (single or double column). When possible, all key symbols should be explained in the figures. The following symbols can be typeset and explained (as well as all lettering) in the legends: + × ■ □ ● ▲ ▼ ◀ ▶ ○ ◇ △ ▽ ▷ ◁ ⊕ ⊗ ⊙ ⊖ ◉ * ⋆. All letters and numerals appearing in a particular illustration should be of the same size (approximately 1.4–2 mm height when reduced to 8.4 cm width).
(c) Graphs, electrocardiograms and oscillograms should be prepared by a skilled photographer so that the dark, cross-hatched background is eliminated, the faint portions of the graphs intensified, and a sharp print obtained. This process may be avoided by using blue-ruled instead of black-ruled recording paper for the originals. Kymograph records on sooted paper should be reversed photographically to ensure graphs in black on a white background.
(d) Drawings of complicated chemical structures should be prepared in the same way as graphs.
(e) A calibration bar should be drawn on the micrographs instead of giving a magnification rate in the figure legend.
(f) All illustrations should be referred to as figures and numbered in Arabic numerals (Fig. 1, 2 etc.).
(g) Legends to figures should make these comprehensible without reference to the text.
(h) Tables should be numbered separately in Arabic numerals (Table 1, 2 etc.).
(i) Colour reproduction of illustrations is available at cost. Original high-quality illustrations (preferably slides) should be well protected against possible damage during shipment. Detailed information regarding the use of colour may be obtained from the publisher, at the time of submission of the manuscript to the editors.

7. Proofs
One set of galley proofs will be sent to the author named on the title page (see 3.). Proofs will usually be drawn on lower quality paper. Only printer's errors may be corrected; no changes in, or additions to, the edited manuscript will be allowed. Proofs should be returned within 48 hours to Elsevier Science B.V., Log-in Department, P.O. Box 2759, 1000 CT Amsterdam, The Netherlands, preferably by telefax (+31-20-485.3239). If this period is exceeded no reminders will be sent, the manuscript will be read by the editorial staff of the publisher only and printed without the author's corrections. Authors of short and rapid communications will not receive galley proofs.

8. Page charges and reprints
There will be no page charge. Authors will receive a reprint order from with the acknowledgement of receipt and the copyright transfer form from the publisher: this order form should be mailed to the publisher by return post. Reprints ordered after the journal has been printed will cost considerably more than those ordered immediately.

© 1996 Elsevier Science B.V. All rights reserved

Printed in The Netherlands *Library of Congress Catalog Card Number 68-26539* Published weekly

EUROPEAN JOURNAL OF PHARMACOLOGY

EJP Molecular Pharmacology Section, Volumes 288–291, and EJP Environmental Toxicology and Pharmacology Section, Volumes 292–293, incorporated

Cited in: Biological Abstracts – Chemical Abstracts – Current Contents/Life Sciences – Excerpta Medica (EMBASE) – Index Medicus – Pascal M – Reference Update – Unlisted Drugs – Current Awareness in Biological Sciences (CABS)

CONTENTS

Master author index to volumes 271–293 (1995) 1

Master keyword index to volumes 271–293 (1995) 55

0014-2999(1995)271/293;1-S